Trial_ID,Title,Official_Title,Organization,Lead_Sponsor,Lead_Sponsor_Type,Overall_Status,Start_Date,Primary_Completion_Date,Completion_Date,Study_Type,Study_Phase,Enrollment,Masking,Allocation,Primary_Condition,All_Conditions,Condition_Count,Num_Arms,Num_Interventions,Intervention_Types,Gender,Accepts_Healthy_Volunteers,Primary_Outcome_Count,Secondary_Outcome_Count,Has_Outcome_Data,Has_Results,Primary_Outcomes,Secondary_Outcomes,Outcome_CBR,Outcome_CR,Outcome_DFS,Outcome_DMFS,Outcome_DoR,Outcome_EFS,Outcome_LRFS,Outcome_ORR,Outcome_OS,Outcome_PFS,Outcome_PR,Outcome_QOL,Outcome_RR,Outcome_TOX,Outcome_TTF,Outcome_TTP
NCT00003869,Carboxyamidotriazole in Treating Patients With Stage III or Stage IV Non-small Cell Lung Cancer,"Phase III Randomized, Double-Blind Study of CAI and Placebo in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)",National Cancer Institute (NCI),National Cancer Institute (NCI),NIH,COMPLETED,1999-04,2008-05,2008-05,INTERVENTIONAL,PHASE3,,,,Stage IIIA Non-small Cell Lung Cancer,Stage IIIA Non-small Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer,3,2,4,DRUG; OTHER; PROCEDURE,,,1,5,True,Yes,Overall Survival (OS) (MEDIAN) Months = 11.4 [9.2-13.9],Participants With Severe Non-hematologic Adverse Events (NUMBER) Participants = 38; Time to Disease Progression (TTP) (MEDIAN) Months = 2.8 [2.1-3.8]; Clinically Significant (10-point) Decrease in UNISCALE Quality of Life (QOL)Assessment From Baseline to Week 8 (NUMBER) participants = 28 [1.0-98.0]; Clinically Significant (10-point) Decrease in Functional Assessment of Cancer Therapy for Lung Cancer (FACT-L) Quality of Life (QOL)Assessment From Baseline to Week 8 (NUMBER) participants = 27 [40.2-93.1]; ,,,,,,,,,Overall Survival (OS) (MEDIAN) Months = 11.4 [9.2-13.9],,,Clinically Significant (10-point) Decrease in UNISCALE Quality of Life (QOL)Assessment From Baseline to Week 8 (NUMBER) participants = 28 [1.0-98.0]; Clinically Significant (10-point) Decrease in Functional Assessment of Cancer Therapy for Lung Cancer (FACT-L) Quality of Life (QOL)Assessment From Baseline to Week 8 (NUMBER) participants = 27 [40.2-93.1],,Participants With Severe Non-hematologic Adverse Events (NUMBER) Participants = 38,,
NCT00049543,"Gefitinib in Treating Patients With Stage IB, II, or IIIA Non-small Cell Lung Cancer That Was Completely Removed by Surgery","A Phase III Prospective Randomized, Double-Blind, Placebo-Controlled Trial of the Epidermal Growth Factor Receptor Antagonist, ZD1839 (IRESSA) in Completely Resected Primary Stage IB, II and IIIA Non-",National Cancer Institute (NCI),National Cancer Institute (NCI),NIH,COMPLETED,2002-09,2011-04,2011-04,INTERVENTIONAL,PHASE3,,,,Adenocarcinoma of the Lung,Adenocarcinoma of the Lung; Adenosquamous Cell Lung Cancer; Bronchoalveolar Cell Lung Cancer,9,2,3,DRUG; OTHER,,,1,2,True,Yes,Overall Survival (NUMBER) percentage of 5 years survival rate = 0.52 [0.44-0.58],Disease Free Survival (NUMBER) percentage of 5-year disease free rate = 0.49 [0.42-0.55]; Incidence of Toxicities Graded Using the NCI Common Terminology Criteria for Adverse Events Version 3.0 (NUMBER) participants = 229,,,Disease Free Survival (NUMBER) percentage of 5-year disease free rate = 0.49 [0.42-0.55],,,,,,Overall Survival (NUMBER) percentage of 5 years survival rate = 0.52 [0.44-0.58],,,,,Incidence of Toxicities Graded Using the NCI Common Terminology Criteria for Adverse Events Version 3.0 (NUMBER) participants = 229,,
NCT00050960,"Evaluation of Efficacy, Safety and Tolerability of Targretin Capsules in Patients With Advanced or Metastatic Non-small Cell Lung Cancer",Randomized Phase III Trial Comparing Targretin Capsules/Carboplatin/Paclitaxel Versus Carboplatin/Paclitaxel in Chemotherapy-Naïve Patients With Advanced or Metastatic Non-Small Cell Lung Cancer,Eisai Inc.,Eisai Inc.,INDUSTRY,COMPLETED,2002-05,2004-07,2005-03,INTERVENTIONAL,PHASE3,,,,Non-small Cell Lung Cancer,Non-small Cell Lung Cancer,1,2,2,DRUG,,,1,0,True,Yes,Overall Survival (MEDIAN) Months = 8.5 [7.7-9.3],,,,,,,,,,Overall Survival (MEDIAN) Months = 8.5 [7.7-9.3],,,,,,,
NCT00063154,"Safety and Effect of Pertuzumab in Patients With Advanced Non-Small Cell Lung Cancer, Which Has Progressed After Prior Chemotherapy","A Phase II, Open-label, Multicenter Study to Evaluate the Effect of Tumor-based HER2 Activation on the Efficacy of rhuMAb 2C4 (Pertuzumab) in Subjects With Recurrent Non-Small Cell Lung Cancer","Genentech, Inc.","Genentech, Inc.",INDUSTRY,COMPLETED,2003-07,2005-04,2005-04,INTERVENTIONAL,PHASE2,,,,Non-small Cell Lung Cancer,Non-small Cell Lung Cancer,1,1,1,DRUG,,,1,3,True,Yes,"Percentage of Participants With a Best Overall Response of Complete Response (CR), Partial Response (PR), Stable Disease (SD), or Progressive Disease (PD) (NUMBER) percentage of participants = 0.0","Number of Participants With a Best Overall Response of Complete Response (CR), Partial Response (PR), Stable Disease (SD), or Progressive Disease (PD) With HER2 Phosphorylation + or - Tumors (NUMBER) participants = 0; Progression-free Survival (MEDIAN) weeks = 6.6 [6.0-14.7]; Number of Participants Free From Disease Progression at 3, 6, and 12 Months (NUMBER) participants = 8",,"Percentage of Participants With a Best Overall Response of Complete Response (CR), Partial Response (PR), Stable Disease (SD), or Progressive Disease (PD) (NUMBER) percentage of participants = 0.0; Number of Participants With a Best Overall Response of Complete Response (CR), Partial Response (PR), Stable Disease (SD), or Progressive Disease (PD) With HER2 Phosphorylation + or - Tumors (NUMBER) participants = 0",,,,,,,,Progression-free Survival (MEDIAN) weeks = 6.6 [6.0-14.7],"Percentage of Participants With a Best Overall Response of Complete Response (CR), Partial Response (PR), Stable Disease (SD), or Progressive Disease (PD) (NUMBER) percentage of participants = 0.0; Number of Participants With a Best Overall Response of Complete Response (CR), Partial Response (PR), Stable Disease (SD), or Progressive Disease (PD) With HER2 Phosphorylation + or - Tumors (NUMBER) participants = 0",,,,,
NCT00065182,Comparison of IV Topotecan/Docetaxel to Docetaxel Alone in Second-Line Stage IIIB/IV Non-Small Cell Lung Cancer,WEEKLY IV TOPOTECAN/DOCETAXEL COMBINATION COMPARED TO DOCETAXEL IN PATIENTS WITH PRETREATED ADVANCED NSCLC: AN OPEN-LABEL MULTICENTER RANDOMIZED PHASE III TRIAL,GlaxoSmithKline,GlaxoSmithKline,INDUSTRY,COMPLETED,2003-08-14,2007-08-30,2007-08-30,INTERVENTIONAL,PHASE2,,,,"Lung Cancer, Non-Small Cell","Lung Cancer, Non-Small Cell; Non-Small-Cell Lung Cancer",2,0,2,DRUG,,,1,10,True,Yes,Median Time of Overall Survival (MEDIAN) Weeks = 30.7 [26.1-35.9],"; ; ; ; ; ; Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) (COUNT_OF_PARTICIPANTS) Participants = 186; Number of Participants With Grade 1, 2, 3 or 4 Hematologic Toxicities (COUNT_OF_PARTICIPANTS) Participants = 76; Number of Participants With Grade 3 or 4 Clinical Chemical Toxicities (COUNT_OF_PARTICIPANTS) Participants = 3; Number of Participants With Clinically Significant Abnormal Vital Signs Data (COUNT_OF_PARTICIPANTS) Participants = 0",,,,,,,,,Median Time of Overall Survival (MEDIAN) Weeks = 30.7 [26.1-35.9],,,,,Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) (COUNT_OF_PARTICIPANTS) Participants = 186,,
NCT00085839,Erlotinib vs. Standard Chemotherapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) and Eastern Cooperative Oncology Group (ECOG)Performa,"A Randomized Phase II Study of Single Agent Erlotinib [Tarceva (TM), OSI-774] Versus Standard Chemotherapy in Patients With Previously Untreated Advanced NSCLC and a Poor Performance Status",Astellas Pharma Inc,OSI Pharmaceuticals,INDUSTRY,COMPLETED,2004-02,2007-03,2007-03,INTERVENTIONAL,PHASE2,,,,Non-Small Cell Lung Cancer,Non-Small Cell Lung Cancer,1,2,2,DRUG,,,1,2,True,Yes,Progression-free Survival (MEDIAN) months = 1.91 [1.28-2.69],Overall Survival (MEDIAN) months = 6.57 [3.78-8.25]; Best Tumor Response (NUMBER) participants = 0,,,,,,,,,Overall Survival (MEDIAN) months = 6.57 [3.78-8.25],Progression-free Survival (MEDIAN) months = 1.91 [1.28-2.69],,,,,,
NCT00093756,"Bortezomib, Paclitaxel, Carboplatin and Radiation Therapy for Non-Small Cell Lung Cancer","Phase I/II Study of PS-341 in Combination With Paclitaxel, Carboplatin, and Concurrent Thoracic Radiation Therapy for Non-small Cell Lung Cancer (NSCLC)",National Cancer Institute (NCI),National Cancer Institute (NCI),NIH,COMPLETED,2004-09,2012-01,2013-05,INTERVENTIONAL,PHASE1; PHASE2,,,,Recurrent Non-small Cell Lung Cancer,Recurrent Non-small Cell Lung Cancer; Stage IIIA Non-small Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer,3,1,4,DRUG; RADIATION,,,1,5,True,Yes,The Primary Endpoint of This Trial is the Proportion of Patients Alive at 1 Year. Phase II Patients Only. (NUMBER) proportion of Participants = 0.73,"Confirmed Tumor Response (COUNT_OF_PARTICIPANTS) Participants = 3; ; Progression-free Survival (MEDIAN) months = 8.4 [4.1-10.5]; Overall Survival (MEDIAN) months = 25 [15.6-35.8]; Frequency and Severity of Observed Toxicity, Graded by Common Terminology Criteria for Adverse Events (CTCAE) (COUNT_OF_PARTICIPANTS) Participants = 22",,,,,,,,,Overall Survival (MEDIAN) months = 25 [15.6-35.8],Progression-free Survival (MEDIAN) months = 8.4 [4.1-10.5],,,,"Frequency and Severity of Observed Toxicity, Graded by Common Terminology Criteria for Adverse Events (CTCAE) (COUNT_OF_PARTICIPANTS) Participants = 22",,
NCT00094835,Study to Evaluate Motesanib With or Without Carboplatin/Paclitaxel or Panitumumab in the Treatment of Patients With Advanced Non-Small Cell Lung Cance,"An Open-label, Dose-finding Study to Evaluate the Safety and Pharmacokinetics (PK) of AMG 706 With Carboplatin/Paclitaxel, AMG 706 With Panitumumab and AMG 706 With Panitumumab and Carboplatin/Paclita",Amgen,Amgen,INDUSTRY,COMPLETED,2005-01,2007-03,2007-03,INTERVENTIONAL,PHASE1; PHASE2,,,,Lung Cancer,Lung Cancer; Non-Small Cell Lung Cancer,2,3,4,BIOLOGICAL; DRUG,,,10,1,True,Yes,"Time to Maximum Plasma Concentration of Motesanib (Tmax) for Cycle 1 (MEDIAN) hours = 0.75 [0.5-2.0]; Maximum Observed Plasma Concentration of Motesanib (Cmax) in Cycle 1 (MEAN) ng/mL = 158; Estimated Terminal-phase Half-life (t1/2,z) of Motesanib in Cycle 1 (MEAN) hours = 7.34; Area Under the Plasma Concentration-time Curve for Motesanib in Cycle 1 (MEAN) μg*hr/mL = 0.971; Trough Plasma Concentration at 24 Hours Post-dose (C24) for Motesanib in Cycle 1 (MEAN) ng/mL = 9.12; Time to Maximum Plasma Concentration of Motesanib (Tmax) in Cycle 2 (MEDIAN) hours = 1.5 [1.0-2.0]; Maximum Observed Plasma Concentration of Motesanib (Cmax) in Cycle 2 (MEAN) ng/mL = 148; Estimated Terminal-phase Half-life (t1/2,z) of Motesanib in Cycle 2 (MEAN) hours = 6.41; Area Under the Plasma Concentration-time Curve From Time 0 to 24 Hours Post-dose for Motesanib in Cycle 2 (MEAN) μg*hr/mL = 4.50; Trough Plasma Concentration at 24 Hours Post-dose (C24) for Motesanib in Cycle 2 (MEAN) ng/mL = 43.4",Percentage of Participants With an Overall Objective Response (NUMBER) Percentage of participants = 33,,,,,,,,,,,,,,,,
NCT00094861,Study to Evaluate Palifermin in the Reduction of Dysphagia in Patients With Locally Advanced Non-Small Cell Lung Cancer (NSCLC),A Phase 2 Study to Evaluate the Efficacy and Safety of Palifermin (Recombinant Human Keratinocyte Growth Factor) in the Reduction of Dysphagia in Patients Receiving Concurrent Chemoradiotherapy Follow,Swedish Orphan Biovitrum,Swedish Orphan Biovitrum,INDUSTRY,COMPLETED,2005-01,2007-12,2014-01,INTERVENTIONAL,PHASE2,,,,Dysphagia,Dysphagia; Non-Small Cell Lung Cancer; Lung Cancer,3,2,5,DRUG; RADIATION,,,1,7,True,Yes,Number of Participants With Grade 2 or Higher Dysphagia (NUMBER) participants = 32,Duration of Grade 2 or Higher Dysphagia (MEAN) days = 32.4; Maximal Dysphagia Grade (MEAN) grade = 1.9; Number of Participants With Severe (Grade 3 or Higher) Dysphagia (NUMBER) participants = 13; Number of Participants With Unplanned Breaks in Radiotherapy (NUMBER) participants = 15; Maximal Eastern Cooperative Oncology Group (ECOG) Performance Status Increase (MEAN) units on a scale = 1.5; Number of Participants Hospitalized (NUMBER) participants = 31; Maximal Body Weight Loss (MEAN) kilograms = 4.63,,,,,,,,,,,,,,,,
NCT00095199,Docetaxel or Pemetrexed With or Without Cetuximab in Patients With Recurrent or Progressive Non-Small Cell Lung Cancer,Randomized Phase III Study of Docetaxel or Pemetrexed With or Without Cetuximab in Patients With Recurrent or Progressive Non-Small Cell Lung Cancer After Platinum-Based Therapy,Eli Lilly and Company,Eli Lilly and Company,INDUSTRY,COMPLETED,2005-01,2011-07,2011-07,INTERVENTIONAL,PHASE3,,,,Non Small Cell Lung Cancer,Non Small Cell Lung Cancer,1,4,3,BIOLOGICAL; DRUG,,,1,7,True,Yes,Progression Free Survival (PFS) (MEDIAN) months = 2.89 [2.69-3.22],"Overall Survival (OS) (MEDIAN) months = 6.93 [6.28-7.85]; Proportion of Randomized Participants With the Best Overall Response (OR) of Partial Response (PR) or Complete Response (CR) (Overall Response Rate [ORR]) (NUMBER) proportion of participants = 0.066 [0.038-0.095]; Proportion of Randomized Participants With Best Overall Response (OR) of Partial Response (PR), Complete Response (CR), or Stable Disease (SD) (NUMBER) proportion of participants = 0.522 [0.465-0.578]; Percentage of Participants With Symptomatic Response (Symptom Response Rates) Using the Lung Cancer Subscale (LCS) Scores of Functional Assessment of Cancer Therapy for Participants With Lung Cancer (FACT-L) (NUMBER) percentage of participants = 17.1 [12.7-21.6]; ; Duration of Overall Response (OR) (MEDIAN) months = 4.17 [2.92-5.45]; Number of Participants With Common Toxicity Criteria (CTC) Grade 3 or 4 Toxicities (NUMBER) participants = 179",,"Proportion of Randomized Participants With the Best Overall Response (OR) of Partial Response (PR) or Complete Response (CR) (Overall Response Rate [ORR]) (NUMBER) proportion of participants = 0.066 [0.038-0.095]; Proportion of Randomized Participants With Best Overall Response (OR) of Partial Response (PR), Complete Response (CR), or Stable Disease (SD) (NUMBER) proportion of participants = 0.522 [0.465-0.578]",,,,,,,Overall Survival (OS) (MEDIAN) months = 6.93 [6.28-7.85],Progression Free Survival (PFS) (MEDIAN) months = 2.89 [2.69-3.22],"Proportion of Randomized Participants With the Best Overall Response (OR) of Partial Response (PR) or Complete Response (CR) (Overall Response Rate [ORR]) (NUMBER) proportion of participants = 0.066 [0.038-0.095]; Proportion of Randomized Participants With Best Overall Response (OR) of Partial Response (PR), Complete Response (CR), or Stable Disease (SD) (NUMBER) proportion of participants = 0.522 [0.465-0.578]",,Proportion of Randomized Participants With the Best Overall Response (OR) of Partial Response (PR) or Complete Response (CR) (Overall Response Rate [ORR]) (NUMBER) proportion of participants = 0.066 [0.038-0.095]; Percentage of Participants With Symptomatic Response (Symptom Response Rates) Using the Lung Cancer Subscale (LCS) Scores of Functional Assessment of Cancer Therapy for Participants With Lung Cancer (FACT-L) (NUMBER) percentage of participants = 17.1 [12.7-21.6],Number of Participants With Common Toxicity Criteria (CTC) Grade 3 or 4 Toxicities (NUMBER) participants = 179,,
NCT00098254,BAY 43-9006 (Sorafenib) to Treat Relapsed Non-Small Cell Lung Cancer,Phase II Study of Bay 43-9006 (Sorafenib) With Evaluation of RAS Signal Pathway in Patients With Relapsed Non-Small Cell Lung Cancer,National Institutes of Health Clinical Center (CC),National Cancer Institute (NCI),NIH,COMPLETED,2004-12,2009-11,2011-01,INTERVENTIONAL,PHASE2,,,,Non-Small-Cell Lung Carcinoma,Non-Small-Cell Lung Carcinoma,1,1,1,DRUG,,,3,13,True,Yes,Response Rate (NUMBER) percentage of participants = 6 [1-20]; Progression Free Survival (MEDIAN) months = 3.4 [1.9-3.7]; The Number of Participants With Adverse Events (NUMBER) Participants = 37,"Overall Survival (MEDIAN) months = 11.6 [9.2-16.4]; ; Overall Survival Reported Separately for Participants With a Change in PLGF Below 11 pg/ml and Above 12 pg/ml (MEDIAN) months = 6.6 [4.9-9.2]; Cytokine Levels (MEDIAN) pg/ml = 101 [69-204]; Correlation of Response to Treatment With KRAS Mutational Status (NUMBER) percentage of participants = 60; Overall Survival Associated With Basic Fibroblast Growth Factor (bFGF) (MEDIAN) months = 15.4 [9.2-31.2]; Progression Free Survival Associated With Basic Fibroblast Growth Factor (bFGF) (MEDIAN) months = 4.4 [3.1-5.5]; Percentage of Participants With an Increase or Decrease in the Reverse Contrast Transfer Rate (Kep), Forward Contrast Transfer Rate (Ktrans), and Extravascular Fraction (Ve) With the Dynamic Contrast Enhanced Magnetic Resonance Imaging (DCE-MRI) (NUMBER) Percentage of participants = 19; ; ; ; ; ",,,,,,,,,Overall Survival (MEDIAN) months = 11.6 [9.2-16.4]; Overall Survival Reported Separately for Participants With a Change in PLGF Below 11 pg/ml and Above 12 pg/ml (MEDIAN) months = 6.6 [4.9-9.2]; Overall Survival Associated With Basic Fibroblast Growth Factor (bFGF) (MEDIAN) months = 15.4 [9.2-31.2],Progression Free Survival (MEDIAN) months = 3.4 [1.9-3.7]; Progression Free Survival Associated With Basic Fibroblast Growth Factor (bFGF) (MEDIAN) months = 4.4 [3.1-5.5],,,Response Rate (NUMBER) percentage of participants = 6 [1-20],The Number of Participants With Adverse Events (NUMBER) Participants = 37,,
NCT00100932,"Phase II Study Of E7389, Halichondrin B Analogue, In Patients With Advanced Non-Small Cell Lung Cancer, NSCLC, Who Progressed During Or After Platinum","Phase II Study of E7389, a Halichondrin B Analog, in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC), Who Progressed During or After Platinum-Based Doublet Chemotherapy Stratified for Prior ",Eisai Inc.,Eisai Inc.,INDUSTRY,COMPLETED,2004-12,2008-06,,INTERVENTIONAL,PHASE2,,,,Non-Small-Cell Lung Carcinoma,Non-Small-Cell Lung Carcinoma,1,2,2,DRUG,,,1,3,True,Yes,Overall Objective Response Rate (ORR) (NUMBER) percentage of participants = 11.7,Duration of Response (MEDIAN) Days = 171 [50-291]; Progression Free Survival (MEDIAN) Days = 106 [1-408]; ,,,,,Duration of Response (MEDIAN) Days = 171 [50-291],,,Overall Objective Response Rate (ORR) (NUMBER) percentage of participants = 11.7,,Progression Free Survival (MEDIAN) Days = 106 [1-408],,,Overall Objective Response Rate (ORR) (NUMBER) percentage of participants = 11.7,,,
NCT00102804,Pemetrexed and Best Supportive Care Versus Placebo and Best Supportive Care in Non-Small Cell Lung Cancer (NSCLC),"A Phase 3, Double-Blind, Placebo-Controlled Study of Maintenance Pemetrexed Plus Best Supportive Care Versus Best Supportive Care Immediately Following Induction Treatment for Advanced Non-Small Cell ",Eli Lilly and Company,Eli Lilly and Company,INDUSTRY,COMPLETED,2005-03,2007-08,2013-12,INTERVENTIONAL,PHASE3,,,,Non-Small Cell Lung Cancer,Non-Small Cell Lung Cancer,1,2,3,DRUG; OTHER,,,1,6,True,Yes,Progression-Free Survival (PFS) Time (MEDIAN) months = 4.27 [4.07-4.73],Overall Survival (OS) Time (MEDIAN) months = 13.37 [11.93-15.87]; Time to Objective Progressive Disease (TPD) (MEDIAN) months = 4.27 [4.11-4.73]; Time to Worsening of Symptoms (TWS) (MEDIAN) months = 3.78 [2.86-4.44]; Percentage of Participants With a Complete Response (CR) or Partial Response (PR) (Objective Tumor Response Rate) (NUMBER) percentage of participants = 6.8 [5-10]; Number of Participants With Adverse Events (AEs) (NUMBER) participants = 83; Maximum Improvement Over Baseline in Individual Symptom Scores and Quality of Life Using the LCSS (MEAN) units on a scale = 7.3,,Percentage of Participants With a Complete Response (CR) or Partial Response (PR) (Objective Tumor Response Rate) (NUMBER) percentage of participants = 6.8 [5-10],,,,,,,Overall Survival (OS) Time (MEDIAN) months = 13.37 [11.93-15.87],Progression-Free Survival (PFS) Time (MEDIAN) months = 4.27 [4.07-4.73],Percentage of Participants With a Complete Response (CR) or Partial Response (PR) (Objective Tumor Response Rate) (NUMBER) percentage of participants = 6.8 [5-10],Maximum Improvement Over Baseline in Individual Symptom Scores and Quality of Life Using the LCSS (MEAN) units on a scale = 7.3,Percentage of Participants With a Complete Response (CR) or Partial Response (PR) (Objective Tumor Response Rate) (NUMBER) percentage of participants = 6.8 [5-10],Number of Participants With Adverse Events (AEs) (NUMBER) participants = 83,,
NCT00111839,Effects of Matuzumab in Combination With Pemetrexed for the Treatment of Advanced Lung Cancer,"Randomized, Phase II, Open-Label Controlled Study of Two Different Doses and Schedules of EMD 72000 (Matuzumab) in Combination With Pemetrexed, or Pemetrexed Alone, as Second-Line Treatment for Stage ",EMD Serono,EMD Serono,INDUSTRY,COMPLETED,2005-05-31,2007-07-31,2009-03-31,INTERVENTIONAL,PHASE2,,,,Lung Cancer,Lung Cancer; Non Small Cell Lung Carcinoma,2,3,2,DRUG,,,1,4,True,Yes,Number of Participants With Objective Response Assessed by Independent Review Committee (NUMBER) participants = 2 [1-14],"Overall Survival (OS) (MEDIAN) months = 7.9 [7.2-9.9]; Progression-Free Survival (PFS) (MEDIAN) months = 2.7 [1.6-4.4]; ; Change From Baseline to Cycle 2 in Global Quality of Life (QoL), as Assessed Using Lung Cancer Symptom Scale (LCSS) (MEAN) units on a scale = 35.9",,,,,,,,,Overall Survival (OS) (MEDIAN) months = 7.9 [7.2-9.9],Progression-Free Survival (PFS) (MEDIAN) months = 2.7 [1.6-4.4],,"Change From Baseline to Cycle 2 in Global Quality of Life (QoL), as Assessed Using Lung Cancer Symptom Scale (LCSS) (MEAN) units on a scale = 35.9",,,,
NCT00112294,Study of Taxane/Carboplatin +/- Cetuximab as First-Line Treatment for Patients With Advanced/Metastatic Non-Small Cell Lung Cancer,A Randomized Multicenter Phase III Study of Taxane/Carboplatin/Cetuximab Versus Taxane/Carboplatin as First-Line Treatment for Patients With Advanced/Metastatic Non-Small Cell Lung Cancer,Eli Lilly and Company,Eli Lilly and Company,INDUSTRY,COMPLETED,2004-12,2007-04,2008-08,INTERVENTIONAL,PHASE3,,,,Non-Small-Cell Lung Carcinoma,Non-Small-Cell Lung Carcinoma,1,2,4,DRUG,,,1,15,True,Yes,Median Number of Months of Progression-free Survival (PFS) (MEDIAN) Months = 4.40 [4.11-5.06],"Number of Participants With Complete Response (CR) or Partial Response (PR) (NUMBER) Participants = 87; Number of Participants With Complete Response (CR), Partial Response (PR) or Stable Disease (SD) (NUMBER) Participants = 230; Median Number of Months of Response (MEDIAN) Months = 5.55 [4.40-6.83]; Median Number of Months to Response (MEDIAN) Months = 1.38 [1.08-12.65]; Median Number of Months of Survival (MEDIAN) Months = 9.69 [8.28-11.50]; Number of Participants With Improvement of Symptoms (NUMBER) Participants = 107; ; Number of Participants Who Died, or Experienced Other Serious Adverse Events (SAEs) and Adverse Events (AEs) (NUMBER) Participants = 38; Number of Participants Experiencing AEs Leading to Study Drug Discontinuation (NUMBER) participants = 100; Number of Participants Experiencing Other Significant AEs: Acneform Rash (NUMBER) Participants = 246; Number of Participants Experiencing Other Significant AEs: Infusion Reaction (NUMBER) Participants = 45; Number of Participants Experiencing Other Significant AEs: Cardiac AEs (NUMBER) Participants = 58; Number of Participants Who Exprienced the Most Frequent Grade 3-4 Hematology Abnormalities Occurring in >=5% Participants (NUMBER) Participants = 198; Number of Participants Who Experienced the Most Frequent Grade 3-4 Serum Chemistry Abnormalities Occurring in >=5% Participants (NUMBER) Participants = 33; ",,"Number of Participants With Complete Response (CR) or Partial Response (PR) (NUMBER) Participants = 87; Number of Participants With Complete Response (CR), Partial Response (PR) or Stable Disease (SD) (NUMBER) Participants = 230",,,,,,,,Median Number of Months of Progression-free Survival (PFS) (MEDIAN) Months = 4.40 [4.11-5.06],"Number of Participants With Complete Response (CR) or Partial Response (PR) (NUMBER) Participants = 87; Number of Participants With Complete Response (CR), Partial Response (PR) or Stable Disease (SD) (NUMBER) Participants = 230",,,"Number of Participants Who Died, or Experienced Other Serious Adverse Events (SAEs) and Adverse Events (AEs) (NUMBER) Participants = 38; Number of Participants Experiencing AEs Leading to Study Drug Discontinuation (NUMBER) participants = 100",,
NCT00113516,A Study Of SU011248 As Therapy In Patients With Locally Advanced Or Metastatic Non-Small Cell Lung Cancer,Phase 2 Study Of SU011248 As Consolidation Therapy In Patients With Locally Advanced Or Metastatic Non-Small Cell Lung Cancer,Pfizer,Pfizer,INDUSTRY,COMPLETED,2005-09,2009-03,2009-03,INTERVENTIONAL,PHASE2,,,,Non-small Cell Lung Cancer,Non-small Cell Lung Cancer,1,1,3,DRUG,,,1,36,True,Yes,Proportion of Subjects Surviving at One Year (NUMBER) proportion = 0.405,Progression-free Survival (PFS) (MEDIAN) weeks = 23.1 [21.4-28.2]; Time to Tumor Progression (TTP) (MEDIAN) weeks = 23.6 [22.6-29.3]; Duration of Response (DR) (MEDIAN) weeks = 27.3 [16.3-40.1]; Number of Subjects With Overall Confirmed Objective Disease Response (NUMBER) participants = 23; Overall Survival (OS) (MEDIAN) months = 10.4 [8.1-12.2]; Trough Plasma Concentration (Ctrough) of Sunitinib (MEAN) nanograms (ng)/milliliter (mL) = 57.69; Ctrough of SU-012662 (Sunitinib's Metabolite) (MEAN) ng/mL = 27.54; Ctrough of Total Drug (Sunitinib + SU-012662) (MEAN) ng/mL = 85.23; Dose-Corrected Ctrough of Sunitinib (MEAN) ng/mL = 64.10; Dose-Corrected Ctrough of SU-012662 (Sunitinib's Metabolite) (MEAN) ng/mL = 27.90; Dose-Corrected Ctrough of Total Drug (Sunitinib + SU-012662) (MEAN) ng/mL = 92.00; Vascular Endothelial Growth Factor Receptor 3 (VEGFR3) Concentration at Baseline (MEAN) picograms (pg)/milliliter (mL) = 30382.83; VEGFR3 Ratio to Baseline at Each Time Point (MEAN) ratio = 0.39; VEGF-C Concentration at Baseline (MEAN) pg/mL = 793.19; VEGF-C Ratio to Baseline at Each Time Point (MEAN) ratio = 0.81; Soluble E-Selectin at Baseline (MEAN) nanograms (ng)/mL = 27.06; Soluble E-Selectin Ratio to Baseline at Each Time Point (MEAN) ratio = 0.83; VEGFR3 at Baseline Stratified by Tumor Response (CR or PR or [SD > = 6 Weeks] or PD) (NUMBER) pg/mL = 21660.00; VEGFR3 Ratio to Baseline at Each Time Point Stratified by Tumor Response (CR or PR or [SD > = 6 Weeks] or PD) (NUMBER) ratio = 0.34; VEGF-C at Baseline Stratified by Tumor Response (CR or PR or [SD > = 6 Weeks] or PD) (NUMBER) pg/mL = 704.80; VEGF-C Ratio to Baseline at Each Time Point Stratified by Tumor Response (CR or PR or [SD > = 6 Weeks] or PD) (NUMBER) ratio = 0.73; Soluble E-Selectin at Baseline Stratified by Tumor Response (CR or PR or [SD > = 6 Weeks] or PD) (NUMBER) pg/mL = 26.40; Soluble E-Selectin Ratio to Baseline at Each Time Point Stratified by Tumor Response (CR or PR or [SD > = 6 Weeks] or PD) (NUMBER) ratio = 0.84; Comparison of Kaplan-Meier PFS Curves After Stratification by < or > = Median Levels of VEGFR3 at Baseline and Changes From Baseline (MEDIAN) weeks = 13.1 [10.11-32.91]; Comparison of Kaplan-Meier PFS Curves After Stratification by < or > = Median Levels of VEGF-C at Baseline and Changes From Baseline (MEDIAN) weeks = 16.1 [10.97-32.91]; Comparison of Kaplan-Meier PFS Curves After Stratification by < or > = Median Levels of Soluble E-Selectin at Baseline and Changes From Baseline (MEDIAN) weeks = 11.1 [9.12-22.51]; Comparison of Kaplan-Meier TTP Curves After Stratification by < or > = Median Levels of VEGFR3 at Baseline and Changes From Baseline (MEDIAN) weeks = 15.8 [10.83-32.91]; Comparison of Kaplan-Meier TTP Curves After Stratification by < or > = Median Levels of VEGF-C at Baseline and Changes From Baseline (MEDIAN) weeks = 16.1 [10.97-32.91]; Comparison of Kaplan-Meier TTP Curves After Stratification by < or > = Median Levels of Soluble E-Selectin at Baseline Changes From Baseline (MEDIAN) weeks = 11.1 [9.97-43.30]; Comparison of Kaplan-Meier OS Curves After Stratification by < or > = Median Levels of VEGFR3 at Baseline Changes From Baseline (MEDIAN) months = 8.7 [6.55-20.53]; Comparison of Kaplan-Meier OS Curves After Stratification by < or > = Median Levels of VEGF-C at Baseline and Changes From Baseline (MEDIAN) months = 8.5 [6.32-15.76]; Comparison of Kaplan-Meier OS Curves After Stratification by < or > = Median Levels of Soluble E-Selectin at Baseline and Changes From Baseline (MEDIAN) months = 6.5 [4.24-12.66]; ; ; Change From Baseline in Health Related Quality of Life (HRQOL) and Lung Cancer Related Symptoms as Assessed With the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (EORTC QLQ-C30) (MEAN) scores on a scale = -1.54; Change From Baseline in HRQOL and Lung Cancer Related Symptoms as Assessed With the EORTC QLQ Lung Cancer Module (QLQ-LC13) (MEAN) scores on a scale = 3.40,,,,,Duration of Response (DR) (MEDIAN) weeks = 27.3 [16.3-40.1],,,,Overall Survival (OS) (MEDIAN) months = 10.4 [8.1-12.2]; Comparison of Kaplan-Meier OS Curves After Stratification by < or > = Median Levels of VEGFR3 at Baseline Changes From Baseline (MEDIAN) months = 8.7 [6.55-20.53]; Comparison of Kaplan-Meier OS Curves After Stratification by < or > = Median Levels of VEGF-C at Baseline and Changes From Baseline (MEDIAN) months = 8.5 [6.32-15.76]; Comparison of Kaplan-Meier OS Curves After Stratification by < or > = Median Levels of Soluble E-Selectin at Baseline and Changes From Baseline (MEDIAN) months = 6.5 [4.24-12.66],Progression-free Survival (PFS) (MEDIAN) weeks = 23.1 [21.4-28.2]; Comparison of Kaplan-Meier PFS Curves After Stratification by < or > = Median Levels of VEGFR3 at Baseline and Changes From Baseline (MEDIAN) weeks = 13.1 [10.11-32.91]; Comparison of Kaplan-Meier PFS Curves After Stratification by < or > = Median Levels of VEGF-C at Baseline and Changes From Baseline (MEDIAN) weeks = 16.1 [10.97-32.91]; Comparison of Kaplan-Meier PFS Curves After Stratification by < or > = Median Levels of Soluble E-Selectin at Baseline and Changes From Baseline (MEDIAN) weeks = 11.1 [9.12-22.51],VEGFR3 at Baseline Stratified by Tumor Response (CR or PR or [SD > = 6 Weeks] or PD) (NUMBER) pg/mL = 21660.00; VEGFR3 Ratio to Baseline at Each Time Point Stratified by Tumor Response (CR or PR or [SD > = 6 Weeks] or PD) (NUMBER) ratio = 0.34; VEGF-C at Baseline Stratified by Tumor Response (CR or PR or [SD > = 6 Weeks] or PD) (NUMBER) pg/mL = 704.80; VEGF-C Ratio to Baseline at Each Time Point Stratified by Tumor Response (CR or PR or [SD > = 6 Weeks] or PD) (NUMBER) ratio = 0.73; Soluble E-Selectin at Baseline Stratified by Tumor Response (CR or PR or [SD > = 6 Weeks] or PD) (NUMBER) pg/mL = 26.40; Soluble E-Selectin Ratio to Baseline at Each Time Point Stratified by Tumor Response (CR or PR or [SD > = 6 Weeks] or PD) (NUMBER) ratio = 0.84,Change From Baseline in Health Related Quality of Life (HRQOL) and Lung Cancer Related Symptoms as Assessed With the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (EORTC QLQ-C30) (MEAN) scores on a scale = -1.54; Change From Baseline in HRQOL and Lung Cancer Related Symptoms as Assessed With the EORTC QLQ Lung Cancer Module (QLQ-LC13) (MEAN) scores on a scale = 3.40,,,,Comparison of Kaplan-Meier TTP Curves After Stratification by < or > = Median Levels of VEGFR3 at Baseline and Changes From Baseline (MEDIAN) weeks = 15.8 [10.83-32.91]; Comparison of Kaplan-Meier TTP Curves After Stratification by < or > = Median Levels of VEGF-C at Baseline and Changes From Baseline (MEDIAN) weeks = 16.1 [10.97-32.91]; Comparison of Kaplan-Meier TTP Curves After Stratification by < or > = Median Levels of Soluble E-Selectin at Baseline Changes From Baseline (MEDIAN) weeks = 11.1 [9.97-43.30]
NCT00118144,Bortezomib in Treating Patients With Stage IIIB or Stage IV Lung Cancer,Phase II Study of Bortezomib (PS-341) for Patients With Advanced Bronchiolo-Alveolar Carcinoma (BAC) or Adenocarcinoma With BAC Features,National Cancer Institute (NCI),National Cancer Institute (NCI),NIH,COMPLETED,2005-06,2010-12,2010-12,INTERVENTIONAL,PHASE2,,,,Adenocarcinoma of the Lung,Adenocarcinoma of the Lung; Bronchoalveolar Cell Lung Cancer; Non-small Cell Lung Cancer,6,1,1,DRUG,,,1,2,True,Yes,Objective Response Rate With Bortezomib Evaluated by Both RECIST Criteria and Computer-assisted Image Analysis. (NUMBER) percentage of responders = 5,Progression-free Survival (MEDIAN) Months = 5.5 [2.1-6.4]; Overall Survival (MEAN) Months = 13.6,,,,,,,,Objective Response Rate With Bortezomib Evaluated by Both RECIST Criteria and Computer-assisted Image Analysis. (NUMBER) percentage of responders = 5,Overall Survival (MEAN) Months = 13.6,Progression-free Survival (MEDIAN) Months = 5.5 [2.1-6.4],,,Objective Response Rate With Bortezomib Evaluated by Both RECIST Criteria and Computer-assisted Image Analysis. (NUMBER) percentage of responders = 5,,,
NCT00130728,A Study to Evaluate the Efficacy of Bevacizumab in Combination With Tarceva for Advanced Non-Small Cell Lung Cancer,"A Phase III, Multicenter, Placebo-Controlled, Double-Blind, Randomized Clinical Trial to Evaluate the Efficacy of Bevacizumab in Combination With Tarceva (Erlotinib) Compared With Tarceva Alone for Tr","Genentech, Inc.","Genentech, Inc.",INDUSTRY,COMPLETED,2005-06-08,2008-07-15,2019-12-23,INTERVENTIONAL,PHASE3,,,,Non-Small Cell Lung Cancer,Non-Small Cell Lung Cancer,1,2,3,DRUG,,,1,3,True,Yes,Overall Survival (OS) Among All Randomized Patients (MEDIAN) months = 9.3 [7.39-11.47],Progression-free Survival (PFS) (MEDIAN) months = 3.4 [2.79-4.27]; Percentage of Participants With Objective Response (NUMBER) Percentage of participants = 12.6 [9.1-16.8]; Duration of Objective Response (MEDIAN) months = 9.7 [6.90-19.48],,,,,,,,,Overall Survival (OS) Among All Randomized Patients (MEDIAN) months = 9.3 [7.39-11.47],Progression-free Survival (PFS) (MEDIAN) months = 3.4 [2.79-4.27],,,,,,
NCT00137839,Erlotinib in Women With Previously Untreated Adenocarcinoma of the Lung,A Phase II Study of Erlotinib (OSI-774); Tarceva in Women With Previously Untreated Advance Adenocarcinoma of the Lung,Dana-Farber Cancer Institute,"Pasi A. Janne, MD, PhD",OTHER,COMPLETED,2004-11,2008-11,2019-07,INTERVENTIONAL,PHASE2,,,,Adenocarcinoma,Adenocarcinoma; Non-small Cell Lung Cancer,2,1,1,DRUG,,,1,3,True,Yes,Overall Response Rate (ORR) (NUMBER) percentage of participants = 27.7 [18.5-38.7],Overall Response Rate (ORR) by EGFR Mutation Status (NUMBER) percentage of participants = 56.4 [39.6-72.2]; Overall Survival (OS) (MEDIAN) months = 22.9 [15.7-26.5]; Overall Survival by EGFR Mutation Status (MEDIAN) months = 32.6 [24.4-44.0],,,,,,,,,Overall Survival (OS) (MEDIAN) months = 22.9 [15.7-26.5]; Overall Survival by EGFR Mutation Status (MEDIAN) months = 32.6 [24.4-44.0],,,,Overall Response Rate (ORR) (NUMBER) percentage of participants = 27.7 [18.5-38.7]; Overall Response Rate (ORR) by EGFR Mutation Status (NUMBER) percentage of participants = 56.4 [39.6-72.2],,,
NCT00138203,"Suberoylanilide Hydroxamic Acid in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer",A Phase II Study of Suberoylanilide Hydroxamic Acid (SAHA) in Patients With Relapsed Non-small Cell Lung Cancer,National Cancer Institute (NCI),National Cancer Institute (NCI),NIH,COMPLETED,2005-06,2008-12,2008-12,INTERVENTIONAL,PHASE2,,,,Recurrent Non-small Cell Lung Cancer,Recurrent Non-small Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer,3,1,2,DRUG; OTHER,,,1,3,True,Yes,Response Per RECIST Criteria (NUMBER) participants = 0,Time to Progression (MEDIAN) months = 2.3 [.9-19.4]; Overall Survial (MEDIAN) months = 7.1 [1.4-30]; Toxicity (COUNT_OF_PARTICIPANTS) Participants = 16,,,,,,,,,,,,,,Toxicity (COUNT_OF_PARTICIPANTS) Participants = 16,,Time to Progression (MEDIAN) months = 2.3 [.9-19.4]
NCT00138658,A Study of OGX-011/Gemcitabine/Platinum-Based Regimen in Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC),A Phase 1-2 Study of Weekly OGX-011 Plus a Gemcitabine/Platinum-Based Regimen in Patients With Stage IIIB or IV Non Small Cell Lung Cancer,Achieve Life Sciences,Achieve Life Sciences,INDUSTRY,COMPLETED,2004-11,2010-03,2010-03,INTERVENTIONAL,PHASE1; PHASE2,,,,Non-small Cell Lung Cancer,Non-small Cell Lung Cancer,1,0,1,DRUG,,,1,6,True,Yes,Objective Response Rate of OGX-011 in Combination With Gemcitabine/Platinum-based Regimen (NUMBER) percentage of participants = 26,Progression-free Survival (MEDIAN) months = 4.3 [3.0-5.3]; Overall Survival (MEDIAN) months = 14.1 [9.4-17.5]; Effect of OGX-011 on Serum Clusterin Levels (MEAN) µg/mL = -25.5; Cmax of OGX-011 (MEAN) ng/mL = 64086; t1/2 of OGX-011 (MEAN) hours = 3.7; AUC-0-last (MEAN) ng*h/mL = 260747,,,,,,,,Objective Response Rate of OGX-011 in Combination With Gemcitabine/Platinum-based Regimen (NUMBER) percentage of participants = 26,Overall Survival (MEDIAN) months = 14.1 [9.4-17.5],Progression-free Survival (MEDIAN) months = 4.3 [3.0-5.3],,,Objective Response Rate of OGX-011 in Combination With Gemcitabine/Platinum-based Regimen (NUMBER) percentage of participants = 26,,,
NCT00148798,Study of Cisplatin/Vinorelbine +/- Cetuximab as First-line Treatment of Advanced Non Small Cell Lung Cancer (FLEX),"Open, Randomized, Controlled, Multicenter Phase III Study Comparing Cisplatin/Vinorelbine Plus Cetuximab Versus Cisplatin/Vinorelbine as First-line Treatment for Patients With Epidermal Growth Factor ","Merck KGaA, Darmstadt, Germany","Merck KGaA, Darmstadt, Germany",INDUSTRY,COMPLETED,2004-10,2007-07,2012-05,INTERVENTIONAL,PHASE3,,,,Non Small Cell Lung Cancer (NSCLC),Non Small Cell Lung Cancer (NSCLC),1,2,2,DRUG,,,1,7,True,Yes,Overall Survival Time (OS) (MEDIAN) months = 11.3 [9.4-12.4],Progression-free Survival Time (MEDIAN) months = 4.8 [4.2-5.3]; Best Overall Response Rate (NUMBER) percentage of participants = 36.4 [32.4-40.6]; Disease Control Rate (NUMBER) percentage of participants = 72.5 [68.6-76.2]; Quality of Life (QOL) Assessment European Organisation for the Research and Treatment of Cancer (EORTC) QLQ-C30 Global Health Status (LEAST_SQUARES_MEAN) scores on a scale = 45.72; Quality of Life Assessment (EORTC QLQ-C30) Social Functioning (LEAST_SQUARES_MEAN) scores on a scale = 66.17; A Population Pharmacokinetic (PK) Analysis for Cetuximab in Non-Small Cell Lung Cancer (NSCLC) - Serum Cetuximab Concentrations (MEAN) ug/mL = 223.1; Safety - Number of Patients Experiencing Any Adverse Event (NUMBER) participants = 545,,,,,,,,,Overall Survival Time (OS) (MEDIAN) months = 11.3 [9.4-12.4],Progression-free Survival Time (MEDIAN) months = 4.8 [4.2-5.3],,Quality of Life (QOL) Assessment European Organisation for the Research and Treatment of Cancer (EORTC) QLQ-C30 Global Health Status (LEAST_SQUARES_MEAN) scores on a scale = 45.72; Quality of Life Assessment (EORTC QLQ-C30) Social Functioning (LEAST_SQUARES_MEAN) scores on a scale = 66.17,Best Overall Response Rate (NUMBER) percentage of participants = 36.4 [32.4-40.6],Safety - Number of Patients Experiencing Any Adverse Event (NUMBER) participants = 545,,
NCT00152477,A Study of Paclitaxel/Carboplatin With or Without CDP791 in Patients With Lung Cancer,"A Two-Part, Open Label Phase II Trial: Part One, Dose Escalation Safety; Part Two, Randomized/Comparing CDP791 Plus Carboplatin/Paclitaxel With Carboplatin/Paclitaxel Alone in Subjects With Locally Ad",UCB Pharma,UCB Pharma,INDUSTRY,COMPLETED,2005-08-15,2009-06-25,2009-06-25,INTERVENTIONAL,PHASE2,,,,Carcinoma,Carcinoma; Non-Squamous Non-Small-Cell Lung Cancer,2,3,4,DRUG,,,1,5,True,Yes,Tumor Response Rate (RR) (NUMBER) percentage of participants = 0,Progression Free Survival (PFS) (MEDIAN) weeks = 24.14 [20.29-29.29]; Time to Treatment Failure (MEDIAN) weeks = 13.21 [6.86-20.29]; Overall Survival (MEDIAN) weeks = 36.14 [27.14-64.14]; Duration of Overall Response (MEDIAN) weeks = 21.14; Time to Response (MEDIAN) weeks = 8.57 [8.14-17.43],,,,,,,,,Overall Survival (MEDIAN) weeks = 36.14 [27.14-64.14],Progression Free Survival (PFS) (MEDIAN) weeks = 24.14 [20.29-29.29],,,Tumor Response Rate (RR) (NUMBER) percentage of participants = 0,,Time to Treatment Failure (MEDIAN) weeks = 13.21 [6.86-20.29],
NCT00153803,Erlotinib or Placebo Following Chemoradiotherapy (Chemo/RT) in Stage III Non-Small Cell Lung Cancer (NSCLC),"A National Web-Based Randomized Phase III Study of Erlotinib or Placebo Following Concurrent Docetaxel, Carboplatin, and Thoracic Radiotherapy in Patients With Inoperable Stage III Non-Small Cell Lung",Dartmouth-Hitchcock Medical Center,Dartmouth-Hitchcock Medical Center,OTHER,COMPLETED,2005-05,2014-04,2014-04,INTERVENTIONAL,PHASE3,,,,"Carcinoma, Non-Small-Cell Lung","Carcinoma, Non-Small-Cell Lung; Non-small Cell Lung Cancer; NSCLC",3,2,2,DRUG,,,1,4,True,Yes,Progression Free Survival (MEDIAN) Months = 7.4,"Overall Survival (MEDIAN) Months = 16.5; Percent of Participants Surviving 3 Years (NUMBER) percentage of participants = 37; Serious Adverse Event Profile Relating to Death, Disability, Life-threatening, Hospitalization, and Impairment/Damage for Concurrent Chemoradiation (COUNT_OF_PARTICIPANTS) Participants = 7; Serious Adverse Event Profile Relating to Death, Disability, Life-threatening, Hospitalization, and Impairment/Damage for Erlotinib and Placebo (COUNT_OF_PARTICIPANTS) Participants = 10",,,,,,,,,Overall Survival (MEDIAN) Months = 16.5,Progression Free Survival (MEDIAN) Months = 7.4,,,,,,
NCT00172042,A Study to Evaluate the Safety and Efficacy of Zoledronic Acid in the Prevention or Delaying of Bone Metastasis in Patients With Stage IIIA and IIIB N,A Study to Evaluate the Safety and Efficacy of Zoledronic Acid in the Prevention or Delaying of Bone Metastasis in Patients With Stage IIIA and IIIB Non-small Cell Lung Cancer,Novartis,Novartis Pharmaceuticals,INDUSTRY,COMPLETED,2005-03,2010-05,2010-06,INTERVENTIONAL,PHASE3,,,,Non-Small-Cell Lung Cancer,Non-Small-Cell Lung Cancer,1,2,1,DRUG,,,3,5,True,Yes,Progression-Free Survival (MEDIAN) Months = 9.0 [6.8-12.4]; Kaplan-Meier Estimates for Progression-free Survival (NUMBER) Percentage of participants = 63.0 [56.2-69.0]; Percentage of Participants With Progression-Free Survival Events (NUMBER) Percentage of participants = 60.2,"Percentage of Participants With Bone Metastases at 6, 12, 18, and 24 Months (NUMBER) Percentage of participants = 2.2 [0.4-5.1]; Kaplan-Meier Estimate of the Time to Occurrence of Bone Metastases (NUMBER) Percentage of participants = 2.7 [0.4-5.1]; Percentage of Participants With Skeletal Related Events (SREs) at 12 and 24 Months From Study Entry (NUMBER) Percentage of participants = 2.2; Kaplan-Meier Estimates of the Time to the First Skeletal Related Event (SRE) (NUMBER) Percentage of participants = 1.0 [0.0-2.3]; Kaplan-Meier Estimates for Overall Survival (NUMBER) Percentage of participants = 92.8 [88.4-95.5]",,,,,,,,,Kaplan-Meier Estimates for Overall Survival (NUMBER) Percentage of participants = 92.8 [88.4-95.5],Progression-Free Survival (MEDIAN) Months = 9.0 [6.8-12.4]; Kaplan-Meier Estimates for Progression-free Survival (NUMBER) Percentage of participants = 63.0 [56.2-69.0]; Percentage of Participants With Progression-Free Survival Events (NUMBER) Percentage of participants = 60.2,,,,,,
NCT00191139,"Gemcitabine or Gemcitabine Plus Docetaxel After Cisplatin, Etoposide and Radiation in Non Small Cell Lung Cancer (NSCLC)","A Randomized Study of Gemcitabine Plus Docetaxel After Cisplatin, Etoposide and Radiation Therapy in Stage III Unresectable NSCLC",Eli Lilly and Company,Eli Lilly and Company,INDUSTRY,COMPLETED,2003-03,2008-11,2009-02,INTERVENTIONAL,PHASE2,,,,Non-small Cell Lung Cancer,Non-small Cell Lung Cancer,1,2,5,DRUG; RADIATION,,,1,4,True,Yes,2-Year Survival (NUMBER) percentage of participants = 40.6,Number of Patients With Overall Tumor Response (NUMBER) participants = 24; Progression-Free Survival (MEDIAN) days = 162.5 [82.0-239.0]; Overall Survival (MEDIAN) days = 492.5 [299.0-1034.0]; Lung Cancer Symptom Scale (LCSS) Assessment Post-randomization (NUMBER) participants = 8,,,,,,,,,Overall Survival (MEDIAN) days = 492.5 [299.0-1034.0],Progression-Free Survival (MEDIAN) days = 162.5 [82.0-239.0],,,,,,
NCT00191191,To Investigate Efficacy and Safety of Pemetrexed as Second or Third Line Therapy in Patients With Non-small Cell Lung Cancer (NSCLC),LY231514 500 mg/m2 and LY231514 1000 mg/m2 in Patients With Advanced Non-Small Cell Lung Cancer Who Were Previously Treated With Prior Systemic Anti Cancer Therapy: A Randomized Phase II Trial,Eli Lilly and Company,Eli Lilly and Company,INDUSTRY,COMPLETED,2004-10,2008-10,2008-10,INTERVENTIONAL,PHASE2,,,,Non-small Cell Lung Cancer,Non-small Cell Lung Cancer,1,2,2,DRUG,,,1,4,True,Yes,Best Overall Response (NUMBER) participants = 0,Duration of Response (MEDIAN) months = 4.9 [3.8-8.7]; Progression-Free Survival (PFS) (MEDIAN) months = 3.0 [2.0-3.5]; Change From Baseline to 3 Months in Quality of Life Questionnaire for Cancer Patients Treated With Anticancer Drugs (QOL-ACD) (MEAN) units on a scale = 77.0; Change From Baseline to 3 Months in Functional Assessment of Cancer Therapy for Lung Cancer (FACT-L) Lung Cancer Subscale (LCS) (MEAN) units on a scale = 71.5,,,,,Duration of Response (MEDIAN) months = 4.9 [3.8-8.7],,,,,Progression-Free Survival (PFS) (MEDIAN) months = 3.0 [2.0-3.5],,Change From Baseline to 3 Months in Quality of Life Questionnaire for Cancer Patients Treated With Anticancer Drugs (QOL-ACD) (MEAN) units on a scale = 77.0,,,,
NCT00191308,Molecular Profiling in Lung Cancer Patients,Molecular Profiling and Safety Study of Operable Lung Cancer Patients Treated With Alimta Combined With Cisplatin as Neoadjuvant Chemotherapy,Eli Lilly and Company,Eli Lilly and Company,INDUSTRY,COMPLETED,2005-05,2008-07,2010-12,INTERVENTIONAL,PHASE2,,,,Non-Small Cell Lung Cancer,Non-Small Cell Lung Cancer; Carcinoma,2,1,3,DRUG; PROCEDURE,,,1,4,True,Yes,,Percentage of Participants With Objective Tumor Response (Response Rate) (NUMBER) percentage of participants = 34.5 [17.9-54.3]; Duration of Response (MEDIAN) months = 42.5; Disease Free Survival (DFS) (MEDIAN) months = 43.7; ,,,Disease Free Survival (DFS) (MEDIAN) months = 43.7,,Duration of Response (MEDIAN) months = 42.5,,,,,,,,Percentage of Participants With Objective Tumor Response (Response Rate) (NUMBER) percentage of participants = 34.5 [17.9-54.3],,,
NCT00192036,Multicenter Phase 2 Trial Evaluating Cisplatin-Gemcitabine With Concomitant Thoracic Radiotherapy for Treatment of Inoperable Stage III Non Small Cell,Multicenter Phase II Trial Evaluating Cisplatin-Gemcitabine With Concomitant Thoracic Radiotherapy for Treatment of Inoperable Stage III Non Small Cell Lung Cancer,Eli Lilly and Company,Eli Lilly and Company,INDUSTRY,COMPLETED,2004-08,2008-01,2009-11,INTERVENTIONAL,PHASE2,,,,Non Small Cell Lung Cancer,Non Small Cell Lung Cancer,1,1,3,DRUG; RADIATION,,,1,4,True,Yes,Tumor Response at End of Treatment (NUMBER) participants = 1,Time to Progressive Disease (MEDIAN) months = 10.9 [0.9-39.2]; Overall Survival (MEDIAN) months = 27.9 [0.9-39.2]; Safety of Induction Chemotherapy (NUMBER) participants = 9; Safety of Chemo-radiotherapy (NUMBER) participants = 6,,,,,,,,,Overall Survival (MEDIAN) months = 27.9 [0.9-39.2],,,,,,,
NCT00201825,A Phase II Study of Capecitabine and Docetaxel in Previously Untreated Advanced Non-Small Cell Lung Cancer Patients,A Phase II Study of Capecitabine and Docetaxel in Previously Untreated Advanced Non-Small Cell Lung Cancer Patients,Ohio State University Comprehensive Cancer Center,Tony Bekaii-Saab,OTHER,COMPLETED,2004-12,2012-12,2013-04,INTERVENTIONAL,PHASE2,,,,Lung Cancer,Lung Cancer; Non-Small-Cell Lung Carcinoma,2,1,2,DRUG,,,1,3,True,Yes,Determine Objective Response Rate (NUMBER) patients = 0,Time to Tumor Progression (MEDIAN) months = 3.3 [1.5-4.6]; One Year Survival (MEDIAN) months = 10.5 [3.2-15]; ,,,,,,,,Determine Objective Response Rate (NUMBER) patients = 0,,,,,Determine Objective Response Rate (NUMBER) patients = 0,,,
NCT00216125,Cisplatin/Etoposide/Radiotherapy +/- Consolidation Docetaxel in Advanced Stage III Non-Small Cell Lung Cancer,A Phase III Trial of Cisplatin/Etoposide/Radiotherapy With or Without Consolidation Docetaxel in Patients With Inoperable Locally Advanced Stage III Non-Small Cell Lung Cancer (NSCLC): Hoosier Oncolog,Hoosier Cancer Research Network,"Nasser Hanna, M.D.",OTHER,COMPLETED,2002-02,2006-06,2008-03,INTERVENTIONAL,PHASE3,,,,Non-Small Cell Lung Cancer,Non-Small Cell Lung Cancer,1,3,4,DRUG; RADIATION,,,1,1,True,Yes,Overall Survival (MEDIAN) Months = 21.5 [17.0-34.8],Progression Free Survival (MEDIAN) months = 12.3 [9.4-16.9],,,,,,,,,Overall Survival (MEDIAN) Months = 21.5 [17.0-34.8],Progression Free Survival (MEDIAN) months = 12.3 [9.4-16.9],,,,,,
NCT00216203,Pemetrexed Plus Cetuximab in Patients With Recurrent Non Small Cell Lung Cancer,A Phase I-IIa Dose-Ranging Study of Pemetrexed (Alimta) Plus Cetuximab (Erbitux) in Patients With Recurrent Non-Small Cell Lung Cancer (NSCLC): Hoosier Oncology Group LUN04-79,Hoosier Cancer Research Network,"Nasser Hanna, M.D.",OTHER,COMPLETED,2005-05,2008-12,2008-12,INTERVENTIONAL,PHASE1; PHASE2,,,,Non-Small Cell Lung Cancer,Non-Small Cell Lung Cancer,1,1,2,DRUG,,,2,3,True,Yes,Maximum Tolerated Dose (MTD) of Pemetrexed in Combination With Cetuximab (NUMBER) mg/m^2 every 21 days = 750; Time To Progression (TTP) (MEDIAN) Weeks = 14.6 [6.0-78.7],Median Survival Time (MEDIAN) weeks = 42.0 [8.6-103.9]; Toxicity and Safety Profile (NUMBER) percentage of particpants = 58.3; ,,,,,,,,,,,,,,Toxicity and Safety Profile (NUMBER) percentage of particpants = 58.3,,Time To Progression (TTP) (MEDIAN) Weeks = 14.6 [6.0-78.7]
NCT00227019,Phase 2 Trial of Bevacizumab in Combination With Pemetrexed,Phase II Trial of Bevacizumab in Combination With Pemetrexed as Second Line Therapy in Patients With Stable Brain Metastases From Non-small Cell Lung Cancer (NSCLC) (Excluding Squamous Cell Carcinoma),Stanford University,Heather Wakelee,OTHER,COMPLETED,2006-03,2010-11,2016-12,INTERVENTIONAL,PHASE2,,,,Non-small Cell Lung Cancer (NSCLC),Non-small Cell Lung Cancer (NSCLC); Lung Cancer; Neoplasm Metastasis,3,1,5,DRUG,,,1,2,True,Yes,Incidence of Central Nervous System (CNS) Hemorrhagic Events (NUMBER) CNS hemorrhagic events = 0,Progression-free Survival (PFS) (MEDIAN) months = 7.2 [5.5-9.0]; Overall Survival (OS) (MEDIAN) months = 14.8 [9.4-21.0],,,,,,,,,Overall Survival (OS) (MEDIAN) months = 14.8 [9.4-21.0],Progression-free Survival (PFS) (MEDIAN) months = 7.2 [5.5-9.0],,,,,,
NCT00231465,Phase II Study of Docetaxel + ZD1839 in Elderly Patients With Non-Small Cell Lung Cancer,Phase II Study of Taxotere® (Docetaxel) + ZD1839 (IRESSA®) in Previously Untreated Elderly Patients (≥70 Years Old) With Stage III-b (With Malignant Pleural Effusion [MPE+]) or Stage IV Non-Small Cell,H. Lee Moffitt Cancer Center and Research Institute,H. Lee Moffitt Cancer Center and Research Institute,OTHER,COMPLETED,2003-07,2012-08,2012-08,INTERVENTIONAL,PHASE2,,,,Non-Small Cell Lung Cancer,Non-Small Cell Lung Cancer,1,1,2,DRUG,,,1,2,True,Yes,Overall Response Rate (ORR) (MEAN) percentage of participants = 40 [26-57],Progression Free Survival (PFS) Rate (MEDIAN) Months = 6.9 [3.95-7.8]; Overall Survival (OS) Rate (MEDIAN) Months = 9.59 [4.6-16.3],,,,,,,,,Overall Survival (OS) Rate (MEDIAN) Months = 9.59 [4.6-16.3],Progression Free Survival (PFS) Rate (MEDIAN) Months = 6.9 [3.95-7.8],,,Overall Response Rate (ORR) (MEAN) percentage of participants = 40 [26-57],,,
NCT00240097,"Study of Sequential Topoisomerase, Irinotecan/Oxaliplatin - Etoposide /Carboplatin in Extensive Small Cell Lung Cancer (SCLC)","Study of Sequential Topoisomerase, Irinotecan/Oxaliplatin-Etoposide/Carboplatin in Extensive SCLC",University of Alabama at Birmingham,University of Alabama at Birmingham,OTHER,COMPLETED,2005-06,2010-06,2010-06,INTERVENTIONAL,PHASE2,,,,Non-Small Cell Lung Cancer,Non-Small Cell Lung Cancer,1,2,2,DRUG,,,2,2,True,Yes,Objective Response Rate (Part I) (NUMBER) Participants = 4; ,Progression Free Survival (Part I) (MEDIAN) months = 8.95 [6.5-9.8]; Overall Survival (Part I) (MEDIAN) months = 12.9 [10.2-15.5],,,,,,,,Objective Response Rate (Part I) (NUMBER) Participants = 4,Overall Survival (Part I) (MEDIAN) months = 12.9 [10.2-15.5],Progression Free Survival (Part I) (MEDIAN) months = 8.95 [6.5-9.8],,,Objective Response Rate (Part I) (NUMBER) Participants = 4,,,
NCT00243867,Taxoprexin Plus Carboplatin Treatment for Advanced Lung Cancer,"A Phase III, Randomized, Study of Weekly Taxoprexin Plus Carboplatin Versus Paclitaxel Plus Carboplatin as First Line Chemotherapy in Patients With Advanced Non-Small Cell Lung Cancer","American Regent, Inc.","American Regent, Inc.",INDUSTRY,COMPLETED,2005-11,2008-08,2008-08,INTERVENTIONAL,PHASE3,,,,Non-Small Cell Lung Cancer,Non-Small Cell Lung Cancer,1,2,3,DRUG,,,1,4,True,Yes,Overall Survival (MEDIAN) Months = 8.31 [7.0-9.89],Percentage of Participants Who Achieved an Objective Complete Response or Partial Response (COUNT_OF_PARTICIPANTS) Participants = 40; Duration of Response (MEDIAN) Months = 5.75 [5.09-8.54]; Time to Progression (TTP) (MEDIAN) Months = 3.02 [2.66-4.01]; Time to Treatment Failure (TTF) (MEDIAN) Months = 2.79 [2.10-3.02],,Percentage of Participants Who Achieved an Objective Complete Response or Partial Response (COUNT_OF_PARTICIPANTS) Participants = 40,,,Duration of Response (MEDIAN) Months = 5.75 [5.09-8.54],,,,Overall Survival (MEDIAN) Months = 8.31 [7.0-9.89],,Percentage of Participants Who Achieved an Objective Complete Response or Partial Response (COUNT_OF_PARTICIPANTS) Participants = 40,,,,Time to Treatment Failure (TTF) (MEDIAN) Months = 2.79 [2.10-3.02],Time to Progression (TTP) (MEDIAN) Months = 3.02 [2.66-4.01]
NCT00245063,AZD2171 in Treating Patients With Recurrent Small Cell Lung Cancer,Phase II Study of AZD2171 in Patients With Recurrent Small Cell Lung Cancer,National Cancer Institute (NCI),National Cancer Institute (NCI),NIH,COMPLETED,2006-03,2010-03,2010-03,INTERVENTIONAL,PHASE2,,,,Recurrent Non-small Cell Lung Cancer,Recurrent Non-small Cell Lung Cancer,1,1,3,DRUG; OTHER,,,1,0,True,Yes,Objective Response Rate (NUMBER) percentage of responding patients = 0,,,,,,,,,Objective Response Rate (NUMBER) percentage of responding patients = 0,,,,,Objective Response Rate (NUMBER) percentage of responding patients = 0,,,
NCT00247416,Effects of Carboplatin and Gemcitabine on Stage IIIB Pleural Effusion and Stage IV Lung Cancer,Randomized Phase II Trail of Carboplatin and Gemcitabine Untreated Stage IIIB-pleural Effusion and Stage IV Lung Cancer,University of Kentucky,Susanne Arnold,OTHER,COMPLETED,2005-08,2009-07,2009-07,INTERVENTIONAL,PHASE2,,,,Stage IV Non-small Cell Lung Cancer,Stage IV Non-small Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer,2,2,3,DRUG,,,1,3,True,Yes,Percentage of Participants With Reduction in Grade 3/4 Neutropenia (NUMBER) percentage of participants = 40,Effect of Dexamethasone Pre-treatment on Response Rate. (NUMBER) percentage of responders out of total = 8 [0.1-26.0]; Effect of Dexamethasone Pre-treatment on Overall Survival. (MEDIAN) days = 291 [228-437]; Progression-free Survival (MEDIAN) days = 101 [60-172],,,,,,,,,Effect of Dexamethasone Pre-treatment on Overall Survival. (MEDIAN) days = 291 [228-437],Progression-free Survival (MEDIAN) days = 101 [60-172],,,Effect of Dexamethasone Pre-treatment on Response Rate. (NUMBER) percentage of responders out of total = 8 [0.1-26.0],,,
NCT00257608,A Study Comparing Bevacizumab Therapy With or Without Erlotinib for First-Line Treatment of Non-Small Cell Lung Cancer (ATLAS),"A Randomized, Double-Blind, Placebo-Controlled, Phase IIIb Trial Comparing Bevacizumab Therapy With or Without Erlotinib After Completion of Chemotherapy With Bevacizumab for the First-Line Treatment ","Genentech, Inc.","Genentech, Inc.",INDUSTRY,COMPLETED,2006-01,2014-11,2014-11,INTERVENTIONAL,PHASE3,,,,Non-Small Cell Lung Cancer,Non-Small Cell Lung Cancer,1,2,3,DRUG,,,1,6,True,Yes,Progression-free Survival (PFS) (MEDIAN) months = 3.7 [2.86-4.04],Number of Participants With Prospectively Identified Treatment Emergent Adverse Events (TEAE) During Chemotherapy Phase (NUMBER) participants = 6; Number of Participants With Prospectively Identified Treatment Emergent Adverse Events (TEAE) During Post-Chemotherapy Phase (NUMBER) participants = 2; Number of Participants With Any Adverse Events During Post-Chemotherapy Phase (NUMBER) participants = 319; Incidence of Study Treatment Discontinuation for Reasons Other Than Disease Progression in Chemotherapy Phase (NUMBER) participants = 54; Incidence of Study Treatment Discontinuation (NUMBER) participants = 34; Overall Survival (MEDIAN) months = 13.3 [12.12-14.52],,,,,,,,,Overall Survival (MEDIAN) months = 13.3 [12.12-14.52],Progression-free Survival (PFS) (MEDIAN) months = 3.7 [2.86-4.04],,,,Number of Participants With Prospectively Identified Treatment Emergent Adverse Events (TEAE) During Chemotherapy Phase (NUMBER) participants = 6; Number of Participants With Prospectively Identified Treatment Emergent Adverse Events (TEAE) During Post-Chemotherapy Phase (NUMBER) participants = 2; Number of Participants With Any Adverse Events During Post-Chemotherapy Phase (NUMBER) participants = 319,,
NCT00269152,Feasibility Study of Pemetrexed in Combination With Cisplatin or Carboplatin as Adjuvant Treatment of Non-Small Cell Lung Cancer,A Randomized Phase 2 Study of Pemetrexed in Combination With Cisplatin or Carboplatin as Adjuvant Chemotherapy in Patients With Completely Resected Stage Ib or II Non-Small Cell Lung Cancer,Eli Lilly and Company,Eli Lilly and Company,INDUSTRY,COMPLETED,2005-12,2007-11,2013-07,INTERVENTIONAL,PHASE2,,,,Non-Small Cell Lung Cancer,Non-Small Cell Lung Cancer,1,2,3,DRUG,,,1,4,True,Yes,The Feasibility of Post-Surgery Chemotherapy (NUMBER) participants = 38,Grade III/IV Adverse Events (NUMBER) participants = 9; Overall Survival at 3 Years (NUMBER) percent probability of survival (%) = 82.0 [72.4-91.6]; 3 Year Disease-Free Survival: Probability of Disease-Free Survival at 3 Years (NUMBER) probability of disease-free survival (%) = 61.2 [48.3-74.0]; Overall Survival at 6 Years (NUMBER) percent probability of survival (%) = 72.6 [59.3-85.9],,,3 Year Disease-Free Survival: Probability of Disease-Free Survival at 3 Years (NUMBER) probability of disease-free survival (%) = 61.2 [48.3-74.0],,,,,,Overall Survival at 3 Years (NUMBER) percent probability of survival (%) = 82.0 [72.4-91.6]; Overall Survival at 6 Years (NUMBER) percent probability of survival (%) = 72.6 [59.3-85.9],,,,,Grade III/IV Adverse Events (NUMBER) participants = 9,,
NCT00271505,Avastin/Docetaxel/Carboplatin in Non-Small Cell Lung Cancer,A Phase II Evaluation of Avastin in Combination With Docetaxel and Carboplatin as Chemotherapy in Patients With Metastatic Non-Small Cell Lung Cancer,M.D. Anderson Cancer Center,M.D. Anderson Cancer Center,OTHER,COMPLETED,2005-12-05,2017-07-27,2017-07-27,INTERVENTIONAL,PHASE2,,,,Non-Small Cell Lung Cancer,Non-Small Cell Lung Cancer,1,1,3,DRUG,,,1,2,True,Yes,Time to Progression-Free Survival (PFS) (MEDIAN) months = 7.9 [6.0-11.1],Overall Survival (OS)- 5 Years (MEDIAN) months = 16.5 [13.6-31.2]; Disease Control Rate (MEAN) percentage of participants = 95 [88-100],,,,,,,,,Overall Survival (OS)- 5 Years (MEDIAN) months = 16.5 [13.6-31.2],Time to Progression-Free Survival (PFS) (MEDIAN) months = 7.9 [6.0-11.1],,,,,,Time to Progression-Free Survival (PFS) (MEDIAN) months = 7.9 [6.0-11.1]
NCT00290355,Study to Test the Efficacy of the Vaccine GSK 249553 in Treating Non-small-cell Lung Cancer After Tumour Removal by Surgery,"A Phase IIB Study to Assess the Efficacy of GSK 249553 as Adjuvant Therapy Given to MAGE-3-Positive Patients With Non-Small-Cell Lung Cancer in Stage IB (T2/N0) or II (T1/N1 or T2/N1 or T3/N0), Who Ha",GlaxoSmithKline,GlaxoSmithKline,INDUSTRY,COMPLETED,2002-05-28,2011-07-19,2011-07-19,INTERVENTIONAL,PHASE2,,,,"Lung Cancer, Non-Small Cell","Lung Cancer, Non-Small Cell",1,2,2,BIOLOGICAL,,,1,18,True,Yes,Number of Patients Reporting Confirmed Non-small-cell Lung Cancer (NSCLC) Recurrence (COUNT_OF_PARTICIPANTS) Participants = 37,"Percentage of Patients With Disease Recurrence (NUMBER) Percentage of Patients = 89.1; Number of Patients Reporting Confirmed Non-small-cell Lung Cancer (NSCLC) Recurrence or Death - Disease Free Survival (DFS) (COUNT_OF_PARTICIPANTS) Participants = 49; Number of Participants Who Died - Overall Survival (OS) (COUNT_OF_PARTICIPANTS) Participants = 36; Number of Subjects Seropositive Against MAGE-A3 (COUNT_OF_PARTICIPANTS) Participants = 9; Anti- MAGE-A3 Antibody Concentrations (GEOMETRIC_MEAN) EL.U/mL = 16.9 [14.4-19.8]; Number of Subjects Seropositive Against Protein D (PD) Antigens (COUNT_OF_PARTICIPANTS) Participants = 45; Anti-protein D (Anti-PD) Antibody Concentrations (GEOMETRIC_MEAN) EL.U/mL = 92.2 [78.6-108.0]; Number of Subjects With Cell-mediated Immunity (CMI) Cluster of Differentiation (CD) 4+ Response (COUNT_OF_PARTICIPANTS) Participants = 8; Number of Subjects With Cell-mediated Immunity (CMI) Cluster of Differentiation (CD) 8+ Response (COUNT_OF_PARTICIPANTS) Participants = 2; Number of Subjects With Cell-mediated Immunity (CMI) CD4+ or CD8+ Response (COUNT_OF_PARTICIPANTS) Participants = 10; Number of Patients Reporting Non-small-cell Lung Cancer (NSCLC) Recurrence by Gene Signature (COUNT_OF_PARTICIPANTS) Participants = 13; Number of Subjects With Any and Grade 3 Solicited Local Symptoms (COUNT_OF_PARTICIPANTS) Participants = 116; Number of Subjects With Any, Grade 2/3/4 and Related Solicited General Symptoms (COUNT_OF_PARTICIPANTS) Participants = 87; Number of Subjects With Any Unsolicited Adverse Events (AEs) (COUNT_OF_PARTICIPANTS) Participants = 95; Number of Subjects With Serious Adverse Events (SAEs) (COUNT_OF_PARTICIPANTS) Participants = 41; Number of Subjects With Normal and Abnormal Urinalysis Parameters (COUNT_OF_PARTICIPANTS) Participants = 100; Number of Subjects With Normal and Abnormal Hematological Parameters (COUNT_OF_PARTICIPANTS) Participants = 122; Number of Subjects With Normal and Abnormal Biochemical Parameters (COUNT_OF_PARTICIPANTS) Participants = 97",,,Number of Patients Reporting Confirmed Non-small-cell Lung Cancer (NSCLC) Recurrence or Death - Disease Free Survival (DFS) (COUNT_OF_PARTICIPANTS) Participants = 49,,,,,,Number of Participants Who Died - Overall Survival (OS) (COUNT_OF_PARTICIPANTS) Participants = 36,,,,,Number of Subjects With Any Unsolicited Adverse Events (AEs) (COUNT_OF_PARTICIPANTS) Participants = 95; Number of Subjects With Serious Adverse Events (SAEs) (COUNT_OF_PARTICIPANTS) Participants = 41,,
NCT00308750,First Line Chemotherapy Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC),"A Randomized, Open-label Phase II Study of Pemetrexed (Alimta) Plus Carboplatin With or Without Enzastaurin Hydrochloride, or Docetaxel Plus Carboplatin as First Line Treatment in Patients With Advanc",Eli Lilly and Company,Eli Lilly and Company,INDUSTRY,COMPLETED,2006-03,2009-07,2009-07,INTERVENTIONAL,PHASE2,,,,Non-Small Cell Lung Cancer,Non-Small Cell Lung Cancer,1,3,4,DRUG,,,1,9,True,Yes,Time to Disease Progression (MEDIAN) months = 4.6 [3.2-6.7],; ; Number of Participants With Adverse Events (AEs) or Deaths (COUNT_OF_PARTICIPANTS) Participants = 63; Change From Baseline in Total Functional Assessment of Cancer Therapy-Lung (FACT-L) Scale (LEAST_SQUARES_MEAN) units on a scale = -3.98; Change From Baseline in Total Functional Assessment of Cancer Therapy -Taxane (FACT-Taxane) Scale (LEAST_SQUARES_MEAN) units on a scale = -3.16; Overall Survival (OS) (MEDIAN) months = 7.2 [5.7-11.2]; Number of Participants With Complete Response (CR) or Partial Response (PR) [Tumor Response] (COUNT_OF_PARTICIPANTS) Participants = 9; Duration of CR or PR (Duration of Response) (MEDIAN) months = 7.4 [3.7-8.8]; Time-to-Treatment Failure (TTF) (MEDIAN) months = 2.6 [1.7-3.7],,Number of Participants With Complete Response (CR) or Partial Response (PR) [Tumor Response] (COUNT_OF_PARTICIPANTS) Participants = 9; Duration of CR or PR (Duration of Response) (MEDIAN) months = 7.4 [3.7-8.8],,,Duration of CR or PR (Duration of Response) (MEDIAN) months = 7.4 [3.7-8.8],,,,Overall Survival (OS) (MEDIAN) months = 7.2 [5.7-11.2],,Number of Participants With Complete Response (CR) or Partial Response (PR) [Tumor Response] (COUNT_OF_PARTICIPANTS) Participants = 9; Duration of CR or PR (Duration of Response) (MEDIAN) months = 7.4 [3.7-8.8],,,Number of Participants With Adverse Events (AEs) or Deaths (COUNT_OF_PARTICIPANTS) Participants = 63,,
NCT00312377,ZACTIMA (an Anti-EGFR / Anti-VEGF Agent) Combined With Docetaxel Compared to Docetaxel in Non-small Cell Lung Cancer,"A Phase III, Randomized, Double-Blinded, Multi-Center, Study to Assess the Efficacy of Docetaxel (TAXOTERE™) in Combination With ZD6474 (ZACTIMA™) Versus Docetaxel (TAXOTERE™) With Placebo in Subjects",Sanofi,"Genzyme, a Sanofi Company",INDUSTRY,COMPLETED,2006-05,2008-08,2014-03,INTERVENTIONAL,PHASE3,,,,Non-small Cell Lung Cancer,Non-small Cell Lung Cancer; Lung Cancer,2,2,2,DRUG,,,2,7,True,Yes,Progression-Free Survival (PFS) in the Overall Population (MEDIAN) Weeks = 17.3 [15-18]; Progression-Free Survival (PFS) in the Female Population (MEDIAN) Weeks = 20.1 [17.9-23.9],Overall Survival (OS) in the Overall Population (MEDIAN) Months = 10.6 [9.6-11.5]; Overall Survival (OS) in the Female Population (MEDIAN) Months = 12.7 [10.5-17.1]; Objective Response Rate (ORR) (NUMBER) Participants = 120; Disease Control Rate (DCR) (NUMBER) Participants = 413; Duration of Response (DoR) (MEDIAN) Weeks = 29.9 [7.14-72.29]; Time to Deterioration of Disease-related Symptoms (TDS) by Functional Assessment of Cancer Therapy - Lung (FACT-L) Lung Cancer Subscale (LCS). (MEDIAN) Weeks = 15 [6.1-82.3]; Time to Deterioration of Disease-related Symptoms (TDS) by FACT-L Pulmonary Symptom Index (PSI) (MEDIAN) Weeks = 12.3 [5.9-36.7],,,,,Duration of Response (DoR) (MEDIAN) Weeks = 29.9 [7.14-72.29],,,Objective Response Rate (ORR) (NUMBER) Participants = 120,Overall Survival (OS) in the Overall Population (MEDIAN) Months = 10.6 [9.6-11.5]; Overall Survival (OS) in the Female Population (MEDIAN) Months = 12.7 [10.5-17.1],Progression-Free Survival (PFS) in the Overall Population (MEDIAN) Weeks = 17.3 [15-18]; Progression-Free Survival (PFS) in the Female Population (MEDIAN) Weeks = 20.1 [17.9-23.9],,,Objective Response Rate (ORR) (NUMBER) Participants = 120,,,
NCT00312728,A Study of Bevacizumab in Combination With First- or Second-Line Therapy in Subjects With Treated Brain Metastases Due to Non-Squamous NSCLC (PASSPORT,A Phase II Trial of Bevacizumab in Combination With First- or Second-Line Therapy in Subjects With Treated Brain Metastases Due to Non-Squamous Non-Small Cell Lung Cancer,"Genentech, Inc.","Genentech, Inc.",INDUSTRY,COMPLETED,2006-03,2009-06,2009-06,INTERVENTIONAL,PHASE2,,,,Non-Small Cell Lung Cancer,Non-Small Cell Lung Cancer; Brain Neoplasms,2,1,3,DRUG,,,1,5,True,Yes,Percentage of Participants With Symptomatic National Cancer Institute's Common Terminology Criteria for Adverse Events v3.0 (NCI CTCAE) Grade ≥2 Central Nervous System (CNS) Hemorrhage (NUMBER) percentage of participants = 0 [0-2.5],Overall Survival (OS) in First-line Setting (MEDIAN) Months = 11.8 [9.6-13.9]; Number of Participants With Overall Survival (OS) in First-line Setting [1-Year or More Survival] (NUMBER) participants = 30; OS in First-line and Second-line Settings (MEDIAN) Months = 12.1 [10.3-14.9]; Number of Participants With OS in First-line and Second-line Settings [1-Year or More Survival] (NUMBER) participants = 49; Number of Participants With Selected Adverse Events (NUMBER) participants = 0,,,,,,,,,Overall Survival (OS) in First-line Setting (MEDIAN) Months = 11.8 [9.6-13.9]; Number of Participants With Overall Survival (OS) in First-line Setting [1-Year or More Survival] (NUMBER) participants = 30; OS in First-line and Second-line Settings (MEDIAN) Months = 12.1 [10.3-14.9]; Number of Participants With OS in First-line and Second-line Settings [1-Year or More Survival] (NUMBER) participants = 49,,,,,Percentage of Participants With Symptomatic National Cancer Institute's Common Terminology Criteria for Adverse Events v3.0 (NCI CTCAE) Grade ≥2 Central Nervous System (CNS) Hemorrhage (NUMBER) percentage of participants = 0 [0-2.5]; Number of Participants With Selected Adverse Events (NUMBER) participants = 0,,
NCT00316225,Study of Pemetrexed in Mesothelioma and Lung Cancer Patients With Fluid Around the Lungs or Abdomen,A Phase 2 Study of ALIMTA in Solid Tumor Patients With Stable Third-Space Fluid,Eli Lilly and Company,Eli Lilly and Company,INDUSTRY,COMPLETED,2006-12,2009-03,2009-03,INTERVENTIONAL,PHASE2,,,,Non-small Cell Lung Cancer,Non-small Cell Lung Cancer; Mesothelioma; Lung Neoplasms,3,1,1,DRUG,,,1,4,True,Yes,Overview of Adverse Events (NUMBER) participants = 28,Number of Participants With Common Toxicity Criteria - National Cancer Institute Grade 3 and Grade 4 Toxicities (NUMBER) participants = 1; Pemetrexed Population Pharmacokinetics (PK): Clearance (MEAN) milliliter per minute (mL/min) = 85.6; Pemetrexed Population Pharmacokinetics: Volume of Distribution (MEAN) Liters (L) = 6.61; Discontinuations Due to Adverse Events (NUMBER) participants = 1,,,,,,,,,,,,,,Overview of Adverse Events (NUMBER) participants = 28; Number of Participants With Common Toxicity Criteria - National Cancer Institute Grade 3 and Grade 4 Toxicities (NUMBER) participants = 1; Discontinuations Due to Adverse Events (NUMBER) participants = 1,,
NCT00318136,"A Study of Bevacizumab Plus Carboplatin and Paclitaxel in Subjects With Advanced, Previously Untreated, Squamous Non-Small Cell Lung Cancer (BRIDGE)","A Pilot Study of Bevacizumab Plus Carboplatin and Paclitaxel in Subjects With Advanced, Previously Untreated, Squamous Non-Small Cell Lung Cancer","Genentech, Inc.","Genentech, Inc.",INDUSTRY,COMPLETED,2005-09,2009-07,2009-07,INTERVENTIONAL,PHASE2,,,,Non-small Cell Lung Cancer,Non-small Cell Lung Cancer,1,1,3,DRUG,,,1,3,True,Yes,Incidence of Grade ≥3 Pulmonary Hemorrhage Adverse Events (NUMBER) Percentage of patients = 3.2,Selected Adverse Events (NUMBER) Patients = 2; Adverse Events That Led to Discontinuation of Bevacizumab (NUMBER) Patients = 1; Progression-free Survival (MEDIAN) Months = 6.2 [5.32-7.62],,,,,,,,,,Progression-free Survival (MEDIAN) Months = 6.2 [5.32-7.62],,,,Incidence of Grade ≥3 Pulmonary Hemorrhage Adverse Events (NUMBER) Percentage of patients = 3.2; Selected Adverse Events (NUMBER) Patients = 2; Adverse Events That Led to Discontinuation of Bevacizumab (NUMBER) Patients = 1,,
NCT00322452,First Line IRESSA™ Versus Carboplatin/Paclitaxel in Asia,"Open Label, Randomised, Parallel Group, Multicentre, Ph III Study To Assess Efficacy, Safety & Tolerability Of Gefitinib (IRESSA™) Versus Carboplatin/Paclitaxel DC As 1st-Line Treatment In Selected Pa",AstraZeneca,AstraZeneca,INDUSTRY,COMPLETED,2006-03,2008-04,2010-06,INTERVENTIONAL,PHASE3,,,,Non-Small Cell Lung Cancer,Non-Small Cell Lung Cancer,1,2,3,DRUG,,,1,15,True,Yes,Median Progression Free Survival (PFS) in Months (MEDIAN) Months = 5.7 [5.4-6.8],"Median Overall Survival (OS) in Months at OS Data Cut Off (14th June 2010) (MEDIAN) Months = 18.8 [17.3-20.4]; Objective Tumour Response Rate According to RECIST (NUMBER) Participants = 262; Common Toxicity Criteria (CTC) Grade 3, 4, or 5 Neutropenia (NUMBER) Participants = 4; Common Toxicity Criteria (CTC) Grade 3, 4, or 5 Thrombocytopenia (NUMBER) Participants = 5; Common Toxicity Criteria (CTC) Grade 3, 4, or 5 Leukopenia (NUMBER) Participants = 1; Common Toxicity Criteria (CTC) Grade 3, 4, or 5 Anaemia (NUMBER) Participants = 11; Neurotoxicity (NUMBER) Participants = 30; Rashes/Acnes (NUMBER) Participants = 398; Diarrhoea (NUMBER) Participants = 274; Nausea (NUMBER) Participants = 74; Vomiting (NUMBER) Participants = 59; Common Toxicity Criteria (CTC) Grade 3, 4, or 5 Liver Transaminases (NUMBER) Participants = 57; Quality of Life (QoL) as Measured by the Total Score of the Functional Assessment of Cancer Therapy - Lung Cancer (FACT-L) Questionnaire (NUMBER) Participants = 283; Quality of Life (QoL) as Measured by the Trial Outcome Index (TOI) of the Functional Assessment of Cancer Therapy - Lung Cancer (FACT-L) Questionnaire (NUMBER) Participants = 274; Symptom Improvement as Measured by the Lung Cancer Subscale (LCS) of the FACT-L Questionnaire (NUMBER) Participants = 304",,,,,,,,,Median Overall Survival (OS) in Months at OS Data Cut Off (14th June 2010) (MEDIAN) Months = 18.8 [17.3-20.4],Median Progression Free Survival (PFS) in Months (MEDIAN) Months = 5.7 [5.4-6.8],,Quality of Life (QoL) as Measured by the Total Score of the Functional Assessment of Cancer Therapy - Lung Cancer (FACT-L) Questionnaire (NUMBER) Participants = 283; Quality of Life (QoL) as Measured by the Trial Outcome Index (TOI) of the Functional Assessment of Cancer Therapy - Lung Cancer (FACT-L) Questionnaire (NUMBER) Participants = 274,Objective Tumour Response Rate According to RECIST (NUMBER) Participants = 262,"Common Toxicity Criteria (CTC) Grade 3, 4, or 5 Neutropenia (NUMBER) Participants = 4; Common Toxicity Criteria (CTC) Grade 3, 4, or 5 Thrombocytopenia (NUMBER) Participants = 5; Common Toxicity Criteria (CTC) Grade 3, 4, or 5 Leukopenia (NUMBER) Participants = 1; Common Toxicity Criteria (CTC) Grade 3, 4, or 5 Anaemia (NUMBER) Participants = 11; Neurotoxicity (NUMBER) Participants = 30; Common Toxicity Criteria (CTC) Grade 3, 4, or 5 Liver Transaminases (NUMBER) Participants = 57",,
NCT00323869,"Phase II Bevacizumab, Gemcitabine and Carboplatin in Newly Diagnosed Non-Small Cell Lung Cancer",Phase II Trial of Bevacizumab in Combination With Gemcitabine and Carboplatin in Patients With Newly Diagnosed Non-Small Cell Lung Cancer (Excluding Squamous Cell Carcinoma),Stanford University,Stanford University,OTHER,COMPLETED,2006-06,2013-10,2013-10,INTERVENTIONAL,PHASE2,,,,Lung Cancer,Lung Cancer; Non-small Cell Lung Cancer (NSCLC),2,1,3,DRUG,,,1,8,True,Yes,Progression-free Survival (PFS) (MEDIAN) months = 8.7 [7.8-17.9],Response Rate (CR + PR + SD) (NUMBER) participants = 41; Overall Survival (OS) (MEDIAN) months = 12.8 [10.0-16.5]; Partial Response (PR) (NUMBER) participants = 7; Complete Response (CR) (NUMBER) participants = 0; Stable Disease (SD) (NUMBER) participants = 34; Time-to-First Event (MEDIAN) months = 6.4 [4.8-7.9]; Overall Survival (OS) at 12 Months (NUMBER) participants = 27; Overall Survival (OS) at 24 Months (NUMBER) participants = 5,,Complete Response (CR) (NUMBER) participants = 0,,,,,,,Overall Survival (OS) (MEDIAN) months = 12.8 [10.0-16.5]; Overall Survival (OS) at 12 Months (NUMBER) participants = 27; Overall Survival (OS) at 24 Months (NUMBER) participants = 5,Progression-free Survival (PFS) (MEDIAN) months = 8.7 [7.8-17.9],Response Rate (CR + PR + SD) (NUMBER) participants = 41; Partial Response (PR) (NUMBER) participants = 7,,Response Rate (CR + PR + SD) (NUMBER) participants = 41,,,
NCT00324805,"Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Su",A Phase III Randomized Trial of Adjuvant Chemotherapy With or Without Bevacizumab for Patients With Completely Resected Stage IB (≥ 4 cm) - IIIA Non-small Cell Lung Cancer (NSCLC),National Cancer Institute (NCI),National Cancer Institute (NCI),NIH,COMPLETED,2007-07-19,2015-10-20,2025-01-31,INTERVENTIONAL,PHASE3,,,,Stage IB Lung Non-Small Cell Carcinoma AJCC v7,Stage IB Lung Non-Small Cell Carcinoma AJCC v7; Stage IIA Lung Non-Small Cell Carcinoma AJCC v7; Stage IIB Lung Non-Small Cell Carcinoma AJCC v7,4,2,8,BIOLOGICAL; DRUG; OTHER,,,1,1,True,Yes,,Disease-free Survival (MEDIAN) months = 42.9 [36.7-57.0],,,Disease-free Survival (MEDIAN) months = 42.9 [36.7-57.0],,,,,,,,,,,,,
NCT00343291,A Study of Cetuximab and Bevacizumab in Combination With Paclitaxel and Carboplatin in Stage IIIb/IV NSCLC,"Phase II Randomized, Open-Label Study of Cetuximab and Bevacizumab in Combination With Paclitaxel and Carboplatin in Patients With Stage IIIB/IV Non-Small Cell Lung Cancer",Eli Lilly and Company,Eli Lilly and Company,INDUSTRY,COMPLETED,2006-12,2010-05,2010-12,INTERVENTIONAL,PHASE2,,,,Non-Small Cell Lung Cancer,Non-Small Cell Lung Cancer,1,2,4,BIOLOGICAL; DRUG,,,1,4,True,Yes,Progression Free Survival (PFS) (MEDIAN) months = 6.05 [5.65-7.03],Overall Survival (MEDIAN) months = 12.06 [9.40-19.25]; Percentage of Participants Achieving an Objective Overall Response (Overall Response Rate) (NUMBER) percentage of participants = 51.7 [39.0-64.3]; Duration of Overall Response (MEDIAN) months = 4.86 [4.30-7.16]; Percentage of Participants With Symptomatic Response (Symptom Response Rate) (NUMBER) percentage of participants = 41.9 [27.1-56.6],,,,,,,,,Overall Survival (MEDIAN) months = 12.06 [9.40-19.25],Progression Free Survival (PFS) (MEDIAN) months = 6.05 [5.65-7.03],,,Percentage of Participants Achieving an Objective Overall Response (Overall Response Rate) (NUMBER) percentage of participants = 51.7 [39.0-64.3]; Percentage of Participants With Symptomatic Response (Symptom Response Rate) (NUMBER) percentage of participants = 41.9 [27.1-56.6],,,
NCT00350792,Pemetrexed/Carboplatin Non-Small Cell Lung Cancer (NSCLC) Elderly Patients,A Phase II Trial Pemetrexed Carboplatin as First Line Chemotherapy for Advanced Non-Small Cell Lung Cancer (NSCLC) in Elderly Patients,Eli Lilly and Company,Eli Lilly and Company,INDUSTRY,COMPLETED,2006-08,2008-11,2009-11,INTERVENTIONAL,PHASE2,,,,Non Small Cell Lung Cancer,Non Small Cell Lung Cancer,1,1,2,DRUG,,,1,3,True,Yes,Percentage of Participants With a Complete or Partial Tumor Response (Overall Tumor Response) (NUMBER) percentage of participants = 28.6 [16.58-43.26],Time to Treatment Failure (MEDIAN) weeks = 16.0; Overall Survival (MEDIAN) months = 10.4 [9.1-12.9]; Estimated Probability of One Year Progression-free Survival (MEDIAN) percentage of patients = 13.1 [4.6-21.6],,,,,,,,,Overall Survival (MEDIAN) months = 10.4 [9.1-12.9],Estimated Probability of One Year Progression-free Survival (MEDIAN) percentage of patients = 13.1 [4.6-21.6],,,,,Time to Treatment Failure (MEDIAN) weeks = 16.0,
NCT00356122,Docetaxel & Oxaliplatin in Combination With Bevacizumab as First-Line Treatment in Subjects With Non-Small Cell Lung Cancer (NSCLC),A Phase II Multicenter Study of Docetaxel and Oxaliplatin in Combination With Bevacizumab as First-Line Treatment in Chemotherapy-Naïve Subjects With Unresectable Locally Advanced and/or Recurrent (St,Sanofi,Sanofi,INDUSTRY,COMPLETED,2006-07,2010-08,2010-08,INTERVENTIONAL,PHASE2,,,,Non-Small Cell Lung Cancer,Non-Small Cell Lung Cancer,1,1,3,DRUG,,,1,4,True,Yes,Progression-free Survival (PFS) (MEDIAN) Months = 5.6 [3.7-7.6],Objective Response Rate (MEAN) Percentage of participants = 30.2 [18.3-44.3]; Time-to-treatment Failure (TTF) (MEDIAN) Months = 4.7 [2.9-5.6]; Overall Survival (OS) (MEDIAN) Months = 14.0 [9.9-16.9]; Number of Participants With Treatment-related Toxicities (NUMBER) Participants = 51,,,,,,,,Objective Response Rate (MEAN) Percentage of participants = 30.2 [18.3-44.3],Overall Survival (OS) (MEDIAN) Months = 14.0 [9.9-16.9],Progression-free Survival (PFS) (MEDIAN) Months = 5.6 [3.7-7.6],,,Objective Response Rate (MEAN) Percentage of participants = 30.2 [18.3-44.3],,,
NCT00362882,Docetaxel and Bortezomib in Treating Patients With Progressive or Recurrent Non-Small Cell Lung Cancer,Randomized Phase II Trial of Sequential Versus Concurrent Docetaxel and PS-341 (NSC 681239) in Previously Treated Non-Small Cell Lung Cancer (NSCLC),National Cancer Institute (NCI),National Cancer Institute (NCI),NIH,COMPLETED,2006-07,2010-07,2010-07,INTERVENTIONAL,PHASE2,,,,Non-small Cell Lung Cancer,Non-small Cell Lung Cancer; Recurrent Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer,3,2,6,DRUG; OTHER,,,1,3,True,Yes,Overall Response Rate (NUMBER) percentage of participants = 10,Overall Survival (MEDIAN) Months = 13.3 [7-17]; Disease Control Rate (NUMBER) percentage of participants = 50; Progression-free Survival @ 6 Months (NUMBER) percent of participants = 30,,,,,,,,,Overall Survival (MEDIAN) Months = 13.3 [7-17],Progression-free Survival @ 6 Months (NUMBER) percent of participants = 30,,,Overall Response Rate (NUMBER) percentage of participants = 10,,,
NCT00363766,Study of LY573636-Sodium in Patients With Metastatic Non-Small Cell Lung Cancer,"A Phase 2 Study of LY573636-Sodium Administered as an Intravenous Infusion on Day 1 of a 21-Day Cycle as Third-line Treatment in Patients With Unresectable, Metastatic Non-Small Cell Lung Cancer",Eli Lilly and Company,Eli Lilly and Company,INDUSTRY,COMPLETED,2006-09,2008-10,2008-10,INTERVENTIONAL,PHASE2,,,,Non-Small-Cell Lung Cancer,Non-Small-Cell Lung Cancer,1,1,1,DRUG,,,1,7,True,Yes,Time to Progression (MEDIAN) months = 3.12 [2.04-4.21],Progression-Free Survival (MEDIAN) months = 2.69 [1.38-4.17]; Percentage of Participants With Complete Response or Partial Response (Objective Response Rate) (NUMBER) percentage of participants = 0; Pharmacokinetics: Maximum Concentration (Cmax) of LY573636 (GEOMETRIC_MEAN) micrograms/milliliter (µg/mL) = 379.6; Overall Survival Time (MEDIAN) months = 8.48 [5.06-10.15]; ; Duration of Stable Disease (MEDIAN) months = 4.21 [3.58-5.72]; Number of Participants With Adverse Events (Safety) (COUNT_OF_PARTICIPANTS) Participants = 17,,Percentage of Participants With Complete Response or Partial Response (Objective Response Rate) (NUMBER) percentage of participants = 0,,,,,,Percentage of Participants With Complete Response or Partial Response (Objective Response Rate) (NUMBER) percentage of participants = 0,Overall Survival Time (MEDIAN) months = 8.48 [5.06-10.15],Progression-Free Survival (MEDIAN) months = 2.69 [1.38-4.17],Percentage of Participants With Complete Response or Partial Response (Objective Response Rate) (NUMBER) percentage of participants = 0,,Percentage of Participants With Complete Response or Partial Response (Objective Response Rate) (NUMBER) percentage of participants = 0,Number of Participants With Adverse Events (Safety) (COUNT_OF_PARTICIPANTS) Participants = 17,,Time to Progression (MEDIAN) months = 3.12 [2.04-4.21]
NCT00364351,Efficacy Trial Comparing ZD6474 With Erlotinib in NSCLC After Failure of at Least One Prior Chemotherapy,"A Phase III, International, Randomised, Double Blind, Parallel-Group Study to Assess the Efficacy of Zactima™ Versus Tarceva® in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer",Sanofi,"Genzyme, a Sanofi Company",INDUSTRY,COMPLETED,2006-08,2008-09,2016-11,INTERVENTIONAL,PHASE3,,,,Non Small Cell Lung Cancer,Non Small Cell Lung Cancer,1,2,2,DRUG,,,1,6,True,Yes,Progression-Free Survival (PFS) (MEDIAN) Weeks = 11.3 [0.14-75.43],Overall Survival (OS) (MEDIAN) Months = 6.9 [0.03-18.46]; Objective Response Rate (ORR) (NUMBER) Participants = 75; Disease Control Rate (DCR) (NUMBER) Participants = 254; Time to Deterioration of Disease-related Symptoms (TDS) by EORTC Quality of Life Questionnaire - Pain (MEDIAN) Weeks = 11.1 [4.4-26]; Time to Deterioration of Disease-related Symptoms (TDS) by EORTC Quality of Life Questionnaire - Dyspnoea (MEDIAN) Weeks = 12 [5.7-29.7]; Time to Deterioration of Disease-related Symptoms (TDS) by EORTC Quality of Life Questionnaire - Cough (MEDIAN) Weeks = 15.6 [8.1-36.1],,,,,,,,Objective Response Rate (ORR) (NUMBER) Participants = 75,Overall Survival (OS) (MEDIAN) Months = 6.9 [0.03-18.46],Progression-Free Survival (PFS) (MEDIAN) Weeks = 11.3 [0.14-75.43],,Time to Deterioration of Disease-related Symptoms (TDS) by EORTC Quality of Life Questionnaire - Pain (MEDIAN) Weeks = 11.1 [4.4-26]; Time to Deterioration of Disease-related Symptoms (TDS) by EORTC Quality of Life Questionnaire - Dyspnoea (MEDIAN) Weeks = 12 [5.7-29.7]; Time to Deterioration of Disease-related Symptoms (TDS) by EORTC Quality of Life Questionnaire - Cough (MEDIAN) Weeks = 15.6 [8.1-36.1],Objective Response Rate (ORR) (NUMBER) Participants = 75,,,
NCT00367679,Pazopanib As Pre-Surgical Therapy In Treatment-Naive Subjects With Non-Small Cell Lung Cancer,"A Phase II Open-Label Multicenter Study to Evaluate the Safety and Efficacy of Pazopanib (GW786034) as Neoadjuvant Therapy in Treatment-Naïve Subjects With Stage IA, IB, IIA or IIB (to T2) Resectable ",GlaxoSmithKline,GlaxoSmithKline,INDUSTRY,COMPLETED,2006-11,2008-04,2008-04,INTERVENTIONAL,PHASE2,,,,Non-Small Cell Lung Cancer,"Non-Small Cell Lung Cancer; Lung Cancer, Non-Small Cell",2,1,1,DRUG,,,1,13,True,Yes,Number of Participants Achieving Tumor Shrinkage Based on Change in Tumor Volume (NUMBER) participants = 2,Number of Participants Achieving a Clinical Response Based on RECIST (NUMBER) participants = 0; ; Number of Participants With Shifts From Baseline to Grade 2 or Greater in Hematology Values (NUMBER) participants = 5; Number of Participants With Shifts From Baseline to Grade 2 or Greater in Chemistry Values (NUMBER) participants = 2; Number of Participants With the Indicated Change From Baseline in Systolic and Diastolic Blood Pressure (NUMBER) participants = 12; ; Ratio of Post- to Pretreatment Expression Levels for Each of the Indicated Pazopanib Target Genes (MEDIAN) ratio = 3.234; ; ; ; ; ; Ratio of Post- to Pretreatment Expression Levels for Each of the Indicated Pazopanib Target Proteins (MEDIAN) ratio = -1.35 [-1.644--1.155],,,,,,,,,,,,,,,,
NCT00368927,Sulindac in Preventing Lung Cancer in Current or Former Smokers With Bronchial Dysplasia,"Randomized, Phase IIb Trial of Sulindac in Smokers With Bronchial Dysplasia",National Cancer Institute (NCI),National Cancer Institute (NCI),NIH,COMPLETED,2006-08,2010-05,2010-12,INTERVENTIONAL,PHASE2,,,,Precancerous Condition,Precancerous Condition; Stage I Non-small Cell Lung Cancer; Tobacco Use Disorder,3,2,2,DRUG; OTHER,,,1,1,True,Yes,Percentage of Participants With Response Determined by Change in Histologic Grade of Bronchial Dysplasia as Measured by Mucosal Biopsy Samples Before and After Treatment (NUMBER) percentage of participants = 38.5,Percent Change in Number of Dysplastic Lesions (DL) as Measured by Mucosal Biopsy Samples Before and After the Intervention (MEDIAN) Percent change in number of DL = -55 [-100-100],,,,,,,,,,,,,,,,
NCT00368992,"S0536: Cetuximab, Paclitaxel, Carboplatin, and Bevacizumab in Treating Patients With Advanced Non-Small Cell Lung Cancer","A Phase II Trial of Combination Carboplatin, Paclitaxel, Cetuximab and Bevacizumab (NSC-704865) Followed By Cetuximab and Bevacizumab in Patients With Advanced Non-Small Cell Lung Cancer",National Cancer Institute (NCI),National Cancer Institute (NCI),NIH,COMPLETED,2006-08,2010-10,2010-10,INTERVENTIONAL,PHASE2,,,,Adenocarcinoma of the Lung,Adenocarcinoma of the Lung; Adenosquamous Cell Lung Cancer; Bronchoalveolar Cell Lung Cancer,8,1,3,BIOLOGICAL; DRUG,,,1,3,True,Yes,The Percentage of Patients With Grade 4 (i.e. Life-threatening) Hemorrhage Toxicities Related to Protocol Treatment. (NUMBER) percentage of participants = 2 [0-7],Progression-Free Survival (MEDIAN) Months = 7 [6-8]; Overall Survival (MEDIAN) months = 15 [11-21]; Response Rate (NUMBER) percentage of participants = 56 [44-65],,,,,,,,,Overall Survival (MEDIAN) months = 15 [11-21],Progression-Free Survival (MEDIAN) Months = 7 [6-8],,,Response Rate (NUMBER) percentage of participants = 56 [44-65],,,
NCT00370292,Dosage Schedule Study of Pemetrexed Monochemotherapy for Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC),Pemetrexed Monochemotherapy in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer. A Pilot Study to Define the Best Dosing Schedule for a Planned Phase II Randomized Trial,Eli Lilly and Company,Eli Lilly and Company,INDUSTRY,COMPLETED,2006-09,2008-09,2008-09,INTERVENTIONAL,PHASE2,,,,Non Small Cell Lung Cancer,Non Small Cell Lung Cancer,1,2,2,DRUG,,,2,1,True,Yes,"Mean Deoxycytidine Kinase (dCK) Expression Evaluated at Cycle 1, Cycle 2, and Cycle 3 (MEAN) mRNA relative values (ratio with GAPDH) = 0.92; Mean Human Equilibrative Nucleoside Transporter 1 (hENT) Expression Evaluated at Cycle 1, Cycle 2, and Cycle 3 (MEAN) mRNA relative values (ratio with GAPDH) = 0.86",Best Objective Tumor Response (NUMBER) participants = 1,,,,,,,,,,,,,,,,
NCT00372775,Study Tests The Safety And Effectiveness Of SU011248 In Patients With Non-Small Cell Lung Cancer Having Brain Metastases,A Phase 2 Efficacy And Safety Study Of SU011248 In Patients With Non-Small Cell Lung Cancer And Brain Metastases,Pfizer,Pfizer,INDUSTRY,COMPLETED,2007-03,2009-12,2009-12,INTERVENTIONAL,PHASE2,,,,Non-Small Cell Lung Cancer,Non-Small Cell Lung Cancer,1,1,1,DRUG,,,1,16,True,Yes,Progression-Free Survival (PFS) (MEDIAN) Weeks = 9.4 [7.5-13.1],Time to Tumor Progression (TTP) (MEDIAN) Weeks = 15.1 [8.4-15.8]; Time to Neurological Progression (TNP) (MEDIAN) Weeks = 8.1 [0.4-58.8]; Number of Participants With Objective Disease Response (NUMBER) Participants = 1; Time to Objective Intracranial Progression (MEDIAN) Weeks = 15.4 [12.1-24.8]; Number of Participants With Intracranial Objective Disease Response (NUMBER) Participants = 1; Duration of Response (DR) (NUMBER) Weeks = 32.1; Overall Survival (OS) (MEDIAN) Months = 5.8 [3.1-8.2]; Percentage of Participants Surviving at 1 Year (NUMBER) Percentage of participants = 23.4 [14.0-34.3]; Number of Deaths Due to Intracranial Versus Systemic Progression (NUMBER) Participants = 48; Change From Baseline in Functional Assessment of Cancer Therapy/National Comprehensive Cancer Network (FACT/NCCN) Lung Symptom Index (FLSI) Score (MEAN) Scores on a scale = 17.62 [16.01-19.22]; Change From Baseline in FACT/NCCN Brain Symptom Index (FBrSI) Score (MEAN) Scores on a scale = 45.72 [43.52-47.92]; Trough Plasma Concentrations (Ctrough) of Sunitinib (MEAN) nanograms per milliliter (ng/mL) = 50.89; Ctrough of Sunitinib Metabolite (SU012662) (MEAN) ng/mL = 33.85; ; ; ,,,,,Duration of Response (DR) (NUMBER) Weeks = 32.1,,,,Overall Survival (OS) (MEDIAN) Months = 5.8 [3.1-8.2],Progression-Free Survival (PFS) (MEDIAN) Weeks = 9.4 [7.5-13.1],,,,,,
NCT00373425,A Study of Erlotinib (Tarceva) After Surgery With or Without Adjuvant Chemotherapy in Non-Small Cell Lung Carcinoma (NSCLC) Patients Who Have Epiderma,"A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Single-agent Tarceva® (Erlotinib) Following Complete Tumor Resection With or Without Adjuvant Chemotherapy in Patients Wi",Astellas Pharma Inc,OSI Pharmaceuticals,INDUSTRY,COMPLETED,2006-09,2013-04,2014-06,INTERVENTIONAL,PHASE3,,,,Non-small Cell Lung Cancer,Non-small Cell Lung Cancer,1,2,2,DRUG,,,2,7,True,Yes,Disease Free Survival (DFS) (MEDIAN) months = 50.5; Disease Free Survival (DFS) (MEDIAN) months = 55.0 [47.0-64.5],; ; Disease-free Survival in Participants With EGFR Mutation - Positive Tumors (MEDIAN) months = 46.4; Disease-free Survival in Participants With EGFR Mutation - Positive Tumors (MEDIAN) months = 47.8 [39.8-60.8]; ; ; Number of Participants With Adverse Events (AEs) (NUMBER) participants = 599,,,Disease Free Survival (DFS) (MEDIAN) months = 50.5; Disease Free Survival (DFS) (MEDIAN) months = 55.0 [47.0-64.5]; Disease-free Survival in Participants With EGFR Mutation - Positive Tumors (MEDIAN) months = 46.4; Disease-free Survival in Participants With EGFR Mutation - Positive Tumors (MEDIAN) months = 47.8 [39.8-60.8],,,,,,,,,,,Number of Participants With Adverse Events (AEs) (NUMBER) participants = 599,,
NCT00387465,Azacitidine and Entinostat in Treating Patients With Recurrent Advanced Non-Small Cell Lung Cancer,A Phase I/II Study of Entinostat in Combination With 5-Azacytidine in Patients With Recurrent Advanced Non-Small Cell Lung Cancer,National Cancer Institute (NCI),National Cancer Institute (NCI),NIH,COMPLETED,2006-08,2014-05,2014-11,INTERVENTIONAL,PHASE1; PHASE2,,,,Recurrent Non-Small Cell Lung Carcinoma,Recurrent Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer; Stage IIIB Non-Small Cell Lung Cancer,4,3,3,DRUG,,,2,9,True,Yes,(Phase I) Maximum Tolerated Dose (MTD) of Azacitidine When Given Together With Entinostat as Determined by Number of Participants Experiencing Dose-limiting Toxicity (DLT) (COUNT_OF_PARTICIPANTS) Participants = 0; (Phase II) Objective Response Rate After Treatment With Azacitidine and Entinostat as Assessed by Number of Participants With Response After at Least One Cycle of Therapy (COUNT_OF_PARTICIPANTS) Participants = 1,"Effect of Entinostat and Azacitidine on DNA Methylation and Response (COUNT_OF_PARTICIPANTS) Participants = 8; Major Objective Response After Immediate Subsequent Therapy as Measured by Number of Participants With PR, SD, PD After at Least 1 Cycle of Subsequent Chemotherapy (COUNT_OF_PARTICIPANTS) Participants = 4; Overall Survival (MEDIAN) months = 6.4 [3.8-9.2]; Pharmacokinetic Profile of Azacytidine as Measured by Tmax (MEDIAN) hours = 0.5 [0.25-2.00]; Progression-free Survival (MEDIAN) weeks = 7.4 [7.0-8.0]; Pharmacokinetic Profile of Azacitidine as Measured by Cmax (MEAN) ng/mL = 468; Pharmacokinetic Profile of Azacitidine as Measured by AUC (ng*hr/mL) (MEAN) ng*hr/mL = 675; Average Steady State Trough Concentration (ng/mL) of Entinostat (MEAN) ng/mL = 0.84; Pharmacokinetic Profile of Azacitidine as Measured by Half-life (MEAN) hours = 1.12",,,,,,,,(Phase II) Objective Response Rate After Treatment With Azacitidine and Entinostat as Assessed by Number of Participants With Response After at Least One Cycle of Therapy (COUNT_OF_PARTICIPANTS) Participants = 1,Overall Survival (MEDIAN) months = 6.4 [3.8-9.2],Progression-free Survival (MEDIAN) weeks = 7.4 [7.0-8.0],,,(Phase II) Objective Response Rate After Treatment With Azacitidine and Entinostat as Assessed by Number of Participants With Response After at Least One Cycle of Therapy (COUNT_OF_PARTICIPANTS) Participants = 1,(Phase I) Maximum Tolerated Dose (MTD) of Azacitidine When Given Together With Entinostat as Determined by Number of Participants Experiencing Dose-limiting Toxicity (DLT) (COUNT_OF_PARTICIPANTS) Participants = 0,,
NCT00390806,Oral HYCAMTIN Plus Whole Brain Radiation Therapy In Treatment Of Brain Metastases Resulting From Non-Small Lung Cancer,"A Randomized, Phase III, Open-Label Study of Oral Topotecan Plus Whole-Brain Radiation Therapy (WBRT) Compared With WBRT Alone in Patients With Brain Metastases From Non-Small Cell Lung Cancer",GlaxoSmithKline,GlaxoSmithKline,INDUSTRY,COMPLETED,2006-12,2012-07,2013-09,INTERVENTIONAL,PHASE3,,,,"Lung Cancer, Non-Small Cell","Lung Cancer, Non-Small Cell",1,2,2,DRUG; RADIATION,,,1,30,True,Yes,Overall Survival (MEDIAN) months = 4.0 [3.4-4.8],"Six-month Survival (NUMBER) percentage of participants = 36; Number of Participants With a Complete Response (CR) or a Partial Response (PR) (Central Nervous System [CNS]-Radiologic) (NUMBER) participants = 23; Time to Response (TTR) (CNS-radiologic) (MEDIAN) weeks = 8.0 [7.7-8.1]; Time to Progression (TTP) (CNS-radiologic) (MEDIAN) weeks = 9.7 [8.1-13.9]; Time to Progression (TTP) (All Sites of Disease-radiologic) (MEDIAN) weeks = 8.0 [6.7-8.7]; Number of Participants Who Ranked Each Individual Indicated Neurological Sign and Symptom as None, Mild, Moderate, or Severe at Months 1 and 3 (NUMBER) participants = 93; Number of Participants With the Indicated Investigator Assessment for the Neurological Sign and Symptom of Level of Consciousness at Baseline, Month 1, and Month 3 (NUMBER) participants = 219; Number of Participants With the Indicated Investigator Assessment for the Neurological Sign and Symptom of Headache at Baseline, Month 1, and Month 3 (NUMBER) participants = 141; Number of Participants With the Indicated Investigator Assessment for the Neurological Sign and Symptom of Dizziness/Lightheadedness at Baseline, Month 1, and Month 3 (NUMBER) participants = 160; Number of Participants With the Indicated Investigator Assessment for the Neurological Sign and Symptom of Vertigo at Baseline, Month 1, and Month 3 (NUMBER) participants = 180; Number of Participants With the Indicated Investigator Assessment for the Neurological Sign and Symptom of Nausea/Vomiting at Baseline, Month 1, and Month 3 (NUMBER) participants = 203; Number of Participants With the Indicated Investigator Assessment for the Neurological Sign and Symptom of Visual Problem at Baseline, Month 1, and Month 3 (NUMBER) participants = 181; Number of Participants With the Indicated Investigator Assessment for the Neurological Sign and Symptom of Seizure at Baseline, Month 1, and Month 3 (NUMBER) participants = 218; Number of Participants With the Indicated Investigator Assessment for the Neurological Sign and Symptom of Other Neurological Symptoms at Baseline, Month 1, and Month 3 (NUMBER) participants = 219; Number of Participants With the Indicated Investigator Assessment of Cranial Nerves II-XII at Baseline, Month 1, and Month 3 (NUMBER) participants = 218; Number of Participants With the Indicated Investigator Assessment of Language (Dysphasia or Aphasia) at Baseline, Month 1, and Month 3 (NUMBER) participants = 211; Number of Participants With the Indicated Investigator Assessment of Strength (Right Upper Extremity) at Baseline, Month 1, and Month 3 (NUMBER) participants = 203; Number of Participants With the Indicated Investigator Assessment of Strength (Left Upper Extremity) at Baseline, Month 1, and Month 3 (NUMBER) participants = 197; Number of Participants With the Indicated Investigator Assessment of Strength (Right Lower Extremity) at Baseline, Month 1, and Month 3 (NUMBER) participants = 196; Number of Participants With the Indicated Investigator Assessment of Strength (Left Lower Extremity) at Baseline, Month 1, and Month 3 (NUMBER) participants = 182; Number of Participants With the Indicated Investigator Assessment of Sensation at Baseline, Month 1, and Month 3 (NUMBER) participants = 197; Number of Participants With the Indicated Investigator Assessment of Ataxia (Right Upper Extremity: Finger to Nose Testing) at Baseline, Month 1, and Month 3 (NUMBER) participants = 206; Number of Participants With the Indicated Investigator Assessment of Ataxia (Left Upper Extremity: Finger to Nose Testing) at Baseline, Month 1, and Month 3 (NUMBER) participants = 199; Number of Participants With the Indicated Investigator Assessment of Ataxia (Gait) at Baseline, Month 1, and Month 3 (NUMBER) participants = 172; Number of Participants With the Indicated Investigator Assessment of Ataxia (Balance) at Baseline, Month 1, and Month 3 (NUMBER) participants = 153; Number of Participants With Any Adverse Event (AE; Both Serious and Non-serious) or Serious Adverse Event (SAE) (NUMBER) participants = 204; Number of Participants With the Indicated Worst-case Change From Baseline in the Indicated Chemistry Parameters With Respect to the Normal Range (NUMBER) participants = 32; ; ; Number of Participants Who Died or Progressed (NUMBER) participants = 179",,Number of Participants With a Complete Response (CR) or a Partial Response (PR) (Central Nervous System [CNS]-Radiologic) (NUMBER) participants = 23,,,,,,,Overall Survival (MEDIAN) months = 4.0 [3.4-4.8],,Number of Participants With a Complete Response (CR) or a Partial Response (PR) (Central Nervous System [CNS]-Radiologic) (NUMBER) participants = 23,,,,,Time to Progression (TTP) (CNS-radiologic) (MEDIAN) weeks = 9.7 [8.1-13.9]; Time to Progression (TTP) (All Sites of Disease-radiologic) (MEDIAN) weeks = 8.0 [6.7-8.7]
NCT00391274,Chemotherapy for Patients With Non-Small Cell Lung Cancer (NSCLC),Phase 3 Study of Pemetrexed Versus Docetaxel in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Had Prior Chemotherapy,Eli Lilly and Company,Eli Lilly and Company,INDUSTRY,COMPLETED,2006-10,2008-12,2010-06,INTERVENTIONAL,PHASE3,,,,Non-Small Cell Lung Cancer,Non-Small Cell Lung Cancer,1,2,2,DRUG,,,1,4,True,Yes,Overall Survival (MEDIAN) months = 11.7,Overall Tumor Response (NUMBER) participants = 0; Progression-Free Survival (PFS) (MEDIAN) months = 2.8 [1.8-3.1]; ; Pharmacology Toxicity (NUMBER) participants = 1,,,,,,,,,Overall Survival (MEDIAN) months = 11.7,Progression-Free Survival (PFS) (MEDIAN) months = 2.8 [1.8-3.1],,,,Pharmacology Toxicity (NUMBER) participants = 1,,
NCT00400829,E7389 in Treating Patients With Recurrent or Progressive Stage IIIB or Stage IV Non-Small Cell Lung Cancer,A Phase 2 Study of the Halichondrin B Analog E7389 in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Previously Treated With a Taxane,National Cancer Institute (NCI),National Cancer Institute (NCI),NIH,COMPLETED,2006-11,2011-01,2011-01,INTERVENTIONAL,PHASE2,,,,Recurrent Non-small Cell Lung Cancer,Recurrent Non-small Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer,3,1,1,DRUG,,,1,2,True,Yes,Objective Response Rate (CR or PR) According to RECIST Criteria (NUMBER) percentage of patients responding = 5,Overall Survival (MEDIAN) Months = 11.6 [8.2-13.7]; Progression Free Survival (MEDIAN) Months = 2.7 [1.3-3.9],,,,,,,,Objective Response Rate (CR or PR) According to RECIST Criteria (NUMBER) percentage of patients responding = 5,Overall Survival (MEDIAN) Months = 11.6 [8.2-13.7],Progression Free Survival (MEDIAN) Months = 2.7 [1.3-3.9],Objective Response Rate (CR or PR) According to RECIST Criteria (NUMBER) percentage of patients responding = 5,,Objective Response Rate (CR or PR) According to RECIST Criteria (NUMBER) percentage of patients responding = 5,,,
NCT00402051,Chemotherapy With Pemetrexed in Combination With Platinum for Advanced Non-Small Cell Lung Cancer (NSCLC),A Randomized Phase 2 Study of Pemetrexed in Combination With Cisplatin or Carboplatin in the First Line Therapy of Advanced NSCLC,Eli Lilly and Company,Eli Lilly and Company,INDUSTRY,COMPLETED,2006-11,2008-12,2009-05,INTERVENTIONAL,PHASE2,,,,Non-Small-Cell Lung Cancer,Non-Small-Cell Lung Cancer,1,2,3,DRUG,,,1,4,True,Yes,Percentage of Participants Surviving Progression-Free at 6 Months (Progression Free Survival [PFS] Rate) (NUMBER) percentage = 52.8 [40.3-65.3],Overall Survival (MEDIAN) months = 11.7 [9.2-14.9]; Number of Participants With Tumor Response (as Basis for Response Rate) (NUMBER) participants = 21; Time to Treatment Failure (TTF) (MEDIAN) months = 3.0 [2.3-4.6]; Pharmacology Toxicities (NUMBER) participants = 29,,,,,,,,,Overall Survival (MEDIAN) months = 11.7 [9.2-14.9],Percentage of Participants Surviving Progression-Free at 6 Months (Progression Free Survival [PFS] Rate) (NUMBER) percentage = 52.8 [40.3-65.3],,,Number of Participants With Tumor Response (as Basis for Response Rate) (NUMBER) participants = 21,,Time to Treatment Failure (TTF) (MEDIAN) months = 3.0 [2.3-4.6],
NCT00404924,ZD6474 (ZACTIMA™) Phase III Study in EGFR Failures,A Phase III Study to Assess the Efficacy of ZD6474 (ZACTIMA™) Plus Best Supportive Care Versus Best Supportive Care in Patients With Locally Advanced or Metastatic (Stage IIIB-IV) Non-Small Cell Lung ,Sanofi,"Genzyme, a Sanofi Company",INDUSTRY,COMPLETED,2006-11,2009-10,2014-11,INTERVENTIONAL,PHASE3,,,,Non-Small-Cell Lung Carcinoma,Non-Small-Cell Lung Carcinoma,1,2,2,DRUG; OTHER,,,1,5,True,Yes,Overall Survival (OS) (MEDIAN) Months = 8.5 [7.81-9.76],Progression-Free Survival (PFS) (MEDIAN) month = 1.9 [1.84-2.23]; Objective Response Rate (ORR) (NUMBER) Participants = 16; Disease Control Rate (DCR) (NUMBER) Participants = 189; Duration of Response (DoR) (MEDIAN) Weeks = 23.9 [16.57-27.00]; Time to Deterioration of Disease-related Symptoms (TDS) by Questionnaire - the Lung Cancer Subscale (LCS) a Selection of the FACT-L Focusing on Symptoms of Lung Cancer Plus Pain and Fatigue (LCS-PF) (MEDIAN) weeks = 6.1 [5.14-8.14],,,,,Duration of Response (DoR) (MEDIAN) Weeks = 23.9 [16.57-27.00],,,Objective Response Rate (ORR) (NUMBER) Participants = 16,Overall Survival (OS) (MEDIAN) Months = 8.5 [7.81-9.76],Progression-Free Survival (PFS) (MEDIAN) month = 1.9 [1.84-2.23],,,Objective Response Rate (ORR) (NUMBER) Participants = 16,,,
NCT00408460,Imatinib Mesylate and Paclitaxel in Treating Older Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer,A Phase II Study of Intermittent Gleevec® (Imatinib Mesylate) and Weekly Paclitaxel in Patients Aged 70 or Older With Advanced Non-Small Cell Lung Cancer,University of Washington,University of Washington,OTHER,COMPLETED,2006-02,2010-08,2012-10,INTERVENTIONAL,PHASE2,,,,Malignant Pleural Effusion,Malignant Pleural Effusion; Recurrent Non-small Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer,4,1,2,DRUG,,,1,2,True,Yes,Overall Response Rate (Complete and Partial Responses) as Assessed by RECIST Criteria (COUNT_OF_PARTICIPANTS) Participants = 11,Time to Tumor Progression (MEDIAN) months = 3.6 [0.5-103]; Overall Survival (MEDIAN) months = 7.3 [0.5-60],,,,,,,,,Overall Survival (MEDIAN) months = 7.3 [0.5-60],,Overall Response Rate (Complete and Partial Responses) as Assessed by RECIST Criteria (COUNT_OF_PARTICIPANTS) Participants = 11,,Overall Response Rate (Complete and Partial Responses) as Assessed by RECIST Criteria (COUNT_OF_PARTICIPANTS) Participants = 11,,,
NCT00409006,Chemotherapy for Patients With Non-Small Cell Lung Cancer Who Are Non-Smokers,"A Phase 2 Trial of Pemetrexed and Cisplatin Followed Sequentially by Gefitinib Versus Pemetrexed and Cisplatin in Asian ""Never Smoker"" Patients With Advanced Non-Small Cell Lung Cancer",Eli Lilly and Company,Eli Lilly and Company,INDUSTRY,COMPLETED,2007-02,2009-08,2010-05,INTERVENTIONAL,PHASE2,,,,Non-small Cell Lung Cancer,Non-small Cell Lung Cancer,1,2,3,DRUG,,,1,3,True,Yes,Progression-Free Survival (PFS) (MEDIAN) Months = 9.95 [5.85-16.49],Number of Participants With Tumor Response (NUMBER) Participants = 18 [30.1-62.8]; Duration of Response for Responders (MEDIAN) Months = 12.29 [8.51-15.31]; ,,,,,Duration of Response for Responders (MEDIAN) Months = 12.29 [8.51-15.31],,,,,Progression-Free Survival (PFS) (MEDIAN) Months = 9.95 [5.85-16.49],,,,,,
NCT00409188,Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START),"A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unres",EMD Serono,EMD Serono,INDUSTRY,COMPLETED,2007-01,2012-04,2015-04,INTERVENTIONAL,PHASE3,,,,Non-small Cell Lung Cancer,Non-small Cell Lung Cancer,1,2,3,BIOLOGICAL; DRUG,,,1,4,True,Yes,Overall Survival (MEDIAN) months = 25.6 [22.5-29.2],"Time To Symptom Progression (TTSP) as Measured by the Lung Cancer Symptom Scale (LCSS) (MEDIAN) months = 14.2 [12.9-15.7]; Time To Progression (TTP) (MEDIAN) months = 10.0 [9.1-11.5]; One-, Two- and Three-year Survival Rate (NUMBER) percentage of participants = 77.0; Number of Participants With Treatment Emergent Adverse Events and Injection Site Reactions (NUMBER) participants = 938",,,,,,,,,Overall Survival (MEDIAN) months = 25.6 [22.5-29.2],,,,,Number of Participants With Treatment Emergent Adverse Events and Injection Site Reactions (NUMBER) participants = 938,,Time To Progression (TTP) (MEDIAN) months = 10.0 [9.1-11.5]
NCT00410904,AZD2171 and Pemetrexed Disodium in Treating Patients With Relapsed Non-Small Cell Lung Cancer,Phase 2 Study of AZD2171 (NSC 732208) in Combination With Pemetrexed in Relapsed Non-Small Cell Lung Cancer (NOS: 10029514),National Cancer Institute (NCI),National Cancer Institute (NCI),NIH,COMPLETED,2006-10,2013-07,2014-03,INTERVENTIONAL,PHASE2,,,,Recurrent Non-small Cell Lung Cancer,Recurrent Non-small Cell Lung Cancer,1,1,2,DRUG,,,1,2,True,Yes,Response Rate (Complete and Partial) 2 Separate Cohorts of Relapsed NSCLC Cohort A: Pts Who Have Received Prior Chemo w/o Ever Having Received Bevacizumab. Cohort B: Pts Who Have Received Prior Bevacizumab. (NUMBER) participants = 10,Progression-free Survival (MEDIAN) months = 5.6 [4.1-6.8]; Overall Survival (MEDIAN) months = 11.5 [6.9-14.0],,,,,,,,,Overall Survival (MEDIAN) months = 11.5 [6.9-14.0],Progression-free Survival (MEDIAN) months = 5.6 [4.1-6.8],,,Response Rate (Complete and Partial) 2 Separate Cohorts of Relapsed NSCLC Cohort A: Pts Who Have Received Prior Chemo w/o Ever Having Received Bevacizumab. Cohort B: Pts Who Have Received Prior Bevacizumab. (NUMBER) participants = 10,,,
NCT00413283,Dose/ Schedule Finding Trial of Romiplostim for Chemotherapy-Induced Thrombocytopenia (CIT) in Non-Small Cell Lung Cancer (NSCLC),"Phase 2, Randomized, Double Blind, Placebo-Controlled Dose and Schedule Finding Trial to Evaluate the Safety and Efficacy of AMG 531 For Treatment of Chemotherapy-Induced Thrombocytopenia in Subjects ",Amgen,Amgen,INDUSTRY,COMPLETED,2006-12,2008-12,2009-02,INTERVENTIONAL,PHASE2,,,,Lung Cancer,Lung Cancer; Chemotherapy-Induced Thrombocytopenia; Non-Small Cell Lung Cancer,8,4,5,BIOLOGICAL; DRUG,,,1,5,True,Yes,Number of Participants With Adverse Events (NUMBER) Participants = 12,Duration of Grade 3 or 4 Thrombocytopenia (MEAN) days = 2.1; Number of Participants Experiencing Grade 3 or 4 Thrombocytopenia During the First Treatment Cycle. (NUMBER) Participants = 5; Number of Participants With Platelet Transfusions (NUMBER) Participants = 1; Platelet Count on Day 22 (MEAN) 10^9/L = 281.2; Gemcitabine Dose Reduction on Day 8 of the First Chemotherapy Cycle (NUMBER) Participants = 2,,,,,,,,,,,,,,Number of Participants With Adverse Events (NUMBER) Participants = 12,,
NCT00415363,"Study of Enzastaurin Versus Placebo in the Treatment of Patients With Brain Metastases of Lung Cancer, After Whole Brain Radiation Therapy","A Double-blind, Randomized, Placebo-controlled Multicentre Phase II Study of Maintenance Enzastaurin Following Whole Brain Radiation Therapy in the Treatment of Brain Metastases From Lung Cancer",Eli Lilly and Company,Eli Lilly and Company,INDUSTRY,COMPLETED,2006-12,2011-01,2011-01,INTERVENTIONAL,PHASE2,,,,Non Small Cell Lung Cancer,Non Small Cell Lung Cancer; Small Cell Lung Cancer,2,2,2,DRUG,,,1,11,True,Yes,Time to Progression of Brain Metastases (MEDIAN) months = 6.9 [3.4-11.9],Time to Objective Progression of Brain Metastases (MEDIAN) months = 5.0 [3.1-8.4]; Overall Progression-free Survival (Including Both Progression of Brain and Extracranial Tumor Lesion) (MEDIAN) months = 2.2 [1.1-2.3]; Overall Survival (MEDIAN) months = 3.8 [2.6-5.6]; Overall Response (OR) to Treatment of Extra-cranial Tumor Lesions by Percentage of Participants (NUMBER) percentage of participants = 0 [0-8.6]; Best Overall Tumor Response on Brain Metastases by Percentage of Participants (NUMBER) percentage of participants = 0 [0-8.2]; Health-related Quality of Life (HRQoL) EORTC QLQ-C30 Physical Functioning (MEDIAN) units on a scale = -6.7 [-20.0-0]; HRQoL Questionnaire - EORTC QLQ-C30 Fatigue (MEDIAN) units on a scale = 0 [0-22.2]; HRQoL Questionnaire - EORTC QLQ-C30 Nausea/Vomiting (MEDIAN) units on a scale = 0 [-16.7-16.7]; HRQoL Questionnaire - EORTC QLQ-C30 Diarrhea (MEDIAN) units on a scale = 0 [0-0]; HRQoL Questionnaire - QLQ-BN20 Headache (MEDIAN) units on a scale = 0 [-33.3-0]; Number of Participants With Adverse Events (COUNT_OF_PARTICIPANTS) Participants = 35,,,,,,,,,Overall Survival (MEDIAN) months = 3.8 [2.6-5.6],Overall Progression-free Survival (Including Both Progression of Brain and Extracranial Tumor Lesion) (MEDIAN) months = 2.2 [1.1-2.3],,Health-related Quality of Life (HRQoL) EORTC QLQ-C30 Physical Functioning (MEDIAN) units on a scale = -6.7 [-20.0-0]; HRQoL Questionnaire - EORTC QLQ-C30 Fatigue (MEDIAN) units on a scale = 0 [0-22.2]; HRQoL Questionnaire - EORTC QLQ-C30 Nausea/Vomiting (MEDIAN) units on a scale = 0 [-16.7-16.7]; HRQoL Questionnaire - EORTC QLQ-C30 Diarrhea (MEDIAN) units on a scale = 0 [0-0]; HRQoL Questionnaire - QLQ-BN20 Headache (MEDIAN) units on a scale = 0 [-33.3-0],,Number of Participants With Adverse Events (COUNT_OF_PARTICIPANTS) Participants = 35,,Time to Progression of Brain Metastases (MEDIAN) months = 6.9 [3.4-11.9]
NCT00418886,Efficacy Study Comparing ZD6474 in Combination With Pemetrexed and Pemetrexed Alone in 2nd Line NSCLC Patients,"A Phase III, Randomized, Double-blinded, Parallel Group, Multi-centre Study to Assess the Efficacy and Safety of ZD6474 (ZACTIMA™) in Combination With Pemetrexed (Alimta®) Versus Pemetrexed Alone in P",Sanofi,"Genzyme, a Sanofi Company",INDUSTRY,COMPLETED,2007-01,2008-09,2023-02-14,INTERVENTIONAL,PHASE3,,,,Non Small Cell Lung Cancer,Non Small Cell Lung Cancer; Lung Cancer,2,2,2,DRUG,,,2,8,True,Yes,Progression-Free Survival (PFS) in the Overall Population (MEDIAN) weeks = 17.6 [13.4-18.9]; Progression-Free Survival in the Female Population (MEDIAN) weeks = 17.9 [14.7-22.7],Overall Survival (OS) (MEDIAN) months = 10.5 [8.9-12.3]; Objective Response Rate (ORR) (NUMBER) percentage of participants = 19.1; Disease Control Rate (DCR) (NUMBER) percentage of participants = 56.6; Duration of Response (DoR) (MEDIAN) weeks = 24.1 [17.4-30.0]; Time to Deterioration of Disease-Related Symptoms (TDS) by Lung Cancer Symptom Scale (LCSS) Total Score (MEDIAN) weeks = 18.1 [15.1-23.6]; Time to Deterioration of Disease-Related Symptoms by Average Symptom Burden Index (ASBI) Score (MEDIAN) weeks = 16.0 [14.0-20.3]; Longitudinal Analysis of Lung Cancer Symptom Scale Total Score (LEAST_SQUARES_MEAN) mms on a visual analogue scale = 25.7; Longitudinal Analysis of Average Symptom Burden Index Score (LEAST_SQUARES_MEAN) mms on a visual analogue scale = 21.7,,,,,Duration of Response (DoR) (MEDIAN) weeks = 24.1 [17.4-30.0],,,Objective Response Rate (ORR) (NUMBER) percentage of participants = 19.1,Overall Survival (OS) (MEDIAN) months = 10.5 [8.9-12.3],Progression-Free Survival (PFS) in the Overall Population (MEDIAN) weeks = 17.6 [13.4-18.9]; Progression-Free Survival in the Female Population (MEDIAN) weeks = 17.9 [14.7-22.7],,,Objective Response Rate (ORR) (NUMBER) percentage of participants = 19.1,,,
NCT00446225,Phase III Study (Tarceva®) vs Chemotherapy to Treat Advanced Non-Small Cell Lung Cancer in Patients With Mutations in the TK Domain of EGFR,"Phase III, Multicenter, Open-label, Randomized Trial of Tarceva® vs Chemotherapy in Patients With Advanced NSCLC With Mutations in the TK Domain of the EGFR",Spanish Lung Cancer Group,Spanish Lung Cancer Group,OTHER,COMPLETED,2007-02-15,2012-04-11,2012-12,INTERVENTIONAL,PHASE3,,,,Non-Small Cell Lung Cancer,Non-Small Cell Lung Cancer,1,2,5,DRUG,,,1,3,True,Yes,Progression Free-survival (MEDIAN) months = 9.4 [7.9-12.3],Objective Response (NUMBER) percentage of participants = 2.3; Overall Survival (MEDIAN) months = 33.4 [26.7-39]; Molecular Markers Related to EGFR and Study Pathology (COUNT_OF_UNITS) Sample of serum = 30,,,,,,,,,Overall Survival (MEDIAN) months = 33.4 [26.7-39],,,,,,,
NCT00452413,A Study of Enzastaurin and Erlotinib in Participants With Solid Tumors and Lung Cancer,A Phase 1/2 Trial of Enzastaurin and Erlotinib in Patients With Advanced Solid Tumors and Non-Small Cell Lung Cancer (NSCLC) After Prior Chemotherapy,Eli Lilly and Company,Eli Lilly and Company,INDUSTRY,COMPLETED,2007-05,2009-07,2013-11,INTERVENTIONAL,PHASE1; PHASE2,,,,Non-Small Cell Lung Cancer,Non-Small Cell Lung Cancer; Malignant Solid Tumor,2,1,2,DRUG,,,2,8,True,Yes,Recommended Phase 2 Dose for Enzastaurin Plus Erlotinib Combination Therapy (Assess the Tolerated Dose of the Combination Erlotinib and Enzastaurin) (NUMBER) milligrams per day (mg/day) = 500; Phase 2: Progression-Free Survival (PFS) With the Enzastaurin Plus Erlotinib Combination Regimen (MEDIAN) months = 1.7,"Phase I: Number of Participants Who Experienced Treatment-Emergent Adverse Events (TEAEs) (Safety and AE Profile for Enzastaurin/Erlotinib Combination) (NUMBER) Participants = 4; Phase I: Pharmacokinetic (PK) Interactions Between Enzastaurin and Erlotinib: Apparent Oral Clearance of Erlotinib Under Steady State Conditions During Multiple Dosing (CLss/F) (GEOMETRIC_MEAN) Liters per hour (L/h) = 6.07; Phase I: PK Interactions Between Enzastaurin and Erlotinib: Maximum Observed Plasma Concentration at Steady State (Cmax,ss) (GEOMETRIC_MEAN) nanomoles per liter (nmol/L) = 618; Phase I: PK Interactions Between Enzastaurin and Erlotinib: Area Under the Plasma Concentration Time Curve at Steady State [AUC(Tau,ss)] (GEOMETRIC_MEAN) nanomoles*hours per liter (nmol*h/L) = 6590; Phase 2: Overall Survival (OS) (MEDIAN) months = 8.3 [5.3-14.3]; Phase 2: Duration of Response (MEDIAN) months = 8.7; Phase 2: Percentage of Participants With Tumor Response (NUMBER) percentage of participants = 0 [0-7.3]; Phase 2: Number of Participants Who Experienced TEAEs (Safety and AE Profile) (NUMBER) participants = 48",,,,,Phase 2: Duration of Response (MEDIAN) months = 8.7,,,,Phase 2: Overall Survival (OS) (MEDIAN) months = 8.3 [5.3-14.3],Phase 2: Progression-Free Survival (PFS) With the Enzastaurin Plus Erlotinib Combination Regimen (MEDIAN) months = 1.7,,,,Phase I: Number of Participants Who Experienced Treatment-Emergent Adverse Events (TEAEs) (Safety and AE Profile for Enzastaurin/Erlotinib Combination) (NUMBER) Participants = 4; Phase 2: Number of Participants Who Experienced TEAEs (Safety and AE Profile) (NUMBER) participants = 48,,
NCT00453362,A Study of Changes in FDG- and FLT-PET Imaging in Patients With Non-Small Cell Lung Cancer Following Treatment With Erlotinib,Pilot Study of Changes in FDG- and FLT-PET Imaging in Patients With Non-Small Cell Lung Cancer Following Treatment With Erlotinib,"Genentech, Inc.","Genentech, Inc.",INDUSTRY,COMPLETED,2006-12,2010-04,2010-04-23,INTERVENTIONAL,PHASE1; PHASE2,,,,Non-Small Cell Lung Cancer,Non-Small Cell Lung Cancer,1,1,3,DRUG; OTHER,,,8,5,True,Yes,Progression Free Survival (PFS) of Groups by FDG Response at Day 56 (MEDIAN) weeks = 28.1 [16.14-40.14]; PFS of Patients With FDG-PET Complete Response (CR)/Partial Response (PR) Versus FDG-PET Progressive Disease (PD) in Patients With Computed Tomography (CT) Stable Disease (SD) at Day 56 (MEDIAN) weeks = 32.1 [18-32.14]; Progression Free Survival of Groups by FLT Response at Day 56 (MEDIAN) weeks = 39.9 [18-40.14]; ; ; Overall Survival of Patients With FDG CR/PR Versus FDG PD in Patients With CT SD at Day 56 (MEDIAN) months = 12.2 [4.99-17.84]; ; ,Percentage of Patients With FDG-PET Responses (NUMBER) Percentage of Participants = 7.7 [1.4-23.4]; Percentage of Patients With FLT-PET Responses (NUMBER) Percentage of Participants = 7.7 [1.4-23.4]; FDG Response in Subgroups by CT Response at Day 56 (NUMBER) Percentage of participants = 75 [24.9-98.7]; FLT Response in Subgroups by CT Response at Day 56 (NUMBER) Percentage of participants = 50 [9.8-90.2]; Number of Participants With Adverse Events Due to FLT-PET Imaging (NUMBER) Participants = 0,,PFS of Patients With FDG-PET Complete Response (CR)/Partial Response (PR) Versus FDG-PET Progressive Disease (PD) in Patients With Computed Tomography (CT) Stable Disease (SD) at Day 56 (MEDIAN) weeks = 32.1 [18-32.14],,,,,,,Overall Survival of Patients With FDG CR/PR Versus FDG PD in Patients With CT SD at Day 56 (MEDIAN) months = 12.2 [4.99-17.84],Progression Free Survival (PFS) of Groups by FDG Response at Day 56 (MEDIAN) weeks = 28.1 [16.14-40.14]; PFS of Patients With FDG-PET Complete Response (CR)/Partial Response (PR) Versus FDG-PET Progressive Disease (PD) in Patients With Computed Tomography (CT) Stable Disease (SD) at Day 56 (MEDIAN) weeks = 32.1 [18-32.14]; Progression Free Survival of Groups by FLT Response at Day 56 (MEDIAN) weeks = 39.9 [18-40.14],PFS of Patients With FDG-PET Complete Response (CR)/Partial Response (PR) Versus FDG-PET Progressive Disease (PD) in Patients With Computed Tomography (CT) Stable Disease (SD) at Day 56 (MEDIAN) weeks = 32.1 [18-32.14],,,Number of Participants With Adverse Events Due to FLT-PET Imaging (NUMBER) Participants = 0,,
NCT00459342,"Dasatinib in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer",Phase II Study of Dasatinib in Non Small Cell Lung Cancer,National Cancer Institute (NCI),National Cancer Institute (NCI),NIH,COMPLETED,2007-03,2012-04,2012-04,INTERVENTIONAL,PHASE2,,,,Non-small Cell Lung Cancer,Non-small Cell Lung Cancer; Recurrent Non-small Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer,4,1,1,DRUG,,,2,0,True,Yes,Number of Participants With Objective Response (Complete Response (CR) or Partial Response (PR)) (NUMBER) participants = 1; Progression-free Survival (PFS) (MEDIAN) months = 1.36 [0.16-17.2],,,Number of Participants With Objective Response (Complete Response (CR) or Partial Response (PR)) (NUMBER) participants = 1,,,,,,,,Progression-free Survival (PFS) (MEDIAN) months = 1.36 [0.16-17.2],Number of Participants With Objective Response (Complete Response (CR) or Partial Response (PR)) (NUMBER) participants = 1,,,,,
NCT00478699,Randomized Customized Adjuvant Chemotherapy (GECP-SCAT),"Phase III, Open, Multicenter and Randomized Study of Customized Adjuvant Chemotherapy Based on BRCA1 mRNA Levels in Completely Resected Stages II-IIIA Non-Small-Cell Lung Cancer Patients",Spanish Lung Cancer Group,Spanish Lung Cancer Group,OTHER,COMPLETED,2007-06,2015-06,2015-07,INTERVENTIONAL,PHASE3,,,,Non-small-cell Lung Cancer,Non-small-cell Lung Cancer,1,2,4,DRUG,,,1,1,True,Yes,Estimated Overall Survival (NUMBER) proportion of participants = 0.54 [0.44-0.64],Disease Free Survival (MEDIAN) Month = 38.7 [18.6-58.8],,,Disease Free Survival (MEDIAN) Month = 38.7 [18.6-58.8],,,,,,Estimated Overall Survival (NUMBER) proportion of participants = 0.54 [0.44-0.64],,,,,,,
NCT00481078,"Vorinostat, Carboplatin, and Paclitaxel in Treating Patients With Advanced or Metastatic Non-Small Cell Lung Cancer",Randomized Phase II Study of Vorinostat or Placebo in Combination With Carboplatin and Paclitaxel for Patients With Advanced or Metastatic Non-Small Cell Lung Cancer,National Cancer Institute (NCI),National Cancer Institute (NCI),NIH,COMPLETED,2007-05,2009-07,2009-07,INTERVENTIONAL,PHASE2,,,,Recurrent Non-small Cell Lung Cancer,Recurrent Non-small Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer,3,2,5,DRUG; OTHER,,,1,2,True,Yes,Response Rate (NUMBER) percentage of responding patients = 34 [22-47],Progression-free Survival (MEDIAN) Months = 6 [4.3-6.9]; Overall Survival (MEDIAN) Months = 13,,,,,,,,,Overall Survival (MEDIAN) Months = 13,Progression-free Survival (MEDIAN) Months = 6 [4.3-6.9],,,Response Rate (NUMBER) percentage of responding patients = 34 [22-47],,,
NCT00482014,"A Study of Pemetrexed Plus Carboplatin, or Pemetrexed Plus Cisplatin With Radiation Therapy Followed by Pemetrexed in Patients With Inoperable Non-Sma","Phase 1/2 Study of Pemetrexed (Alimta) Plus Carboplatin, or Pemetrexed Plus Cisplatin With Concurrent Radiation Therapy Followed by Every-21-Day Pemetrexed Consolidation in Patients With Favorable-Pro",Eli Lilly and Company,Eli Lilly and Company,INDUSTRY,COMPLETED,2007-05,2011-10,2011-10,INTERVENTIONAL,PHASE1; PHASE2,,,,Non-Small-Cell Lung Cancer,Non-Small-Cell Lung Cancer,1,2,4,DRUG; RADIATION,,,3,6,True,Yes,; ; Phase 2 - Survival Probability at 2 Years (MEAN) percentage survival = 45.4 [29.5-60.0],Phase 1 - Pharmacology Toxicity: Number of Participants With Dose Limiting Toxicities (DLTs) (NUMBER) participants = 1; Phase 1 - Percentage of Participants With Complete Response or Partial Response (Response Rate) (NUMBER) percentage of participants = 0 [0.0-0.0]; Phase 2 - Pharmacology Toxicity: Number of Participants With Adverse Events (NUMBER) participants = 21 [6.0-12.6]; Phase 2 - Time to Progression (MEDIAN) months = 8.8 [6.0-12.6]; Phase 2 - Median Survival (MEDIAN) months = 18.7; Phase 2 - Percentage of Participants With Complete Response or Partial Response (Response Rate) (NUMBER) percentage of participants = 6.5 [1.4-17.9],,Phase 1 - Percentage of Participants With Complete Response or Partial Response (Response Rate) (NUMBER) percentage of participants = 0 [0.0-0.0]; Phase 2 - Percentage of Participants With Complete Response or Partial Response (Response Rate) (NUMBER) percentage of participants = 6.5 [1.4-17.9],,,,,,,,,Phase 1 - Percentage of Participants With Complete Response or Partial Response (Response Rate) (NUMBER) percentage of participants = 0 [0.0-0.0]; Phase 2 - Percentage of Participants With Complete Response or Partial Response (Response Rate) (NUMBER) percentage of participants = 6.5 [1.4-17.9],,Phase 1 - Percentage of Participants With Complete Response or Partial Response (Response Rate) (NUMBER) percentage of participants = 0 [0.0-0.0]; Phase 2 - Percentage of Participants With Complete Response or Partial Response (Response Rate) (NUMBER) percentage of participants = 6.5 [1.4-17.9],Phase 1 - Pharmacology Toxicity: Number of Participants With Dose Limiting Toxicities (DLTs) (NUMBER) participants = 1; Phase 2 - Pharmacology Toxicity: Number of Participants With Adverse Events (NUMBER) participants = 21 [6.0-12.6],,Phase 2 - Time to Progression (MEDIAN) months = 8.8 [6.0-12.6]
NCT00487669,Phase II Study of Combination of Paclitaxel Poliglumex and Alimta for Advanced Non-small Cell Lung Cancer (NSCLC),"Phase II Study of the Combination of Paclitaxel Poliglumex (CT-2103, Xyotax) and Pemetrexed (Alimta) for the Treatment of Patients With Advanced Non-small Cell Lung Cancer.",Dartmouth-Hitchcock Medical Center,Dartmouth-Hitchcock Medical Center,OTHER,COMPLETED,2006-10,2009-11,2009-11,INTERVENTIONAL,PHASE2,,,,Advanced Non-small Cell Lung Cancer,Advanced Non-small Cell Lung Cancer,1,1,1,DRUG,,,1,2,True,Yes,To Evaluate the Overall Response Rate (Complete Plus Partial Responses by RECIST Criteria) to the Combination of Paclitaxel Poliglumex and Pemetrexed as Therapy in Patients With Advanced NSCLC. (NUMBER) participants = 5,Time to Progression (MEDIAN) months = 3.8 [1.5-9.2]; Overall Survival (MEDIAN) months = 7.7 [3.7-21.4],,,,,,,,,Overall Survival (MEDIAN) months = 7.7 [3.7-21.4],,To Evaluate the Overall Response Rate (Complete Plus Partial Responses by RECIST Criteria) to the Combination of Paclitaxel Poliglumex and Pemetrexed as Therapy in Patients With Advanced NSCLC. (NUMBER) participants = 5,,To Evaluate the Overall Response Rate (Complete Plus Partial Responses by RECIST Criteria) to the Combination of Paclitaxel Poliglumex and Pemetrexed as Therapy in Patients With Advanced NSCLC. (NUMBER) participants = 5,,,Time to Progression (MEDIAN) months = 3.8 [1.5-9.2]
NCT00492206,Study of Cetuximab With Radiation Followed by Consolidation Chemotherapy for NSCLC,A Phase II Study of Cetuximab in Combination With External Beam Radiation Followed By Consolidation Chemotherapy for Patients With Locally Advanced Non-Small Cell Lung Cancer (NSCLC),University of Pittsburgh,University of Pittsburgh,OTHER,COMPLETED,2006-06,2012-02,2012-02,INTERVENTIONAL,PHASE2,,,,Non Small Cell Lung Cancer (NSCLC),Non Small Cell Lung Cancer (NSCLC),1,1,1,DRUG,,,1,3,True,Yes,Overall Survival (OS) (MEDIAN) months = 19.4 [15.4-26],"Progression-free Survival (PFS) (MEDIAN) months = 9.3 [8.5-17.2]; Best Overall Response Rate (ORR) (Number of Participants) (NUMBER) participants = 4; EGFR (Epidermal Growth Factor Receptor) Gene Mutation and Akt, pAkt, and MAPKinase (NUMBER) percentage of tumors = 65",,,,,,,,,Overall Survival (OS) (MEDIAN) months = 19.4 [15.4-26],Progression-free Survival (PFS) (MEDIAN) months = 9.3 [8.5-17.2],,,Best Overall Response Rate (ORR) (Number of Participants) (NUMBER) participants = 4,,,
NCT00499109,Phase III of RRM1 & ERCC1 Directed Customized Chemotherapy for the Treatment of Patients With NSCLC,Randomized Phase III Multicenter Trial of RRM1 & ERCC1 Directed Customized Chemotherapy Versus Standard of Care for 1st Line Treatment of Patients With Advanced Non-Small-Cell Lung Cancer,H. Lee Moffitt Cancer Center and Research Institute,H. Lee Moffitt Cancer Center and Research Institute,OTHER,COMPLETED,2007-05,2013-04,2013-11,INTERVENTIONAL,PHASE3,,,,Non-Small Cell Lung Cancer,Non-Small Cell Lung Cancer,1,2,4,DRUG,,,1,2,True,Yes,Progression Free Survival (PFS) (NUMBER) estimated percentage of participants = 52 [45.2-59.8],Overall Survival (OS) (NUMBER) estimated percentage of participants = 46.1 [39.3-54]; Response Rate (RR) (NUMBER) participants = 0,,,,,,,,,Overall Survival (OS) (NUMBER) estimated percentage of participants = 46.1 [39.3-54],Progression Free Survival (PFS) (NUMBER) estimated percentage of participants = 52 [45.2-59.8],,,Response Rate (RR) (NUMBER) participants = 0,,,
NCT00499655,Erlotinib Hydrochloride With or Without Celecoxib in Treating Patients With Stage IIIB-IV Non-Small Cell Lung Cancer,"A Randomized, Placebo-Controlled Phase II Clinical Trial of Combination Erlotinib (Tarceva) and Celecoxib (Celebrex) Versus Erlotinib (Tarceva)/Placebo in Advanced Non-Small Cell Lung Cancer Patients",City of Hope Medical Center,City of Hope Medical Center,OTHER,COMPLETED,2007-11,2016-12,2016-12,INTERVENTIONAL,PHASE2,,,,Recurrent Non-small Cell Lung Cancer,Recurrent Non-small Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer,3,2,9,DRUG; GENETIC; OTHER,,,1,4,True,Yes,Progression-free Survival (MEDIAN) Months = 3.5 [1.8-5.5],Number of Participants With Overall Response (COUNT_OF_PARTICIPANTS) Participants = 17; Progression-free Survival - Elevated PGEM (MEDIAN) Months = 2.2 [1.8-5.5]; Progression-free Survival - EGRF (MEDIAN) Months = 1.8 [1.7-3.5]; Progression-free Survival - Low PGEM (MEDIAN) Months = 5.4 [1.7-7.2],,,,,,,,,,Progression-free Survival (MEDIAN) Months = 3.5 [1.8-5.5]; Progression-free Survival - Elevated PGEM (MEDIAN) Months = 2.2 [1.8-5.5]; Progression-free Survival - EGRF (MEDIAN) Months = 1.8 [1.7-3.5]; Progression-free Survival - Low PGEM (MEDIAN) Months = 5.4 [1.7-7.2],,,,,,
NCT00517595,Phase II Study Alimta and Gemzar + Avastin as First Line Chemotherapy for Elderly Patients With Stage IIIB/IV NSCLC,A Phase II Study of Pemetrexed and Gemcitabine Plus Bevacizumab as First Line Chemotherapy for Elderly Patients With Stage IIIB/IV Non-Small Cell Lung Cancer,Accelerated Community Oncology Research Network,Accelerated Community Oncology Research Network,OTHER,COMPLETED,2007-08,2011-04,2011-04,INTERVENTIONAL,PHASE2,,,,Non-Small Cell Lung Cancer,Non-Small Cell Lung Cancer,1,0,1,DRUG,,,1,3,True,Yes,Progression Free Survival (PFS) (MEDIAN) Months = 4.90 [3.82-5.76],Time to Progression (TTP) (MEDIAN) Months = 5.56 [4.61-7.57]; Overall Survival (OS) (MEDIAN) Months = 8.78 [6.71-19.9]; Overall Response (NUMBER) Participants = 0,,,,,,,,,Overall Survival (OS) (MEDIAN) Months = 8.78 [6.71-19.9],Progression Free Survival (PFS) (MEDIAN) Months = 4.90 [3.82-5.76],,,,,,Time to Progression (TTP) (MEDIAN) Months = 5.56 [4.61-7.57]
NCT00518011,A Study of Tarceva (Erlotinib) and Gemcitabine in Treatment-Naive Patients With Advanced Non-Small Cell Lung Cancer.,"A Randomized, Open Label Study Comparing the Effect of First-line Therapy With Tarceva + Gemcitabine Versus Gemcitabine Monotherapy on Treatment Response in Treatment-naïve Patients With Advanced Non-",Hoffmann-La Roche,Hoffmann-La Roche,INDUSTRY,COMPLETED,2007-08,2009-02,2009-02,INTERVENTIONAL,PHASE2,,,,Non-Squamous Non-Small Cell Lung Cancer,Non-Squamous Non-Small Cell Lung Cancer,1,2,2,DRUG,,,1,7,True,Yes,Progression Free Survival (MEDIAN) Week = 23.3 [7.1-24.9],Objective Response Rate (NUMBER) Percentage of participants = 0; Disease Control Rate (NUMBER) Percentage of participants = 50; Duration of Response (MEAN) Week = 16.3; Overall Survival (MEDIAN) Week = 21.1; Mean Change in Pulse Rate From Baseline (MEAN) beats per minute = 2.37; Mean Change in Blood Pressure From Baseline (MEAN) mm Hg = 3.00; Mean Change in Body Temperature From Baseline (MEAN) Fahrenheit = -0.02,,,,,Duration of Response (MEAN) Week = 16.3,,,Objective Response Rate (NUMBER) Percentage of participants = 0,Overall Survival (MEDIAN) Week = 21.1,Progression Free Survival (MEDIAN) Week = 23.3 [7.1-24.9],,,Objective Response Rate (NUMBER) Percentage of participants = 0,,,
NCT00520676,Chemotherapy in Treating Patients With Non-Small Cell Lung Cancer,A Randomized Phase 3 Study Comparing Pemetrexed-Carboplatin With Docetaxel-Carboplatin as First-Line Treatment for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer,Eli Lilly and Company,Eli Lilly and Company,INDUSTRY,COMPLETED,2007-10,2010-07,2010-07,INTERVENTIONAL,PHASE3,,,,Non-Small Cell Lung Cancer,Non-Small Cell Lung Cancer,1,2,3,DRUG,,,1,6,True,Yes,Survival Without Grade 3 or 4 Toxicity (MEDIAN) months = 3.2 [2.1-3.7],Overall Survival (OS) (MEDIAN) months = 14.9 [12.2-19.0]; Progression-free Survival (PFS) (MEDIAN) months = 5.8 [4.8-6.4]; Percentage of Participants With Tumor Response (Response Rate) (NUMBER) percentage of participants = 34.0 [25.0-43.8]; Survival Without Clinically Important Grade 3 or 4 Toxicity (MEDIAN) months = 3.6 [3.0-8.0]; Survival Without Grade 4 Toxicity (MEDIAN) participants = 12.2 [8.4-14.9]; Number of Participants With Adverse Events (AEs) (NUMBER) participants = 94,,,,,,,,,Overall Survival (OS) (MEDIAN) months = 14.9 [12.2-19.0],Progression-free Survival (PFS) (MEDIAN) months = 5.8 [4.8-6.4],,,Percentage of Participants With Tumor Response (Response Rate) (NUMBER) percentage of participants = 34.0 [25.0-43.8],Survival Without Grade 3 or 4 Toxicity (MEDIAN) months = 3.2 [2.1-3.7]; Survival Without Clinically Important Grade 3 or 4 Toxicity (MEDIAN) months = 3.6 [3.0-8.0]; Survival Without Grade 4 Toxicity (MEDIAN) participants = 12.2 [8.4-14.9]; Number of Participants With Adverse Events (AEs) (NUMBER) participants = 94,,
NCT00529100,"Concurrent Pemetrexed, Cisplatin and Radiation Therapy in Patients With Stage IIIA/B Non Small Cell Lung Cancer",A Phase I/II Study of Concurrent Pemetrexed/Cisplatin/Radiation in Stage IIIA/B Non-Small Cell Lung Cancer,Eli Lilly and Company,Eli Lilly and Company,INDUSTRY,COMPLETED,2005-12,2010-08,2012-09,INTERVENTIONAL,PHASE1; PHASE2,,,,Non-Small Cell Lung Cancer,Non-Small Cell Lung Cancer,1,2,5,DRUG; PROCEDURE,,,2,7,True,Yes,Phase 1: Maximum Tolerated Dose (MTD) of Pemetrexed in Combination With Cisplatin and Radiation Therapy (NUMBER) milligrams per square meter (mg/m^2) = 500; Phase 2: Percentage of Participants With Overall Survival (OS) at 1 Year (NUMBER) percentage of participants = 79.0 [66.1-92.0],Phase 1: Number of Participants With Adverse Events (AE; Toxicity) (NUMBER) participants = 5; Phase 2: Percentage of Participants With Overall Survival (OS) at 2 Years and 3 Years (NUMBER) percentage of participants = 56.4 [40.8-72.0]; Phase 2: Time to Progressive Disease (PD) (MEDIAN) months = 13.7 [10.2-19.2]; Phase 2: Percentage of Participants With Progression Free Survival (PFS) (NUMBER) percentage of participants = 48.7 [33.0-64.4]; Progression Free Survival (PFS) (MEDIAN) months = 11.8 [9.8-19.2]; Phase 2: Percentage of Participants With Objective Tumor Response (Response Rate) (NUMBER) percentage of participants = 0 [0-0]; Phase 2: Site of Progressive Disease (PD) (NUMBER) participants = 8,,,,,,,,,Phase 2: Percentage of Participants With Overall Survival (OS) at 1 Year (NUMBER) percentage of participants = 79.0 [66.1-92.0]; Phase 2: Percentage of Participants With Overall Survival (OS) at 2 Years and 3 Years (NUMBER) percentage of participants = 56.4 [40.8-72.0],Phase 2: Percentage of Participants With Progression Free Survival (PFS) (NUMBER) percentage of participants = 48.7 [33.0-64.4]; Progression Free Survival (PFS) (MEDIAN) months = 11.8 [9.8-19.2],,,Phase 2: Percentage of Participants With Objective Tumor Response (Response Rate) (NUMBER) percentage of participants = 0 [0-0],Phase 1: Number of Participants With Adverse Events (AE; Toxicity) (NUMBER) participants = 5,,
NCT00530621,Study of Enzastaurin Versus Placebo With Pemetrexed for Participants With Advanced or Metastatic Lung Cancer,A Phase 2 Double-Blind Randomized Study of Oral Enzastaurin HCl Versus Placebo Concurrently With Pemetrexed (Alimta®) as Second-Line Therapy in Patients With Advanced or Metastatic Non-Small Cell Lung,Eli Lilly and Company,Eli Lilly and Company,INDUSTRY,COMPLETED,2007-09,2008-10,2008-10,INTERVENTIONAL,PHASE2,,,,Non-small Cell Lung Cancer,Non-small Cell Lung Cancer,1,2,3,DRUG,,,1,5,True,Yes,Progression-Free Survival (PFS) (MEDIAN) months = 2.96 [1.87-3.58],Overall Survival (OS) (MEDIAN) months = 9.63; Time-to-Worsening (TW) in Lung Cancer Symptom Scale (LCSS) - Health Related Quality of Life (HRQoL) Subscale (MEDIAN) months = 3.06 [2.37-4.63]; Duration of Disease Control (DDC) (MEDIAN) months = 5.32 [3.58-7.13]; Percentage of Participants With Complete Response or Partial Response (Tumor Response Rate) (NUMBER) percentage of participants = 3.9; Tumor Biomarkers (MEAN) H-scores = 55.96,,Percentage of Participants With Complete Response or Partial Response (Tumor Response Rate) (NUMBER) percentage of participants = 3.9,,,,,,,Overall Survival (OS) (MEDIAN) months = 9.63,Progression-Free Survival (PFS) (MEDIAN) months = 2.96 [1.87-3.58],Percentage of Participants With Complete Response or Partial Response (Tumor Response Rate) (NUMBER) percentage of participants = 3.9,Time-to-Worsening (TW) in Lung Cancer Symptom Scale (LCSS) - Health Related Quality of Life (HRQoL) Subscale (MEDIAN) months = 3.06 [2.37-4.63],Percentage of Participants With Complete Response or Partial Response (Tumor Response Rate) (NUMBER) percentage of participants = 3.9,,,
NCT00531284,"Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma","Phase 1b/2, Multicenter Open-label Study of the Safety and Activity of Carfilzomib in Subjects With Relapsed Solid Tumors, Multiple Myeloma or Lymphoma",Amgen,Amgen,INDUSTRY,COMPLETED,2007-09,2014-10,2017-05-22,INTERVENTIONAL,PHASE1; PHASE2,,,,Ovarian Cancer,Ovarian Cancer; Renal Cancer; Non-small Cell Lung Cancer,7,17,2,DRUG,,,2,12,True,Yes,Phase 1b: Number of Participants With Dose-limiting Toxicities (DLT) (NUMBER) participants = 0; Phase 2: Percentage of Participants With an Overall Response After 4 Treatment Cycles (NUMBER) percentage of participants = 15.4 [7.6-26.5],Percentage of Participants With an Overall Response Throughout the Study (NUMBER) percentage of participants = 100.0 [29.2-100.0]; Duration of Response (MEDIAN) months = 6.2; Progression-Free Survival (MEDIAN) months = 5.1; Time to Progression (MEDIAN) months = 5.1; Maximum Observed Plasma Concentration of Carfilzomib (GEOMETRIC_MEAN) ng/mL = 2390; Time to Maximum Observed Plasma Concentration (Tmax) of Carfilzomib (MEDIAN) hours = 0.0500 [0-0.167]; Area Under the Plasma Concentration-time Curve From Time Zero to the Last Concentration Measured (AUC0-last) for Carfilzomib (GEOMETRIC_MEAN) h*ng/mL = 251; Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC0-inf) for Carfilzomib (GEOMETRIC_MEAN) h*ng/mL = 223; Elimination Half-life (t½) of Carfilzomib (MEDIAN) hours = 0.444 [0.152-2.20]; Clearance (CL) of Carfilzomib (MEAN) liters/hour = 263; Volume of Distribution at Steady State (Vss) of Carfilzomib (MEAN) liters = 27.7; Mean Residence Time (MRT) Extrapolated to Infinity for Carfilzomib (MEAN) hours = 0.0902,,,,,Duration of Response (MEDIAN) months = 6.2,,,,,Progression-Free Survival (MEDIAN) months = 5.1,,,,,,Time to Progression (MEDIAN) months = 5.1
NCT00531934,A Study of Management of Tarceva - Induced Rash in Patients With Non-Small Cell Lung Cancer.,"A Randomized, Open Label Study to Evaluate the Effect of Doxycycline on Tarceva-induced Skin Rash in Patients With Non-small Cell Lung Cancer After Failure of First Line Chemotherapy",Hoffmann-La Roche,Hoffmann-La Roche,INDUSTRY,COMPLETED,2007-10,2010-08,2010-08,INTERVENTIONAL,PHASE2,,,,Non-Small Cell Lung Cancer,Non-Small Cell Lung Cancer,1,2,2,DRUG,,,1,31,True,Yes,Percentage of Participants With at Least One Skin Rash (Folliculitis) of Any Grade During the First 4 Months of Treatment (NUMBER) percentage of participants = 71.2,Number of Skin Rash (Folliculitis) Events During the First 4 Months of Treatment (NUMBER) rash events = 57; Percentage of Participants With Skin Rash (Folliculitis) During the First 4 Months of Treatment By Type (NUMBER) percentage of participants = 55.8; Percentage of Participants With Skin Rash (Folliculitis) During the First 4 Months of Treatment By Maximal Intensity (NUMBER) percentage of participants = 61.5; Percentage of Participants With at Least One Skin Rash (Folliculitis) of Any Grade After the First 4 Months of Treatment (NUMBER) percentage of participants = 2.7; Number of Skin Rash (Folliculitis) Events After the First 4 Months of Treatment (NUMBER) rash events = 2; Number of Participants With Skin Rash (Folliculitis) After the First 4 Months of Treatment By Type (NUMBER) participants = 1; Number of Participants With Skin Rash (Folliculitis) After the First 4 Months of Treatment By Intensity (NUMBER) participants = 2; Time Free From Skin Rash (Folliculitis) During the First 4 Months of Treatment - Number of Participants With an Event (NUMBER) participants = 52; Time Free From Skin Rash (Folliculitis) During the First 4 Months of Treatment - Time to Event (MEDIAN) days = 14 [13-22]; Percentage of Participants Estimated to be Event Free at 4 Months (NUMBER) percentage of participants = 24.7; Time Free From Skin Rash (Folliculitis) During the Whole Treatment Period - Number of Participants With an Event (NUMBER) participants = 53; Time Free From Skin Rash (Folliculitis) During the Whole Treatment Period - Time to Event (MEDIAN) days = 14 [13-22]; Percentage of Participants Estimated to be Event Free at 12 Months (NUMBER) percentage of participants = 19.8; Duration of Skin Rash (Folliculitis) During the First 4 Months of Treatment (MEAN) days = 59.6; Duration of Skin Rash (Folliculitis) During the Whole Treatment Period (MEDIAN) days = 86.7; Percentage of Participants With Other Skin Lesions of Any Grade During the First 4 Months of Treatment (NUMBER) percentage of participants = 39.7; Percentage of Participants With Other Skin Lesions During the First 4 Months of Treatment By Type (NUMBER) percentage of participants = 37.0; Percentage of Participants With Other Skin Lesions During the First 4 Months of Treatment By Maximal Intensity (NUMBER) percentage of participants = 69.0; Percentage of Participants With Erlotinib Dose Reduction by Reason for Reduction (NUMBER) percentage of participants = 80.0; Percentage of Participants With Doxycycline Dose Reduction by Reason for Reduction (NUMBER) percentage of participants = 50.0; Percentage of Participants With Global Disease Control by Visit (NUMBER) percentage of participants = 88.2; Percentage of Participants by Best Global Response Under Treatment (NUMBER) percentage of participants = 15.5; Progression-Free Survival (PFS) - Percentage of Participants With an Event (NUMBER) percentage of participants = 91.8; Progression-Free Survival (PFS) - Time to Event (MEDIAN) days = 63.0 [56.0-107.0]; Percentage of Participants Estimated to be Progression Free at 4 and 12 Months (NUMBER) percentage of participants = 30.1; Overall Survival (OS) - Percentage of Participants With an Event (NUMBER) percentage of participants = 71.2; Overall Survival (OS) - Time to Event (MEDIAN) days = 227.0 [153.0-282.0]; Percentage of Participants Estimated to be Alive at 4 and 12 Months (NUMBER) percentage of participants = 68.5; Dermatology Life Quality Index (DLQI) Global Score (MEAN) units on a scale = 0.2; Percentage of Participants by DLQI Global Score Classification of Disease Effect on Quality of Life (NUMBER) percentage of participants = 98.5; Quality of Life Score as Assessed by Visual Analog Scale (VAS) (MEAN) mm = 81.4,,,,,,,,,Overall Survival (OS) - Percentage of Participants With an Event (NUMBER) percentage of participants = 71.2; Overall Survival (OS) - Time to Event (MEDIAN) days = 227.0 [153.0-282.0],Progression-Free Survival (PFS) - Percentage of Participants With an Event (NUMBER) percentage of participants = 91.8; Progression-Free Survival (PFS) - Time to Event (MEDIAN) days = 63.0 [56.0-107.0],,Percentage of Participants by DLQI Global Score Classification of Disease Effect on Quality of Life (NUMBER) percentage of participants = 98.5; Quality of Life Score as Assessed by Visual Analog Scale (VAS) (MEAN) mm = 81.4,,,,
NCT00531960,A Study of Tarceva (Erlotinib) in Combination With Avastin (Bevacizumab) in Patients With Advanced Non-Small Cell Lung Cancer.,"A Randomized, Open-label Study Comparing the Anti-tumor Effect of Treatment With Tarceva Plus Avastin Versus Chemotherapy Plus Avastin in Patients With Advanced Non-small Cell Lung Cancer",Hoffmann-La Roche,Hoffmann-La Roche,INDUSTRY,COMPLETED,2008-01,2010-01,2010-01,INTERVENTIONAL,PHASE2,,,,Non-Small Cell Lung Cancer,Non-Small Cell Lung Cancer,1,2,3,DRUG,,,2,4,True,Yes,Percentage of Participants With Disease Progression or Death (NUMBER) percentage of participants = 72.1; PFS (MEDIAN) weeks = 34.6 [25.0-42.4],Percentage of Participants Who Died (NUMBER) percentage of participants = 45.9; ; Percentage of Participants With a Best Overall Response (BOR) of Confirmed Complete Response (CR) or Partial Response (PR) According to RECIST V 1.0 (NUMBER) percentage of participants = 44.3 [31.5-57.6]; Percentage of Participants With Disease Control According to RECIST V 1.0 (NUMBER) percentage of participants = 85.2 [73.8-93.0],,Percentage of Participants With a Best Overall Response (BOR) of Confirmed Complete Response (CR) or Partial Response (PR) According to RECIST V 1.0 (NUMBER) percentage of participants = 44.3 [31.5-57.6],,,,,,,,PFS (MEDIAN) weeks = 34.6 [25.0-42.4],Percentage of Participants With a Best Overall Response (BOR) of Confirmed Complete Response (CR) or Partial Response (PR) According to RECIST V 1.0 (NUMBER) percentage of participants = 44.3 [31.5-57.6],,,,,
NCT00533429,Study of Pemetrexed + Carboplatin + Bevacizumab + Enzastaurin Versus Pemetrexed + Carboplatin + Bevacizumab + Placebo in Participants With Non-Small C,"Protocol H6Q-MC-S034(a) Randomized, Double-Blind, Phase 2 Study of Pemetrexed + Carboplatin + Bevacizumab + Enzastaurin Versus Pemetrexed + Carboplatin + Bevacizumab + Placebo in Chemonaive Patients W",Eli Lilly and Company,Eli Lilly and Company,INDUSTRY,COMPLETED,2007-10,2009-02,2009-02,INTERVENTIONAL,PHASE2,,,,Non-small Cell Lung Cancer,Non-small Cell Lung Cancer,1,2,5,DRUG,,,1,5,True,Yes,Progression-Free Survival (PFS) (NUMBER) months = 3.5 [2.0-5.8],Percentage of Participants With Complete Response (CR) or Partial Response (PR) (Response Rate) (NUMBER) percentage of participants = 20.0 [2.5-37.5]; Overall Survival (OS) (MEDIAN) months = 9.1; Time to Progressive Disease (TTPD) (MEDIAN) Months = 4.3 [1.7-5.8]; Duration of Response (DoR) (MEDIAN) Months = 4.7; Pharmacology Toxicity and Adverse Events (AEs) (COUNT_OF_PARTICIPANTS) Participants = 19,,Percentage of Participants With Complete Response (CR) or Partial Response (PR) (Response Rate) (NUMBER) percentage of participants = 20.0 [2.5-37.5],,,Duration of Response (DoR) (MEDIAN) Months = 4.7,,,,Overall Survival (OS) (MEDIAN) months = 9.1,Progression-Free Survival (PFS) (NUMBER) months = 3.5 [2.0-5.8],Percentage of Participants With Complete Response (CR) or Partial Response (PR) (Response Rate) (NUMBER) percentage of participants = 20.0 [2.5-37.5],,Percentage of Participants With Complete Response (CR) or Partial Response (PR) (Response Rate) (NUMBER) percentage of participants = 20.0 [2.5-37.5],Pharmacology Toxicity and Adverse Events (AEs) (COUNT_OF_PARTICIPANTS) Participants = 19,,
NCT00540514,Albumin-bound Paclitaxel (ABI-007) for Patients With Advanced Non-Small Cell Lung Cancer,"A Randomized, Phase III Trial of ABI-007 and Carboplatin Compared With Taxol and Carboplatin as First-Line Therapy in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)",Celgene,Celgene,INDUSTRY,COMPLETED,2007-11-01,2009-10-01,2013-02-01,INTERVENTIONAL,PHASE3,,,,Non-Small Cell Lung Carcinoma,Non-Small Cell Lung Carcinoma,1,2,3,DRUG,,,1,7,True,Yes,Percentage of Participants Who Achieved an Objective Confirmed Complete Response or Partial Response by Blinded Radiology Assessment (NUMBER) percentage of participants = 33 [28.6-36.7],Progression-free Survival by Blinded Radiology Assessment (MEDIAN) months = 6.3 [5.6-7.0]; Overall Participant Survival (MEDIAN) months = 12.1 [10.8-12.9]; Percentage of Participants With Controlled Disease (NUMBER) percentage of participants = 53 [48.3-56.9]; Duration of Response in Responding Patients (MEDIAN) months = 9.6 [8.3-10.8]; Number of Participants With Adverse Events (AEs) (NUMBER) participants = 483; ; SPARC Status and Correlation With Overall Survival (NUMBER) participants = 17 [3.3-23.1],,Percentage of Participants Who Achieved an Objective Confirmed Complete Response or Partial Response by Blinded Radiology Assessment (NUMBER) percentage of participants = 33 [28.6-36.7],,,Duration of Response in Responding Patients (MEDIAN) months = 9.6 [8.3-10.8],,,,SPARC Status and Correlation With Overall Survival (NUMBER) participants = 17 [3.3-23.1],Progression-free Survival by Blinded Radiology Assessment (MEDIAN) months = 6.3 [5.6-7.0],Percentage of Participants Who Achieved an Objective Confirmed Complete Response or Partial Response by Blinded Radiology Assessment (NUMBER) percentage of participants = 33 [28.6-36.7],,,Number of Participants With Adverse Events (AEs) (NUMBER) participants = 483,,
NCT00550173,A Study for Non-Smoker Patients With Nonsquamous Non-Small Cell Lung Cancer,"A Randomized Phase 2 Study Comparing Erlotinib-Pemetrexed, Pemetrexed Alone, and Erlotinib Alone, as Second-Line Treatment for Non-Smoker Patients With Locally Advanced or Metastatic Nonsquamous Non-S",Eli Lilly and Company,Eli Lilly and Company,INDUSTRY,COMPLETED,2007-11,2012-01,2012-01,INTERVENTIONAL,PHASE2,,,,Non-Small-Cell Lung Cancer,Non-Small-Cell Lung Cancer,1,3,2,DRUG,,,1,7,True,Yes,Progression-Free Survival (PFS) (MEDIAN) months = 7.4 [4.4-12.9],"Percentage of Participants With a Tumor Response of Complete Response (CR) or Partial Response (PR) [Tumor Response Rate (TRR)] (NUMBER) percentage of participants = 44.7; Overall Survival (OS) (MEDIAN) months = 20.5 [17.1-25.0]; Number of Participants With Adverse Events (NUMBER) participants = 25; Percentage of Participants With CR, PR, and Stable Disease (SD) - Disease Control Rate (DCR) (NUMBER) percentage of participants = 64.5; Time to Worsening of Symptoms (TWS) on Lung Cancer Symptoms Scale (LCSS) (MEDIAN) months = 1.0 [0.9-1.6]; Number of Participants With Mutated or Non-Mutated Epidermal Growth Factor Receptor (EGFR) Genotype Status (NUMBER) participants = 7; Probability of OS at 12 Months (NUMBER) percent chance of survival = 40.2 [28.3-51.8]",,Percentage of Participants With a Tumor Response of Complete Response (CR) or Partial Response (PR) [Tumor Response Rate (TRR)] (NUMBER) percentage of participants = 44.7,,,,,,,Overall Survival (OS) (MEDIAN) months = 20.5 [17.1-25.0]; Probability of OS at 12 Months (NUMBER) percent chance of survival = 40.2 [28.3-51.8],Progression-Free Survival (PFS) (MEDIAN) months = 7.4 [4.4-12.9],Percentage of Participants With a Tumor Response of Complete Response (CR) or Partial Response (PR) [Tumor Response Rate (TRR)] (NUMBER) percentage of participants = 44.7,,Percentage of Participants With a Tumor Response of Complete Response (CR) or Partial Response (PR) [Tumor Response Rate (TRR)] (NUMBER) percentage of participants = 44.7,Number of Participants With Adverse Events (NUMBER) participants = 25,,
NCT00556322,"A Study of Tarceva (Erlotinib) and Standard of Care Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC","An Open-label, Randomized Study to Evaluate the Effect of Tarceva, Compared With Alimta (Pemetrexed) or Taxotere (Docetaxel),on Survival in Patients With Advanced, Recurrent or Metastatic Non-small Ce",Hoffmann-La Roche,Hoffmann-La Roche,INDUSTRY,COMPLETED,2006-03,2012-06,2012-06,INTERVENTIONAL,PHASE3,,,,Non-Small Cell Lung Cancer,Non-Small Cell Lung Cancer,1,2,2,DRUG,,,3,19,True,Yes,Percentage of Participants Who Died (All Participants; Data Cutoff: 07 September 2010) (NUMBER) percentage of participants = 81.0; Duration of Overall Survival in All Participants (Data Cutoff 07 September 2010) (MEDIAN) months = 5.5 [4.4-7.1]; Probable Percentage of Participants Remaining Alive at 1 Year (NUMBER) percentage of participants = 24.0 [18.0-30.0],Percentage of Participants Who Died in Epidermal Growth Factor Receptor (EGFR) Positive and Negative Population (NUMBER) percentage of participants = 79.9; Duration of OS in EGFR Positive and Negative Population (MEDIAN) months = 5.5 [4.1-7.5]; Probable Percentage of Participants Remaining Alive at 1 Year in the EGFR Positive and Negative Population (NUMBER) percentage of participants = 27.0 [19.0-34.0]; Percentage of Participants With Disease Progression or Death (All Participants; Data Cut Off 07 September 2010) (NUMBER) percentage of participants = 83.3; Progression-Free Survival (PFS) in All Participants (Data Cutoff 07 September 2010) (MEDIAN) weeks = 8.6 [7.1-12.1]; Probable Percentage of Participants Remaining Alive and Progression Free at 6 Months (NUMBER) percentage of participants = 17.0 [12.0-22.0]; Percentage of Participants With Disease Progression or Death in EGFR Positive and Negative Population (Data Cut Off 07 September 2010) (NUMBER) percentage of participants = 79.9; PFS in EGFR Positive and Negative Population (Data Cutoff 07 September 2010) (MEDIAN) weeks = 8.9 [7.1-12.6]; Probable Percentage of Participants Remaining Alive and Progression Free at 6 Months in EGFR Positive and Negative Population (NUMBER) percentage of participants = 20.0 [13.0-28.0]; Percentage of Participants Achieving a Best Overall Response of Confirmed Complete Response (CR) or Partial Response (PR) as Assessed by the Investigator Using RECIST (NUMBER) percentage of participants = 6.3 [3.5-10.4]; Percentage of Participants With Deterioration in Quality of Life Determined Using Functional Assessment of Cancer Therapy - Lung (FACT-L) (NUMBER) percentage of participants = 66.1; Time to Deterioration in Quality of Life Using FACT-L (MEDIAN) weeks = 9.0 [7.1-11.6]; Probable Percentage of Participants Remaining Without Deterioration in Quality of Life at 6 Months as Assessed by FACT-L (NUMBER) percentage of participants = 25.0 [17.0-34.0]; Percentage of Participants With Symptomatic Progression Using FACT-L (NUMBER) percentage of participants = 60.6; Time to Symptomatic Progression Using FACT-L (MEDIAN) weeks = 9.0 [7.0-12.1]; Probable Percentage of Participants With Symptomatic Progression at 6 Months as Assessed by FACT-L (NUMBER) percentage of participants = 27 [18-36]; Percentage of Participants With Deterioration in the Trial Outcome Index (TOI) (NUMBER) percentage of participants = 60.0; Time to Deterioration in the TOI (MEDIAN) weeks = 9.3 [7.6-13.0]; Probable Percentage of Participants With Deterioration in the TOI at 6 Months as Assessed by FACT-L (NUMBER) percentage of participants = 28 [19-37],,Percentage of Participants Achieving a Best Overall Response of Confirmed Complete Response (CR) or Partial Response (PR) as Assessed by the Investigator Using RECIST (NUMBER) percentage of participants = 6.3 [3.5-10.4],,,,,,,Duration of Overall Survival in All Participants (Data Cutoff 07 September 2010) (MEDIAN) months = 5.5 [4.4-7.1]; Duration of OS in EGFR Positive and Negative Population (MEDIAN) months = 5.5 [4.1-7.5],Progression-Free Survival (PFS) in All Participants (Data Cutoff 07 September 2010) (MEDIAN) weeks = 8.6 [7.1-12.1]; PFS in EGFR Positive and Negative Population (Data Cutoff 07 September 2010) (MEDIAN) weeks = 8.9 [7.1-12.6],Percentage of Participants Achieving a Best Overall Response of Confirmed Complete Response (CR) or Partial Response (PR) as Assessed by the Investigator Using RECIST (NUMBER) percentage of participants = 6.3 [3.5-10.4],Percentage of Participants With Deterioration in Quality of Life Determined Using Functional Assessment of Cancer Therapy - Lung (FACT-L) (NUMBER) percentage of participants = 66.1; Time to Deterioration in Quality of Life Using FACT-L (MEDIAN) weeks = 9.0 [7.1-11.6]; Probable Percentage of Participants Remaining Without Deterioration in Quality of Life at 6 Months as Assessed by FACT-L (NUMBER) percentage of participants = 25.0 [17.0-34.0],,,,
NCT00556712,"A Study of Tarceva (Erlotinib) Following Platinum-Based Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (N","A Randomized, Double-blind Study to Evaluate the Effect of Tarceva or Placebo Following Platinum-based CT on Overall Survival and Disease Progression in Patients With Advanced, Recurrent or Metastatic",Hoffmann-La Roche,Hoffmann-La Roche,INDUSTRY,COMPLETED,2006-01,2010-11,2010-11,INTERVENTIONAL,PHASE3,,,,Non-Small Cell Lung Cancer,Non-Small Cell Lung Cancer,1,2,2,DRUG,,,6,30,True,Yes,Percentage of Participants With PD According to Response Evaluation Criteria in Solid Tumors (RECIST) or Death (Data Cutoff 17 May 2008) (NUMBER) percentage of participants = 89.5; PFS in All Participants (Data Cutoff 17 May 2008) (MEDIAN) weeks = 11.1 [8.1-11.7]; Probable Percentage of Participants Remaining Alive and Free of Disease Progression at 6 Months (Data Cutoff 17 May 2008) (NUMBER) percentage of participants = 15.0 [12.0-19.0]; Percentage of Epidermal Growth Factor Receptor (EGFR) Immunohistochemistry (IHC) Positive Participants With PD or Death (Data Cutoff 17 May 2008) (NUMBER) percentage of participants = 89.4; PFS in EGFR IHC Positive Population (Data Cutoff 17 May 2008) (MEDIAN) weeks = 11.1 [7.1-11.7]; Probable Percentage of Participants in the EGFR IHC Positive Population Remaining Alive and Progression Free at 6 Months (Data Cutoff 17 May 2008) (NUMBER) percentage of participants = 16.0 [12.0-21.0],"Percentage of All Participants Who Died (Data Cutoff 12 January 2012) (NUMBER) percentage of participants = 87.1; Overall Survival (OS) in All Participants (Data Cutoff 12 January 2012) (MEDIAN) months = 11.0 [9.9-12.0]; Probable Percentage of Participants Remaining Alive at 1 Year (Data Cutoff 12 January 2012) (NUMBER) percentage of participants = 45.0 [41.0-50.0]; Percentage of EGFR IHC Positive Participants Who Died (Data Cutoff 12 January 2012) (NUMBER) percentage of participants = 87.5; OS in EGFR IHC Positive Population (Data Cutoff 12 January 2012) (MEDIAN) months = 11.0 [9.7-12.8]; Probable Percentage of Participants in the EGFR IHC Positive Population Remaining Alive at 1 Year (Data Cutoff 12 January 2012) (NUMBER) percentage of participants = 47.0 [41.0-52.0]; Percentage of EGFR IHC Negative Participants With PD or Death (Data Cutoff 17 May 2008) (NUMBER) percentage of participants = 89.8; PFS in EGFR IHC Negative Participants (Data Cutoff 17 May 2008) (MEDIAN) weeks = 9.0 [6.4-12.0]; Probable Percentage of Participants in the EGFR IHC Negative Population Remaining Alive and Free of Disease Progression at 6 Months (Data Cutoff 17 May 2008) (NUMBER) percentage of participants = 11.0 [2.0-20.0]; Percentage of EGFR IHC Negative Participants Who Died (Data Cutoff 17 May 2008) (NUMBER) percentage of participants = 50.8; OS in EGFR IHC Negative Participants (Data Cutoff 17 May 2008) (MEDIAN) months = 10.2 [7.4-11.2]; Probable Percentage of Participants in the EGFR IHC Negative Population Remaining Alive at 1 Year (Data Cutoff 17 May 2008) (NUMBER) percentage of participants = 20.0 [3.0-37.0]; Time to Progression (Data Cutoff 17 May 2008) (MEDIAN) weeks = 11.3 [8.1-11.9]; Probable Percentage of Participants Remaining Progression-Free in the TTP Analysis at 6 Months (Data Cutoff 17 May 2008) (NUMBER) percentage of participants = 15.0 [11.0-19.0]; Percentage of Participants With a Best Overall Response (BOR) of Confirmed Complete Response (CR) or Partial Response (PR) According to RECIST (Data Cutoff 17 May 2008) (NUMBER) percentage of participants = 5.4 [3.5-7.9]; Percentage of Participants With a CR, PR, Stable Disease (SD), or PD According to RECIST (Data Cutoff 17 May 2008) (NUMBER) percentage of participants = 0.7 [0.1-2.0]; Percentage of Participants With a Response Upgrade From BL According to RECIST (Data Cutoff 17 May 2008) (NUMBER) percentage of participants = 1.3 [0.5-2.9]; Percentage of Participants With a Change of PR to CR or SD to PR or CR From BL to End of Treatment According to RECIST (Data Cutoff 17 May 2008) (NUMBER) percentage of participants = 0.4 [0.1-1.6]; Percentage of Participants With CR, PR, or SD or With SD [Maintained For Greater Than (>) 12 Weeks] or CR or PR (Data Cutoff 17 May 2008) (NUMBER) percentage of participants = 50.8 [46.0-55.5]; Percentage of Participants With Symptom Progression Assessed Using the Lung Cancer Subscale (LCS) (Data Cutoff 17 May 2008) (NUMBER) percentage of participants = 44.1; Time to Symptom Progression (Data Cutoff 17 May 2008) (MEDIAN) weeks = 17.6 [12.4-19.1]; Probable Percentage of Participants Remaining Without Symptom Progression at 6 Months (Data Cutoff 17 May 2008) (NUMBER) percentage of participants = 35.0 [27.0-42.0]; Percentage of Participants With Deterioration Assessed Using the Trial Outcome Index (Data Cutoff 17 May 2008) (NUMBER) percentage of participants = 43.1; Time to Deterioration in TOI (Data Cutoff 17 May 2008) (MEDIAN) weeks = 18.9 [13.6-24.1]; Probable Percentage of Participants Remaining Without Deterioration in TOI at 6 Months (Data Cutoff 17 May 2008) (NUMBER) percentage of participants = 41.0 [34.0-48.0]; Percentage of Participants With Deterioration in Quality of Life Assessed Using TOI, SWB, and EWB (Data Cutoff 17 May 2008) (NUMBER) percentage of participants = 51.7; Time to Deterioration in QoL (Data Cutoff 17 May 2008) (MEDIAN) weeks = 12.3 [11.9-17.9]; Probable Percentage of Participants Remaining Without Deterioration in QoL at 6 Months (Data Cutoff 17 May 2008) (NUMBER) percentage of participants = 34.0 [27.0-40.0]; Functional Assessment of Chronic Illness Therapy - Lung (FACT-L) Scores (Data Cutoff 17 May 2008) (MEAN) score on a scale = 20.85; Change From BL in FACT-L Scores (Data Cutoff 17 May 2008) (MEAN) score on a scale = 0.22",,"Percentage of Participants With a Best Overall Response (BOR) of Confirmed Complete Response (CR) or Partial Response (PR) According to RECIST (Data Cutoff 17 May 2008) (NUMBER) percentage of participants = 5.4 [3.5-7.9]; Percentage of Participants With a Change of PR to CR or SD to PR or CR From BL to End of Treatment According to RECIST (Data Cutoff 17 May 2008) (NUMBER) percentage of participants = 0.4 [0.1-1.6]; Percentage of Participants With CR, PR, or SD or With SD [Maintained For Greater Than (>) 12 Weeks] or CR or PR (Data Cutoff 17 May 2008) (NUMBER) percentage of participants = 50.8 [46.0-55.5]",,,,,,,Overall Survival (OS) in All Participants (Data Cutoff 12 January 2012) (MEDIAN) months = 11.0 [9.9-12.0]; OS in EGFR IHC Positive Population (Data Cutoff 12 January 2012) (MEDIAN) months = 11.0 [9.7-12.8]; OS in EGFR IHC Negative Participants (Data Cutoff 17 May 2008) (MEDIAN) months = 10.2 [7.4-11.2],PFS in All Participants (Data Cutoff 17 May 2008) (MEDIAN) weeks = 11.1 [8.1-11.7]; PFS in EGFR IHC Positive Population (Data Cutoff 17 May 2008) (MEDIAN) weeks = 11.1 [7.1-11.7]; PFS in EGFR IHC Negative Participants (Data Cutoff 17 May 2008) (MEDIAN) weeks = 9.0 [6.4-12.0],"Percentage of Participants With a Best Overall Response (BOR) of Confirmed Complete Response (CR) or Partial Response (PR) According to RECIST (Data Cutoff 17 May 2008) (NUMBER) percentage of participants = 5.4 [3.5-7.9]; Percentage of Participants With a Change of PR to CR or SD to PR or CR From BL to End of Treatment According to RECIST (Data Cutoff 17 May 2008) (NUMBER) percentage of participants = 0.4 [0.1-1.6]; Percentage of Participants With CR, PR, or SD or With SD [Maintained For Greater Than (>) 12 Weeks] or CR or PR (Data Cutoff 17 May 2008) (NUMBER) percentage of participants = 50.8 [46.0-55.5]","Percentage of Participants With Deterioration in Quality of Life Assessed Using TOI, SWB, and EWB (Data Cutoff 17 May 2008) (NUMBER) percentage of participants = 51.7; Time to Deterioration in QoL (Data Cutoff 17 May 2008) (MEDIAN) weeks = 12.3 [11.9-17.9]; Probable Percentage of Participants Remaining Without Deterioration in QoL at 6 Months (Data Cutoff 17 May 2008) (NUMBER) percentage of participants = 34.0 [27.0-40.0]",,,,Time to Progression (Data Cutoff 17 May 2008) (MEDIAN) weeks = 11.3 [8.1-11.9]; Probable Percentage of Participants Remaining Progression-Free in the TTP Analysis at 6 Months (Data Cutoff 17 May 2008) (NUMBER) percentage of participants = 15.0 [11.0-19.0]
NCT00563784,TARCEVA (Erlotinib) in Combination With Chemoradiation in Patients With Stage IIIA/B Non-Small Cell Lung Cancer (NSCLC),A Phase II Study of TARCEVA (Erlotinib) in Combination With Chemoradiation in Patients With Stage IIIA/B Non-Small Cell Lung Cancer (NSCLC),M.D. Anderson Cancer Center,M.D. Anderson Cancer Center,OTHER,COMPLETED,2007-11,2018-05-30,2018-05-30,INTERVENTIONAL,PHASE2,,,,Non-Small Cell Lung Cancer,Non-Small Cell Lung Cancer; Lung Cancer,2,1,4,DRUG; RADIATION,,,1,1,True,Yes,Time To First Disease Progression (MEDIAN) Month = 14 [9.0-18.6],Overall Survival and Disease Local Control Rate (NUMBER) percentage of participants = 35.9,,,,,,,,,Overall Survival and Disease Local Control Rate (NUMBER) percentage of participants = 35.9,,,,,,,
NCT00564733,FDG-Labeled PET Scan in Planning Chemotherapy in Treating Patients With Stage IIIB or IV Non-Small Cell Lung Cancer,FDG-PET Based Chemotherapy Selection for Metastatic Non-Small Cell Lung Cancer,University of Washington,University of Washington,OTHER,COMPLETED,2007-10,2011-09,2012-03,INTERVENTIONAL,PHASE2,,,,Malignant Pleural Effusion,Malignant Pleural Effusion; Stage IIIB Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer,3,1,8,DRUG; OTHER; PROCEDURE; RADIATION,,,1,0,True,Yes,Overall Response Rate (Patients That Achieve a CR or PR) (NUMBER) participants = 13,,,Overall Response Rate (Patients That Achieve a CR or PR) (NUMBER) participants = 13,,,,,,,,,Overall Response Rate (Patients That Achieve a CR or PR) (NUMBER) participants = 13,,Overall Response Rate (Patients That Achieve a CR or PR) (NUMBER) participants = 13,,,
NCT00567359,"Erlotinib in Patients With Resected, Early Stage NSCLC With Confirmed Mutations in the EGFR","A Phase II Trial of Adjuvant Erlotinib in Patients With Resected, Early Stage Non-Small Cell Lung Cancer (NSCLC) With Confirmed Mutations in the Epidermal Growth Factor Receptor (EGFR)",Massachusetts General Hospital,Massachusetts General Hospital,OTHER,COMPLETED,2007-12,2017-12,2017-12,INTERVENTIONAL,PHASE2,,,,Non-small Cell Lung Cancer,Non-small Cell Lung Cancer,1,1,1,DRUG,,,1,3,True,Yes,2-year Disease-free Survival (COUNT_OF_PARTICIPANTS) Participants = 88,Number of Participants With Treat Related Serious Adverse Events (COUNT_OF_PARTICIPANTS) Participants = 20; ; ,,,2-year Disease-free Survival (COUNT_OF_PARTICIPANTS) Participants = 88,,,,,,,,,,,Number of Participants With Treat Related Serious Adverse Events (COUNT_OF_PARTICIPANTS) Participants = 20,,
NCT00577707,Erlotinib and Chemotherapy for Patients With Stage IB-IIIA NSCLC With EGFR Mutations (ECON),A Phase II Study of Erlotinib and Chemotherapy for Patients With Stage IB-IIIA NSCLC With EGFR Mutations (ECON),Memorial Sloan Kettering Cancer Center,Memorial Sloan Kettering Cancer Center,OTHER,COMPLETED,2007-11,2011-12,2011-12,INTERVENTIONAL,PHASE2,,,,Non Small Cell Lung Cancer,Non Small Cell Lung Cancer; Lung Cancer,2,1,4,DRUG; PROCEDURE,,,1,2,True,Yes,Number of Patients With Pathologic Complete Response Rate (NUMBER) participants = 1,; ,,Number of Patients With Pathologic Complete Response Rate (NUMBER) participants = 1,,,,,,,,,,,Number of Patients With Pathologic Complete Response Rate (NUMBER) participants = 1,,,
NCT00588445,Phase II Trial to Correlate Radiographic Response Induced By Gefitinib With Mutations in the Protein-Tyrosine Kinase Domain of the EGF Receptor Gene,Phase II Trial to Correlate Radiographic Response Induced By Gefitinib With Mutations in the Protein-Tyrosine Kinase Domain of the EGF Receptor Gene in Patients With NSCLC,Memorial Sloan Kettering Cancer Center,Memorial Sloan Kettering Cancer Center,OTHER,COMPLETED,2004-06,2010-09,2010-09,INTERVENTIONAL,PHASE2,,,,Lung Cancer,Lung Cancer; Non-small Cell Lung Cancer; Bronchioloalveolar Cancer,3,1,1,DRUG,,,1,1,True,Yes,The Radiographic Response to Gefitinib (NUMBER) participants = 21,Microarray Analysis to Identify Gene(s) or Gene Clusters That Exhibit Changes in Gene Expression; Time to Relapse and Overall Survival Data (NUMBER) percentage of participants = 85,,,,,,,,,Microarray Analysis to Identify Gene(s) or Gene Clusters That Exhibit Changes in Gene Expression; Time to Relapse and Overall Survival Data (NUMBER) percentage of participants = 85,,,,,,,
NCT00590902,"Ph II OSI-774 (Erlotinib,Tarceva) In Advanced Bronchioloalveolar Cell Lung Cancer","Multicenter Phase II Trial of OSI-774 (Erlotinib, Tarceva) In Patients With Advanced Bronchioloalveolar Cell Lung Cancer",Memorial Sloan Kettering Cancer Center,Memorial Sloan Kettering Cancer Center,OTHER,COMPLETED,2002-03,2013-02,2013-02,INTERVENTIONAL,PHASE2,,,,Bronchioloalveolar Cell Variant of Non-small Cell Lung Cancer,Bronchioloalveolar Cell Variant of Non-small Cell Lung Cancer,1,1,1,DRUG,,,1,0,True,Yes,Overall Objective Response of OSI-774 (NUMBER) participants = 1,,,,,,,,,,,,,,,,,
NCT00591838,A Phase I/II Trial of Stereotactic Body Radiation Therapy,A Phase I/II Trial of Stereotactic Body Radiation Therapy (SBRT) Dose Escalation in the Treatment of Patients With Inoperable Stage I/II Non-Small Cell Lung Cancer Arising Within the Zone of the Proxi,Washington University School of Medicine,Washington University School of Medicine,OTHER,COMPLETED,2006-09-21,2018-06-12,2018-06-12,INTERVENTIONAL,PHASE1; PHASE2,,,,Inoperable Stage I/II Non-small Cell Lung Cancer,Inoperable Stage I/II Non-small Cell Lung Cancer,1,5,1,RADIATION,,,4,4,True,Yes,Phase I Portion Only: Determine the Maximum Tolerated Dose of SBRT (NUMBER) Gy x 5 fractions = 11; Phase I Portion Only: Number of Participants With Acute Treatment Related Grade 3-5 Toxicity (COUNT_OF_PARTICIPANTS) Participants = 0; Phase I Portion Only: Number of Participants With Late Treatment Related Grade 3-5 Toxicity (COUNT_OF_PARTICIPANTS) Participants = 0; Phase II Portion Only: Local Control Rate (NUMBER) percentage of participants = 85 [62-95],Phase II Only: Regional Nodal Recurrence Rate (NUMBER) percentage of participants = 0; Phase II Only: Disseminated Recurrence Rate (NUMBER) percentage of participants = 27 [15-45]; Phase II Only: Disease-free Survival Rate (NUMBER) percentage of participants = 28 [16-42]; Phase II Only: Overall Survival Rate (NUMBER) percentage of participants = 43 [28-57],,,Phase II Only: Disease-free Survival Rate (NUMBER) percentage of participants = 28 [16-42],,,,,,Phase II Only: Overall Survival Rate (NUMBER) percentage of participants = 43 [28-57],,,,,Phase I Portion Only: Number of Participants With Acute Treatment Related Grade 3-5 Toxicity (COUNT_OF_PARTICIPANTS) Participants = 0; Phase I Portion Only: Number of Participants With Late Treatment Related Grade 3-5 Toxicity (COUNT_OF_PARTICIPANTS) Participants = 0,,
NCT00600015,Sorafenib/Erlotinib Versus Erlotinib Alone in Previously Treated Advanced Non-Small-Cell Lung Cancer (NSCLC),A Randomized Double-Blind Placebo-Controlled Phase II Trial of Sorafenib and Erlotinib or Erlotinib Alone in Previously Treated Advanced Non-Small Cell Lung Cancer,"SCRI Development Innovations, LLC","SCRI Development Innovations, LLC",OTHER,COMPLETED,2008-02,2009-02,2009-02,INTERVENTIONAL,PHASE2,,,,Non-Small Cell Lung Cancer,Non-Small Cell Lung Cancer,1,2,2,DRUG,,,3,3,True,Yes,Overall Objective Response Rate (ORR) (NUMBER) percentage of participants = 8.1 [3.77-14.83]; Progression Free Survival (PFS) (MEDIAN) Months = 3.38 [2.30-3.81]; Disease Control Rate (DCR) (NUMBER) percentage of participants = 54 [44-64],Duration of Response (MEAN) months = 4.6430; 6-month PFS (NUMBER) percentage of participants = 29; Overall Survival (OS) (MEDIAN) Months = 7.62 [5.35-10.54],,,,,Duration of Response (MEAN) months = 4.6430,,,Overall Objective Response Rate (ORR) (NUMBER) percentage of participants = 8.1 [3.77-14.83],Overall Survival (OS) (MEDIAN) Months = 7.62 [5.35-10.54],Progression Free Survival (PFS) (MEDIAN) Months = 3.38 [2.30-3.81]; 6-month PFS (NUMBER) percentage of participants = 29,,,Overall Objective Response Rate (ORR) (NUMBER) percentage of participants = 8.1 [3.77-14.83],,,
NCT00600821,A Study Of AG-013736 (Axitinib) Or Bevacizumab (Avastin) In Combination With Paclitaxel And Carboplatin In Patients With Advanced Lung Cancer.,Randomized Phase 2 Trial Of AG013736 Or Bevacizumab In Combination With Paclitaxel And Carboplatin As First Line Treatment For Patients With Advanced Non Small Cell Lung Cancer,Pfizer,Pfizer,INDUSTRY,COMPLETED,2008-04,2011-04,2012-10,INTERVENTIONAL,PHASE2,,,,Non-Small-Cell Lung Carcinoma,Non-Small-Cell Lung Carcinoma; Adenocarcinoma,2,2,6,DRUG,,,1,10,True,Yes,Progression Free Survival (PFS) (MEDIAN) Months = 5.7 [4.1-7.5],"Overall Survival (OS) (MEDIAN) Months = 10.6 [7.5-16.4]; Percentage of Participants With Objective Response (OR) (NUMBER) Percentage of participants = 29.3 [18.1-42.7]; Duration of Response (DR) (MEDIAN) Months = 4.4 [4.2-6.7]; ; European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ-C30) Score (MEAN) Units on a scale = 66.29; European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score (MEAN) Units on a scale = 37.50; ; Circulating Endothelial Cells (CEC) in Blood: Total CEC (MEAN) Cells/milliliter (cells/mL) = 46815.38; Circulating Endothelial Cells (CEC) in Blood (MEAN) Flourescent Intensity Unit (FIU) = 1936317.98; Plasma Concentration of Soluble Proteins (MEAN) Picogram/mL (pg/mL) = 49740.29",,,,,Duration of Response (DR) (MEDIAN) Months = 4.4 [4.2-6.7],,,,Overall Survival (OS) (MEDIAN) Months = 10.6 [7.5-16.4],Progression Free Survival (PFS) (MEDIAN) Months = 5.7 [4.1-7.5],,"European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ-C30) Score (MEAN) Units on a scale = 66.29; European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score (MEAN) Units on a scale = 37.50",,,,
NCT00602030,Study to Evaluate Erlotinib With or Without SNDX-275 (Entinostat) in the Treatment of Patients With Advanced NSCLC,"A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 2 Study With a Lead in Phase of Erlotinib With or Without SNDX-275 in Patients With NSCLC After Failure In Up to Two Prior Chemotherap",Syndax Pharmaceuticals,Syndax Pharmaceuticals,INDUSTRY,COMPLETED,2008-01-08,2010-02-04,2012-02-01,INTERVENTIONAL,PHASE1; PHASE2,,,,Non-Small-Cell Lung Carcinoma,"Non-Small-Cell Lung Carcinoma; Carcinoma, Non-Small Cell Lung",2,5,3,DRUG,,,2,14,True,Yes,Identification of Safe-dose for the Phase 2 Double-blind Phase in the Lead-in Phase (NUMBER) milligrams (mg) = 10; 4-Month Progression-free Survival (PFS) Rate in the Double-blind Phase (NUMBER) percentage of participants = 24.0 [12.2-35.8],Objective Response Rate (ORR) in the Double-blind Phase (NUMBER) percentage of participants = 9.2 [2.2-16.3]; 6-Month PFS Rate in the Double-blind Phase (NUMBER) percentage of participants = 10.8 [3.2-18.3]; Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) by Severity in the Double-blind Phase (COUNT_OF_PARTICIPANTS) Participants = 29; Number of Participants With Grade 3 or 4 Laboratory Variables in the Double-blind Phase (COUNT_OF_PARTICIPANTS) Participants = 1; Vital Sign Values: Systolic Blood Pressure in the Double-blind Phase (MEAN) mm Hg = 125.3; Vital Sign Values: Diastolic Blood Pressure in the Double-blind Phase (MEAN) mm Hg = 72.5; Vital Sign Values: Heart Rate in the Double-blind Phase (MEAN) beats per minute (bpm) = 87.5; Vital Sign Values: Respiration Rate in the Double-blind Phase (MEAN) breaths per minute = 18.5; Vital Sign Values: Temperature in the Double-blind Phase (MEAN) degrees Celsius (C) = 97.5; Vital Sign Values: Weight in the Double-blind Phase (MEAN) kilograms (kg) = 77.9; Cmax: Maximum Plasma Concentration of Entinostat in the Lead-in Phase (MEAN) ng/mL = 19.6; Tmax: Time to Cmax of Entinostat in the Lead-in Phase (MEAN) hour = 0.83; AUC(0-24): Area Under the Concentration-time Curve From Time 0 to 24 Hours in the Lead-in Phase (MEAN) ng*hr/mL = 46.5; AUC(0-last): Area Under the Concentration-time Curve From Time 0 to Last Quantifiable Concentration in the Lead-in Phase (MEAN) ng*hr/mL = 152.1,,,,,,,,Objective Response Rate (ORR) in the Double-blind Phase (NUMBER) percentage of participants = 9.2 [2.2-16.3],,4-Month Progression-free Survival (PFS) Rate in the Double-blind Phase (NUMBER) percentage of participants = 24.0 [12.2-35.8]; 6-Month PFS Rate in the Double-blind Phase (NUMBER) percentage of participants = 10.8 [3.2-18.3],,,Objective Response Rate (ORR) in the Double-blind Phase (NUMBER) percentage of participants = 9.2 [2.2-16.3],Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) by Severity in the Double-blind Phase (COUNT_OF_PARTICIPANTS) Participants = 29,,
NCT00602797,Vinorelbine Tartrate and Paclitaxel in Treating Older Patients With Advanced Non-Small Cell Lung Cancer,Phase II Study of Weekly Vinorelbine and Paclitaxel in Elderly Patients With Advanced Non-Small Cell Lung Cancer,University of Nebraska,University of Nebraska,OTHER,COMPLETED,2007-12-17,2014-08-01,2014-08-01,INTERVENTIONAL,PHASE2,,,,Recurrent Non-Small Cell Lung Carcinoma,Recurrent Non-Small Cell Lung Carcinoma; Stage IV Non-Small Cell Lung Cancer,2,1,4,DRUG; OTHER,,,1,2,True,Yes,Progression-free Survival. (MEDIAN) Months = 7.8 [1.92-13.56],Incidence of >Grade 3 Treatment-Emergent Non-hematological Adverse Events (COUNT_OF_PARTICIPANTS) Participants = 6; Response Rate Based on RECIST Criteria (COUNT_OF_PARTICIPANTS) Participants = 5,,,,,,,,,,Progression-free Survival. (MEDIAN) Months = 7.8 [1.92-13.56],,,Response Rate Based on RECIST Criteria (COUNT_OF_PARTICIPANTS) Participants = 5,Incidence of >Grade 3 Treatment-Emergent Non-hematological Adverse Events (COUNT_OF_PARTICIPANTS) Participants = 6,,
NCT00606021,"A Study Comparing of Two Different Chemotherapy Regimens, in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer","A Randomized Phase 2 Study Comparing Pemetrexed Plus Best Supportive Care With Best Supportive Care as Maintenance, Following First-Line Treatment With Pemetrexed-Cisplatin, in Patients With Advanced ",Eli Lilly and Company,Eli Lilly and Company,INDUSTRY,COMPLETED,2008-01,2010-12,2010-12,INTERVENTIONAL,PHASE2,,,,Non Small Cell Lung Cancer,Non Small Cell Lung Cancer,1,2,2,DRUG,,,1,5,True,Yes,Progression Free Survival During Maintenance Phase (MEDIAN) months = 3.2 [2.9-6.1],Progression Free Survival During Overall Period (Induction Phase [IP] + Maintenance Phase [MP]) (MEDIAN) months = 6.2 [6.0-8.3]; Overall Survival During Maintenance Phase (MEDIAN) months = 12.2 [5.6-20.6]; Overall Survival During Overall Period (IP + MP) (MEDIAN) months = 15.4 [8.4-23.7]; Number of Participants With Adverse Events (AEs) During Overall Period (NUMBER) participants = 15; Tumor Response Rate and Disease Control Rate After Induction Phase (IP) (NUMBER) percentage of participants = 0 [0.0-12.3],,,,,,,,,Overall Survival During Maintenance Phase (MEDIAN) months = 12.2 [5.6-20.6]; Overall Survival During Overall Period (IP + MP) (MEDIAN) months = 15.4 [8.4-23.7],Progression Free Survival During Maintenance Phase (MEDIAN) months = 3.2 [2.9-6.1]; Progression Free Survival During Overall Period (Induction Phase [IP] + Maintenance Phase [MP]) (MEDIAN) months = 6.2 [6.0-8.3],,,Tumor Response Rate and Disease Control Rate After Induction Phase (IP) (NUMBER) percentage of participants = 0 [0.0-12.3],Number of Participants With Adverse Events (AEs) During Overall Period (NUMBER) participants = 15,,
NCT00606502,Study of Pralatrexate vs. Erlotinib for Non-Small Cell Lung Cancer After at Least 1 Prior Platinum-based Treatment,"A Randomized, Phase 2b, Multi-center Study of Pralatrexate Versus Erlotinib in Patients With Stage IIIB/IV Non-small Cell Lung Cancer After Failure of at Least 1 Prior Platinum-based Treatment","Spectrum Pharmaceuticals, Inc","Spectrum Pharmaceuticals, Inc",INDUSTRY,COMPLETED,2008-01,2010-06-24,2010-06-24,INTERVENTIONAL,PHASE2,,,,Non-small Cell Lung Cancer,Non-small Cell Lung Cancer,1,2,4,DIETARY_SUPPLEMENT; DRUG,,,1,3,True,Yes,Overall Survival (OS) of Patients Receiving Pralatrexate vs. Erlotinib (MEDIAN) Months Survival = 6.7 [5.3-9.0],Response Rate (RR) to Treatment of Patients Receiving Pralatrexate vs. Erlotinib (NUMBER) Participants = 2; Progression-free Survival (PFS) of Patients Receiving Pralatrexate vs. Erlotinib (MEDIAN) months = 3.4 [2.1-4.7]; Adverse Events of Patients Receiving Pralatrexate vs. Erlotinib (NUMBER) Treated Participants = 75,,,,,,,,,Overall Survival (OS) of Patients Receiving Pralatrexate vs. Erlotinib (MEDIAN) Months Survival = 6.7 [5.3-9.0],Progression-free Survival (PFS) of Patients Receiving Pralatrexate vs. Erlotinib (MEDIAN) months = 3.4 [2.1-4.7],,,Response Rate (RR) to Treatment of Patients Receiving Pralatrexate vs. Erlotinib (NUMBER) Participants = 2,Adverse Events of Patients Receiving Pralatrexate vs. Erlotinib (NUMBER) Treated Participants = 75,,
NCT00609518,A Study for Patients With Non-Squamous Non-Small Cell Lung Cancer,Pemetrexed With Simplified Folate and Dexamethasone Supplementation Versus Pemetrexed With Standard Supplementation as Second-line Chemotherapy for Patients With Non-squamous Non-small Cell Lung Cance,Eli Lilly and Company,Eli Lilly and Company,INDUSTRY,COMPLETED,2008-02,2009-10,2010-06,INTERVENTIONAL,PHASE2,,,,Non Small Cell Lung Cancer,Non Small Cell Lung Cancer,1,2,6,DIETARY_SUPPLEMENT; DRUG,,,1,3,True,Yes,Safety: Number of Participants With Drug-Related Grade 3 or 4 Toxicity (NUMBER) participants = 15,Proportion of Participants With Best Overall Tumor Response (Response Rate) (MEAN) proportion of patients = 0.118 [0.044-0.239]; Overall Survival (MEDIAN) months = 8.2 [5.4-11.7]; Progression-free Survival (PFS) (MEDIAN) months = 3.7 [2.9-4.9],,,,,,,,,Overall Survival (MEDIAN) months = 8.2 [5.4-11.7],Progression-free Survival (PFS) (MEDIAN) months = 3.7 [2.9-4.9],,,Proportion of Participants With Best Overall Tumor Response (Response Rate) (MEAN) proportion of patients = 0.118 [0.044-0.239],Safety: Number of Participants With Drug-Related Grade 3 or 4 Toxicity (NUMBER) participants = 15,,
NCT00609804,Sorafenib and Erlotinib or Sorafenib Alone in Advanced Non-Small Cell Lung Cancer Progressing on Erlotinib,Randomized Phase II Trial of Sorafenib and Erlotinib or Sorafenib Alone in Patients With Advanced Non-Small Cell Lung Cancer Progressing on Erlotinib,"SCRI Development Innovations, LLC","SCRI Development Innovations, LLC",OTHER,COMPLETED,2008-03,2012-05,2014-11,INTERVENTIONAL,PHASE2,,,,Non-Small Cell Lung Cancer,Non-Small Cell Lung Cancer,1,2,2,DRUG,,,1,2,True,Yes,Progression-free Survival (PFS) (MEDIAN) months = 3.1 [1.7-3.7],Overall Response Rate (NUMBER) participants = 2; Number of Participants With Treatment-emergent Adverse Events as a Measure of Safety and Tolerability (NUMBER) participants = 1,,,,,,,,,,Progression-free Survival (PFS) (MEDIAN) months = 3.1 [1.7-3.7],,,Overall Response Rate (NUMBER) participants = 2,Number of Participants With Treatment-emergent Adverse Events as a Measure of Safety and Tolerability (NUMBER) participants = 1,,
NCT00614822,"Carboplatin, Bevacizumab and Pemetrexed in Advanced Non Small Cell Lung Cancer","A Phase II Trial of Carboplatin, Bevacizumab and Pemetrexed in Advanced Non-Small Cell Lung Cancer",Christiana Care Health Services,Christiana Care Health Services,OTHER,COMPLETED,2007-11,2016-08-22,2016-08-22,INTERVENTIONAL,PHASE2,,,,Non Small Cell Lung Cancer,Non Small Cell Lung Cancer,1,1,1,DRUG,,,2,2,True,Yes,Progression Free Survival (MEDIAN) weeks = 28 [0-132.4]; Overall Survival (MEDIAN) weeks = 49 [0-62.7],Number of Participants With Complete and Partial Tumor Responses (COUNT_OF_PARTICIPANTS) Participants = 1; Number of Participants With Adverse Events (COUNT_OF_PARTICIPANTS) Participants = 1,,,,,,,,,Overall Survival (MEDIAN) weeks = 49 [0-62.7],Progression Free Survival (MEDIAN) weeks = 28 [0-132.4],,,,Number of Participants With Adverse Events (COUNT_OF_PARTICIPANTS) Participants = 1,,
NCT00621049,"Carboplatin, Docetaxel, Bevacizumab, and Erlotinib Versus Chemotherapy Alone in Resected NSCLC","Randomized Phase II Trial of Adjuvant Carboplatin, Docetaxel, Bevacizumab, and Erlotinib Versus Chemotherapy Alone in Patients With Resected Non-Small Cell Lung Cancer","SCRI Development Innovations, LLC","SCRI Development Innovations, LLC",OTHER,COMPLETED,2007-12,2013-07,2014-02,INTERVENTIONAL,PHASE2,,,,Non-Small Cell Lung Cancer,Non-Small Cell Lung Cancer,1,2,2,DRUG,,,1,3,True,Yes,,Safety (NUMBER) participants = 37; 2-year Survival (NUMBER) percentage of participants = 78.2; ,,,,,,,,,,,,,,,,
NCT00638937,AZD0530 to Treat Recurrent Stage IIIB/IV NSCLC Previously Treated With Combination Chemotherapy,"A Phase 2 Study of AZD0530 in Patients With Advanced, Recurrent Non-Small Cell Lung Cancer Who Have Previously Received Platinum-Based Combination Chemotherapy",National Cancer Institute (NCI),National Cancer Institute (NCI),NIH,COMPLETED,2008-02,2013-06,2013-06,INTERVENTIONAL,PHASE2,,,,Recurrent Non-small Cell Lung Cancer,Recurrent Non-small Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer,3,1,1,DRUG,,,1,7,True,Yes,Rate of Disease Control (Freedom From Disease Progression) (NUMBER) participants = 4,Objective Response Rate (Complete and Partial Response) (NUMBER) participants = 2; Stable Disease Rate (NUMBER) participants = 4; Duration of Response or Stable Disease (MEDIAN) months = 1.8 [1.6-2.8]; Median Progression-free Survival (MEDIAN) months = 1.8 [1.6-2.8]; Progression-free Survival (MEDIAN) months = 1.8 [1.6-2.8]; Median Overall Survival (MEDIAN) months = 7.6 [5.2-17.1]; Overall Survival (NUMBER) percentage of participants = 43,,,,,Duration of Response or Stable Disease (MEDIAN) months = 1.8 [1.6-2.8],,,Objective Response Rate (Complete and Partial Response) (NUMBER) participants = 2,Median Overall Survival (MEDIAN) months = 7.6 [5.2-17.1]; Overall Survival (NUMBER) percentage of participants = 43,Median Progression-free Survival (MEDIAN) months = 1.8 [1.6-2.8]; Progression-free Survival (MEDIAN) months = 1.8 [1.6-2.8],Objective Response Rate (Complete and Partial Response) (NUMBER) participants = 2,,Objective Response Rate (Complete and Partial Response) (NUMBER) participants = 2,,,
NCT00642473,A Study of Metronidazole Cream in the Prevention and Treatment of Tarceva (Erlotinib)-Associated Rash,A Phase II Trial Assessing Metronidazol Actavis 1% Topical Cream in the Prevention and Treatment of Erlotinib Associated Rash,Hoffmann-La Roche,Hoffmann-La Roche,INDUSTRY,COMPLETED,2008-02,2009-03,2009-03,INTERVENTIONAL,PHASE2,,,,Non-Squamous Non-Small Cell Lung Cancer,Non-Squamous Non-Small Cell Lung Cancer,1,2,3,DRUG; OTHER,,,2,0,True,Yes,Percentage of Participants With Erlotinib Associated Rash Stratified by Severity Grade at Week 2 (NUMBER) percentage of participants = 11; Percentage of Participants With Erlotinib Associated Rash Stratified by Severity Grade at Week 4 (NUMBER) percentage of participants = 13,,,,,,,,,,,,,,,,,
NCT00642759,"Carboplatin, Abraxane, and Bevacizumab in Previously Untreated Patients With Advanced Non-Small Cell Lung Cancer","A Phase II Trial of Carboplatin, Abraxane, and Bevacizumab in Previously Untreated Patients With Advanced Non-Small Cell Lung Cancer",Massachusetts General Hospital,Massachusetts General Hospital,OTHER,COMPLETED,2008-04,2015-04,2015-04,INTERVENTIONAL,PHASE2,,,,Non-small Cell Lung Cancer,Non-small Cell Lung Cancer,1,1,3,DRUG,,,1,3,True,Yes,6-month Progression Free Survival Rate (NUMBER) percentage of participants = 74 [57-97],"Objective Response Rate to Carboplatin, Abraxane and Avastin (COUNT_OF_PARTICIPANTS) Participants = 13; 6 Month Survival Rate (NUMBER) percentage of participants surviving = 83 [65-91]; Overall Survival (MEDIAN) Months = 13.7 [9.3-24.9]",,,,,,,,"Objective Response Rate to Carboplatin, Abraxane and Avastin (COUNT_OF_PARTICIPANTS) Participants = 13",Overall Survival (MEDIAN) Months = 13.7 [9.3-24.9],6-month Progression Free Survival Rate (NUMBER) percentage of participants = 74 [57-97],,,"Objective Response Rate to Carboplatin, Abraxane and Avastin (COUNT_OF_PARTICIPANTS) Participants = 13",,,
NCT00647426,Phase II Study of Sorafenib + Carboplatin and Docetaxel in First Line Treatment of Stage IIIB/IV NSCLC,A Phase II Study of Sorafenib in Combination With Carboplatin and Docetaxel in the First Line Treatment of Stage IIIB/IV Non-Small Cell Lung Cancer,Abramson Cancer Center at Penn Medicine,Abramson Cancer Center at Penn Medicine,OTHER,COMPLETED,2007-11,2011-08,2012-12,INTERVENTIONAL,PHASE2,,,,Non-Small Cell Lung Cancer,Non-Small Cell Lung Cancer,1,1,1,DRUG,,,1,3,True,Yes,,; ; ,,,,,,,,,,,,,,,,
NCT00652340,APRiCOT-L: Study to Evaluate Efficacy and Safety of Apricoxib With Erlotinib in Patients With Non-small Cell Lung Cancer,"APRiCOT-L (Apricoxib in Combination Oncology Treatment - Lung) A Randomized, Double-Blind, Placebo-Controlled Multicenter Phase 2 Study of the Efficacy and Safety of Apricoxib in Combination With Erlo","Tragara Pharmaceuticals, Inc.","Tragara Pharmaceuticals, Inc.",INDUSTRY,COMPLETED,2008-04,2010-06,2012-03,INTERVENTIONAL,PHASE2,,,,Recurrent Non Small Cell Lung Cancer,Recurrent Non Small Cell Lung Cancer,1,2,2,DRUG,,,1,1,True,Yes,Time to Disease Progression (TDP) (MEDIAN) months = 1.80 [1.40-2.80],Overall Survival (MEDIAN) months = 5.90 [4.10-8.50],,,,,,,,,Overall Survival (MEDIAN) months = 5.90 [4.10-8.50],,,,,,,
NCT00654030,Allogeneic Cellular Vaccine 1650-G for Non-Small Cell Lung Cancer,Allogeneic Cellular Vaccine 1650-G for Non-Small Cell Lung Cancer (NSCLC),University of Kentucky,Edward Hirschowitz,OTHER,COMPLETED,2006-10,2009-11,2009-11,INTERVENTIONAL,PHASE2,,,,Non-Small Cell Lung Cancer,Non-Small Cell Lung Cancer,1,1,1,DRUG,,,1,0,True,Yes,Number of Participants Responding to the Vaccine (COUNT_OF_PARTICIPANTS) Participants = 6,,,,,,,,,,,,,,,,,
NCT00655850,Lower Dose Chemotherapy Given More Frequent With Avastin to Treat Advanced Non-Squamous Non-Small Cell Lung Cancer,Pilot Phase II Study of Metronomic Chemotherapy in Combination With Avastin in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer,University of Alabama at Birmingham,University of Alabama at Birmingham,OTHER,COMPLETED,2008-03,2015-09,2016-09,INTERVENTIONAL,PHASE2,,,,Non-Small Cell Lung Cancer,Non-Small Cell Lung Cancer,1,1,3,BIOLOGICAL; DRUG,,,1,3,True,Yes,Progression-Free Survival (PFS) (MEDIAN) months = 8.5 [5-10],Number of Participants With Adverse Events (NUMBER) participants = 36; Overall Survival (OS) (MEDIAN) months = 25.5 [15-35]; Objective Response Rate (COUNT_OF_PARTICIPANTS) Participants = 22,,,,,,,,Objective Response Rate (COUNT_OF_PARTICIPANTS) Participants = 22,Overall Survival (OS) (MEDIAN) months = 25.5 [15-35],Progression-Free Survival (PFS) (MEDIAN) months = 8.5 [5-10],,,Objective Response Rate (COUNT_OF_PARTICIPANTS) Participants = 22,Number of Participants With Adverse Events (NUMBER) participants = 36,,
NCT00661778,A Study of Avastin (Bevacizumab) in Combination With Docetaxel and Cisplatin in Patients With Metastatic or Locally Advanced Non-small Cell Lung Cance,An Open Label Study to Assess the Effect of First-line Treatment With Avastin in Combination With Docetaxel and Cisplatin on Progression-free Survival in Patients With Metastatic or Locally Advanced N,Hoffmann-La Roche,Hoffmann-La Roche,INDUSTRY,COMPLETED,2007-07,2011-07,2011-07,INTERVENTIONAL,PHASE2,,,,Non-small Cell Lung Cancer,Non-small Cell Lung Cancer,1,1,3,DRUG,,,1,4,True,Yes,Progression-free Survival (MEDIAN) Months = 8.95 [6.92-9.97],Percentage of Participants With an Objective Response (NUMBER) Percentage of participants = 67.39; ; Overall Survival (MEDIAN) Months = 12.74 [9.48-17.79]; 1-year Survival (NUMBER) Percentage of participants = 53.46 [39.19-67.45],,,,,,,,,Overall Survival (MEDIAN) Months = 12.74 [9.48-17.79],Progression-free Survival (MEDIAN) Months = 8.95 [6.92-9.97],,,,,,
NCT00668707,Adjuvant Melatonin for Prevention of Lung Cancer Recurrence and Mortality,Adjuvant Melatonin for Prevention of Lung Cancer Recurrence and Mortality: A Randomized Placebo Controlled Clinical Trial,The Canadian College of Naturopathic Medicine,The Canadian College of Naturopathic Medicine,OTHER,COMPLETED,2007-09,2017-03-09,2017-11-30,INTERVENTIONAL,PHASE3,,,,Non Small Cell Lung Cancer,Non Small Cell Lung Cancer,1,2,2,DIETARY_SUPPLEMENT,,,1,11,True,Yes,Lung Cancer Recurrence or Mortality - 2 Years (COUNT_OF_PARTICIPANTS) Participants = 80,Quality of Life (LEAST_SQUARES_MEAN) Score on a scale of 0-100 = 21.4 [19.1-23.7]; Fatigue (LEAST_SQUARES_MEAN) Score on a scale of 0-100 = 59.8 [56.3-62.9]; Sleep (LEAST_SQUARES_MEAN) Score on a scale of 0-100 = 56.7 [52.5-61.0]; Pain Levels (MEAN) Score on a scale of 0-10 = 2.4; Anxiety (MEAN) Score on a scale of 0-63 = 8.2; Depression (MEAN) Score on a scale of 0-63 = 8.1; Adverse Events (Chemotherapy) (COUNT_OF_PARTICIPANTS) Participants = 44; Lung Cancer Recurrence or Mortality - 5 Years (COUNT_OF_PARTICIPANTS) Participants = 133; Blood Tests to Examine the Effects of Melatonin on the Immune System (Raw Values) (MEAN) Percent killing of K62 cells = 49.8; Adverse Events (Radiation) (COUNT_OF_PARTICIPANTS) Participants = 8; Blood Tests to Examine the Effects of Melatonin on the Immune System (Comparison Between Groups) (MEAN) Ratio of percent cytotoxicity = 1.1 [0.97-1.23],,,,,,,,,,,,Quality of Life (LEAST_SQUARES_MEAN) Score on a scale of 0-100 = 21.4 [19.1-23.7],,Adverse Events (Chemotherapy) (COUNT_OF_PARTICIPANTS) Participants = 44; Adverse Events (Radiation) (COUNT_OF_PARTICIPANTS) Participants = 8; Blood Tests to Examine the Effects of Melatonin on the Immune System (Comparison Between Groups) (MEAN) Ratio of percent cytotoxicity = 1.1 [0.97-1.23],,
NCT00686959,Chemotherapy and Radiation in Treating Participants With Stage 3 Non-Small Cell Lung Cancer,"Phase 3 Study of Pemetrexed, Cisplatin, and Radiotherapy Followed by Consolidation Pemetrexed Versus Etoposide, Cisplatin, and Radiotherapy Followed by Consolidation Cytotoxic Chemotherapy of Choice i",Eli Lilly and Company,Eli Lilly and Company,INDUSTRY,COMPLETED,2008-09,2014-10,2014-11,INTERVENTIONAL,PHASE3,,,,Non Small Cell Lung Cancer,Non Small Cell Lung Cancer,1,2,7,DRUG; RADIATION,,,1,5,True,Yes,Overall Survival (MEDIAN) months = 26.81 [20.40-30.92],"Progression-free Survival (PFS) (MEDIAN) months = 11.37 [10.25-13.21]; Objective Response Rate (Complete Response [CR] + Partial Response [PR]) (NUMBER) percentage of participants = 35.9 [30.46-41.58]; Survival Rates at 1, 2, and 3 Years (NUMBER) probability of survival = 0.76 [0.70-0.80]; First Site of Disease Failure in Terms of Relapse (NUMBER) percentage of participants = 37.3 [30.0-45.2]; Percentage of Participants With a Post Baseline Swallowing Diary Score >=4 (NUMBER) percentage of participants = 33.8 [26.7-37.5]",,Objective Response Rate (Complete Response [CR] + Partial Response [PR]) (NUMBER) percentage of participants = 35.9 [30.46-41.58],,,,,,Objective Response Rate (Complete Response [CR] + Partial Response [PR]) (NUMBER) percentage of participants = 35.9 [30.46-41.58],Overall Survival (MEDIAN) months = 26.81 [20.40-30.92],Progression-free Survival (PFS) (MEDIAN) months = 11.37 [10.25-13.21],Objective Response Rate (Complete Response [CR] + Partial Response [PR]) (NUMBER) percentage of participants = 35.9 [30.46-41.58],,Objective Response Rate (Complete Response [CR] + Partial Response [PR]) (NUMBER) percentage of participants = 35.9 [30.46-41.58],,,
NCT00687297,Study of Vandetanib Combined With Chemotherapy to Treat Advanced Non-small Cell Lung Cancer,"A Randomized Phase II Study Evaluating Vandetanib (ZD6474) in Combination With Docetaxel and Carboplatin Followed by Placebo or Maintenance Therapy With Vandetanib in Patients With IIIb, IV or Recurre","PrECOG, LLC.","PrECOG, LLC.",OTHER,COMPLETED,2008-04,2011-01,2011-04,INTERVENTIONAL,PHASE2,,,,Lung Cancer,Lung Cancer; Non Small Cell Lung Cancer,2,2,5,DRUG,,,1,2,True,Yes,Progression-free Survival (MEDIAN) Months = 4.5 [3.6-4.9],Objective Response Rate (NUMBER) percentage of participants = 18.8 [10.9-29.0]; Progression-free Survival (MEDIAN) months = 4.5 [3.3-5.8],,,,,,,,Objective Response Rate (NUMBER) percentage of participants = 18.8 [10.9-29.0],,Progression-free Survival (MEDIAN) Months = 4.5 [3.6-4.9]; Progression-free Survival (MEDIAN) months = 4.5 [3.3-5.8],,,Objective Response Rate (NUMBER) percentage of participants = 18.8 [10.9-29.0],,,
NCT00693992,Sunitinib Malate as Maintenance Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Previously Treated With Combination,"Randomized, Phase III, Double-Blind Placebo-Controlled Trial of Sunitinib (NSC #736511) as Maintenance Therapy in Non-progressing Patients Following an Initial Four Cycles of Platinum-Based Combinatio",National Cancer Institute (NCI),National Cancer Institute (NCI),NIH,COMPLETED,2008-06-15,2013-11-08,2015-05-28,INTERVENTIONAL,PHASE3,,,,Stage IIIB Lung Non-Small Cell Cancer AJCC v7,Stage IIIB Lung Non-Small Cell Cancer AJCC v7; Stage IV Non-Small Cell Lung Cancer AJCC v7,2,2,4,DRUG; OTHER,,,1,5,True,Yes,Progression Free Survival (PFS) (MEDIAN) months = 4.3 [3.2-4.9],Overall Survival (OS) (MEDIAN) months = 11.7 [9.9-14.0]; Response Rate (RR) (NUMBER) percentage of participants = 11; Percentage of Deterioration in QOL at 3 Months Using the EORTC QLQ-C30 Global Health Subscale (NUMBER) percentage of patients = 55.8; Percentage of Deterioration in Symptom Progression at 3 Months Using the EORTC LC13 Dyspnea Subscale (NUMBER) percentage of patients = 31.5; Grade and Type of Toxicity as Assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0 (NUMBER) percentage of participants = 26,,,,,,,,,Overall Survival (OS) (MEDIAN) months = 11.7 [9.9-14.0],Progression Free Survival (PFS) (MEDIAN) months = 4.3 [3.2-4.9],,Percentage of Deterioration in QOL at 3 Months Using the EORTC QLQ-C30 Global Health Subscale (NUMBER) percentage of patients = 55.8,Response Rate (RR) (NUMBER) percentage of participants = 11,Grade and Type of Toxicity as Assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0 (NUMBER) percentage of participants = 26,,
NCT00698815,Pemetrexed and/or Sunitinib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer,A Randomized Phase II Study to Assess the Efficacy of Pemetrexed or Sunitinib (NSC # 736511) or Pemetrexed Plus Sunitinib in the Second-Line Treatment of Advanced Non-small Cell Lung Cancer,National Cancer Institute (NCI),National Cancer Institute (NCI),NIH,COMPLETED,2008-04-15,2011-12-01,,INTERVENTIONAL,PHASE2,,,,Recurrent Non-Small Cell Lung Carcinoma,Recurrent Non-Small Cell Lung Carcinoma; Stage IIIB Non-Small Cell Lung Cancer AJCC v7; Stage IV Non-Small Cell Lung Cancer AJCC v7,3,3,3,DRUG; OTHER,,,1,3,True,Yes,18 Week Progression-free Survival (PFS) Rate (NUMBER) percentage of participants = 54 [40-71],PFS (MEDIAN) months = 4.9 [2.1-8.8]; Overall Response Rate (NUMBER) percentage of participants = 14 [5-29]; Overall Survival (OS) (MEDIAN) months = 10.5 [8.3-20.2],,,,,,,,,Overall Survival (OS) (MEDIAN) months = 10.5 [8.3-20.2],18 Week Progression-free Survival (PFS) Rate (NUMBER) percentage of participants = 54 [40-71]; PFS (MEDIAN) months = 4.9 [2.1-8.8],,,Overall Response Rate (NUMBER) percentage of participants = 14 [5-29],,,
NCT00700180,A Study of Avastin (Bevacizumab) in Combination With Carboplatin-Based Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Non-Small Cell,"A Randomized, Open-label Study to Explore the Correlation of Biomarkers With Response Rate in Chemo-naive Patients With Advanced or Recurrent Non-squamous Non-small Cell Lung Cancer Who Receive Treatm",Hoffmann-La Roche,Hoffmann-La Roche,INDUSTRY,COMPLETED,2008-09,2012-09,2012-09,INTERVENTIONAL,PHASE2,,,,Non-Small Cell Lung Cancer,Non-Small Cell Lung Cancer,1,2,3,DRUG,,,1,8,True,Yes,Percentage of Participants With a Best Overall Response of Complete Response (CR) or Partial Response (PR) by Dichotomized Baseline Plasma Marker Level (NUMBER) percentage of participants = 42.86,"Progression-Free Survival - Percentage of Participants With an Event (NUMBER) percentage of participants = 83.1; Progression-Free Survival - Time to Event (MEDIAN) months = 6.8 [5.9-7.4]; Percentage of Participants With Objective Response (NUMBER) percentage of participants = 37.1 [29.4-45.3]; Percentage of Participants With Measurable Disease at Baseline Who Achieved CR, PR, or Stable Disease (SD) for at Least 6 Weeks (NUMBER) percentage of participants = 76.8 [69.3-83.3]; Duration of Response - Percentage of Participants With an Event (NUMBER) percentage of participants = 80.4; Duration of Response - Time to Event (MEDIAN) months = 5.8 [5.2-7.0]; Overall Survival - Percentage of Participants With an Event (NUMBER) percentage of participants = 64.3; Overall Survival - Time to Event (MEDIAN) months = 13.4 [10.5-18.1]",,Percentage of Participants With a Best Overall Response of Complete Response (CR) or Partial Response (PR) by Dichotomized Baseline Plasma Marker Level (NUMBER) percentage of participants = 42.86,,,Duration of Response - Percentage of Participants With an Event (NUMBER) percentage of participants = 80.4; Duration of Response - Time to Event (MEDIAN) months = 5.8 [5.2-7.0],,,,Overall Survival - Percentage of Participants With an Event (NUMBER) percentage of participants = 64.3; Overall Survival - Time to Event (MEDIAN) months = 13.4 [10.5-18.1],Progression-Free Survival - Percentage of Participants With an Event (NUMBER) percentage of participants = 83.1; Progression-Free Survival - Time to Event (MEDIAN) months = 6.8 [5.9-7.4],Percentage of Participants With a Best Overall Response of Complete Response (CR) or Partial Response (PR) by Dichotomized Baseline Plasma Marker Level (NUMBER) percentage of participants = 42.86,,,,,
NCT00701558,A Study of First Line Treatment With Tarceva (Erlotinib) in Combination With Gemcitabine in Patients With Unresectable Advanced and/or Metastatic Non-,An Open Label Study to Evaluate the Effect of First Line Treatment With Tarceva in Combination With Gemcitabine on Disease Progression in Patients With Unresectable Advanced and/or Metastatic Non-smal,Hoffmann-La Roche,Hoffmann-La Roche,INDUSTRY,COMPLETED,2008-08,2010-10,2010-12,INTERVENTIONAL,PHASE2,,,,Non-small Cell Lung Cancer Metastatic,Non-small Cell Lung Cancer Metastatic,1,1,2,DRUG,,,2,1,True,Yes,Time to Disease Progression (MEDIAN) weeks = 15 [7-36]; Overall Response Rate (ORR) (NUMBER) percentage of participants = 15.8,Overall Survival (MEDIAN) weeks = 39 [27-51],,,,,,,,,Overall Survival (MEDIAN) weeks = 39 [27-51],,,,Overall Response Rate (ORR) (NUMBER) percentage of participants = 15.8,,,
NCT00718315,"A Study of Verutex (Fusidic Acid), Eritex (Erythromycin) and Fisiogel in the Management of Tarceva-Associated Rash.","A Randomized, Open Label Study to Compare the Use of the Dermatological Creams Verutex, Eritex and Fisiogel in the Management of Skin Rash Associated With Tarceva Treatment in Patients With Locally Ad",Hoffmann-La Roche,Hoffmann-La Roche,INDUSTRY,COMPLETED,2009-04,2012-06,2012-06,INTERVENTIONAL,PHASE3,,,,Non-Small Cell Lung Cancer,Non-Small Cell Lung Cancer,1,3,4,DRUG,,,2,7,True,Yes,Percentage of Participants Who Develop Skin Rash (NUMBER) percentage of participants = 60.0 [47.1-72.0]; Percentage of Participants With Skin Rash Stratified by Severity Grade (NUMBER) percentage of participants = 29.8,Time to Appearance of Skin Rash (MEDIAN) Days = 16.0 [15.0-28.0]; Percentage of Participants With Erythema (NUMBER) percentage of participants = 56.7 [44.8-67.9]; Percentage of Participants With Pruritus (NUMBER) percentage of participants = 36.1 [25.2-48.6]; Percentage of Participants With Pain (NUMBER) percentage of participants = 16.4 [9.4-27.1]; Percentage of Participants With Erythema Stratified by Severity Grade (NUMBER) percentage of participants = 37.7; Percentage of Participants With Pruritus Stratified by Severity Grade (NUMBER) percentage of participants = 63.9; Percentage of Participants With Pain Stratified by Severity Grade (NUMBER) percentage of participants = 82.0,,,,,,,,,,,,,,,,
NCT00723957,A Randomized Phase 2 Study of Ixabepilone Plus Carboplatin and Paclitaxel Plus Carboplatin in Advanced Nonsmall-Cell Lung Cancer,A Randomized Phase 2 Study of Ixabepilone Plus Carboplatin and Paclitaxel Plus Carboplatin in Patients With Advanced Non-small Cell Lung Cancer,R-Pharm,R-Pharm,INDUSTRY,COMPLETED,2008-12,2010-05,2011-08,INTERVENTIONAL,PHASE2,,,,Advanced/Metastatic Non-Small Cell Lung Cancer,Advanced/Metastatic Non-Small Cell Lung Cancer,1,2,3,DRUG,,,1,8,True,Yes,Progression-free Survival in the Subgroup of Participants With βIII-tubulin Positive Tumors (MEDIAN) Months = 4.27 [2.89-5.65],"Progression-free Survival in the Subgroup of Participants With βIII-tubulin Negative Tumors (MEDIAN) Months = 5.78 [5.29-8.41]; Progression-free Survival in the Overall Population (MEDIAN) Months = 5.29 [4.14-5.88]; Percentage of Participants With Best Response of Complete Response (CR) or Partial Response (PR) (MEAN) Percentage of participants = 17.0 [8.1-29.80]; Time to Response (MEDIAN) Weeks = 12.1 [5.1-19.3]; Number of Participants With Death as Outcome, Drug-related Adverse Events (AEs), Serious AEs (SAEs), Drug-related SAEs, AEs Leading to Discontinuation, and Drug-related Peripheral Neuropathy (NUMBER) Participants = 28; Number of Participants With Hematology Laboratory Results of Grade 3 or 4 (NUMBER) Participants = 31; Number of Participants With Grade 3 or 4 Abnormalities in Liver Function and Urine Laboratory Test Results (NUMBER) Participants = 1; Median Length of Survival in the Overall Population and in the Subgroups of Patients With βIII-tubulin Positive (β3T+) and βIII-tubulin Negative (β3T-)Tumors (MEDIAN) Months = 10.61 [7.16-13.96]",,Percentage of Participants With Best Response of Complete Response (CR) or Partial Response (PR) (MEAN) Percentage of participants = 17.0 [8.1-29.80],,,,,,,,Progression-free Survival in the Subgroup of Participants With βIII-tubulin Positive Tumors (MEDIAN) Months = 4.27 [2.89-5.65]; Progression-free Survival in the Subgroup of Participants With βIII-tubulin Negative Tumors (MEDIAN) Months = 5.78 [5.29-8.41]; Progression-free Survival in the Overall Population (MEDIAN) Months = 5.29 [4.14-5.88],Percentage of Participants With Best Response of Complete Response (CR) or Partial Response (PR) (MEAN) Percentage of participants = 17.0 [8.1-29.80],,,"Number of Participants With Death as Outcome, Drug-related Adverse Events (AEs), Serious AEs (SAEs), Drug-related SAEs, AEs Leading to Discontinuation, and Drug-related Peripheral Neuropathy (NUMBER) Participants = 28",,
NCT00735696,A Study of Ramucirumab (IMC-1121B) With Paclitaxel and Carboplatin in Non-small Cell Lung Cancer,"A Phase 2, Open-label Study of IMC-1121B in Combination With Paclitaxel and Carboplatin as First-line Therapy in Patients With Stage IIIB/IV Non-small Cell Lung Cancer",Eli Lilly and Company,Eli Lilly and Company,INDUSTRY,COMPLETED,2009-01,2011-10,2012-01,INTERVENTIONAL,PHASE2,,,,Non Small Cell Lung Cancer,Non Small Cell Lung Cancer,1,1,3,BIOLOGICAL; DRUG,,,1,8,True,Yes,Percentage of Participants Who Are Progression-free (PFS) at 6 Months (NUMBER) percentage of participants = 59.0 [41.3-72.9],Summary of Participants Reporting Adverse Events (NUMBER) participants = 34; Percentage of Participants With Complete Response (CR) or Partial Response (PR) (Objective Response Rate ([ORR]) (NUMBER) percentage of participants = 55.0 [38.5-70.7]; Duration of Response (MEDIAN) months = 5.54 [4.27-8.21]; Overall Survival (OS) at 1 Year (NUMBER) percentage of participants = 74.6 [57.9-85.4]; Progression-free Survival (PFS) (MEDIAN) months = 7.85 [5.49-9.86]; Overall Survival (OS) (MEDIAN) months = 16.85 [14.82-28.58]; Serum Anti-Ramucirumab Antibody Assessment (NUMBER) participants = 1; Maximum Concentration of Ramucirumab (Cmax) (MEAN) micrograms/milliliter (mcg/mL) = 372,,Percentage of Participants With Complete Response (CR) or Partial Response (PR) (Objective Response Rate ([ORR]) (NUMBER) percentage of participants = 55.0 [38.5-70.7],,,Duration of Response (MEDIAN) months = 5.54 [4.27-8.21],,,Percentage of Participants With Complete Response (CR) or Partial Response (PR) (Objective Response Rate ([ORR]) (NUMBER) percentage of participants = 55.0 [38.5-70.7],Overall Survival (OS) at 1 Year (NUMBER) percentage of participants = 74.6 [57.9-85.4]; Overall Survival (OS) (MEDIAN) months = 16.85 [14.82-28.58],Progression-free Survival (PFS) (MEDIAN) months = 7.85 [5.49-9.86],Percentage of Participants With Complete Response (CR) or Partial Response (PR) (Objective Response Rate ([ORR]) (NUMBER) percentage of participants = 55.0 [38.5-70.7],,Percentage of Participants With Complete Response (CR) or Partial Response (PR) (Objective Response Rate ([ORR]) (NUMBER) percentage of participants = 55.0 [38.5-70.7],Summary of Participants Reporting Adverse Events (NUMBER) participants = 34,,
NCT00741988,Ixabepilone and Carboplatin +/- Bevacizumab in Advanced Non-Small-Cell Lung Cancer,Phase II Trial of Ixabepilone and Carboplatin With or Without Bevacizumab in Patients With Previously Untreated Advanced Non-Small-Cell Lung Cancer,"SCRI Development Innovations, LLC","SCRI Development Innovations, LLC",OTHER,COMPLETED,2008-09,2010-09,2012-09,INTERVENTIONAL,PHASE2,,,,Non-Small Cell Lung Cancer,Non-Small Cell Lung Cancer,1,2,3,DRUG,,,1,3,True,Yes,"Overall Response Rate (ORR), the Percentage of Patients Who Experience an Objective Benefit From Treatment (NUMBER) percentage of participants = 29 [16-45]","Progression Free Survival, the Length of Time, That Patients Were Alive From Their First Date of Treatment Until Worsening of Their Disease (MEDIAN) months = 5.3 [2.8-8.6]; Overall Survival (OS), the Length of Time, in Months, That Patients Were Alive From Their First Date of Protocol Treatment Until Death (MEDIAN) months = 9.3 [6.4-16.6]; Number of Participants Experiencing Treatment Related Toxicity (COUNT_OF_PARTICIPANTS) Participants = 4",,,,,,,,,"Overall Survival (OS), the Length of Time, in Months, That Patients Were Alive From Their First Date of Protocol Treatment Until Death (MEDIAN) months = 9.3 [6.4-16.6]","Progression Free Survival, the Length of Time, That Patients Were Alive From Their First Date of Treatment Until Worsening of Their Disease (MEDIAN) months = 5.3 [2.8-8.6]",,,"Overall Response Rate (ORR), the Percentage of Patients Who Experience an Objective Benefit From Treatment (NUMBER) percentage of participants = 29 [16-45]",Number of Participants Experiencing Treatment Related Toxicity (COUNT_OF_PARTICIPANTS) Participants = 4,,
NCT00745875,ZD4054 (Zibotentan) Phase II Non-Small Cell Lung Cancer Study,"A Phase II, Double-blind, Placebo Controlled, Randomised Study to Assess the Efficacy and Safety of ZD4054 (Zibotentan) in Combination With Pemetrexed (Alimta®) vs. Pemetrexed Alone in Patients With N",AstraZeneca,AstraZeneca,INDUSTRY,COMPLETED,2008-08,2010-01,2010-01,INTERVENTIONAL,PHASE2,,,,Non Small Cell Lung Cancer,Non Small Cell Lung Cancer; Lung Cancer,2,2,3,DRUG,,,1,1,True,Yes,Time to Death (MEDIAN) Days = 193 [27-437],Progression-free Survival (MEDIAN) Days = 87 [27-283],,,,,,,,,,Progression-free Survival (MEDIAN) Days = 87 [27-283],,,,,,
NCT00753714,Zactima in Non Small Cell Lung Cancer (NSCLC) ELderly Patients In Combination With or Versus Gemcitabine,"Phase II, Randomised, Double-blind, Two-arm, Parallel Study of Vandetanib (ZACTIMA™ , ZD6474) Plus Gemcitabine (Gemzar® ) or Gemcitabine Plus Placebo as First Line Treatment of Advanced (Stage IIIB or",Sanofi,"Genzyme, a Sanofi Company",INDUSTRY,COMPLETED,2008-10,2011-04,2011-12,INTERVENTIONAL,PHASE2,,,,Non Small Cell Lung Cancer,Non Small Cell Lung Cancer,1,2,3,DRUG,,,1,4,True,Yes,Progression Free Survival (MEDIAN) days = 183 [116-214],Overall Survival (MEDIAN) days = 262 [170-356]; Overall Objective Response (NUMBER) Participants = 9; Duration of Response (MEDIAN) days = 225; The Safety and Tolerability Profile of ZD6474 (Vandetanib) in Combination With Gemcitabine (NUMBER) Adverse Events = 378,,,,,Duration of Response (MEDIAN) days = 225,,,,Overall Survival (MEDIAN) days = 262 [170-356],Progression Free Survival (MEDIAN) days = 183 [116-214],,,,The Safety and Tolerability Profile of ZD6474 (Vandetanib) in Combination With Gemcitabine (NUMBER) Adverse Events = 378,,
NCT00762034,"A Study of Pemetrexed, Carboplatin and Bevacizumab in Participants With Nonsquamous Non-Small Cell Lung Cancer","Randomized, Open-Label, Phase 3 Study of Pemetrexed Plus Carboplatin and Bevacizumab Followed by Maintenance Pemetrexed and Bevacizumab Versus Paclitaxel Plus Carboplatin and Bevacizumab Followed by M",Eli Lilly and Company,Eli Lilly and Company,INDUSTRY,COMPLETED,2008-12,2012-04,2014-12,INTERVENTIONAL,PHASE3,,,,Non-small Cell Lung Cancer,Non-small Cell Lung Cancer,1,2,6,BIOLOGICAL; DRUG,,,1,27,True,Yes,Overall Survival (MEDIAN) months = 12.55 [11.30-14.03],"Percentage of Participants With a Complete Response (CR) and Partial Response (PR) (Overall Response Rate) (NUMBER) percentage of participants = 34.1 [29.8-38.6]; Percentage of Participants With a Complete Response (CR), Partial Response (PR), and Stable Disease (SD) (Disease Control Rate) (NUMBER) percentage of participants = 65.9 [61.4-70.2]; Progression Free Survival Time (MEDIAN) months = 6.04 [5.55-6.87]; Time to Progressive Disease (MEDIAN) months = 7.03 [6.24-8.05]; Safety and Toxicity Profile of Study Treatments (NUMBER) participants = 111; Duration of Hospitalizations Per Participant (MEAN) days = 9.4; Number of Participants Who Received a Transfusion (NUMBER) participants = 116; Number of Participants Receiving Concomitant Medication (NUMBER) participants = 406; Change From Baseline in Participant Reported Outcomes as Assessed by the Functional Assessment of Cancer Therapy - General (FACT-G) (LEAST_SQUARES_MEAN) units on a scale = 0.51; Change From Baseline in Participant Reported Outcomes as Assessed by the Functional Assessment of Cancer Therapy - Lung (FACT-L) (LEAST_SQUARES_MEAN) units on a scale = 1.88; Change From Baseline in Participant Reported Outcomes as Assessed by the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group- Neurotoxicity (FACT/GOG-Ntx) (LEAST_SQUARES_MEAN) units on a scale = -0.60; Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) for Pemetrexed (GEOMETRIC_MEAN) micrograms per milliliter (μg/mL) = 122; Pharmacokinetics (PK): Elimination Half-life (t1/2) for Pemetrexed (GEOMETRIC_MEAN) hours (hr) = 2.88; Pharmacokinetics (PK): Area Under the Concentration Time Curve From Zero to Infinity (AUC(0-∞)) for Pemetrexed (GEOMETRIC_MEAN) microgram*hour per milliliter (μg•hr/mL) = 203; Pharmacokinetics (PK): Pemetrexed Clearance (CL) (GEOMETRIC_MEAN) milliliters per minute (mL/min) = 72.1; Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) for Total (Bound and Unbound) Platinum and Unbound Platinum (GEOMETRIC_MEAN) micrograms per milliliter (μg/mL) = 18.4; Pharmacokinetics (PK): Elimination Half-life (t1/2) for Total (Bound and Unbound) Platinum and Unbound Platinum (GEOMETRIC_MEAN) hours (hr) = 65.6; Pharmacokinetics (PK): Area Under the Concentration Time Curve From Zero to Infinity (AUC(0-∞)) for Total (Bound and Unbound) Platinum and Unbound Platinum (GEOMETRIC_MEAN) microgram*hour per milliliter (μg•hr/mL) = 160; Pharmacokinetics (PK): Platinum Clearance (CL) for Total (Bound and Unbound) and Unbound Forms (GEOMETRIC_MEAN) liters per hour (L/hr) = 2.02; Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) for Bevacizumab (GEOMETRIC_MEAN) micrograms per milliliter (μg/mL) = 276; Pharmacokinetics (PK): Elimination Half-life (t1/2) for Bevacizumab (GEOMETRIC_MEAN) days = 14.8; Pharmacokinetics (PK): Area Under the Concentration Time Curve From Zero to Infinity (AUC(0-∞)) Bevacizumab (GEOMETRIC_MEAN) microgram*day per milliliter (μg•day/mL) = 3070; Pharmacokinetics (PK): Bevacizumab Clearance (CL) (GEOMETRIC_MEAN) liters per day (L/day) = 0.341; Translational Research: Number of Participants With Epidermal Growth Factor Receptor (EGFR) Mutations (NUMBER) participants = 11; Translational Research: Overall Survival (OS) Based on Nuclear Thyroid Transcription Factor-1 (TTF-1) Expression Regardless of Study Treatment (MEDIAN) months = 14.9 [12.8-17.6]; Translational Research: Overall Survival (OS) Based on Cytoplasmic and Nuclear Thymidylate Synthase (TS) Expression (MEDIAN) months = 12.9 [10.8-16.9]; Translational Research: Overall Survival (OS) Based on Cytoplasmic and Membrane Folate Receptor Alpha (FR-α) Expression (MEDIAN) months = 14.4 [11.4-22.2]",,"Percentage of Participants With a Complete Response (CR) and Partial Response (PR) (Overall Response Rate) (NUMBER) percentage of participants = 34.1 [29.8-38.6]; Percentage of Participants With a Complete Response (CR), Partial Response (PR), and Stable Disease (SD) (Disease Control Rate) (NUMBER) percentage of participants = 65.9 [61.4-70.2]",,,,,,,Overall Survival (MEDIAN) months = 12.55 [11.30-14.03]; Translational Research: Overall Survival (OS) Based on Nuclear Thyroid Transcription Factor-1 (TTF-1) Expression Regardless of Study Treatment (MEDIAN) months = 14.9 [12.8-17.6]; Translational Research: Overall Survival (OS) Based on Cytoplasmic and Nuclear Thymidylate Synthase (TS) Expression (MEDIAN) months = 12.9 [10.8-16.9]; Translational Research: Overall Survival (OS) Based on Cytoplasmic and Membrane Folate Receptor Alpha (FR-α) Expression (MEDIAN) months = 14.4 [11.4-22.2],Progression Free Survival Time (MEDIAN) months = 6.04 [5.55-6.87],"Percentage of Participants With a Complete Response (CR) and Partial Response (PR) (Overall Response Rate) (NUMBER) percentage of participants = 34.1 [29.8-38.6]; Percentage of Participants With a Complete Response (CR), Partial Response (PR), and Stable Disease (SD) (Disease Control Rate) (NUMBER) percentage of participants = 65.9 [61.4-70.2]",,Percentage of Participants With a Complete Response (CR) and Partial Response (PR) (Overall Response Rate) (NUMBER) percentage of participants = 34.1 [29.8-38.6],Safety and Toxicity Profile of Study Treatments (NUMBER) participants = 111; Change From Baseline in Participant Reported Outcomes as Assessed by the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group- Neurotoxicity (FACT/GOG-Ntx) (LEAST_SQUARES_MEAN) units on a scale = -0.60,,
NCT00769067,A Randomized Trial Of PF-00299804 Taken Orally Versus Erlotinib Taken Orally For Treatment Of Advanced Non-Small Cell Lung Cancer That Has Progressed ,A Randomized Phase 2 Trial Of Pf-00299804 Versus Erlotinib For The Treatment Of Advanced Non-small Cell Lung Cancer After Failure Of At Least One Prior Chemotherapy Regimen,Pfizer,Pfizer,INDUSTRY,COMPLETED,2008-11,2010-10,2014-08,INTERVENTIONAL,PHASE2,,,,Non-small Cell Lung Cancer,Non-small Cell Lung Cancer,1,2,2,DRUG,,,1,7,True,Yes,Progression-Free Survival (PFS) (MEDIAN) weeks = 8.3 [7.9-11.7],Categorical Summary of Overall Scale Change in European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) (NUMBER) participants = 14; Categorical Summary of Overall Scale Change in European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Lung Cancer Module (EORTC QLQ-LC13) (NUMBER) participants = 18; Dermatology Life Quality Index (DLQI) (MEAN) units on a scale = 0.70; Percentage of Participants With Objective Response (NUMBER) percentage of participants = 5.3 [1.7-12.0]; Best Overall Response (BOR) (NUMBER) participants = 0; Duration of Response (DR) (MEDIAN) weeks = 40.1 [24.7-72.0]; Overall Survival (OS) (MEDIAN) weeks = 32.3 [24.0-40.3],,,,,Duration of Response (DR) (MEDIAN) weeks = 40.1 [24.7-72.0],,,,Overall Survival (OS) (MEDIAN) weeks = 32.3 [24.0-40.3],Progression-Free Survival (PFS) (MEDIAN) weeks = 8.3 [7.9-11.7],,Categorical Summary of Overall Scale Change in European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) (NUMBER) participants = 14; Categorical Summary of Overall Scale Change in European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Lung Cancer Module (EORTC QLQ-LC13) (NUMBER) participants = 18,,,,
NCT00771953,0822GCC: Phase 2 Study of Efficacy and Safety of Apricoxib/Placebo With Docetaxel or Pemetrexed in Non-Small Cell Lung Cancer,"0822GCC Randomized, Double-Blind, Placebo-Controlled Multicenter Phase 2 Study of the Efficacy and Safety of Apricoxib in Combination With Either Docetaxel or Pemetrexed in Non-Small Cell Lung Cancer ","University of Maryland, Baltimore","University of Maryland, Baltimore",OTHER,COMPLETED,2008-11,2012-05,2014-12,INTERVENTIONAL,PHASE2,,,,Lung Cancer,Lung Cancer; Non Small Cell Lung Cancer,2,2,3,DRUG,,,1,0,True,Yes,Progression Free Survival (MEDIAN) days = 75 [47-104],,,,,,,,,,,Progression Free Survival (MEDIAN) days = 75 [47-104],,,,,,
NCT00778167,Erlotinib Hydrochloride With or Without Cixutumumab in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer,A Phase I/Randomized Phase II Study of the Anti-IGF-1R Monoclonal Antibody IMC-A12 in Combination With Erlotinib Compared With Erlotinib Alone in Patients With Advanced Non-Small Cell Lung Cancer (NSC,National Cancer Institute (NCI),National Cancer Institute (NCI),NIH,COMPLETED,2008-10,2012-05,2012-05,INTERVENTIONAL,PHASE1; PHASE2,,,,Recurrent Non-small Cell Lung Cancer,Recurrent Non-small Cell Lung Cancer; Stage IIIA Non-small Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer,4,2,3,BIOLOGICAL; DRUG; OTHER,,,1,0,True,Yes,Safety and Tolerability of IMC-A12 in Combination With Erlotinib Hydrochloride as Graded by Common Terminology Criteria for Adverse Event (CTCAE) Version 3.0 (DLTs During Cycle One) (NUMBER) Participants = 4,,,,,,,,,,,,,,,Safety and Tolerability of IMC-A12 in Combination With Erlotinib Hydrochloride as Graded by Common Terminology Criteria for Adverse Event (CTCAE) Version 3.0 (DLTs During Cycle One) (NUMBER) Participants = 4,,
NCT00783705,Inositol in Preventing Lung Cancer in Current or Former Smokers With Bronchial Dysplasia,Phase IIb Randomized Comparative Study of the Efficacy and Safety of Myo-inositol Versus Placebo in Smokers With Bronchial Dysplasia,National Cancer Institute (NCI),National Cancer Institute (NCI),NIH,COMPLETED,2008-11,2014-05,2014-05,INTERVENTIONAL,PHASE2,,,,Non-small Cell Lung Cancer,Non-small Cell Lung Cancer; Squamous Lung Dysplasia,2,2,2,DRUG; OTHER,,,2,18,True,Yes,Percentage of Participants With Response Determined by Change in the Histologic Grade of Bronchial Dysplasia as Measured by Mucosal Biopsy Samples on Participant-specific Analysis. (NUMBER) percentage of participants = 26.3; Percentage of Participants With Response Determined by Change in the Histologic Grade of Bronchial Dysplasia as Measured by Mucosal Biopsy Samples on Lesion-specific Analysis. (NUMBER) percentage of participants = 10.2,Percent Change in the Number of Bronchial Dysplastic Lesions Before and After Treatment (MEAN) percentage change in number of lesions = -53.5; Mean Percent Change in Ki-67 Expression Level in the Bronchial Biopsies With Dysplasia (MEAN) percentage of Ki67 expression level = -22.8; ; Change in Inflammatory Biomarkers Levels (CC-16) in Bronchoalveolar Lavage Samples as Assessed by Enzyme-linked Immunoassay (ELISA) (MEDIAN) ng/mL = -66.96 [-127.56-52.26]; Change in Inflammatory Biomarkers Levels (IL-6) in Bronchoalveolar Lavage Samples as Assessed by Enzyme-linked Immunoassay (ELISA) (MEDIAN) pg/mL = -0.68 [-2.78-0.34]; Change in Inflammatory Biomarkers Levels (CCL-2) in Bronchoalveolar Lavage Samples as Assessed by Enzyme-linked Immunoassay (ELISA) (MEDIAN) pg/mL = -9.25 [-44.32-8.62]; Change in Inflammatory Biomarkers Levels (MPO) in Bronchoalveolar Lavage Samples as Assessed by Enzyme-linked Immunoassay (ELISA) (MEDIAN) ng/mL = -3.46 [-8.17-2.77]; Change in Inflammatory Biomarkers Levels (CC18) in Bronchoalveolar Lavage Samples as Assessed by Enzyme-linked Immunoassay (ELISA) (MEDIAN) ng/mL = -121.47 [-1234.7-1122.9]; Change in Inflammatory Biomarkers Levels (SFTPD) in Bronchoalveolar Lavage Samples as Assessed by Enzyme-linked Immunoassay (ELISA) (MEDIAN) ng/mL = -12.39 [-47.12-5.72]; Change in Inflammatory Biomarkers Levels (Total Glutathione) in Bronchoalveolar Lavage Samples as Assessed by Enzyme-linked Immunoassay (ELISA) (MEDIAN) umol/L = -0.25 [-1.98-0.48]; Change in Inflammatory Biomarkers Levels (CC-16) in Plasma Samples as Assessed by ELISA (MEDIAN) ng/mL = -0.08 [-0.82-0.92]; Change in Inflammatory Biomarkers Levels (CRP) in Plasma Samples as Assessed by ELISA (MEDIAN) ng/mL = 161.18 [-248.55-744.31]; Change in Inflammatory Biomarkers Levels (IL-6) in Plasma Samples as Assessed by ELISA (MEDIAN) pg/mL = 0.06 [-0.74-0.46]; Change in Inflammatory Biomarkers Levels (CCL-2) in Plasma Samples as Assessed by ELISA (MEDIAN) pg/mL = 2.19 [-35.08-29.56]; Change in Inflammatory Biomarkers Levels (MPO) in Plasma Samples as Assessed by ELISA (MEDIAN) ng/mL = 0.20 [-2.05-2.17]; Change in Inflammatory Biomarkers Levels (Nitrotyrosine) in Plasma Samples as Assessed by ELISA (MEDIAN) mmol/L = 0.77 [-2.84-4.68]; Change in Inflammatory Biomarkers Levels (CC18) in Plasma Samples as Assessed by ELISA (MEDIAN) ng/mL = 1.50 [-0.6-3.19]; Change in Inflammatory Biomarkers Levels (SFTPD) in Plasma Samples as Assessed by ELISA (MEDIAN) ng/mL = -0.28 [-0.93-1.51],,,,,,,,,,,,,,,,
NCT00789373,A Study of Induction and Maintenance Treatment of Advanced Non-squamous Non-Small Cell Lung Cancer,"A Phase 3, Double-Blind, Placebo-Controlled Study of Maintenance Pemetrexed Plus Best Supportive Care Versus Best Supportive Care Immediately Following Induction Treatment With Pemetrexed + Cisplatin ",Eli Lilly and Company,Eli Lilly and Company,INDUSTRY,COMPLETED,2008-11,2010-06,2017-11,INTERVENTIONAL,PHASE3,,,,Non-Small Cell Lung Cancer,Non-Small Cell Lung Cancer,1,2,5,DRUG; OTHER,,,1,9,True,Yes,Investigator-assessed Objective Progression-free Survival (PFS) (MEDIAN) months = 4.11 [3.15-4.57],Independently-assessed Objective Progression-free Survival (PFS) (MEDIAN) months = 3.94 [2.96-4.24]; Overall Survival (OS) (MEDIAN) months = 13.86 [12.75-16.03]; Change From Baseline in the EuroQol Instrument (EQ-5D) Index Score (MEAN) units on a scale = 0.77; Change From Baseline in EuroQol Instrument (EQ-5D) Visual Analog Scale (VAS) (MEAN) units on a scale = 71.1; Percentage of Participants With Hospitalizations Due to Adverse Events or Requiring Transfusion (Resource Utilization) (NUMBER) percentage of participants = 8.4; Percentage of Participants With a Non-Serious Adverse Event (AE) During Maintenance Phase (NUMBER) percentage of participants = 59.9; Percentage of Participants With Serious Adverse Events During Maintenance Phase (NUMBER) percentage of participants = 18.9; Percentage of Participants With Objective Tumor Response (Response Rate) During Maintenance Phase of Study up to Primary Data Cut-Off (NUMBER) percentage of participants = 46.2; Percentage of Participants With Independently-Assessed Objective Tumor Response (Response Rate) During Maintenance Phase Up to Primary Data Cut-Off (NUMBER) percentage of participants = 46.2 [41.0-51.6],,,,,,,,,Overall Survival (OS) (MEDIAN) months = 13.86 [12.75-16.03],Investigator-assessed Objective Progression-free Survival (PFS) (MEDIAN) months = 4.11 [3.15-4.57]; Independently-assessed Objective Progression-free Survival (PFS) (MEDIAN) months = 3.94 [2.96-4.24],,Change From Baseline in the EuroQol Instrument (EQ-5D) Index Score (MEAN) units on a scale = 0.77; Change From Baseline in EuroQol Instrument (EQ-5D) Visual Analog Scale (VAS) (MEAN) units on a scale = 71.1,Percentage of Participants With Objective Tumor Response (Response Rate) During Maintenance Phase of Study up to Primary Data Cut-Off (NUMBER) percentage of participants = 46.2; Percentage of Participants With Independently-Assessed Objective Tumor Response (Response Rate) During Maintenance Phase Up to Primary Data Cut-Off (NUMBER) percentage of participants = 46.2 [41.0-51.6],Percentage of Participants With Hospitalizations Due to Adverse Events or Requiring Transfusion (Resource Utilization) (NUMBER) percentage of participants = 8.4; Percentage of Participants With Serious Adverse Events During Maintenance Phase (NUMBER) percentage of participants = 18.9,,
NCT00800202,A Study of Avastin (Bevacizumab) in Patients With Non-Squamous Non-Small Cell Lung Cancer With Asymptomatic Untreated Brain Metastasis,An Open Label Study to Assess the Effect of Avastin (Bevacizumab) Combined With First Line Paclitaxel-carboplatin or Second Line Tarceva (Erlotinib) on Progression-free Survival in Non-squamous Non-sm,Hoffmann-La Roche,Hoffmann-La Roche,INDUSTRY,COMPLETED,2009-04,2012-10,2012-10,INTERVENTIONAL,PHASE2,,,,Non-Small Cell Lung Cancer,Non-Small Cell Lung Cancer,1,2,4,DRUG,,,3,4,True,Yes,Percentage of Participants Achieving Progression-Free Survival (PFS) Without Disease Progression or Death at 6 Months (NUMBER) percentage of participants = 56.5 [43.8-67.4]; Percentage of Participants With Disease Progression or Death (NUMBER) percentage of participants = 89.6; Time to Disease Progression or Death (MEDIAN) months = 6.7 [5.7-7.1],Percentage of Participants Who Died (NUMBER) percentage of participants = 83.6; Probability of Being Alive at 12 and 18 Months (NUMBER) percent = 64.2 [51.5-74.4]; Time to Death (MEDIAN) months = 16.0 [12.0-21.0]; Percentage of Participants Achieving a Best Overall Response of Complete Response or Partial Response as Assessed by the Investigator Using RECIST (NUMBER) percentage of participants = 62.7 [50.0-74.2],,Percentage of Participants Achieving a Best Overall Response of Complete Response or Partial Response as Assessed by the Investigator Using RECIST (NUMBER) percentage of participants = 62.7 [50.0-74.2],,,,,,,,Percentage of Participants Achieving Progression-Free Survival (PFS) Without Disease Progression or Death at 6 Months (NUMBER) percentage of participants = 56.5 [43.8-67.4],Percentage of Participants Achieving a Best Overall Response of Complete Response or Partial Response as Assessed by the Investigator Using RECIST (NUMBER) percentage of participants = 62.7 [50.0-74.2],,,,,
NCT00806286,Study of Carboplatin/Paclitaxel With or Without Investigational Drug (CS-7017) in Subjects With Metastatic Non-small Cell Lung Cancer,Phase 2 Randomized Study of Carboplatin/Paclitaxel With or Without CS-7017 in Chemotherapy-Naïve Subjects With Metastatic Non-Small Cell Lung Cancer,Daiichi Sankyo,Daiichi Sankyo,INDUSTRY,COMPLETED,2008-12,2012-01,2012-08,INTERVENTIONAL,PHASE2,,,,Metastatic Non-small Cell Lung Cancer,Metastatic Non-small Cell Lung Cancer,1,2,4,DRUG,,,2,3,True,Yes,Percentage of Participants With Progression-Free Survival at 18 Weeks Following Administration of Carboplatin/Paclitaxel With or Without CS-7017 in Chemotherapy-naïve Participants With Metastatic Non-small Cell Lung Cancer (NUMBER) percentage of participants = 40.2 [25.7-54.2]; Percentage of Participants With Progression-Free Survival Based on Radiologic and Clinical Assessments and Death After Carboplatin/Paclitaxel With or Without CS-7017 in Chemotherapy-naïve Participants With Metastatic Non-small Cell Lung Cancer (NUMBER) percentage of participants = 37.9 [23.5-52.1],Summary of Kaplan-Meier Analysis of Overall Survival Following Administration of Carboplatin/Paclitaxel With or Without CS-7017 in Chemotherapy-naïve Participants With Metastatic Non-small Cell Lung Cancer (MEDIAN) days = 244.0 [158.0-353.0]; Number of Participants With Best Overall Tumor Response and Objective Response Rate Following Administration of Carboplatin/Paclitaxel With or Without CS-7017 in Chemotherapy-naïve Participants With Metastatic Non-small Cell Lung Cancer (COUNT_OF_PARTICIPANTS) Participants = 0; Number of Participants With Treatment-Emergent Adverse Events Related to CS-7017/Placebo Following Administration of Carboplatin/Paclitaxel With or Without CS-7017 in Chemotherapy-naïve Participants With Metastatic Non-small Cell Lung Cancer (COUNT_OF_PARTICIPANTS) Participants = 42,,,,,,,,Number of Participants With Best Overall Tumor Response and Objective Response Rate Following Administration of Carboplatin/Paclitaxel With or Without CS-7017 in Chemotherapy-naïve Participants With Metastatic Non-small Cell Lung Cancer (COUNT_OF_PARTICIPANTS) Participants = 0,Summary of Kaplan-Meier Analysis of Overall Survival Following Administration of Carboplatin/Paclitaxel With or Without CS-7017 in Chemotherapy-naïve Participants With Metastatic Non-small Cell Lung Cancer (MEDIAN) days = 244.0 [158.0-353.0],Percentage of Participants With Progression-Free Survival at 18 Weeks Following Administration of Carboplatin/Paclitaxel With or Without CS-7017 in Chemotherapy-naïve Participants With Metastatic Non-small Cell Lung Cancer (NUMBER) percentage of participants = 40.2 [25.7-54.2]; Percentage of Participants With Progression-Free Survival Based on Radiologic and Clinical Assessments and Death After Carboplatin/Paclitaxel With or Without CS-7017 in Chemotherapy-naïve Participants With Metastatic Non-small Cell Lung Cancer (NUMBER) percentage of participants = 37.9 [23.5-52.1],,,Number of Participants With Best Overall Tumor Response and Objective Response Rate Following Administration of Carboplatin/Paclitaxel With or Without CS-7017 in Chemotherapy-naïve Participants With Metastatic Non-small Cell Lung Cancer (COUNT_OF_PARTICIPANTS) Participants = 0,Number of Participants With Treatment-Emergent Adverse Events Related to CS-7017/Placebo Following Administration of Carboplatin/Paclitaxel With or Without CS-7017 in Chemotherapy-naïve Participants With Metastatic Non-small Cell Lung Cancer (COUNT_OF_PARTICIPANTS) Participants = 42,,
NCT00820755,Trial With Cetuximab in Maintenance Therapy After Platinum Based Chemotherapy in First Line Treatment of Non-small Cell Lung Cancer (NSCLC),"Open, Randomized, Multinational Phase IIIb Trial Evaluating the Activity and Safety of Cetuximab as 250 mg/m^2 Weekly and 500 mg/m^2 Every Two Weeks Maintenance Therapy After Platinum-based Chemothera","Merck KGaA, Darmstadt, Germany","Merck KGaA, Darmstadt, Germany",INDUSTRY,COMPLETED,2009-01,2011-12,2013-06,INTERVENTIONAL,PHASE3,,,,Non-Small Cell Lung Cancer (NSCLC),Non-Small Cell Lung Cancer (NSCLC),1,3,3,DRUG,,,2,7,True,Yes,Overall Survival (OS) Time (MEDIAN) months = 16.1 [13.6-18.2]; Percentage of Participants With 1-year Overall Survival (NUMBER) percentage of participants = 62.8 [54.7-70.0],Overall Survival (OS) Time (From Randomization to Cetuximab Maintenance Regimen Until Death) (MEDIAN) months = 12.6 [10.1-14.8]; Time to Treatment Failure (MEDIAN) months = 5.8 [5.6-6.6]; Time to Treatment Failure (From Randomization to Cetuximab Maintenance Regimen Until Death) (MEDIAN) months = 2.6 [2.1-2.8]; Percentage of Participants With Best Unconfirmed Tumor Response in the Combination Therapy Phase (NUMBER) percentage of participants = 36.2 [32.3-40.2]; Percentage of Participant With Best Unconfirmed Tumor Response for the Whole Study Period (NUMBER) percentage of participants = 54.8 [46.6-62.7]; Percentage of Participants With Disease Control in the Combination Therapy Phase (NUMBER) percentage of participants = 65.7 [61.7-69.5]; Percentage of Participants With Disease Control for the Whole Study Period (NUMBER) percentage of participants = 98.7 [95.5-99.8],,,,,,,,,Overall Survival (OS) Time (MEDIAN) months = 16.1 [13.6-18.2]; Percentage of Participants With 1-year Overall Survival (NUMBER) percentage of participants = 62.8 [54.7-70.0]; Overall Survival (OS) Time (From Randomization to Cetuximab Maintenance Regimen Until Death) (MEDIAN) months = 12.6 [10.1-14.8],,,,,,Time to Treatment Failure (MEDIAN) months = 5.8 [5.6-6.6]; Time to Treatment Failure (From Randomization to Cetuximab Maintenance Regimen Until Death) (MEDIAN) months = 2.6 [2.1-2.8],
NCT00826449,Dasatinib and Erlotinib in Non-Small Cell Lung Cancer (NSCLC),Phase I-II Study of Dasatinib and Erlotinib in Non-Small Cell Lung Cancer,M.D. Anderson Cancer Center,M.D. Anderson Cancer Center,OTHER,COMPLETED,2009-02,2014-06,2014-06,INTERVENTIONAL,PHASE1; PHASE2,,,,Lung Cancer,Lung Cancer; Non-Small Cell Lung Cancer,2,1,2,DRUG,,,1,2,True,Yes,Phase I: Maximum Tolerable Dose (MTD) of Dasatinib Given With Erlotinib Hydrochloride (NUMBER) mg/day = 70,Phase II: Number of Participant With Response According to Response Evaluation Criteria in Solid Tumors (RECIST) (NUMBER) participants = 0; Phase II: Progression-Free Survival (PFS) Rate (NUMBER) Percentage of Participants = 53,,,,,,,,,,Phase II: Progression-Free Survival (PFS) Rate (NUMBER) Percentage of Participants = 53,,,,,,
NCT00828841,Phase 2b Study of Cetuximab With Platinum-Based Chemo as First Line Treatment of Recurrent or Advanced NSCLC,A Multi-Center Randomized Phase 2b Study of Cetuximab (Erbitux) in Combination With Platinum-Based Chemotherapy as First Line Treatment of Patients With Recurrent or Advanced Non-Small Cell Lung Cance,Accelerated Community Oncology Research Network,Accelerated Community Oncology Research Network,OTHER,COMPLETED,2008-12,2012-07,2012-08,INTERVENTIONAL,PHASE2,,,,Non-Small Cell Lung Cancer,Non-Small Cell Lung Cancer,1,3,5,DRUG,,,1,2,True,Yes,Overall Survival by Treatment Arm (MEDIAN) Months = 9.5 [8.3-11.4],1-year Survival by Treatment Arm (NUMBER) percentage of participants = 39.7 [33.7-46.6]; Overall Survival by Histology (MEDIAN) Months = 8.7 [7.4-10.1],,,,,,,,,Overall Survival by Treatment Arm (MEDIAN) Months = 9.5 [8.3-11.4]; Overall Survival by Histology (MEDIAN) Months = 8.7 [7.4-10.1],,,,,,,
NCT00854308,"A Study of MetMAb Administered to Patients With Advanced Non-Small Cell Lung Cancer, in Combination With Tarceva (Erlotinib)","A Randomized, Phase II, Multicenter, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Activity of MetMAb, a Monovalent Antagonist Antibody to the Receptor Met, Administered to Patients","Genentech, Inc.","Genentech, Inc.",INDUSTRY,COMPLETED,2009-04,2010-11,2012-01,INTERVENTIONAL,PHASE2,,,,Non-Small Cell Lung Cancer,Non-Small Cell Lung Cancer,1,2,3,DRUG,,,2,3,True,Yes,Progression-free Survival (NUMBER) months = 2.2 [1.38-2.86]; Progression-free Survival in Patients With Met Diagnostic-Positive Tumors (MEDIAN) months = 2.9 [1.38-6.21],Percentage of Participants With Objective Response (NUMBER) Percentage of participants = 5.8 [2.0-13.9]; Percentage of Participants With Objective Response in Patients With Met Diagnostic-Positive Tumors (NUMBER) Percentage of participants = 8.6 [2.4-21.5]; ,,,,,,,,,,Progression-free Survival (NUMBER) months = 2.2 [1.38-2.86]; Progression-free Survival in Patients With Met Diagnostic-Positive Tumors (MEDIAN) months = 2.9 [1.38-6.21],,,,,,
NCT00855894,A Study of the Combination of Erlotinib and Pertuzumab in Patients With Relapsed Non-small Cell Lung Cancer,An Open-label Phase II Multicenter Study of the Safety and Activity (as Measured by FDG-PET Imaging Changes) of the Combination of Erlotinib and Pertuzumab in Patients With Relapsed Non-small Cell Lun,"Genentech, Inc.","Genentech, Inc.",INDUSTRY,COMPLETED,2009-03,2012-03,2012-03,INTERVENTIONAL,PHASE2,,,,Non-Small Cell Lung Cancer,Non-Small Cell Lung Cancer,1,1,2,DRUG,,,1,4,True,Yes,Percentage of Patients With a 2-deoxy-2-[18F]Fluoro-D-glucose-positron Emission Tomography (FDG-PET) Response at Day 56 in All Patients and in Epidermal Growth Factor Receptor (EGFR) Mutant and Wild-type Subgroups (NUMBER) Percentage of patients = 19.5 [9.2-33.9],Progression-free Survival (PFS) (MEDIAN) Months = 1.9 [1.87-3.38]; Overall Survival (OS) (MEDIAN) Months = 8.7 [4.70-9.99]; Percentage of Patients With an Objective Response (OR) (NUMBER) Percentage of patients = 7.3 [2.0-19.0]; Percentage of Patients With Disease Control (DC) at Day 56 (NUMBER) Percentage of patients = 31.7 [19.0-46.9],,,,,,,,,Overall Survival (OS) (MEDIAN) Months = 8.7 [4.70-9.99],Progression-free Survival (PFS) (MEDIAN) Months = 1.9 [1.87-3.38],,,,,,
NCT00864721,Sunitinib Non Small Cell Lung Cancer Patients Over 70,Phase II Trial of Sunitinib Malate in Previously Untreated NSCLC Patients Over the Age of 70,US Oncology Research,US Oncology Research,INDUSTRY,COMPLETED,2009-02,2012-07,2012-07,INTERVENTIONAL,PHASE2,,,,Non Small Cell Lung Cancer,Non Small Cell Lung Cancer,1,1,1,DRUG,,,1,4,True,Yes,Disease Control Rate (DCR) (NUMBER) percentage of participants = 63.3 [49.9-75.4],Overall Response Rates (OR) (NUMBER) percentage of participants = 6.7 [1.8-16.2]; Progression-free Survival (PFS) (MEDIAN) months = 3.0 [0.1-25.1]; 1-year Overall Survival (OS) Rate. (NUMBER) percentage of participants alive at 1yr = 26 [16-38]; Time to Progression (TTP) (MEDIAN) months = 4.5 [0.1-25.1],,,,,,,,,1-year Overall Survival (OS) Rate. (NUMBER) percentage of participants alive at 1yr = 26 [16-38],Progression-free Survival (PFS) (MEDIAN) months = 3.0 [0.1-25.1],,,Overall Response Rates (OR) (NUMBER) percentage of participants = 6.7 [1.8-16.2],,,Time to Progression (TTP) (MEDIAN) months = 4.5 [0.1-25.1]
NCT00867009,A Study of Induction and Maintenance Treatment of Advanced or Metastatic Non Squamous Non-Small Cell Lung Cancer,A Phase 2 Study of Pemetrexed and Cisplatin Plus Cetuximab Followed by Pemetrexed and Cetuximab Maintenance Therapy in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (Stage II,Eli Lilly and Company,Eli Lilly and Company,INDUSTRY,COMPLETED,2009-04,2011-05,2014-09,INTERVENTIONAL,PHASE2,,,,Non-Small-Cell Lung Cancer,Non-Small-Cell Lung Cancer,1,1,3,DRUG,,,1,3,True,Yes,Percentage of Participants With a Tumor Response (Objective Tumor Response Rate) (NUMBER) percentage of participants = 38.5,"Progression-free Survival (PFS) (MEDIAN) months = 5.82 [0.03-18.89]; The Percentage of Participants Still Living at One Year (One Year Survival Rate) (NUMBER) percentage of participants = 45; The Percentage of Participants With Complete Response (CR), Partial Response (PR) or Stable Disease (SD) (Disease Control Rate [DCR]) (NUMBER) percentage of participants = 59.6",,"The Percentage of Participants With Complete Response (CR), Partial Response (PR) or Stable Disease (SD) (Disease Control Rate [DCR]) (NUMBER) percentage of participants = 59.6",,,,,,,,Progression-free Survival (PFS) (MEDIAN) months = 5.82 [0.03-18.89],"The Percentage of Participants With Complete Response (CR), Partial Response (PR) or Stable Disease (SD) (Disease Control Rate [DCR]) (NUMBER) percentage of participants = 59.6",,Percentage of Participants With a Tumor Response (Objective Tumor Response Rate) (NUMBER) percentage of participants = 38.5,,,
NCT00870870,A Study of IMC-A12 (Cixutumumab) With and Without Other Standard Chemotherapies in Participants With Lung Cancer Who Have Not Received Chemotherapy Be,"Randomized, Open Label, Stratified Phase 2 Trial of Gemcitabine, Carboplatin, and Cetuximab With Vs. Without IMC-A12 in Chemotherapy-Naive Patients With Advanced/Metastatic Non-Small Cell Lung Cancer",Eli Lilly and Company,Eli Lilly and Company,INDUSTRY,COMPLETED,2009-03,2012-04,2012-05,INTERVENTIONAL,PHASE2,,,,Non-Small Cell Lung Cancer,Non-Small Cell Lung Cancer,1,2,7,BIOLOGICAL; DRUG,,,1,14,True,Yes,Percentage of Participants With Complete Response (CR) or Partial Response (PR) [Objective Response Rate (ORR)] (NUMBER) percentage of participants = 31.0 [14.2-47.9],Overall Survival (OS) (MEDIAN) months = 11.5 [5.3-14.8]; Progression-Free Survival (PFS) (MEDIAN) months = 4.2 [2.9-6.2]; Time To Progression (TTP) (MEDIAN) months = 5.8 [3.9-6.7]; Duration of Response (MEDIAN) months = 4.8 [4.2-5.3]; Number of Participants With Adverse Events (AEs) or Deaths (COUNT_OF_PARTICIPANTS) Participants = 4; ; ; ; ; ; ; ; ; ,,Percentage of Participants With Complete Response (CR) or Partial Response (PR) [Objective Response Rate (ORR)] (NUMBER) percentage of participants = 31.0 [14.2-47.9],,,Duration of Response (MEDIAN) months = 4.8 [4.2-5.3],,,Percentage of Participants With Complete Response (CR) or Partial Response (PR) [Objective Response Rate (ORR)] (NUMBER) percentage of participants = 31.0 [14.2-47.9],Overall Survival (OS) (MEDIAN) months = 11.5 [5.3-14.8],Progression-Free Survival (PFS) (MEDIAN) months = 4.2 [2.9-6.2],Percentage of Participants With Complete Response (CR) or Partial Response (PR) [Objective Response Rate (ORR)] (NUMBER) percentage of participants = 31.0 [14.2-47.9],,Percentage of Participants With Complete Response (CR) or Partial Response (PR) [Objective Response Rate (ORR)] (NUMBER) percentage of participants = 31.0 [14.2-47.9],Number of Participants With Adverse Events (AEs) or Deaths (COUNT_OF_PARTICIPANTS) Participants = 4,,Time To Progression (TTP) (MEDIAN) months = 5.8 [3.9-6.7]
NCT00871403,Study of Pazopanib and Pemetrexed in Advanced Non-small Cell Lung Cancer,"An Open-label, Multicentre, Randomised Phase II Study of Pazopanib in Combination With Pemetrexed in First-line Treatment of Subjects With Predominantly Non-squamous Cell Stage IIIBwet/IV Non-small Ce",GlaxoSmithKline,GlaxoSmithKline,INDUSTRY,COMPLETED,2009-07,2011-03,2011-03,INTERVENTIONAL,PHASE2,,,,"Lung Cancer, Non-Small Cell","Lung Cancer, Non-Small Cell",1,2,2,DRUG,,,1,3,True,Yes,Progression-free Survival (PFS) (MEDIAN) weeks = 25.0 [17.3-34.1],"; Best Overall Response, Assessed as the Number of Participants With the Indicated Tumor Response: Investigator Assessed Only (NUMBER) participants = 0; Percentage of Participants With a Complete Response or a Partial Response (NUMBER) percentage of participants = 14",,Percentage of Participants With a Complete Response or a Partial Response (NUMBER) percentage of participants = 14,,,,,,,,Progression-free Survival (PFS) (MEDIAN) weeks = 25.0 [17.3-34.1],Percentage of Participants With a Complete Response or a Partial Response (NUMBER) percentage of participants = 14,,,,,
NCT00871923,Tarceva With Whole Brain Radiation Therapy - Brain Mets From Non-Small Cell Lung Cancer,A Phase II Study to Determine the Efficacy of Tarceva® (Erlotinib Hydrochloride) With Concurrent Whole Brain Radiation Therapy in Patients With Brain Metastases From Non-Small Cell Lung Cancer (NSCLC),M.D. Anderson Cancer Center,M.D. Anderson Cancer Center,OTHER,COMPLETED,2009-03-26,2019-12-04,2019-12-04,INTERVENTIONAL,PHASE2,,,,Non-small Cell Lung Cancer,Non-small Cell Lung Cancer; Brain Cancer,2,1,2,DRUG; RADIATION,,,1,1,True,Yes,Median Survival (MEDIAN) months = 11.8 [7.4-19.1],Number of Participants With Overall Survival (COUNT_OF_PARTICIPANTS) Participants = 27,,,,,,,,,Number of Participants With Overall Survival (COUNT_OF_PARTICIPANTS) Participants = 27,,,,,,,
NCT00883779,A Study of Tarceva (Erlotinib) or Placebo in Combination With Platinum-Based Therapy as First Line Treatment in Patients With Advanced or Recurrent No,"A Randomized, Placebo-controlled, Double-blind Phase III Study of the Effect of First-line Treatment With Intercalated Tarceva Versus Placebo in Combination With Gemcitabine/Platinum on Progression-fr",Hoffmann-La Roche,Hoffmann-La Roche,INDUSTRY,COMPLETED,2009-04,2014-12,2014-12,INTERVENTIONAL,PHASE3,,,,Non-Squamous Non-Small Cell Lung Cancer,Non-Squamous Non-Small Cell Lung Cancer,1,2,4,DRUG,,,1,15,True,Yes,Median Progression Free Survival (PFS) Time (MEDIAN) months = 6.0 [6.0-7.0],Percentage of Participants Alive and Free From Disease Progression (NUMBER) percentage of participants = 6.2; Median PFS Time Based on Different Subgroups (MEDIAN) months = 6.5 [6-7]; Median Overall Survival (OS) Time-Overall and Among Different Subgroups (MEDIAN) months = 15.2 [12.7-17.5]; Percentage of Participants Alive at the End of Study-Overall and Among Different Subgroups (NUMBER) percentage of participants = 13.3; Non-Progression Rate: Percentage of Participants With a Confirmed Best Overall Response of Either Complete Response (CR) or Partial Response (PR) or Stable Disease (SD) for At Least 16 Weeks (NUMBER) percentage of participants = 64.4 [57.8-70.7]; Objective Response Rate: Percentage of Participants With a Confirmed Best Overall Response of CR or PR (NUMBER) percentage of participants = 17.8 [13.0-23.4]; Duration of Response (MEDIAN) months = 5.6 [5-6]; Time to Progression (MEDIAN) months = 6.5 [6-7]; Percentage of Participants With Symptomatic Progression Assessed Using the Lung Cancer Subscale (LCS) (NUMBER) percentage of participants = 72.4; Time to Symptomatic Progression (MEAN) months = 6.6 [6-9]; Percentage of Participants With Deterioration in Trial Outcome Index (TOI) Using FACT-L Version 4.0 (NUMBER) percentage of participants = 75.6; Time to Deterioration in TOI Using FACT-L Version 4.0 (MEDIAN) months = 5.6 [4-7]; Percentage of Participants With Deterioration in Quality of Life (QOL) Using FACT-L Version 4.0 (NUMBER) percentage of participants = 79.6; Time to Deterioration in QOL Using FACT-L Version 4.0 (MEDIAN) months = 4.5 [4-6]; Median Follow-up Time During the Study (MEDIAN) months = 50.3 [47.6-52.5],,Non-Progression Rate: Percentage of Participants With a Confirmed Best Overall Response of Either Complete Response (CR) or Partial Response (PR) or Stable Disease (SD) for At Least 16 Weeks (NUMBER) percentage of participants = 64.4 [57.8-70.7]; Objective Response Rate: Percentage of Participants With a Confirmed Best Overall Response of CR or PR (NUMBER) percentage of participants = 17.8 [13.0-23.4],,,Duration of Response (MEDIAN) months = 5.6 [5-6],,,Objective Response Rate: Percentage of Participants With a Confirmed Best Overall Response of CR or PR (NUMBER) percentage of participants = 17.8 [13.0-23.4],Median Overall Survival (OS) Time-Overall and Among Different Subgroups (MEDIAN) months = 15.2 [12.7-17.5],Median Progression Free Survival (PFS) Time (MEDIAN) months = 6.0 [6.0-7.0]; Median PFS Time Based on Different Subgroups (MEDIAN) months = 6.5 [6-7],Non-Progression Rate: Percentage of Participants With a Confirmed Best Overall Response of Either Complete Response (CR) or Partial Response (PR) or Stable Disease (SD) for At Least 16 Weeks (NUMBER) percentage of participants = 64.4 [57.8-70.7]; Objective Response Rate: Percentage of Participants With a Confirmed Best Overall Response of CR or PR (NUMBER) percentage of participants = 17.8 [13.0-23.4],Percentage of Participants With Deterioration in Quality of Life (QOL) Using FACT-L Version 4.0 (NUMBER) percentage of participants = 79.6; Time to Deterioration in QOL Using FACT-L Version 4.0 (MEDIAN) months = 4.5 [4-6],Objective Response Rate: Percentage of Participants With a Confirmed Best Overall Response of CR or PR (NUMBER) percentage of participants = 17.8 [13.0-23.4],,,Time to Progression (MEDIAN) months = 6.5 [6-7]
NCT00887549,A Study of Thymidylate Synthase Expression in Patients With Non-Small Cell Lung Cancer,"An Exploratory, Prospective Phase II Study to Investigate Progression-Free Survival, Response and Overall Survival Seen With Pemetrexed/Cisplatin and the Role of Thymidylate Synthase Expression",Eli Lilly and Company,Eli Lilly and Company,INDUSTRY,COMPLETED,2009-04,2010-07,2011-06,INTERVENTIONAL,PHASE2,,,,Non-Small Cell Lung Cancer,Non-Small Cell Lung Cancer,1,1,2,DRUG,,,1,3,True,Yes,Progression Free Survival (PFS) (MEDIAN) months = 5.5 [3.9-6.9],Percentage of Participants With Tumor Response (Tumor Response Rate) (NUMBER) percentage of participants = 30 [19.62-42.13]; Percentage of Participants With Concordance Between Local and Central Histological Diagnosis (NUMBER) percentage of participants = 78.6 [67.1-87.5]; Percentage of Participants Surviving at 18 Months (Overall Survival Rate) (NUMBER) percentage of participants = 37.1 [25.89-49.52],,,,,,,,,Percentage of Participants Surviving at 18 Months (Overall Survival Rate) (NUMBER) percentage of participants = 37.1 [25.89-49.52],Progression Free Survival (PFS) (MEDIAN) months = 5.5 [3.9-6.9],,,Percentage of Participants With Tumor Response (Tumor Response Rate) (NUMBER) percentage of participants = 30 [19.62-42.13],,,
NCT00887783,Navelbine And Radiotherapy in Locally Advanced Lung Cancer,Induction Chemotherapy With Carboplatin and Navelbine Oral(R) Followed by Concomitant Navelbine Oral(R) and Irradiation in Local-regionally Advanced Non-small Cell Lung Cancer. A Randomized Phase II S,Odense University Hospital,Odense University Hospital,OTHER,COMPLETED,2009-05-01,2016-09-01,2016-09-01,INTERVENTIONAL,PHASE2,,,,Non-small Cell Lung Cancer,Non-small Cell Lung Cancer,1,2,3,DRUG; RADIATION,,,1,5,True,Yes,Local Failure Free Survival (MEDIAN) months = 9.4 [2.8-67],Number of Participants Who Experienced Early Toxicity to Concurrent Vinorelbine and Radiotherapy (NUMBER) participants = 7; ; Overall Survival (MEDIAN) Months = 25.3 [3.0-68]; ; Disease Free Survival (MEDIAN) Months = 8.4 [.2-68],,,Disease Free Survival (MEDIAN) Months = 8.4 [.2-68],,,,,,Overall Survival (MEDIAN) Months = 25.3 [3.0-68],,,,,Number of Participants Who Experienced Early Toxicity to Concurrent Vinorelbine and Radiotherapy (NUMBER) participants = 7,,
NCT00888511,Tarceva And Radiotherapy in Locally Advanced Lung Cancer Non-small Cell Lung Cancer,Concomitant Tarceva® and Irradiation in Patients in Local-regionally Advanced Non-small Cell Lung Cancer. A Phase II Study,Odense University Hospital,Olfred Hansen,OTHER,COMPLETED,2009-05,2016-05,2016-05,INTERVENTIONAL,PHASE2,,,,Non-small Cell Lung Cancer,Non-small Cell Lung Cancer,1,1,2,DRUG; RADIATION,,,1,7,True,Yes,Progression Free Survival (MEDIAN) months = 9.4 [1.7-68],; ; ; ; ; ; ,,,,,,,,,,Progression Free Survival (MEDIAN) months = 9.4 [1.7-68],,,,,,
NCT00890825,AZD6244 in Combination With Docetaxel Versus Docetaxel Alone in KRAS Mutation Positive NSCLC Patients,"Phase II, Double-Blind, Randomised, Placebo-Controlled Study to Assess the Efficacy of AZD6244 in Combination With Docetaxel, Compared With Docetaxel Alone, in 2nd Line Patients With KRAS Mutation Pos",AstraZeneca,AstraZeneca,INDUSTRY,COMPLETED,2009-04-20,2011-05-11,2016-11-02,INTERVENTIONAL,PHASE2,,,,Non Small Cell Lung Cancer,Non Small Cell Lung Cancer,1,2,3,DRUG,,,1,6,True,Yes,Overall Survival (COUNT_OF_PARTICIPANTS) Participants = 29,Progression Free Survival (COUNT_OF_PARTICIPANTS) Participants = 35; Objective Response Rate (COUNT_OF_PARTICIPANTS) Participants = 16; Duration of Response (MEAN) Days = 193.4; Change From Baseline in Tumour Size at 6 Week. (LEAST_SQUARES_MEAN) Percentage change from baseline = -16.98 [-27.1--6.85]; Change From Baseline in Tumour Size at Week 12 (LEAST_SQUARES_MEAN) Percent change from baseline = -19.38 [-34.7--4.09]; Alive and Progression-Free at 6 Months (NUMBER) percentage = 37.1,,,,,Duration of Response (MEAN) Days = 193.4,,,Objective Response Rate (COUNT_OF_PARTICIPANTS) Participants = 16,Overall Survival (COUNT_OF_PARTICIPANTS) Participants = 29,Progression Free Survival (COUNT_OF_PARTICIPANTS) Participants = 35,,,Objective Response Rate (COUNT_OF_PARTICIPANTS) Participants = 16,,,
NCT00892710,Trial of Poor Performance Status Patients (ToPPS),Randomized Phase II Trial of Pemetrexed vs. Pemetrexed/Bevacizumab vs. Pemetrexed/Carboplatin/Bevacizumab in Patients With Stage IIIB/IV Non-Small-Cell Lung Cancer and ECOG Performance Status 2,"SCRI Development Innovations, LLC","SCRI Development Innovations, LLC",OTHER,COMPLETED,2009-06,2014-07,2015-05,INTERVENTIONAL,PHASE2,,,,Non Small Cell Lung Cancer,Non Small Cell Lung Cancer,1,3,3,DRUG,,,1,5,True,Yes,Progression Free Survival (PFS) (MEDIAN) months = 2.8 [1.5-4.1],"Overall Response Rate (ORR), the Number of Patients Who Experience an Objective Benefit From Treatment (NUMBER) participants = 7; Time to Progression (TTP) (MEDIAN) months = 3.5 [1.6-5.5]; Time to Treatment Failure (TTTF) (MEDIAN) months = 2.4 [.5-21.2]; Overall Survival (OS) (MEDIAN) months = 7.7 [3.0-11.2]; 6-month and 12-month Overall Survival Probability (NUMBER) probability out of 1 = 0.52 [0.37-0.65]",,,,,,,,,Overall Survival (OS) (MEDIAN) months = 7.7 [3.0-11.2]; 6-month and 12-month Overall Survival Probability (NUMBER) probability out of 1 = 0.52 [0.37-0.65],Progression Free Survival (PFS) (MEDIAN) months = 2.8 [1.5-4.1],,,"Overall Response Rate (ORR), the Number of Patients Who Experience an Objective Benefit From Treatment (NUMBER) participants = 7",,Time to Treatment Failure (TTTF) (MEDIAN) months = 2.4 [.5-21.2],Time to Progression (TTP) (MEDIAN) months = 3.5 [1.6-5.5]
NCT00896454,Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium,"A Single-arm, Multicenter, Proof-of-concept Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium Despite Recent Treatment With IV Bisphosphonates",Amgen,Amgen,INDUSTRY,COMPLETED,2009-11-16,2012-09-13,2013-08-21,INTERVENTIONAL,PHASE2,,,,Breast Cancer,Breast Cancer; Hypercalcemia of Malignancy; Colon Cancer,16,1,1,DRUG,,,1,8,True,Yes,Percentage of Participants With a Response Within 10 Days of First Dose of Denosumab (NUMBER) percentage of participants = 63.6 [45.1-79.6],Percentage of Participants With a Response by Visit (NUMBER) percentage of participants = 9.1 [1.9-24.3]; Percentage of Participants With a Complete Response by Visit (NUMBER) percentage of participants = 3.0 [0.1-15.8]; Time to Response (MEDIAN) days = 9.0 [5.00-19.00]; Time to Complete Response (MEDIAN) days = 23.0 [11.00-43.00]; Duration of Response (MEDIAN) days = 104.0; Duration of Complete Response (MEDIAN) days = 34.0 [1.00-134.00]; Time to Relapse/Nonresponse of Hypercalcemia of Malignancy (MEDIAN) days = 19.0 [5.00-114.00]; Change From Baseline in Corrected Serum Calcium (MEDIAN) mmol/L = -0.13 [-0.31-0.09],,Percentage of Participants With a Complete Response by Visit (NUMBER) percentage of participants = 3.0 [0.1-15.8]; Time to Complete Response (MEDIAN) days = 23.0 [11.00-43.00]; Duration of Complete Response (MEDIAN) days = 34.0 [1.00-134.00],,,Duration of Response (MEDIAN) days = 104.0,,,,,,,,,,,
NCT00906282,"Preoperative Pemetrexed and Carboplatin for Select Stage IB, II, and III Non-Squamous Non-Small-Cell Lung Cancer","Phase II Trial of Preoperative Pemetrexed and Carboplatin in Patients With Select Stage IB, II, and III Non-Squamous Non-Small-Cell Lung Cancer","SCRI Development Innovations, LLC","SCRI Development Innovations, LLC",OTHER,COMPLETED,2009-06,2015-08,2015-09,INTERVENTIONAL,PHASE2,,,,Non Small Cell Lung Cancer,Non Small Cell Lung Cancer,1,1,2,DRUG,,,1,4,True,Yes,3-Year Overall Survival Rate (NUMBER) percentage of participants = 45 [30-60],Objective Tumor Response (NUMBER) percentage of participants = 41; Pathologic Response Rate (NUMBER) percentage of participants = 100; Rate of Residual Disease as an Assessment of Pathological Partial Response (pPR) (MEDIAN) centimeters = 2.5 [0.5-9.5]; Complete Resection Rate (NUMBER) percentage of patients = 70,,,,,,,,,3-Year Overall Survival Rate (NUMBER) percentage of participants = 45 [30-60],,Rate of Residual Disease as an Assessment of Pathological Partial Response (pPR) (MEDIAN) centimeters = 2.5 [0.5-9.5],,Pathologic Response Rate (NUMBER) percentage of participants = 100,,,
NCT00915005,"Trial of Image-Guided Adaptive Conformal Photon vs Proton Therapy, With Concurrent Chemotherapy, for Locally Advanced Non-Small Cell Lung Carcinoma: T","A Bayesian Randomized Trial of Image-Guided Adaptive Conformal Photon vs Proton Therapy, With Concurrent Chemotherapy, for Locally Advanced Non-Small Cell Lung Carcinoma: Treatment Related Pneumonitis",M.D. Anderson Cancer Center,M.D. Anderson Cancer Center,OTHER,COMPLETED,2009-06,2020-02-24,2020-02-24,INTERVENTIONAL,PHASE2,,,,Non-Small-Cell Lung Carcinoma,Non-Small-Cell Lung Carcinoma,1,4,4,DRUG; RADIATION,,,2,0,True,Yes,"The Incidence and Time to Development of Common Terminology Criteria for Adverse Events, Version 3.0 (CTCAE v3.0) Grade > 3 Treatment-related Pneumonitis (TRP) (NUMBER) participants = 2; The Incidence and Time to Development of Local Failure (LF) (NUMBER) participants = 18",,,,,,,,,,,,,,,"The Incidence and Time to Development of Common Terminology Criteria for Adverse Events, Version 3.0 (CTCAE v3.0) Grade > 3 Treatment-related Pneumonitis (TRP) (NUMBER) participants = 2",,
NCT00918203,A Study of Paclitaxel/Carboplatin With or Without Olaratumab (IMC-3G3) in Previously Untreated Locally Advanced or Metastatic Non-Small Cell Lung Canc,A Randomized Phase 2 Study of Human Anti-PDGFRα Monoclonal Antibody (IMC-3G3) With Paclitaxel/Carboplatin or Paclitaxel/Carboplatin Alone in Previously Untreated Patients With Locally Advanced or Meta,Eli Lilly and Company,Eli Lilly and Company,INDUSTRY,COMPLETED,2010-01,2013-08,2017-11-17,INTERVENTIONAL,PHASE2,,,,Non-Small Cell Lung Cancer,Non-Small Cell Lung Cancer,1,2,3,BIOLOGICAL; DRUG,,,1,12,True,Yes,Progression-Free Survival (PFS) (MEDIAN) weeks = 19.1 [16.4-23.6],"Number of Participants With Adverse Events (AE) and Serious Adverse Events (SAE) (NUMBER) participants = 66; Safety and Tolerability of Olaratumab Administered at a More Rapid Rate (25mg/Min With Minimum Infusion Time of 30 Minutes), Determined by Number of Participants With Treatment Related Adverse Events (NUMBER) participants = 66; Overall Survival (OS) (MEDIAN) weeks = 51.3 [39.7-68.7]; Percentage of Participants Who Achieve Best Overall Tumor Response of Complete Response (CR) or Partial Response (PR) Objective Tumor Response Rate (ORR) (NUMBER) percentage of participants = 41.8 [29.8-54.5]; Median Duration of Response (MEDIAN) weeks = 14.4 [12.7-18.1]; ; Percentage of Participants With Anti-Olaratumab Antibodies (NUMBER) percentage of participants = 4.4; Pharmacokinetics (PK) - Area Under the Curve (AUC) 0-168 of Olaratumab (GEOMETRIC_MEAN) microgram*hour/milliliter (ug*hr/mL) = 47600; PK - Maximum Concentration (Cmax) of Olaratumab (GEOMETRIC_MEAN) micrograms/milliliter (ug/mL) = 489; PK - Half-Life (t1/2) of Olaratumab (GEOMETRIC_MEAN) days = 5.79 [4.29-8.78]; PK - Clearance (Cl) of Olaratumab (GEOMETRIC_MEAN) Liter/hour (L/h) = 0.0218; PK - Steady State Volume of Distribution (Vss) of Olaratumab (GEOMETRIC_MEAN) Liter (L) = 4.22",,Percentage of Participants Who Achieve Best Overall Tumor Response of Complete Response (CR) or Partial Response (PR) Objective Tumor Response Rate (ORR) (NUMBER) percentage of participants = 41.8 [29.8-54.5],,,Median Duration of Response (MEDIAN) weeks = 14.4 [12.7-18.1],,,,Overall Survival (OS) (MEDIAN) weeks = 51.3 [39.7-68.7],Progression-Free Survival (PFS) (MEDIAN) weeks = 19.1 [16.4-23.6],Percentage of Participants Who Achieve Best Overall Tumor Response of Complete Response (CR) or Partial Response (PR) Objective Tumor Response Rate (ORR) (NUMBER) percentage of participants = 41.8 [29.8-54.5],,Percentage of Participants Who Achieve Best Overall Tumor Response of Complete Response (CR) or Partial Response (PR) Objective Tumor Response Rate (ORR) (NUMBER) percentage of participants = 41.8 [29.8-54.5],"Number of Participants With Adverse Events (AE) and Serious Adverse Events (SAE) (NUMBER) participants = 66; Safety and Tolerability of Olaratumab Administered at a More Rapid Rate (25mg/Min With Minimum Infusion Time of 30 Minutes), Determined by Number of Participants With Treatment Related Adverse Events (NUMBER) participants = 66",,
NCT00942825,Triplet Combination First Line Treatment in Non Small Cell Lung Cancer (NSCLC),"Phase II Study of a Triplet Combination of CBP501, Pemetrexed and Cisplatin as First Line Treatment in Patients With Stage IV Non-squamous Non Small Cell Lung Cancer (NSCLC)",CanBas Co. Ltd.,CanBas Co. Ltd.,INDUSTRY,COMPLETED,2009-04,2013-07,2013-07,INTERVENTIONAL,PHASE2,,,,Metastatic Non-squamous Non Small Cell Lung Cancer,Metastatic Non-squamous Non Small Cell Lung Cancer,1,2,2,DRUG,,,1,0,True,Yes,"The Primary Efficacy Endpoint is Progression Free Survival, Analyzed in the Treated Population. PFS is Assessed From Randomization Until Either Tumor Progression, as Per RECIST Criteria, or Until Death Due to Any Reason. (MEDIAN) days = 140 [107-171]",,,,,,,,,,,"The Primary Efficacy Endpoint is Progression Free Survival, Analyzed in the Treated Population. PFS is Assessed From Randomization Until Either Tumor Progression, as Per RECIST Criteria, or Until Death Due to Any Reason. (MEDIAN) days = 140 [107-171]",,,,,,
NCT00948675,Study of Participants With Advanced Non-Small Cell Lung Cancer,A Study of Pemetrexed Plus Carboplatin Followed by Maintenance Pemetrexed vs Paclitaxel Plus Carboplatin and Bevacizumab Followed by Maintenance Bevacizumab in Patients With Advanced NCSLC of Nonsquam,Eli Lilly and Company,Eli Lilly and Company,INDUSTRY,COMPLETED,2009-09-01,2013-01-31,2020-11-06,INTERVENTIONAL,PHASE3,,,,Advanced Non-Small Cell Lung Cancer,Advanced Non-Small Cell Lung Cancer,1,2,4,BIOLOGICAL; DRUG,,,1,4,True,Yes,Progression Free Survival Without Grade 4 Toxicity (G4PFS) as Measured by the Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0 (MEDIAN) months = 3.91 [2.73-4.37],"Progression Free Survival (PFS) (MEDIAN) months = 4.44 [4.21-5.32]; Overall Survival (OS) (MEDIAN) months = 10.51 [9.26-11.96]; Percentage of Participants With Complete Response or Partial Response (Overall Tumor Response Rate) (NUMBER) percentage of participants = 23.6 [17.7-30.5]; Disease Control Rates Defined as Complete Response (CR), Partial Response (PR), and Stable Disease (SD) (NUMBER) percentage of participants = 59.9 [52.4-67.1]",,"Percentage of Participants With Complete Response or Partial Response (Overall Tumor Response Rate) (NUMBER) percentage of participants = 23.6 [17.7-30.5]; Disease Control Rates Defined as Complete Response (CR), Partial Response (PR), and Stable Disease (SD) (NUMBER) percentage of participants = 59.9 [52.4-67.1]",,,,,,,Overall Survival (OS) (MEDIAN) months = 10.51 [9.26-11.96],Progression Free Survival (PFS) (MEDIAN) months = 4.44 [4.21-5.32],"Percentage of Participants With Complete Response or Partial Response (Overall Tumor Response Rate) (NUMBER) percentage of participants = 23.6 [17.7-30.5]; Disease Control Rates Defined as Complete Response (CR), Partial Response (PR), and Stable Disease (SD) (NUMBER) percentage of participants = 59.9 [52.4-67.1]",,Percentage of Participants With Complete Response or Partial Response (Overall Tumor Response Rate) (NUMBER) percentage of participants = 23.6 [17.7-30.5],Progression Free Survival Without Grade 4 Toxicity (G4PFS) as Measured by the Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0 (MEDIAN) months = 3.91 [2.73-4.37],,
NCT00950365,Pemetrexed Disodium With or Without Erlotinib Hydrochloride in Treating Patients With Stage IIIB-IV or Recurrent Non-Small Cell Lung Cancer,A Randomized Phase II Study of Schedule-Modulated Concomitant Pemetrexed (Alimta) and Erlotinib (Tarceva) vs Single Agent Pemetrexed (Alimta®) in Patients With Progressive or Recurrent Non-small Cell ,Albert Einstein College of Medicine,Albert Einstein College of Medicine,OTHER,COMPLETED,2006-04,2017-11-17,2017-11-17,INTERVENTIONAL,PHASE2,,,,Bronchioloalveolar Carcinoma,Bronchioloalveolar Carcinoma; Large Cell Lung Carcinoma; Lung Adenocarcinoma,6,2,3,DRUG; OTHER,,,1,2,True,Yes,PFS (Progression Free Survival) (MEDIAN) months = 8 [0-19],Objective Response Rate (CR +PR) Evaluated Using RECIST (NUMBER) percentage of participants = 12 [0-25]; Overall Survival (COUNT_OF_PARTICIPANTS) Participants = 25,,,,,,,,Objective Response Rate (CR +PR) Evaluated Using RECIST (NUMBER) percentage of participants = 12 [0-25],Overall Survival (COUNT_OF_PARTICIPANTS) Participants = 25,PFS (Progression Free Survival) (MEDIAN) months = 8 [0-19],,,Objective Response Rate (CR +PR) Evaluated Using RECIST (NUMBER) percentage of participants = 12 [0-25],,,
NCT00960115,Study of Tecemotide (L-BLP25) in Participants With Stage III Unresectable Non-small Cell Lung Cancer (NSCLC) Following Primary Chemoradiotherapy,Combined Phase I/II Clinical Study of EMD531444(L-BLP25 or BLP25 Liposome Vaccine) in Subjects With Stage III Unresectable Non-small Cell Lung Cancer Following Primary Chemoradiotherapy,"Merck KGaA, Darmstadt, Germany","Merck KGaA, Darmstadt, Germany",INDUSTRY,COMPLETED,2008-12,2014-05,2015-06,INTERVENTIONAL,PHASE1; PHASE2,,,,Non-small Cell Lung Cancer,Non-small Cell Lung Cancer,1,2,4,BIOLOGICAL; DRUG; OTHER,,,1,3,True,Yes,Overall Survival (OS) Time (MEDIAN) Months = 32.4,Time To Progression (TTP) - Investigator Read (MEDIAN) Months = 11.3 [6.5-12.9]; Progression Free Survival (PFS) Time - Investigator Read (MEDIAN) Months = 11.6 [6.9-13.9]; Time to Treatment Failure (TTF) (MEDIAN) Months = 8.0 [4.6-11.5],,,,,,,,,Overall Survival (OS) Time (MEDIAN) Months = 32.4,Progression Free Survival (PFS) Time - Investigator Read (MEDIAN) Months = 11.6 [6.9-13.9],,,,,Time to Treatment Failure (TTF) (MEDIAN) Months = 8.0 [4.6-11.5],Time To Progression (TTP) - Investigator Read (MEDIAN) Months = 11.3 [6.5-12.9]
NCT00961415,AVAPERL1 Study: A Study of Avastin (Bevacizumab) With or Without Pemetrexed as Maintenance Therapy After Avastin in First Line in Patients With Non-Sq,"Open-label Study of Bevacizumab Maintenance Therapy (AVASTIN®) With or Without Pemetrexed After First-line Chemotherapy With Bevacizumab-cisplatin-pemetrexed in Patients With Advanced, Metastatic or R",Hoffmann-La Roche,Hoffmann-La Roche,INDUSTRY,COMPLETED,2009-08,2011-05,2011-05,INTERVENTIONAL,PHASE3,,,,Non-Squamous Non-Small Cell Lung Cancer,Non-Squamous Non-Small Cell Lung Cancer,1,3,3,DRUG,,,1,7,True,Yes,Progression Free Survival During Maintenance Treatment Phase (MEDIAN) Months = 6.6 [6.0-7.8],Overall Survival During Maintenance Treatment Phase (MEDIAN) Months = 15.7; Best Overall Response Rate During Maintenance Treatment Phase (NUMBER) percentage of participants = 50 [40.9-59.1]; Duration of Response During Maintenance Treatment Phase (MEDIAN) Months = 5.7 [4.9-7.2]; Duration of Disease Control During Maintenance Treatment Phase (MEDIAN) Months = 4.9 [3.9-5.7]; Incidence of Adverse Events and Serious Adverse Event (NUMBER) Participants = 116; Number of Participants With Marked Laboratory Abnormalities (NUMBER) Participants = 18; Quality of Life (MEAN) Score on scale = 57.9,,,,,Duration of Response During Maintenance Treatment Phase (MEDIAN) Months = 5.7 [4.9-7.2],,,,Overall Survival During Maintenance Treatment Phase (MEDIAN) Months = 15.7,Progression Free Survival During Maintenance Treatment Phase (MEDIAN) Months = 6.6 [6.0-7.8],,Quality of Life (MEAN) Score on scale = 57.9,Best Overall Response Rate During Maintenance Treatment Phase (NUMBER) percentage of participants = 50 [40.9-59.1],Incidence of Adverse Events and Serious Adverse Event (NUMBER) Participants = 116,,
NCT00963807,A Comparison of FLT to FDG PET/CT in the Early Assessment of Chemotherapy Response in Stage IB-IIIA Resectable NSCLC,Phase II Single-Arm Trial Comparing the Use of FLT PET to Standard Computed Tomography to Assess the Treatment Response of Neoadjuvant Docetaxel and Cisplatin in Stage IB-IIIA Resectable Non-small Cel,National Cancer Institute (NCI),National Cancer Institute (NCI),NIH,COMPLETED,2009-09,2012-08,2014-11,INTERVENTIONAL,PHASE2,,,,Recurrent Non-Small Cell Lung Carcinoma,Recurrent Non-Small Cell Lung Carcinoma; Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma,6,1,7,DRUG; PROCEDURE,,,3,2,True,Yes,Change in 18F-Fluorothymidine (FLT) Uptake (MEAN) SULmax = -0.4; Change in FLT Uptake (MEAN) SULmax = 0.2; Change in FLT Uptake in Responders and Non-responders (MEAN) SULmax = -1.8,Change in 18F-Fluorodeoxyglucose (FDG) Uptake (MEAN) SULmax = -3.8; Overall Response Rate Reported as a Proportion of the Total Number of Patients Who Received at Least One Cycle of Therapy Assessed Using Response Evaluation Criteria in Solid Tumors (RECIST) (NUMBER) percentage of participants = 33,,,,,,,,,,,,,Overall Response Rate Reported as a Proportion of the Total Number of Patients Who Received at Least One Cycle of Therapy Assessed Using Response Evaluation Criteria in Solid Tumors (RECIST) (NUMBER) percentage of participants = 33,,,
NCT00976456,Efficacy Study of Avastin® With Pemetrexed +/- Carboplatin to Treat Elderly Patients With Non-small Cell Lung Cancer,Open-label Study of Bevacizumab (Avastin®) in Combination With Pemetrexed or Pemetrexed and Carboplatin as First-line Treatment of Patients With Advanced or Recurrent Non-squamous Non-small Cell Lung ,Martha-Maria Krankenhaus Halle-Dölau gGmbH,PD Dr. med. Wolfgang Schuette,OTHER,COMPLETED,2009-09,2014-10,2014-10,INTERVENTIONAL,PHASE3,,,,Non-squamous Non-small Cell Lung Cancer,Non-squamous Non-small Cell Lung Cancer,1,2,2,DRUG,,,1,1,True,Yes,Progression Free Survival (MEDIAN) months = 4.8 [4.3-6.0],Overall Survival (MEDIAN) months = 11.6 [8.6-14.4],,,,,,,,,Overall Survival (MEDIAN) months = 11.6 [8.6-14.4],Progression Free Survival (MEDIAN) months = 4.8 [4.3-6.0],,,,,,
NCT00977470,Erlotinib With or Without Hydroxychloroquine in Chemo-Naive Advanced NSCLC and (EGFR) Mutations,Phase II Study of Erlotinib With or Without Hydroxychloroquine in Patients With Previously Untreated Advanced NSCLC and EGFR Mutations,Massachusetts General Hospital,Massachusetts General Hospital,OTHER,ACTIVE_NOT_RECRUITING,2009-10,2015-05,2027-12,INTERVENTIONAL,PHASE2,,,,Non-small Cell Lung Cancer,Non-small Cell Lung Cancer,1,2,2,DRUG,,,2,3,True,Yes,Median Progression Free Survival (MEDIAN) months = 10.8 [9.0-13.6]; Nine-month Progression-free Survival Rate (NUMBER) percentage of participants = 71 [53-83],"Treatment Related Toxicity, > 10% Frequency, Any Grade (COUNT_OF_PARTICIPANTS) Participants = 30; Objective Tumor Response Rate Following Treatment With Erlotinib and With Erlotinib/HCQ. (COUNT_OF_PARTICIPANTS) Participants = 1; ",,,,,,,,,,Median Progression Free Survival (MEDIAN) months = 10.8 [9.0-13.6]; Nine-month Progression-free Survival Rate (NUMBER) percentage of participants = 71 [53-83],,,Objective Tumor Response Rate Following Treatment With Erlotinib and With Erlotinib/HCQ. (COUNT_OF_PARTICIPANTS) Participants = 1,"Treatment Related Toxicity, > 10% Frequency, Any Grade (COUNT_OF_PARTICIPANTS) Participants = 30",,
NCT00981058,First-line Treatment of Participants With Stage IV Squamous Non-Small Cell Lung Cancer With Necitumumab and Gemcitabine-Cisplatin,"A Randomized, Multicenter, Open-Label Phase 3 Study of Gemcitabine-Cisplatin Chemotherapy Plus Necitumumab (IMC-11F8) Versus Gemcitabine-Cisplatin Chemotherapy Alone in the First-Line Treatment of Pat",Eli Lilly and Company,Eli Lilly and Company,INDUSTRY,COMPLETED,2010-01-07,2013-06-17,2024-05-30,INTERVENTIONAL,PHASE3,,,,Non Small Cell Lung Cancer,Non Small Cell Lung Cancer,1,2,3,BIOLOGICAL; DRUG,,,1,8,True,Yes,Overall Survival Time (OS) (MEDIAN) Months = 11.5 [10.4-12.6],Progression-Free Survival (PFS) (MEDIAN) months = 5.7 [5.6-6.0]; Percentage of Participants Achieving Complete Response (CR) and Partial Response (PR) (Objective Response Rate [ORR]) (NUMBER) percentage of participants = 31.2 [27.4-35.2]; Time to Treatment Failure (TTF) (MEDIAN) Months = 4.3 [4.2-4.8]; Mean Change From Baseline in Patient Reported Outcomes (PRO) Using the European Quality of Life-5 Dimension (EQ-5D) (MEAN) units on a scale = -0.0053; Mean Change From Baseline in PRO Using the Outcomes Lung Cancer Symptom Scale (LCSS) (MEAN) millimeter (mm) = 1.8; Number of Participants With an Epidermal Growth Factor Hormone (EGFR) Protein Expression Measured by Immunohistochemistry (IHC) (NUMBER) participants = 24; Pharmacokinetics (PK): Minimum Concentration (Cmin) of Necitumumab (GEOMETRIC_MEAN) micrograms/milliliter (ug/mL) = 52.4; Number of Participants With a Serum Anti-Necitumumab Antibody Assessment (NUMBER) participants = 81,,Percentage of Participants Achieving Complete Response (CR) and Partial Response (PR) (Objective Response Rate [ORR]) (NUMBER) percentage of participants = 31.2 [27.4-35.2],,,,,,Percentage of Participants Achieving Complete Response (CR) and Partial Response (PR) (Objective Response Rate [ORR]) (NUMBER) percentage of participants = 31.2 [27.4-35.2],Overall Survival Time (OS) (MEDIAN) Months = 11.5 [10.4-12.6],Progression-Free Survival (PFS) (MEDIAN) months = 5.7 [5.6-6.0],Percentage of Participants Achieving Complete Response (CR) and Partial Response (PR) (Objective Response Rate [ORR]) (NUMBER) percentage of participants = 31.2 [27.4-35.2],Mean Change From Baseline in Patient Reported Outcomes (PRO) Using the European Quality of Life-5 Dimension (EQ-5D) (MEAN) units on a scale = -0.0053,Percentage of Participants Achieving Complete Response (CR) and Partial Response (PR) (Objective Response Rate [ORR]) (NUMBER) percentage of participants = 31.2 [27.4-35.2],,Time to Treatment Failure (TTF) (MEDIAN) Months = 4.3 [4.2-4.8],
NCT00982111,First-line Treatment of Patients With Stage IV Nonsquamous Non-Small Cell Lung Cancer With Necitumumab (IMC-11F8) and Pemetrexed-Cisplatin,"A Randomized, Multicenter, Open-Label Phase 3 Study of Pemetrexed-Cisplatin Chemotherapy Plus Necitumumab (IMC-11F8) Versus Pemetrexed-Cisplatin Chemotherapy Alone in the First-Line Treatment of Patie",Eli Lilly and Company,Eli Lilly and Company,INDUSTRY,COMPLETED,2009-11-02,2012-11-14,2020-12-23,INTERVENTIONAL,PHASE3,,,,Non Small Cell Lung Cancer,Non Small Cell Lung Cancer,1,2,3,BIOLOGICAL; DRUG,,,1,9,True,Yes,Overall Survival Time (OS) (MEDIAN) Months = 11.3 [9.5-13.4],Progression-Free Survival (PFS) (MEDIAN) Months = 5.6 [5.1-6.0]; Percentage of Participants Who Achieve Best Overall Tumor Response of Complete Response (CR) or Partial Response (PR) (Objective Tumor Response Rate [ORR]) (NUMBER) percentage of participants = 31.1 [26.3-36.4]; Time to Treatment Failure (TTF) (MEDIAN) Months = 3.5 [3.2-3.9]; Pharmacokinetics (PK): Minimum Concentration (Cmin) of Necitumumab (GEOMETRIC_MEAN) micrograms/milliliter (ug/ml) = 57.5; Number of Participants With Serum Anti-Necitumumab Antibody Assessment (Immunogenicity) (NUMBER) participants = 37; Mean Change From Baseline in Patient Reported Outcomes (PRO) Using the European Quality of Life-5 Dimensions (EQ-5D) (MEAN) units on a scale = 0.0419; Mean Change From Baseline in PRO as Measured Using the Lung Cancer Symptom Scale (LCSS) (MEAN) millimeter (mm) = 4.6; Epidermal Growth Factor Hormone (EGFR) Protein Expression Measured by Immunohistochemistry (IHC) (MEAN) H-Score = 69.06; Percentage of Participants With EGFR Measured by IHC (NUMBER) percentage of participants = 58.8,,Percentage of Participants Who Achieve Best Overall Tumor Response of Complete Response (CR) or Partial Response (PR) (Objective Tumor Response Rate [ORR]) (NUMBER) percentage of participants = 31.1 [26.3-36.4],,,,,,,Overall Survival Time (OS) (MEDIAN) Months = 11.3 [9.5-13.4],Progression-Free Survival (PFS) (MEDIAN) Months = 5.6 [5.1-6.0],Percentage of Participants Who Achieve Best Overall Tumor Response of Complete Response (CR) or Partial Response (PR) (Objective Tumor Response Rate [ORR]) (NUMBER) percentage of participants = 31.1 [26.3-36.4],Mean Change From Baseline in Patient Reported Outcomes (PRO) Using the European Quality of Life-5 Dimensions (EQ-5D) (MEAN) units on a scale = 0.0419,Percentage of Participants Who Achieve Best Overall Tumor Response of Complete Response (CR) or Partial Response (PR) (Objective Tumor Response Rate [ORR]) (NUMBER) percentage of participants = 31.1 [26.3-36.4],,Time to Treatment Failure (TTF) (MEDIAN) Months = 3.5 [3.2-3.9],
NCT00986674,Carboplatin and Paclitaxel Combined With Cetuximab and/or IMC-A12 in Patients With Advanced Non-Small Cell Lung Cancer,"Three-Arm Randomized Phase II Study of Carboplatin and Paclitaxel in Combination With Cetuximab, IMC-A12 or Both in Patients With Advanced Non-Small Cell Lung Cancer Who Will Not Receive Bevacizumab-B",National Cancer Institute (NCI),National Cancer Institute (NCI),NIH,COMPLETED,2009-09,2013-08,2013-12,INTERVENTIONAL,PHASE2,,,,Recurrent Non-small Cell Lung Cancer,Recurrent Non-small Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer,3,3,4,BIOLOGICAL; DRUG,,,1,2,True,Yes,Progression Free Survival (MEDIAN) months = 3.4 [2.6-5.8],Overall Survival (MEDIAN) months = 9.8 [7.4-17.2]; Response Rate (NUMBER) percentage of participants = 11.1 [3.1-26.1],,,,,,,,,Overall Survival (MEDIAN) months = 9.8 [7.4-17.2],Progression Free Survival (MEDIAN) months = 3.4 [2.6-5.8],,,Response Rate (NUMBER) percentage of participants = 11.1 [3.1-26.1],,,
NCT00988858,A Study of Advanced or Metastatic Non-small Cell Lung Cancer,A Phase 2 Study to Evaluate LY2603618 in Combination With Pemetrexed in Patients With Advanced or Metastatic Non-small Cell Lung Cancer,Eli Lilly and Company,Eli Lilly and Company,INDUSTRY,COMPLETED,2009-11,2012-07,2014-11,INTERVENTIONAL,PHASE2,,,,Non Small Cell Lung Cancer,Non Small Cell Lung Cancer,1,1,2,DRUG,,,1,8,True,Yes,Overall Tumor Response - Percentage of Participants Achieving Complete Response (CR) or Partial Response (PR) [Overall Response Rate (ORR)] (NUMBER) percentage of participants = 9.1 [3.7-18.2],"Percentage of Participants Who Achieved a Best Response of Complete Response (CR), Partial Response (PR), or Stable Disease (SD) (Clinical Benefit Rate) (NUMBER) percentage of participants = 45.5 [33.9-57.4]; Progression-free Survival (PFS) (MEDIAN) months = 2.3 [1.4-3.3]; Duration of Response (MEDIAN) months = 8.7; Change in Symptom Burden Scores of Lung Cancer Symptom Scale (LCSS) (NUMBER) participants = 12; Pharmacokinetics (PK): Maximum Plasma Concentration (Cmax) of LY2603618 (GEOMETRIC_MEAN) nanogram per milliliter (ng/mL) = 3430; PK: Maximum Plasma Concentration (Cmax) of Pemetrexed (GEOMETRIC_MEAN) microgram per milliliter (μg/mL) = 102; PK: Area Under the Plasma Concentration vs. Time Curve From Time Zero to Infinity [AUC(0-∞)] of LY2603618 (GEOMETRIC_MEAN) nanograms*hour per milliliter (ng*h/mL) = 38000; PK: Area Under the Plasma Concentration vs. Time Curve From Time Zero to Infinity [AUC(0-∞)] of Pemetrexed (GEOMETRIC_MEAN) microgram*hour per milliliter (µg*hr/mL) = 193","Percentage of Participants Who Achieved a Best Response of Complete Response (CR), Partial Response (PR), or Stable Disease (SD) (Clinical Benefit Rate) (NUMBER) percentage of participants = 45.5 [33.9-57.4]","Overall Tumor Response - Percentage of Participants Achieving Complete Response (CR) or Partial Response (PR) [Overall Response Rate (ORR)] (NUMBER) percentage of participants = 9.1 [3.7-18.2]; Percentage of Participants Who Achieved a Best Response of Complete Response (CR), Partial Response (PR), or Stable Disease (SD) (Clinical Benefit Rate) (NUMBER) percentage of participants = 45.5 [33.9-57.4]",,,Duration of Response (MEDIAN) months = 8.7,,,,,Progression-free Survival (PFS) (MEDIAN) months = 2.3 [1.4-3.3],"Overall Tumor Response - Percentage of Participants Achieving Complete Response (CR) or Partial Response (PR) [Overall Response Rate (ORR)] (NUMBER) percentage of participants = 9.1 [3.7-18.2]; Percentage of Participants Who Achieved a Best Response of Complete Response (CR), Partial Response (PR), or Stable Disease (SD) (Clinical Benefit Rate) (NUMBER) percentage of participants = 45.5 [33.9-57.4]",,Overall Tumor Response - Percentage of Participants Achieving Complete Response (CR) or Partial Response (PR) [Overall Response Rate (ORR)] (NUMBER) percentage of participants = 9.1 [3.7-18.2],,,
NCT00995761,Biweekly Schedule of Docetaxel and Cisplatin in High Risk Patients With Unresectable Non-small Cell Lung Cancer (NSCLC),Phase II Study of Biweekly Schedule of Docetaxel and Cisplatin in High Risk Patients With Unresectable Non-small Cell Lung Cancer,Gyeongsang National University Hospital,Gyeongsang National University Hospital,OTHER,COMPLETED,2009-10,2012-08,2012-08,INTERVENTIONAL,PHASE2,,,,Non-small Cell Lung Cancer,Non-small Cell Lung Cancer,1,1,1,DRUG,,,2,1,True,Yes,Response Rates Confirmed With CT or MRI (NUMBER) percentage of participants = 64.6 [52.1-77.1]; ,,,,,,,,,,,,,,Response Rates Confirmed With CT or MRI (NUMBER) percentage of participants = 64.6 [52.1-77.1],,,
NCT00997334,Erlotinib Therapy and Subsequent Development of Mechanisms of Secondary Resistance in Patients With NSCLC,First-Line Erlotinib Therapy and the Subsequent Development of Mechanisms of Secondary Resistance in Patients With Non-Small Cell Lung Cancer and Known Sensitizing EGFR Mutations,Dana-Farber Cancer Institute,"David M. Jackman, MD",OTHER,COMPLETED,2010-02,2015-05,2017-01,INTERVENTIONAL,PHASE2,,,,Non-small Cell Lung Cancer,Non-small Cell Lung Cancer,1,1,1,DRUG,,,1,1,True,Yes,Resistance Mechanism (NUMBER) participants = 23,Progression-Free Survival (MEDIAN) months = 11.1 [9.1-14.8],,,,,,,,,,Progression-Free Survival (MEDIAN) months = 11.1 [9.1-14.8],,,,,,
NCT01000480,"A Study of Pemetrexed and Cisplatin, in Non Small Cell Lung Cancer","Phase 2 Study of Pemetrexed and Cisplatin as Induction, Followed by Pemetrexed and Cisplatin With Concurrent Thoracic Radiotherapy, in Patients With Unresectable, Locally Advanced, Stage III, Nonsquam",Eli Lilly and Company,Eli Lilly and Company,INDUSTRY,COMPLETED,2009-10,2013-01,2013-07,INTERVENTIONAL,PHASE2,,,,Non Small Cell Lung Cancer,Non Small Cell Lung Cancer,1,1,3,DRUG; RADIATION,,,1,2,True,Yes,1 Year Progression Free Survival (NUMBER) percentage of participants = 53.7 [44.8-62.5],Overall Survival (MEDIAN) months = 26.2; Number of Participants With an Objective Tumor Response (NUMBER) participants = 9,,,,,,,,,Overall Survival (MEDIAN) months = 26.2,1 Year Progression Free Survival (NUMBER) percentage of participants = 53.7 [44.8-62.5],,,,,,
NCT01004250,A Study of Pemetrexed and Bevacizumab for Participants With Advanced Non-Small Cell Cancer,"A Single-Arm, Phase 2 Trial of Pemetrexed, Cisplatin,and Bevacizumab as Induction, Followed by Pemetrexed and Bevacizumab as Maintenance, in First-Line Treatment of Nonsquamous Advanced NSCLC",Eli Lilly and Company,Eli Lilly and Company,INDUSTRY,COMPLETED,2009-10,2012-11,2013-12,INTERVENTIONAL,PHASE2,,,,Non-Small Cell Lung Cancer,Non-Small Cell Lung Cancer,1,1,3,DRUG,,,1,4,True,Yes,Progression-Free Survival (MEDIAN) Months = 6.9 [5.7-8.3],Overall Survival (MEDIAN) Months = 14.7 [11.5-19.7]; Percentage of Participants With Confirmed Complete Response or Partial Response During Study Treatment (Induction and Maintenance) (NUMBER) Percentage of Participants = 42.2 [32.8-52.0]; Percentage of Participants With Confirmed Response Complete or Partial Response During the Induction Treatment Only (NUMBER) Percentage of Participants = 34.9 [26.0-44.6]; Percentage of Participants With Confirmed Complete Response or Partial Response During the Maintenance Therapy Only (NUMBER) Percentage of Participants = 11.1 [4.9-20.7],,Percentage of Participants With Confirmed Complete Response or Partial Response During Study Treatment (Induction and Maintenance) (NUMBER) Percentage of Participants = 42.2 [32.8-52.0]; Percentage of Participants With Confirmed Complete Response or Partial Response During the Maintenance Therapy Only (NUMBER) Percentage of Participants = 11.1 [4.9-20.7],,,,,,,Overall Survival (MEDIAN) Months = 14.7 [11.5-19.7],Progression-Free Survival (MEDIAN) Months = 6.9 [5.7-8.3],Percentage of Participants With Confirmed Complete Response or Partial Response During Study Treatment (Induction and Maintenance) (NUMBER) Percentage of Participants = 42.2 [32.8-52.0]; Percentage of Participants With Confirmed Response Complete or Partial Response During the Induction Treatment Only (NUMBER) Percentage of Participants = 34.9 [26.0-44.6]; Percentage of Participants With Confirmed Complete Response or Partial Response During the Maintenance Therapy Only (NUMBER) Percentage of Participants = 11.1 [4.9-20.7],,,,,
NCT01005680,A Study Comparing Two Different Chemotherapy Types in Chinese Patients With Advanced Non Small Cell Lung Cancer,A Randomized Phase 3 Study Comparing Pemetrexed Plus Cisplatin With Gemcitabine Plus Cisplatin as First-Line Treatment in Patients With Advanced Non-squamous Non-Small Cell Lung Cancer.,Eli Lilly and Company,Eli Lilly and Company,INDUSTRY,COMPLETED,2009-11,2012-11,2012-11,INTERVENTIONAL,PHASE3,,,,Non Small Cell Lung Cancer,Non Small Cell Lung Cancer,1,2,3,DRUG,,,1,6,True,Yes,Overall Survival (OS) (MEDIAN) months = 17.54 [13.34-22.67],Progression Free Survival (PFS) (MEDIAN) months = 5.88 [4.99-6.47]; Time to Progressive Disease (TtPD) (MEDIAN) months = 5.82 [4.76-6.47]; Duration of Response (DoR) (MEDIAN) months = 4.53 [4.17-5.88]; ; Tumor Response Rate (NUMBER) percentage of participants = 24.8; Risk/Benefit Ratio (NUMBER) ratio = 0.70,,,,,Duration of Response (DoR) (MEDIAN) months = 4.53 [4.17-5.88],,,,Overall Survival (OS) (MEDIAN) months = 17.54 [13.34-22.67],Progression Free Survival (PFS) (MEDIAN) months = 5.88 [4.99-6.47],,,Tumor Response Rate (NUMBER) percentage of participants = 24.8,,,
NCT01011075,Study of Gleevec and Weekly Paclitaxel in Patients Aged 70 or Older With Advanced Non-small Cell Lung Cancer,A Phase II Study of Intermittent Gleevec® (Imatinib Mesylate) and Weekly Paclitaxel in Patients Aged 70 or Older With Advanced Non-small Cell Lung Cancer,New Mexico Cancer Research Alliance,New Mexico Cancer Research Alliance,OTHER,COMPLETED,2009-08,2011-07,2012-07,INTERVENTIONAL,PHASE2,,,,Non-small Cell Lung Cancer,Non-small Cell Lung Cancer,1,1,2,DRUG,,,1,3,True,Yes,Response Rate (NUMBER) Percentage of Participants = 32 [17.4-50.5],Overall Survival (MEDIAN) Months = 7.3 [5-16]; Progression Free Survival (MEDIAN) Months = 3.6 [3-7]; Toxicities (NUMBER) Number of events = 34,,,,,,,,,Overall Survival (MEDIAN) Months = 7.3 [5-16],Progression Free Survival (MEDIAN) Months = 3.6 [3-7],,,Response Rate (NUMBER) Percentage of Participants = 32 [17.4-50.5],,,
NCT01017874,A Study of Alimta/Cisplatin/Gefitinib for Asian Non-smoking Participants With Non Small Cell Lung Cancer,A Randomized Ph 3 Study Comparing First-Line Pemetrexed/Cisplatin Followed by Gefitinib With Gefitinib Alone in East Asian Never Smoker or Light Ex-Smoker Patients With Locally Advanced or Metastatic ,Eli Lilly and Company,Eli Lilly and Company,INDUSTRY,COMPLETED,2009-11,2013-04,2014-10,INTERVENTIONAL,PHASE3,,,,Non Small Cell Lung Cancer,Non Small Cell Lung Cancer,1,2,4,DRUG,,,1,6,True,Yes,Progression Free Survival (PFS) (MEDIAN) months = 8.38 [6.44-11.14],"Overall Survival (OS) (MEDIAN) months = 26.87 [20.76-35.12]; Percentage of Participants With Complete Response (CR) or Partial Response (PR) [Tumor Response Rate (TRR)] (NUMBER) percentage of participants = 41.5 [32.5-51.0]; Percentage of Participants With Complete Response (CR), Partial Response (PR) or Stable Disease (SD) [Disease Control Rate (DCR)] (NUMBER) percentage of participants = 71.2 [62.1-79.2]; Time to Progressive Disease (TtPD) (MEDIAN) months = 8.61 [6.60-11.20]; Duration of Tumor Response (MEDIAN) months = 12.09 [7.16-22.11]; Time to Worsening of Health-Related Quality of Life (TWQ) Using the Participant-Rated Lung Cancer Symptom Scale (LCSS) (MEDIAN) months = 2.99 [1.71-3.68]",,"Percentage of Participants With Complete Response (CR) or Partial Response (PR) [Tumor Response Rate (TRR)] (NUMBER) percentage of participants = 41.5 [32.5-51.0]; Percentage of Participants With Complete Response (CR), Partial Response (PR) or Stable Disease (SD) [Disease Control Rate (DCR)] (NUMBER) percentage of participants = 71.2 [62.1-79.2]",,,,,,,Overall Survival (OS) (MEDIAN) months = 26.87 [20.76-35.12],Progression Free Survival (PFS) (MEDIAN) months = 8.38 [6.44-11.14],"Percentage of Participants With Complete Response (CR) or Partial Response (PR) [Tumor Response Rate (TRR)] (NUMBER) percentage of participants = 41.5 [32.5-51.0]; Percentage of Participants With Complete Response (CR), Partial Response (PR) or Stable Disease (SD) [Disease Control Rate (DCR)] (NUMBER) percentage of participants = 71.2 [62.1-79.2]",Time to Worsening of Health-Related Quality of Life (TWQ) Using the Participant-Rated Lung Cancer Symptom Scale (LCSS) (MEDIAN) months = 2.99 [1.71-3.68],Percentage of Participants With Complete Response (CR) or Partial Response (PR) [Tumor Response Rate (TRR)] (NUMBER) percentage of participants = 41.5 [32.5-51.0],,,
NCT01027598,"Randomized, Double-Blind Trial of Erlotinib/Pazopanib or Erlotinib/Placebo in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer","A Randomized Phase II Double-Blind Trial of Erlotinib and Pazopanib, or Erlotinib and Placebo in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer (NSCLC)","SCRI Development Innovations, LLC","SCRI Development Innovations, LLC",OTHER,COMPLETED,2010-01,2014-04,2014-06,INTERVENTIONAL,PHASE2,,,,Non Small Cell Lung Cancer,Non Small Cell Lung Cancer,1,2,2,DRUG,,,1,2,True,Yes,Progression-free Survival (MEDIAN) months = 2.6 [1.9-3.2],Overall Survival (MEDIAN) months = 6.76 [4.7-8.1]; Objective Response Rate (ORR) (NUMBER) percentage of evaluated participants = 12.12,,,,,,,,Objective Response Rate (ORR) (NUMBER) percentage of evaluated participants = 12.12,Overall Survival (MEDIAN) months = 6.76 [4.7-8.1],Progression-free Survival (MEDIAN) months = 2.6 [1.9-3.2],,,Objective Response Rate (ORR) (NUMBER) percentage of evaluated participants = 12.12,,,
NCT01040780,Safety and Efficacy Study of Icotinb in Non-small Cell Lung Cancer (NSCLC) Patients,"A Randomized,Double-blind,Multicenter Phase III Trial to Evaluate the Safety and Efficacy of Icotinib and Gefitinib in Advanced NSCLC Patients Previously Treated With Chemotherapy","Betta Pharmaceuticals Co., Ltd.","Betta Pharmaceuticals Co., Ltd.",INDUSTRY,COMPLETED,2009-02,2010-03,2011-12,INTERVENTIONAL,PHASE3,,,,Non-small Cell Lung Cancer,Non-small Cell Lung Cancer,1,2,2,DRUG,,,1,4,True,Yes,Progression Free Survival (MEDIAN) months = 4.6 [3.5-6.3],Overall Survival (MEDIAN) months = 13.3 [11.1-16.2]; Best Tumor Response (NUMBER) percentage of patients = 0.5; Time To Progression (MEDIAN) months = 5.2 [3.6-6.6]; Safety and Tolerability (NUMBER) participants = 166,,,,,,,,,Overall Survival (MEDIAN) months = 13.3 [11.1-16.2],Progression Free Survival (MEDIAN) months = 4.6 [3.5-6.3],,,,,,Time To Progression (MEDIAN) months = 5.2 [3.6-6.6]
NCT01042288,"Carboplatin, Pemetrexed, and Panitumumab in Patients With Advanced Non-Squamous K-ras Wild Type NSCLC","A Phase II Trial of Carboplatin, Pemetrexed, and Panitumumab in Patients With Advanced Non-Squamous K-ras Wild Type Non-Small-Cell Lung Cancer","SCRI Development Innovations, LLC","SCRI Development Innovations, LLC",OTHER,COMPLETED,2010-06,2014-12,2015-07,INTERVENTIONAL,PHASE2,,,,Non-Small-Cell Lung Cancer,Non-Small-Cell Lung Cancer,1,1,3,DRUG,,,1,4,True,Yes,Median Time to Progression (TTP) (MEDIAN) months = 6.11 [5.42-9.07],Median Progression-free Survival (PFS) (MEDIAN) months = 5.75 [4.99-8.05]; Median Overall Survival (OS) (MEDIAN) months = 17.02 [11.33-19.68]; Objective Response Rate (NUMBER) percentage of evaluated participants = 53; Frequency of Adverse Events and Severity as a Measure of Toxicity (NUMBER) participants = 55,,,,,,,,Objective Response Rate (NUMBER) percentage of evaluated participants = 53,Median Overall Survival (OS) (MEDIAN) months = 17.02 [11.33-19.68],Median Progression-free Survival (PFS) (MEDIAN) months = 5.75 [4.99-8.05],,,Objective Response Rate (NUMBER) percentage of evaluated participants = 53,Frequency of Adverse Events and Severity as a Measure of Toxicity (NUMBER) participants = 55,,Median Time to Progression (TTP) (MEDIAN) months = 6.11 [5.42-9.07]
NCT01045421,"Alisertib in Adults With Nonhematological Malignancies, Followed by Alisertib in Lung, Breast, Head and Neck or Gastroesophageal Malignancies","A Phase 1 Dose Escalation Study of MLN8237, an Aurora A Kinase Inhibitor, in Adult Patients With Nonhematological Malignancies, Followed by a Phase 2 of MLN8237 in Lung, Breast, Head and Neck, or Gast","Millennium Pharmaceuticals, Inc.","Millennium Pharmaceuticals, Inc.",INDUSTRY,COMPLETED,2010-02,2013-05,2014-04,INTERVENTIONAL,PHASE1; PHASE2,,,,Advanced Nonhematological Malignancies,Advanced Nonhematological Malignancies; Non-Small Cell Lung Cancer; Small Cell Lung Cancer,6,1,1,DRUG,,,2,12,True,Yes,Phase 1: Number of Participants With Dose-Limiting Toxicities (DLTs) (NUMBER) participants = 0; Phase 2: Percentage of Participants With Objective Response (NUMBER) percentage of participants = 18 [9-32],Phase 2: Progression-free Survival (PFS) (MEDIAN) days = 164 [78-239]; Phase 2: Time to Disease Progression (TTP) (MEDIAN) days = 164 [78-239]; Phase 2: Duration of Response (DOR) (MEDIAN) days = 169 [85-313]; Phase 2: Number of Participants Reporting One or More Treatment-emergent Adverse Events and Serious Adverse Events (NUMBER) participants = 52; Phase 1: Cmax- Maximum Observed Plasma Concentration for Alisertib (GEOMETRIC_MEAN) nanomole (nM) = 297; Phase 1: Tmax- Time to Reach the Maximum Plasma Concentration (Cmax) for Alisertib (MEDIAN) hours = 2.9; Phase 1: AUC(0-tau): Area Under the Plasma Concentration-time Curve From Time 0 to Time Tau Over the Dosing Interval for Alisertib (GEOMETRIC_MEAN) nanomole*hour (nM*hr) = 2640; Phase 1: Terminal Phase Elimination Half-life (T1/2) for Alisertib (MEAN) hours = 20.6; Phase 1: Rac- Accumulation Ratio for Alisertib (MEAN) ratio = 3.3; Phase 1: Peak to Trough Ratio for Alisertib (MEAN) ratio = 1.7; Phase 1: Steady State Oral Clearance (CLss/F) for Alisertib (GEOMETRIC_MEAN) L/hr = 2.2; Phase 2: Relationship Between Clinical Response and Molecular Markers of Response (NUMBER) percentage of participants = 0,,,,,Phase 2: Duration of Response (DOR) (MEDIAN) days = 169 [85-313],,,,,Phase 2: Progression-free Survival (PFS) (MEDIAN) days = 164 [78-239],,,,Phase 2: Number of Participants Reporting One or More Treatment-emergent Adverse Events and Serious Adverse Events (NUMBER) participants = 52,,
NCT01059643,"A Study in Ovarian, Non-Small Cell Lung, Prostate, Colorectal, Gastroesophageal Cancers, and Squamous Cell Carcinoma of the Head and Neck","A Phase 2 Indication Identification Study of LY2523355 in Patients With Ovarian, Non-Small Cell Lung, Prostate, Colorectal, Gastroesophageal Cancers, and Squamous Cell Carcinoma of the Head and Neck",Eli Lilly and Company,Eli Lilly and Company,INDUSTRY,COMPLETED,2011-04,2012-12,2012-12,INTERVENTIONAL,PHASE2,,,,Ovarian Cancer,Ovarian Cancer; Non Small Cell Lung Cancer; Prostate Cancer,7,1,2,DRUG,,,1,6,True,Yes,Percentage of Participants With a Complete Response (CR) or Partial Response (PR) (NUMBER) percentage of participants = 0 [0.0-17.1],"Progression Free Survival (PFS) (MEDIAN) months = 1.30 [1.28-2.69]; Percentage of Participants Who Achieved a Best Response of Complete Response (CR), Partial Response (PR) or Stable Disease (SD) (NUMBER) percentage of participants = 37.5 [17.8-60.9]; Tumor Marker Values as Relevant to Specific Tumor Types at Baseline (COUNT_OF_PARTICIPANTS) Participants = 2; Change in Tumor Size at Smallest Size (Best Response) (MEAN) percentage of change = 15.4; Pharmacokinetics, Maximum Plasma Concentration (Cmax) of LY2523355 and Metabolite LSN2546307 (GEOMETRIC_MEAN) nanograms per milliliter (ng/mL) = 125; Pharmacokinetics, Intracycle Accumulation Ratio (Ra) of LY2523355 (GEOMETRIC_MEAN) ratio = 1.02",,"Percentage of Participants With a Complete Response (CR) or Partial Response (PR) (NUMBER) percentage of participants = 0 [0.0-17.1]; Percentage of Participants Who Achieved a Best Response of Complete Response (CR), Partial Response (PR) or Stable Disease (SD) (NUMBER) percentage of participants = 37.5 [17.8-60.9]",,,,,,,,Progression Free Survival (PFS) (MEDIAN) months = 1.30 [1.28-2.69],"Percentage of Participants With a Complete Response (CR) or Partial Response (PR) (NUMBER) percentage of participants = 0 [0.0-17.1]; Percentage of Participants Who Achieved a Best Response of Complete Response (CR), Partial Response (PR) or Stable Disease (SD) (NUMBER) percentage of participants = 37.5 [17.8-60.9]",,,,,
NCT01076231,Proton Beam Radiation Therapy and Chemotherapy in Treating Patients With Stage III Non-Small Cell Lung Cancer That Can Be Removed By Surgery,Feasibility and PhaseI/II Trial of Preoperative Proton Beam Radiotherapy With Concurrent Chemotherapy for Resectable Stage IIIA or Superior Sulcus NSCLC,Abramson Cancer Center at Penn Medicine,Abramson Cancer Center at Penn Medicine,OTHER,COMPLETED,2010-01,2016-12,2018-05-24,INTERVENTIONAL,PHASE1; PHASE2,,,,Stage IIIA Non-small Cell Lung Cancer,Stage IIIA Non-small Cell Lung Cancer,1,1,4,DRUG; PROCEDURE; RADIATION,,,3,1,True,Yes,Number of Participants Deemed Feasible to Receive Intervention (COUNT_OF_PARTICIPANTS) Participants = 21; Dose-limiting Toxicity (COUNT_OF_PARTICIPANTS) Participants = 0; Late Toxicity (COUNT_OF_PARTICIPANTS) Participants = 0,Pathologic CR Rate (NUMBER) complete response rate percentage = 21,,Pathologic CR Rate (NUMBER) complete response rate percentage = 21,,,,,,,,,,,Pathologic CR Rate (NUMBER) complete response rate percentage = 21,Dose-limiting Toxicity (COUNT_OF_PARTICIPANTS) Participants = 0; Late Toxicity (COUNT_OF_PARTICIPANTS) Participants = 0,,
NCT01077713,A Study of Avastin (Bevacizumab) in Combination With Gemcitabine With or Without Cisplatin in First-Line Treatment of Elderly Patients With Non-Small ,Randomised Phase II Trial of Bevacizumab (AVASTIN®) in Combination With Gemcitabine or Attenuated Doses of Cisplatin and Gemcitabine as First-line Treatment of Elderly Patients With Advanced Non-squam,Hoffmann-La Roche,Hoffmann-La Roche,INDUSTRY,COMPLETED,2010-02,2014-07,2014-07,INTERVENTIONAL,PHASE2,,,,Non-Squamous Non-Small Cell Lung Cancer,Non-Squamous Non-Small Cell Lung Cancer,1,2,4,DRUG,,,1,9,True,Yes,Percentage of Participants Alive and Without Progressive Disease at Month 6 (NUMBER) percentage of participants = 25.6 [12.5-38.6],Percentage of Participants With Disease Progression or Death (NUMBER) percentage of participants = 86.0; Progression Free Survival (PFS) (MEDIAN) months = 4.33 [2.20-5.97]; Percentage of Participants Alive at 12 Months After Randomization (NUMBER) percentage of participants = 37.2 [22.8-51.7]; Percentage of Participants Who Died (NUMBER) percentage of participants = 69.8; Overall Survival (OS) (MEDIAN) months = 5.66 [3.38-13.0]; Percentage of Participants by Best Overall Response (NUMBER) percentage of participants = 0.0 [0.0-0.0]; Percentage of Participants With an Objective Response (NUMBER) percentage of participants = 11.6 [2.05-21.2]; Percentage of Participants With Disease Control (NUMBER) percentage of participants = 53.5 [38.6-68.4]; Duration of Response (DoR) (MEDIAN) months = 5.23,,,,,Duration of Response (DoR) (MEDIAN) months = 5.23,,,,Overall Survival (OS) (MEDIAN) months = 5.66 [3.38-13.0],Progression Free Survival (PFS) (MEDIAN) months = 4.33 [2.20-5.97],,,,,,
NCT01101334,Study of Erlotinib With or Without Investigational Drug (CS-7017) in Subjects With Advanced Non-small Cell Lung Cancer,Phase 2 Study of CS-7017 and Erlotinib in Subjects With Advanced Non-Small Cell Lung Cancer Who Failed First Line Therapy,Daiichi Sankyo,Daiichi Sankyo,INDUSTRY,COMPLETED,2010-03,2013-04,2013-04,INTERVENTIONAL,PHASE2,,,,Advanced Non-small Cell Lung Cancer (NSCLC),Advanced Non-small Cell Lung Cancer (NSCLC),1,2,2,DRUG,,,1,3,True,Yes,Summary of Analysis of Progression-Free Survival Following Administration of CS-7017 and Erlotinib in Participants With Advanced Non-Small Cell Lung Cancer Who Failed First Line Therapy (MEDIAN) months = 4.1 [2.7-6.7],Analysis of Overall Survival Following Administration of CS-7017 and Erlotinib in Participants With Advanced Non-Small Cell Lung Cancer Who Failed First Line Therapy (MEDIAN) months = 7.6 [3.8-12.0]; Overall Response Rate Following Administration of CS-7017 and Erlotinib in Participants With Advanced Non-Small Cell Lung Cancer Who Failed First Line Therapy (COUNT_OF_PARTICIPANTS) Participants = 9; Summary of Treatment-Emergent Adverse Events (TEAEs) Occurring in ≥10% of Participants Following Administration of CS-7017 and Erlotinib in Participants With Advanced Non-Small Cell Lung Cancer Who Failed First Line Therapy (COUNT_OF_PARTICIPANTS) Participants = 44,,,,,,,,,Analysis of Overall Survival Following Administration of CS-7017 and Erlotinib in Participants With Advanced Non-Small Cell Lung Cancer Who Failed First Line Therapy (MEDIAN) months = 7.6 [3.8-12.0],Summary of Analysis of Progression-Free Survival Following Administration of CS-7017 and Erlotinib in Participants With Advanced Non-Small Cell Lung Cancer Who Failed First Line Therapy (MEDIAN) months = 4.1 [2.7-6.7],,,Overall Response Rate Following Administration of CS-7017 and Erlotinib in Participants With Advanced Non-Small Cell Lung Cancer Who Failed First Line Therapy (COUNT_OF_PARTICIPANTS) Participants = 9,Summary of Treatment-Emergent Adverse Events (TEAEs) Occurring in ≥10% of Participants Following Administration of CS-7017 and Erlotinib in Participants With Advanced Non-Small Cell Lung Cancer Who Failed First Line Therapy (COUNT_OF_PARTICIPANTS) Participants = 44,,
NCT01102231,Chemoradiotherapy in Stage III Non-small Cell Lung Cancer (NSCLC),Phase II Study of Pemetrexed + Cetuximab + Cisplatin With Concurrent Chemoradiotherapy in Stage III Non-small Cell Lung Cancer (NSCLC),Intergroupe Francophone de Cancerologie Thoracique,Intergroupe Francophone de Cancerologie Thoracique,OTHER,COMPLETED,2010-03,2014-01,2015-12,INTERVENTIONAL,PHASE2,,,,Stage III Non-small Cell Lung Cancer,Stage III Non-small Cell Lung Cancer,1,1,3,DRUG; RADIATION,,,1,2,True,Yes,Disease-Control Rate (COUNT_OF_PARTICIPANTS) Participants = 89,18-month Overall Survival Rate (NUMBER) percentage of participant = 42.4 [32.6-51.9]; Progression Free Survival (MEDIAN) Months = 14.4 [11.2-18.8],,,,,,,,,18-month Overall Survival Rate (NUMBER) percentage of participant = 42.4 [32.6-51.9],Progression Free Survival (MEDIAN) Months = 14.4 [11.2-18.8],,,,,,
NCT01104155,"Eribulin Mesylate in Combination With Intermittent Erlotinib in Patients With Previously Treated, Advanced Non-Small Cell Lung Cancer","The Purpose of This Study is to Investigate Two Different Dose Regimens of Eribulin Mesylate in Combination With Intermittent Erlotinib in Patients With Previously Treated, Advanced Non-small Cell Lun",Eisai Inc.,Eisai Inc.,INDUSTRY,COMPLETED,2010-02-22,2011-04-07,2017-01-18,INTERVENTIONAL,PHASE2,,,,Non-small Cell Lung Cancer,Non-small Cell Lung Cancer,1,2,2,DRUG,,,1,4,True,Yes,Objective Response Rate (ORR) (NUMBER) Percentage of participants = 12.7 [5.6-23.5],Duration of Response (DOR) (MEDIAN) Months = 9.4; Progression-Free Survival (PFS) (MEDIAN) Months = 3.5 [1.9-4.7]; Disease Control Rate (DCR) (NUMBER) Percentage of participants = 47.6 [34.9-60.6]; Overall Survival (OS) (MEDIAN) Months = 7.6 [6.3-11.0],,,,,Duration of Response (DOR) (MEDIAN) Months = 9.4,,,Objective Response Rate (ORR) (NUMBER) Percentage of participants = 12.7 [5.6-23.5],Overall Survival (OS) (MEDIAN) Months = 7.6 [6.3-11.0],Progression-Free Survival (PFS) (MEDIAN) Months = 3.5 [1.9-4.7],,,Objective Response Rate (ORR) (NUMBER) Percentage of participants = 12.7 [5.6-23.5],,,
NCT01107444,Study of LY2181308 in Combination With Docetaxel Versus Docetaxel in Patients With Non-Small Cell Lung Cancer,A Randomized Phase 2 Study of LY2181308 in Combination With Docetaxel Versus Docetaxel in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Were Previously Treated With First,Eli Lilly and Company,Eli Lilly and Company,INDUSTRY,COMPLETED,2010-05,2011-12,2012-06,INTERVENTIONAL,PHASE2,,,,Non-small Cell Lung Cancer,Non-small Cell Lung Cancer,1,2,2,DRUG,,,1,12,True,Yes,Change From Baseline in Tumor Size to the End of Cycle 2 (MEAN) Log Ratio of Tumor Size = 1.06,Number of Participants With Characterization of Toxicities as Defined by Common Terminology Criteria for Adverse Events (CTCAE) Coding (COUNT_OF_PARTICIPANTS) Participants = 98; Progression Free Survival (PFS) (MEDIAN) Months = 2.83 [1.84-3.65]; Pharmacokinetics: Area Under the Concentration Curve From Zero to 4 Hours (AUC[0-4]) for LY2181309 and Docetaxel (GEOMETRIC_MEAN) nanograms*hours per milliliter (ng*h/mL) = 1642; Pharmacokinetics: Area Under the Drug Concentration-Time Curve From Zero to Infinity (AUC[0 ∞]) of LY2181309 and Docetaxel (GEOMETRIC_MEAN) nanograms*hours per milliliter (ng*h/mL) = 1905; Overall Survival (OS) (MEDIAN) months = 7.9 [6.6-9.7]; Time to Worsening of Symptoms as Defined by Lung Cancer Symptom Score (LCSS) Questionnaire (MEDIAN) Months = 1.0 [0.7-1.0]; ; Time to Documented Disease Progression (MEDIAN) Months = 2.9 [2.0-3.7]; Percent of Participants Having a Partial Response (PR) or a Complete Response (CR) (NUMBER) Percentage of participants = 6.1; Duration of Response (MEDIAN) Months = 2.8; Lung Cancer Symptom Scale (LCSS) Average Symptom Burden Index (ASBI) on Cycle 2 Day 1 (MEDIAN) units on a scale = 22 [11-34]; Lung Cancer Symptom Scale (LCSS) Average Total Score at Cycle 2 Day 1 (MEDIAN) units on a scale = 27 [11-38],,Percent of Participants Having a Partial Response (PR) or a Complete Response (CR) (NUMBER) Percentage of participants = 6.1,,,Duration of Response (MEDIAN) Months = 2.8,,,,Overall Survival (OS) (MEDIAN) months = 7.9 [6.6-9.7],Progression Free Survival (PFS) (MEDIAN) Months = 2.83 [1.84-3.65],Percent of Participants Having a Partial Response (PR) or a Complete Response (CR) (NUMBER) Percentage of participants = 6.1,,,Number of Participants With Characterization of Toxicities as Defined by Common Terminology Criteria for Adverse Events (CTCAE) Coding (COUNT_OF_PARTICIPANTS) Participants = 98,,
NCT01109524,Safety Study of Cetuximab in Combination With Cisplatin and Vinorelbine to Treat Advanced Non-small Cell Lung Cancer,Cisplatin and Vinorelbine in Combination With Cetuximab as First Line Treatment for Patients With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC): a Single Arm Multicenter Safety Phase 2 Study,Eli Lilly and Company,Eli Lilly and Company,INDUSTRY,COMPLETED,2010-07,2012-09,2012-09,INTERVENTIONAL,PHASE2,,,,Lung Neoplasms,Lung Neoplasms; Carcinoma; Cancer of the Lung,4,1,3,DRUG,,,7,0,True,Yes,"Number of Participants With Any Treatment-emergent Adverse Events (AEs), Serious Adverse Events (SAEs), Deaths, and AEs Leading to Discontinuation of at Least One Study Drug, - Treated Population (NUMBER) participants = 3; Number of Participants With Grades 3 and 4 Treatment-emergent Adverse Events (AEs) of Special Interest - Treated Population (NUMBER) participants = 5; Number of Participants With Liver Function Serum Chemistry Laboratory Abnormalities - Treated Population (NUMBER) participants = 37; Number of Participants With Hematology Laboratory Abnormalities - Treated Population (NUMBER) participants = 51; Number of Participants With Renal Function Serum Chemistry Laboratory Abnormalities - Treated Population (NUMBER) participants = 42; Number of Participants With Drug-Related Treatment-emergent AEs, Drug-Related SAEs, and Drug-Related AEs Leading to Discontinuation of at Least One Study Drug, - Treated Population (NUMBER) participants = 16; Number of Participants With Grades 3 and 4 Drug-Related Treatment-emergent AEs of Special Interest - Treated Population (NUMBER) participants = 5",,,,,,,,,,,,,,,"Number of Participants With Any Treatment-emergent Adverse Events (AEs), Serious Adverse Events (SAEs), Deaths, and AEs Leading to Discontinuation of at Least One Study Drug, - Treated Population (NUMBER) participants = 3; Number of Participants With Grades 3 and 4 Treatment-emergent Adverse Events (AEs) of Special Interest - Treated Population (NUMBER) participants = 5; Number of Participants With Drug-Related Treatment-emergent AEs, Drug-Related SAEs, and Drug-Related AEs Leading to Discontinuation of at Least One Study Drug, - Treated Population (NUMBER) participants = 16",,
NCT01124864,A Study of AUY922 in Non-small-cell Lung Cancer Patients Who Have Received Previous Two Lines of Chemotherapy.,"A Phase II, Multi-center, Open-label Study of AUY922 Administered IV on a Once-weekly Schedule in Patients With Advanced Non-small-cell Lung Cancer Who Have Received at Least Two Lines of Prior Chemot",Novartis,Novartis Pharmaceuticals,INDUSTRY,COMPLETED,2010-10,2014-08,2014-08,INTERVENTIONAL,PHASE2,,,,Non-small-cell Lung Cancer,Non-small-cell Lung Cancer,1,5,1,DRUG,,,1,5,True,Yes,Response Assessment by Study Stratum - Per Investigator Assessment (NUMBER) Participants = 0,Overall Survival Rate Using Kaplan Meier Estimates - Per Investigator Radiological Review (NUMBER) Percentage of participants = 68.7 [47.0-83.0]; Progression Free Survival (PFS) Rate as Per Investigator Using Kaplan Meier Estimates - Per Investigator Radiological Review (NUMBER) Percentage of participants = 31.5 [14.9-49.6]; Pharmacokinetics (PK) of Plasma Concentration of AUY922 and Its Metabolite BJP762: AUCinf (MEAN) h*ng/mL = 2101.27; Pharmacokinetics (PK) of Plasma Concentration of AUY922 and Its Metabolite BJP762: AUClast (MEAN) h*ng/mL = 1997.04; Pharmacokinetics (PK) of Plasma Concentration of AUY922 and Its Metabolite BJP762: Cmax (MEAN) ng/mL = 1130.59,,,,,,,,,Overall Survival Rate Using Kaplan Meier Estimates - Per Investigator Radiological Review (NUMBER) Percentage of participants = 68.7 [47.0-83.0],Progression Free Survival (PFS) Rate as Per Investigator Using Kaplan Meier Estimates - Per Investigator Radiological Review (NUMBER) Percentage of participants = 31.5 [14.9-49.6],,,,,,
NCT01126736,Eribulin Mesylate Administered in Combination With Pemetrexed Versus Pemetrexed Alone as Second Line Therapy in Patients With Stage IIIB or IV Nonsqua,"An Open-Label, Multicenter, Randomized Phase Ib/II Study of Eribulin Mesylate Administered in Combination With Pemetrexed Versus Pemetrexed Alone as Second Line Therapy in Patients With Stage IIIB or ",Eisai Inc.,Eisai Inc.,INDUSTRY,COMPLETED,2010-06-10,2012-12-31,2015-03-18,INTERVENTIONAL,PHASE1; PHASE2,,,,Non Small Cell Lung Cancer,Non Small Cell Lung Cancer,1,3,3,DRUG,,,3,1,True,Yes,Phase 1b: Number of Participants With Dose-Limiting Toxicity (DLTs) (COUNT_OF_PARTICIPANTS) Participants = 0; Phase 1b: Percentage of Participants With Grade 3 or Higher Treatment Emergent Adverse Events (TEAEs) (NUMBER) percentage of participants = 100.0; Phase 2: Percentage of Participants Who Experienced TEAEs (NUMBER) percentage of participants = 97.6,Phase 2: Progression-free Survival (PFS) (MEDIAN) weeks = 18.1 [8.43-34.14],,,,,,,,,,Phase 2: Progression-free Survival (PFS) (MEDIAN) weeks = 18.1 [8.43-34.14],,,,Phase 1b: Number of Participants With Dose-Limiting Toxicity (DLTs) (COUNT_OF_PARTICIPANTS) Participants = 0; Phase 1b: Percentage of Participants With Grade 3 or Higher Treatment Emergent Adverse Events (TEAEs) (NUMBER) percentage of participants = 100.0,,
NCT01139775,A Study in Non Small Cell Lung Cancer,A Phase 1/Randomized Phase 2 Study to Evaluate LY2603618 in Combination With Pemetrexed and Cisplatin in Patients With Stage IV Non-small Cell Lung Cancer,Eli Lilly and Company,Eli Lilly and Company,INDUSTRY,COMPLETED,2011-02,2013-05,2014-08,INTERVENTIONAL,PHASE1; PHASE2,,,,Non Small Cell Lung Cancer,Non Small Cell Lung Cancer,1,3,3,DRUG,,,2,13,True,Yes,Phase 2: Progression-Free Survival Time (MEDIAN) months = 4.7 [4.2-7.1]; Phase 1: Recommended Phase 2 Dose of LY2603618 (NUMBER) mg = 275,"Phase 2: Overall Survival (MEDIAN) months = 12.9; Phase 2: Overall Tumor Response Rate: Percentage of Participants Who Achieved a Confirmed Best Response of Completed Response (CR) or Partial Response (PR) (NUMBER) percentage of participants = 43.6 [28.0-60.0]; Phase 2: Change in Tumor Size (MEAN) centimeters = -0.30; Phase 1: Pharmacokinetic: Maximum Plasma Concentration (Cmax) (LY2603618) (GEOMETRIC_MEAN) ng/mL = 1810; Phase 1: Pharmacokinetic: Cmax (Pemetrexed and Cisplatin) (GEOMETRIC_MEAN) ng/mL = 88300; Phase 1: Pharmacokinetic: Area Under the Plasma Concentration Versus Time Curve (AUC) (LY2603618) (GEOMETRIC_MEAN) ng*h/mL = 8700; Phase 1: Pharmacokinetic: AUC (Pemetrexed and Cisplatin) (GEOMETRIC_MEAN) ng*h/mL = 159000; Phase 2: Pharmacokinetic: Cmax (LY2603618) (GEOMETRIC_MEAN) ng/mL = 4130; Phase 2: Pharmacokinetic: AUC (LY2603618) (GEOMETRIC_MEAN) ng*h/mL = 31400; Phase 2: Change From Baseline to Long-term Follow up in Lung Cancer Symptom Scale (LCSS) (MEAN) units on a scale = -10.7; Phase 1: Document Any Antitumor Activity Per Radiological Scans and/or Tumor Markers (NUMBER) percentage of participants = 0 [0-0]; ; Phase 2: Clinical Benefit Rate: Percentage of Participant Who Achieved a Response of Stable Disease (SD), Partial Response (PR), or Complete Response (CR) (NUMBER) percentage of participants = 69.2 [52.0-83.0]","Phase 2: Clinical Benefit Rate: Percentage of Participant Who Achieved a Response of Stable Disease (SD), Partial Response (PR), or Complete Response (CR) (NUMBER) percentage of participants = 69.2 [52.0-83.0]","Phase 2: Clinical Benefit Rate: Percentage of Participant Who Achieved a Response of Stable Disease (SD), Partial Response (PR), or Complete Response (CR) (NUMBER) percentage of participants = 69.2 [52.0-83.0]",,,,,,,Phase 2: Overall Survival (MEDIAN) months = 12.9,Phase 2: Progression-Free Survival Time (MEDIAN) months = 4.7 [4.2-7.1],"Phase 2: Overall Tumor Response Rate: Percentage of Participants Who Achieved a Confirmed Best Response of Completed Response (CR) or Partial Response (PR) (NUMBER) percentage of participants = 43.6 [28.0-60.0]; Phase 2: Clinical Benefit Rate: Percentage of Participant Who Achieved a Response of Stable Disease (SD), Partial Response (PR), or Complete Response (CR) (NUMBER) percentage of participants = 69.2 [52.0-83.0]",,Phase 2: Overall Tumor Response Rate: Percentage of Participants Who Achieved a Confirmed Best Response of Completed Response (CR) or Partial Response (PR) (NUMBER) percentage of participants = 43.6 [28.0-60.0],,,
NCT01165021,A Study of Pemetrexed/Cisplatin as Pre-operative Treatment of Early Stage Nonsquamous Non-Small Cell Lung Cancer,An Exploratory Phase 2 Study of Pemetrexed/Cisplatin as Pre-operative Chemotherapy in the Treatment of Stage IIIAN2 Nonsquamous Non-Small Cell Lung Cancer,Eli Lilly and Company,Eli Lilly and Company,INDUSTRY,COMPLETED,2010-11,2013-07,2016-04,INTERVENTIONAL,PHASE2,,,,Non Small Cell Lung Cancer,Non Small Cell Lung Cancer,1,1,5,DRUG,,,1,4,True,Yes,Percentage of Participants With Complete Response (CR) or Partial Response (PR) [Overall Response Rate (ORR)] (NUMBER) percentage of participants = 41.2 [18.4-67.1],"Percentage of Participants With No Viable Tumor Cells in Resected Lung Tissue [Pathological Complete Remission (pCR)] (NUMBER) percentage of participants = 93.3 [68.1-99.8]; Percentage of Participants Who Exhibit a Downward Shift in Tumor Extent From Stage IIIAN2 to Stages IIIA, II, I, or Stage 0 (NUMBER) percentage of participants = 29.4 [10.3-56.0]; Overall Survival (OS) (MEDIAN) months = 34.6; Progression-Free Survival (PFS) (MEDIAN) months = 12.4 [7.0-21.7]",,Percentage of Participants With Complete Response (CR) or Partial Response (PR) [Overall Response Rate (ORR)] (NUMBER) percentage of participants = 41.2 [18.4-67.1],,,,,,,Overall Survival (OS) (MEDIAN) months = 34.6,Progression-Free Survival (PFS) (MEDIAN) months = 12.4 [7.0-21.7],Percentage of Participants With Complete Response (CR) or Partial Response (PR) [Overall Response Rate (ORR)] (NUMBER) percentage of participants = 41.2 [18.4-67.1],,Percentage of Participants With Complete Response (CR) or Partial Response (PR) [Overall Response Rate (ORR)] (NUMBER) percentage of participants = 41.2 [18.4-67.1],,,
NCT01168973,A Study of Chemotherapy and Ramucirumab Versus Chemotherapy Alone in Second Line Non-Small Cell Lung Cancer (NSCLC) Participants Who Received Prior Fi,"A Randomized, Double-Blind, Phase 3 Study of Docetaxel and Ramucirumab Versus Docetaxel and Placebo in the Treatment of Stage IV Non-Small Cell Lung Cancer Following Disease Progression After One Prio",Eli Lilly and Company,Eli Lilly and Company,INDUSTRY,COMPLETED,2010-12,2013-12,2016-08,INTERVENTIONAL,PHASE3,,,,Non-Small Cell Lung Cancer,Non-Small Cell Lung Cancer,1,2,3,BIOLOGICAL; DRUG,,,1,7,True,Yes,Overall Survival (MEDIAN) months = 10.5 [9.5-11.2],Progression-Free Survival (PFS) Time (MEDIAN) months = 4.5 [4.2-5.3]; Percentage of Participants Achieving an Objective Response (Objective Response Rate) (NUMBER) percentage of participants = 22.9 [19.7-26.4]; Percentage of Participants Achieving Disease Control (Disease Control Rate) (NUMBER) percentage of participants = 64.0 [60.1-67.8]; Maximum Improvement on Lung Cancer Symptom Scale (LCSS) (MEAN) mm = -10.9; Change From Baseline to 30-Day Follow-Up Visit on European Quality of Life Questionnaire-5 Dimension (EQ-5D) Health State Scores (MEAN) units on a scale = -0.140; Maximum and Minimum Serum Concentrations (Cmax and Cmin) of Ramucirumab (GEOMETRIC_MEAN) micrograms per milliliter (mcg/mL) = 262; Number of Participants With Anti-Ramucirumab Antibodies (NUMBER) participants = 9,,,,,,,,Percentage of Participants Achieving an Objective Response (Objective Response Rate) (NUMBER) percentage of participants = 22.9 [19.7-26.4],Overall Survival (MEDIAN) months = 10.5 [9.5-11.2],Progression-Free Survival (PFS) Time (MEDIAN) months = 4.5 [4.2-5.3],,Change From Baseline to 30-Day Follow-Up Visit on European Quality of Life Questionnaire-5 Dimension (EQ-5D) Health State Scores (MEAN) units on a scale = -0.140,Percentage of Participants Achieving an Objective Response (Objective Response Rate) (NUMBER) percentage of participants = 22.9 [19.7-26.4],,,
NCT01174563,A Study on the Correlation Between Tarceva (Erlotinib) - Induced Rash and Efficacy in EGFR Mutated Participants With Advanced Non-Small Cell Lung Canc,A Multi-Center Study Investigating the Correlation Between TARCEVA ®-Induced Rash and Efficacy Among EGFR-mutated NSCLC Patients Receiving First-line Therapy,Hoffmann-La Roche,Hoffmann-La Roche,INDUSTRY,COMPLETED,2011-05-23,2016-12-20,2016-12-20,INTERVENTIONAL,PHASE2,,,,Non-Squamous Non-Small Cell Lung Cancer,Non-Squamous Non-Small Cell Lung Cancer,1,1,1,DRUG,,,1,2,True,Yes,Progression-free Survival (PFS) According to Grade of Rash (MEDIAN) months = 2.16,Percentage of Participants With Erlotinib Dose Reductions Due to Rash Grade 3-4 (NUMBER) percentage of participants = 8.5; Progression-Free Survival (PFS) in Participants With Erlotinib Dose Reductions Due to Rash Grade 3-4 (MEDIAN) months = 13.72 [7.31-50.13],,,,,,,,,,Progression-free Survival (PFS) According to Grade of Rash (MEDIAN) months = 2.16; Progression-Free Survival (PFS) in Participants With Erlotinib Dose Reductions Due to Rash Grade 3-4 (MEDIAN) months = 13.72 [7.31-50.13],,,,,,
NCT01177397,"Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myelom","A Phase 1/2, Multi-Center, Open-Label, Dose Finding Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the mTOR Kinase Inhibitor CC-223 Administered Orally to Subje",Celgene,Celgene,INDUSTRY,COMPLETED,2010-07-20,2016-11-15,2016-12-09,INTERVENTIONAL,PHASE1; PHASE2,,,,Multiple Myeloma,Multiple Myeloma; Diffuse Large B-Cell Lymphoma; Glioblastoma Multiforme,7,1,1,DRUG,,,10,14,True,Yes,Part A: Number of Participants With Dose-limiting Toxicities (COUNT_OF_PARTICIPANTS) Participants = 0; Maximum Observed Plasma Concentration (Cmax) of CC-223 (GEOMETRIC_MEAN) ng/mL = 45.8; Time to Maximum Concentration (Tmax) of CC-223 (MEDIAN) Hours = 1.00 [1.00-1.00]; Area Under the Plasma Concentration-Time Curve From Time 0 to the Last Measurable Concentration (AUCt) for CC-223 (GEOMETRIC_MEAN) ng*h/mL = 318; Area Under the Concentration Time-Curve From 0-24 Hours After a Dose (AUC0-24) for CC-223 (GEOMETRIC_MEAN) ng*h/mL = 319; Area Under the Plasma Concentration-Time Curve From Time 0 Extrapolated to Infinity (AUCinf) For CC-223 (GEOMETRIC_MEAN) ng*h/mL = 353; Part A: Terminal Elimination Phase Half-Life (T1/2) of CC-223 (GEOMETRIC_MEAN) Hours = 7.68; Apparent Total Body Clearance (CL/F) of CC-223 (GEOMETRIC_MEAN) L/h = 21.2; Apparent Volume of Distribution (Vz/F) of CC-223 (GEOMETRIC_MEAN) L = 235; Part B: Progression Free Survival (PFS) Rate at 6 Months for GBM Participants (NUMBER) Percentage of participants = 0,Part A: Percent Change From Baseline in Levels of Phosphorylated Ribosomal Protein S6 (pS6RP) in Stimulated B Cells (MEDIAN) Percent change = -19.4 [-19.4--19.4]; Part A: Percent Change From Baseline in Levels of Phosphorylated Elongation I Initiation Binding Protein (p4E-BP1) in Stimulated T Cells (MEDIAN) Percent change in p4E-BP1 = -20.7 [-20.7--20.7]; Part A: Percent Change From Baseline in Levels of Phosphorylated Protein Kinase B (pAKT) in Stimulated Monocytes (MEDIAN) Percent change in pAKT = -26.9 [-26.9--26.9]; Part B: Percent Change From Baseline in p4E-BP1 in Monocytes by Tumor Cohort (MEDIAN) Percent change in p4E-BP1 = -23.5 [-100.0-157.1]; Part B: Percent Change From Baseline in p4E-BP1 in Monocytes in the HCC and NET Cohorts by Dose (MEDIAN) Percent change in p4E-BP1 = -28.3 [-100.0-127.6]; Part B: Percent Change From Baseline in Levels of pAKT in Monocytes by Tumor Cohort (MEDIAN) Percent change in pAKT = -68.1 [-86.5-43.9]; Part B: Percent Change From Baseline in Levels of pAKT in Monocytes in the HCC and NET Cohorts by Dose (MEDIAN) Percent change in pAKT = -55.5 [-86.2-27.1]; Part B: Percent Change From Baseline in pS6RP Levels in Tumor Tissue by Tumor Type (MEDIAN) Percent change in pS6RP = 22 [-37-66]; Part A: Overall Response Rate (NUMBER) Percentage of participants = 0; Part B: Overall Response Rate (NUMBER) Percentage of participants = 3.8 [0.1-19.6]; Maximum Observed Concentration (Cmax) of Metabolite M1 (GEOMETRIC_MEAN) ng/mL = 143; Time to Maximum Concentration (Tmax) of Metabolite M1 (MEDIAN) Hours = 8.00 [8.00-8.00]; Area Under the Plasma Concentration-Time Curve From Time 0 to the Last Measurable Concentration (AUCt) for Metabolite M1 (GEOMETRIC_MEAN) ng*h/mL = 4583; Area Under the Concentration Time-Curve From 0-24 Hours After a Dose (AUC0-24) for Metabolite M1 (GEOMETRIC_MEAN) ng*h/mL = 2712,,,,,,,,,,Part B: Progression Free Survival (PFS) Rate at 6 Months for GBM Participants (NUMBER) Percentage of participants = 0,,,Part A: Overall Response Rate (NUMBER) Percentage of participants = 0; Part B: Overall Response Rate (NUMBER) Percentage of participants = 3.8 [0.1-19.6],,,
NCT01183858,A Study of Tarceva (Erlotinib) to Compare Two Different Doses in in Currently Smoking Patients With Advanced or Metastatic Non-Small Cell Lung Cancer ,"A Prospective, Double-blind Randomized Phase III Study of 300 mg Versus 150 mg Erlotinib in Current Smokers With Locally Advanced or Metastatic NSCLC in Second-line Setting After Failure on Chemothera",Hoffmann-La Roche,Hoffmann-La Roche,INDUSTRY,COMPLETED,2010-10,2013-10,2014-02,INTERVENTIONAL,PHASE3,,,,Non-Small Cell Lung Cancer,Non-Small Cell Lung Cancer,1,2,1,DRUG,,,2,6,True,Yes,Progression-Free Survival (PFS) (MEDIAN) weeks = 6.86 [6.29-12.00]; Progression-Free Survival (PFS) at the End of Study (MEDIAN) weeks = 6.86 [6.29-12.00],Overall Survival (OS) (MEDIAN) months = 6.77 [5.65-8.77]; Overall Response Rate (ORR) (NUMBER) percentage of participants = 0.0 [0.0-0.0]; Disease Control Rate (DCR) (NUMBER) percentage of participants = 40.3 [32.4-48.5]; Time to Progression (TTP) (MEDIAN) weeks = 9.86 [6.43-12.14]; Number of Participants With Adverse Events (AEs) at the End of the Study (NUMBER) participants = 130; Overall Survival (OS) at the End of Study (MEDIAN) months = 7.00 [5.65-8.84],,,,,,,,,Overall Survival (OS) (MEDIAN) months = 6.77 [5.65-8.77]; Overall Survival (OS) at the End of Study (MEDIAN) months = 7.00 [5.65-8.84],Progression-Free Survival (PFS) (MEDIAN) weeks = 6.86 [6.29-12.00]; Progression-Free Survival (PFS) at the End of Study (MEDIAN) weeks = 6.86 [6.29-12.00],,,Overall Response Rate (ORR) (NUMBER) percentage of participants = 0.0 [0.0-0.0],Number of Participants With Adverse Events (AEs) at the End of the Study (NUMBER) participants = 130,,Time to Progression (TTP) (MEDIAN) weeks = 9.86 [6.43-12.14]
NCT01194453,Pemetrexed Plus Cisplatin Versus Gemcitabine Plus Cisplatin for Advanced NSCLC Metastatic Non-small Cell Lung Cancer,"A Phase 2,Open-label Study of First Line Pemetrexed Plus Cisplatin Versus Gemcitabine Plus Cisplatin for Advanced and Metastatic Non Small Cell Lung Cancer and Biomarker Study",Sun Yat-sen University,Sun Yat-sen University,OTHER,COMPLETED,2009-11,2010-09,2012-08,INTERVENTIONAL,PHASE2,,,,Non-small Cell Lung Cancer,Non-small Cell Lung Cancer; Efficacy,2,2,2,DRUG,,,1,1,True,Yes,Progression Free Survival (PFS) (MEDIAN) day = 168 [139-183],Response Rate (NUMBER) percentage = 24.41,,,,,,,,,,Progression Free Survival (PFS) (MEDIAN) day = 168 [139-183],,,Response Rate (NUMBER) percentage = 24.41,,,
NCT01204697,A Study of Erlotinib [Tarceva] as Monotherapy or Intermittent Dosing With Docetaxel in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer,A Randomized Phase II Trial of Erlotinib or Intermittent Dosing of Erlotinib and Docetaxel in Male Former-smokers With Locally Advanced or Metastatic Squamous NSCLC in Second-line Setting After Failur,Hoffmann-La Roche,Hoffmann-La Roche,INDUSTRY,COMPLETED,2010-11,2014-07,2014-07,INTERVENTIONAL,PHASE2,,,,Non-Squamous Non-Small Cell Lung Cancer,Non-Squamous Non-Small Cell Lung Cancer,1,2,3,DRUG,,,1,5,True,Yes,Percentage of Participants Free From Disease Progression or Death at 6 Months (NUMBER) percentage of participants = 8.3 [0.0-17.4],Progression-free Survival (PFS) (MEDIAN) months = 2.33 [2.13-4.13]; Overall Survival (OS) (MEDIAN) months = 5.61 [3.54-8.69]; Percentage of Participants With a Best Overall Response of Complete Response (CR) or Partial Response (PR) (NUMBER) percentage of participants = 2.8 [0.0-8.15]; Percentage of Participants With Disease Control (NUMBER) percentage of participants = 41.7 [25.6-57.8]; ,,Percentage of Participants With a Best Overall Response of Complete Response (CR) or Partial Response (PR) (NUMBER) percentage of participants = 2.8 [0.0-8.15],,,,,,,Overall Survival (OS) (MEDIAN) months = 5.61 [3.54-8.69],Progression-free Survival (PFS) (MEDIAN) months = 2.33 [2.13-4.13],Percentage of Participants With a Best Overall Response of Complete Response (CR) or Partial Response (PR) (NUMBER) percentage of participants = 2.8 [0.0-8.15],,,,,
NCT01211483,Study of Erlotinib With or Without Investigational Drug (U3-1287) in Subjects With Advanced Non-small Cell Lung Cancer,"Randomized, Placebo-controlled, Double-blind Phase 1b/2 Study of U3-1287 (AMG 888) in Combination With Erlotinib in EGFR Treatment Naïve Subjects With Advanced Non-Small Cell Lung Cancer (NSCLC) Who H",Daiichi Sankyo,Daiichi Sankyo,INDUSTRY,COMPLETED,2010-09,2013-10,2013-11-23,INTERVENTIONAL,PHASE1; PHASE2,,,,NSCLC (Advanced Non-small Cell Lung Cancer),NSCLC (Advanced Non-small Cell Lung Cancer),1,3,3,DRUG,,,3,10,True,Yes,Progression-Free Survival Following U3-1287 (AMG 888) in Combination With Erlotinib (MEDIAN) months = 1.4 [1.3-2.7]; Progression-Free Survival in Participants With High Heregulin-Expressing Tumors Following U3-1287 (AMG 888) in Combination With Erlotinib (MEDIAN) months = 3.4 [1.2-5.7]; Progression-Free Survival in Participants With Low Heregulin-Expressing Tumors Following U3-1287 (AMG 888) in Combination With Erlotinib (MEDIAN) months = 1.4 [1.1-8.5],Overall Survival Following U3-1287 (AMG 888) in Combination With Erlotinib (MEDIAN) months = 5.3 [4.0-6.9]; Objective Response Following U3-1287 (AMG 888) in Combination With Erlotinib (COUNT_OF_PARTICIPANTS) Participants = 6; Time to Objective Response Following U3-1287 (AMG 888) in Combination With Erlotinib (MEDIAN) weeks = 6.14 [5.29-6.43]; Duration of Stable Disease Following U3-1287 (AMG 888) in Combination With Erlotinib (MEDIAN) weeks = 25.14 [18.14-36.14]; Time to Disease Progression Following U3-1287 (AMG 888) in Combination With Erlotinib (MEDIAN) weeks = 9.29 [6.14-16.14]; Pharmacokinetic Parameter of Cycle 3 Patritumab Area Under the Concentration-time Curve Over the Dosing Interval 0 to τ (AUC) Following U3-1287 (AMG 888) in Combination With Erlotinib (MEAN) hour*ug/mL = 61316.6; Pharmacokinetic Parameter of Cycle 3 Patritumab Concentration End of Infusion (CEOI) and Minimum (Trough) Concentration (Cmin) Following U3-1287 (AMG 888) in Combination With Erlotinib (MEAN) ug/mL = 473.67; Erlotinib Concentrations at Cycle 3 Day 1 Following U3-1287 (AMG 888) in Combination With Erlotinib (MEAN) ng/mL = 837.42; Pharmacokinetic Parameter of Erlotinib Trough (Cmin) Concentrations From Participants Receiving 150 mg Erlotinib Following U3-1287 (AMG 888) in Combination With Erlotinib (MEAN) ng/mL = 0; Treatment-Emergent Adverse Events Occurring in ≥10% of Participants Following U3-1287 (AMG 888) in Combination With Erlotinib (COUNT_OF_PARTICIPANTS) Participants = 7,,,,,,,,,Overall Survival Following U3-1287 (AMG 888) in Combination With Erlotinib (MEDIAN) months = 5.3 [4.0-6.9],Progression-Free Survival Following U3-1287 (AMG 888) in Combination With Erlotinib (MEDIAN) months = 1.4 [1.3-2.7]; Progression-Free Survival in Participants With High Heregulin-Expressing Tumors Following U3-1287 (AMG 888) in Combination With Erlotinib (MEDIAN) months = 3.4 [1.2-5.7]; Progression-Free Survival in Participants With Low Heregulin-Expressing Tumors Following U3-1287 (AMG 888) in Combination With Erlotinib (MEDIAN) months = 1.4 [1.1-8.5],,,,Treatment-Emergent Adverse Events Occurring in ≥10% of Participants Following U3-1287 (AMG 888) in Combination With Erlotinib (COUNT_OF_PARTICIPANTS) Participants = 7,,
NCT01229150,Randomized Phase II Study of AZD6244 (Mitogen-activated Protein Kinase Inhibitor) MEK-Inhibitor With Erlotinib in KRAS Wild Type Advanced Non-Small Ce,Randomized Phase II Study of AZD6244 MEK-Inhibitor With Erlotinib in KRAS Wild Type and KRAS Mutant Advanced Non-Small Cell Lung Cancer,National Institutes of Health Clinical Center (CC),National Cancer Institute (NCI),NIH,COMPLETED,2010-10-26,2013-09-30,2015-11-21,INTERVENTIONAL,PHASE2,,,,Non Small Cell Lung Carcinoma,Non Small Cell Lung Carcinoma,1,4,3,DRUG,,,2,5,True,Yes,Progression Free Survival (MEDIAN) Months = 2.3 [2.0-4.6]; Objective Response (NUMBER) participants = 3,Number of Participants With Adverse Events (NUMBER) Participants = 49; Percentage of Participants With Disease Control/Stabilization (NUMBER) percentage of participants = 43 [25.5-52.6]; Overall Survival (MEDIAN) Months = 21.8; Percentage of Th17 in Cluster of Differentiation 4 (CD4)+T Cells at Baseline in Relation to Response (MEAN) Percentage of Th17 in CD4+T Cells = 0.19; ,,,,,,,,,Overall Survival (MEDIAN) Months = 21.8,Progression Free Survival (MEDIAN) Months = 2.3 [2.0-4.6],,,,Number of Participants With Adverse Events (NUMBER) Participants = 49,,
NCT01232452,A Study in Non-Small Cell Lung Cancer,"An Open-label, Multicenter, Randomized Phase 2 Study Evaluating the Safety and Efficacy of Cisplatin and Pemetrexed With or Without Cixutumumab as First-Line Therapy in Patients With Advanced Nonsquam",Eli Lilly and Company,Eli Lilly and Company,INDUSTRY,COMPLETED,2011-04,2013-01,2016-06,INTERVENTIONAL,PHASE2,,,,Non-Small-Cell Lung Carcinoma,Non-Small-Cell Lung Carcinoma,1,2,3,DRUG,,,1,11,True,Yes,Progression-free Survival (PFS) (MEDIAN) months = 5.45 [3.88-6.05],"Percentage of Participants Achieving an Objective Response Rate (ORR) (NUMBER) percentage of participants = 37.9 [27.7-49.0]; Overall Survival (OS) (MEDIAN) Months = 10.68; Duration of Response (DOR) (MEDIAN) Months = 4.90 [4.17-6.28]; Time to Progressive Disease (TTPS) (MEDIAN) Months = 6.05 [5.32-7.79]; Time to Worsening of Symptoms as Measured by Lung Cancer Symptom Scale (LCSS) Score (MEDIAN) Months = 2.14 [1.54-2.99]; Change in Tumor Size (CTS) (MEAN) Percent Change = -23.88; Pharmacokinetics (PK): Maximum Serum Concentration (Cmax) of Cixutumumab, Cycle 1 (First Infusion) and Cycle 4 (Fourth Infusion) (GEOMETRIC_MEAN) microgram/milliliter (ug/mL) = 481; PK: Area Under the Concentration Time Curve (AUC[0-inf]) of Cixutumumab, Cycle 1 (i.e. First Infusion) (GEOMETRIC_MEAN) microgram*hour/milliliter (ug*hr/mL) = 73200; PK: Area Under the Concentration Time Curve During 1 Dosing Interval (i.e. 504 hr, AUC(0-tau) of Cixutumumab, Cycle 4 (i.e. Fourth Infusion) (GEOMETRIC_MEAN) (ug*hr/mL) = 79700; ; ",,,,,Duration of Response (DOR) (MEDIAN) Months = 4.90 [4.17-6.28],,,Percentage of Participants Achieving an Objective Response Rate (ORR) (NUMBER) percentage of participants = 37.9 [27.7-49.0],Overall Survival (OS) (MEDIAN) Months = 10.68,Progression-free Survival (PFS) (MEDIAN) months = 5.45 [3.88-6.05],,,Percentage of Participants Achieving an Objective Response Rate (ORR) (NUMBER) percentage of participants = 37.9 [27.7-49.0],,,
NCT01243775,BELotaxel(Docetaxel) and bellOXa(Oxaliplatin) in Advanced NSCLC,Phase II Trial of First Line Docetaxel and Oxaliplatin in Stage IV or Relapsed Non-Small Cell Lung Cancer,Chonnam National University Hospital,Chonnam National University Hospital,OTHER,COMPLETED,2010-11,2013-01,2013-01,INTERVENTIONAL,PHASE2,,,,Non-Small Cell Lung Cancer,Non-Small Cell Lung Cancer,1,1,2,DRUG,,,1,3,True,Yes,Response Rate (NUMBER) participants = 11,Progression Free Survival (MEDIAN) months = 3.6 [2.8-4.5]; Overall Survival (MEDIAN) months = 10.9 [8.2-13.6]; Neutropenia Grade 3-4 (NUMBER) participants = 17,,,,,,,,,Overall Survival (MEDIAN) months = 10.9 [8.2-13.6],Progression Free Survival (MEDIAN) months = 3.6 [2.8-4.5],,,Response Rate (NUMBER) participants = 11,,,
NCT01250119,"A Study to Assess the Incidence of EGFR Mutation in Patients With Newly Diagnosed Locally Advanced or Metastatic Non-Small Cell Lung Cancer in the UK,",Assess the Incidence of Mutations in the Tyrosine Kinase Domain of the Endothelial Growth Factor Receptor in UK Patients With Newly Diagnosed Metastatic or Recurrent Non-small Cell Lung Cancer and to ,Hoffmann-La Roche,Hoffmann-La Roche,INDUSTRY,COMPLETED,2011-03,2014-05,2014-05,INTERVENTIONAL,PHASE2,,,,Non-Squamous Non-Small Cell Lung Cancer,Non-Squamous Non-Small Cell Lung Cancer,1,1,1,DRUG,,,2,9,True,Yes,Percentage of Participants Who Tested Positive for EGFR Mutations (NUMBER) percentage of participants = 8.1; Percentage of Participants With EGFR Mutations by Subgroup (NUMBER) percentage of participants = 0.0,Percentage of Participants With a Response by Best Objective Tumor Response (NUMBER) percentage of participants = 0.0; Probability of Being Alive and Free of Progression by Timepoint (NUMBER) probability of being alive = 1.00 [1.00-1.00]; Survival Time in Months (MEDIAN) months = 12.57 [10.10-16.53]; Quality of Life Assessment Using EuroQol(EQ) 5D Visual Analog Score (VAS) Instrument (MEAN) mm = 62.6; Percentage of Participants With Problems With Mobility as Assessed Using the EQ-5D (NUMBER) percentage of participants = 43.9; Percentage of Participants With Problems With Self-Care as Assessed Using the EQ-5D (NUMBER) percentage of participants = 78.0; Percentage of Participants With Problems With Usual Activities as Assessed Using the EQ-5D (NUMBER) percentage of participants = 39.0; Percentage of Participants With Pain/Discomfort as Assessed Using the EQ-5D (NUMBER) percentage of participants = 29.3; Percentage of Participants With Anxiety/Depression as Assessed Using the EQ-5D (NUMBER) percentage of participants = 52.5,,,,,,,,,,,,Quality of Life Assessment Using EuroQol(EQ) 5D Visual Analog Score (VAS) Instrument (MEAN) mm = 62.6,,,,
NCT01259089,Hsp90 Inhibitor AUY922 and Erlotinib Hydrochloride in Treating Patients With Stage IIIB-IV Non-Small Cell Lung Cancer,"A Phase I/II Trial of Hsp 90 Inhibitor AUY-922 in Patients With Lung Adenocarcinoma With ""Acquired Resistance"" to EGFR Tyrosine Kinase Inhibitors",Northwestern University,Northwestern University,OTHER,COMPLETED,2011-04-27,2013-06-04,2014-09-29,INTERVENTIONAL,PHASE1; PHASE2,,,,Adenocarcinoma of the Lung,Adenocarcinoma of the Lung; Non-small Cell Lung Cancer,2,1,6,DRUG; GENETIC; OTHER; PROCEDURE,,,2,5,True,Yes,"Maximally Tolerated Dose (MTD) of AUY922 and Erlotinib Treatment Combination (Phase I) (NUMBER) Number of DLTs seen = 0; Overall Response Rate (ORR), Defined as Complete Response(CR) + Partial Response (PR) Using the Modified RECIST 1.1 Criteria for All Patients Treated at Dose of 70mg/m2 AUG922 (COUNT_OF_PARTICIPANTS) Participants = 4",Toxicity as Assessed by NCI CTCAE Version 4.00 When AUG922 Administered at Its MTD (Phase I and II) (NUMBER) participants = 24; Incidence of Reported Adverse Events in Phase I (NUMBER) participants = 11; Progression-free Survival (Phase II) (MEDIAN) Months = 1.7 [1.1-4.9]; Overall Survival (Phase II) (MEDIAN) Months = 7.4 [4.0-17.9]; ,,"Overall Response Rate (ORR), Defined as Complete Response(CR) + Partial Response (PR) Using the Modified RECIST 1.1 Criteria for All Patients Treated at Dose of 70mg/m2 AUG922 (COUNT_OF_PARTICIPANTS) Participants = 4",,,,,,,Overall Survival (Phase II) (MEDIAN) Months = 7.4 [4.0-17.9],Progression-free Survival (Phase II) (MEDIAN) Months = 1.7 [1.1-4.9],"Overall Response Rate (ORR), Defined as Complete Response(CR) + Partial Response (PR) Using the Modified RECIST 1.1 Criteria for All Patients Treated at Dose of 70mg/m2 AUG922 (COUNT_OF_PARTICIPANTS) Participants = 4",,"Overall Response Rate (ORR), Defined as Complete Response(CR) + Partial Response (PR) Using the Modified RECIST 1.1 Criteria for All Patients Treated at Dose of 70mg/m2 AUG922 (COUNT_OF_PARTICIPANTS) Participants = 4",Toxicity as Assessed by NCI CTCAE Version 4.00 When AUG922 Administered at Its MTD (Phase I and II) (NUMBER) participants = 24; Incidence of Reported Adverse Events in Phase I (NUMBER) participants = 11,,
NCT01260181,A Study of Erlotinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor Mutations,"Phase II, Open-Label Study of Erlotinib (Tarceva®) Treatment in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Present Activating Mutations in the Tyrosine Kinase Domain o",Hoffmann-La Roche,Hoffmann-La Roche,INDUSTRY,COMPLETED,2011-03-31,2017-09-29,2017-09-29,INTERVENTIONAL,PHASE2,,,,Non-Squamous Non-Small Cell Lung Cancer,Non-Squamous Non-Small Cell Lung Cancer,1,1,1,DRUG,,,1,5,True,Yes,Percentage of Participants With Objective Response (Complete Response [CR]/Partial Response [PR]) Based on Computer Tomography (CT) or Magnetic Resonance Imaging (MRI) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1 (NUMBER) percentage of participants = 63.3 [46.1-80.6],Progression Free Survival (PFS) Based on CT or MRI According to RECIST v 1.1 (MEDIAN) weeks = 40 [31-63]; Overall Survival (MEDIAN) weeks = 83 [56-125]; Percentage of Participants With Adverse Events (NUMBER) percentage of participants = 29; Percentage of Participants With Epidermal Growth Factor Receptor (EGFR) Mutation in Study Population (NUMBER) percentage of participants = 40; Median Time Taken From the First Response Until Disease Progression Based on RECIST v 1.1 as Determined by the Investigator (MEDIAN) weeks = 41.5 [32-63],,Percentage of Participants With Objective Response (Complete Response [CR]/Partial Response [PR]) Based on Computer Tomography (CT) or Magnetic Resonance Imaging (MRI) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1 (NUMBER) percentage of participants = 63.3 [46.1-80.6],,,,,,,Overall Survival (MEDIAN) weeks = 83 [56-125],Progression Free Survival (PFS) Based on CT or MRI According to RECIST v 1.1 (MEDIAN) weeks = 40 [31-63],Percentage of Participants With Objective Response (Complete Response [CR]/Partial Response [PR]) Based on Computer Tomography (CT) or Magnetic Resonance Imaging (MRI) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1 (NUMBER) percentage of participants = 63.3 [46.1-80.6],,,Percentage of Participants With Adverse Events (NUMBER) percentage of participants = 29,,
NCT01281124,Azacitidine in Treating Patients With Previously Treated Advanced Non-Small Cell Lung Cancer,Pilot Phase II Study of 5-Azacytidine in Previously Treated Patients With Advanced NSCLC,National Cancer Institute (NCI),National Cancer Institute (NCI),NIH,COMPLETED,2011-01-12,2011-04-15,2012-09-12,INTERVENTIONAL,PHASE2,,,,Recurrent Lung Non-Small Cell Carcinoma,Recurrent Lung Non-Small Cell Carcinoma; Stage IV Lung Non-Small Cell Cancer AJCC v7,2,1,3,DRUG; OTHER,,,1,2,True,Yes,,; ,,,,,,,,,,,,,,,,
NCT01285609,Phase 3 Trial in Squamous Non Small Cell Lung Cancer Subjects Comparing Ipilimumab Versus Placebo in Addition to Paclitaxel and Carboplatin,"Randomized, Multicenter, Double-Blind, Phase 3 Trial Comparing the Efficacy of Ipilimumab in Addition to Paclitaxel and Carboplatin Versus Placebo in Addition to Paclitaxel and Carboplatin in Subjects",Bristol-Myers Squibb,Bristol-Myers Squibb,INDUSTRY,COMPLETED,2011-01-16,2015-06-09,2017-08-22,INTERVENTIONAL,PHASE3,,,,Lung Cancer - Non Small Cell Squamous,Lung Cancer - Non Small Cell Squamous,1,2,4,DRUG,,,1,2,True,Yes,Overall Survival (OS) in Participants Who Received at Least One Dose of Blinded Study Therapy at Primary Endpoint (MEDIAN) months = 13.37 [11.76-14.78],Overall Survival (OS) in All Randomized Participants at Primary Endpoint (MEDIAN) months = 10.94 [9.56-12.02]; Median Number of Months With Progression Free Survival (PFS) Per mWHO in Participants Who Have Received at Least One Dose of Blinded Study Therapy at Primary Endpoint (MEDIAN) months = 5.55 [5.36-5.85],,,,,,,,,Overall Survival (OS) in Participants Who Received at Least One Dose of Blinded Study Therapy at Primary Endpoint (MEDIAN) months = 13.37 [11.76-14.78]; Overall Survival (OS) in All Randomized Participants at Primary Endpoint (MEDIAN) months = 10.94 [9.56-12.02],Median Number of Months With Progression Free Survival (PFS) Per mWHO in Participants Who Have Received at Least One Dose of Blinded Study Therapy at Primary Endpoint (MEDIAN) months = 5.55 [5.36-5.85],,,,,,
NCT01291017,"Cyclin Dependent Kinase (CDK)4/6 Inhibitor, PD0332991 in Advanced Non-small Cell Lung Cancer NSCLC.","A Phase II Clinical Trail of the Cyclin Dependent Kinase (CDK)4/6 Inhibitor, PD0332991 in Previously Treated, Advanced NSCLC Patients With Wildtype Retinoblastoma Protein (RB) and Inactive Cyclin Depe",University of Florida,University of Florida,OTHER,COMPLETED,2011-02,2014-02,2015-02,INTERVENTIONAL,PHASE2,,,,Non-small Cell Lung Cancer,Non-small Cell Lung Cancer,1,1,1,DRUG,,,1,4,True,Yes,Tumor Response by Direct RECIST Measurement (NUMBER) participants = 0,Overall Survival (MEDIAN) weeks = 20.3; Progression-free Survival (MEDIAN) Weeks = 8; ; Grade of Study Drug Toxicity (NUMBER) Events = 9,,,,,,,,,Overall Survival (MEDIAN) weeks = 20.3,Progression-free Survival (MEDIAN) Weeks = 8,,,,Grade of Study Drug Toxicity (NUMBER) Events = 9,,
NCT01294306,MK2206 and Erlotinib Hydrochloride in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Progressed After Previous Response to Erloti,Phase II Trial of the Akt Inhibitor MK-2206 Plus Erlotinib (OSI-774) in Patients With Advanced Non-small Cell Lung Cancer Who Have Progressed After Previous Response (Including Stable Disease) With Er,National Cancer Institute (NCI),National Cancer Institute (NCI),NIH,COMPLETED,2011-02,2015-08,2015-08,INTERVENTIONAL,PHASE2,,,,Adenosquamous Lung Carcinoma,Adenosquamous Lung Carcinoma; Bronchioloalveolar Carcinoma; Large Cell Lung Carcinoma,6,1,4,DRUG; OTHER,,,2,3,True,Yes,Disease-control Rate (NUMBER) percentage of subjects = 40; Objective Response (NUMBER) percentage of subjects = 9,Median Progression-free Survival (MEDIAN) Months = 4.4 [2.7-6.6]; Toxicity of Akt Inhibitor MK2206 Plus Erlotinib Hydrochloride (NUMBER) participants = 0; Median Overall Survival (MEDIAN) Months = 10.6 [8.6-23.2],,,,,,,,,Median Overall Survival (MEDIAN) Months = 10.6 [8.6-23.2],Median Progression-free Survival (MEDIAN) Months = 4.4 [2.7-6.6],,,,Toxicity of Akt Inhibitor MK2206 Plus Erlotinib Hydrochloride (NUMBER) participants = 0,,
NCT01297491,Safety and Efficacy of BKM120 in Patients With Metastatic Non-small Cell Lung Cancer,An Open Label Two-stage Study of Orally Administered BKM120 in Patients With Metastatic Non-small Cell Lung Cancer With Activated PI3K Pathway,Novartis,Novartis Pharmaceuticals,INDUSTRY,COMPLETED,2011-05,2014-10,2014-10,INTERVENTIONAL,PHASE2,,,,Non-small Cell Lung Cancer,Non-small Cell Lung Cancer,1,2,1,DRUG,,,1,5,True,Yes,Progression Free Survival (PFS) Rate as Per Investigator Local Review Measured Using RECIST 1.1 of Patients at Week 12 (NUMBER) Percentage of participants = 23.3 [9.9-42.3],Overall Survival (OS) Using Kaplan-Meier Estimates (MEDIAN) Months = 7.98 [5.95-10.09]; Overall Response Rate (ORR) Based on Investigator Assessment (NUMBER) Percentage of participants = 3.3; Disease Control Rate (DCR) (NUMBER) Percentage of participants = 46.7; Time to Response (TTR) (NUMBER) Days = 41; Duration of Response (DoR) (NUMBER) Days = 73,,,,,Duration of Response (DoR) (NUMBER) Days = 73,,,,Overall Survival (OS) Using Kaplan-Meier Estimates (MEDIAN) Months = 7.98 [5.95-10.09],Progression Free Survival (PFS) Rate as Per Investigator Local Review Measured Using RECIST 1.1 of Patients at Week 12 (NUMBER) Percentage of participants = 23.3 [9.9-42.3],,,Overall Response Rate (ORR) Based on Investigator Assessment (NUMBER) Percentage of participants = 3.3,,,
NCT01310036,A Study of Tarceva (Erlotinib) as First Line Therapy in Participants With Non-Small Cell Lung Cancer Harbouring Epidermal Growth Factor Receptor (EGFR,An Open-Label Multicenter Study of Erlotinib (Tarceva®) as First Line Therapy Until and Beyond RECIST Progression in NSCLC Patients Who Harbour EGFR Mutations,Hoffmann-La Roche,Hoffmann-La Roche,INDUSTRY,COMPLETED,2011-04-30,2014-02-14,2016-12-30,INTERVENTIONAL,PHASE2,,,,Non-Squamous Non-Small Cell Lung Cancer,Non-Squamous Non-Small Cell Lung Cancer,1,1,1,DRUG,,,1,7,True,Yes,"Progression-free Survival Per RECIST, v. 1.1 (PFS1) (MEDIAN) months = 11.000 [9.267-11.200]","Progression-free Survival Per Investigator (PFS2) (MEDIAN) months = 15.000 [13.067-18.700]; Objective Response Rate (ORR) for All Participants and Participants With EGFR Mutation E19del or L858R (NUMBER) percentage of participants = 72.3 [64.3-79.3]; Disease Control Rate (DCR) for All Participants and Participants With EGFR Mutation E19del or L858R (NUMBER) percentage of participants = 84.5 [77.6-89.9]; Progression-free Survival for Participants With EGFR Mutation E19del or L858R Per RECIST, v. 1.1 (PFS1) (MEDIAN) months = 11.000 [9.267-11.200]; Overall Survival (OS) for All Participants and Participants With EGFR Mutation E19del or L858R (MEDIAN) months = 31.633 [28.100-36.133]; Number of Participants With Adverse Events (NUMBER) participants = 206; ",,,,,,,,Objective Response Rate (ORR) for All Participants and Participants With EGFR Mutation E19del or L858R (NUMBER) percentage of participants = 72.3 [64.3-79.3],Overall Survival (OS) for All Participants and Participants With EGFR Mutation E19del or L858R (MEDIAN) months = 31.633 [28.100-36.133],"Progression-free Survival Per RECIST, v. 1.1 (PFS1) (MEDIAN) months = 11.000 [9.267-11.200]; Progression-free Survival Per Investigator (PFS2) (MEDIAN) months = 15.000 [13.067-18.700]; Progression-free Survival for Participants With EGFR Mutation E19del or L858R Per RECIST, v. 1.1 (PFS1) (MEDIAN) months = 11.000 [9.267-11.200]",,,Objective Response Rate (ORR) for All Participants and Participants With EGFR Mutation E19del or L858R (NUMBER) percentage of participants = 72.3 [64.3-79.3],Number of Participants With Adverse Events (NUMBER) participants = 206,,
NCT01327612,Open Label Extension Study of Conatumumab and Ganitumab (AMG 479),A Phase 2 Open Label Extension Study of Conatumumab and AMG 479,Amgen,Amgen,INDUSTRY,COMPLETED,2011-03-03,2020-02-05,2020-02-05,INTERVENTIONAL,PHASE2,,,,Advanced Solid Tumors,Advanced Solid Tumors; Carcinoid; Colorectal Cancer,9,4,4,BIOLOGICAL; DRUG,,,2,5,True,Yes,Number of Participants With Adverse Events (COUNT_OF_PARTICIPANTS) Participants = 2; Number of Participants With Serious Adverse Events (COUNT_OF_PARTICIPANTS) Participants = 1,Maximum Change From Baseline in Blood Pressure (MEAN) mmHg = 5.5; Minimum Change From Baseline in Blood Pressure (MEAN) mmHg = -28.5; Number of Participants With CTCAE Grade 3 or Higher Clinical Laboratory Toxicities (COUNT_OF_PARTICIPANTS) Participants = 0; Best Overall Response (COUNT_OF_PARTICIPANTS) Participants = 0; Number of Participants With Disease Progression or Death Due to Disease Progression (COUNT_OF_PARTICIPANTS) Participants = 1,,,,,,,,,,,,,,Number of Participants With Adverse Events (COUNT_OF_PARTICIPANTS) Participants = 2; Number of Participants With Serious Adverse Events (COUNT_OF_PARTICIPANTS) Participants = 1,,
NCT01328951,A Study of First-line Maintenance Erlotinib Versus Erlotinib at Disease Progression in Participants With Advanced Non-Small Cell Lung Cancer (NSCLC) W,"A Randomized, Double-Blind, Placebo-Controlled Phase III Study of First-Line Maintenance Tarceva Versus Tarceva at the Time of Disease Progression in Patients With Advanced Non-Small Cell Lung Cancer ",Hoffmann-La Roche,Hoffmann-La Roche,INDUSTRY,COMPLETED,2011-09,2015-12,2016-01,INTERVENTIONAL,PHASE3,,,,Non-Squamous Non-Small Cell Lung Cancer,Non-Squamous Non-Small Cell Lung Cancer,1,2,3,DRUG,,,3,6,True,Yes,Percentage of Participants Who Died During the Overall Study (NUMBER) percentage of participants = 73.2; Overall Survival (OS) as Median Time to Event During the Overall Study (MEDIAN) months = 9.46 [8.38-11.33]; Percentage of Participants Event-Free (Alive) at 1 Year During the Overall Study (NUMBER) percentage of participants = 41.75 [36.20-47.30],"Percentage of Participants Who Died or Experienced Disease Progression During Blinded Treatment (NUMBER) percentage of participants = 95.0; Progression-Free Survival (PFS) as Median Time to Event During Blinded Treatment (MEDIAN) weeks = 12.00 [11.71-12.29]; Percentage of Participants Event-Free (Alive and No Disease Progression) at 6 Months During Blinded Treatment (NUMBER) percentage of participants = 24.22 [19.50-28.94]; Percentage of Participants With Complete Response (CR) or Partial Response (PR) According to RECIST During Blinded Treatment (NUMBER) percentage of participants = 3.7 [1.95-6.44]; Percentage of Participants by Best Overall Response According to RECIST During Blinded Treatment (NUMBER) percentage of participants = 0.6 [0.08-2.23]; Percentage of Participants With CR, PR, or SD According to RECIST During Blinded Treatment (NUMBER) percentage of participants = 59.2 [53.59-64.62]",,Percentage of Participants With Complete Response (CR) or Partial Response (PR) According to RECIST During Blinded Treatment (NUMBER) percentage of participants = 3.7 [1.95-6.44],,,,,,,Overall Survival (OS) as Median Time to Event During the Overall Study (MEDIAN) months = 9.46 [8.38-11.33],Progression-Free Survival (PFS) as Median Time to Event During Blinded Treatment (MEDIAN) weeks = 12.00 [11.71-12.29],Percentage of Participants With Complete Response (CR) or Partial Response (PR) According to RECIST During Blinded Treatment (NUMBER) percentage of participants = 3.7 [1.95-6.44],,,,,
NCT01342965,A Study of Erlotinib (Tarceva) Versus Gemcitabine/Cisplatin as First-line Treatment in Patients With Non-small Cell Lung Cancer With EGFR Mutations,"A Multicenter, Open-label, Randomized Phase III Study to Evaluate the Efficacy and Safety of Erlotinib (Tarceva®) Versus Gemcitabine/Cisplatin as the First-line Treatment for Stage IIIB/IV Non-small C",Hoffmann-La Roche,Hoffmann-La Roche,INDUSTRY,COMPLETED,2011-03,2012-07,2014-04,INTERVENTIONAL,PHASE3,,,,Non-Small Cell Lung Cancer,Non-Small Cell Lung Cancer,1,2,2,DRUG,,,1,6,True,Yes,Investigator-assessed Duration of Progression-free Survival (MEDIAN) Months = 11.0,Percentage of Responders as Assessed by the Investigator (NUMBER) Percentage of responders = 68.2; Percentage of Participants With Disease Control (NUMBER) Percentage of participants = 91.8; Duration of Response (MEDIAN) Months = 10.8 [7.0-12.6]; Overall Survival (MEDIAN) Months = 28.9 [25.8-30.5]; ; ,,,,,Duration of Response (MEDIAN) Months = 10.8 [7.0-12.6],,,,Overall Survival (MEDIAN) Months = 28.9 [25.8-30.5],Investigator-assessed Duration of Progression-free Survival (MEDIAN) Months = 11.0,,,,,,
NCT01351415,A Study of Bevacizumab in Combination With Standard of Care Treatment in Participants With Advanced Non-squamous Non-small Cell Lung Cancer (NSCLC),"An Open-label, Randomized, Phase IIIb Trial Evaluating the Efficacy and Safety of Standard of Care +/- Continuous Bevacizumab Treatment Beyond Progression of Disease (PD) in Patients With Advanced Non",Hoffmann-La Roche,Hoffmann-La Roche,INDUSTRY,COMPLETED,2011-06-25,2016-06-25,2016-06-25,INTERVENTIONAL,PHASE3,,,,Non-Squamous Non-Small Cell Lung Cancer,Non-Squamous Non-Small Cell Lung Cancer,1,2,4,DRUG,,,1,7,True,Yes,Overall Survival (OS) (MEDIAN) Months = 11.86 [10.22-13.67],"Progression-free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) (MEDIAN) Months = 5.45 [4.21-5.68]; Percentage of Participants With Objective Response According to RECIST v1.1 (NUMBER) Percentage of Participants = 8.6 [5.86-12.21]; Percentage of Participants With Disease Control According to RECIST v1.1 (NUMBER) Percentage of Participants = 80.2 [75.57-84.36]; Duration of Response (DoR) According to RECIST v1.1 (MEDIAN) Months = 7.46 [5.39-8.54]; Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) (NUMBER) Percentage of Participants = 97.5; Time to Progression (TTP) According to RECIST v1.1 (MEDIAN) Months = 5.55 [4.86-6.18]; Percentage of Participants Who Are Alive at Month 6, 12, and 18 (NUMBER) Percentage of Participants = 0.8 [0.73-0.82]",,,,,Duration of Response (DoR) According to RECIST v1.1 (MEDIAN) Months = 7.46 [5.39-8.54],,,,Overall Survival (OS) (MEDIAN) Months = 11.86 [10.22-13.67],Progression-free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) (MEDIAN) Months = 5.45 [4.21-5.68],,,,Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) (NUMBER) Percentage of Participants = 97.5,,Time to Progression (TTP) According to RECIST v1.1 (MEDIAN) Months = 5.55 [4.86-6.18]
NCT01355484,Phase III Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC),"Phase III, Randomized, Double-Blind, Placebo Controlled Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer on First Line Platinum Plus a Taxane Chemotherapy",GTx,GTx,INDUSTRY,COMPLETED,2011-07,2013-05,2014-06,INTERVENTIONAL,PHASE3,,,,Muscle Wasting,Muscle Wasting; Non Small Cell Lung Cancer,2,2,2,DRUG,,,2,0,True,Yes,Physical Function (NUMBER) percentage of subjects = 29.4 [22.4-37.1]; Lean Body Mass (NUMBER) percentage of subjects = 41.9 [34.1-49.9],,,,,,,,,,,,,,,,,
NCT01355497,Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC) on First Line Platinum,"Phase III, Randomized, Double-Blind, Placebo-Controlled Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer on First Line Platinum Plus a Non-Taxane Chemothera",GTx,GTx,INDUSTRY,COMPLETED,2011-07,2013-05,2014-06,INTERVENTIONAL,PHASE3,,,,Muscle Wasting,Muscle Wasting; Non-Small Cell Lung Cancer,2,2,2,DRUG,,,2,0,True,Yes,Physical Function (NUMBER) percentage of subjects = 19.5 [13.6-26.5]; Lean Body Mass (NUMBER) percentage of subjects = 46.5 [38.6-54.6],,,,,,,,,,,,,,,,,
NCT01360554,ARCHER 1009 : A Study Of Dacomitinib (PF-00299804) Vs. Erlotinib In The Treatment Of Advanced Non-Small Cell Lung Cancer,"Archer 1009:a Randomized, Double Blind Phase 3 Efficacy And Safety Study Of Pf-00299804 (Dacomitinib) Versus Erlotinib For The Treatment Of Advanced Non-small Cell Lung Cancer Following Progression Af",Pfizer,Pfizer,INDUSTRY,COMPLETED,2011-06-16,2013-09-30,2015-09-14,INTERVENTIONAL,PHASE3,,,,Non-Small Cell Lung Cancer,Non-Small Cell Lung Cancer,1,2,4,DRUG,,,2,15,True,Yes,Progression-Free Survival (PFS) Per Independent Radiologic Review. (MEDIAN) Months = 2.6 [1.9-2.8]; Progression-Free Survival (PFS) Per Independent Radiologic Review in KRAS Wild-type (WT) Participants. (MEDIAN) Months = 2.6 [1.9-2.9],"PFS Based on Investigator Review. (MEDIAN) Months = 1.9 [1.9-2.6]; PFS Based on Investigator Review in KRAS-WT Participants. (MEDIAN) Months = 1.9 [1.8-2.7]; Overall Survival (OS). (MEDIAN) Months = 7.9 [6.8-9.0]; OS in KRAS-WT Participants. (MEDIAN) Months = 8.1 [6.7-9.4]; Best Overall Response (BOR) Per Independent Radiologic Review. (NUMBER) Participants = 6; BOR Per Investigator Review. (NUMBER) Participants = 2; Duration of Response (DR) Based on Independent Radiologic Review. (MEDIAN) Months = 9.2 [6.9-20.2]; DR Based on Investigator Review. (MEDIAN) Months = 10.4 [7.4-16.6]; Trough Concentrations (Ctrough) of Dacomitinib. (GEOMETRIC_MEAN) Trough Plasma Concentration (ng/mL) = 61.0102; Trough Concentrations (Ctrough) of PF-05199265. (GEOMETRIC_MEAN) Trough Plasma Concentration (ng/mL) = 6.3695; Time to Deterioration (TTD) in Pain, Dyspnea, Fatigue or Cough Patient Reported Disease Symptoms. (MEDIAN) Months = 1.0 [1.0-1.9]; Mean and Difference in Mean in Functioning and Global Quality of Life (QOL) as Assessed by the European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC-QLQ-C30) (MEAN) Units on a scale. = 56.4068 [54.631-58.183]; Mean and Difference in Mean in QLQ-C30 Symptoms as Assessed by the EORTC-QLQ-C30. (MEAN) Units on a scale. = 28.5960 [25.841-31.351]; Mean and Difference in Mean in Lung Cancer Symptom Scores as Assessed by the EORTC QLQ- LC13. (MEAN) Units on a scale. = 10.1934 [8.360-12.027]; Mean and Difference in Mean of the EuroQoL-5 Dimensions (EQ-5D) Visual Analogue Scale (VAS) Score (MEAN) Units on a scale. = 65.1908 [63.519-66.863]",,,,,Duration of Response (DR) Based on Independent Radiologic Review. (MEDIAN) Months = 9.2 [6.9-20.2],,,,Overall Survival (OS). (MEDIAN) Months = 7.9 [6.8-9.0]; OS in KRAS-WT Participants. (MEDIAN) Months = 8.1 [6.7-9.4],Progression-Free Survival (PFS) Per Independent Radiologic Review. (MEDIAN) Months = 2.6 [1.9-2.8]; Progression-Free Survival (PFS) Per Independent Radiologic Review in KRAS Wild-type (WT) Participants. (MEDIAN) Months = 2.6 [1.9-2.9]; PFS Based on Investigator Review. (MEDIAN) Months = 1.9 [1.9-2.6]; PFS Based on Investigator Review in KRAS-WT Participants. (MEDIAN) Months = 1.9 [1.8-2.7],,Mean and Difference in Mean in Functioning and Global Quality of Life (QOL) as Assessed by the European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC-QLQ-C30) (MEAN) Units on a scale. = 56.4068 [54.631-58.183],,,,
NCT01362296,An Open-label Study of GSK1120212 Compared With Docetaxel in Stage IV KRAS-mutant Non-small Cell Lung Cancer,"A Phase II, Open-label, Multicenter, Randomized Study to Assess the Efficacy and Safety of GSK1120212 Compared With Docetaxel in 2nd Line Subjects With Targeted Mutations (KRAS, NRAS, BRAF, MEK1) in L",GlaxoSmithKline,GlaxoSmithKline,INDUSTRY,COMPLETED,2011-09,2012-09,2013-09,INTERVENTIONAL,PHASE2,,,,"Lung Cancer, Non-Small Cell","Lung Cancer, Non-Small Cell",1,2,2,DRUG,,,1,19,True,Yes,Progression-Free Survival (PFS) as Assessed by the Investigator (INV) (MEDIAN) Weeks = 11.7 [7.0-12.4],Number of Participants With the Indicated Worst-case On-therapy Change From Baseline in the Indicated Clinical Chemistry Parameters: Randomized Phase (NUMBER) Participants = 57; Number of Participants With the Indicated Worst-case On-therapy Change From Baseline in the Indicated Clinical Chemistry Parameters: Crossover Phase (NUMBER) Participants = 15; Number of Participants With the Indicated Worst-case On-therapy Change From Baseline in the Indicated Hematology Parameters: Randomized Phase (NUMBER) Participants = 0; Number of Participants With the Indicated Worst-case On-therapy Change From Baseline in the Indicated Hematology Parameters: Crossover Phase (NUMBER) Participants = 0; Number of Participants With the Indicated Worst-case On-therapy Change From Baseline With Respect to Normal Ranges in the Indicated Clinical Chemistry Parameters: Randomized Phase (NUMBER) Participants = 1; Number of Participants With the Indicated Worst-case On-therapy Change From Baseline With Respect to Normal Ranges in the Indicated Clinical Chemistry Parameters: Crossover Phase (NUMBER) Participants = 0; Number of Participants With the Indicated Worst-case On-therapy Change From Baseline With Respect to Normal Ranges in the Indicated Hematology Parameters: Randomized Phase (NUMBER) Participants = 0; Number of Participants With the Indicated Worst-case On-therapy Change From Baseline With Respect to Normal Ranges in the Indicated Hematology Parameters: Crossover Phase (NUMBER) Participants = 0; Number of Participants With Any Serious Adverse Event (SAE) or Non-serious Adverse Event (AE): Randomized Phase (NUMBER) Participants = 87; Number of Participants With Any SAE or Non-serious AE: Crossover Phase (NUMBER) Participants = 22; Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP): Randomized Phase (MEAN) millimeters of mercury (mmHg) = 13.5; Change From Baseline in SBP and DBP: Crossover Phase (MEAN) mmHg = 8.7; Change From Baseline in Heart Rate: Randomized Phase (MEAN) Beats per minute = 10.4; Change From Baseline in Heart Rate: Crossover Phase (MEAN) Beats per minute = 8.5; Number of Participants With a Best Response of Either a Complete Response (CR) or Partial Response (PR) as Assessed by the Investigator: Randomized Phase (NUMBER) Participants = 0; Number of Participants With a Best Response of Either a CR or PR as Assessed by the Investigator: Crossover Phase (NUMBER) Participants = 0; Duration of Response (DOR) as Assessed by the Investigator: Randomized Phase (MEAN) Weeks = 6.7; Overall Survival (OS) (MEDIAN) Months = 8.1 [6.8-10.0]; GSK1120212 Plasma Pharmacokinetic (PK) Concentration (MEAN) Nanograms (ng)/milliliter (mL) = 16.1,,Number of Participants With a Best Response of Either a Complete Response (CR) or Partial Response (PR) as Assessed by the Investigator: Randomized Phase (NUMBER) Participants = 0; Number of Participants With a Best Response of Either a CR or PR as Assessed by the Investigator: Crossover Phase (NUMBER) Participants = 0,,,Duration of Response (DOR) as Assessed by the Investigator: Randomized Phase (MEAN) Weeks = 6.7,,,,Overall Survival (OS) (MEDIAN) Months = 8.1 [6.8-10.0],Progression-Free Survival (PFS) as Assessed by the Investigator (INV) (MEDIAN) Weeks = 11.7 [7.0-12.4],Number of Participants With a Best Response of Either a Complete Response (CR) or Partial Response (PR) as Assessed by the Investigator: Randomized Phase (NUMBER) Participants = 0; Number of Participants With a Best Response of Either a CR or PR as Assessed by the Investigator: Crossover Phase (NUMBER) Participants = 0,,,Number of Participants With Any SAE or Non-serious AE: Crossover Phase (NUMBER) Participants = 22,,
NCT01372384,"A Study of Tarceva (Erlotinib) in Patients With Locally Advanced, Metastatic or Recurrent Non-Small Cell Cancer Who Present Epidermal Growth Factor Re","Phase II, Open-label Study of Erlotinib (Tarceva®) Treatment in Patients With Locally Advanced, Metastatic or Recurrent Non-small Cell Lung Cancer Who Present Activating Mutations in the Tyrosine Kina",Hoffmann-La Roche,Hoffmann-La Roche,INDUSTRY,COMPLETED,2012-01,2014-01,2014-01,INTERVENTIONAL,PHASE2,,,,Non-Squamous Non-Small Cell Lung Cancer,Non-Squamous Non-Small Cell Lung Cancer,1,1,1,DRUG,,,1,3,True,Yes,Progression-free Survival (Tumour Assessments According to RECIST Criteria) (MEDIAN) Days = 223 [137-297],Objective Response Rate (Investigator Assessed) (NUMBER) Percentage = 83.3 [35.87-99.58]; Safety: Incidence of Adverse Events (NUMBER) participants = 6; Overall Survival (MEDIAN) Days = 401 [160-670],,,,,,,,Objective Response Rate (Investigator Assessed) (NUMBER) Percentage = 83.3 [35.87-99.58],Overall Survival (MEDIAN) Days = 401 [160-670],Progression-free Survival (Tumour Assessments According to RECIST Criteria) (MEDIAN) Days = 223 [137-297],,,Objective Response Rate (Investigator Assessed) (NUMBER) Percentage = 83.3 [35.87-99.58],Safety: Incidence of Adverse Events (NUMBER) participants = 6,,
NCT01378962,A Study of Tarceva (Erlotinib) in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (TRIGGER),"Phase II, Open-label Study of Erlotinib (Tarceva®) Treatment in Patients With Locally Advanced or Metastatic Non-small-cell Lung Cancer Who Present Activating Mutations in the Tyrosine Kinase Domain o",Hoffmann-La Roche,Hoffmann-La Roche,INDUSTRY,COMPLETED,2011-03-31,2013-06-30,2017-01-31,INTERVENTIONAL,PHASE2,,,,Non-Squamous Non-Small Cell Lung Cancer,Non-Squamous Non-Small Cell Lung Cancer,1,1,1,DRUG,,,3,7,True,Yes,Percentage of Participants With Disease Progression or Death at 12 Months After Baseline (NUMBER) percentage of participants = 42; Progression-Free Survival (PFS) (MEDIAN) months = 12.58 [10.25-16.95]; Probability of Being Progression Free 12 Months After Baseline (MEAN) probability of being progression-free = 0.51,"Percentage of Participants Who Died (NUMBER) percentage of participants = 28; Overall Survival (OS) (MEAN) months = 17.48; Percentage of Participants With a Response by Best Overall Response (NUMBER) percentage of participants = 6; Percentage of Participants With Objective Response (NUMBER) percentage of participants = 68 [53-80]; Percentage of Participants Achieving CR, PR, or SD as Best Overall Response (NUMBER) percentage of participants = 80 [66-90]; Percentage of Participants With Primary and Secondary Resistance (NUMBER) percentage of participants = 8.33; Percentage of Participants With Epidermal Growth Factor Receptor (EGFR) Mutation by Mutation Type (NUMBER) percentage of participants = 0.00",,,,,,,,,Overall Survival (OS) (MEAN) months = 17.48,Progression-Free Survival (PFS) (MEDIAN) months = 12.58 [10.25-16.95],,,,,,
NCT01380769,A Phase 2 Study of CRLX101(NLG207) in Patients With Advanced Non-Small Cell Lung Cancer,"A Randomized, Phase 2, Study to Assess the Safety and Activity of CRLX101, a Nanoparticle Formulation of Camptothecin, in Patients With Advanced Non-Small Cell Lung Cancer Who Have Failed One or Two P",Lumos Pharma,NewLink Genetics Corporation,INDUSTRY,COMPLETED,2011-06,2013-02,2014-10,INTERVENTIONAL,PHASE2,,,,Non-Small Cell Lung Cancer,Non-Small Cell Lung Cancer,1,2,2,DRUG; OTHER,,,1,1,True,Yes,To Compare Overall Survival of Patients Treated With CRLX101 + BSC to Those Patients Treated With BSC Only (MEDIAN) months = 6.3 [4.70-8.68],Assess Objective Response Rate (ORR) of CRLX101+ BSC Compared to BSC Only (NUMBER) Percentage of Participants = 6.2,,,,,,,,Assess Objective Response Rate (ORR) of CRLX101+ BSC Compared to BSC Only (NUMBER) Percentage of Participants = 6.2,To Compare Overall Survival of Patients Treated With CRLX101 + BSC to Those Patients Treated With BSC Only (MEDIAN) months = 6.3 [4.70-8.68],,,,Assess Objective Response Rate (ORR) of CRLX101+ BSC Compared to BSC Only (NUMBER) Percentage of Participants = 6.2,,,
NCT01387269,Safety and Efficacy of Anamorelin HCl in Patients With Non-Small Cell Lung Cancer-Cachexia (ROMANA 1),Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): A Randomized Double-Blind Placebo-Controlled Multicenter Phase III Study to Evaluate the Safety and Efficacy of Anamor,"Helsinn Therapeutics (U.S.), Inc","Helsinn Therapeutics (U.S.), Inc",INDUSTRY,COMPLETED,2011-07,2014-01,2015-02,INTERVENTIONAL,PHASE3,,,,Cachexia,Cachexia; Non-Small Cell Lung Cancer,2,2,2,DRUG,,,2,3,True,Yes,Change in Lean Body Mass (MEDIAN) kg = 0.99 [0.61-1.36]; Change in Handgrip Strength (MEDIAN) kg = -1.10 [-1.69--0.40],Change in A/CS Domain Score (LEAST_SQUARES_MEAN) scores on a scale = 4.12; Change in FACIT-F Fatigue Domain Score (LEAST_SQUARES_MEAN) scores on a scale = 0.26; Change in Body Weight (LEAST_SQUARES_MEAN) kg = 2.20,,,,,,,,,,,,,,,,
NCT01387282,Safety and Efficacy of Anamorelin HCl in Patients With Non-Small Cell Lung Cancer-Cachexia (ROMANA 2),Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): A Randomized Double-Blind Placebo-Controlled Multicenter Phase III Study to Evaluate the Safety and Efficacy of Anamor,"Helsinn Therapeutics (U.S.), Inc","Helsinn Therapeutics (U.S.), Inc",INDUSTRY,COMPLETED,2011-07,2013-11,2015-02,INTERVENTIONAL,PHASE3,,,,Cachexia,Cachexia; Non-Small Cell Lung Cancer,2,2,2,DRUG,,,2,3,True,Yes,Change in Lean Body Mass (MEDIAN) kg = 0.65 [0.38-0.91]; Change in Handgrip Strength (MEDIAN) kg = -1.49 [-2.06--0.58],Change in A/CS Domain Score (LEAST_SQUARES_MEAN) scores on a scale = 3.48; Change in FACIT-F Fatigue Domain Score (LEAST_SQUARES_MEAN) scores on a scale = 1.37; Change in Body Weight (LEAST_SQUARES_MEAN) kg = 0.95,,,,,,,,,,,,,,,,
NCT01395758,Erlotinib Plus Tivantinib (ARQ 197) Versus Single Agent Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer,A Phase 2 Randomized Open-label Study of Erlotinib Plus Tivantinib (ARQ 197) Versus Single Agent Chemotherapy in Previously Treated KRAS Mutation Positive Subjects With Locally Advanced or Metastatic ,"ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)","ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)",INDUSTRY,COMPLETED,2011-07,2016-08,2016-08,INTERVENTIONAL,PHASE2,,,,Metastatic Non-Small Cell Lung Cancer,Metastatic Non-Small Cell Lung Cancer,1,2,2,DRUG,,,1,3,True,Yes,Progression-free Survival (PFS) Among Subjects With KRAS Mutation Positive NSCLC (ITT Population) Treated With Erlotinib Plus Tivantinib Compared to Single Agent Chemotherapy. (MEDIAN) weeks = 7.3 [6.86-24.14],Overall Survival (OS) Among All Eligible Subjects (ITT Population) Treated With Erlotinib Plus Tivantinib Compared to Chemotherapy. (MEDIAN) months = 6.8 [4.97-10.70]; Objective Response Rate (ORR) Among All Eligible Subjects (ITT Population) Treated With Erlotinib Plus Tivantinib Compared to Chemotherapy. (COUNT_OF_PARTICIPANTS) Participants = 0; ORR Among Subjects in the Crossover Period Treated With Erlotinib Plus Tivantinib (COUNT_OF_PARTICIPANTS) Participants = 2,,,,,,,,Objective Response Rate (ORR) Among All Eligible Subjects (ITT Population) Treated With Erlotinib Plus Tivantinib Compared to Chemotherapy. (COUNT_OF_PARTICIPANTS) Participants = 0; ORR Among Subjects in the Crossover Period Treated With Erlotinib Plus Tivantinib (COUNT_OF_PARTICIPANTS) Participants = 2,Overall Survival (OS) Among All Eligible Subjects (ITT Population) Treated With Erlotinib Plus Tivantinib Compared to Chemotherapy. (MEDIAN) months = 6.8 [4.97-10.70],Progression-free Survival (PFS) Among Subjects With KRAS Mutation Positive NSCLC (ITT Population) Treated With Erlotinib Plus Tivantinib Compared to Single Agent Chemotherapy. (MEDIAN) weeks = 7.3 [6.86-24.14],,,Objective Response Rate (ORR) Among All Eligible Subjects (ITT Population) Treated With Erlotinib Plus Tivantinib Compared to Chemotherapy. (COUNT_OF_PARTICIPANTS) Participants = 0,,,
NCT01395914,Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study (ROMANA 3),Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study,"Helsinn Therapeutics (U.S.), Inc","Helsinn Therapeutics (U.S.), Inc",INDUSTRY,COMPLETED,2011-07,2014-06,2015-02,INTERVENTIONAL,PHASE3,,,,Cachexia,Cachexia; Non-Small Cell Lung Cancer,2,2,2,DRUG,,,1,3,True,Yes,Percentage of Participants With Treatment-emergent Adverse Events (NUMBER) percentage of participants = 52,Change in Body Weight (LEAST_SQUARES_MEAN) kg = 3.06; Change in Handgrip Strength of the Non-Dominant Hand (LEAST_SQUARES_MEAN) kg = -0.83; Change in A/CS Domain Score (LEAST_SQUARES_MEAN) scores on a scale = 4.46,,,,,,,,,,,,,,Percentage of Participants With Treatment-emergent Adverse Events (NUMBER) percentage of participants = 52,,
NCT01404260,Intercalating and Maintenance Use of Iressa Versus Chemotherapy in Selected Advanced Non Small Cell Lung Cancer,Intercalating and Maintenance Use of Iressa vs. Chemotherapy in Selected Advanced NSCLC: a Randomised Study,Guangdong Association of Clinical Trials,Guangdong Association of Clinical Trials,OTHER,COMPLETED,2011-06,2015-03,2015-10,INTERVENTIONAL,PHASE3,,,,Non-small Cell Lung Cancer,Non-small Cell Lung Cancer,1,2,2,DRUG,,,1,0,True,Yes,Progression Free Survival (MEDIAN) months = 9.7 [5.9-11.3],,,,,,,,,,,Progression Free Survival (MEDIAN) months = 9.7 [5.9-11.3],,,,,,
NCT01438307,Phase II Study of Cabazitaxel-XRP6258 in Advanced Non-Small Cell Lung Cancer,Phase II Study of a Novel Taxane (Cabazitaxel-XRP6258) in Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC) Patients,University of Alabama at Birmingham,University of Alabama at Birmingham,OTHER,COMPLETED,2011-09,2014-09,2015-09,INTERVENTIONAL,PHASE2,,,,Non-small Cell Lung Cancer (NSCLC),Non-small Cell Lung Cancer (NSCLC); Stage IV NSCLC; Metastatic NSCLC,3,2,2,DRUG,,,1,3,True,Yes,Objective Response Rate (NUMBER) participants = 0,Progression Free Survival (MEDIAN) months = 3 [1.0-5.0]; Number of Patients With Any Graded Adverse Event (COUNT_OF_PARTICIPANTS) Participants = 14; Overall Survival (MEDIAN) months = 6 [0.50-7.0],,,,,,,,Objective Response Rate (NUMBER) participants = 0,Overall Survival (MEDIAN) months = 6 [0.50-7.0],Progression Free Survival (MEDIAN) months = 3 [1.0-5.0],,,Objective Response Rate (NUMBER) participants = 0,,,
NCT01454934,"A Randomized, Open-label, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Treatment of Physician's Choice in Subjects W",,Eisai Inc.,Eisai Inc.,INDUSTRY,COMPLETED,2011-12-09,2014-05-30,2016-05-02,INTERVENTIONAL,PHASE3,,,,Non-Small Cell Lung Cancer (NSCLC),Non-Small Cell Lung Cancer (NSCLC),1,2,2,DRUG,,,1,2,True,Yes,Overall Survival (OS) (MEDIAN) months = 9.5 [7.4-11.4],Progression Free Survival (PFS) by Response Evaluation Criteria in Solid Tumors (RECIST) (MEDIAN) months = 3.0 [2.6-3.9]; Objective Response Rate (ORR) (NUMBER) percentage of participants = 12.2 [8.6-16.7],,,,,,,,Objective Response Rate (ORR) (NUMBER) percentage of participants = 12.2 [8.6-16.7],Overall Survival (OS) (MEDIAN) months = 9.5 [7.4-11.4],Progression Free Survival (PFS) by Response Evaluation Criteria in Solid Tumors (RECIST) (MEDIAN) months = 3.0 [2.6-3.9],,,Objective Response Rate (ORR) (NUMBER) percentage of participants = 12.2 [8.6-16.7],,,
NCT01459497,Hypofractionated Image-Guided Radiation Therapy (IGRT) in Patients With Stage II-III Non-Small Cell Lung Cancer,Phase III Randomized Study of Standard Versus Accelerated Hypofractionated Image-Guided Radiation Therapy (IGRT) in Patients With Stage II-III Non-Small Cell Lung Cancer and Poor Performance Status,University of Texas Southwestern Medical Center,University of Texas Southwestern Medical Center,OTHER,COMPLETED,2012-10,2019-07-11,2023-10-19,INTERVENTIONAL,PHASE3,,,,Non-small Cell Lung Cancer,Non-small Cell Lung Cancer,1,2,2,RADIATION,,,1,7,True,Yes,"Overall Survival of Standard Radiation (CFRT) Versus Accelerated, Hypofractionated, Image-guided Conformal Radiotherapy (IGRT) in Treatment of Stage II-III NSCLC in Patients With Poor Performance Status at 1 Year. (NUMBER) percentage of participants = 37.7 [24.2-51.0]","Toxicities of Two Radiotherapy Treatment Regimens in Patients With Stage II-III Non-Small Cell Lung Cancer (NSCLC) and Poor Performance Status (NUMBER) events = 144; Time to Local Progression of Two Radiotherapy Treatment Regimens in Patients With Stage II-III NSCLC and Poor Performance Status (MEDIAN) months = 6.4 [4.1-7.8]; Disease-free Survival of Two Radiotherapy Treatment Regimens in Patients With Stage II-III NSCLC and Poor Performance Status. (NUMBER) percentage of participants = 4; ; Cost Effectiveness of Two Radiotherapy Treatment Regimens in Patients With Stage II-III NSCLC and Poor Performance Status. (MEAN) Cost of Treatment (in USD) = 26,984 [14714-39253]; Quality Adjusted Life Survival Time of Two Radiotherapy Treatment Regimens in Patients With Stage II-III NSCLC and Poor Performance Status. (MEAN) days = 100 [70-130]; Quality Adjusted Life Survival Time of Two Radiotherapy Treatment Regimens in Patients With Stage II-III NSCLC and Poor Performance Status. (MEAN) adjusted days of follow up = 106 [73-139]",,,Disease-free Survival of Two Radiotherapy Treatment Regimens in Patients With Stage II-III NSCLC and Poor Performance Status. (NUMBER) percentage of participants = 4,,,,,,"Overall Survival of Standard Radiation (CFRT) Versus Accelerated, Hypofractionated, Image-guided Conformal Radiotherapy (IGRT) in Treatment of Stage II-III NSCLC in Patients With Poor Performance Status at 1 Year. (NUMBER) percentage of participants = 37.7 [24.2-51.0]",,,,,,,
NCT01465802,Study Of Dacomitinib (PF-00299804) In Advanced NSCLC Patients (Post Chemo Or Select First Line) To Evaluate Prophylactic Intervention On Derm And GI A,ARCHER 1042: A PHASE 2 STUDY OF DACOMITINIB IN ADVANCED NON-SMALL CELL LUNG CANCER (POST-CHEMOTHERAPY OR SELECT FIRST LINE PATIENTS) TO EVALUATE PROPHYLACTIC INTERVENTION ON DERMATOLOGIC AND GASTROINT,Pfizer,Pfizer,INDUSTRY,COMPLETED,2011-12-26,2015-05-18,2015-05-18,INTERVENTIONAL,PHASE2,,,,Non Small Cell Lung Cancer (NSCLC),Non Small Cell Lung Cancer (NSCLC),1,3,5,DRUG,,,11,7,True,Yes,"Percentage of Participants With Select Dermatologic Adverse Events of Interest (SDAEI) (All Causality, All Grade) in the First 8 Weeks of Treatment by Treatment Arm for Cohort I (NUMBER) Percentage of Participants = 79.3 [66.6-88.8]; Percentage of Participants With SDAEI (All Causality, Grade Greater Than or Equal to [≥] 2) in the First 8 Weeks of Treatment by Treatment Arm for Cohort I (NUMBER) Percentage of Participants = 46.6 [33.3-60.1]; Mean Change From Baseline (Cycle 1 Day 1) Skindex-16 Scale Scores (Total Score, Symptoms Score, Emotion Score, and Functioning Score) by Treatment Arm for Cohort I (MEAN) Score on a scale = 2.3; Percentage of Participants With Diarrhea AEs (All Causality, All Grade and Grade ≥2) in the First 8 Weeks of Treatment for Cohort II (NUMBER) Percentage of Participants = 83.1 [71.0-91.6]; Mean Change From Baseline (Cycle 1 Day 1) Modified Oral Mucositis Daily Questionnaire (OMDQ) Scores (Mouth and Throat Soreness Categories and Scale, and Diarrhea Categories and Scale) for Cohort II (MEAN) Score on a scale = 0.8; Percentage of Participants With SDAEI (All Causality, All Grade) in the First 8 Weeks of Treatment for Cohort II (NUMBER) Percentage of Participants = 79.7 [67.2-89.0]; Percentage of Participants With SDAEI (All Causality, Grade ≥2) in the First 8 Weeks of Treatment for Cohort II (NUMBER) Percentage of Participants = 35.6 [23.6-49.1]; Mean Change From Baseline (Cycle 1 Day 1) Skindex-16 Scale Scores (Total Score, Symptoms Score, Emotion Score, and Functioning Score) for Cohort II (MEAN) Score on a scale = 0.1; Mean Area Under the Plasma Concentration Time Curve From 0 to 24 Hours (AUC0-24) and From 0 to 120 Hours (AUC0-120) for Dacomitinib and Its Metabolite PF-05199265 on Cycle 1 Days 10 to 15 for Cohort III (GEOMETRIC_MEAN) ng*hr/mL = 1712.88; Mean Maximum Observed Plasma Concentrations (Cmax) for Dacomitinib and Its Metabolite PF-05199265 on Cycle 1 Days 10 to 15 for Cohort III (GEOMETRIC_MEAN) ng/mL = 79.68; Median Time of Occurrence of Cmax (Tmax) for Dacomitinib and Its Metabolite PF-05199265 on Cycle 1 Days 10 to 15 for Cohort III (MEDIAN) hours (hr) = 5.850 [0-24.30]","Percentage of Participants Receiving Any Concomitant Drug or Non-Drug Treatment for SDAEI, Diarrhea and Mucositis for Cohort I by Treatment Arm, Cohort II, and Cohort III (NUMBER) Percentage of Participants = 69.7; Mean AUC From 0 to the End of the Dosing Interval (AUC0-tau) for Dacomitinib and Its Metabolite PF-05199265 on Cycle 2 Day 1 for Cohort I (GEOMETRIC_MEAN) ng*hr/mL = 1801.96; Mean Cmax for Dacomitinib and Its Metabolite PF-05199265 on Cycle 2 Day 1 for Cohort I (GEOMETRIC_MEAN) ng/mL = 88.15; Median Tmax for Dacomitinib and Its Metabolite PF-05199265 on Cycle 2 Day 1 for Cohort I (MEDIAN) hr = 4.000 [0-24.00]; Mean Apparent Clearance (CL/F) for Dacomitinib on Cycle 2 Day 1 for Cohort I (GEOMETRIC_MEAN) Liters per hour = 29.94; Mean Plasma Trough Concentrations (Ctrough) for Dacomitinib by Visit for Cohorts I, II and III (GEOMETRIC_MEAN) ng/mL = 65.477; Mean Plasma Ctrough for PF-05199265 by Visit for Cohorts I, II and III (GEOMETRIC_MEAN) ng/mL = 6.988",,,,,,,,,,,,,,"Percentage of Participants With Select Dermatologic Adverse Events of Interest (SDAEI) (All Causality, All Grade) in the First 8 Weeks of Treatment by Treatment Arm for Cohort I (NUMBER) Percentage of Participants = 79.3 [66.6-88.8]",,
NCT01473563,A Study of Home Administration of Pemetrexed as Maintenance Treatment for Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC),Home Delivery of Pemetrexed as Maintenance Treatment in Patients Who Have Not Progressed After Induction Therapy for Advanced Nonsquamous Nonsmall Cell Lung Cancer: A Feasibility Study,Eli Lilly and Company,Eli Lilly and Company,INDUSTRY,COMPLETED,2011-12,2013-09,2013-09,INTERVENTIONAL,PHASE2,,,,Nonsquamous Non-Small Cell Neoplasm of Lung,Nonsquamous Non-Small Cell Neoplasm of Lung; Non-Small Cell Lung Cancer Metastatic; Non-Small Cell Lung Cancer Stage IIIB,3,1,1,DRUG,,,1,14,True,Yes,Percentage of Participants Who Adhered to Treatment Administration at Home (NUMBER) percentage of participants = 100 [100-100],"Change From Baseline in the European Quality of Life Instrument (EQ-5D) Visual Analogue Scale (VAS) (MEAN) units on a scale = 3.0; Change From Baseline in the EQ-5D Index Score (MEAN) units on a scale = 0.03; Maximum Improvement Over Baseline in Individual Lung Cancer Symptoms Scale (LCSS) Item Scores (MEAN) mm = 16.3; Participant Satisfaction: Chemotherapy at Hospital (NUMBER) participants = 8; Participant Satisfaction: Chemotherapy at Home (NUMBER) participants = 37; Participant Satisfaction: Regarding the Study Nurse (NUMBER) participants = 37; Participant Satisfaction: Preferences Regarding Home and/or Hospital Treatment (NUMBER) participants = 33; Physician Satisfaction: Distant Management of Participant (NUMBER) investigators = 2; Resource Utilization: Number of Participants With an Unplanned Use of Healthcare Resources (NUMBER) participants = 29; Resource Utilization: Unplanned Health Care Visits, Consultations, and Diagnostic Services (NUMBER) participants = 8; Resource Utilization: Duration of Health Care Visits (MEAN) hours = 1.67; Resource Utilization: Distances Traveled (MEAN) kilometers (km) = 19.7; Overall Survival (OS) at 6 Months (NUMBER) percentage of participants = 73 [58.1-82.8]; Time to Treatment Failure (TTF) (MEDIAN) months = 3.0 [2.3-4.2]",,,,,,,,,Overall Survival (OS) at 6 Months (NUMBER) percentage of participants = 73 [58.1-82.8],,,Change From Baseline in the European Quality of Life Instrument (EQ-5D) Visual Analogue Scale (VAS) (MEAN) units on a scale = 3.0,,,Time to Treatment Failure (TTF) (MEDIAN) months = 3.0 [2.3-4.2],
NCT01487265,Trial of Erlotinib and BKM120 in Patients With Advanced Non Small Cell Lung Cancer Previously Sensitive to Erlotinib,Phase II Trial of Erlotinib and BKM120 in Patients With Advanced Non Small Cell Lung Cancer Previously Sensitive to Erlotinib,"SCRI Development Innovations, LLC","SCRI Development Innovations, LLC",OTHER,COMPLETED,2014-03,2016-05-31,2017-12-11,INTERVENTIONAL,PHASE2,,,,Non Small Cell Lung Cancer,Non Small Cell Lung Cancer,1,1,1,DRUG,,,1,4,True,Yes,Progression Free Survival at 3 Months (NUMBER) percentage of participants = 50.4,Overall Survival (MEDIAN) months = 12.2 [7.2-33.3]; Duration of Response (NUMBER) months = 3.2; Objective Response Rate (NUMBER) percentage of participants = 5.4 [0.7-18.2]; Number of Participants With Serious and Non-serious Adverse Events as a Measure of Safety. (NUMBER) participants = 37,,,,,Duration of Response (NUMBER) months = 3.2,,,Objective Response Rate (NUMBER) percentage of participants = 5.4 [0.7-18.2],Overall Survival (MEDIAN) months = 12.2 [7.2-33.3],Progression Free Survival at 3 Months (NUMBER) percentage of participants = 50.4,,,Objective Response Rate (NUMBER) percentage of participants = 5.4 [0.7-18.2],Number of Participants With Serious and Non-serious Adverse Events as a Measure of Safety. (NUMBER) participants = 37,,
NCT01513174,Study With Gefitinib in Combination With Olaparib (AZD2281) Versus Gefitinib Alone,"Multicenter, Randomized, Phase Ib/IIb Study to Evaluate the Efficacy and Tolerability of Gefitinib in Combination With Olaparib (AZD2281) Versus Gefitinib Alone, in Patients With EGFR Mutation Positiv",Spanish Lung Cancer Group,Spanish Lung Cancer Group,OTHER,COMPLETED,2011-08,2016-07,2016-07,INTERVENTIONAL,PHASE1; PHASE2,,,,Non Small Cell Lung Cancer,Non Small Cell Lung Cancer,1,2,2,DRUG,,,1,2,True,Yes,Progression-free Survival (PFS) (MEDIAN) Month = 10.9 [9.3-13.3],Overall Survival (MEDIAN) Month = 23.1 [19.1-28.5]; Best Global Response During Treatment Period (NUMBER) participants = 2,,,,,,,,,Overall Survival (MEDIAN) Month = 23.1 [19.1-28.5],Progression-free Survival (PFS) (MEDIAN) Month = 10.9 [9.3-13.3],,,,,,
NCT01529112,"A Study Comparing the Combination of the Best Supportive Care Plus E7080 Versus Best Supportive Care Alone, in Patients With Advanced Lung Cancer or L","A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Oral E7080 in Addition to Best Supportive Care (BSC) Versus BSC Alone in Patients With Locally Advanced or Metastatic Non-Squamous Non",Eisai Inc.,Eisai Inc.,INDUSTRY,COMPLETED,2011-11,2014-01-21,2015-06-27,INTERVENTIONAL,PHASE2,,,,Non-Small Cell Lung Cancer,Non-Small Cell Lung Cancer,1,2,3,DRUG,,,1,10,True,Yes,Overall Survival (OS) (MEDIAN) weeks = 38.4 [26.57-47.86],Number of Participants With Treatment Emergent Non-serious Adverse Events (AEs) and Treatment Emergent Serious Adverse Events (SAEs) (NUMBER) Participants = 83; 6-Month Survival Rate (NUMBER) Percentage of Participants = 61.6 [50.24-71.1]; 1-year Survival Rate (NUMBER) Percentage of Participants = 35.8 [25.13-46.54]; Progression-Free Survival (PFS) (MEDIAN) weeks = 20.9 [15.86-23.86]; Overall Response Rate (ORR) (NUMBER) Percentage of Participants = 10.1 [4.7-18.3]; Response Duration (RD) (MEDIAN) Weeks = 24.2 [12.71-33.14]; Disease Control Rate (DCR) (NUMBER) Percentage of Participants = 42.7 [32.3-53.6]; The Percentage of Participants With The European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30 Symptom Scores Achieving Clinically Significant Deterioration on Quality of Life (QOL) (NUMBER) Percentage of participants = 59.8; The Percentage of Participants With The European Organization for Research and Treatment of Cancer (EORTC) Module QLQ-LC13 (Lung Cancer 13) Symptom Scores Achieving Clinically Significant Deterioration on QOL (NUMBER) Percentage of participants = 16.3; Pharmacokinetic (PK) Profile of Lenvatinib in Subjects With Non Small Cell Lung Cancer (NSCLC) (MEAN) nanograms per milliliter = 93.4,,,,,,,,,Overall Survival (OS) (MEDIAN) weeks = 38.4 [26.57-47.86],Progression-Free Survival (PFS) (MEDIAN) weeks = 20.9 [15.86-23.86],,The Percentage of Participants With The European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30 Symptom Scores Achieving Clinically Significant Deterioration on Quality of Life (QOL) (NUMBER) Percentage of participants = 59.8; The Percentage of Participants With The European Organization for Research and Treatment of Cancer (EORTC) Module QLQ-LC13 (Lung Cancer 13) Symptom Scores Achieving Clinically Significant Deterioration on QOL (NUMBER) Percentage of participants = 16.3,Overall Response Rate (ORR) (NUMBER) Percentage of Participants = 10.1 [4.7-18.3],Number of Participants With Treatment Emergent Non-serious Adverse Events (AEs) and Treatment Emergent Serious Adverse Events (SAEs) (NUMBER) Participants = 83,,
NCT01544179,A Study of IRESSA Treatment Beyond Progression in Addition to Chemotherapy Versus Chemotherapy Alone,"A Phase III Randomised, Double Blind, Placebo Controlled, Parallel, Multicentre Study to Assess the Efficacy and Safety of Continuing IRESSA 250 mg in Addition to Chemotherapy Versus Chemotherapy Alon",AstraZeneca,AstraZeneca,INDUSTRY,COMPLETED,2012-03-15,2014-05-05,2019-11-20,INTERVENTIONAL,PHASE3,,,,Non-Small Cell Lung Cancer,Non-Small Cell Lung Cancer,1,2,4,DRUG,,,2,10,True,Yes,"Progression-Free Survival (Site Read, Investigator Assessment) (NUMBER) Patients with a progression event = 98 [4.5-5.7]; Median Progression-Free Survival (Site Read, Investigator Assessment) (MEDIAN) Months = 5.4 [4.5-5.7]",Overall Survival (OS) (NUMBER) Number of patients with an OS event = 50 [10.4-19.0]; Median Overall Survival (OS) at Time of PFS Analysis (MEDIAN) Months = 14.8 [10.4-19.0]; Objective Response Rate (ORR) (Site Read Data) (NUMBER) Percentage of Participants = 31.6 [0.55-1.55]; Disease Control Rate (DCR) (NUMBER) Percentage of Participants = 84.2 [0.74-2.62]; Improvement in Trial Outcome Index (NUMBER) Number of participants improving = 36 [0.74-2.62]; Time to Worsening in Trial Outcome Index (MEDIAN) Weeks = 12.1 [8.7-18.1]; Improvement in FACT-L Total Score (NUMBER) Number of patients improving = 44 [0.74-2.62]; Time to Worsening in FACT-L Total Score (MEDIAN) Weeks = 12.0 [6.0-15.0]; Improvement in Lung Cancer Subscale (NUMBER) Number of participants improving = 54; Time to Worsening in Lung Cancer Subscale (MEDIAN) Weeks = 14.6 [9.1-24.3],,,,,,,,Objective Response Rate (ORR) (Site Read Data) (NUMBER) Percentage of Participants = 31.6 [0.55-1.55],Overall Survival (OS) (NUMBER) Number of patients with an OS event = 50 [10.4-19.0]; Median Overall Survival (OS) at Time of PFS Analysis (MEDIAN) Months = 14.8 [10.4-19.0],"Progression-Free Survival (Site Read, Investigator Assessment) (NUMBER) Patients with a progression event = 98 [4.5-5.7]; Median Progression-Free Survival (Site Read, Investigator Assessment) (MEDIAN) Months = 5.4 [4.5-5.7]; Median Overall Survival (OS) at Time of PFS Analysis (MEDIAN) Months = 14.8 [10.4-19.0]",,,Objective Response Rate (ORR) (Site Read Data) (NUMBER) Percentage of Participants = 31.6 [0.55-1.55],,,
NCT01557959,"Docetaxel, Cisplatin, Pegfilgrastim, and Erlotinib Hydrochloride in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer",Phase II Study of Sequential Dose-Dense Chemotherapy and Dose-Intense Erlotinib for the Initial Treatment of Advanced Non-Small Cell Lung Cancer,Wake Forest University Health Sciences,Wake Forest University Health Sciences,OTHER,COMPLETED,2007-07,2011-02,2011-02,INTERVENTIONAL,PHASE2,,,,Adenocarcinoma of the Lung,Adenocarcinoma of the Lung; Adenosquamous Cell Lung Cancer; Bronchoalveolar Cell Lung Cancer,9,1,8,BIOLOGICAL; DRUG; GENETIC; OTHER,,,1,2,True,Yes,Time to Progression (MEDIAN) months = 4.63 [3.68-6.05],Response Rate Among Subgroups of Patients According to Molecular Profiles Including Tumor Characteristics and Genetic Polymorphisms From Peripheral Blood (COUNT_OF_PARTICIPANTS) Participants = 3; Median Survival Among Subgroups of Patients According to Molecular Profiles Including Tumor Characteristics and Genetic Polymorphisms From Peripheral Blood (MEDIAN) Months = 20.5,,,,,,,,,,,,,Response Rate Among Subgroups of Patients According to Molecular Profiles Including Tumor Characteristics and Genetic Polymorphisms From Peripheral Blood (COUNT_OF_PARTICIPANTS) Participants = 3,,,Time to Progression (MEDIAN) months = 4.63 [3.68-6.05]
NCT01573702,Stereotactic Radiosurgery or Other Local Ablation Then Erlotinib in Epidermal Growth Factor Receptor (EGFR),Phase II Study of Stereotactic Radiosurgery or Other Local Ablation Followed by Erlotinib for Patients With Epidermal Growth Factor Receptor(EGFR) Mutation Who Have Previously Progressed on an Epiderm,UNC Lineberger Comprehensive Cancer Center,UNC Lineberger Comprehensive Cancer Center,OTHER,COMPLETED,2012-12-11,2019-03-15,2019-03-15,INTERVENTIONAL,PHASE2,,,,Non Small Cell Lung Cancer,Non Small Cell Lung Cancer,1,1,2,DRUG; PROCEDURE,,,1,4,True,Yes,Percentage of Participants With Progression Free Survival (NUMBER) percentage of participants = 64 [42.5-82],Percentage of Participants With Local Control of Sites on Erlotinib Following Stereotactic Radiosurgery (SRS) (COUNT_OF_PARTICIPANTS) Participants = 7; Median Overall Survival (MEDIAN) Months = 29 [21.7-36.3]; Toxicity Rate From Stereotactic Radiosurgery (SRS) (COUNT_OF_PARTICIPANTS) Participants = 4; Toxicity Rate Attributed to Erlotinib (COUNT_OF_PARTICIPANTS) Participants = 5,,,,,,,,,Median Overall Survival (MEDIAN) Months = 29 [21.7-36.3],Percentage of Participants With Progression Free Survival (NUMBER) percentage of participants = 64 [42.5-82],,,,Toxicity Rate From Stereotactic Radiosurgery (SRS) (COUNT_OF_PARTICIPANTS) Participants = 4; Toxicity Rate Attributed to Erlotinib (COUNT_OF_PARTICIPANTS) Participants = 5,,
NCT01610336,"A Safety and Efficacy Study of INC280 and Gefitinib in Patients With EGFR Mutated, c-MET-amplified NSCLC Who Have Progressed After EGFRi Treatment","A Phase IB/II, Open Label, Multicenter Study of INC280 Administered Orally in Combination With Gefitinib in Adult Patients With EGFR Mutated, c-MET-amplified Non-small Cell Lung Cancer Who Have Progre",Novartis,Novartis Pharmaceuticals,INDUSTRY,COMPLETED,2012-04-05,2016-06-10,2020-05-27,INTERVENTIONAL,PHASE2,,,,Non-small Cell Lung Cancer,Non-small Cell Lung Cancer,1,11,2,DRUG,,,2,12,True,Yes,Phase Ib: Frequency of Dose Limiting Toxicities (DLTs) (COUNT_OF_PARTICIPANTS) Participants = 0; Phase II : Overall Response Rate (ORR) (COUNT_OF_PARTICIPANTS) Participants = 12,Phase Ib and II: Number of Participants With Adverse Events (AEs) (COUNT_OF_PARTICIPANTS) Participants = 5; Phase Ib and II: Number of Participants With Serious Adverse Events (SAEs) (COUNT_OF_PARTICIPANTS) Participants = 1; Phase Ib and II: Number of Patients With Dose Reductions of INC280 by Dose Level (COUNT_OF_PARTICIPANTS) Participants = 5; Phase Ib and II: Number of Patients With Dose Interruptions of Gefitinib by Dose Level (COUNT_OF_PARTICIPANTS) Participants = 5; Phase II: Overall Survival (OS) (MEDIAN) Months = 12.3 [8.1-15.4]; Phase II: Progression Free Survival (PFS) (MEDIAN) Months = 5.1 [3.6-5.6]; Phase II: Duration of Response (DoR) (MEDIAN) Months = 5.6 [3.7-6.2]; Phase I: PK Parameters AUCtau of INC280 and Gefitinib (MEAN) hr∙ng/mL = 4510; Phase I: PK Parameters Cmax of INC280 and Gefitinib (MEAN) ng/mL = 826; Phase I: PK Parameters Tmax of INC280 and Gefitinib (MEDIAN) Hours = 1.96 [1.50-3.92]; Phase I: PK Parameters Apparent Systemic Plasma Clearance Rate of INC280 and Gefitinib (MEAN) L/hr = 26.9; Phase I: PK Parameters Half-life of INC280 and Gefitinib (MEAN) hours = 3.86,,,,,Phase II: Duration of Response (DoR) (MEDIAN) Months = 5.6 [3.7-6.2],,,,Phase II: Overall Survival (OS) (MEDIAN) Months = 12.3 [8.1-15.4],Phase II: Progression Free Survival (PFS) (MEDIAN) Months = 5.1 [3.6-5.6],,,Phase II : Overall Response Rate (ORR) (COUNT_OF_PARTICIPANTS) Participants = 12,Phase Ib and II: Number of Participants With Adverse Events (AEs) (COUNT_OF_PARTICIPANTS) Participants = 5; Phase Ib and II: Number of Participants With Serious Adverse Events (SAEs) (COUNT_OF_PARTICIPANTS) Participants = 1,,
NCT01620190,Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Previously Treated Advanced Non-small Cell Lung Cancer,A Phase II Study of Weekly Abraxane for Patients With Advanced NSCLC With EGFR Mutations or With Durable Response to an EGFR Tyrosine Kinase Inhibitor Following Front Line Therapy With EGFR Tyrosine K,University of Washington,University of Washington,OTHER,COMPLETED,2012-12-02,2017-10-24,2019-04-29,INTERVENTIONAL,PHASE2,,,,Recurrent Non-Small Cell Lung Carcinoma,Recurrent Non-Small Cell Lung Carcinoma; Stage IV Non-Small Cell Lung Cancer,2,1,2,DRUG; OTHER,,,1,4,True,Yes,Overall Response Rate (Complete and Partial Response) Defined by RECIST 1.1 Criteria (COUNT_OF_PARTICIPANTS) Participants = 0,"Overall Percentage of Patients Experiencing Toxicity Within a Clinically Significant Category Defined as Neutropenia, Neutropenic Fever, or Neuropathy. (COUNT_OF_PARTICIPANTS) Participants = 4; Overall Survival (MEDIAN) weeks = 36 [16.8-68]; Overall Percentage of Patients Experiencing Grade 3 or Higher Toxicity. (COUNT_OF_PARTICIPANTS) Participants = 8; Time to Progression. (MEDIAN) weeks = 10.2 [3.4-60.9]",,,,,,,,,Overall Survival (MEDIAN) weeks = 36 [16.8-68],,Overall Response Rate (Complete and Partial Response) Defined by RECIST 1.1 Criteria (COUNT_OF_PARTICIPANTS) Participants = 0,,Overall Response Rate (Complete and Partial Response) Defined by RECIST 1.1 Criteria (COUNT_OF_PARTICIPANTS) Participants = 0,"Overall Percentage of Patients Experiencing Toxicity Within a Clinically Significant Category Defined as Neutropenia, Neutropenic Fever, or Neuropathy. (COUNT_OF_PARTICIPANTS) Participants = 4; Overall Percentage of Patients Experiencing Grade 3 or Higher Toxicity. (COUNT_OF_PARTICIPANTS) Participants = 8",,Time to Progression. (MEDIAN) weeks = 10.2 [3.4-60.9]
NCT01631552,Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer,A Phase I/II Study of IMMU-132 (hRS7-SN38 Antibody Drug Conjugate) in Patients With Epithelial Cancer,Gilead Sciences,Gilead Sciences,INDUSTRY,COMPLETED,2012-12-17,2019-03-01,2020-08-13,INTERVENTIONAL,PHASE1; PHASE2,,,,Gastric Adenocarcinoma,Gastric Adenocarcinoma; Esophageal Cancer; Hepatocellular Carcinoma,16,4,1,DRUG,,,5,12,True,Yes,"Percentage of Participants Experiencing Any Treatment Emergent Adverse Events and Serious Treatment Emergent Adverse Events (NUMBER) Percentage of participants = 100.0; Percentage of Participants Who Permanently Discontinued Sacituzumab Govitecan-hziy (SG) Due to Any Adverse Events, Excluding Adverse Events Leading to Death (NUMBER) Percentage of participants = 2.8; Percentage of Participants Who Required Dose Interruption Due to Any Adverse Events (NUMBER) Percentage of participants = 45.4; Objective Response Rate (ORR) by Independent Central Review (ICR) (NUMBER) Percentage of participants = 34.3 [25.4-44.0]; Objective Response Rate by Local Assessment (NUMBER) Percentage of participants = 33.3 [24.6-43.1]","Duration of Response by ICR (MEDIAN) months = 9.1 [4.6-11.3]; Duration of Response by Local Assessment (MEDIAN) months = 7.7 [4.9-10.8]; Time to Response by ICR (MEDIAN) months = 2.2 [1.6-7.6]; Time to Response by Local Assessments (MEDIAN) months = 2.0 [1.6-13.5]; Clinical Benefit Rate (CBR) by Local Assessment (NUMBER) Percentage of participants = 45.4 [35.8-55.2]; Progression Free Survival (PFS) by Local Assessment (MEDIAN) months = 5.6 [4.8-6.6]; Overall Survival by Local Assessment (MEDIAN) months = 13.0 [11.2-14.0]; Pharmacokinetic (PK) Parameter: T1/2 of Total Antibody, SN-38 Glucuronide, Total SN-38, Sacituzumab Govitecan-hziy, and Free SN-38 (GEOMETRIC_MEAN) hours = 66.6; PK Parameter: AUC0-24 of Total Antibody, SN-38 Glucuronide, Total SN-38, Sacituzumab Govitecan-hziy, and Free SN-38 (GEOMETRIC_MEAN) microgram*hour per liter = 4940; PK Parameter: AUC0-168 of Total Antibody, SN-38 Glucuronide, Total SN-38, Sacituzumab Govitecan-hziy, and Free SN-38 (GEOMETRIC_MEAN) microgram*hour per liter = 20800; PK Parameter: AUC0-inf of Total Antibody, SN-38 Glucuronide, Total SN-38, Sacituzumab Govitecan-hziy, and Free SN-38 (GEOMETRIC_MEAN) microgram*hour per liter = 25100; PK Parameter: Cmax of Total Antibody, SN-38 Glucuronide, Total SN-38, Sacituzumab Govitecan-hziy, and Free SN-38 (GEOMETRIC_MEAN) microgram per liter = 245",Clinical Benefit Rate (CBR) by Local Assessment (NUMBER) Percentage of participants = 45.4 [35.8-55.2],,,,Duration of Response by ICR (MEDIAN) months = 9.1 [4.6-11.3]; Duration of Response by Local Assessment (MEDIAN) months = 7.7 [4.9-10.8],,,Objective Response Rate (ORR) by Independent Central Review (ICR) (NUMBER) Percentage of participants = 34.3 [25.4-44.0]; Objective Response Rate by Local Assessment (NUMBER) Percentage of participants = 33.3 [24.6-43.1],Overall Survival by Local Assessment (MEDIAN) months = 13.0 [11.2-14.0],Progression Free Survival (PFS) by Local Assessment (MEDIAN) months = 5.6 [4.8-6.6],,,Objective Response Rate (ORR) by Independent Central Review (ICR) (NUMBER) Percentage of participants = 34.3 [25.4-44.0]; Objective Response Rate by Local Assessment (NUMBER) Percentage of participants = 33.3 [24.6-43.1],"Percentage of Participants Experiencing Any Treatment Emergent Adverse Events and Serious Treatment Emergent Adverse Events (NUMBER) Percentage of participants = 100.0; Percentage of Participants Who Permanently Discontinued Sacituzumab Govitecan-hziy (SG) Due to Any Adverse Events, Excluding Adverse Events Leading to Death (NUMBER) Percentage of participants = 2.8; Percentage of Participants Who Required Dose Interruption Due to Any Adverse Events (NUMBER) Percentage of participants = 45.4",,
NCT01639001,A Study Of Crizotinib Versus Chemotherapy In Previously Untreated ALK Positive East Asian Non-Small Cell Lung Cancer Patients,"PHASE 3, RANDOMIZED, OPEN-LABEL STUDY OF THE EFFICACY AND SAFETY OF CRIZOTINIB VERSUS PEMETREXED/CISPLATIN OR PEMETREXED/CARBOPLATIN IN PREVIOUSLY UNTREATED EAST ASIAN PATIENTS WITH NON-SQUAMOUS CARCI",Pfizer,Pfizer,INDUSTRY,COMPLETED,2012-09-29,2015-06-30,2020-01-08,INTERVENTIONAL,PHASE3,,,,NSCLC (Non-small Cell Lung Cancer),NSCLC (Non-small Cell Lung Cancer),1,2,3,DRUG,,,1,19,True,Yes,Progression-Free Survival (PFS) Based on IRR by Treatment Arm (MEDIAN) Months = 11.1 [8.3-12.6],"Objective Response Rate (ORR) - Percentage of Participants With Objective Response Based on IRR (NUMBER) Percentage of participants = 87.5 [79.6-93.2]; Overall Survival (OS) (MEDIAN) Months = 33.7 [26.5-42.5]; Percentage of Participants With Disease Control at 12 Weeks Based on IRR (NUMBER) Percentage of participants = 82.7 [74.0-89.4]; Estimate of the Percentage of Participants Surviving at 1 Year and at 18 Months (NUMBER) Percentage of paricipants = 79.3 [70.0-86.0]; Duration of Response (DR) Based on IRR (MEDIAN) Weeks = 44.4 [35.9-60.0]; Time to Tumor Response (TTR) Based on IRR (MEDIAN) Weeks = 6.3 [5.1-24.9]; Time to Progression (TTP) Based on IRR (MEDIAN) Months = 12.0 [8.4-15.4]; ; Extracranial Time to Progression (EC-TTP) Based on IRR (MEDIAN) Months = 18.0 [12.3-20.9]; Time to Deterioration (TTD) in Participant Reported Pain, Dyspnea, or Cough Assessed Using Quality of Life Questionnaire Supplement Module for Lung Cancer (QLQ-LC13) (MEDIAN) Months = 2.8 [1.4-6.9]; Change From Baseline in Functioning and Global Quality of Life (QOL) as Assessed by the European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC-QLQ-C30) (MEAN) Units on a scale = 5.0891 [2.53-7.64]; Change From Baseline Scores in QLQ-C30 Symptoms as Assessed by the EORTC-QLQ-C30 (MEAN) Units on a scale = -1.5967 [-4.18-0.99]; Change From Baseline in Lung Cancer Symptom Scores as Assessed by the EORTC Quality of Life Questionnaire-Lung Cancer 13 (QLQ-LC13) (MEAN) Units on a scale = -2.0837 [-4.41-0.24]; Change From Baseline in General Health Status as Assessed by EuroQol 5D (EQ-5D)-Visual Analog Scale (VAS) (MEAN) Units on a scale = 3.4209 [1.20-5.64]; Change From Baseline in General Health Status as Assessed by EQ-5D-Index (MEAN) Units on a scale = 0.0502 [0.02-0.08]; Percentage of Participants With Visual Disturbance as Assessed by Visual Symptom Assessment Questionnaire (VSAQ-ALK) (NUMBER) Percentage of participants = 6.8; Agreement Between Central Laboratory ALK FISH and ALK IHC Test Results - Molecular Profiling Evaluable (COUNT_OF_PARTICIPANTS) Participants = 218 [91.4-94.9]; Percentage of Participants With Treatment-Emergent Adverse Events (AEs; All Causalities) (NUMBER) Percentage of participants = 99.0; Percentage of Participants With Treatment-Emergent AEs (Treatment Related) (NUMBER) Percentage of participants = 98.1",,,,,Duration of Response (DR) Based on IRR (MEDIAN) Weeks = 44.4 [35.9-60.0],,,Objective Response Rate (ORR) - Percentage of Participants With Objective Response Based on IRR (NUMBER) Percentage of participants = 87.5 [79.6-93.2],Overall Survival (OS) (MEDIAN) Months = 33.7 [26.5-42.5],Progression-Free Survival (PFS) Based on IRR by Treatment Arm (MEDIAN) Months = 11.1 [8.3-12.6],,"Time to Deterioration (TTD) in Participant Reported Pain, Dyspnea, or Cough Assessed Using Quality of Life Questionnaire Supplement Module for Lung Cancer (QLQ-LC13) (MEDIAN) Months = 2.8 [1.4-6.9]; Change From Baseline in Functioning and Global Quality of Life (QOL) as Assessed by the European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC-QLQ-C30) (MEAN) Units on a scale = 5.0891 [2.53-7.64]; Change From Baseline in Lung Cancer Symptom Scores as Assessed by the EORTC Quality of Life Questionnaire-Lung Cancer 13 (QLQ-LC13) (MEAN) Units on a scale = -2.0837 [-4.41-0.24]; Change From Baseline in General Health Status as Assessed by EuroQol 5D (EQ-5D)-Visual Analog Scale (VAS) (MEAN) Units on a scale = 3.4209 [1.20-5.64]",Objective Response Rate (ORR) - Percentage of Participants With Objective Response Based on IRR (NUMBER) Percentage of participants = 87.5 [79.6-93.2],Percentage of Participants With Treatment-Emergent Adverse Events (AEs; All Causalities) (NUMBER) Percentage of participants = 99.0,,Time to Progression (TTP) Based on IRR (MEDIAN) Months = 12.0 [8.4-15.4]; Extracranial Time to Progression (EC-TTP) Based on IRR (MEDIAN) Months = 18.0 [12.3-20.9]
NCT01642004,Study of BMS-936558 (Nivolumab) Compared to Docetaxel in Previously Treated Advanced or Metastatic Squamous Cell Non-small Cell Lung Cancer (NSCLC) (C,An Open-Label Randomized Phase III Trial of BMS-936558 (Nivolumab) Versus Docetaxel in Previously Treated Advanced or Metastatic Squamous Cell Non-small Cell Lung Cancer (NSCLC),Bristol-Myers Squibb,Bristol-Myers Squibb,INDUSTRY,COMPLETED,2012-10-16,2014-11-17,2021-08-16,INTERVENTIONAL,PHASE3,,,,Squamous Cell Non-small Cell Lung Cancer,Squamous Cell Non-small Cell Lung Cancer,1,2,2,BIOLOGICAL; DRUG,,,3,9,True,Yes,Overall Survival (OS) Time in Months for All Randomized Participants at Primary Endpoint (MEDIAN) months = 9.23 [7.33-13.27]; Overall Survival (OS) Rate in All Randomized Participants (NUMBER) Percent probability of OS = 63.7 [55.0-71.2]; Number of Deaths From Any Cause in All Randomized Participants at Primary Endpoint (NUMBER) Participants = 86,Objective Response Rate (ORR) in All Randomized Participants (NUMBER) Percentage of participants = 20.0 [13.6-27.7]; Time To Response (TTR) in Months for All Confirmed Responders (MEDIAN) Months = 2.23 [1.6-11.8]; Duration of Objective Response (DOR) in Months for All Confirmed Responders (MEDIAN) Months = 24.51 [9.76-69.65]; Progression Free Survival Rate (PFSR) (NUMBER) Percentage of participants = 38.4 [30.0-46.8]; Progression-Free Survival (PFS) Time in Months for All Randomized Participants (MEDIAN) Months = 3.48 [2.14-5.06]; Percentage of Participants Experiencing Disease-related Symptom Improvement by Week 12 (NUMBER) percentage of participants = 18.5 [12.4-26.1]; Overall Survival (OS) Time in Months by Baseline PD-L1 Expression for All Randomized Participants (MEDIAN) Months = 9.95 [5.82-16.69]; Objective Response Rate (ORR) by Baseline PD-L1 Expression for All Randomized Participants (NUMBER) Percentage of participants = 21.4 [10.3-36.8]; Progression Free Survival (PFS) Time in Months by Baseline PD-L1 Expression for All Randomized Participants (MEDIAN) Months = 5.06 [2.10-7.56],,,,,,,,Objective Response Rate (ORR) in All Randomized Participants (NUMBER) Percentage of participants = 20.0 [13.6-27.7]; Objective Response Rate (ORR) by Baseline PD-L1 Expression for All Randomized Participants (NUMBER) Percentage of participants = 21.4 [10.3-36.8],Overall Survival (OS) Time in Months for All Randomized Participants at Primary Endpoint (MEDIAN) months = 9.23 [7.33-13.27]; Overall Survival (OS) Rate in All Randomized Participants (NUMBER) Percent probability of OS = 63.7 [55.0-71.2]; Overall Survival (OS) Time in Months by Baseline PD-L1 Expression for All Randomized Participants (MEDIAN) Months = 9.95 [5.82-16.69],Progression Free Survival Rate (PFSR) (NUMBER) Percentage of participants = 38.4 [30.0-46.8]; Progression-Free Survival (PFS) Time in Months for All Randomized Participants (MEDIAN) Months = 3.48 [2.14-5.06]; Progression Free Survival (PFS) Time in Months by Baseline PD-L1 Expression for All Randomized Participants (MEDIAN) Months = 5.06 [2.10-7.56],,,Objective Response Rate (ORR) in All Randomized Participants (NUMBER) Percentage of participants = 20.0 [13.6-27.7]; Objective Response Rate (ORR) by Baseline PD-L1 Expression for All Randomized Participants (NUMBER) Percentage of participants = 21.4 [10.3-36.8],,,
NCT01642251,Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer,Phase I and Randomized Phase II Double Blind Clinical Trial of Cisplatin and Etoposide in Combination With Veliparib (ABT-888) or Placebo as Frontline Therapy for Extensive Stage Small Cell Lung Cance,National Cancer Institute (NCI),National Cancer Institute (NCI),NIH,COMPLETED,2012-09-28,2016-12-08,2018-07-02,INTERVENTIONAL,PHASE1; PHASE2,,,,Extensive Stage Small Cell Lung Carcinoma,Extensive Stage Small Cell Lung Carcinoma; Large Cell Lung Carcinoma; Neuroendocrine Carcinoma,5,2,4,DRUG,,,2,2,True,Yes,Recommended Phase II Dose (Phase I) (NUMBER) mg = 100; Progression Free Survival (Phase II) (MEDIAN) months = 6.1 [5.9-6.2],Overall Survival (OS) (MEDIAN) months = 10.3 [8.9-12.0]; Overall Response Rate (ORR) (NUMBER) percentage of patients = 72 [59-82],,,,,,,,,Overall Survival (OS) (MEDIAN) months = 10.3 [8.9-12.0],Progression Free Survival (Phase II) (MEDIAN) months = 6.1 [5.9-6.2],,,Overall Response Rate (ORR) (NUMBER) percentage of patients = 72 [59-82],,,
NCT01649947,Modulation of Autophagy in Patients With Advanced/Recurrent Non-small Cell Lung Cancer - Phase II,Modulation of Autophagy With Hydroxychloroquine in Patients With Advanced/Recurrent Non-small Cell Lung Cancer - a Phase II Study. A Study of The Cancer Institute of New Jersey Oncology Group (CINJOG),"Rutgers, The State University of New Jersey","Rutgers, The State University of New Jersey",OTHER,COMPLETED,2011-12-23,2015-06-30,2015-06-30,INTERVENTIONAL,PHASE2,,,,Non-small Cell Lung Cancer,Non-small Cell Lung Cancer; Advanced Non-small Cell Lung Cancer; Recurrent Non-small Cell Lung Cancer,3,2,4,DRUG,,,1,1,True,Yes,"Antitumor Activity, as Measured by Tumor Response Rate of Hydroxychloroquine, Paclitaxel, Carboplatin, and Bevacizumab (for Eligible Patients) in Patients With Advanced or Recurrent NSCLC Cancer (NUMBER) percentage of participants = 55 [23.4-83.0]",Progression Free Survival (PFS) (MEDIAN) months = 4.2 [1.8-6.4],,,,,,,,,,Progression Free Survival (PFS) (MEDIAN) months = 4.2 [1.8-6.4],,,"Antitumor Activity, as Measured by Tumor Response Rate of Hydroxychloroquine, Paclitaxel, Carboplatin, and Bevacizumab (for Eligible Patients) in Patients With Advanced or Recurrent NSCLC Cancer (NUMBER) percentage of participants = 55 [23.4-83.0]",,,
NCT01657799,Comparison of Veliparib and Whole Brain Radiation Therapy (WBRT) Versus Placebo and WBRT in Adults With Brain Metastases From Non-Small Cell Lung Canc,"A Randomized, Double-Blind, Phase 2, Dose-Ranging Study to Evaluate the Safety and Efficacy of Veliparib and Whole Brain Radiation Therapy Versus Placebo and Whole Brain Radiation Therapy in Subjects ",AbbVie,"AbbVie (prior sponsor, Abbott)",INDUSTRY,COMPLETED,2012-10-19,2015-01-22,2015-01-22,INTERVENTIONAL,PHASE2,,,,Brain Metastases From Non-small Cell Lung Cancer,Brain Metastases From Non-small Cell Lung Cancer,1,3,3,DRUG; RADIATION,,,1,3,True,Yes,Overall Survival (MEDIAN) days = 185 [137-251],Best Tumor Response Rate (NUMBER) percentage of participants = 41.2 [31.5-51.4]; Time to Intracranial Progression (Radiographic) (MEDIAN) days = 259; Time to Clinical Brain Metastasis Progression (MEDIAN) days = 348,,,,,,,,,Overall Survival (MEDIAN) days = 185 [137-251],,,,Best Tumor Response Rate (NUMBER) percentage of participants = 41.2 [31.5-51.4],,,
NCT01658813,"5-Fluorouracil Followed by Interferon-alfa-2b in Previously-treated Metastatic Gastrointestinal, Kidney, or Lung Cancer","Phase II Trial of Chemoimmunotherapy With 5-Fluorouracil Followed by Interferon-alfa-2b in Previously-treated Metastatic Gastrointestinal, Kidney, or Lung Cancer",Western Regional Medical Center,Western Regional Medical Center,OTHER,COMPLETED,2012-07,2014-07,2014-07,INTERVENTIONAL,PHASE2,,,,Gastrointestinal Cancer Metastatic,Gastrointestinal Cancer Metastatic; Renal Cell Cancer Metastatic; Non Small Cell Lung Cancer Metastatic,3,1,1,DRUG,,,1,4,True,Yes,,; ; ; ,,,,,,,,,,,,,,,,
NCT01667562,A Study of Erlotinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer,"Phase IIIb, Open-Label Study of Erlotinib (Tarceva®) Treatment in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Present Activating Mutations in the Tyrosine Kinase Domain",Hoffmann-La Roche,Hoffmann-La Roche,INDUSTRY,COMPLETED,2012-01-20,2017-09-07,2017-09-07,INTERVENTIONAL,PHASE3,,,,Non-Small Cell Lung Cancer,Non-Small Cell Lung Cancer,1,2,1,DRUG,,,1,5,True,Yes,Progression-Free Survival as Assessed by Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 (v 1.1) (MEDIAN) months = 9.574 [5.525-13.662],Proportion of Participants With Objective Response as Assessed by RECIST v 1.1 (NUMBER) proportion of participants = 0.67 [0.49-0.81]; Proportion of Participants With Disease Control as Assessed by RECIST v 1.1 (NUMBER) proportion of participants = 0.97 [0.82-1.00]; Proportion of Participants With Epidermal Growth Factor Receptor (EGFR) Mutations (NUMBER) proportion of participants = 0.08 [0.06-0.11]; Percentage of Participants With Adverse Events (NUMBER) percentage of participants = 76.7; Change From Baseline to End of Study in Quality of Life Score Using The Functional Assessment of Cancer Therapy Lung (FACT-L) (MEAN) unit on a scale = -2.83,,,,,,,,,,Progression-Free Survival as Assessed by Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 (v 1.1) (MEDIAN) months = 9.574 [5.525-13.662],,Change From Baseline to End of Study in Quality of Life Score Using The Functional Assessment of Cancer Therapy Lung (FACT-L) (MEAN) unit on a scale = -2.83,,Percentage of Participants With Adverse Events (NUMBER) percentage of participants = 76.7,,
NCT01673867,Study of BMS-936558 (Nivolumab) Compared to Docetaxel in Previously Treated Metastatic Non-squamous NSCLC,An Open-Label Randomized Phase III Trial of BMS-936558 (Nivolumab) Versus Docetaxel in Previously Treated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC),Bristol-Myers Squibb,Bristol-Myers Squibb,INDUSTRY,COMPLETED,2012-11-02,2015-02-05,2021-12-17,INTERVENTIONAL,PHASE3,,,,Non-Squamous Cell Non-small Cell Lung Cancer,Non-Squamous Cell Non-small Cell Lung Cancer,1,2,2,BIOLOGICAL; DRUG,,,1,7,True,Yes,Overall Survival (OS) Time in Months for All Randomized Participants at Primary Endpoint (MEDIAN) Months = 12.19 [9.66-14.98],Objective Response Rate (ORR) (NUMBER) Percentage of participants = 19.5 [15.1-24.5]; Time To Objective Response (TTOR) (MEDIAN) Months = 2.10 [1.2-34.6]; Duration of Objective Response (DOOR) (MEDIAN) Months = 17.15 [10.78-30.75]; Progression-Free Survival (PFS) (MEDIAN) Months = 2.33 [2.17-3.32]; Percentage of Participants Experiencing Disease-Related Symptom Improvement by Week 12 (NUMBER) Percentage of participants = 17.8 [13.6-22.7]; Overall Survival (OS) by PD-L1 Expression at Baseline (MEDIAN) Months = 19.91 [15.08-26.12]; Objective Response Rate (ORR) by PD-L1 Expression at Baseline (NUMBER) Percentage of participants = 36.2 [26.5-46.7],,,,,,,,Objective Response Rate (ORR) (NUMBER) Percentage of participants = 19.5 [15.1-24.5]; Objective Response Rate (ORR) by PD-L1 Expression at Baseline (NUMBER) Percentage of participants = 36.2 [26.5-46.7],Overall Survival (OS) Time in Months for All Randomized Participants at Primary Endpoint (MEDIAN) Months = 12.19 [9.66-14.98]; Overall Survival (OS) by PD-L1 Expression at Baseline (MEDIAN) Months = 19.91 [15.08-26.12],Progression-Free Survival (PFS) (MEDIAN) Months = 2.33 [2.17-3.32],,,Objective Response Rate (ORR) (NUMBER) Percentage of participants = 19.5 [15.1-24.5]; Objective Response Rate (ORR) by PD-L1 Expression at Baseline (NUMBER) Percentage of participants = 36.2 [26.5-46.7],,,
NCT01676714,Study of Dovitinib and Biomarkers in Advanced Non-Small Cell Lung Cancer or Advanced Colorectal Cancer,Phase II Study of Dovitinib and Pilot Study of Fibroblast Growth Factor Receptor Biomarkers in Advanced Non-Small Cell Lung Cancer or Advanced Colorectal Cancer Previously Treated With Anti-Vascular E,"University of California, Davis","University of California, Davis",OTHER,COMPLETED,2013-02,2016-01,2016-06,INTERVENTIONAL,PHASE2,,,,Non-Small Cell Lung Cancer,Non-Small Cell Lung Cancer; Colorectal Cancer,2,1,1,DRUG,,,1,3,True,Yes,Overall Response Rate (COUNT_OF_PARTICIPANTS) Participants = 1,Disease Control Rate (NUMBER) participants = 1; Progression Free Survival (MEDIAN) months = 1.9 [0.23-4.1]; Number of Patients Who Experienced Treatment Related Toxicities (COUNT_OF_PARTICIPANTS) Participants = 7,,,,,,,,,,Progression Free Survival (MEDIAN) months = 1.9 [0.23-4.1],,,Overall Response Rate (COUNT_OF_PARTICIPANTS) Participants = 1,,,
NCT01685060,LDK378 in Adult Patients With ALK-activated NSCLC Previously Treated With Chemotherapy and Crizotinib,"A Phase II, Multicenter, Single-arm Study of Oral LDK378 in Adult Patients With ALK-activated Non-small Cell Lung Cancer Previously Treated With Chemotherapy and Crizotinib",Novartis,Novartis Pharmaceuticals,INDUSTRY,COMPLETED,2012-11-26,2016-03-29,2016-03-29,INTERVENTIONAL,PHASE2,,,,Non-Small Cell Lung Cancer,Non-Small Cell Lung Cancer,1,1,1,DRUG,,,1,11,True,Yes,Overall Response Rate (ORR) to LDK378 Per Investigator Assessment (NUMBER) Percentage of participants = 40.7 [32.5-49.3],ORR Per Blinded Independent Review Committee (BIRC) Assessment (NUMBER) Percentage of participants = 35.7 [27.8-44.2]; Duration of Response (DOR) by Investigator (MEDIAN) Months = 10.6 [7.4-14.7]; Duration of Response (DOR) by BIRC (MEDIAN) Months = 12.9 [9.3-18.4]; Disease Control Rate (DCR) (NUMBER) Percentage of participants = 76.4 [68.5-83.2]; Time to Response (TTR) Per Investigator (MEAN) Months = 3.0 [1.6-18.7]; Time to Response (TTR) Per BIRC (MEAN) Months = 2.2 [1.6-10.9]; Progression-free Survival (PFS) Per Investigator (MEDIAN) months = 5.8 [5.4-7.6]; Progression-free Survival (PFS) Per BIRC (MEDIAN) months = 7.4 [5.6-10.9]; Overall Intracranial Response Rate (OIRR) Per Investigator (NUMBER) Percentage of participants = 45.0 [23.1-68.5]; Overall Intracranial Response Rate (OIRR) Per BIRC (NUMBER) Percentage of participants = 35.7 [18.6-55.9]; Overall Survival (OS) (MEDIAN) Months = 15.6 [13.6-24.2],,,,,Duration of Response (DOR) by Investigator (MEDIAN) Months = 10.6 [7.4-14.7]; Duration of Response (DOR) by BIRC (MEDIAN) Months = 12.9 [9.3-18.4],,,ORR Per Blinded Independent Review Committee (BIRC) Assessment (NUMBER) Percentage of participants = 35.7 [27.8-44.2],Overall Survival (OS) (MEDIAN) Months = 15.6 [13.6-24.2],Progression-free Survival (PFS) Per Investigator (MEDIAN) months = 5.8 [5.4-7.6]; Progression-free Survival (PFS) Per BIRC (MEDIAN) months = 7.4 [5.6-10.9],,,Overall Response Rate (ORR) to LDK378 Per Investigator Assessment (NUMBER) Percentage of participants = 40.7 [32.5-49.3]; Overall Intracranial Response Rate (OIRR) Per Investigator (NUMBER) Percentage of participants = 45.0 [23.1-68.5]; Overall Intracranial Response Rate (OIRR) Per BIRC (NUMBER) Percentage of participants = 35.7 [18.6-55.9],,,
NCT01685138,LDK378 in Crizotinib naïve Adult Patients With ALK-activated Non-small Cell Lung Cancer,"A Phase II, Multicenter, Single-arm Study of Oral LDK378 in Crizotinib naïve Adult Patients With ALK-activated Non-small Cell Lung Cancer",Novartis,Novartis Pharmaceuticals,INDUSTRY,COMPLETED,2012-12-20,2018-01-22,2018-01-22,INTERVENTIONAL,PHASE2,,,,Non-Small Cell Lung Cancer,Non-Small Cell Lung Cancer,1,1,1,DRUG,,,1,10,True,Yes,Overall Response Rate (ORR) by Investigator Assessment (NUMBER) Percentage of participants = 67.7 [58.8-75.9],ORR by Blinded Independent Review Committee (BIRC) (NUMBER) Percentage of participants = 63.7 [54.6-72.2]; Duration of Response (DOR) as Per Investigator (MEDIAN) Months = 24.0 [14.8-37.5]; Duration of Response (DOR) as Per BIRC (MEDIAN) Months = 27.3 [16.6-44.3]; Disease Control Rate (DCR) as Per Investigator and BIRC (NUMBER) Percentage of participants = 90.3 [83.7-94.9]; Time to Response (TTR) as Per Investigator (MEAN) Months = 2.5; Time to Response (TTR) as Per BIRC (MEAN) Months = 2.2; Overall Intracranial Response Rate (OIRR) as Per Investigator (NUMBER) Percentage of participants = 20.0 [2.5-55.6]; Overall Intracranial Response Rate (OIRR) as Per BIRC (NUMBER) Percentage of participants = 61.5 [31.6-86.1]; Progression-free Survival (PFS) Per Investigator and BIRC (MEDIAN) Months = 16.6 [11.0-23.2]; Overall Survival (OS) (MEDIAN) Months = 51.3 [42.7-55.3],,,,,Duration of Response (DOR) as Per Investigator (MEDIAN) Months = 24.0 [14.8-37.5]; Duration of Response (DOR) as Per BIRC (MEDIAN) Months = 27.3 [16.6-44.3],,,ORR by Blinded Independent Review Committee (BIRC) (NUMBER) Percentage of participants = 63.7 [54.6-72.2],Overall Survival (OS) (MEDIAN) Months = 51.3 [42.7-55.3],Progression-free Survival (PFS) Per Investigator and BIRC (MEDIAN) Months = 16.6 [11.0-23.2],,,Overall Response Rate (ORR) by Investigator Assessment (NUMBER) Percentage of participants = 67.7 [58.8-75.9]; Overall Intracranial Response Rate (OIRR) as Per Investigator (NUMBER) Percentage of participants = 20.0 [2.5-55.6]; Overall Intracranial Response Rate (OIRR) as Per BIRC (NUMBER) Percentage of participants = 61.5 [31.6-86.1],,,
NCT01702844,Single Arm on the Tolerability of Weekly Nab-paclitaxel,"LCCC 1210 - Phase II, Multicenter, Single Arm Study of the Tolerability of Weekly Nab-paclitaxel as Second Line Treatment for Elderly Patients With Advanced Lung Cancer",UNC Lineberger Comprehensive Cancer Center,UNC Lineberger Comprehensive Cancer Center,OTHER,COMPLETED,2013-06-25,2017-06-23,2019-07-12,INTERVENTIONAL,PHASE2,,,,Non Small Cell Lung Cancer (NSCLC),Non Small Cell Lung Cancer (NSCLC),1,1,1,DRUG,,,1,3,True,Yes,Number of Subjects Without Any Adverse Events Grade 3 or Higher (COUNT_OF_PARTICIPANTS) Participants = 28,Median Overall Survival (MEDIAN) Months = 9.3 [6.4-12.1]; Median Progression Free Survival (MEDIAN) Months = 5.2 [2.0-7.4]; Overall Response Rate (NUMBER) percentage of patients with response = 34.2 [19.6-51.4],,,,,,,,,Median Overall Survival (MEDIAN) Months = 9.3 [6.4-12.1],Median Progression Free Survival (MEDIAN) Months = 5.2 [2.0-7.4],,,Overall Response Rate (NUMBER) percentage of patients with response = 34.2 [19.6-51.4],Number of Subjects Without Any Adverse Events Grade 3 or Higher (COUNT_OF_PARTICIPANTS) Participants = 28,,
NCT01703091,A Study of Docetaxel and Ramucirumab Versus Docetaxel and Placebo in the Treatment of Stage IV Non-Small Cell Lung Cancer,"A Randomized, Double-Blind, Phase 2 Study of Docetaxel and Ramucirumab Versus Docetaxel and Placebo in the Treatment of Stage IV Non-Small Cell Lung Cancer Following Disease Progression After One Prio",Eli Lilly and Company,Eli Lilly and Company,INDUSTRY,COMPLETED,2012-12,2014-12,2016-07,INTERVENTIONAL,PHASE2,,,,Non-small Cell Lung Cancer Metastatic,Non-small Cell Lung Cancer Metastatic,1,2,3,DRUG,,,1,5,True,Yes,Progression-Free Survival (PFS) (MEDIAN) Months = 5.22 [3.52-6.97],"Overall Survival (OS) (MEDIAN) Months = 15.15 [12.45-26.55]; Percentage of Participants Who Achieved Best Overall Tumor Response of Complete Response (CR) or Partial Response (PR) [Objective Tumor Response Rate (ORR)] (NUMBER) Percentage of Participants = 28.9 [19.1-40.5]; Percentage of Participants Who Achieved Best Overall Disease Response of CR, PR or Stable Disease (SD) [Disease Control Rate (DCR)] (NUMBER) Percentage of Participants = 78.9 [68.1-87.5]; Change From Baseline in European Quality of Life Questionnaire - 5 Dimension (EQ-5D) Index Score (MEAN) Units on a Scale = -0.024; Change From Baseline in Lung Cancer Symptom Scale (LCSS) (MEAN) Millimeter = -12.5",,Percentage of Participants Who Achieved Best Overall Tumor Response of Complete Response (CR) or Partial Response (PR) [Objective Tumor Response Rate (ORR)] (NUMBER) Percentage of Participants = 28.9 [19.1-40.5],,,,,,,Overall Survival (OS) (MEDIAN) Months = 15.15 [12.45-26.55],Progression-Free Survival (PFS) (MEDIAN) Months = 5.22 [3.52-6.97],"Percentage of Participants Who Achieved Best Overall Tumor Response of Complete Response (CR) or Partial Response (PR) [Objective Tumor Response Rate (ORR)] (NUMBER) Percentage of Participants = 28.9 [19.1-40.5]; Percentage of Participants Who Achieved Best Overall Disease Response of CR, PR or Stable Disease (SD) [Disease Control Rate (DCR)] (NUMBER) Percentage of Participants = 78.9 [68.1-87.5]",Change From Baseline in European Quality of Life Questionnaire - 5 Dimension (EQ-5D) Index Score (MEAN) Units on a Scale = -0.024,Percentage of Participants Who Achieved Best Overall Tumor Response of Complete Response (CR) or Partial Response (PR) [Objective Tumor Response Rate (ORR)] (NUMBER) Percentage of Participants = 28.9 [19.1-40.5],,,
NCT01708954,Erlotinib Hydrochloride and Cabozantinib-s-Malate Alone or in Combination as Second or Third Line Therapy in Treating Patients With Stage IV Non-small,"A Randomized Phase II Trial of Erlotinib, Cabozantinib, or Erlotinib Plus Cabozantinib as 2nd or 3rd Line Therapy in Patients With EGFR Wild-Type NSCLC",National Cancer Institute (NCI),National Cancer Institute (NCI),NIH,ACTIVE_NOT_RECRUITING,2013-02-13,2015-08-14,2026-03-18,INTERVENTIONAL,PHASE2,,,,Recurrent Lung Non-Small Cell Carcinoma,Recurrent Lung Non-Small Cell Carcinoma; Stage IV Lung Non-Small Cell Cancer AJCC v7,2,4,3,DRUG; OTHER,,,1,4,True,Yes,Progression-free Survival (PFS) (MEDIAN) months = 1.8 [1.7-2.2],Overall Survival (OS) (MEDIAN) months = 5.1 [3.3-9.3]; Proportion of Patients With Objective Response (NUMBER) proportion of participants = 0.03 [0.0009-0.141]; Proportion of Patients With MET Positivity (NUMBER) proportion of participants = 0.80 [0.61-0.92]; Proportion of Patients With Worst Grade Toxicities of Grade 3 or Higher (NUMBER) Proportion of participants = 0.325 [0.204-0.466],,,,,,,,,Overall Survival (OS) (MEDIAN) months = 5.1 [3.3-9.3],Progression-free Survival (PFS) (MEDIAN) months = 1.8 [1.7-2.2],,,,,,
NCT01721759,Study of Nivolumab (BMS-936558) in Patients With Advanced or Metastatic Squamous Cell Nonsmall-cell Lung Cancer Who Have Received At Least 2 Prior Sys,A Single-Arm Phase 2 Study of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Squamous Cell Non-Small Cell Lung Cancer Who Have Received At Least Two Prior Systemic Regimens,Bristol-Myers Squibb,Bristol-Myers Squibb,INDUSTRY,COMPLETED,2012-11-16,2014-01-22,2021-04-22,INTERVENTIONAL,PHASE2,,,,Squamous Cell Non-small Cell Lung Cancer,Squamous Cell Non-small Cell Lung Cancer,1,1,1,DRUG,,,2,2,True,Yes,Objective Response Rate (ORR) as Assessed by Independent Radiology Review Committee (IRC) (NUMBER) Percentage of Participants = 14.5 [8.7-22.2]; Duration of Response (DOR) as Assessed by Independent Radiology Review Committee (IRC) (MEDIAN) Months = 12 [6.7-19.3],Objective Response Rate (ORR) as Assessed by Investigator (NUMBER) Percentage of Participants = 15.4 [9.4-23.2]; Duration of Response (DOR) as Assessed by Investigator (MEDIAN) Months = 16.00 [12.45-29.54],,,,,Duration of Response (DOR) as Assessed by Independent Radiology Review Committee (IRC) (MEDIAN) Months = 12 [6.7-19.3]; Duration of Response (DOR) as Assessed by Investigator (MEDIAN) Months = 16.00 [12.45-29.54],,,Objective Response Rate (ORR) as Assessed by Independent Radiology Review Committee (IRC) (NUMBER) Percentage of Participants = 14.5 [8.7-22.2]; Objective Response Rate (ORR) as Assessed by Investigator (NUMBER) Percentage of Participants = 15.4 [9.4-23.2],,,,,Objective Response Rate (ORR) as Assessed by Independent Radiology Review Committee (IRC) (NUMBER) Percentage of Participants = 14.5 [8.7-22.2]; Objective Response Rate (ORR) as Assessed by Investigator (NUMBER) Percentage of Participants = 15.4 [9.4-23.2],,,
NCT01725165,Surgery and/or Radiation Therapy or Standard Therapy and/or Clinical Observation in Treating Patients With Previously Treated Stage IV Non-small Cell ,A Randomized Phase II Study Assessing the Efficacy of Local Consolidative Therapy for Non-Small Cell Lung Cancer Patients With Induced Oligometastatic Disease,M.D. Anderson Cancer Center,M.D. Anderson Cancer Center,OTHER,COMPLETED,2012-11-28,2024-05-08,2024-05-08,INTERVENTIONAL,PHASE2,,,,Recurrent Lung Non-Small Cell Carcinoma,Recurrent Lung Non-Small Cell Carcinoma; Stage IV Non-Small Cell Lung Cancer AJCC v7,2,2,6,OTHER; PROCEDURE; RADIATION,,,1,1,True,Yes,Progression-free Survival (PFS) (MEDIAN) Months = 14.2 [7.4-23.1],Time to New Lesion Progression (MEDIAN) Months = 14.2 [5.7-24.3],,,,,,,,,,Progression-free Survival (PFS) (MEDIAN) Months = 14.2 [7.4-23.1],,,,,,
NCT01737502,Sirolimus and Auranofin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer or Small Cell Lung Cancer,A Phase I-II Trial of Combined PKCι and mTOR Inhibition for Patients With Advanced or Recurrent Lung Cancer (NSCLC and SCLC) Without Standard Treatment Options,Mayo Clinic,Mayo Clinic,OTHER,COMPLETED,2014-05-14,2023-04-24,2023-04-24,INTERVENTIONAL,PHASE1; PHASE2,,,,Extensive Stage Small Cell Lung Carcinoma,Extensive Stage Small Cell Lung Carcinoma; Lung Adenocarcinoma; Recurrent Non-Small Cell Lung Carcinoma,8,1,4,DRUG; OTHER,,,3,4,True,Yes,Number of Phase 1 Patients Experiencing a DLT (COUNT_OF_PARTICIPANTS) Participants = 0; Number Phase 1 Patients Experiencing a Grade 3+ AE (COUNT_OF_PARTICIPANTS) Participants = 2; Progression-free Survival Rate (NUMBER) percentage of participants = 66.7 [9.4-99.2],Overall Survival Time (MEDIAN) months = 4.9; Progression-free Survival Time (MEDIAN) months = 4.9; Number of Patients Achieving a Complete Response (CR) or Partial Response (PR) Noted as the Objective Status (COUNT_OF_PARTICIPANTS) Participants = 1; Duration of Response (MEAN) months = 16.25 [14.7-17.8],,Number of Patients Achieving a Complete Response (CR) or Partial Response (PR) Noted as the Objective Status (COUNT_OF_PARTICIPANTS) Participants = 1,,,Duration of Response (MEAN) months = 16.25 [14.7-17.8],,,,Overall Survival Time (MEDIAN) months = 4.9,Progression-free Survival Rate (NUMBER) percentage of participants = 66.7 [9.4-99.2]; Progression-free Survival Time (MEDIAN) months = 4.9,Number of Patients Achieving a Complete Response (CR) or Partial Response (PR) Noted as the Objective Status (COUNT_OF_PARTICIPANTS) Participants = 1,,,Number Phase 1 Patients Experiencing a Grade 3+ AE (COUNT_OF_PARTICIPANTS) Participants = 2,,
NCT01750281,Assess Efficacy and Safety of AZD6244 in Combination With Docetaxel in Patients Receiving Second Line Non Small Cell Lung Cancer Treatment.,"A Phase II, Double-Blind, Randomised, Placebo-Controlled Study to Assess the Efficacy and Safety of Selumetinib (AZD6244; ARRY-142886) (Hyd-Sulfate) in Combination With Docetaxel, Compared With Placeb",AstraZeneca,AstraZeneca,INDUSTRY,COMPLETED,2012-12-18,2016-01-27,2022-10-31,INTERVENTIONAL,PHASE2,,,,Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV,Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV,1,3,4,DRUG,,,1,1,True,Yes,Progression Free Survival (PFS) (MEDIAN) Months = 4.3 [1.4-5.6],Overall Survival (OS) (MEDIAN) Months = 11.5 [4.6-28.0],,,,,,,,,Overall Survival (OS) (MEDIAN) Months = 11.5 [4.6-28.0],Progression Free Survival (PFS) (MEDIAN) Months = 4.3 [1.4-5.6],,,,,,
NCT01752400,AUY922 for Advanced ALK-positive NSCLC,"A Phase II Open-Label Trial of AUY922, an HSP90 Inhibitor, in Patients With ALK-Rearranged Advanced Non-Small Cell Lung Cancer and Acquired Resistance to Prior ALK Tyrosine Kinase Inhibition",Massachusetts General Hospital,Massachusetts General Hospital,OTHER,COMPLETED,2013-01,2017-06,2017-11,INTERVENTIONAL,PHASE2,,,,Non Small Cell Lung Cancer,Non Small Cell Lung Cancer,1,1,1,DRUG,,,1,7,True,Yes,Objective Response Rate (COUNT_OF_PARTICIPANTS) Participants = 0,Progression-free Survival (MEDIAN) Months = 1.43 [1.3-2.8]; Disease Control Rate (COUNT_OF_PARTICIPANTS) Participants = 0; Number of Participants Who Develop Adverse Events on AUY922 (COUNT_OF_PARTICIPANTS) Participants = 6; Number of Participants With Concurrent KRAS Mutations (COUNT_OF_PARTICIPANTS) Participants = 0; ; ALK Mutation Status (COUNT_OF_PARTICIPANTS) Participants = 1; Median Overall Survival (MEDIAN) Months = 26.87 [9.03-26.87],,,,,,,,Objective Response Rate (COUNT_OF_PARTICIPANTS) Participants = 0,Median Overall Survival (MEDIAN) Months = 26.87 [9.03-26.87],Progression-free Survival (MEDIAN) Months = 1.43 [1.3-2.8],,,Objective Response Rate (COUNT_OF_PARTICIPANTS) Participants = 0,Number of Participants Who Develop Adverse Events on AUY922 (COUNT_OF_PARTICIPANTS) Participants = 6,,
NCT01753414,Radical Resection Vs. Ablative Stereotactic Radiotherapy in Patients With Operable Stage I NSCLC,POSTILV: A RANDOMIZED PHASE II TRIAL IN PATIENTS WITH OPERABLE STAGE I NON-SMALL CELL LUNG CANCER: RADICAL RESECTION VERSUS ABLATIVE STEREOTACTIC RADIOTHERAPY - This is a Limited Participation Study.,Radiation Therapy Oncology Group,Radiation Therapy Oncology Group,NETWORK,ACTIVE_NOT_RECRUITING,2012-12,2023-04-03,2026-01,INTERVENTIONAL,PHASE2,,,,Non-small Cell Lung Cancer,Non-small Cell Lung Cancer,1,2,2,PROCEDURE; RADIATION,,,1,11,True,Yes,Percentage of Participants Alive Without Local-regional Failure at Two Years (Local-regional Tumor Control) (NUMBER) percentage of participants = 95.2 [70.7-99.3],Overall Survival (Percentage of Participants Alive) (NUMBER) percentage of participants = 85.7 [62.0-95.2]; Percentage of Participants With Local-regional Failure (LRF) (NUMBER) percentage of participants = 4.8 [0.3-20.2]; Percentage of Participants With Distant Failure (NUMBER) percentage of participants = 23.8 [8.3-43.6]; Percentage of Participants Alive Without Disease [Disease-free Survival (DFS)] (NUMBER) percentage of participants = 65.0 [40.3-81.5]; Number of Participants by Failure Site (COUNT_OF_PARTICIPANTS) Participants = 2; Best PET Tumor Response (COUNT_OF_PARTICIPANTS) Participants = 0; Number of Participants by Highest Grade Adverse Event Reported (COUNT_OF_PARTICIPANTS) Participants = 7; Number of Participants With Surgical and Radiation Treatment Credentialing Completed and Documented Before Enrollment (Trial Feasibility) (COUNT_OF_PARTICIPANTS) Participants = 22; Number of Eligible Participants (Trial Feasibility) (COUNT_OF_PARTICIPANTS) Participants = 17; Number of Participants With Baseline Forms Completed and Provided Within 30 Days of Randomization (Trial Feasibility) (COUNT_OF_PARTICIPANTS) Participants = 12; Number of Participants Lost to Follow-up (Trial Feasibility) (COUNT_OF_PARTICIPANTS) Participants = 1,,,Percentage of Participants Alive Without Disease [Disease-free Survival (DFS)] (NUMBER) percentage of participants = 65.0 [40.3-81.5],,,,,,Overall Survival (Percentage of Participants Alive) (NUMBER) percentage of participants = 85.7 [62.0-95.2],,,,,,,
NCT01763645,A Safety and Efficacy Study of BCD-021 With Paclitaxel and Carboplatin Compared to Avastin With Paclitaxel and Carboplatin in Non-Small Cell Lung Canc,"International Multicenter Randomized Double Blind Phase III Trial Comparing Safety and Efficacy of BCD-021 (CJSC BIOCAD, Russia) and Paclitaxel + Carboplatin to Avastin® (F. Hoffmann-La Roche Ltd, Swi",Biocad,Biocad,INDUSTRY,COMPLETED,2012-10,2014-11,2014-11,INTERVENTIONAL,PHASE3,,,,Non-small Cell Lung Cancer,Non-small Cell Lung Cancer,1,2,3,DRUG,,,2,5,True,Yes,Overall Response Rate (NUMBER) percentage of participans = 34.63; Area Under the Curve After the First Test Drug Administration (MEDIAN) (ng/ml)*hour = 26951463 [6114172.35-68355846],Complete Response Rate (NUMBER) percentage of patients = 1.85 [0.33-9.77]; Partial Response Rate (NUMBER) percentage of patients = 40.74 [28.68-54.03]; Stabilization Rate (NUMBER) percentage of patients = 51.85 [38.85-64.60]; Progression Rate (NUMBER) percentage of patients = 5.56 [1.91-15.11]; Occurrence of Anti-bevacizumab Antibodies (NUMBER) percentage of patients = 1.47,,Complete Response Rate (NUMBER) percentage of patients = 1.85 [0.33-9.77],,,,,,,,,Partial Response Rate (NUMBER) percentage of patients = 40.74 [28.68-54.03],,Overall Response Rate (NUMBER) percentage of participans = 34.63; Complete Response Rate (NUMBER) percentage of patients = 1.85 [0.33-9.77]; Partial Response Rate (NUMBER) percentage of patients = 40.74 [28.68-54.03],,,
NCT01763788,A Study of Necitumumab in the First-Line Treatment of Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC),"An Open-Label, Multicenter, Phase 1b/2 Study to Evaluate Necitumumab in Combination With Gemcitabine and Cisplatin in the First-Line Treatment of Patients With Advanced (Stage IV) Squamous Non-Small C",Eli Lilly and Company,Eli Lilly and Company,INDUSTRY,COMPLETED,2013-05-07,2017-06-28,2018-10-17,INTERVENTIONAL,PHASE1; PHASE2,,,,Squamous Non-small Cell Lung Cancer,Squamous Non-small Cell Lung Cancer,1,2,3,DRUG,,,2,13,True,Yes,Phase 1b: Number of Participants With Dose Limiting Toxicities (DLTs) (COUNT_OF_PARTICIPANTS) Participants = 0; Phase 2: Overall Survival (OS) (MEDIAN) Months = 14.92 [13.37-18.17],Phase 2: Progression Free Survival (PFS) (MEDIAN) Months = 4.21 [4.14-4.27]; Phase 1b: Percentage of Participants Who Achieve Best Overall Tumor Response of Complete Response or Partial Response (Objective Tumor Response Rate [ORR]) (NUMBER) percentage of participants = 0.0 [0.0-0.0]; Phase 2: Percentage of Participants Who Achieve Best Overall Tumor Response of Complete Response or Partial Response (Objective Tumor Response Rate [ORR]) (NUMBER) percentage of participants = 51.1 [40.8-61.4]; Phase 2: Time to Treatment Failure (TTF) (MEDIAN) Months = 4.16 [4.01-4.24]; Phase 2: Change From Baseline in EuroQol 5-Dimensional 3 Level (EuroQol-5D-3L) Index Score (MEAN) Score on a scale = 0.04; Phase 2: Change From Baseline in EuroQol 5-Dimensional 3 Level (EuroQol-5D-3L) Visual Analog Scale (VAS) (MEAN) units on a scale = 7.81; Phase 2: Change From Baseline in Lung Cancer Symptom Scale (LCSS) (MEAN) units on a scale = -4.48; Phase 1b: Pharmacokinetics (PK): Maximum Concentration (Cmax) of Necitumumab (GEOMETRIC_MEAN) micrograms/milliliter (µg/ml) = 454; Phase 1b: PK: Cmax of Gemcitabine and Cisplatin (GEOMETRIC_MEAN) nanogram per milliliter (ng/mL) = 17400; ; Phase 1b: PK: Area Under the Plasma Concentration-Time Curve From Time Zero to Infinite Time (AUC[0-infinity]) of Gemcitabine and Cisplatin (GEOMETRIC_MEAN) nanogram*hour per milliliter (ng*h/mL) = 8710; Phase 2: PK: Minimum Concentration (Ctrough) of Necitumumab (GEOMETRIC_MEAN) microgram per milliliter (µg/mL) = 77.9; Phase 2: Number of Participants With Serum Anti-Necitumumab Antibody Assessment (Immunogenicity) (COUNT_OF_PARTICIPANTS) Participants = 4,,Phase 1b: Percentage of Participants Who Achieve Best Overall Tumor Response of Complete Response or Partial Response (Objective Tumor Response Rate [ORR]) (NUMBER) percentage of participants = 0.0 [0.0-0.0]; Phase 2: Percentage of Participants Who Achieve Best Overall Tumor Response of Complete Response or Partial Response (Objective Tumor Response Rate [ORR]) (NUMBER) percentage of participants = 51.1 [40.8-61.4],,,,,,,Phase 2: Overall Survival (OS) (MEDIAN) Months = 14.92 [13.37-18.17],Phase 2: Progression Free Survival (PFS) (MEDIAN) Months = 4.21 [4.14-4.27],Phase 1b: Percentage of Participants Who Achieve Best Overall Tumor Response of Complete Response or Partial Response (Objective Tumor Response Rate [ORR]) (NUMBER) percentage of participants = 0.0 [0.0-0.0]; Phase 2: Percentage of Participants Who Achieve Best Overall Tumor Response of Complete Response or Partial Response (Objective Tumor Response Rate [ORR]) (NUMBER) percentage of participants = 51.1 [40.8-61.4],Phase 2: Change From Baseline in EuroQol 5-Dimensional 3 Level (EuroQol-5D-3L) Index Score (MEAN) Score on a scale = 0.04; Phase 2: Change From Baseline in EuroQol 5-Dimensional 3 Level (EuroQol-5D-3L) Visual Analog Scale (VAS) (MEAN) units on a scale = 7.81,Phase 1b: Percentage of Participants Who Achieve Best Overall Tumor Response of Complete Response or Partial Response (Objective Tumor Response Rate [ORR]) (NUMBER) percentage of participants = 0.0 [0.0-0.0]; Phase 2: Percentage of Participants Who Achieve Best Overall Tumor Response of Complete Response or Partial Response (Objective Tumor Response Rate [ORR]) (NUMBER) percentage of participants = 51.1 [40.8-61.4],,Phase 2: Time to Treatment Failure (TTF) (MEDIAN) Months = 4.16 [4.01-4.24],
NCT01769391,A Study of Necitumumab and Chemotherapy in Participants With Stage IV Squamous Non-Small Cell Lung Cancer,"A Randomized, Multicenter, Open-Label, Phase 2 Study of Paclitaxel-Carboplatin Chemotherapy Plus Necitumumab (IMC-11F8) Versus Paclitaxel-Carboplatin Chemotherapy Alone in the First-Line Treatment of ",Eli Lilly and Company,Eli Lilly and Company,INDUSTRY,COMPLETED,2013-01,2015-04,2017-07,INTERVENTIONAL,PHASE2,,,,Squamous Non Small Cell Lung Cancer,Squamous Non Small Cell Lung Cancer,1,2,3,DRUG,,,1,7,True,Yes,Percentage of Participants Who Achieve Best Overall Tumor Response of Complete Response (CR) or Partial Response (PR) (Objective Response Rates [ORR]) (NUMBER) percentage of participants = 48.9 [38.5-59.5],"Overall Survival (OS) (MEDIAN) months = 13.2 [9.7-15.9]; Pharmacokinetics (PK): Maximum Concentration (Cmax) of Necitumumab (GEOMETRIC_MEAN) microgram/milliliter (μg/mL) = 262.418; Percentage of Participants With Anti Necitumumab Antibodies (NUMBER) percentage of participants = 2.8; Progression-Free Survival (MEDIAN) months = 5.4 [4.2-5.7]; Percentage of Participants Who Achieve Best Overall Disease Response of Complete Response (CR), Partial Response (PR) or Stable Disease (SD) (Disease Control Rate [DCR]) (NUMBER) percentage of participants = 87.2 [78.8-93.2]; Percent Change in Tumor Size (CTS) (MEAN) percent change in tumor size = -44.3; Pharmacokinetics (PK): Minimum Concentration (Cmin) of Necitumumab (GEOMETRIC_MEAN) nanogram/milliliter (ng/mL) = 59.269",,"Percentage of Participants Who Achieve Best Overall Tumor Response of Complete Response (CR) or Partial Response (PR) (Objective Response Rates [ORR]) (NUMBER) percentage of participants = 48.9 [38.5-59.5]; Percentage of Participants Who Achieve Best Overall Disease Response of Complete Response (CR), Partial Response (PR) or Stable Disease (SD) (Disease Control Rate [DCR]) (NUMBER) percentage of participants = 87.2 [78.8-93.2]",,,,,,Percentage of Participants Who Achieve Best Overall Tumor Response of Complete Response (CR) or Partial Response (PR) (Objective Response Rates [ORR]) (NUMBER) percentage of participants = 48.9 [38.5-59.5],Overall Survival (OS) (MEDIAN) months = 13.2 [9.7-15.9],Progression-Free Survival (MEDIAN) months = 5.4 [4.2-5.7],"Percentage of Participants Who Achieve Best Overall Tumor Response of Complete Response (CR) or Partial Response (PR) (Objective Response Rates [ORR]) (NUMBER) percentage of participants = 48.9 [38.5-59.5]; Percentage of Participants Who Achieve Best Overall Disease Response of Complete Response (CR), Partial Response (PR) or Stable Disease (SD) (Disease Control Rate [DCR]) (NUMBER) percentage of participants = 87.2 [78.8-93.2]",,Percentage of Participants Who Achieve Best Overall Tumor Response of Complete Response (CR) or Partial Response (PR) (Objective Response Rates [ORR]) (NUMBER) percentage of participants = 48.9 [38.5-59.5],,,
NCT01773109,Etirinotecan Pegol (NKTR-102) in NSCLC,Phase 2 Study of Etirinotecan Pegol (NKTR-102) in the Treatment of Patients With Metastatic and Recurrent Non-Small Cell Lung Cancer (NSCLC) After Failure of 2nd Line Treatment,Abramson Cancer Center at Penn Medicine,Abramson Cancer Center at Penn Medicine,OTHER,COMPLETED,2013-01,2016-01,2017-03-15,INTERVENTIONAL,PHASE2,,,,Metastatic Non Small Cell Lung Cancer,Metastatic Non Small Cell Lung Cancer; Recurrent Non Small Cell Lung Cancer,2,1,1,DRUG,,,1,0,True,Yes,Overall Objective Response Rate (COUNT_OF_PARTICIPANTS) Participants = 2,,,,,,,,,Overall Objective Response Rate (COUNT_OF_PARTICIPANTS) Participants = 2,,,,,Overall Objective Response Rate (COUNT_OF_PARTICIPANTS) Participants = 2,,,
NCT01774721,ARCHER1050: A Study of Dacomitinib vs. Gefitinib in 1st-Line Treatment Of Advanced NSCLC.,"ARCHER 1050: A RANDOMIZED, OPEN-LABEL, PHASE 3, EFFICACY AND SAFETY STUDY OF DACOMITINIB (PF-00299804) VERSUS GEFITINIB FOR THE FIRST LINE TREATMENT OF LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LU",Pfizer,Pfizer,INDUSTRY,COMPLETED,2013-05-09,2016-07-29,2022-01-27,INTERVENTIONAL,PHASE3,,,,Non-small Cell Lung Cancer With EGFR-Activating Mutations,Non-small Cell Lung Cancer With EGFR-Activating Mutations,1,2,2,DRUG,,,1,24,True,Yes,Progression Free Survival (PFS) Based on Independent Radiologic Central (IRC) Review (MEDIAN) months = 14.7 [11.1-16.6],"Overall Survival (OS) (MEDIAN) months = 34.1 [29.5-39.8]; OS at 30 Months (OS30m) (NUMBER) probability of survival = 56.4 [49.6-62.7]; Progression Free Survival (PFS) Based on Investigator Assessment (MEDIAN) months = 16.6 [12.9-18.4]; Number of Participants With Best Overall Response (BOR) Based on IRC Review (COUNT_OF_PARTICIPANTS) Participants = 12; Number of Participants With Best Overall Response (BOR) Based on Investigator Assessment (COUNT_OF_PARTICIPANTS) Participants = 2; Duration of Response (DoR) (MEDIAN) months = 14.8 [12.0-17.4]; Objective Response Rate (ORR) Based on IRC Review (NUMBER) percentage of participants = 74.9 [68.7-80.4]; Objective Response Rate (ORR) Based on Investigator Assessment (NUMBER) percentage of participants = 75.3 [69.2-80.8]; Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) (COUNT_OF_PARTICIPANTS) Participants = 226; Number of Participants With Laboratory Test Abnormalities of Grade 3 or Higher Severity Based on NCI CTCAE Version 4.03: Biochemistry and Haematology (COUNT_OF_PARTICIPANTS) Participants = 5; Number of Participants With Laboratory Test Abnormalities: Urinalysis (COUNT_OF_PARTICIPANTS) Participants = 1; Number of Participants With Clinically Significant Abnormalities in Vital Signs (COUNT_OF_PARTICIPANTS) Participants = 16; Number of Participants With Clinically Significant Abnormality in Electrocardiogram (ECG) (COUNT_OF_PARTICIPANTS) Participants = 5; Number of Participants With Maximum Relative Decrease From Baseline >20% in Left Ventricular Ejection Fraction (LVEF) (COUNT_OF_PARTICIPANTS) Participants = 5; Health Related Quality of Life (HRQOL): Time to Deterioration (TTD) in Pain, Dyspnea, Fatigue or Cough (MEDIAN) months = 3.8 [2.3-4.8]; Overall Mean Scores of Euro Quality of Life-5 Dimension Visual Analog Scale (EQ-5D VAS) (MEAN) units on a scale = 73.3869 [71.608-75.166]; Maximum Observed Plasma Concentration (Cmax) of Dacomitinib and Its Metabolite PF-05199265 (MEAN) nanogram per milliliter (ng/mL) = 84.19; Time to Reach Maximum Observed Plasma Concentration (Tmax) of Dacomitinib and Its Metabolite PF-05199265 (MEDIAN) hour = 4.03 [2.0-24.0]; Area Under the Plasma Concentration-Time Curve From Time Zero (0) to End of Dosing Interval (AUCtau) of Dacomitinib and Its Metabolite PF-05199265 (MEAN) nanogram*hour/milliliter (ng*hr/mL) = 1712.08; Averaged Plasma Concentration at Steady State (Cavg) of Dacomitinib and Its Metabolite PF-05199265 (MEAN) ng/mL = 71.33; Minimum Observed Plasma Concentration (Cmin) of Dacomitinib and Its Metabolite PF-05199265 (MEAN) ng/mL = 60.64; Fluctuation Coefficient Between Trough and Peak Plasma Concentration (DF) of Dacomitinib and Its Metabolite PF-05199265 (MEAN) Fluctuation coefficient = 0.2883; Apparent Clearance (CL) of Dacomitinib (MEAN) Liter/hour = 27.61; Pre-dose Plasma Concentrations (Ctrough) of Dacomitinib and Its Metabolite PF-05199265 (MEAN) ng/mL = 70.24",,,,,Duration of Response (DoR) (MEDIAN) months = 14.8 [12.0-17.4],,,Objective Response Rate (ORR) Based on IRC Review (NUMBER) percentage of participants = 74.9 [68.7-80.4]; Objective Response Rate (ORR) Based on Investigator Assessment (NUMBER) percentage of participants = 75.3 [69.2-80.8],Overall Survival (OS) (MEDIAN) months = 34.1 [29.5-39.8]; OS at 30 Months (OS30m) (NUMBER) probability of survival = 56.4 [49.6-62.7],Progression Free Survival (PFS) Based on Independent Radiologic Central (IRC) Review (MEDIAN) months = 14.7 [11.1-16.6]; Progression Free Survival (PFS) Based on Investigator Assessment (MEDIAN) months = 16.6 [12.9-18.4],,"Health Related Quality of Life (HRQOL): Time to Deterioration (TTD) in Pain, Dyspnea, Fatigue or Cough (MEDIAN) months = 3.8 [2.3-4.8]; Overall Mean Scores of Euro Quality of Life-5 Dimension Visual Analog Scale (EQ-5D VAS) (MEAN) units on a scale = 73.3869 [71.608-75.166]",Objective Response Rate (ORR) Based on IRC Review (NUMBER) percentage of participants = 74.9 [68.7-80.4]; Objective Response Rate (ORR) Based on Investigator Assessment (NUMBER) percentage of participants = 75.3 [69.2-80.8],Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) (COUNT_OF_PARTICIPANTS) Participants = 226,,
NCT01788566,A Study of Gemcitabine-Cisplatin Chemotherapy Plus Necitumumab in the First-Line Treatment of Participants With Squamous Lung Cancer,"A Single-Arm, Multicenter, Open-Label, Phase 2 Study of Gemcitabine-Cisplatin Chemotherapy Plus Necitumumab (IMC-11F8) in the First-Line Treatment of Patients With Stage IV Squamous Non-Small Cell Lun",Eli Lilly and Company,Eli Lilly and Company,INDUSTRY,COMPLETED,2013-03,2014-08,2015-12,INTERVENTIONAL,PHASE2,,,,Non-small Cell Lung Cancer,Non-small Cell Lung Cancer,1,1,3,DRUG,,,1,6,True,Yes,Percentage of Participants Who Achieve Best Overall Tumor Response of Complete Response (CR) or Partial Response (PR) Objective Tumor Response Rate (ORR) (NUMBER) Percentage of participants = 48.1 [34.34-62.16],"Overall Survival (OS) (MEDIAN) months = 11.7; Progression Free Survival (PFS) (MEDIAN) months = 5.6 [3.68-6.87]; Number of Participants Who Achieve Best Overall Disease Response of Complete Response (CR), Partial Response (PR) or Stable Disease (SD) [Disease Control Rate (DCR)] (NUMBER) percentage of participants = 81.5 [68.57-90.75]; Percent Change in Tumor Size (CTS) (MEAN) percent change = 39.68; Pharmacokinetics (PK): Minimum (Cmin) Maximum Concentration (Cmax) of Necitumumab (GEOMETRIC_MEAN) micrograms/milliliter (ug/ml) = 70.8; Number of Participants With Anti-Necitumumab Antibodies (NUMBER) participants = 9",,"Percentage of Participants Who Achieve Best Overall Tumor Response of Complete Response (CR) or Partial Response (PR) Objective Tumor Response Rate (ORR) (NUMBER) Percentage of participants = 48.1 [34.34-62.16]; Number of Participants Who Achieve Best Overall Disease Response of Complete Response (CR), Partial Response (PR) or Stable Disease (SD) [Disease Control Rate (DCR)] (NUMBER) percentage of participants = 81.5 [68.57-90.75]",,,,,,,Overall Survival (OS) (MEDIAN) months = 11.7,Progression Free Survival (PFS) (MEDIAN) months = 5.6 [3.68-6.87],"Percentage of Participants Who Achieve Best Overall Tumor Response of Complete Response (CR) or Partial Response (PR) Objective Tumor Response Rate (ORR) (NUMBER) Percentage of participants = 48.1 [34.34-62.16]; Number of Participants Who Achieve Best Overall Disease Response of Complete Response (CR), Partial Response (PR) or Stable Disease (SD) [Disease Control Rate (DCR)] (NUMBER) percentage of participants = 81.5 [68.57-90.75]",,Percentage of Participants Who Achieve Best Overall Tumor Response of Complete Response (CR) or Partial Response (PR) Objective Tumor Response Rate (ORR) (NUMBER) Percentage of participants = 48.1 [34.34-62.16],,,
NCT01801111,A Study of Alectinib (RO5424802) in Participants With Non-Small Cell Lung Cancer Who Have Anaplastic Lymphoma Kinase (ALK) Mutation and Failed Crizoti,"An Open-Label, Non-Randomized, Multicenter Phase I/II Trial of RO5424802 Given Orally to Non-Small Cell Lung Cancer Patients Who Have ALK Mutation and Who Have Failed Crizotinib Treatment",Hoffmann-La Roche,Hoffmann-La Roche,INDUSTRY,COMPLETED,2013-06-20,2014-10-24,2017-10-27,INTERVENTIONAL,PHASE1; PHASE2,,,,Non-Small-Cell Lung Carcinoma,Non-Small-Cell Lung Carcinoma,1,1,2,DRUG,,,4,32,True,Yes,; ; Percentage of Participants Achieving Objective Response (Complete Response [CR] or Partial Response [PR]) as Assessed by Independent Radiological Review Committee (IRC) in Response Evaluable (RE) Population (NUMBER) percentage of participants = 50.8 [41.62-59.98]; Percentage of Participants Achieving Objective Response (CR or PR) as Assessed by IRC in Chemotherapy-Pretreated Participants (NUMBER) percentage of participants = 44.8 [34.63-55.29],"Percentage of Participants Achieving Objective Response (CR or PR) as Assessed by IRC in Chemotherapy-Naive Participants (NUMBER) percentage of participants = 73.1; Percentage of Participants Achieving Objective Response (CR or PR) as Assessed by Investigator in RE Population (NUMBER) percentage of participants = 51.4 [42.80-60.04]; Percentage of Participants Achieving Objective Response (CR or PR) as Assessed by Investigator in Chemotherapy-Pretreated Participants (NUMBER) percentage of participants = 50.0; Percentage of Participants Achieving Objective Response (CR or PR) as Assessed by Investigator in Chemotherapy-Naive Participants (NUMBER) percentage of participants = 57.1; Duration of Response (DoR) as Assessed by IRC in RE Population (MEDIAN) months = 15.2 [11.2-24.9]; Percentage of Participants With PD as Assessed by IRC According to RECIST v1.1 or Death From Any Cause in Safety Population (NUMBER) percentage of participants = 71.0; Progression Free Survival (PFS) as Assessed by IRC in Safety Population (MEDIAN) months = 8.9 [5.6-12.8]; Percentage of Participants Who Died of Any Cause (NUMBER) percentage of participants = 54.3; Overall Survival (OS) (MEDIAN) months = 29.2 [21.5-44.4]; Percentage of Participants Achieving CR, PR or Stable Disease (SD) According to RECIST v1.1 in RE Population (NUMBER) percentage of participants = 63.9 [54.75-72.43]; Percentage of Participants Achieving Central Nervous System (CNS) Objective Response as Assessed by IRC According to RECIST v1.1 (NUMBER) percentage of participants = 58.8 [40.70-75.35]; Percentage of Participants Achieving CNS Objective Response as Assessed by IRC According to Radiology Assessment in Neuro-Oncology (RANO) Criteria (NUMBER) percentage of participants = 44.1 [27.19-62.11]; CNS Duration of Response (CDoR) as Assessed by IRC According to RECIST v1.1 (MEDIAN) months = 11.1; CDoR as Assessed by IRC According to RANO Criteria (MEDIAN) months = 7.6 [7.4-7.6]; Percentage of Participants With CNS Progression as Assessed by IRC According to RECIST v 1.1 (NUMBER) percentage of participants = 18.8; Maximum Observed Plasma Concentration (Cmax) of Alectinib (GEOMETRIC_MEAN) nanograms per milliliter (ng/mL) = 204; Time to Cmax (Tmax) of Alectinib (MEDIAN) hrs = 5.89 [2.00-10.00]; Time to Last Measurable Plasma Concentration (Tlast) of Alectinib (GEOMETRIC_MEAN) hrs = 11.59; Area Under the Plasma Concentration-Time Curve From Time 0 to 10 Hours Post-dose (AUC[0-10]) of Alectinib (GEOMETRIC_MEAN) hrs*nanograms per milliliter (hrs*ng/mL) = 1140; Area Under the Plasma Concentration-Time Curve From Time 0 to Tlast (AUC[0-last]) of Alectinib (GEOMETRIC_MEAN) hrs*ng/mL = 1340; Cmax of Alectinib Metabolite (GEOMETRIC_MEAN) nanograms per milliliter (ng/mL) = 57.2; Tmax of Alectinib Metabolite (MEDIAN) hrs = 8.03 [5.97-11.18]; Tlast of Alectinib Metabolite (GEOMETRIC_MEAN) hrs = 11.59; AUC(0-10) of Alectinib Metabolite (GEOMETRIC_MEAN) hrs*ng/mL = 300; AUC(0-last) of Alectinib Metabolite (GEOMETRIC_MEAN) hrs*ng/mL = 378; Metabolite to Parent Ratio Based on AUC(0-10) (GEOMETRIC_MEAN) Ratio = 0.278; Metabolite to Parent Ratio Based on AUC(0-last) (GEOMETRIC_MEAN) Ratio = 0.298; Trough Plasma Concentration (Ctrough) of Alectinib (GEOMETRIC_MEAN) ng/mL = 761; Ctrough of Alectinib Metabolite (GEOMETRIC_MEAN) ng/mL = 244; Peak to Trough Ratio of Alectinib (GEOMETRIC_MEAN) Ratio = 1.23; Accumulation Ratio of Alectinib (GEOMETRIC_MEAN) Ratio = 6.95; Accumulation Ratio of Alectinib Metabolite (GEOMETRIC_MEAN) Ratio = 8.68",,Percentage of Participants Achieving Objective Response (Complete Response [CR] or Partial Response [PR]) as Assessed by Independent Radiological Review Committee (IRC) in Response Evaluable (RE) Population (NUMBER) percentage of participants = 50.8 [41.62-59.98],,,Duration of Response (DoR) as Assessed by IRC in RE Population (MEDIAN) months = 15.2 [11.2-24.9]; CNS Duration of Response (CDoR) as Assessed by IRC According to RECIST v1.1 (MEDIAN) months = 11.1; CDoR as Assessed by IRC According to RANO Criteria (MEDIAN) months = 7.6 [7.4-7.6],,,,Overall Survival (OS) (MEDIAN) months = 29.2 [21.5-44.4],Progression Free Survival (PFS) as Assessed by IRC in Safety Population (MEDIAN) months = 8.9 [5.6-12.8],"Percentage of Participants Achieving Objective Response (Complete Response [CR] or Partial Response [PR]) as Assessed by Independent Radiological Review Committee (IRC) in Response Evaluable (RE) Population (NUMBER) percentage of participants = 50.8 [41.62-59.98]; Percentage of Participants Achieving Objective Response (CR or PR) as Assessed by IRC in Chemotherapy-Pretreated Participants (NUMBER) percentage of participants = 44.8 [34.63-55.29]; Percentage of Participants Achieving Objective Response (CR or PR) as Assessed by IRC in Chemotherapy-Naive Participants (NUMBER) percentage of participants = 73.1; Percentage of Participants Achieving Objective Response (CR or PR) as Assessed by Investigator in RE Population (NUMBER) percentage of participants = 51.4 [42.80-60.04]; Percentage of Participants Achieving Objective Response (CR or PR) as Assessed by Investigator in Chemotherapy-Pretreated Participants (NUMBER) percentage of participants = 50.0; Percentage of Participants Achieving Objective Response (CR or PR) as Assessed by Investigator in Chemotherapy-Naive Participants (NUMBER) percentage of participants = 57.1; Percentage of Participants Achieving CR, PR or Stable Disease (SD) According to RECIST v1.1 in RE Population (NUMBER) percentage of participants = 63.9 [54.75-72.43]",,,,,
NCT01802632,AZD9291 First Time In Patients Ascending Dose Study,"Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of AZD9291 in Patients With Advanced Non Small Cell Lung Cancer Who Progressed on Prior Therapy With an Epidermal Growth Factor Receptor",AstraZeneca,AstraZeneca,INDUSTRY,COMPLETED,2013-03-04,2015-05-01,2023-12-13,INTERVENTIONAL,PHASE1; PHASE2,,,,Advanced Non Small Cell Lung Cancer,Advanced Non Small Cell Lung Cancer; Advanced (Inoperable) Non Small Cell Lung Cancer,2,1,1,DRUG,,,3,3,True,Yes,Objective Response Rate (ORR) for Dose Expansion Population (NUMBER) % of participants = 61.7 [54.1-68.9]; Best Objective Response (BOR) for Dose Escalation Population (NUMBER) % of participants = 58.1 [54.1-68.9]; Objective Response Rate (ORR) for Extension Population (NUMBER) % of participants = 61.3 [54.2-68.1],Duration of Response (DoR) for Dose Expansion Population (MEDIAN) months = 11.1 [8.3-13.8]; Progression-Free Survival (PFS) for Dose Expansion Population (MEDIAN) months = 9.7 [8.3-12.5]; Best Objective Response (BOR) for 80mg AZD9291 Extension Population (NUMBER) % of participants = 0.5 [54.1-68.9],,,,,Duration of Response (DoR) for Dose Expansion Population (MEDIAN) months = 11.1 [8.3-13.8],,,Objective Response Rate (ORR) for Dose Expansion Population (NUMBER) % of participants = 61.7 [54.1-68.9]; Objective Response Rate (ORR) for Extension Population (NUMBER) % of participants = 61.3 [54.2-68.1],,Progression-Free Survival (PFS) for Dose Expansion Population (MEDIAN) months = 9.7 [8.3-12.5],,,Objective Response Rate (ORR) for Dose Expansion Population (NUMBER) % of participants = 61.7 [54.1-68.9]; Objective Response Rate (ORR) for Extension Population (NUMBER) % of participants = 61.3 [54.2-68.1],,,
NCT01806675,18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy,Phase 1-2 18F-FPPRGD2 PET/CT or PET/MRI Imaging of αvβ3 Integrins Expression as a Biomarker of Angiogenesis,Stanford University,Sanjiv Sam Gambhir,OTHER,COMPLETED,2013-03-04,2016-12-07,2019-04,INTERVENTIONAL,PHASE1; PHASE2,,,,Adult Giant Cell Glioblastoma,Adult Giant Cell Glioblastoma; Adult Glioblastoma; Adult Gliosarcoma,44,3,2,DRUG,,,1,4,True,Yes,Change From Baseline in Maximum Standard Uptake Values (SUVmax) (MEDIAN) ratio = -0.98,; Change in Tumor Size (MEDIAN) centimeters = 0.9; Tumor Response Rate by EORTC Criteria (NUMBER) participants = 2; ,,,,,,,,,,,,,Tumor Response Rate by EORTC Criteria (NUMBER) participants = 2,,,
NCT01813734,Ponatinib in Advanced NSCLC w/ RET Translocations,"A Phase II, Open-Label Study of Ponatinib, A Multi-Targeted Oral Tyrosine Kinase Inhibitor, in Advanced Non-Small Cell Lung Cancer Harboring RET Translocations",Massachusetts General Hospital,Massachusetts General Hospital,OTHER,COMPLETED,2013-09,2018-06,2018-08,INTERVENTIONAL,PHASE2,,,,Non Small Cell Lung Cancer,Non Small Cell Lung Cancer,1,1,1,DRUG,,,1,4,True,Yes,Overall Response Rate (COUNT_OF_PARTICIPANTS) Participants = 0,Disease Control Rate (COUNT_OF_PARTICIPANTS) Participants = 5; Median Progression-Free Survival (NUMBER) Months = 3.8 [1.83-5.3]; 1 Year Overall Survival Rate (COUNT_OF_PARTICIPANTS) Participants = 5; Number of Participants With Adverse Events (COUNT_OF_PARTICIPANTS) Participants = 2,,,,,,,,,1 Year Overall Survival Rate (COUNT_OF_PARTICIPANTS) Participants = 5,Median Progression-Free Survival (NUMBER) Months = 3.8 [1.83-5.3],,,Overall Response Rate (COUNT_OF_PARTICIPANTS) Participants = 0,Number of Participants With Adverse Events (COUNT_OF_PARTICIPANTS) Participants = 2,,
NCT01820754,Evaluation of Circulating T Cells and Tumor Infiltrating Lymphocytes (TILs) During / After Pre-Surgery Chemotherapy in Non-Small Cell Lung Cancer (NSC,Evaluation of Circulating T Cells and Tumor Infiltrating Lymphocytes With Specificities Against Tumor Associated Antigens During and After Neoadjuvant Chemotherapy and Phased Ipilimumab in Non-Small C,Duke University,Duke University,OTHER,COMPLETED,2013-03,2018-04-30,2018-04-30,INTERVENTIONAL,PHASE2,,,,Non Small Cell Lung Cancer,Non Small Cell Lung Cancer,1,1,2,DRUG,,,1,4,True,Yes,Percentage of Subjects With Detectable Circulating T Cells After Treatment (NUMBER) Percentage of participants = 16.7,Feasibility and Tolerability of Neoadjuvant Chemotherapy Plus Ipilimumab and Surgery (COUNT_OF_PARTICIPANTS) Participants = 24; ; Number of Subjects Experiencing a Metastasis by Site of Metastasis (COUNT_OF_PARTICIPANTS) Participants = 1; Patterns of Pathologic Response and Response Evaluation Criteria in Solid Tumor (RECIST) Response (COUNT_OF_PARTICIPANTS) Participants = 14,,,,,,,,,,,,,,,,
NCT01824901,Docetaxel With or Without FGFR Inhibitor AZD4547 in Treating Patients With Recurrent Non-Small Cell Lung Cancer,A Phase I/Randomized Phase II Study of Docetaxel With or Without AZD4547 in Recurrent FGFR1-Amplified Squamous Non-Small Cell Lung Cancer,Eastern Cooperative Oncology Group,ECOG-ACRIN Cancer Research Group,NETWORK,COMPLETED,2014-01-15,2014-07-09,2015-04,INTERVENTIONAL,PHASE1; PHASE2,,,,Recurrent Non-small Cell Lung Cancer,Recurrent Non-small Cell Lung Cancer; Squamous Cell Lung Cancer,2,4,2,DRUG,,,1,0,True,Yes,,,,,,,,,,,,,,,,,,
NCT01827267,Neratinib With and Without Temsirolimus for Patients With HER2 Activating Mutations in Non-Small Cell Lung Cancer,A Phase 2 Study of Neratinib and Neratinib Plus Temsirolimus in Patients With Non-Small Cell Lung Cancer Carrying Known HER2 Activating Mutations,"Puma Biotechnology, Inc.","Puma Biotechnology, Inc.",INDUSTRY,COMPLETED,2013-07-01,2016-09-20,2017-10-06,INTERVENTIONAL,PHASE2,,,,HER2-mutant Non-Small Cell Lung Cancer,HER2-mutant Non-Small Cell Lung Cancer,1,2,2,DRUG,,,1,4,True,Yes,Objective Response Rate (ORR) (COUNT_OF_PARTICIPANTS) Participants = 0,Clinical Benefit Rate (CBR) (COUNT_OF_PARTICIPANTS) Participants = 6; Duration of Response (DOR) (COUNT_OF_PARTICIPANTS) Participants = 0; Progression Free Survival (PFS) (MEDIAN) months = 2.9 [1.4-9.8]; Overall Survival (OS) (MEDIAN) months = 10.0 [4.9-18.9],Clinical Benefit Rate (CBR) (COUNT_OF_PARTICIPANTS) Participants = 6,,,,Duration of Response (DOR) (COUNT_OF_PARTICIPANTS) Participants = 0,,,Objective Response Rate (ORR) (COUNT_OF_PARTICIPANTS) Participants = 0,Overall Survival (OS) (MEDIAN) months = 10.0 [4.9-18.9],Progression Free Survival (PFS) (MEDIAN) months = 2.9 [1.4-9.8],,,Objective Response Rate (ORR) (COUNT_OF_PARTICIPANTS) Participants = 0,,,
NCT01828099,LDK378 Versus Chemotherapy in Previously Untreated Patients With ALK Rearranged Non-small Cell Lung Cancer,"A Phase III Multicenter, Randomized Study of Oral LDK378 Versus Standard Chemotherapy in Previously Untreated Adult Patients With ALK Rearranged (ALK-positive), Stage IIIB or IV, Non-squamous Non-smal",Novartis,Novartis Pharmaceuticals,INDUSTRY,COMPLETED,2013-07-09,2016-06-24,2024-01-07,INTERVENTIONAL,PHASE3,,,,Non-Small Cell Lung Cancer,Non-Small Cell Lung Cancer,1,2,4,DRUG,,,1,24,True,Yes,Progression Free Survival (PFS) by Blinded Independent Review Committee (BIRC) (MEDIAN) Months = 16.6 [12.6-27.2],"Overall Survival (OS) (MEDIAN) Months = 62.9 [44.2-77.6]; Overall Response Rate (ORR) by BIRC Assessment (NUMBER) Percentage of participants = 72.5 [65.5-78.7]; Overall Response Rate (ORR) by Investigator Assessment (NUMBER) Percentage of participants = 73.5 [66.7-79.7]; Duration of Response (DOR) by BIRC Assessment (MEDIAN) Months = 23.9; Duration of Response (DOR) by Investigator Assessment (MEDIAN) Months = 22.6 [17.7-26.2]; Disease Control Rate (DCR) by BIRC Assessment (NUMBER) Percentage of participants = 84.7 [78.7-89.5]; Disease Control Rate (DCR) by Investigator Assessment (NUMBER) Percentage of participants = 89.4 [84.1-93.4]; Time to Response (TTR) by BIRC Assessment (MEDIAN) Weeks = 6.14 [5.1-61.7]; Time to Response (TTR) by Investigator Assessment (MEDIAN) Weeks = 6.29 [5.1-71.9]; PFS by Investigator Assessment (MEDIAN) Months = 16.8 [13.5-22.8]; Overall Intracranial Response Rate (OIRR) (NUMBER) Percentage of participants = 72.7 [49.8-89.3]; Intracranial Disease Control Rate (IDCR) (NUMBER) Percentage of participants = 86.4 [65.1-97.1]; Duration of Intracranial Response (DOIR) (MEDIAN) Months = 16.6; Time to Definitive 10 Point Deterioration in the Composite Endpoint of Pain, Cough or Dyspnea in the European Organization for Research and Treatment of Cancer Quality of Life (EORTC QLQ)- Lung Cancer (LC) 13 Questionnaire (MEDIAN) Months = 76.0; Time to Definitive Deterioration in the Composite Endpoint of Pain, Cough or Dyspnea in the Lung Cancer Symptom Scale (LCSS) (MEDIAN) Months = 104.0; Least Squares Mean Scores on the EORTC-QLQ C30 (LEAST_SQUARES_MEAN) Score on a scale = 69.4; Least Squares Mean Scores on the EORTC QLQ- LC13 (LEAST_SQUARES_MEAN) Score on a scale = 16.2; Least Squares Mean Scores on the Lung Cancer Symptom Scale (LCSS) (LEAST_SQUARES_MEAN) Score on a Scale = 20.9; Least Squares Mean Scores on the EQ-5D-5L Index (LEAST_SQUARES_MEAN) Score on a Scale = 0.80; Least Squares Mean Scores on the EQ-5D-5L Visual Analogue Score (VAS) (LEAST_SQUARES_MEAN) Score on a Scale = 77.2; Cmax of LDK378 (GEOMETRIC_MEAN) nanogram (ng) / mililiter (ml) = 162; Tmax of LDK378 (MEDIAN) hours = 6.00 [4.00-8.00]; Tlast of LDK378 (MEDIAN) Hours = 24.0 [23.7-24.2]; AUC0-24 of LDK378 (GEOMETRIC_MEAN) hours*ng/mL = 2540",,,,,Duration of Response (DOR) by BIRC Assessment (MEDIAN) Months = 23.9; Duration of Response (DOR) by Investigator Assessment (MEDIAN) Months = 22.6 [17.7-26.2],,,,Overall Survival (OS) (MEDIAN) Months = 62.9 [44.2-77.6],Progression Free Survival (PFS) by Blinded Independent Review Committee (BIRC) (MEDIAN) Months = 16.6 [12.6-27.2]; PFS by Investigator Assessment (MEDIAN) Months = 16.8 [13.5-22.8],,"Time to Definitive 10 Point Deterioration in the Composite Endpoint of Pain, Cough or Dyspnea in the European Organization for Research and Treatment of Cancer Quality of Life (EORTC QLQ)- Lung Cancer (LC) 13 Questionnaire (MEDIAN) Months = 76.0",Overall Response Rate (ORR) by BIRC Assessment (NUMBER) Percentage of participants = 72.5 [65.5-78.7]; Overall Response Rate (ORR) by Investigator Assessment (NUMBER) Percentage of participants = 73.5 [66.7-79.7]; Overall Intracranial Response Rate (OIRR) (NUMBER) Percentage of participants = 72.7 [49.8-89.3],,,
NCT01828112,LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib,"A Phase III, Multicenter, Randomized, Open-label Study of Oral LDK378 Versus Standard Chemotherapy in Adult Patients With ALK-rearranged (ALK-positive) Advanced Non-small Cell Lung Cancer Who Have Bee",Novartis,Novartis Pharmaceuticals,INDUSTRY,COMPLETED,2013-06-28,2016-01-26,2023-11-10,INTERVENTIONAL,PHASE3,,,,Non-Small Cell Lung Cancer,Non-Small Cell Lung Cancer,1,2,3,DRUG,,,1,25,True,Yes,Progression Free Survival (PFS) Per Blinded Independent Review Committee (BIRC) (MEDIAN) months = 5.4 [4.1-6.9],Overall Survival (OS) (MEDIAN) months = 17.7 [14.2-23.7]; Progression Free Survival (PFS) Per Investigator Assessment (MEDIAN) months = 6.2 [4.4-7.9]; Overall Response Rate (ORR) Per BIRC (NUMBER) percentage of participants = 40.9 [31.8-50.4]; Overall Response Rate (ORR) Per Investigator Assessment (NUMBER) percentage of participants = 44.3 [35.1-53.9]; Duration of Response (DOR) Per BIRC (MEDIAN) months = 7.6 [5.4-8.3]; Duration of Response (DOR) Per Investigator Assessment (MEDIAN) months = 6.7 [5.5-8.3]; Disease Control Rate (DCR) Per BIRC (NUMBER) percentage of participants = 76.5 [67.7-83.9]; Disease Control Rate (DCR) Per Investigator Assessment (NUMBER) percentage of participants = 80.0 [71.5-86.9]; Time to Response (TTR) Per BIRC (MEDIAN) weeks = 6.71 [4.9-52.3]; Time to Response (TTR) Per Investigator Assessment (MEDIAN) weeks = 6.43 [4.9-45.4]; Overall Intracranial Response Rate (OIRR) Per BIRC (NUMBER) percentage of participants = 10.6 [4.4-20.6]; Intracranial Disease Control Rate (IDCR) Per BIRC (NUMBER) percentage of participants = 71.2 [58.7-81.7]; Duration of Intracranial Response (DOIR) Per BIRC (MEDIAN) months = 8.3; Least Squares Mean Scores on the European Organization for Research and Treatment of Cancer's Core Quality of Life Questionnaire (EORTC-QLQC30) (LEAST_SQUARES_MEAN) score on a scale = 62.9; EORTC QLQ-LC13 Time to Definitive Deterioration (MEDIAN) months = 13.4 [8.4-16.7]; Least Squares Mean Scores on the Lung Cancer Symptom Scale (LCSS) (LEAST_SQUARES_MEAN) millimeters = 22.0; Least Squares Mean Scores on the EQ-5D-5L Index (LEAST_SQUARES_MEAN) score on a scale = 0.7837; Least Squares Mean Scores on the EQ-5D Visual Analogue Scale (VAS) (LEAST_SQUARES_MEAN) score on a scale = 71.8; Cmax for Ceritinib (GEOMETRIC_MEAN) ng/mL = 90.4; Tmax for Ceritinib (MEDIAN) hours = 6.03 [4.17-23.6]; Tlast for Ceritinib (MEDIAN) hours = 24 [23.6-24.1]; AUC0-24h for Ceritinib (GEOMETRIC_MEAN) h*ng/mL = 1470; ; ; Post-Hoc: All Collected Deaths (COUNT_OF_PARTICIPANTS) Participants = 0,,,,,Duration of Response (DOR) Per BIRC (MEDIAN) months = 7.6 [5.4-8.3]; Duration of Response (DOR) Per Investigator Assessment (MEDIAN) months = 6.7 [5.5-8.3],,,,Overall Survival (OS) (MEDIAN) months = 17.7 [14.2-23.7],Progression Free Survival (PFS) Per Blinded Independent Review Committee (BIRC) (MEDIAN) months = 5.4 [4.1-6.9]; Progression Free Survival (PFS) Per Investigator Assessment (MEDIAN) months = 6.2 [4.4-7.9],,Least Squares Mean Scores on the European Organization for Research and Treatment of Cancer's Core Quality of Life Questionnaire (EORTC-QLQC30) (LEAST_SQUARES_MEAN) score on a scale = 62.9,Overall Response Rate (ORR) Per BIRC (NUMBER) percentage of participants = 40.9 [31.8-50.4]; Overall Response Rate (ORR) Per Investigator Assessment (NUMBER) percentage of participants = 44.3 [35.1-53.9]; Overall Intracranial Response Rate (OIRR) Per BIRC (NUMBER) percentage of participants = 10.6 [4.4-20.6],,,
NCT01829113,Phase II Trial of Carboplatin and Pemetrexed +/- OGX-427 in Untreated Stage IV Non-Squamous-Non-Small-Cell Lung Cancer,Double-Blind Randomized Phase II Trial of Carboplatin and Pemetrexed With or Without OGX-427 in Patients With Previously Untreated Stage IV Non-Squamous-Non-Small-Cell Lung Cancer (The Spruce Clinical,"SCRI Development Innovations, LLC","SCRI Development Innovations, LLC",OTHER,COMPLETED,2013-07,2017-04-19,2017-04-19,INTERVENTIONAL,PHASE2,,,,Non Squamous Non Small Cell Lung Cancer,Non Squamous Non Small Cell Lung Cancer,1,2,2,DRUG,,,1,3,True,Yes,Median Progression-Free Survival (MEDIAN) months = 6 [3.3-8],Number of OGX-427 Versus Placebo Participants With an Objective Response (COUNT_OF_PARTICIPANTS) Participants = 21; Median Overall Survival (MEDIAN) Months = 10.8 [8.9-14.8]; Number of Patients With a Treatment-Related Adverse Event as a Measure of Safety. (COUNT_OF_PARTICIPANTS) Participants = 63,,,,,,,,,Median Overall Survival (MEDIAN) Months = 10.8 [8.9-14.8],Median Progression-Free Survival (MEDIAN) months = 6 [3.3-8],,,,Number of Patients With a Treatment-Related Adverse Event as a Measure of Safety. (COUNT_OF_PARTICIPANTS) Participants = 63,,
NCT01833143,Bortezomib in KRAS-Mutant Non-Small Cell Lung Cancer in Never Smokers or Those With KRAS G12D,A Phase 2 Trial of Bortezomib in KRAS-Mutant Non-Small Cell Lung Cancer in Never Smokers or Those With KRAS G12D,Memorial Sloan Kettering Cancer Center,Memorial Sloan Kettering Cancer Center,OTHER,COMPLETED,2013-04-11,2019-08-28,2019-08-28,INTERVENTIONAL,PHASE2,,,,Non-Small Cell Lung Cancer,Non-Small Cell Lung Cancer,1,1,2,DRUG,,,1,3,True,Yes,Radiographic Response Rate (COUNT_OF_PARTICIPANTS) Participants = 1,Progression Free Survival (MEDIAN) months = 1 [1-6]; Participants Evaluated for Toxicity (COUNT_OF_PARTICIPANTS) Participants = 17; Overall Survival (MEDIAN) months = 13 [6-30],,,,,,,,,Overall Survival (MEDIAN) months = 13 [6-30],Progression Free Survival (MEDIAN) months = 1 [1-6],,,Radiographic Response Rate (COUNT_OF_PARTICIPANTS) Participants = 1,Participants Evaluated for Toxicity (COUNT_OF_PARTICIPANTS) Participants = 17,,
NCT01846416,A Study of Atezolizumab in Participants With Programmed Death-Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSC,"A Phase II, Multicenter, Single-arm Study of MPDL3280A in Patients With PD-L1-Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer","Genentech, Inc.","Genentech, Inc.",INDUSTRY,COMPLETED,2013-05-30,2015-01-07,2017-12-18,INTERVENTIONAL,PHASE2,,,,Non-Small Cell Lung Cancer,Non-Small Cell Lung Cancer,1,3,1,DRUG,,,1,13,True,Yes,Percentage of Participants With Objective Response According to Modified Response Evaluation Criteria in Solid Tumors (RECIST) (NUMBER) percentage of participants = 32 [17-51],"Percentage of Participants With Objective Response According to RECIST Version 1.1 (v1.1) (NUMBER) percentage of participants = 29 [14-48]; Duration of Objective Response According to RECIST v1.1 (MEDIAN) months = 9.2 [2.3-30.4]; Percentage of Participants With 6-Month Duration of Objective Response (NUMBER) percentage of participants = 75.0; Percentage of Participants With Disease Progression or Death According to RECIST v1.1 (NUMBER) percentage of participants = 67.7; Progression-Free Survival (PFS) According to RECIST v1.1 (MEDIAN) months = 4.5 [0.9-37.9]; Percentage of Participants With PFS at Month 6, Month 12 and Month 30 According to RECIST v1.1 (NUMBER) percentage of participants = 33.50; Percentage of Participants With Disease Progression or Death According to Modified RECIST (NUMBER) percentage of participants = 58.1; PFS According to Modified RECIST (MEDIAN) months = 5.5 [0.9-37.9]; Percentage of Participants With PFS at Month 6, Month 12 and Month 30 According to Modified RECIST (NUMBER) percentage of participants = 43.12; Percentage of Participants With Death (NUMBER) percentage of participants = 74.2; Overall Survival (OS) (MEDIAN) months = 14.4 [12.8-22.1]; Maximum Plasma Concentration (Cmax) for Atezolizumab (GEOMETRIC_MEAN) micrograms per milliliter (mcg/mL) = 405; Minimum Plasma Concentration (Cmin) for Atezolizumab (GEOMETRIC_MEAN) mcg/mL = 68.8",,,,,,,,,Overall Survival (OS) (MEDIAN) months = 14.4 [12.8-22.1],"Progression-Free Survival (PFS) According to RECIST v1.1 (MEDIAN) months = 4.5 [0.9-37.9]; Percentage of Participants With PFS at Month 6, Month 12 and Month 30 According to RECIST v1.1 (NUMBER) percentage of participants = 33.50; PFS According to Modified RECIST (MEDIAN) months = 5.5 [0.9-37.9]; Percentage of Participants With PFS at Month 6, Month 12 and Month 30 According to Modified RECIST (NUMBER) percentage of participants = 43.12",,,,,,
NCT01853878,A Study to Demonstrate the Benefit of a New Kind of Anti-cancer Treatment [PReferentially Expressed Antigen of MElanoma (PRAME) Immunotherapy] for Pat,GSK2302032A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer,GlaxoSmithKline,GlaxoSmithKline,INDUSTRY,COMPLETED,2013-06-12,2016-08-24,2016-08-24,INTERVENTIONAL,PHASE2,,,,"Lung Cancer, Non-Small Cell","Lung Cancer, Non-Small Cell",1,2,2,BIOLOGICAL,,,1,9,True,Yes,Time to Occurrence of Any Recurrence of Disease (NUMBER) person-year rate = 0.217,; ; ; ; Number of Subjects With Any Unsolicited Adverse Events (AEs) (COUNT_OF_PARTICIPANTS) Participants = 78; ; Number of Subjects With Any Abnormal Hematological and Biochemical Parameters (COUNT_OF_PARTICIPANTS) Participants = 26; Number of Subjects With Any Serious Adverse Events (SAEs) (COUNT_OF_PARTICIPANTS) Participants = 14; Number of Subjects With Any Adverse Events (AEs) by Intensity Grade. (COUNT_OF_PARTICIPANTS) Participants = 35,,,,,,,,,,,,,,Number of Subjects With Any Unsolicited Adverse Events (AEs) (COUNT_OF_PARTICIPANTS) Participants = 78; Number of Subjects With Any Serious Adverse Events (SAEs) (COUNT_OF_PARTICIPANTS) Participants = 14; Number of Subjects With Any Adverse Events (AEs) by Intensity Grade. (COUNT_OF_PARTICIPANTS) Participants = 35,,
NCT01854034,Phase 2 Study of AUY922 in NSCLC Patients With Exon 20 Insertion Mutations in EGFR,Phase II Study of AUY922 in NSCLC Patients With Exon 20 Insertion Mutations in EGFR,Massachusetts General Hospital,Massachusetts General Hospital,OTHER,COMPLETED,2013-07,2017-03,2017-03,INTERVENTIONAL,PHASE2,,,,Non Small Cell Lung Cancer,Non Small Cell Lung Cancer,1,1,1,DRUG,,,1,3,True,Yes,Overall Response Rate (COUNT_OF_PARTICIPANTS) Participants = 5,Median Progression Free and Overall Survival (MEDIAN) Months = 9.9 [4.5-19.2]; The Number of Participants With Treatment Related Serious Adverse Events (COUNT_OF_PARTICIPANTS) Participants = 6; Exon 20 EGFR Mutations Among Participants That Responded to Treatment (NUMBER) participants = 1,,,,,,,,,Median Progression Free and Overall Survival (MEDIAN) Months = 9.9 [4.5-19.2],,,,Overall Response Rate (COUNT_OF_PARTICIPANTS) Participants = 5,The Number of Participants With Treatment Related Serious Adverse Events (COUNT_OF_PARTICIPANTS) Participants = 6,,
NCT01858389,A Study Of Dacomitinib (PF-00299804) In Patients With Advanced Non-Small Cell Lung Cancer,Phase 2 Open Label Trial Of Oral Intermittent Dacomitinib In Patients With Advanced Nsclc,Pfizer,Pfizer,INDUSTRY,COMPLETED,2013-07,2015-09,2015-09,INTERVENTIONAL,PHASE2,,,,Non-small Cell Lung Cancer,Non-small Cell Lung Cancer,1,2,2,DRUG,,,2,7,True,Yes,Best Overall Response (BOR) in Participants With T790M Mutation (NUMBER) Participants = 0; Objective Response Rate (ORR) in Participants With T790M Mutation (NUMBER) Percentage of participants = 6.3 [0.2-30.2],Disease Control Rate (DCR) for Participants With T790M Mutation (NUMBER) Percentage of participants = 50 [24.7-75.3]; Duration of Response in Participants With T790M Mutation (NUMBER) Months = 2.83; Progression-free Survival (MEDIAN) Months = 2.3 [1.4-4.4]; Progression-free Survival at 4 Months (NUMBER) Percentage of participants = 37.5 [15.4-59.8]; Maximum Plasma Concentration (Cmax) for Dacomitinib and PF-05199265 (MEAN) ng/mL = 96.76; Time to Maximum Plasma Concentration (Tmax) for Dacomitinib and PF-05199265 (MEDIAN) Hours = 6.07 [1.3-10.9]; Changes From Time-matched Baseline in Adjusted Fridericia Corrected QT Interval (QTcF) on Echocardiogram (ECG) (MEAN) msecs = 1.7 [-2.33-5.64],,,,,Duration of Response in Participants With T790M Mutation (NUMBER) Months = 2.83,,,Objective Response Rate (ORR) in Participants With T790M Mutation (NUMBER) Percentage of participants = 6.3 [0.2-30.2],,Progression-free Survival (MEDIAN) Months = 2.3 [1.4-4.4]; Progression-free Survival at 4 Months (NUMBER) Percentage of participants = 37.5 [15.4-59.8],,,Objective Response Rate (ORR) in Participants With T790M Mutation (NUMBER) Percentage of participants = 6.3 [0.2-30.2],,,
NCT01866410,Cabozantinib-S-Malate and Erlotinib Hydrochloride in Treating Patients With Previously Treated Metastatic Non-Small Cell Lung Cancer,Phase II Trial of XL184 (Cabozantinib) Plus Erlotinib in Patients With Advanced EGFR-Mutant Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Epidermal Growth Factor Receptor (EGFR) Tyrosine K,National Cancer Institute (NCI),National Cancer Institute (NCI),NIH,COMPLETED,2013-05-20,2018-03-30,2018-03-30,INTERVENTIONAL,PHASE2,,,,Recurrent Non-Small Cell Lung Carcinoma,Recurrent Non-Small Cell Lung Carcinoma; Stage IV Non-Small Cell Lung Cancer AJCC v7,2,1,3,DRUG; OTHER,,,1,5,True,Yes,Objective Response Rate (NUMBER) percentage of participants = 10.8 [0.3-21.3],Percentage of Patients With a Greater Than 30% Increase in Tumor Doubling Time (NUMBER) percentage of participants = 79 [62-91]; Number of Adverse Events (COUNT_OF_PARTICIPANTS) Participants = 1; Best Response Patient Count (COUNT_OF_PARTICIPANTS) Participants = 4; Progression-free Survival (MEDIAN) months = 3.6 [2.0-5.6]; Overall Survival (MEDIAN) months = 13.3,,,,,,,,Objective Response Rate (NUMBER) percentage of participants = 10.8 [0.3-21.3],Overall Survival (MEDIAN) months = 13.3,Progression-free Survival (MEDIAN) months = 3.6 [2.0-5.6],,,Objective Response Rate (NUMBER) percentage of participants = 10.8 [0.3-21.3],Number of Adverse Events (COUNT_OF_PARTICIPANTS) Participants = 1,,
NCT01871805,A Study of Alectinib (CH5424802/RO5424802) in Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC),A Phase I/II Study of the ALK Inhibitor CH5424802/ RO5424802 in Patients With ALK-Rearranged Non-Small Cell Lung Cancer Previously Treated With Crizotinib,Hoffmann-La Roche,Hoffmann-La Roche,INDUSTRY,COMPLETED,2013-09-30,2014-10-24,2017-08-31,INTERVENTIONAL,PHASE1; PHASE2,,,,Non-Small Cell Lung Cancer,Non-Small Cell Lung Cancer,1,2,1,DRUG,,,3,25,True,Yes,Number of Participants With Dose Limiting Toxicities (DLTs): Phase I (NUMBER) participants = 0; Recommended Phase II Dose (RP2D): Phase I (NUMBER) mg = 600; Percentage of Participants With Objective Response According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) by Independent Review Committee (IRC): Phase II (NUMBER) percentage of participants = 52.2 [39.67-64.60],Percentage of Participants With Objective Response According to RECIST v1.1 by Investigator: Phase I (NUMBER) percentage of participants = 69.2 [38.57-90.91]; Duration of Response (DOR) According to RECIST v1.1 by Investigator: Phase I (MEDIAN) months = 12.2 [4.9-20.9]; Percentage of Participants With Objective Response According to RECIST v1.1 by Investigator: Phase II (NUMBER) percentage of participants = 52.9 [41.87-63.67]; Percentage of Participants With Disease Control According to RECIST v1.1 by Investigator: Phase II (NUMBER) percentage of participants = 66.7 [55.75-76.42]; Percentage of Participants With Disease Progression According to RECIST v1.1 by IRC or Death : Phase II (NUMBER) percentage of participants = 66.7; Progression-Free Survival (PFS) According to RECIST v1.1 by IRC: Phase II (MEDIAN) months = 8.2 [6.3-12.6]; Percentage of Participants With Disease Progression According to RECIST v1.1 by Investigator or Death : Phase II (NUMBER) percentage of participants = 70.1; PFS According to RECIST v1.1 by Investigator: Phase II (MEDIAN) months = 8.4 [5.5-12.7]; Percentage of Participants Who Died Due to Any Cause: Phase II (NUMBER) percentage of participants = 51.7; Overall Survival (OS) Time: Phase II (MEDIAN) months = 27.9; DOR According to RECIST v1.1 by IRC: Phase II (MEDIAN) months = 14.9; DOR According to RECIST v1.1 by Investigator: Phase II (MEDIAN) months = 13.3 [8.8-18.2]; Percentage of Participants With Central Nervous System Objective Response (COR) According to RECIST v1.1 by IRC: Phase II (NUMBER) percentage of participants = 75.0 [47.62-92.73]; Percentage of Participants With COR According to Response Assessment in Neuro-Oncology (RANO) Criteria by IRC: Phase II (NUMBER) percentage of participants = 54.5 [23.38-83.25]; CNS Duration of Response (CDOR) According to RECIST v1.1 by IRC: Phase II (MEDIAN) months = 11.1; CDOR According to RANO Criteria by IRC: Phase II (MEDIAN) months = 12.1; Percentage of Participants With CNS Progression According to RECIST v1.1 by IRC: Phase II (NUMBER) percentage of participants = 0 [0.00-20.59]; ; Maximum Observed Plasma Concentration (Cmax) After Single Dose of Alectinib: Phase I (MEAN) nanograms per milliliter (ng/mL) = 73.5; Cmax After Multiple Dose of Alectinib: Phase I (MEAN) ng/mL = 259; Area Under the Plasma Concentration (AUC) Versus Time Curve Extrapolated to Infinity (AUCinf) After Single Dose of Alectinib: Phase I (MEAN) hour*ng/mL = 1360; AUC From Time Zero to Last Measurable Concentration (AUClast) After Multiple Dose of Alectinib: Phase I (MEAN) hour*ng/mL = 1800; Ctrough After Multiple Dose of Alectinib: Phase II (MEAN) ng/mL = 473; Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ-C30): Phase II (MEAN) units on a scale = 53.59; Change From Baseline in EORTC Quality of Life Questionnaire Lung Cancer 13 (EORTC QLQ-LC13): Phase II (MEAN) units on a scale = 30.85,,,,,Duration of Response (DOR) According to RECIST v1.1 by Investigator: Phase I (MEDIAN) months = 12.2 [4.9-20.9]; DOR According to RECIST v1.1 by IRC: Phase II (MEDIAN) months = 14.9; DOR According to RECIST v1.1 by Investigator: Phase II (MEDIAN) months = 13.3 [8.8-18.2]; CNS Duration of Response (CDOR) According to RECIST v1.1 by IRC: Phase II (MEDIAN) months = 11.1; CDOR According to RANO Criteria by IRC: Phase II (MEDIAN) months = 12.1,,,,Overall Survival (OS) Time: Phase II (MEDIAN) months = 27.9,Progression-Free Survival (PFS) According to RECIST v1.1 by IRC: Phase II (MEDIAN) months = 8.2 [6.3-12.6]; PFS According to RECIST v1.1 by Investigator: Phase II (MEDIAN) months = 8.4 [5.5-12.7],,Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ-C30): Phase II (MEAN) units on a scale = 53.59; Change From Baseline in EORTC Quality of Life Questionnaire Lung Cancer 13 (EORTC QLQ-LC13): Phase II (MEAN) units on a scale = 30.85,,,,
NCT01880528,Lisinopril in Reducing Shortness of Breath Caused by Radiation Therapy in Patients With Lung Cancer,A Double-Blind Pilot Study to Measure the Effect of Lisinopril vs. Placebo on Pulmonary Distress in Patients Receiving External Beam Radiotherapy to the Lung,Mayo Clinic,Mayo Clinic,OTHER,COMPLETED,2013-05-31,2013-06-05,2019-01-29,INTERVENTIONAL,PHASE2,,,,Dyspnea,Dyspnea; Non-small Cell Lung Cancer; Small Cell Lung Cancer,3,2,2,DRUG,,,1,4,True,Yes,"Incidence of Grade 3 or Higher Hypotension, Acute Kidney Injury, Allergic Reaction, or Anaphylaxis, as Measured Using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 4.0 (NUMBER) percentage of patients = 0","Acute Respiratory Distress (Dyspnea), Measured Using of the Maximum Score, at Any Time, of the Shortness of Breath Question (Item #4) on the LCSS (Worst Dyspnea Score) (MEAN) score on a scale = 77.5; Experience Shortness of Breath During Exercise as Measured Using Item #3 on the Symptom Experience Questionnaire (SEQ) at Week 4 (MEAN) score on a scale = 100; Quality of Life (Dyspnea When Climbing Stairs) Assessed Using Item #5 of the European Organization for Research on the Treatment of Cancer Lung Cancer Module Survey (EORTC-QLQ-LC13) at Week 4 (MEAN) score on a scale = 83.3; Total LCSS Score as Measure by the Lung Cancer Symptom Scale (LCSS) at Week 4 (MEAN) score on a scale = 83.8",,,,,,,,,,,,Quality of Life (Dyspnea When Climbing Stairs) Assessed Using Item #5 of the European Organization for Research on the Treatment of Cancer Lung Cancer Module Survey (EORTC-QLQ-LC13) at Week 4 (MEAN) score on a scale = 83.3,,"Incidence of Grade 3 or Higher Hypotension, Acute Kidney Injury, Allergic Reaction, or Anaphylaxis, as Measured Using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 4.0 (NUMBER) percentage of patients = 0",,
NCT01903993,A Randomized Phase 2 Study of Atezolizumab (an Engineered Anti-PDL1 Antibody) Compared With Docetaxel in Participants With Locally Advanced or Metasta,"A Phase II, Open-label, Multicenter, Randomized Study to Investigate the Efficacy and Safety of MPDL3280A (Anti-PD-L1 Antibody) Compared With Docetaxel in Patients With Non-Small Cell Lung Cancer Afte",Hoffmann-La Roche,Hoffmann-La Roche,INDUSTRY,COMPLETED,2013-08-06,2015-11-19,2018-09-06,INTERVENTIONAL,PHASE2,,,,Non-Small Cell Lung Cancer,Non-Small Cell Lung Cancer,1,2,2,DRUG,,,1,6,True,Yes,Overall Survival (OS) (MEDIAN) months = 9.7 [8.6-12.0],Objective Response Rate (ORR) (NUMBER) percentage of participants = 14.7 [9.33-21.57]; Progression-Free Survival (PFS) (MEDIAN) months = 3.4 [2.8-4.1]; Duration of Response (DOR) (MEDIAN) months = 7.2 [5.6-12.5]; ORR (Modified RECIST) (NUMBER) percentage of participants = 16.7 [10.98-23.78]; PFS (Modified RECIST) (MEDIAN) months = 4.2 [3.9-6.9]; DOR (Modified RECIST) (MEDIAN) months = 14.9,,,,,Duration of Response (DOR) (MEDIAN) months = 7.2 [5.6-12.5]; DOR (Modified RECIST) (MEDIAN) months = 14.9,,,Objective Response Rate (ORR) (NUMBER) percentage of participants = 14.7 [9.33-21.57]; ORR (Modified RECIST) (NUMBER) percentage of participants = 16.7 [10.98-23.78],Overall Survival (OS) (MEDIAN) months = 9.7 [8.6-12.0],Progression-Free Survival (PFS) (MEDIAN) months = 3.4 [2.8-4.1]; PFS (Modified RECIST) (MEDIAN) months = 4.2 [3.9-6.9],,,Objective Response Rate (ORR) (NUMBER) percentage of participants = 14.7 [9.33-21.57],,,
NCT01905657,Study of Two Doses of Pembrolizumab (MK-3475) Versus Docetaxel in Previously Treated Participants With Non-Small Cell Lung Cancer (MK-3475-010/KEYNOTE,A Phase II/III Randomized Trial of Two Doses of MK-3475 (SCH900475) Versus Docetaxel in Previously Treated Subjects With Non-Small Cell Lung Cancer,Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,INDUSTRY,COMPLETED,2013-08-09,2015-09-30,2020-09-30,INTERVENTIONAL,PHASE2; PHASE3,,,,Non Small Cell Lung Cancer (NSCLC),Non Small Cell Lung Cancer (NSCLC),1,3,2,BIOLOGICAL; DRUG,,,4,2,True,Yes,Overall Survival (OS) (MEDIAN) Months = 14.9; Progression-free Survival (PFS) by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) (MEDIAN) Months = 5.2 [4.0-6.5]; Percentage of Participants Experiencing Adverse Events (AEs) (NUMBER) Percentage of Participants = 97.6; Percentage of Participants Discontinuing Study Drug Due to AEs (NUMBER) Percentage of Participants = 8.3,Overall Response Rate (ORR) by RECIST 1.1 (NUMBER) Percentage of Participants = 30.2 [22.7-38.6]; ,,,,,,,,,Overall Survival (OS) (MEDIAN) Months = 14.9,Progression-free Survival (PFS) by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) (MEDIAN) Months = 5.2 [4.0-6.5],,,Overall Response Rate (ORR) by RECIST 1.1 (NUMBER) Percentage of Participants = 30.2 [22.7-38.6],Percentage of Participants Experiencing Adverse Events (AEs) (NUMBER) Percentage of Participants = 97.6,,
NCT01928576,Phase II Anti-PD1 Epigenetic Therapy Study in NSCLC.,A Phase II Study of Epigenetic Therapy With Azacitidine and Entinostat With Concurrent Nivolumab in Subjects With Metastatic Non-Small Cell Lung Cancer.,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,OTHER,COMPLETED,2013-11-06,2023-04-04,2023-04-04,INTERVENTIONAL,PHASE2,,,,Non-Small Cell Lung Cancer,Non-Small Cell Lung Cancer; Epigenetic Therapy,2,6,4,DRUG,,,1,4,True,Yes,Objective Response (COUNT_OF_PARTICIPANTS) Participants = 4,Progression Free Survival (MEDIAN) months = 4.6 [3.7-13.7]; Time to Progression (MEDIAN) months = 4.6 [3.4-13.7]; Overall Survival (MEDIAN) months = 10.5 [7.7-25.1]; Safety and Tolerability as Assessed by Number of Participants With Dose-limiting Toxicities (COUNT_OF_PARTICIPANTS) Participants = 0,,,,,,,,,Overall Survival (MEDIAN) months = 10.5 [7.7-25.1],Progression Free Survival (MEDIAN) months = 4.6 [3.7-13.7],,,,,,Time to Progression (MEDIAN) months = 4.6 [3.4-13.7]
NCT01933932,Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral,"A Phase III, Double-Blind, Randomised, Placebo-Controlled Study to Assess the Efficacy and Safety of Selumetinib (AZD6244; ARRY-142886) (Hyd-Sulfate) in Combination With Docetaxel, in Patients Receivi",AstraZeneca,AstraZeneca,INDUSTRY,ACTIVE_NOT_RECRUITING,2013-09-25,2016-06-07,2025-12-31,INTERVENTIONAL,PHASE3,,,,Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV,Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV,1,2,4,DRUG,,,1,5,True,Yes,Progression-Free Survival (PFS) (MEDIAN) Months = 3.9 [1.5-5.9],Overall Survival (OS) (MEDIAN) Months = 8.7 [3.6-16.8]; Objective Response Rate (ORR) (NUMBER) Number of responders = 51; Duration of Response (DoR) (MEDIAN) Days = 88.0 [82.0-126.0]; Symptom Improvement Rate Using Average Symptom Burden Index (ASBI) of the Lung Cancer Symptom Scale (LCSS) (NUMBER) Number of patients with improvements = 49; Time to Symptom Progression Using Average Symptom Burden Index (ASBI) of the Lung Cancer Symptom Scale (LCSS) (MEDIAN) Months = 1.6 [0.4-4.6],,,,,Duration of Response (DoR) (MEDIAN) Days = 88.0 [82.0-126.0],,,Objective Response Rate (ORR) (NUMBER) Number of responders = 51,Overall Survival (OS) (MEDIAN) Months = 8.7 [3.6-16.8],Progression-Free Survival (PFS) (MEDIAN) Months = 3.9 [1.5-5.9],,,Objective Response Rate (ORR) (NUMBER) Number of responders = 51,,,
NCT01935336,Study of Ponatinib in Patients With Lung Cancer Preselected Using Different Candidate Predictive Biomarkers,A Phase II Study of Ponatinib in Cohorts of Patients With Lung Cancer Preselected Using Different Candidate Predictive Biomarkers,"University of Colorado, Denver","University of Colorado, Denver",OTHER,COMPLETED,2013-09-24,2017-01,2017-11,INTERVENTIONAL,PHASE2,,,,Adenocarcinoma of the Lung,Adenocarcinoma of the Lung; Extensive Stage Small Cell Lung Cancer; Limited Stage Small Cell Lung Cancer,8,1,1,DRUG,,,3,1,True,Yes,Biomarker FGFR1 (ISH/SISH) Score (Part A) (MEAN) gene copy number = 0.93 [0.87-0.97]; Overlapping Frequency of FGFR1 (ISH/SISH) Biomarkers (Part A) (MEAN) gene copy number = 0.049 [0.018-0.104]; Objective Response Rate (ORR) Per RECIST v1.1 (Part B) (COUNT_OF_PARTICIPANTS) Participants = 0,"Incidence of Adverse Events, Graded According to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v4.0 (NUMBER) participants = 0",,,,,,,,Objective Response Rate (ORR) Per RECIST v1.1 (Part B) (COUNT_OF_PARTICIPANTS) Participants = 0,,,,,Objective Response Rate (ORR) Per RECIST v1.1 (Part B) (COUNT_OF_PARTICIPANTS) Participants = 0,"Incidence of Adverse Events, Graded According to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v4.0 (NUMBER) participants = 0",,
NCT01941316,Study of Carfilzomib With Irinotecan in Irinotecan-Sensitive Malignancies and Small Cell Lung Cancer Patients,Phase 1b/II Trial of Carfilzomib With Irinotecan in Irinotecan-Sensitive Malignancies (Phase Ib) and Small Cell Lung Cancer Patients (Phase II) Who Have Progressed on Prior Platinum-based Chemotherapy,Cancer Research and Biostatistics Clinical Trials Consortium,Cancer Research and Biostatistics Clinical Trials Consortium,NETWORK,COMPLETED,2013-11,2018-12-31,2019-07-01,INTERVENTIONAL,PHASE1; PHASE2,,,,Small Cell Lung Carcinoma,Small Cell Lung Carcinoma; Non Small Cell Lung Carcinoma; Irinotecan Sensitive Cancers,3,4,2,DRUG,,,2,3,True,Yes,Phase Ib: Maximum Tolerated Dose (NUMBER) mg/m^2 Carfilzomib = 20; Phase II: Overall Survival Rate at 6 Months (NUMBER) Proportion with 6-month OS by KM = 0.59 [0.41-0.73],Overall Response Rate (NUMBER) proportion of patients = 0.250; Phase II: Progression-Free Survival Rate at 6 Months (NUMBER) Proportion with 6-month PFS by KM = 0.32 [0.18-0.47]; Phase Ib: Dose Limiting Toxicities (NUMBER) Dose Limiting Toxicities = 0,,,,,,,,,Phase II: Overall Survival Rate at 6 Months (NUMBER) Proportion with 6-month OS by KM = 0.59 [0.41-0.73],Phase II: Progression-Free Survival Rate at 6 Months (NUMBER) Proportion with 6-month PFS by KM = 0.32 [0.18-0.47],,,Overall Response Rate (NUMBER) proportion of patients = 0.250,,,
NCT01945021,"Phase II Safety and Efficacy Study of Crizotinib in East Asian Patients With ROS1 Positive, ALK Negative Advanced NSCLC","Phase II, Open Label, Single Arm Study of the Efficacy and Safety of Crizotinib in East Asian Patients With Advanced ALK-Negative NSCLC Harboring a Translocation or Inversion Involving the c-ROS Oncog",Pfizer,Pfizer,INDUSTRY,COMPLETED,2013-09-30,2015-07-31,2020-01-22,INTERVENTIONAL,PHASE2,,,,Non Small Cell Lung Cancer,Non Small Cell Lung Cancer; ROS1 Proto Oncogene; Crizotinib,3,1,1,DRUG,,,1,10,True,Yes,Independent Radiology Reviewed Overall Objective Response (ORR) (COUNT_OF_PARTICIPANTS) Participants = 88,"IRR-Assessed Duration of Response (DR) (MEDIAN) Months = 19.7; IRR-Assessed Time to Tumor Response (TTR) (MEDIAN) Months = 1.9 [1.6-15.8]; IRR Assessed Disease Control Rate (DCR) at 8 Weeks (NUMBER) Percentage of participants = 88.2 [81.3-93.2]; IRR-Assessed Progression Free Survival (PFS) (MEDIAN) Months = 15.9 [12.9-24.0]; Overall Survival (OS) (MEDIAN) Months = 44.2; Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious AEs, Treatment Emergent Treatment Related AEs and SAEs, Grade 3 or 4 Treatment Emergent AEs and Grade 3 or 4 Treatment Emergent Treatment Related AEs (COUNT_OF_PARTICIPANTS) Participants = 127; Number of Participants With a Shift in Hematology Laboratory Results From Baseline Grade </=2 to Worst Grade 3 or Grade 4 (COUNT_OF_PARTICIPANTS) Participants = 0; Number of Participants With a Shift of Chemistry Laboratory Results From Baseline Grade </=2 to Worst Grade 3 or Grade 4 (COUNT_OF_PARTICIPANTS) Participants = 1; Change From Baseline to Cycle 60 in the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life (QOL) Questionnaire Core 30 (QLQ-C30) Scores (MEAN) Units on a scale = 11.85; Change From Baseline to Cycle 60 in the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Lung Cancer Module 13 Scores (MEAN) Units on a scale = -4.74",,,,,IRR-Assessed Duration of Response (DR) (MEDIAN) Months = 19.7,,,,Overall Survival (OS) (MEDIAN) Months = 44.2,IRR-Assessed Progression Free Survival (PFS) (MEDIAN) Months = 15.9 [12.9-24.0],,Change From Baseline to Cycle 60 in the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life (QOL) Questionnaire Core 30 (QLQ-C30) Scores (MEAN) Units on a scale = 11.85; Change From Baseline to Cycle 60 in the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Lung Cancer Module 13 Scores (MEAN) Units on a scale = -4.74,,"Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious AEs, Treatment Emergent Treatment Related AEs and SAEs, Grade 3 or 4 Treatment Emergent AEs and Grade 3 or 4 Treatment Emergent Treatment Related AEs (COUNT_OF_PARTICIPANTS) Participants = 127",,
NCT01948141,Nintedanib in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Failed Up to Two Previous Chemotherapy Regimens,FGFR1 Amplification as A Predictor of Efficacy in A Biomarker-Driven Phase II Study of BIBF 1120 in Advanced Squamous Cell Lung Cancer Patients Who Have Failed Up to Two Prior Chemotherapeutic Regimen,Roswell Park Cancer Institute,Roswell Park Cancer Institute,OTHER,COMPLETED,2014-01-30,2016-08-16,2016-08-16,INTERVENTIONAL,PHASE2,,,,Recurrent Non-small Cell Lung Cancer,Recurrent Non-small Cell Lung Cancer; Squamous Cell Lung Cancer; Stage III Non-small Cell Lung Cancer,4,1,1,DRUG,,,1,7,True,Yes,6-month Progression Free Survival (PFS) Rate Within the Entire FGFR1 Amplified Group (NUMBER) percentage of participants = 0 [0-65.8],"Compare the 6-month PFS Rate for the Entire FGFR1 Amplified Group Versus the FGFR1 Non-amplified Patients. (NUMBER) percentage of participants = 0; Compare the 6-month PFS Rate for Each FGFR1 Amplified Group (Low, Intermediate, and High) Versus FGFR1 Non-amplified Patients. (NUMBER) percentage of participants = 0; ; Overall Survival (OS) (MEDIAN) months = 10.2 [4-16.4]; Tumor Response Rate (NUMBER) percentage of participants = 0 [0-66]; Incidence of Adverse Events (AEs) (NUMBER) percentage of participants = 100 [61-100]; Progression Free Survival (MEDIAN) months = 2.7 [1.7-15.1]",,,,,,,,,Overall Survival (OS) (MEDIAN) months = 10.2 [4-16.4],"6-month Progression Free Survival (PFS) Rate Within the Entire FGFR1 Amplified Group (NUMBER) percentage of participants = 0 [0-65.8]; Compare the 6-month PFS Rate for the Entire FGFR1 Amplified Group Versus the FGFR1 Non-amplified Patients. (NUMBER) percentage of participants = 0; Compare the 6-month PFS Rate for Each FGFR1 Amplified Group (Low, Intermediate, and High) Versus FGFR1 Non-amplified Patients. (NUMBER) percentage of participants = 0; Progression Free Survival (MEDIAN) months = 2.7 [1.7-15.1]",,,Tumor Response Rate (NUMBER) percentage of participants = 0 [0-66],Incidence of Adverse Events (AEs) (NUMBER) percentage of participants = 100 [61-100],,
NCT01951157,A Clinical Study in Three-arm of Lurbinectedin (PM01183) Alone or in Combination With Gemcitabine and a Control Arm With Docetaxel as Second Line Trea,A Randomized-Controlled Three-arm Phase II Study of Lurbinectedin (PM01183) Alone or In Combination With Gemcitabine and a Control Arm With Docetaxel as Second-Line Treatment in Unresectable Non-Small,PharmaMar,PharmaMar,INDUSTRY,COMPLETED,2013-09-11,2016-11,2016-11,INTERVENTIONAL,PHASE2,,,,Non-Small Cell Lung Cancer (NSCLC),Non-Small Cell Lung Cancer (NSCLC),1,3,3,DRUG,,,1,7,True,Yes,Progression-free Survival Rate at Four Months (PFS4) (NUMBER) percentage of participants = 27.3 [10.7-50.2],Progression-free Survival (MEDIAN) months = 3.1 [1.8-4]; Progression-free Survival Rate at Six Months (PFS6) (NUMBER) percentage of participants = 18.2 [2.1-34.3]; Overall Response Rate (NUMBER) percentage of participants = 9.1 [1.1-29.2]; Objective Response Per RECIST v.1.1 (COUNT_OF_PARTICIPANTS) Participants = 2; Duration of Response (MEDIAN) months = 1.2 [0.8-1.6]; Overall Survival (OS) (MEDIAN) months = 9.4; Information on Quality of Life (QoL) (MEAN) units on a scale = 27.2 [18.4-36.1],,,,,Duration of Response (MEDIAN) months = 1.2 [0.8-1.6],,,,Overall Survival (OS) (MEDIAN) months = 9.4,Progression-free Survival Rate at Four Months (PFS4) (NUMBER) percentage of participants = 27.3 [10.7-50.2]; Progression-free Survival (MEDIAN) months = 3.1 [1.8-4]; Progression-free Survival Rate at Six Months (PFS6) (NUMBER) percentage of participants = 18.2 [2.1-34.3],,Information on Quality of Life (QoL) (MEAN) units on a scale = 27.2 [18.4-36.1],Overall Response Rate (NUMBER) percentage of participants = 9.1 [1.1-29.2],,,
NCT01951586,Denosumab in Combination With Chemotherapy as First-line Treatment of Metastatic Non-small Cell Lung Cancer,"A Randomized, Double-blind, Multi-center Phase 2 Trial of Denosumab in Combination With Chemotherapy as First-line Treatment of Metastatic Non-small Cell Lung Cancer",Amgen,Amgen,INDUSTRY,COMPLETED,2013-12-31,2016-07-29,2017-11-28,INTERVENTIONAL,PHASE2,,,,Non-Small Cell Lung Cancer,Non-Small Cell Lung Cancer,1,2,5,DRUG,,,1,10,True,Yes,Overall Survival (OS) (MEDIAN) months = 10.9 [9.26-15.54],Correlation of Tumor Tissue RANK Expression With Overall Survival (NUMBER) hazard ratio = 0.84 [0.65-1.09]; Correlation of Tumor Tissue RANK Ligand Expression With Overall Survival (NUMBER) hazard ratio = 0.77 [0.63-0.95]; Objective Response Rate (NUMBER) percentage of participants = 43.4; Correlation of Tumor Tissue RANK Expression With Objective Response Rate (NUMBER) odds ratio = 1.00 [0.67-1.50]; Correlation of Tumor Tissue RANKL Expression With Objective Response Rate (NUMBER) odds ratio = 1.27 [0.88-1.83]; Clinical Benefit Rate (NUMBER) percentage of participants = 53.9; Progression-free Survival (PFS) (MEDIAN) months = 5.7 [4.37-7.16]; Serum Denosumab Trough Levels in Participants Who Received Q3W Dosing (MEAN) ng/mL = 8590; Serum Denosumab Trough Levels in Participants Who Received Q4W Dosing (MEAN) ng/mL = 8990; Number of Participants With Treatment-emergent Adverse Events (NUMBER) participants = 76,Clinical Benefit Rate (NUMBER) percentage of participants = 53.9,,,,,,,Objective Response Rate (NUMBER) percentage of participants = 43.4; Correlation of Tumor Tissue RANK Expression With Objective Response Rate (NUMBER) odds ratio = 1.00 [0.67-1.50]; Correlation of Tumor Tissue RANKL Expression With Objective Response Rate (NUMBER) odds ratio = 1.27 [0.88-1.83],Overall Survival (OS) (MEDIAN) months = 10.9 [9.26-15.54]; Correlation of Tumor Tissue RANK Expression With Overall Survival (NUMBER) hazard ratio = 0.84 [0.65-1.09]; Correlation of Tumor Tissue RANK Ligand Expression With Overall Survival (NUMBER) hazard ratio = 0.77 [0.63-0.95],Progression-free Survival (PFS) (MEDIAN) months = 5.7 [4.37-7.16],,,Objective Response Rate (NUMBER) percentage of participants = 43.4; Correlation of Tumor Tissue RANK Expression With Objective Response Rate (NUMBER) odds ratio = 1.00 [0.67-1.50]; Correlation of Tumor Tissue RANKL Expression With Objective Response Rate (NUMBER) odds ratio = 1.27 [0.88-1.83],Number of Participants With Treatment-emergent Adverse Events (NUMBER) participants = 76,,
NCT01966003,Efficacy and Safety Study of ABP 215 Compared With Bevacizumab in Patients With Advanced Non-Small Cell Lung Cancer,"A Randomized, Double-blind, Phase 3 Study Evaluating the Efficacy and Safety of ABP 215 Compared With Bevacizumab in Subjects With Advanced Non-Small Cell Lung Cancer",Amgen,Amgen,INDUSTRY,COMPLETED,2013-11-11,2015-07-23,2015-07-23,INTERVENTIONAL,PHASE3,,,,Non-small Cell Lung Cancer Metastatic,Non-small Cell Lung Cancer Metastatic,1,2,4,DRUG,,,1,5,True,Yes,Percentage of Participants With an Objective Response (NUMBER) percentage of participants = 39.0,Duration of Response (MEDIAN) months = 5.8 [4.9-7.7]; Progression-free Survival (MEDIAN) months = 6.6 [6.3-7.9]; Number of Participants With Adverse Events (NUMBER) participants = 308; Number of Participants Who Developed Anti-drug Antibodies (NUMBER) participants = 4; ,,,,,Duration of Response (MEDIAN) months = 5.8 [4.9-7.7],,,,,Progression-free Survival (MEDIAN) months = 6.6 [6.3-7.9],,,,Number of Participants With Adverse Events (NUMBER) participants = 308,,
NCT01967823,T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Cancer,Phase II Study of Metastatic Cancer That Expresses NY-ESO-1 Using Lymphodepleting Conditioning Followed by Infusion of Anti-NY ESO-1 Murine TCR-Gene Engineered Lymphocytes,National Institutes of Health Clinical Center (CC),National Cancer Institute (NCI),NIH,COMPLETED,2013-10-24,2020-04-06,2020-04-06,INTERVENTIONAL,PHASE2,,,,Melanoma,Melanoma; Meningioma; Breast Cancer,5,1,4,BIOLOGICAL; DRUG,,,1,1,True,Yes,Percentage of Participants With a Response (NUMBER) percentage of participants = 10,Percentage of T Cell Receptor (TCR) in Cluster of Differentiation 3 (CD3) + Cells (NUMBER) Percentage of Tcells = 81,,,,,,,,,,,,,,,,
NCT01970865,A Study Of PF-06463922 An ALK/ROS1 Inhibitor In Patients With Advanced Non Small Cell Lung Cancer With Specific Molecular Alterations,PHASE 1/2 STUDY OF PF-06463922 (AN ALK/ROS1 TYROSINE KINASE INHIBITOR) IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER HARBORING SPECIFIC MOLECULAR ALTERATIONS,Pfizer,Pfizer,INDUSTRY,COMPLETED,2014-01-08,2017-03-15,2023-05-24,INTERVENTIONAL,PHASE1; PHASE2,,,,ALK-positive Non Small Cell Lung Cancer (NSCLC) and ROS1-positive NSCLC,ALK-positive Non Small Cell Lung Cancer (NSCLC) and ROS1-positive NSCLC,1,2,2,DRUG,,,2,70,True,Yes,Number of Participants With Cycle 1 Dose-Limiting Toxicities (DLTs) in Phase 1 (COUNT_OF_PARTICIPANTS) Participants = 0; Percentage of Participants With Overall and Intracranial Objective Response (Phase 2) (NUMBER) Percentage of participants = 90.0 [73.5-97.9],"Percentage of Participants With Overall and Intracranial Objective Response (Phase 1) (NUMBER) Percentage of participants = 39.0 [24.2-55.5]; Time to Tumor Response (TTR) and Intracranial TTR (Phase 1) (MEDIAN) Months = 1.4 [1.2-15.2]; Number of Participants With Duration of Response (DOR) and Intracranial DOR (Phase 1) (COUNT_OF_PARTICIPANTS) Participants = 1; Percentage of Participants Achieving Disease Control and Intracranial Disease Control at 12 and 24 Weeks (Phase 1) (NUMBER) Percentage of participants = 53.7 [37.4-69.3]; Probability of First Event Being a Central Nervous System (CNS) Progression, Non CNS Progression, or Death (Phase 1) (NUMBER) Probability of events = 0.260; Progression-Free Survival (PFS) (Phase 1) (MEDIAN) Months = 5.4 [2.7-11.8]; Overall Survival (OS) (Phase 1) (MEDIAN) Months = 22.3; Maximum Observed Plasma Concentration (Cmax) of PF-06463922 Following Single Oral Doses (Phase 1) (GEOMETRIC_MEAN) Nanograms per milliliter (ng/mL) = 50.80; Maximum Observed Plasma Concentration (Cmax) of PF-06463922 Following Multiple Oral Doses (Phase 1) (GEOMETRIC_MEAN) ng/mL = 67.29; Time for Cmax (Tmax) of PF-06463922 Following Single Oral Doses (Phase 1) (MEDIAN) Hours = 1.98 [1.00-2.97]; Time for Cmax (Tmax) of PF-06463922 Following Multiple Oral Doses (Phase 1) (MEDIAN) Hours = 1.00 [1.00-1.08]; Area Under the Plasma Concentration-Time Profile From Time Zero to Time Tau (AUCtau) of PF-06463922 Following Single Oral Doses (Phase 1) (GEOMETRIC_MEAN) Nanogram*hour/milliliter (ng*hr/mL) = 488.2; Area Under the Plasma Concentration-Time Profile From Time Zero to Time Tau (AUCtau) of PF-06463922 Following Multiple Oral Doses (Phase 1) (GEOMETRIC_MEAN) ng*hr/mL = 752.1; ; ; Apparent Oral Clearance (CL/F) of PF-06463922 Following Multiple Oral Doses (Phase 1) (GEOMETRIC_MEAN) L/hr = 13.27; ; Observed Accumulation Ratio (Rac) of PF-06463922 Following Multiple Oral Doses (Phase 1) (MEAN) Ratio = 1.543; ; ; Renal Clearance (CLr) of PF-06463922 (Phase 1) (GEOMETRIC_MEAN) ml/hour = 61.31; Percent of PF-06463922 Recovered Unchanged in Urine up to Dosing Interval (AEtau%) (Phase 1) (MEAN) Percentage of recovered PF-06463922 = 0.4017; Maximum Observed Plasma Concentration (Cmax) of Midazolam (Phase 1) (GEOMETRIC_MEAN) ng/mL = 16.06; Time for Cmax (Tmax) of Midazolam (Phase 1) (MEDIAN) Hours = 0.50 [0.50-1.00]; Area Under the Plasma Concentration-Time Profile From Time Zero to the Time of the Last Quantifiable Concentration (AUClast) of Midazolam (Phase 1) (GEOMETRIC_MEAN) ng*hr/mL = 51.30; Area Under the Plasma Concentration-Time Profile From Time Zero Extrapolated to Infinite Time (AUCinf) of Midazolam (Phase 1) (GEOMETRIC_MEAN) ng*hr/mL = 54.53; Apparent Oral Clearance (CL/F) of Midazolam (Phase 1) (GEOMETRIC_MEAN) L/hr = 36.68; Apparent Volume of Distribution (Vz/F) of Midazolam (Phase 1) (GEOMETRIC_MEAN) Liters = 229.0; Terminal Half-Life of Midazolam (Phase 1) (MEAN) Hours = 4.620; Number of Participants With ALK Mutation Based on Plasma CNA Analysis (Phase 1) (COUNT_OF_PARTICIPANTS) Participants = 14; Number of Participants With ALK Mutation Based on Tumor Tissue Analysis (Phase 1) (COUNT_OF_PARTICIPANTS) Participants = 7; Number of Participants Who Improved, Worsened or Remained Stable in EORTC QLQ-C30 (Phase 1) (COUNT_OF_PARTICIPANTS) Participants = 19; Number of Participants Who Improved, Worsened or Remained Stable in EORTC QLQ-LC13 (Phase 1) (COUNT_OF_PARTICIPANTS) Participants = 9; Change From Baseline in Mini Mental State Examination (MMSE) Score (Phase 1) (MEAN) Units on a scale = 1.0; Time to Tumor Response (TTR) and Intracranial TTR (Phase 2 and DDI Sub-study) (MEDIAN) Months = 1.4 [1.2-5.4]; Duration of Response (DOR) and Intracranial DOR (Phase 2 and DDI Substudy) (MEDIAN) Months = 17.16 [12.45-35.09]; Percentage of Participants Achieving Disease Control and Intracranial Disease Control at Week 12 and 24 (Phase 2 and DDI Substudy) (NUMBER) Percentage of participants = 93.3 [77.9-99.2]; Time to Progression on the Last Prior Therapy (Phase 2) (MEDIAN) Months = 11.5 [7.2-19.6]; Time to Tumor Progression (TTP) and Intracranial TTP (Phase 2 and DDI Substudy) (MEDIAN) Months = 17.7 [12.5-40.5]; Probability of First Event Being a Central Nervous System (CNS) Progression, Non CNS Progression, or Death (Phase 2) (NUMBER) Probability of events = 0.179; Progression-Free Survival (PFS) (Phase 2 and DDI Substudy) (MEDIAN) Months = 16.6 [11.8-28.3]; ; Maximum Observed Plasma Concentration (Cmax) of PF-06463922 (Phase 2) (GEOMETRIC_MEAN) ng/mL = 695.2; Time for Cmax (Tmax) of PF-06463922 (Phase 2) (MEDIAN) Hours = 1.15 [0.50-4.02]; Area Under the Plasma Concentration-Time Profile From Time Zero Extrapolated to Infinite Time (AUCinf) of PF-06463922 (Phase 2) (GEOMETRIC_MEAN) ng*hour/mL = 9088; Area Under the Plasma Concentration-Time Profile From Time Zero to Time Tau (AUCtau) of PF-06463922 (Phase 2) (GEOMETRIC_MEAN) ng*hour/mL = 5308; Apparent Oral Clearance (CL/F) of PF-06463922 (Phase 2) (GEOMETRIC_MEAN) Liter/hour = 11.01; Apparent Volume of Distribution (Vz/F) of PF-06463922 (Phase 2) (GEOMETRIC_MEAN) Liters = 351.5; Terminal Half-Life of PF-06463922 (Phase 2) (MEAN) Hours = 23.58; Observed Accumulation Ratio (Rac) of PF-06463922 Following Multiple Oral Doses (Phase 2) (MEAN) Ratio = 1.082; Steady State Accumulation Ratio (Rss) of PF-06463922 Following Multiple Oral Doses (Phase 2) (MEAN) Ratio = 0.6577; Number of Participants With ALK Mutation Based on Plasma CNA Analysis (Phase 2) (COUNT_OF_PARTICIPANTS) Participants = 0; Number of Participants With ALK Mutation Based on Tumor Tissue Analysis (Phase 2) (COUNT_OF_PARTICIPANTS) Participants = 0; Number of Participants Who Improved, Worsened or Remained Stable in EORTC QLQ-C30 (Phase 2 and DDI Sub-study) (COUNT_OF_PARTICIPANTS) Participants = 17; Number of Participants Who Improved, Worsened or Remained Stable in EORTC QLQ-LC13 (Phase 2 and DDI Sub-study) (COUNT_OF_PARTICIPANTS) Participants = 11; Number of Participants With Treatment-Emergent Adverse Events (Phase 1, Phase 2 and DDI Sub-study) (COUNT_OF_PARTICIPANTS) Participants = 3; Number of Participants With Laboratory Abnormalities (Phase 1, Phase 2 and DDI Sub-study) - Hematology (COUNT_OF_PARTICIPANTS) Participants = 3; Number of Participants With Laboratory Abnormalities (Phase 1, Phase 2 and DDI Sub-study) - Chemistry (COUNT_OF_PARTICIPANTS) Participants = 2; Number of Participants With Laboratory Abnormalities (Phase 1, Phase 2 and DDI Sub-study) - Coagulation, Lipids and Urinalysis (COUNT_OF_PARTICIPANTS) Participants = 1; Number of Participants With Vital Signs Data Meeting Pre-defined Criteria (Phase 1, Phase 2 and DDI Sub-study) (COUNT_OF_PARTICIPANTS) Participants = 0; Number of Participants With Maximum Decrease From Baseline Greater Than or Equal to 20 Percent in Left Ventricular Ejection Fraction (LVEF) (Phase 1, Phase 2 and DDI Sub-study) (COUNT_OF_PARTICIPANTS) Participants = 1; Number of Participants With Absolute Values and Change From Baseline in QTcF Meeting Pre-defined Criteria (Phase 1, Phase 2 and DDI Sub-study) (COUNT_OF_PARTICIPANTS) Participants = 1; Number of Participants With Suicidal Ideation and Suicidal Behavior (Phase 2) (COUNT_OF_PARTICIPANTS) Participants = 1; Change From Baseline in Total Scores for Beck Depression Inventory (BDI)-II (Mood Assessment) (Phase 2) (LEAST_SQUARES_MEAN) Units on a scale = -2.59 [-4.82--0.37]; Change From Baseline in Total Scores for Detection Test (Cognitive Function Assessment) (Phase 2) (LEAST_SQUARES_MEAN) Units on a scale = 0.01 [-0.04-0.05]; Change From Baseline in Total Scores for Identification Test (Cognitive Function Assessment) (Phase 2) (LEAST_SQUARES_MEAN) Units on a scale = -0.02 [-0.05-0.01]; Change From Baseline in Total Scores for One Back Test (Cognitive Function Assessment) (Phase 2) (LEAST_SQUARES_MEAN) Units on a scale = 0.01 [-0.02-0.05]; Change From Baseline in Total Scores for International Shopping List Test (Cognitive Function Assessment) (Phase 2) (LEAST_SQUARES_MEAN) Units on a scale = -0.02 [-1.89-1.84]; Change From Baseline in Total Scores for International Shopping List Test-Delayed Recall (Cognitive Function Assessment) (Phase 2) (LEAST_SQUARES_MEAN) Units on a scale = 0.10 [-0.85-1.06]; Number of Participants With Absolute Values and Change From Baseline in PR Interval Meeting Pre-defined Criteria (Phase 2 and DDI Substudy) (COUNT_OF_PARTICIPANTS) Participants = 4",,,,,Number of Participants With Duration of Response (DOR) and Intracranial DOR (Phase 1) (COUNT_OF_PARTICIPANTS) Participants = 1; Duration of Response (DOR) and Intracranial DOR (Phase 2 and DDI Substudy) (MEDIAN) Months = 17.16 [12.45-35.09],,,,Overall Survival (OS) (Phase 1) (MEDIAN) Months = 22.3,Progression-Free Survival (PFS) (Phase 1) (MEDIAN) Months = 5.4 [2.7-11.8]; Progression-Free Survival (PFS) (Phase 2 and DDI Substudy) (MEDIAN) Months = 16.6 [11.8-28.3],Number of Participants With Absolute Values and Change From Baseline in PR Interval Meeting Pre-defined Criteria (Phase 2 and DDI Substudy) (COUNT_OF_PARTICIPANTS) Participants = 4,,,"Number of Participants With Treatment-Emergent Adverse Events (Phase 1, Phase 2 and DDI Sub-study) (COUNT_OF_PARTICIPANTS) Participants = 3",,Time to Progression on the Last Prior Therapy (Phase 2) (MEDIAN) Months = 11.5 [7.2-19.6]; Time to Tumor Progression (TTP) and Intracranial TTP (Phase 2 and DDI Substudy) (MEDIAN) Months = 17.7 [12.5-40.5]
NCT01982955,Tepotinib With Gefitinib in Participants With Locally Advanced or Metastatic NSCLC (INSIGHT),"A Phase Ib/II Multicenter, Randomized, Open Label Trial to Compare Tepotinib (MSC2156119J) Combined With Gefitinib Versus Chemotherapy as Second-Line Treatment in Subjects With MET Positive, Locally A","Merck KGaA, Darmstadt, Germany","Merck KGaA, Darmstadt, Germany",INDUSTRY,COMPLETED,2013-12-23,2017-12-12,2021-10-14,INTERVENTIONAL,PHASE1; PHASE2,,,,Non-small Cell Lung Cancer,Non-small Cell Lung Cancer,1,5,5,DRUG,,,3,41,True,Yes,Phase 1b: Number of Participants Experiencing at Least One Dose Limiting Toxicity (DLT) (COUNT_OF_PARTICIPANTS) Participants = 0; Phase 1b: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious TEAEs (COUNT_OF_PARTICIPANTS) Participants = 6; Phase 2 (Randomized Part Only): Progression-free Survival (PFS) Based on Tumor Assessment by the Investigator (MEDIAN) Months = 4.86 [3.88-6.87],"Phase 1b: Area Under the Plasma Concentration Versus Time Curve From Time Zero to the Last Sampling Time AUC (0-t) of Tepotinib, Its Metabolites and Gefitinib (GEOMETRIC_MEAN) nanogram*hour per milliliter (ng*h/mL) = 6280; Phase 1b: Area Under the Plasma Concentration-Time Curve Within 1 Dosing Interval (AUC 0-tau) of Tepotinib, Its Metabolites and Gefitinib (GEOMETRIC_MEAN) ng*h/mL = 6280; Phase 1b: Maximum Observed Plasma Concentration (Cmax) of Tepotinib, Its Metabolites and Gefitinib (GEOMETRIC_MEAN) Nanogram per Milliliter (ng/mL) = 375; Phase 1b: Average Observed Plasma Concentration (Cavg) of Tepotinib, Its Metabolites and Gefitinib (GEOMETRIC_MEAN) ng/mL = 654; Phase 1b: Minimum Observed Plasma Concentration (Cmin) of Tepotinib, Its Metabolites and Gefitinib (GEOMETRIC_MEAN) ng/mL = 534; Phase 1b: Time to Reach Maximum Plasma Concentration (Tmax) of Tepotinib, Its Metabolites and Gefitinib (MEDIAN) Hours = 8.00 [4.00-8.00]; ; Phase 1b: Apparent Total Body Clearance From Plasma (CL/F) of Tepotinib and Gefitinib (GEOMETRIC_MEAN) liter per hour (L/h) = 17.3; ; ; ; ; Phase 1b: Percentage of Participants With Objective Response Based on Tumor Response Assessment According to Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST v1.1) Criteria (NUMBER) Percentage of Participants = 33.3 [6.3-72.9]; Phase 1b: Percentage of Participants With Disease Control Based on Tumor Response Assessment According to Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST v1.1) Criteria (NUMBER) Percentage of Participants = 50.0 [15.3-84.7]; Phase 1b: Number of Participants With Treatment-Related Treatment-Emergent Adverse Events (TEAEs) and Treatment-Related Serious TEAEs According to National Cancer Institute Common Toxicity Criteria for Adverse Events Version 4.03 (COUNT_OF_PARTICIPANTS) Participants = 6; Phase 1b: Number of Participants With Grade 3/4 Treatment-Emergent Adverse Events (TEAEs) and Grade 3/4 Treatment-Related TEAEs According to National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI-CTCAE) Version 4.03 (COUNT_OF_PARTICIPANTS) Participants = 5; Phase 1b: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) Leading to Permanent Treatment Discontinuation (COUNT_OF_PARTICIPANTS) Participants = 0; Phase 1b: Number of Participants With Death and Reasons (COUNT_OF_PARTICIPANTS) Participants = 0; Phase 1b: Number of Participants With Laboratory Test Abnormalities of Grade 3 or Higher Severity Based on NCI-CTCAE Version 4.03 Reported as Treatment-Emergent Adverse Events (TEAEs) (COUNT_OF_PARTICIPANTS) Participants = 2; Phase 1b: Number of Participants With Clinically Significant Abnormalities in Vital Signs (COUNT_OF_PARTICIPANTS) Participants = 0; Phase 1b: Number of Participants With Clinically Significant Abnormalities in 12-Lead Electrocardiograms (ECG) Findings (COUNT_OF_PARTICIPANTS) Participants = 0; Phase 1b: Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Score of 2 or Higher Than 2 (COUNT_OF_PARTICIPANTS) Participants = 1; Phase 2: Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs, Treatment-Related TEAEs and Treatment-Related Serious TEAEs According to National Cancer Institute Common Toxicity Criteria for Adverse Events Version 4.03 (COUNT_OF_PARTICIPANTS) Participants = 31; Phase 2: Number of Participants With Greater Than or Equal to (>=) Grade 3 Treatment-Emergent Adverse Events (TEAEs) and >= Grade 3 Treatment-Related TEAEs According to National Cancer Institute Common Toxicity Criteria for Adverse Events Version 4.03 (COUNT_OF_PARTICIPANTS) Participants = 20; Phase 2: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) Leading to Permanent Treatment Discontinuation (COUNT_OF_PARTICIPANTS) Participants = 3; Phase 2: Number of Participants With Death and Reasons (COUNT_OF_PARTICIPANTS) Participants = 21; Phase 2: Number of Participants With Laboratory Test Abnormalities of Grade 3 or Higher Severity Based on NCI-CTCAE Version 4.03 Reported as Treatment-Emergent Adverse Events (TEAEs) (COUNT_OF_PARTICIPANTS) Participants = 0; Phase 2: Number of Participants With Clinically Significant Abnormalities in Vital Signs (COUNT_OF_PARTICIPANTS) Participants = 0; Phase 2: Number of Participants With Clinically Significant Abnormalities in 12-Lead Electrocardiograms (ECG) Findings (COUNT_OF_PARTICIPANTS) Participants = 2; Phase 2: Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Score of 2 or Higher Than 2 (COUNT_OF_PARTICIPANTS) Participants = 6; Phase 2 (Randomized Part Only): Progression-free Survival (PFS) Based on Tumor Assessment by Independent Review Committee (IRC) (MEDIAN) Months = 10.15 [4.24-19.32]; Phase 2: (Randomized Part Only): Overall Survival (OS) Time (MEDIAN) Months = 17.25 [12.12-29.14]; Phase 2 (Randomized Part Only): Percentage of Participants With Objective Response Based on Tumor Response Assessment According to Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST v1.1) Criteria (NUMBER) Percentage of Participants = 45.2 [29.7-61.3]; Phase 2 (Randomized Part Only): Percentage of Participants With Disease Control Based on Tumor Response Assessment According to Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST v1.1) Criteria (NUMBER) Percentage of Participants = 83.9 [69.0-93.4]; Phase 2 (Non-Randomized Part Only): Progression-free Survival (PFS) Based on Tumor Assessment by Investigator (MEDIAN) Months = 1.41 [1.35-4.90]; Phase 2 (Non-Randomized Part Only): Progression-free Survival (PFS) Based on Tumor Assessment by Independent Review Committee (IRC) (MEDIAN) Months = 2.63 [1.38-2.73]; Phase 2: (Non-Randomized Part Only): Overall Survival (OS) Time (MEDIAN) Months = 25.86 [13.08-39.66]; Phase 2 (Non-Randomized Part Only): Percentage of Participants With Objective Response Based on Tumor Response Assessment According to Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST v1.1) Criteria (NUMBER) Percentage of Participants = 0 [0.0-18.1]; Phase 2 (Non-Randomized Part Only): Percentage of Participants With Disease Control Based on Tumor Response Assessment According to Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST v1.1) Criteria (NUMBER) Percentage of Participants = 40 [19.1-64.0]; Phase 2: Change From Baseline in European Organization for the Research and Treatment of Cancer Quality of Life (EORTC QLQ-C30) Global Health Status Scale Score at End of Treatment (EOT) (MEAN) Units on a Scale = -16.29; Phase 2: Time-to-Symptom Progression (TTSP) (MEDIAN) Months = 5.75 [1.41-11.86]",,,,,,,,,Phase 2: (Randomized Part Only): Overall Survival (OS) Time (MEDIAN) Months = 17.25 [12.12-29.14]; Phase 2: (Non-Randomized Part Only): Overall Survival (OS) Time (MEDIAN) Months = 25.86 [13.08-39.66],Phase 2 (Randomized Part Only): Progression-free Survival (PFS) Based on Tumor Assessment by the Investigator (MEDIAN) Months = 4.86 [3.88-6.87]; Phase 2 (Randomized Part Only): Progression-free Survival (PFS) Based on Tumor Assessment by Independent Review Committee (IRC) (MEDIAN) Months = 10.15 [4.24-19.32]; Phase 2 (Non-Randomized Part Only): Progression-free Survival (PFS) Based on Tumor Assessment by Investigator (MEDIAN) Months = 1.41 [1.35-4.90]; Phase 2 (Non-Randomized Part Only): Progression-free Survival (PFS) Based on Tumor Assessment by Independent Review Committee (IRC) (MEDIAN) Months = 2.63 [1.38-2.73],,Phase 2: Change From Baseline in European Organization for the Research and Treatment of Cancer Quality of Life (EORTC QLQ-C30) Global Health Status Scale Score at End of Treatment (EOT) (MEAN) Units on a Scale = -16.29,,"Phase 1b: Number of Participants Experiencing at Least One Dose Limiting Toxicity (DLT) (COUNT_OF_PARTICIPANTS) Participants = 0; Phase 1b: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious TEAEs (COUNT_OF_PARTICIPANTS) Participants = 6; Phase 1b: Number of Participants With Treatment-Related Treatment-Emergent Adverse Events (TEAEs) and Treatment-Related Serious TEAEs According to National Cancer Institute Common Toxicity Criteria for Adverse Events Version 4.03 (COUNT_OF_PARTICIPANTS) Participants = 6; Phase 1b: Number of Participants With Grade 3/4 Treatment-Emergent Adverse Events (TEAEs) and Grade 3/4 Treatment-Related TEAEs According to National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI-CTCAE) Version 4.03 (COUNT_OF_PARTICIPANTS) Participants = 5; Phase 1b: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) Leading to Permanent Treatment Discontinuation (COUNT_OF_PARTICIPANTS) Participants = 0; Phase 1b: Number of Participants With Laboratory Test Abnormalities of Grade 3 or Higher Severity Based on NCI-CTCAE Version 4.03 Reported as Treatment-Emergent Adverse Events (TEAEs) (COUNT_OF_PARTICIPANTS) Participants = 2; Phase 2: Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs, Treatment-Related TEAEs and Treatment-Related Serious TEAEs According to National Cancer Institute Common Toxicity Criteria for Adverse Events Version 4.03 (COUNT_OF_PARTICIPANTS) Participants = 31; Phase 2: Number of Participants With Greater Than or Equal to (>=) Grade 3 Treatment-Emergent Adverse Events (TEAEs) and >= Grade 3 Treatment-Related TEAEs According to National Cancer Institute Common Toxicity Criteria for Adverse Events Version 4.03 (COUNT_OF_PARTICIPANTS) Participants = 20; Phase 2: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) Leading to Permanent Treatment Discontinuation (COUNT_OF_PARTICIPANTS) Participants = 3; Phase 2: Number of Participants With Laboratory Test Abnormalities of Grade 3 or Higher Severity Based on NCI-CTCAE Version 4.03 Reported as Treatment-Emergent Adverse Events (TEAEs) (COUNT_OF_PARTICIPANTS) Participants = 0",,
NCT01996332,A Study of Tarceva (Erlotinib) Monotherapy in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC),An Open-label Study of the Effect of Tarceva Monotherapy on Treatment Response in Patients With Advanced Non-small Cell Lung Cancer for Whom Tarceva Monotherapy is Considered the Best Option,Hoffmann-La Roche,Hoffmann-La Roche,INDUSTRY,COMPLETED,2004-04,2012-10,2012-10,INTERVENTIONAL,PHASE2,,,,Non-Small Cell Lung Cancer,Non-Small Cell Lung Cancer,1,1,1,DRUG,,,1,2,True,Yes,Time to Disease Progression or Death by Line of Treatment (MEDIAN) months = 3.4 [2.9-4.1],Percentage of Participants Achieving Clinical Benefit by Line of Treatment (NUMBER) percentage of participants = 70.32 [65.21-75.08]; Overall Survival (OS) by Line of Treatment (MEDIAN) months = 6.4 [5.8-7.4],,,,,,,,,Overall Survival (OS) by Line of Treatment (MEDIAN) months = 6.4 [5.8-7.4],,,,,,,
NCT01998919,A Study of Tarceva (Erlotinib) in Combination With Platinum Based Chemotherapy in Patients With Non-Small Cell Lung Cancer.,"A Randomised, Placebo-controlled, Double-blind Phase II of Sequential Administration of Tarceva (Erlotinib) or Placebo in Combination With Gemcitabine/Platinum as First-line Treatment in Patients With",Hoffmann-La Roche,Hoffmann-La Roche,INDUSTRY,COMPLETED,2006-08,2011-11,2011-11,INTERVENTIONAL,PHASE2,,,,Non-Small Cell Lung Cancer,Non-Small Cell Lung Cancer,1,2,5,DRUG,,,1,6,True,Yes,Percentage of Participants With Non-Progression at Week 8 as Assessed by Response Evaluation Criteria in Solid Tumors (RECIST) (NUMBER) percentage of participants = 76.9 [66.0-85.7],Percentage of Participants With Non-Progression at Week 16 as Assessed by RECIST (NUMBER) percentage of participants = 53.8 [42.2-65.2]; Percentage of Participants With Confirmed CR or PR as Assessed by RECIST (NUMBER) percentage of participants = 24.4 [15.3-35.4]; Duration of Response (MEDIAN) weeks = 24.1 [17-33]; Time to Progression (MEDIAN) weeks = 24.1 [18-28]; Progression-Free Survival (PFS) (MEDIAN) weeks = 23.4 [17-25]; Overall Survival (MEDIAN) weeks = 75.7 [60-105],,Percentage of Participants With Confirmed CR or PR as Assessed by RECIST (NUMBER) percentage of participants = 24.4 [15.3-35.4],,,Duration of Response (MEDIAN) weeks = 24.1 [17-33],,,,Overall Survival (MEDIAN) weeks = 75.7 [60-105],Progression-Free Survival (PFS) (MEDIAN) weeks = 23.4 [17-25],Percentage of Participants With Confirmed CR or PR as Assessed by RECIST (NUMBER) percentage of participants = 24.4 [15.3-35.4],,,,,Time to Progression (MEDIAN) weeks = 24.1 [18-28]
NCT02008227,A Study of Atezolizumab Compared With Docetaxel in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinu,"A Phase III, Open-Label, Multicenter, Randomized Study to Investigate the Efficacy and Safety of Atezolizumab (Anti-PD-L1 Antibody) Compared With Docetaxel in Patients With Non-Small Cell Lung Cancer ",Hoffmann-La Roche,Hoffmann-La Roche,INDUSTRY,COMPLETED,2014-03-11,2016-07-07,2019-01-09,INTERVENTIONAL,PHASE3,,,,Non-Squamous Non-Small Cell Lung Cancer,Non-Squamous Non-Small Cell Lung Cancer,1,2,2,DRUG,,,8,29,True,Yes,Percentage of Participants Who Died: PP-ITT (NUMBER) Percentage of Participants = 70.1; Percentage of Participants Who Died: Tumor Cells (TC)1/2/3 or Tumor-Infiltrating Immune Cells (IC)1/2/3 Subgroup of PP (NUMBER) Percentage of Participants = 67.1; Overall Survival (OS): PP-ITT (MEDIAN) Months = 9.6 [8.6-11.2]; OS: TC1/2/3 or IC1/2/3 Subgroup of PP (MEDIAN) Months = 10.3 [8.8-12.0]; OS: SP-ITT (MEDIAN) Months = 9.8 [8.8-11.3]; OS: TC1/2/3 Or IC1/2/3 Subgroup of SP (MEDIAN) Months = 10.8 [9.3-12.0]; OS: TC2/3 or IC2/3 Subgroup of SP (MEDIAN) Months = 11.4 [9.3-12.9]; OS: TC3 or IC3 Subgroup of SP (MEDIAN) Months = 9.7 [7.9-11.6],"Percentage of Participants With Disease Progression (PD) as Determined by Investigator Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) or Death: PP-ITT (NUMBER) Percentage of Participants = 88.2; Percentage of Participants With PD as Determined by Investigator Using RECIST v1.1 or Death: TC1/2/3 or IC1/2/3 Subgroup of PP (NUMBER) Percentage of Participants = 86.9; Progression-Free Survival (PFS) as Determined by Investigator Using RECIST v1.1: PP-ITT (MEDIAN) Months = 4.0 [3.3-4.2]; PFS as Determined by Investigator Using RECIST v1.1: TC1/2/3 or IC1/2/3 Subgroup of PP (MEDIAN) Months = 4.1 [2.9-4.3]; Percentage of Participants With Objective Response as Determined Using RECIST v1.1: PP-ITT (NUMBER) Percentage of Participants = 13.4 [10.32-17.02]; Percentage of Participants With Objective Response as Determined Using RECIST v1.1: TC1/2/3 or IC1/2/3 Subgroup of PP (NUMBER) Percentage of Participants = 16.2 [11.62-21.74]; Duration of Response (DOR) as Determined by Investigator Using RECIST v1.1: PP-ITT (MEDIAN) Months = 6.2 [4.9-7.6]; DOR as Determined by Investigator Using RECIST v1.1: TC1/2/3 or IC1/2/3 Subgroup of PP (MEDIAN) Months = 6.2 [4.9-9.2]; Percentage of Participants With Anti-Therapeutic Antibodies (ATAs) Against Atezolizumab (NUMBER) Percentage of Participants = 30.4; Maximum Observed Serum Atezolizumab Concentration (Cmax) (MEAN) Microgram per milliliter (mcg/mL) = 400; Minimum Observed Serum Atezolizumab Concentration (Cmin) (MEAN) mcg/mL = 2.59; Time to Deterioration (TTD) in Patient-Reported Lung Cancer Symptoms, Using the European Organization for Research and Treatment of Cancer (EORTC) Quality-of-Life Questionnaire (QLQ) Lung Cancer Supplemental Module 13 (LC13) (MEDIAN) Months = 8.3 [4.6-12.5]; EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items (MEAN) Units on a scale = 26.58; EORTC QLQ-C30 Questionnaire Score: Functional Subscales (MEAN) Units on a scale = 83.38; EORTC QLQ-C30 Questionnaire Score: GHS Scale (MEAN) Units on a scale = 60.55; EORTC QLQ-C30 Questionnaire Score: Symptom Subscale (MEAN) Units on a scale = 8.01; EORTC QLQ-LC13 Questionnaire Score: Alopecia (MEAN) Units on a scale = 13.89; EORTC QLQ-LC13 Questionnaire Score: Coughing (MEAN) Units on a scale = 38.73; EORTC QLQ-LC13 Questionnaire Score: Dysphagia (MEAN) Units on a scale = 6.20; EORTC QLQ-LC13 Questionnaire Score: Dyspnea (MEAN) Units on a scale = 28.55; EORTC QLQ-LC13 Questionnaire Score: Hemoptysis (MEAN) Units on a scale = 4.32; EORTC QLQ-LC13 Questionnaire Score: Pain in Arm or Shoulder (MEAN) Units on a scale = 20.49; EORTC QLQ-LC13 Questionnaire Score: Pain in Chest (MEAN) Units on a scale = 17.92; EORTC QLQ-LC13 Questionnaire Score: Peripheral Neuropathy (MEAN) Units on a scale = 19.26; EORTC QLQ-LC13 Questionnaire Score: Pain in Other Parts (MEAN) Units on a scale = 27.52; EORTC QLQ-LC13 Questionnaire Score: Sore Mouth (MEAN) Units on a scale = 5.68; PFS as Determined by Investigator Using RECIST v1.1: SP-ITT (MEDIAN) Months = 3.8 [3.3-4.1]; Percentage of Participants With Objective Response as Determined Using RECIST v1.1: SP-ITT (NUMBER) Percentage of Participants = 11.8 [9.32-14.59]; DOR as Determined by Investigator Using RECIST v1.1: SP ITT (MEDIAN) Months = 6.3 [5.5-7.6]",,,,,Duration of Response (DOR) as Determined by Investigator Using RECIST v1.1: PP-ITT (MEDIAN) Months = 6.2 [4.9-7.6]; DOR as Determined by Investigator Using RECIST v1.1: TC1/2/3 or IC1/2/3 Subgroup of PP (MEDIAN) Months = 6.2 [4.9-9.2]; DOR as Determined by Investigator Using RECIST v1.1: SP ITT (MEDIAN) Months = 6.3 [5.5-7.6],,,,Overall Survival (OS): PP-ITT (MEDIAN) Months = 9.6 [8.6-11.2],Progression-Free Survival (PFS) as Determined by Investigator Using RECIST v1.1: PP-ITT (MEDIAN) Months = 4.0 [3.3-4.2]; PFS as Determined by Investigator Using RECIST v1.1: TC1/2/3 or IC1/2/3 Subgroup of PP (MEDIAN) Months = 4.1 [2.9-4.3]; PFS as Determined by Investigator Using RECIST v1.1: SP-ITT (MEDIAN) Months = 3.8 [3.3-4.1],,,,,,
NCT02013206,A Study of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer Naive to Chemotherapy,An Parallel Phase II Study of Tarceva (Erlotinib) in Patients With Advanced Non-small Cell Lung Cancer (Stage IIIB/IV) Not Pre-treated by Chemotherapy Including Dose Escalation to Toxicity in Current ,Hoffmann-La Roche,Hoffmann-La Roche,INDUSTRY,COMPLETED,2006-09,2010-10,2010-10,INTERVENTIONAL,PHASE2,,,,Non-Small Cell Lung Cancer,Non-Small Cell Lung Cancer,1,2,1,DRUG,,,1,7,True,Yes,Non-Progression Rate (NPR) at 8 Weeks (NUMBER) percentage of participants = 41.4 [23.5-61.1],Objective Response Rate (NUMBER) percentage of participants = 17 [5.9-35.8]; Disease Control Rate (NUMBER) percentage of participants = 41 [23.5-61.1]; Duration of Response (MEDIAN) months = 13.1 [4.6-13.1]; Time to Progression (MEDIAN) months = 1.9 [1.0-5.6]; Progression-Free Survival (MEDIAN) months = 1.9 [1.0-5.6]; Overall Survival (MEDIAN) months = 9.9 [5.6-14.0]; Safety: Number of Participants With Adverse Events (AE) and Serious Adverse Events (SAE) (NUMBER) participants = 26,,,,,Duration of Response (MEDIAN) months = 13.1 [4.6-13.1],,,Objective Response Rate (NUMBER) percentage of participants = 17 [5.9-35.8],Overall Survival (MEDIAN) months = 9.9 [5.6-14.0],Progression-Free Survival (MEDIAN) months = 1.9 [1.0-5.6],,,Objective Response Rate (NUMBER) percentage of participants = 17 [5.9-35.8],Safety: Number of Participants With Adverse Events (AE) and Serious Adverse Events (SAE) (NUMBER) participants = 26,,Time to Progression (MEDIAN) months = 1.9 [1.0-5.6]
NCT02031458,A Study of Atezolizumab in Participants With Programmed Death - Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer,"A Phase II, Multicenter, Single-Arm Study OF Atezolizumab In Patients With PD-L1-Positive Locally Advanced Or Metastatic Non-Small Cell Lung Cancer",Hoffmann-La Roche,Hoffmann-La Roche,INDUSTRY,COMPLETED,2014-01-22,2015-05-28,2019-01-11,INTERVENTIONAL,PHASE2,,,,Non-Small Cell Lung Cancer,Non-Small Cell Lung Cancer,1,1,1,DRUG,,,1,22,True,Yes,Percentage of Participants Achieving Objective Response (ORR) Per Response Evaluation Criteria In Solid Tumors (RECIST) Version (v) 1.1 as Assessed by Independent Review Facility (IRF) (NUMBER) percentage of participants = 26.2 [16.0-38.5],Percentage of Participants Achieving Objective Response Per RECIST v1.1 as Assessed by the Investigator (INV) (NUMBER) percentage of participants = 30.8 [19.9-43.5]; Percentage of Participants Achieving Objective Response Per Modified RECIST as Assessed by the INV (NUMBER) percentage of participants = 20.0 [11.1-31.8]; ; DOR as Assessed by INV Per RECIST v1.1 (MEDIAN) months = 8.5 [5.6-8.5]; ; Progression Free Survival (PFS) as Assessed by IRF Per RECIST v1.1 (MEDIAN) months = 5.5 [2.7-8.3]; PFS as Assessed by INV Per RECIST v1.1 (MEDIAN) months = 7.1; PFS as Assessed by INV Per Modified RECIST (MEDIAN) months = 7.1; Overall Survival : Percentage of Participants Without Event (Death) (NUMBER) percentage of participants = 70.8; ; Percentage of Participants Without an Event (Death) at 6 Months (NUMBER) percentage of participants = 79.2 [69.1-89.3]; Percentage of Participants Without an Event (Death) at 12 Months (NUMBER) percentage of participants = 58.6 [40.7-76.5]; PFS: Percentage of Participants Alive and Progression Free at 6 Months (NUMBER) percentage of participants = 57.4 [44.7-70.1]; PFS: Percentage of Participants Alive and Progression Free at 12 Months (NUMBER) percentage of participants = 33.1 [14.9-51.3]; Time in Response (TIR) as Assessed by INV Per RECIST v1.1 (MEDIAN) months = 0.033; TIR as Assessed by INV Per Modified RECIST (MEDIAN) months = 0.033; TIR as Assessed by IRF Per RECIST v1.1 (MEDIAN) months = 0.033; Atezolizumab Serum Concentrations (MEAN) micrograms per milliliter (μg/mL) = 0.285; Percentage of Participants With Positive Anti-Therapeutic Antibody (Anti-Atezolizumab Antibody) Status (NUMBER) percentage of participants = 7.4; Percentage of Participants With Event (Disease Progression or Death) as Assessed by IRF Per RECIST v1.1 (NUMBER) percentage of participants = 58.5; Percentage of Participants With Event (Disease Progression or Death) as Assessed by INV Per RECIST v1.1 (NUMBER) percentage of participants = 50.8; Percentage of Participants With Event (Disease Progression or Death) as Assessed by INV Per Modified RECIST v1.1 (NUMBER) percentage of participants = 36.9,,,,,DOR as Assessed by INV Per RECIST v1.1 (MEDIAN) months = 8.5 [5.6-8.5],,,,Overall Survival : Percentage of Participants Without Event (Death) (NUMBER) percentage of participants = 70.8,Progression Free Survival (PFS) as Assessed by IRF Per RECIST v1.1 (MEDIAN) months = 5.5 [2.7-8.3]; PFS as Assessed by INV Per RECIST v1.1 (MEDIAN) months = 7.1; PFS as Assessed by INV Per Modified RECIST (MEDIAN) months = 7.1,,,,,,
NCT02039674,A Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy or Immunotherapy in Participants With Non-small Cell Lung Cancer (MK-3475-021/KEYN,A Phase I/II Study of MK-3475 (SCH900475) in Combination With Chemotherapy or Immunotherapy in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Carcinoma,Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,INDUSTRY,COMPLETED,2014-02-21,2016-11-07,2021-10-18,INTERVENTIONAL,PHASE1; PHASE2,,,,Non-small Cell Lung Carcinoma,Non-small Cell Lung Carcinoma,1,14,8,BIOLOGICAL; DRUG,,,3,3,True,Yes,Part 2 Cohorts G+ and G-: Objective Response Rate (ORR) (NUMBER) Percentage of Participants = 55.0 [41.6-67.9]; Part 2 Cohorts D4 and H: Objective Response Rate (ORR) (NUMBER) Percentage of Participants = 29.5 [16.8-45.2]; All Cohorts: Number of Participants Who Experienced a Dose-limiting Toxicity (DLT) (COUNT_OF_PARTICIPANTS) Participants = 0,Part 2 Cohorts G+ and G-: Progression-Free Survival (PFS) (MEDIAN) Months = 24.5 [9.7-36.3]; Part 2 Cohorts G+ and G-: Overall Survival (OS) (MEDIAN) Months = 34.5; ,,,,,,,,Part 2 Cohorts G+ and G-: Objective Response Rate (ORR) (NUMBER) Percentage of Participants = 55.0 [41.6-67.9]; Part 2 Cohorts D4 and H: Objective Response Rate (ORR) (NUMBER) Percentage of Participants = 29.5 [16.8-45.2],Part 2 Cohorts G+ and G-: Overall Survival (OS) (MEDIAN) Months = 34.5,Part 2 Cohorts G+ and G-: Progression-Free Survival (PFS) (MEDIAN) Months = 24.5 [9.7-36.3],,,Part 2 Cohorts G+ and G-: Objective Response Rate (ORR) (NUMBER) Percentage of Participants = 55.0 [41.6-67.9]; Part 2 Cohorts D4 and H: Objective Response Rate (ORR) (NUMBER) Percentage of Participants = 29.5 [16.8-45.2],All Cohorts: Number of Participants Who Experienced a Dose-limiting Toxicity (DLT) (COUNT_OF_PARTICIPANTS) Participants = 0,,
NCT02040870,LDK378 in Adult Chinese Patients With ALK-rearranged (ALK-positive) Advanced Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib,"A Phase I/II, Multicenter, Open-label, Single-arm Study of LDK378, Administered Orally in Adult Chinese Patients With ALK-rearranged (ALK-positive) Advanced Non-small Cell Lung Cancer (NSCLC) Previous",Novartis,Novartis Pharmaceuticals,INDUSTRY,COMPLETED,2014-03-07,2017-07-27,2017-07-27,INTERVENTIONAL,PHASE1; PHASE2,,,,Non-Small Cell Lung Cancer,Non-Small Cell Lung Cancer,1,1,1,DRUG,,,5,13,True,Yes,"Primary Pharmacokinetics (PK) Parameters of of LDK378 After Daily Oral Dose: AUClast, AUC0-24h, AUCinf (GEOMETRIC_MEAN) ng*hr/mL = 10100; Primary Pharmacokinetics (PK) Parameter of of LDK378 After Daily Oral Dose: AUC0-24h (GEOMETRIC_MEAN) ng*hr/mL = 22000; Primary Pharmacokinetics (PK) Parameter of LDK378 After Daily Oral Dose: Cmax (GEOMETRIC_MEAN) ng/mL = 233; Primary Pharmacokinetics (PK) Parameter of LDK378 After Daily Oral Dose: Tmax (MEDIAN) hour = 5.94 [2.95-8.08]; Overall Summary of Adverse Events (AEs) - Per Occurence (NUMBER) occurrences = 65",Overall Response Rate (ORR) Per RECIST 1.1 Per Investigator Assessment (NUMBER) Percentage of participants = 41.7; ORR Per RECIST 1.1 Per Blind Independent Review Committee (BIRC) Assessment (NUMBER) Percentage of participants = 32.0 [23.2-42.0]; Duration of Response (DOR) Per Investigator Assessment (MEDIAN) months = 7.5 [5.7-9.4]; Disease Control Rate (DCR) Per Investigator Assessment (NUMBER) Percentage of participants = 77.7 [68.4-85.3]; Time to Response (TTR) Per Investigator Assessment (MEDIAN) Months = 1.90 [1.6-12.9]; Overall Intracranial Response Rate (OIRR) Per Investigator Assessment (NUMBER) Percentage of participants = 39.1 [19.7-61.5]; Overall Intracranial Response Rate (OIRR) Per BIRC Assessment (NUMBER) Percentage of participants = 0 [0.0-33.6]; Progression Free Survival (PFS) Per Investigator Assessment (MEDIAN) Months = 7.2 [4.1-7.5]; Overall Survival (OS) (MEDIAN) Months = 17.5 [10.8-24.3]; Duration of Response (DOR) Per BIRC Assessment (MEDIAN) months = 9.2 [7.3-14.7]; Disease Control Rate (DCR) Per BIRC Assessment (NUMBER) Percentage of participants = 67.0 [57.0-75.9]; Time to Response (TTR) Per BIRC Assessment (MEDIAN) Months = 1.80 [1.6-3.7]; Progression Free Survival (PFS) Per BIRC Assessment (MEDIAN) Months = 3.8 [3.6-5.6],,,,,Duration of Response (DOR) Per Investigator Assessment (MEDIAN) months = 7.5 [5.7-9.4]; Duration of Response (DOR) Per BIRC Assessment (MEDIAN) months = 9.2 [7.3-14.7],,,ORR Per RECIST 1.1 Per Blind Independent Review Committee (BIRC) Assessment (NUMBER) Percentage of participants = 32.0 [23.2-42.0],Overall Survival (OS) (MEDIAN) Months = 17.5 [10.8-24.3],Progression Free Survival (PFS) Per Investigator Assessment (MEDIAN) Months = 7.2 [4.1-7.5]; Progression Free Survival (PFS) Per BIRC Assessment (MEDIAN) Months = 3.8 [3.6-5.6],,,Overall Response Rate (ORR) Per RECIST 1.1 Per Investigator Assessment (NUMBER) Percentage of participants = 41.7; Overall Intracranial Response Rate (OIRR) Per Investigator Assessment (NUMBER) Percentage of participants = 39.1 [19.7-61.5]; Overall Intracranial Response Rate (OIRR) Per BIRC Assessment (NUMBER) Percentage of participants = 0 [0.0-33.6],Overall Summary of Adverse Events (AEs) - Per Occurence (NUMBER) occurrences = 65,,
NCT02041533,"An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+","An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer",Bristol-Myers Squibb,Bristol-Myers Squibb,INDUSTRY,COMPLETED,2014-03-27,2016-07-01,2022-05-27,INTERVENTIONAL,PHASE3,,,,Stage IV or Recurrent Non-Small Cell Lung Cancer,Stage IV or Recurrent Non-Small Cell Lung Cancer,1,2,6,BIOLOGICAL; DRUG,,,1,5,True,Yes,Progression-Free Survival in Participants With PD-L1 Expression >= 5% (MEDIAN) Months = 4.21 [2.96-5.55],Progression-Free Survival in All Randomized Participants (MEDIAN) Months = 4.21 [3.06-5.52]; Overall Survival in Participants With PD-L1 Expression >= 5% (MEDIAN) Months = 14.36 [11.66-17.08]; Overall Survival in All Randomized Participants (MEDIAN) Months = 13.73 [11.76-15.41]; Objective Response Rate (ORR) in Participants With PD-L1 Expression >= 5% (NUMBER) Percentage of participants = 26.1 [20.3-32.5]; Disease-related Symptom Improvement Rate by Week 12 (NUMBER) Percentage of participants = 35.4 [29.7-41.4],,,,,,,,Objective Response Rate (ORR) in Participants With PD-L1 Expression >= 5% (NUMBER) Percentage of participants = 26.1 [20.3-32.5],Overall Survival in Participants With PD-L1 Expression >= 5% (MEDIAN) Months = 14.36 [11.66-17.08]; Overall Survival in All Randomized Participants (MEDIAN) Months = 13.73 [11.76-15.41],Progression-Free Survival in Participants With PD-L1 Expression >= 5% (MEDIAN) Months = 4.21 [2.96-5.55]; Progression-Free Survival in All Randomized Participants (MEDIAN) Months = 4.21 [3.06-5.52],,,Objective Response Rate (ORR) in Participants With PD-L1 Expression >= 5% (NUMBER) Percentage of participants = 26.1 [20.3-32.5],,,
NCT02045446,Maintenance Chemotherapy Versus Consolidative Stereotactic Body Radiation Therapy (SBRT) Plus Maintenance Chemotherapy for Stage IV Non-Small Cell Lun,Maintenance Chemotherapy Versus Consolidative Stereotactic Body Radiation Therapy (SBRT) Plus Maintenance Chemotherapy for Stage IV Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II Trial,University of Texas Southwestern Medical Center,University of Texas Southwestern Medical Center,OTHER,COMPLETED,2014-02,2022-02-17,2022-05-02,INTERVENTIONAL,PHASE2,,,,Stage IV Non-Small Cell Lung Cancer,Stage IV Non-Small Cell Lung Cancer,1,2,2,DRUG; RADIATION,,,1,4,True,Yes,Progression Free Survival (MEDIAN) months = 3.5 [3.387-4.315],In-field Local Control Versus Out-of-field Disease Progression (NUMBER) Patients = 4; Toxicities (NUMBER) adverse events = 2; Overall Survival (MEDIAN) days = 189 [28-587]; Duration of Maintenance Chemotherapy (MEDIAN) cycles = 3 [1-15],,,,,,,,,Overall Survival (MEDIAN) days = 189 [28-587],Progression Free Survival (MEDIAN) months = 3.5 [3.387-4.315],,,,Toxicities (NUMBER) adverse events = 2,,
NCT02047344,"Efficacy, Safety and Pharmacokinetics Study of Antroquinonol to Treat NSCLC","A Single-Arm, Open-Label, Phase II Trial Evaluating the Efficacy, Safety and Pharmacokinetics of Antroquinonol in Patients With Stage IV (Including Pleural Effusion) Non Squamous NSCLC Who Have Failed",Golden Biotechnology Corporation,Golden Biotechnology Corporation,INDUSTRY,COMPLETED,2013-10,2018-12-07,2018-12-07,INTERVENTIONAL,PHASE2,,,,Non-small Cell Lung Cancer Stage IV,Non-small Cell Lung Cancer Stage IV,1,1,1,DRUG,,,1,3,True,Yes,Progression Free Survival Rate (COUNT_OF_PARTICIPANTS) Participants = 4,Cmax (MEAN) ng/mL = 276.87; Disease Control Rate (DCR) (NUMBER) percentage of participants = 40 [5.3-85.3]; T½: the Time Required for a Quantity to Reduce to Half Its Initial Value (MEAN) hours = 3 [0.5-4],,,,,,,,,,Progression Free Survival Rate (COUNT_OF_PARTICIPANTS) Participants = 4,,,,,,
NCT02066636,A Safety Trial of Nivolumab in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least ,A Phase IIIb/IV Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Systemic Regi,Bristol-Myers Squibb,Bristol-Myers Squibb,INDUSTRY,COMPLETED,2014-04-09,2021-10-06,2021-10-06,INTERVENTIONAL,PHASE3,,,,Non Small Cell Lung Cancer (NSCLC),Non Small Cell Lung Cancer (NSCLC),1,2,1,DRUG,,,1,6,True,Yes,The Number of Participants With Treatment Related Select Adverse Events (Grade 3-4 and Grade 5) (COUNT_OF_PARTICIPANTS) Participants = 3,Median Time to Onset of Select Adverse Events (Grade 3-5) (MEDIAN) Weeks = 12.14 [11.0-45.4]; Median Time to Resolution of Select Adverse Events (Grade 3-5) (MEDIAN) Weeks = 3.43 [0.4-36.1]; The Number of Participants Who Received Immune Modulating Medication (or Hormonal Replacement Therapy) for Any Grade Select Adverse Events (COUNT_OF_PARTICIPANTS) Participants = 1; The Number of Participants Who Received ≥ 40 mg Prednisone Equivalents for Any Grade Select Adverse Events (COUNT_OF_PARTICIPANTS) Participants = 0; ; The Number of Participants With High Grade (Grade 3-4 and Grade 5) Select Adverse Events (COUNT_OF_PARTICIPANTS) Participants = 7,,,,,,,,,,,,,,The Number of Participants With Treatment Related Select Adverse Events (Grade 3-4 and Grade 5) (COUNT_OF_PARTICIPANTS) Participants = 3; Median Time to Onset of Select Adverse Events (Grade 3-5) (MEDIAN) Weeks = 12.14 [11.0-45.4]; Median Time to Resolution of Select Adverse Events (Grade 3-5) (MEDIAN) Weeks = 3.43 [0.4-36.1]; The Number of Participants Who Received Immune Modulating Medication (or Hormonal Replacement Therapy) for Any Grade Select Adverse Events (COUNT_OF_PARTICIPANTS) Participants = 1; The Number of Participants Who Received ≥ 40 mg Prednisone Equivalents for Any Grade Select Adverse Events (COUNT_OF_PARTICIPANTS) Participants = 0; The Number of Participants With High Grade (Grade 3-4 and Grade 5) Select Adverse Events (COUNT_OF_PARTICIPANTS) Participants = 7,,
NCT02073968,PET-Adjusted Intensity Modulated Radiation Therapy and Combination Chemotherapy in Treating Patients With Stage II-IV Non-small Cell Lung Cancer,PET-Adjusted IMRT for NSCLC Trial (PAINT),Albert Einstein College of Medicine,Albert Einstein College of Medicine,OTHER,COMPLETED,2013-07,2017-12,2020-11,INTERVENTIONAL,PHASE2,,,,Metastatic Malignant Neoplasm in the Brain,Metastatic Malignant Neoplasm in the Brain; Recurrent Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma,7,1,6,DRUG; PROCEDURE; RADIATION,,,1,6,True,Yes,Metabolic Response of All Pulmonary Lesions and Thoracic Lymph Nodes (COUNT_OF_PARTICIPANTS) Participants = 24,"Incidence of Grade >= 2 Radiation-induced Lung Toxicity, Scored Using Common Terminology Criteria for Adverse Events (CTCAE), Version (v.) 4 (COUNT_OF_PARTICIPANTS) Participants = 7; Incidence of Grade >= 3 Treatment-related Toxicity, Scored Using CTCAE, v. 4 (COUNT_OF_PARTICIPANTS) Participants = 30; Locoregional Progression-free Survival Assessed Using the Response Evaluation Criteria in Solid Tumors (RECIST) Criteria (NUMBER) percentage with LRPFS at 1 year = 50; Lung Cancer Cause-specific Survival (MEDIAN) months = 28 [28-28]; Overall Survival (NUMBER) percentage of patients alive at 1 year = 74; Progression-free Survival Assessed Using the RECIST Criteria (NUMBER) percentage of patients w/ PFS at 1 year = 26",,,,,,,,,Overall Survival (NUMBER) percentage of patients alive at 1 year = 74,Locoregional Progression-free Survival Assessed Using the Response Evaluation Criteria in Solid Tumors (RECIST) Criteria (NUMBER) percentage with LRPFS at 1 year = 50; Progression-free Survival Assessed Using the RECIST Criteria (NUMBER) percentage of patients w/ PFS at 1 year = 26,,,,"Incidence of Grade >= 2 Radiation-induced Lung Toxicity, Scored Using Common Terminology Criteria for Adverse Events (CTCAE), Version (v.) 4 (COUNT_OF_PARTICIPANTS) Participants = 7; Incidence of Grade >= 3 Treatment-related Toxicity, Scored Using CTCAE, v. 4 (COUNT_OF_PARTICIPANTS) Participants = 30",,
NCT02075840,A Study Comparing Alectinib With Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer Participants,"Randomized, Multicenter, Phase III, Open-Label Study of Alectinib Versus Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer",Hoffmann-La Roche,Hoffmann-La Roche,INDUSTRY,COMPLETED,2014-08-19,2017-02-09,2025-04-28,INTERVENTIONAL,PHASE3,,,,Non-Small Cell Lung Cancer,Non-Small Cell Lung Cancer,1,2,2,DRUG,,,2,26,True,Yes,; Percentage of Participants With PFS Event by Investigator Assessment (NUMBER) Percentage of Participants = 40.8,PFS Independent Review Committee (IRC)-Assessed (MEDIAN) months = 25.7; Percentage of Participants With PFS Event by IRC (NUMBER) Percentage of Participants = 41.4; Percentage of Participants With Central Nervous System (CNS) Progression as Determined by IRC Using RECIST V1.1 Criteria (NUMBER) Percentage of Participants = 11.8; Percentage of Participants With Central Nervous System (CNS) Progression as Determined by IRC Using Revised Assessment in Neuro Oncology (RANO) Criteria (NUMBER) Percentage of Participants = 10.5; Percentage of Participants With Objective Response Rate (ORR) of Complete Response (CR) or Partial Response (PR) as Determined by The Investigators According to RECIST V1.1 Criteria (NUMBER) Percentage of Participants = 82.9 [75.95-88.51]; ; ; Percentage of Participants With OS Event (NUMBER) Percentage of Participants = 23.0; Percentage of Participants With CNS ORR of CR or PR IRC-assessed According to RECIST v1.1 Criteria (NUMBER) Percentage of Participants = 81.0 [58.09-94.55]; CNS DOR IRC-assessed According to RECIST v1.1 Criteria (MEDIAN) months = 17.3; Percentage of Participants With Adverse Events (NUMBER) Percentage of Participants = 97.0; Area Under The Concentration-Time Curve (AUC) of Alectinib (GEOMETRIC_MEAN) hr*ng/mL = 713; Maximum Concentration (Cmax) of Alectinib (GEOMETRIC_MEAN) nanogram/milliliter (ng/mL) = 211; Time to Reach Cmax (Tmax) of Alectinib (MEDIAN) hours = 6.03 [1.98-12.00]; AUC of Alectinib Metabolite (GEOMETRIC_MEAN) hr*ng/mL = 142; Cmax of Alectinib Metabolite (GEOMETRIC_MEAN) nanogram/milliliter (ng/mL) = 56.2; Tmax of Alectinib Metabolite (MEDIAN) hours = 8.00 [5.98-12.00]; ; Percentage of Participants With Deterioration by EORTC Quality Of Life Questionnaire Core 30 (C30) (NUMBER) Percentage of Participants = 21.7; ; Percentage of Participants With Deterioration by EORTC Quality of Life Questionnaire Lung Cancer Module 13 (LC13) (NUMBER) Percentage of Participants = 11; Health-Related Quality of Life (HRQoL) by EORTC Quality of Life Questionnaire C30 Score (MEDIAN) Score on a scale = 66.67 [8.3-100.0]; HRQoL by EORTC Quality of Life Questionnaire LC13 Score Coughing (MEDIAN) Score on a scale = 33.33 [0.0-100.0]; HRQoL by EORTC Quality of Life Questionnaire LC13 Score Dyspnoea (MEDIAN) Score on a scale = 22.22 [0.0-100.0]; HRQoL by EORTC Quality of Life Questionnaire LC13 Score Pain in Chest (MEDIAN) Score on a scale = 33.33 [0.0-100.0]; HRQoL by EORTC Quality of Life Questionnaire LC13 Score Pain in Arm and Shoulder (MEDIAN) Score on a scale = 0.0 [0.0-100.0],,Percentage of Participants With Objective Response Rate (ORR) of Complete Response (CR) or Partial Response (PR) as Determined by The Investigators According to RECIST V1.1 Criteria (NUMBER) Percentage of Participants = 82.9 [75.95-88.51]; Percentage of Participants With CNS ORR of CR or PR IRC-assessed According to RECIST v1.1 Criteria (NUMBER) Percentage of Participants = 81.0 [58.09-94.55],,,CNS DOR IRC-assessed According to RECIST v1.1 Criteria (MEDIAN) months = 17.3,,,Percentage of Participants With Objective Response Rate (ORR) of Complete Response (CR) or Partial Response (PR) as Determined by The Investigators According to RECIST V1.1 Criteria (NUMBER) Percentage of Participants = 82.9 [75.95-88.51]; Percentage of Participants With CNS ORR of CR or PR IRC-assessed According to RECIST v1.1 Criteria (NUMBER) Percentage of Participants = 81.0 [58.09-94.55],Percentage of Participants With OS Event (NUMBER) Percentage of Participants = 23.0,Percentage of Participants With PFS Event by Investigator Assessment (NUMBER) Percentage of Participants = 40.8; PFS Independent Review Committee (IRC)-Assessed (MEDIAN) months = 25.7; Percentage of Participants With PFS Event by IRC (NUMBER) Percentage of Participants = 41.4,Percentage of Participants With Objective Response Rate (ORR) of Complete Response (CR) or Partial Response (PR) as Determined by The Investigators According to RECIST V1.1 Criteria (NUMBER) Percentage of Participants = 82.9 [75.95-88.51]; Percentage of Participants With CNS ORR of CR or PR IRC-assessed According to RECIST v1.1 Criteria (NUMBER) Percentage of Participants = 81.0 [58.09-94.55],Percentage of Participants With Deterioration by EORTC Quality Of Life Questionnaire Core 30 (C30) (NUMBER) Percentage of Participants = 21.7; Percentage of Participants With Deterioration by EORTC Quality of Life Questionnaire Lung Cancer Module 13 (LC13) (NUMBER) Percentage of Participants = 11; Health-Related Quality of Life (HRQoL) by EORTC Quality of Life Questionnaire C30 Score (MEDIAN) Score on a scale = 66.67 [8.3-100.0]; HRQoL by EORTC Quality of Life Questionnaire LC13 Score Coughing (MEDIAN) Score on a scale = 33.33 [0.0-100.0]; HRQoL by EORTC Quality of Life Questionnaire LC13 Score Dyspnoea (MEDIAN) Score on a scale = 22.22 [0.0-100.0]; HRQoL by EORTC Quality of Life Questionnaire LC13 Score Pain in Chest (MEDIAN) Score on a scale = 33.33 [0.0-100.0]; HRQoL by EORTC Quality of Life Questionnaire LC13 Score Pain in Arm and Shoulder (MEDIAN) Score on a scale = 0.0 [0.0-100.0],Percentage of Participants With Objective Response Rate (ORR) of Complete Response (CR) or Partial Response (PR) as Determined by The Investigators According to RECIST V1.1 Criteria (NUMBER) Percentage of Participants = 82.9 [75.95-88.51],Percentage of Participants With Adverse Events (NUMBER) Percentage of Participants = 97.0,,
NCT02082210,A Study of Emibetuzumab in Combination With Ramucirumab (LY3009806) in Participants With Advanced Cancer,A Phase 1b/2 Study of Ramucirumab in Combination With LY2875358 in Patients With Advanced Cancer,Eli Lilly and Company,Eli Lilly and Company,INDUSTRY,COMPLETED,2014-03-07,2017-12-05,2018-01-24,INTERVENTIONAL,PHASE1; PHASE2,,,,Advanced Cancer,Advanced Cancer; Gastric Adenocarcinoma; Gastroesophageal Junction Adenocarcinoma,6,2,2,DRUG,,,2,8,True,Yes,Number of Participants Who Experienced Dose-Limiting Toxicities (DLTs) (COUNT_OF_PARTICIPANTS) Participants = 0; Part B: Percentage of Participants Who Exhibit Complete Response (CR) or Partial Response (PR) [Overall Response Rate (ORR)] (NUMBER) percentage of participants = 6.3 [0-30],Pharmacokinetics (PK): Maximum Observed Plasma Concentration (Cmax) of Emibetuzumab (GEOMETRIC_MEAN) Microgram per milliliter (µg/mL) = 210; Part B: Percentage of Participants Who Exhibit Stable Disease (SD) or Confirmed Response (CR) or Partial Response (PR) (Disease Control Rate [DCR]) (NUMBER) percentage of participants = 50 [20-80]; Part B: Progression Free Survival (PFS) (MEDIAN) months = 1.64 [1.35-4.60]; Pharmacokinetics: Area Under the Concentration-Time Curve (AUC) From Time Zero to Tlast of Emibetuzumab (GEOMETRIC_MEAN) Microgram * hour per milliliter(µg*h/mL) = 29800; ; Number of Participants With Treatment Emergent Anti-Emibetuzumab Antibodies (COUNT_OF_PARTICIPANTS) Participants = 0; ; Number of Participants With Treatment Emergent Anti-Ramucirumab Antibodies (COUNT_OF_PARTICIPANTS) Participants = 1,,Part B: Percentage of Participants Who Exhibit Complete Response (CR) or Partial Response (PR) [Overall Response Rate (ORR)] (NUMBER) percentage of participants = 6.3 [0-30],,,,,,,,Part B: Progression Free Survival (PFS) (MEDIAN) months = 1.64 [1.35-4.60],Part B: Percentage of Participants Who Exhibit Complete Response (CR) or Partial Response (PR) [Overall Response Rate (ORR)] (NUMBER) percentage of participants = 6.3 [0-30]; Part B: Percentage of Participants Who Exhibit Stable Disease (SD) or Confirmed Response (CR) or Partial Response (PR) (Disease Control Rate [DCR]) (NUMBER) percentage of participants = 50 [20-80],,Part B: Percentage of Participants Who Exhibit Complete Response (CR) or Partial Response (PR) [Overall Response Rate (ORR)] (NUMBER) percentage of participants = 6.3 [0-30],,,
NCT02085070,MK-3475 in Melanoma and NSCLC Patients With Brain Metastases,A Phase 2 Study of MK-3475 in Patients With Metastatic Melanoma and Non-Small Cell Lung Cancer With Untreated Brain Metastases,Yale University,Yale University,OTHER,COMPLETED,2014-03,2020-02-27,2020-02-27,INTERVENTIONAL,PHASE2,,,,Melanoma,Melanoma; Non-Small Cell Lung Cancer; Brain Metastases,3,2,1,DRUG,,,1,0,True,Yes,Overall Response in the Brain by mRECIST (NUMBER) participants = 17,,,,,,,,,,,,,,,,,
NCT02087423,A Global Study to Assess the Effects of MEDI4736 (Durvalumab) in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer,"A Phase II,Non-comparative,Open Label, Multi-centre, International Study of MEDI4736, in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer (Stage IIIB-IV) Who Have Received at Le",AstraZeneca,AstraZeneca,INDUSTRY,COMPLETED,2014-02-25,2016-06-03,2025-03-26,INTERVENTIONAL,PHASE2,,,,Non-Small Cell Lung Cancer,Non-Small Cell Lung Cancer,1,1,1,DRUG,,,1,3,True,Yes,Objective Response Rate (ORR) (NUMBER) % of patients evaluable for response = 12.2 [5.7-21.8],Time to Response (TTR) (MEDIAN) Months = 1.9 [1.6-16.7]; Duration of Response (DoR) (MEDIAN) Months = 12.3; Overall Survival (OS) (MEDIAN) Months = 13.3 [6.3-24.5],,,,,Duration of Response (DoR) (MEDIAN) Months = 12.3,,,Objective Response Rate (ORR) (NUMBER) % of patients evaluable for response = 12.2 [5.7-21.8],Overall Survival (OS) (MEDIAN) Months = 13.3 [6.3-24.5],,,,Objective Response Rate (ORR) (NUMBER) % of patients evaluable for response = 12.2 [5.7-21.8],,,
NCT02094261,Phase II AZD9291 Open Label Study in NSCLC After Previous EGFR TKI Therapy in EGFR and T790M Mutation Positive Tumours,"Phase II, Open Label, Single-arm Study to Assess Safety and Efficacy of AZD9291 in Patients With Locally Advanced/Metastatic NSCLC Whose Disease Has Progressed With Previous EGFR TKI and Whose Tumours",AstraZeneca,AstraZeneca,INDUSTRY,COMPLETED,2014-05-20,2015-05-01,2023-11-07,INTERVENTIONAL,PHASE2,,,,Non Small Cell Lung Cancer,Non Small Cell Lung Cancer,1,1,1,DRUG,,,1,3,True,Yes,Objective Response Rate (ORR) (NUMBER) % of participants = 70.9 [64.0-77.1],Duration of Response (DoR) (MEDIAN) months = 7.8 [1.3-8.4]; Disease Control Rate (DCR) (NUMBER) % of participants = 91.5 [86.7-94.9]; Progression-Free Survival (PFS) (MEDIAN) months = 8.6 [8.28-9.72],,,,,Duration of Response (DoR) (MEDIAN) months = 7.8 [1.3-8.4],,,Objective Response Rate (ORR) (NUMBER) % of participants = 70.9 [64.0-77.1],,Progression-Free Survival (PFS) (MEDIAN) months = 8.6 [8.28-9.72],,,Objective Response Rate (ORR) (NUMBER) % of participants = 70.9 [64.0-77.1],,,
NCT02108964,"A Phase I/II, Multicenter, Open-label Study of EGFRmut-TKI EGF816, Administered Orally in Adult Patients With EGFRmut Solid Malignancies","A Phase I/II, Multicenter, Open-label Study of EGFRmut-TKI EGF816, Administered Orally in Adult Patients With EGFRmut Solid Malignancies",Novartis,Novartis Pharmaceuticals,INDUSTRY,COMPLETED,2014-06-06,2018-03-22,2023-08-15,INTERVENTIONAL,PHASE1; PHASE2,,,,Advanced Non-small Cell Lung Cancer,Advanced Non-small Cell Lung Cancer,1,2,1,DRUG,,,2,15,True,Yes,Number of Participants With Dose Limiting Toxicities (DLTs) (Phase I Part) (COUNT_OF_PARTICIPANTS) Participants = 0; Overall Response Rate (ORR) by Blinded Independent Review Committee (BIRC) (Phase II Part) (NUMBER) Percentage of participants = 64.4 [48.80-78.10],Progression-free Survival (PFS) by Investigator Assessment (Phase I & Phase II Parts) (MEDIAN) Months = 6.3 [1.54-47.80]; Duration of Response (DOR) by Investigator Assessment (Phase I & II Parts) (MEDIAN) Months = 46.2; Observed Maximum Plasma Concentration (Cmax) of EGF816 and Metabolite LMI258 (Phase I & Phase II Part) (GEOMETRIC_MEAN) ng/mL = 333; Time to Maximum Plasma Concentration (Tmax) of EGF816 and Metabolite LMI258 (Phase I & Phase II Part). Tmax is the Time to Reach Maximum (Peak) Plasma Drug Concentration (Time). (GEOMETRIC_MEAN) hour (hr) = 2.83; Area Under the Serum Concentration-time Curve From Time Zero to the End of the Dosing Interval Tau (AUCtau) of EGF816 and Metabolite LMI258 (Phase I & Phase II Part) (GEOMETRIC_MEAN) ng*hr/mL = 4340; Percentage Change From Baseline in H-score for Immunohistochemistry (IHC) Biomarkers From Tumor Tissue Samples (Phase I Part) (MEAN) percentage change = -10.0; Overall Response Rate (ORR) by Investigator Assessment (Phase I & II Parts) (NUMBER) Percentage of participants = 41.7; Disease Control Rate (DCR) by Investigator Assessment (Phase I & II Parts) (NUMBER) Percentage of participants = 83.3; ; Number of Participants With Dose Interruptions and Dose Reductions (Phase I & II Parts) (COUNT_OF_PARTICIPANTS) Participants = 3; Duration of Response (DOR) by BIRC (Phase II Part) (MEDIAN) Months = 18.6 [14.88-31.41]; Disease Control Rate (DCR) by BIRC (Phase II Part) (NUMBER) Percentage of participants = 93.3 [81.70-98.60]; Progression-Free Survival (PFS) by BIRC (Phase II Part) (MEDIAN) months = 18.9 [14.75-29.44]; Time to Response (TTR) by BIRC (Phase II Part) (MEDIAN) Months = 48.3 [22.93-58.84]; Overall Survival (OS) (Phase II Part) (MEDIAN) Months = 48.3 [22.93-58.84],,,,,Duration of Response (DOR) by Investigator Assessment (Phase I & II Parts) (MEDIAN) Months = 46.2; Duration of Response (DOR) by BIRC (Phase II Part) (MEDIAN) Months = 18.6 [14.88-31.41],,,,Overall Survival (OS) (Phase II Part) (MEDIAN) Months = 48.3 [22.93-58.84],Progression-free Survival (PFS) by Investigator Assessment (Phase I & Phase II Parts) (MEDIAN) Months = 6.3 [1.54-47.80]; Progression-Free Survival (PFS) by BIRC (Phase II Part) (MEDIAN) months = 18.9 [14.75-29.44],,,Overall Response Rate (ORR) by Blinded Independent Review Committee (BIRC) (Phase II Part) (NUMBER) Percentage of participants = 64.4 [48.80-78.10]; Overall Response Rate (ORR) by Investigator Assessment (Phase I & II Parts) (NUMBER) Percentage of participants = 41.7,,,
NCT02125461,A Global Study to Assess the Effects of MEDI4736 Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cance,"A Phase III, Randomised, Double-blind, Placebo-controlled, Multi-centre, International Study of MEDI4736 as Sequential Therapy in Patients With Locally Advanced, Unresectable Non-Small Cell Lung Cance",AstraZeneca,AstraZeneca,INDUSTRY,COMPLETED,2014-05-07,2017-02-13,2023-08-24,INTERVENTIONAL,PHASE3,,,,Non-Small Cell Lung Cancer,Non-Small Cell Lung Cancer,1,2,2,DRUG; OTHER,,,2,11,True,Yes,Progression Free Survival Based on Blinded Independent Central Review (BICR) According to Response Evaluation Criteria in Solid Tumors (RECIST 1.1) (MEDIAN) Months = 16.8 [13.0-18.1]; ,"Objective Response Rate (ORR) Based on BICR Assesments According to RECIST 1.1 (NUMBER) Percentage of patients = 30.0 [25.79-34.53]; ; Proportion of Patients Alive and Progression Free at 12 Months From (APF12) Based on BICR Assessments According to RECIST 1.1 (NUMBER) Percentage of patients = 55.9 [51.0-60.4]; Proportion of Patients Alive and Progression Free at 18 Months From (APF18) Based on BICR Assessments According to RECIST 1.1 (NUMBER) Percentage of patients = 44.2 [37.7-50.5]; Time to Death or Distant Metastasis (TTDM) Based on BICR Assessments According to RECIST 1.1 (MEDIAN) Months = 28.3 [24.0-34.9]; Percentage of Patients Alive at 24 Months (OS24) (NUMBER) Percentage of patients = 66.3 [61.7-70.4]; Time to Second Progression or Death (PFS2) (MEDIAN) Months = 28.3 [25.1-34.7]; Time to Deterioration of Global Health Status / Health-Related Quality of Life (HRQoL), Assessed Using European Organization for Research and Treatment of Cancer 30-Item Core Quality of Life Questionnaire (EORTC QLQ-C30) (MEDIAN) Months = 7.4 [5.5-9.3]; Time to Deterioration of Primary Patient-Reported Outcome (PRO) Symptoms, Assessed Using European Organization for Research and Treatment of Cancer QoL Lung Cancer Module (EORTC QLQ-LC13) (MEDIAN) Months = 2.8 [1.9-3.7]; Pharmacokinetics (PK) of Durvalumab; Peak and Trough Serum Concentrations (GEOMETRIC_MEAN) Micrograms per milliliter = 191.00; Number of Patients With Anti-Drug Antibody (ADA) Response to Durvalumab (COUNT_OF_PARTICIPANTS) Participants = 19",,,,,,,,Objective Response Rate (ORR) Based on BICR Assesments According to RECIST 1.1 (NUMBER) Percentage of patients = 30.0 [25.79-34.53],,Progression Free Survival Based on Blinded Independent Central Review (BICR) According to Response Evaluation Criteria in Solid Tumors (RECIST 1.1) (MEDIAN) Months = 16.8 [13.0-18.1],,"Time to Deterioration of Global Health Status / Health-Related Quality of Life (HRQoL), Assessed Using European Organization for Research and Treatment of Cancer 30-Item Core Quality of Life Questionnaire (EORTC QLQ-C30) (MEDIAN) Months = 7.4 [5.5-9.3]; Time to Deterioration of Primary Patient-Reported Outcome (PRO) Symptoms, Assessed Using European Organization for Research and Treatment of Cancer QoL Lung Cancer Module (EORTC QLQ-LC13) (MEDIAN) Months = 2.8 [1.9-3.7]",Objective Response Rate (ORR) Based on BICR Assesments According to RECIST 1.1 (NUMBER) Percentage of patients = 30.0 [25.79-34.53],,,
NCT02142738,Study of Pembrolizumab (MK-3475) Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (MK-3475-024/KEY,A Randomized Open-Label Phase III Trial of Pembrolizumab Versus Platinum Based Chemotherapy in 1L Subjects With PD-L1 Strong Metastatic Non-Small Cell Lung Cancer,Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,INDUSTRY,COMPLETED,2014-08-25,2016-05-09,2021-05-27,INTERVENTIONAL,PHASE3,,,,Non-Small Cell Lung Carcinoma,Non-Small Cell Lung Carcinoma,1,6,6,DRUG,,,1,2,True,Yes,Progression Free Survival (PFS) Rate at Month 6 (NUMBER) Percentage of Participants = 62.1 [53.8-69.4],Overall Survival (OS) Rate (NUMBER) Percentage of Participants = 70.3 [62.3-76.9]; Objective Response Rate (ORR) (NUMBER) Percentage of Participants = 44.8 [36.8-53.0],,,,,,,,Objective Response Rate (ORR) (NUMBER) Percentage of Participants = 44.8 [36.8-53.0],Overall Survival (OS) Rate (NUMBER) Percentage of Participants = 70.3 [62.3-76.9],Progression Free Survival (PFS) Rate at Month 6 (NUMBER) Percentage of Participants = 62.1 [53.8-69.4],,,Objective Response Rate (ORR) (NUMBER) Percentage of Participants = 44.8 [36.8-53.0],,,
NCT02151604,Hyperpolarized Xenon Gas MR Imaging in NSCLC Radiotherapy,A Study to Determine Regional Lung Function in Patients With Non-small Cell Lung Cancer (NSCLC) Undergoing Radiotherapy Using Hyperpolarized Xenon Gas MR Imaging,Oxford University Hospitals NHS Trust,Oxford University Hospitals NHS Trust,OTHER,COMPLETED,2014-04-23,2020-12-31,2020-12-31,INTERVENTIONAL,PHASE2,,,,Non-small Cell Lung Cancer,Non-small Cell Lung Cancer,1,1,1,DRUG,,,1,2,True,Yes,Number of Participants With a Change From Baseline in Ventilation Map Using Hyperpolarized Xe-129 MR Imaging (COUNT_OF_PARTICIPANTS) Participants = 6,Number of Participants With a Change in Ventilation and ADC Maps Using Hyperpolarized Xe-129 MR Imaging From Baseline to 3 Months Post Radiotherapy Completion (COUNT_OF_PARTICIPANTS) Participants = 3; Correlation Between Change in Ventilation/ ADC Maps Using Hyperpolarized Xe-129 MR Imaging and Change in Lung Function From Baseline to Follow-up (During Treatment) (NUMBER) Pearson's Coorelation Coefficient = 0.60,,,,,,,,,,,,,,,,
NCT02152631,A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung Cancer,JUNIPER: A Randomized Phase 3 Study of Abemaciclib Plus Best Supportive Care Versus Erlotinib Plus Best Supportive Care in Patients With Stage IV NSCLC With a Detectable KRAS Mutation Who Have Progres,Eli Lilly and Company,Eli Lilly and Company,INDUSTRY,ACTIVE_NOT_RECRUITING,2014-10-03,2017-09-15,2025-12,INTERVENTIONAL,PHASE3,,,,Non Small Cell Lung Cancer,Non Small Cell Lung Cancer,1,2,2,DRUG,,,1,6,True,Yes,Overall Survival (OS) (MEDIAN) months = 7.4 [6.5-8.8],Percentage of Participants With Complete Response (CR) or Partial Response (PR) (Objective Response Rate [ORR]) (NUMBER) percentage of participants = 8.9 [5.5-12.3]; Progression Free Survival (PFS) (NUMBER) months = 3.6 [2.8-3.8]; Change From Baseline in MD Anderson Symptom Inventory-Lung Cancer (MDASI-LC) Score (LEAST_SQUARES_MEAN) units on a scale = 0.20; Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve During 1 Dosing Interval at Steady State (GEOMETRIC_MEAN) Hour*nanogram/milliliter (h*ng/mL) = 3350; Change From Baseline in European Quality of Life - 5 Dimensions - 5 Level (EQ-5D-5L) Score (LEAST_SQUARES_MEAN) units on a scale = -0.08; Resource Utilization: Percentage of Participants Who Are Hospitalized (NUMBER) percentage of participants = 40.4,,Percentage of Participants With Complete Response (CR) or Partial Response (PR) (Objective Response Rate [ORR]) (NUMBER) percentage of participants = 8.9 [5.5-12.3],,,,,,Percentage of Participants With Complete Response (CR) or Partial Response (PR) (Objective Response Rate [ORR]) (NUMBER) percentage of participants = 8.9 [5.5-12.3],Overall Survival (OS) (MEDIAN) months = 7.4 [6.5-8.8],Progression Free Survival (PFS) (NUMBER) months = 3.6 [2.8-3.8],Percentage of Participants With Complete Response (CR) or Partial Response (PR) (Objective Response Rate [ORR]) (NUMBER) percentage of participants = 8.9 [5.5-12.3],Change From Baseline in European Quality of Life - 5 Dimensions - 5 Level (EQ-5D-5L) Score (LEAST_SQUARES_MEAN) units on a scale = -0.08,Percentage of Participants With Complete Response (CR) or Partial Response (PR) (Objective Response Rate [ORR]) (NUMBER) percentage of participants = 8.9 [5.5-12.3],,,
NCT02175017,ONO-4538 Study in Patients With Advanced Non-Small Cell Lung Cancer,"ONO-4538 Multicenter, Open-label, Uncontrolled, Phase II Study in Advanced Non-small Cell Lung Cancer",Ono Pharmaceutical Co. Ltd,Ono Pharmaceutical Co. Ltd,INDUSTRY,COMPLETED,2014-06,2015-11,2021-02,INTERVENTIONAL,PHASE2,,,,Advanced Non-small Cell Lung Cancer (NSCLC),Advanced Non-small Cell Lung Cancer (NSCLC),1,2,2,DRUG,,,1,4,True,Yes,Response Rate (Centrally Assessed) (NUMBER) percentage of participants = 13.6 [6.4-26.7],Response Rate (Investigator-assessed) (NUMBER) percentage of participants = 18.2 [9.5-32.0]; ; Progression Free Survival (Centrally Assessed) (MEDIAN) days = 67.0 [41.0-182.0]; ,,,,,,,,,,Progression Free Survival (Centrally Assessed) (MEDIAN) days = 67.0 [41.0-182.0],,,Response Rate (Centrally Assessed) (NUMBER) percentage of participants = 13.6 [6.4-26.7]; Response Rate (Investigator-assessed) (NUMBER) percentage of participants = 18.2 [9.5-32.0],,,
NCT02179671,"Immune-Modulated Study of Selected Small Molecules (Gefitinib, AZD9291, or Selumetinib + Docetaxel) or a 1st Immune-Mediated Therapy (IMT; Tremelimuma","A Phase IIa, Open-Label, Multi-Center, Multi-Cohort, Immune-Modulated Study of Selected Small Molecules (Gefitinib, AZD9291, or Selumetinib + Docetaxel) or a 1st Immune-Mediated Therapy (IMT; Tremelim",AstraZeneca,AstraZeneca,INDUSTRY,COMPLETED,2014-07-25,2016-06-11,2016-06-11,INTERVENTIONAL,PHASE2,,,,Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (Stage IIIB-IV),Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (Stage IIIB-IV),1,4,4,DRUG,,,1,4,True,Yes,Confirmed Complete Response (CR) Rate (NUMBER) patients (%) = 0,Objective Response Rate (ORR) (NUMBER) patients (%) = 11.1 [1.2-36.8]; Progression-free Survival (NUMBER) patients = 1; ; Overall Survival (NUMBER) patients = 0,,Confirmed Complete Response (CR) Rate (NUMBER) patients (%) = 0,,,,,,Objective Response Rate (ORR) (NUMBER) patients (%) = 11.1 [1.2-36.8],Overall Survival (NUMBER) patients = 0,Progression-free Survival (NUMBER) patients = 1,,,Objective Response Rate (ORR) (NUMBER) patients (%) = 11.1 [1.2-36.8],,,
NCT02186847,Chemotherapy and Radiation Therapy With or Without Metformin Hydrochloride in Treating Patients With Stage III Non-small Cell Lung Cancer,Randomized Phase II Trial of Concurrent Chemoradiotherapy +/- Metformin HCL in Locally Advanced NSCLC,NRG Oncology,NRG Oncology,OTHER,COMPLETED,2014-08,2019-04-16,2025-09-04,INTERVENTIONAL,PHASE2,,,,Adenosquamous Lung Carcinoma,Adenosquamous Lung Carcinoma; Bronchioloalveolar Carcinoma; Large Cell Lung Carcinoma,9,2,4,DRUG; RADIATION,,,1,4,True,Yes,Percentage of Participants Alive Without Progression (Progression-free Survival) (NUMBER) percentage of participants = 60.4 [48.5-70.4],Percentage of Participants Alive (Overall Survival) (NUMBER) percentage of participants = 38.5; Percentage of Participants With Local-regional Progression (NUMBER) percentage of participants = 17.2 [9.7-26.6]; Percentage of Participants With Distant Metastases (NUMBER) percentage of participants = 17.2 [9.7-26.6]; Percentage of Participants With Treatment-related Grade 3 or Higher Adverse Events (NUMBER) percentage of participants = 67.1 [55.4-77.5],,,,,,,,,Percentage of Participants Alive (Overall Survival) (NUMBER) percentage of participants = 38.5,Percentage of Participants Alive Without Progression (Progression-free Survival) (NUMBER) percentage of participants = 60.4 [48.5-70.4],,,,Percentage of Participants With Treatment-related Grade 3 or Higher Adverse Events (NUMBER) percentage of participants = 67.1 [55.4-77.5],,
NCT02195232,Cancer Associated Thrombosis and Isoquercetin (CATIQ),"Randomized, Placebo-controlled, Double-blind Phase II/III Trial of Oral Isoquercetin to Prevent Venous Thromboembolic Events in Cancer Patients.",Dana-Farber Cancer Institute,"Jeffrey Zwicker, MD",OTHER,COMPLETED,2015-01,2018-12,2019-10-22,INTERVENTIONAL,PHASE2; PHASE3,,,,Thromboembolism of Vein VTE in Colorectal Cancer,Thromboembolism of Vein VTE in Colorectal Cancer; Thromboembolism of Vein in Pancreatic Cancer; Thromboembolism of Vein in Non-small Cell Lung Cancer,3,2,1,DRUG,,,1,2,True,Yes,Percent Change in D-dimer Value (MEDIAN) percent change = 9.9 [-51.1-74.2],Number of Participants With Hemorrhage (COUNT_OF_PARTICIPANTS) Participants = 2; Cumulative Incidence of VTE at 56 Days (NUMBER) participants = 0,,,,,,,,,,,,,,,,
NCT02220894,Study of Pembrolizumab (MK-3475) Versus Platinum-Based Chemotherapy for Participants With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Advanced or ,"A Randomized, Open Label, Phase III Study of Overall Survival Comparing Pembrolizumab (MK-3475) Versus Platinum Based Chemotherapy in Treatment Naïve Subjects With PD-L1 Positive Advanced or Metastati",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,INDUSTRY,COMPLETED,2014-10-30,2018-09-04,2022-09-12,INTERVENTIONAL,PHASE3,,,,Non-small Cell Lung Cancer,Non-small Cell Lung Cancer,1,2,4,BIOLOGICAL; DRUG,,,3,8,True,Yes,Overall Survival (OS) in Participants With a Tumor Proportion Score (TPS) of ≥50% (MEDIAN) Months = 20.0 [15.9-24.2]; Overall Survival (OS) in Participants With a Tumor Proportion Score (TPS) of ≥20% (MEDIAN) Months = 18.0 [15.4-21.9]; Overall Survival (OS) in Participants With a Tumor Proportion Score (TPS) of ≥1% (MEDIAN) Months = 16.4 [14.0-19.7],Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR) in Participants With a Tumor Proportion Score (TPS) of ≥50% (MEDIAN) Months = 6.5 [5.9-8.5]; Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR) in Participants With a Tumor Proportion Score (TPS) of ≥20% (MEDIAN) Months = 6.2 [5.1-7.4]; Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR) in Participants With a Tumor Proportion Score (TPS) of ≥1% (MEDIAN) Months = 5.4 [4.3-6.2]; Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR) in Participants With a Tumor Proportion Score (TPS) of ≥50% (NUMBER) Percentage of participants = 39.1 [33.6-44.9]; Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR) in Participants With a Tumor Proportion Score (TPS) of ≥20% (NUMBER) Percentage of participants = 33.2 [28.6-37.9]; Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR) in Participants With a Tumor Proportion Score (TPS) of ≥1% (NUMBER) Percentage of participants = 27.2 [23.7-30.8]; Number of Participants Who Experienced At Least One Adverse Event (AE) (COUNT_OF_PARTICIPANTS) Participants = 608; Number of Participants Who Discontinued Study Treatment Due to an Adverse Event (AE) (COUNT_OF_PARTICIPANTS) Participants = 126,,,,,,,,Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR) in Participants With a Tumor Proportion Score (TPS) of ≥50% (NUMBER) Percentage of participants = 39.1 [33.6-44.9]; Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR) in Participants With a Tumor Proportion Score (TPS) of ≥20% (NUMBER) Percentage of participants = 33.2 [28.6-37.9]; Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR) in Participants With a Tumor Proportion Score (TPS) of ≥1% (NUMBER) Percentage of participants = 27.2 [23.7-30.8],Overall Survival (OS) in Participants With a Tumor Proportion Score (TPS) of ≥50% (MEDIAN) Months = 20.0 [15.9-24.2]; Overall Survival (OS) in Participants With a Tumor Proportion Score (TPS) of ≥20% (MEDIAN) Months = 18.0 [15.4-21.9]; Overall Survival (OS) in Participants With a Tumor Proportion Score (TPS) of ≥1% (MEDIAN) Months = 16.4 [14.0-19.7],Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR) in Participants With a Tumor Proportion Score (TPS) of ≥50% (MEDIAN) Months = 6.5 [5.9-8.5]; Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR) in Participants With a Tumor Proportion Score (TPS) of ≥20% (MEDIAN) Months = 6.2 [5.1-7.4]; Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR) in Participants With a Tumor Proportion Score (TPS) of ≥1% (MEDIAN) Months = 5.4 [4.3-6.2],,,Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR) in Participants With a Tumor Proportion Score (TPS) of ≥50% (NUMBER) Percentage of participants = 39.1 [33.6-44.9]; Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR) in Participants With a Tumor Proportion Score (TPS) of ≥20% (NUMBER) Percentage of participants = 33.2 [28.6-37.9]; Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR) in Participants With a Tumor Proportion Score (TPS) of ≥1% (NUMBER) Percentage of participants = 27.2 [23.7-30.8],,,
NCT02221739,Study of Combined Ionizing Radiation and Ipilimumab in Metastatic Non-small Cell Lung Cancer (NSCLC),Phase II Study of Combined Ionizing Radiation and Ipilimumab in Metastatic Non-small Cell Lung Cancer (NSCLC),NYU Langone Health,NYU Langone Health,OTHER,COMPLETED,2014-07-01,2015-04-15,2015-10-27,INTERVENTIONAL,PHASE1; PHASE2,,,,Non-small Cell Lung Cancer (NSCLC),Non-small Cell Lung Cancer (NSCLC),1,1,2,DRUG; RADIATION,,,1,1,True,Yes,Therapeutic Efficacy of Anti-CTLA-4 mAb and Concurrent Local RT in NSCLC Patients With Metastatic Disease. (COUNT_OF_PARTICIPANTS) Participants = 7,Number pf Patients With Objective Radioactive Responses to Measure the Effects of RT and Anti-CTLA-4 mAb on Development of Anti-tumor Immunity Measured by T Cell Clone Frequency (COUNT_OF_PARTICIPANTS) Participants = 7,,,,,,,,,,,,,,,,
NCT02259621,"Neoadjuvant Nivolumab, or Nivolumab in Combination With Ipilimumab, in Resectable NSCLC","Neoadjuvant Nivolumab, or Nivolumab in Combination With Ipilimumab, in Resectable Non-Small-Cell Lung Cancer.",Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,OTHER,ACTIVE_NOT_RECRUITING,2014-09,2022-10-14,2027-10,INTERVENTIONAL,PHASE2,,,,Non-Small Cell Lung Cancer,Non-Small Cell Lung Cancer,1,3,4,DRUG,,,2,2,True,Yes,"Safety as Measured by Number of Participants With Grade 3 and 4 Lab Abnormalities, as Defined by CTCAE v4.03 (COUNT_OF_PARTICIPANTS) Participants = 1; Safety as Assessed by Number of Grade 3 and 4 Adverse Events (NUMBER) events = 1",; ,,,,,,,,,,,,,,"Safety as Measured by Number of Participants With Grade 3 and 4 Lab Abnormalities, as Defined by CTCAE v4.03 (COUNT_OF_PARTICIPANTS) Participants = 1; Safety as Assessed by Number of Grade 3 and 4 Adverse Events (NUMBER) events = 1",,
NCT02262325,Hypofractionated Boost Before Chemoradiation for Patients With Stage II-III Non-small Cell Lung Cancer Unsuitable for Surgery,A Phase II Trial Combining Hypofractionated Radiation Boost With Conventionally-Fractionated Chemoradiation in Locally Advanced Non-small Cell Lung Cancer Not Suitable for Surgery,Ohio State University Comprehensive Cancer Center,Ohio State University Comprehensive Cancer Center,OTHER,COMPLETED,2015-06-08,2024-04-15,2024-04-15,INTERVENTIONAL,PHASE2,,,,Recurrent Non-small Cell Lung Cancer,Recurrent Non-small Cell Lung Cancer; Stage IIA Non-small Cell Lung Cancer; Stage IIB Non-small Cell Lung Cancer,5,1,5,DRUG; OTHER; RADIATION,,,1,11,True,Yes,"Primary Tumor Control Rate, as Measured From the Time of Treatment Completion Until the First Documented Date of Local Failure (NUMBER) percentage of participants = 100",Number of Adverse Events (NUMBER) Number of Events = 2; Tolerability Measured by the Number of Patients Who Discontinue Treatment (NUMBER) participants = 0; Regional Control (NUMBER) percentage of participants = 81.6; Distant Control (NUMBER) percentage of participants = 70.3; Disease-free Survival (DFS) (NUMBER) percentage of participants = 46.1; Overall Survival (OS) (NUMBER) percentage of participants = 50.3; Objective Response Rate as Measured by Response Evaluation Criteria in Solid Tumors Criteria (NUMBER) percentage of participants = 72.7; Changes in Tumor Perfusion Measured by MR-DCE/PWI Amp and Kep (MEAN) percentage of change = 2.9; Changes in Tumor Perfusion Measured by MR-DCE/PWI Kpe and Kel (MEDIAN) percentage of change = 5.1 [-11.1-24.6]; Changes in Diffusion Measured by MR-diffusion (MEAN) percentage of change = 23; Changes in Hypoxia Measured by BOLD Sequences (MEAN) percentage of change = -87.1,,,Disease-free Survival (DFS) (NUMBER) percentage of participants = 46.1,,,,,Objective Response Rate as Measured by Response Evaluation Criteria in Solid Tumors Criteria (NUMBER) percentage of participants = 72.7,Overall Survival (OS) (NUMBER) percentage of participants = 50.3,,,,Objective Response Rate as Measured by Response Evaluation Criteria in Solid Tumors Criteria (NUMBER) percentage of participants = 72.7,Number of Adverse Events (NUMBER) Number of Events = 2,,
NCT02264210,Icotinib for Completed Resected IB NSCLC With EGFR Mutation,"A Randomized, Phase II Trial of Icotinib Versus Observation as Adjuvant Treatment in Stage IB Non-Small Cell Lung Cancer Harboring Activating Epidermal Growth Factor Receptor Mutation",Sun Yat-sen University,Sun Yat-sen University,OTHER,COMPLETED,2015-01,2020-12,2022-07,INTERVENTIONAL,PHASE2,,,,Lung Neoplasms,Lung Neoplasms; Squamous Cell Lung Cancer; Adenocarcinoma of the Lung,7,2,1,DRUG,,,1,0,True,Yes,3-year Disease-Free Survival (MEDIAN) Percentage of patients at 3 years = 96.1 [91.3-99.9],,,,3-year Disease-Free Survival (MEDIAN) Percentage of patients at 3 years = 96.1 [91.3-99.9],,,,,,,,,,,,,
NCT02264990,Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's Choice of Standard Chemotherapy in Adults Receiving First Cytotoxic Ch,"A Randomized, Open-Label, Multicenter, Phase 3 Trial Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's Choice of Standard Chemotherapy in Subjects Receiving First Cytotoxic Che",AbbVie,AbbVie,INDUSTRY,COMPLETED,2014-09-30,2019-11-14,2020-02-21,INTERVENTIONAL,PHASE3,,,,Non-squamous Non-small Cell Lung Cancer,Non-squamous Non-small Cell Lung Cancer,1,2,5,DRUG,,,1,5,True,Yes,Overall Survival (OS) in the Lung Subtype Panel Positive Subgroup (MEDIAN) months = 9.2 [5.1-11.7],Progression Free Survival (PFS) in the Lung Subtype Panel Positive Subgroup (MEDIAN) months = 5.2 [2.8-6.2]; Objective Response Rate (ORR) in the Lung Subtype Panel Positive Subgroup (NUMBER) percentage of participants = 30.0 [16.6-46.5]; Overall Survival in All Participants (MEDIAN) months = 12.1 [10.0-13.7]; Progression Free Survival (PFS) in All Participants (MEDIAN) months = 6.7 [5.6-7.2]; Objective Response Rate (ORR) in All Participants (NUMBER) percentage of participants = 29.0 [23.9-34.5],,,,,,,,Objective Response Rate (ORR) in the Lung Subtype Panel Positive Subgroup (NUMBER) percentage of participants = 30.0 [16.6-46.5]; Objective Response Rate (ORR) in All Participants (NUMBER) percentage of participants = 29.0 [23.9-34.5],Overall Survival (OS) in the Lung Subtype Panel Positive Subgroup (MEDIAN) months = 9.2 [5.1-11.7]; Overall Survival in All Participants (MEDIAN) months = 12.1 [10.0-13.7],Progression Free Survival (PFS) in the Lung Subtype Panel Positive Subgroup (MEDIAN) months = 5.2 [2.8-6.2]; Progression Free Survival (PFS) in All Participants (MEDIAN) months = 6.7 [5.6-7.2],,,Objective Response Rate (ORR) in the Lung Subtype Panel Positive Subgroup (NUMBER) percentage of participants = 30.0 [16.6-46.5]; Objective Response Rate (ORR) in All Participants (NUMBER) percentage of participants = 29.0 [23.9-34.5],,,
NCT02283749,BrUOG L301 With Non-Small Cell Lung Cancer and Bone Metastases,BrUOG L301: Xofigo Following Frontline-Line Chemotherapy For Patients With Non-Small Cell Lung Cancer and Bone Metastases,Brown University,Angela Taber MD,OTHER,COMPLETED,2015-09,2018-07-05,2018-11-13,INTERVENTIONAL,PHASE2,,,,Non Small Cell Lung Cancer With Bone Metastatses,Non Small Cell Lung Cancer With Bone Metastatses,1,1,1,BIOLOGICAL,,,1,2,True,Yes,Number of Symptomatic Skeletal Events (SSE) in Patients Receiving Xofigo With NSCLC and Bone Metastases (NUMBER) Number of participants experiencing SSE = 1,Progression-free Survival of Patients With NSCLC and Bone Metastases and Stable or Responding Disease After Front-line Chemotherapy Treated With Xofigo (COUNT_OF_PARTICIPANTS) Participants = 2; Overall Survival of Patients With NSCLC and Bone Metastases and Stable or Responding Disease After Front-line Chemotherapy Treated With Xofigo (COUNT_OF_PARTICIPANTS) Participants = 5,,,,,,,,,Overall Survival of Patients With NSCLC and Bone Metastases and Stable or Responding Disease After Front-line Chemotherapy Treated With Xofigo (COUNT_OF_PARTICIPANTS) Participants = 5,Progression-free Survival of Patients With NSCLC and Bone Metastases and Stable or Responding Disease After Front-line Chemotherapy Treated With Xofigo (COUNT_OF_PARTICIPANTS) Participants = 2,,,,,,
NCT02289833,"A Study of Trastuzumab Emtansine in Participants With Human Epidermal Growth Factor Receptor (HER)2 Immunohistochemistry (IHC)-Positive, Locally Advan","A Phase 2, Multicenter, Single-Arm Study of Trastuzumab Emtansine in Patients With HER2 IHC-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Received At Least One Prior Che",Hoffmann-La Roche,Hoffmann-La Roche,INDUSTRY,COMPLETED,2014-12-15,2016-10-25,2018-08-20,INTERVENTIONAL,PHASE2,,,,Non-Small Cell Lung Cancer,Non-Small Cell Lung Cancer,1,2,1,DRUG,,,1,15,True,Yes,Percentage of Participants With Objective Response as Per Investigator Assessment According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v. 1.1) (NUMBER) percentage of participants = 0 [0-11.9],"Percentage of Participants Who Died (NUMBER) percentage of participants = 79.3; Overall Survival (OS) (MEDIAN) months = 12.2 [3.8-23.6]; Percentage of Participants With PFS Event of Disease Progression, as Per Investigator Assessment According to RECIST v. 1.1, or Death (NUMBER) percentage of participants = 100; Progression-Free Survival (PFS) as Per Investigator Assessment According to RECIST v. 1.1 (MEDIAN) months = 2.6 [1.4-2.8]; Percentage of Participants With DOR Event of Disease Progression, Assessed According to RECIST v1.1 (NUMBER) percentage of participants = 75.0 [2.9-8.3]; Duration of Objective Response (DOR) Assessed According to RECIST v1.1 (MEDIAN) months = 7.3; Percentage of Participants With Clinical Benefit as Per Investigator Assessment According to RECIST, v1.1 (NUMBER) percentage of participants = 6.9 [0.85-22.77]; Percentage of Participants With Adverse Events (AEs) and Serious AEs (SAEs) (NUMBER) percentage of participants = 93.1; Maximum Observed Concentration (Cmax) for Trastuzumab Emtansine and Total Trastuzumab (MEAN) micrograms per milliliter (ug/mL) = 78.7; AUCinf for Trastuzumab Emtansine and Total Trastuzumab (MEAN) days times ug/mL (day* ug/mL) = 324; Elimination Half-Life (t1/2) for Trastuzumab Emtansine and Total Trastuzumab (MEAN) days = 3.2; Volume of Distribution (Vss) for Trastuzumab Emtansine and Total Trastuzumab (MEAN) milliliters kilogram (mL/kg) = 51.1; Clearance (CL) for Trastuzumab Emtansine and Total Trastuzumab (MEAN) mL/day/kg = 11.35; Maximum Observed Concentration (Cmax) for N2'- Deacetyl-N2'-(3-mercapto-1-oxopropyl)-Maytansine (DM1) (MEAN) nanograms per milliliter (ng/mL) = 4.3; Percentage of Participants With Treatment-Emergent Anti-Drug Antibodies (ADAs) (NUMBER) percentage of participants = 0",,,,,"Percentage of Participants With DOR Event of Disease Progression, Assessed According to RECIST v1.1 (NUMBER) percentage of participants = 75.0 [2.9-8.3]",,,,Overall Survival (OS) (MEDIAN) months = 12.2 [3.8-23.6],"Percentage of Participants With PFS Event of Disease Progression, as Per Investigator Assessment According to RECIST v. 1.1, or Death (NUMBER) percentage of participants = 100; Progression-Free Survival (PFS) as Per Investigator Assessment According to RECIST v. 1.1 (MEDIAN) months = 2.6 [1.4-2.8]",,,,Percentage of Participants With Adverse Events (AEs) and Serious AEs (SAEs) (NUMBER) percentage of participants = 93.1,,
NCT02296125,AZD9291 Versus Gefitinib or Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer,"A Phase III, Double-blind, Randomised Study to Assess the Safety and Efficacy of AZD9291 Versus a Standard of Care Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor as First Line Treatment in",AstraZeneca,AstraZeneca,INDUSTRY,ACTIVE_NOT_RECRUITING,2014-12-03,2017-06-19,2025-12-31,INTERVENTIONAL,PHASE3,,,,Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer,Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer,1,2,6,DRUG,,,2,11,True,Yes,"Median Progression Free Survival (PFS) (Months) (MEDIAN) Months = 18.9 [15.2-21.4]; Percentage of Participants in Progression Free Survival at 6, 12, and 18 Months (NUMBER) Percentage of Participants = 88.4",Objective Response Rate (ORR) (NUMBER) Percentage of participants = 76.7 [71.29-81.53]; Duration of Response (DoR) (MEDIAN) Months = 17.2 [13.8-22.0]; Disease Control Rate (DCR) (NUMBER) Percentage of participants = 97.1 [94.4-98.8]; Depth of Response (MEAN) percentage of change = -52.36; Overall Survival (OS)- Number of Participants With an Event (COUNT_OF_PARTICIPANTS) Participants = 155; ; ; ; Participants Reported Outcome by Cancer Therapy Satisfaction Questionnaire 16 Items (CTSQ-16 Questionnaire) (MEAN) Unit on scale = 74.1; Change From Baseline in European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life (QLQ) Questionnaires Lung Cancer 13 (QLQ-LC13) (LEAST_SQUARES_MEAN) Unit on scale = -4.04 [-5.63--2.45]; Change From Baseline in European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 Items (EORTC QLQ-C30) (LEAST_SQUARES_MEAN) Unit on scale = -5.48 [-7.45--3.52],,,,,Duration of Response (DoR) (MEDIAN) Months = 17.2 [13.8-22.0],,,Objective Response Rate (ORR) (NUMBER) Percentage of participants = 76.7 [71.29-81.53],Overall Survival (OS)- Number of Participants With an Event (COUNT_OF_PARTICIPANTS) Participants = 155,"Median Progression Free Survival (PFS) (Months) (MEDIAN) Months = 18.9 [15.2-21.4]; Percentage of Participants in Progression Free Survival at 6, 12, and 18 Months (NUMBER) Percentage of Participants = 88.4",,Change From Baseline in European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life (QLQ) Questionnaires Lung Cancer 13 (QLQ-LC13) (LEAST_SQUARES_MEAN) Unit on scale = -4.04 [-5.63--2.45]; Change From Baseline in European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 Items (EORTC QLQ-C30) (LEAST_SQUARES_MEAN) Unit on scale = -5.48 [-7.45--3.52],Objective Response Rate (ORR) (NUMBER) Percentage of participants = 76.7 [71.29-81.53],,,
NCT02299141,Nintedanib in Molecularly Selected Patients With Advanced Non-Small Cell Lung Cancer,A Pilot Study of Nintedanib in Molecularly Selected Patients With Advanced Non-Small Cell Lung Cancer (NSCLC),Washington University School of Medicine,Washington University School of Medicine,OTHER,COMPLETED,2015-05-07,2020-01-09,2025-04-23,INTERVENTIONAL,PHASE2,,,,"Carcinoma, Non-Small-Cell Lung","Carcinoma, Non-Small-Cell Lung; Non-Small Cell Lung Cancer; Nonsmall Cell Lung Cancer",3,1,1,DRUG,,,1,4,True,Yes,Response Rate (RR) (COUNT_OF_PARTICIPANTS) Participants = 3,Median Progression-free Survival (PFS) (MEDIAN) months = 4.3 [1.8-7.9]; Response Rate by Mutation Type (COUNT_OF_PARTICIPANTS) Participants = 3; Unique Genetic Variations Associated With Extreme Responders (Both Non-responders and Responders) (NUMBER) mutations = 1; ,,,,,,,,,,Median Progression-free Survival (PFS) (MEDIAN) months = 4.3 [1.8-7.9],,,Response Rate (RR) (COUNT_OF_PARTICIPANTS) Participants = 3; Response Rate by Mutation Type (COUNT_OF_PARTICIPANTS) Participants = 3,,,
NCT02308020,"A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer, Non-small Cell Lung Cancer, or Melanoma That Has Spread to the Brain","A Phase 2 Study of Abemaciclib in Patients With Brain Metastases Secondary to Hormone Receptor Positive Breast Cancer, Non-small Cell Lung Cancer, or Melanoma",Eli Lilly and Company,Eli Lilly and Company,INDUSTRY,COMPLETED,2015-04-20,2018-11-08,2019-11-08,INTERVENTIONAL,PHASE2,,,,Breast Cancer,Breast Cancer; Non-small Cell Lung Cancer; Melanoma,4,6,1,DRUG,,,1,10,True,Yes,Percentage of Participants Achieving Complete Response (CR) or Partial Response (PR): Objective Intracranial Response Rate (OIRR) (NUMBER) percentage of participants = 0,"Percentage of Participants With CR, PR, Stable Disease (SD), Progressive Disease (PD), or Not Evaluable (NE): Best Overall Intracranial Response (BOIR) (NUMBER) percentage of participants = 0; Duration of CR or PR: Duration of Intracranial Response (DOIR) (MEDIAN) Months = 8.8 [3.0-14.3]; Percentage of Participants With Best Overall Intracranial Response (BOIR) of CR, PR, or SD: Intracranial Disease Control Rate (IDCR) (NUMBER) percentage of participants = 52.2; Percentage of Participants With BOIR of CR, PR, or SD With Duration of SD for at Least 6 Months: Intracranial Clinical Benefit Rate (ICBR) (NUMBER) percentage of participants = 13.0; Overall Survival (OS) (MEDIAN) months = 10.06 [4.21-14.30]; Percentage of Participants With a Best Response of CR or PR: Extracranial Objective Response Rate (EORR) (NUMBER) percentage of participants = 0; Percentage of Participants With a Best Overall Response of CR, PR, or SD: Extracranial Disease Control Rate (EDCR) (NUMBER) percentage of participants = 40.7; Progression Free Survival (PFS) Bi-compartmental (MEDIAN) Months = 2.07 [1.35-3.32]; Change From Baseline in Neurologic Symptoms on the MD Anderson Inventory-Brain Tumor (MDASI-BT) Subscale (MEAN) units on a scale = -0.98; Pharmacokinetics (PK): Steady State Minimum Concentration (Cmin) of Abemaciclib and Its Metabolites LSN2839567 (M2), LSN3106726 (M20), and LSN3106729 (M18) (GEOMETRIC_MEAN) nanogram/milliliter (ng/mL) = 133","Percentage of Participants With BOIR of CR, PR, or SD With Duration of SD for at Least 6 Months: Intracranial Clinical Benefit Rate (ICBR) (NUMBER) percentage of participants = 13.0",Percentage of Participants Achieving Complete Response (CR) or Partial Response (PR): Objective Intracranial Response Rate (OIRR) (NUMBER) percentage of participants = 0; Duration of CR or PR: Duration of Intracranial Response (DOIR) (MEDIAN) Months = 8.8 [3.0-14.3]; Percentage of Participants With a Best Response of CR or PR: Extracranial Objective Response Rate (EORR) (NUMBER) percentage of participants = 0,,,,,,Percentage of Participants With a Best Response of CR or PR: Extracranial Objective Response Rate (EORR) (NUMBER) percentage of participants = 0,Overall Survival (OS) (MEDIAN) months = 10.06 [4.21-14.30],Progression Free Survival (PFS) Bi-compartmental (MEDIAN) Months = 2.07 [1.35-3.32],Percentage of Participants Achieving Complete Response (CR) or Partial Response (PR): Objective Intracranial Response Rate (OIRR) (NUMBER) percentage of participants = 0,,Percentage of Participants Achieving Complete Response (CR) or Partial Response (PR): Objective Intracranial Response Rate (OIRR) (NUMBER) percentage of participants = 0; Percentage of Participants With a Best Response of CR or PR: Extracranial Objective Response Rate (EORR) (NUMBER) percentage of participants = 0,,,
NCT02312622,Phase 2 Etirinotecan Pegol in Refractory Brain Metastases & Advanced Lung Cancer / Metastatic Breast Cancer,A Phase 2 Study of Etirinotecan Pegol (NKTR-102) in Patients With Refractory Brain Metastases and Advanced Lung Cancer or Metastatic Breast Cancer (MBC),Stanford University,Joel Neal,OTHER,COMPLETED,2015-08,2018-09-08,2019-07,INTERVENTIONAL,PHASE2,,,,Stage IV Non-small Cell Lung Cancer (NSCLC),Stage IV Non-small Cell Lung Cancer (NSCLC); Recurrent Non-small Cell Lung Cancer (NSCLC); Extensive-stage Small Cell Lung Cancer (SCLC),6,3,1,DRUG,,,1,9,True,Yes,Central Nervous System (CNS) Disease Control Rate (Cohort A and C) (COUNT_OF_PARTICIPANTS) Participants = 2,Overall Disease Control Rate (Cohort A and C) (NUMBER) participants = 2; Overall Response Rate (Cohort A and C) (COUNT_OF_PARTICIPANTS) Participants = 1; Systemic (Non-CNS) Disease Control Rate (Cohort A and C) (COUNT_OF_PARTICIPANTS) Participants = 3; Systemic (Non-CNS) Response Rate (Cohort A and C) (COUNT_OF_PARTICIPANTS) Participants = 1; Progression-free Survival (PFS) (Cohort A and C) (MEDIAN) months = 2.66 [1.35-6.74]; Overall Survival (Cohort A and C) (MEDIAN) months = 7.00 [5.13-48]; Central Nervous System (CNS) Disease Control (Cohort B) (COUNT_OF_PARTICIPANTS) Participants = 0; Systemic Disease Control (Cohort B) (COUNT_OF_PARTICIPANTS) Participants = 0; Related Adverse Events (Toxicity) (NUMBER) adverse events = 70,,,,,,,,,Overall Survival (Cohort A and C) (MEDIAN) months = 7.00 [5.13-48],Progression-free Survival (PFS) (Cohort A and C) (MEDIAN) months = 2.66 [1.35-6.74],,,Overall Response Rate (Cohort A and C) (COUNT_OF_PARTICIPANTS) Participants = 1; Systemic (Non-CNS) Response Rate (Cohort A and C) (COUNT_OF_PARTICIPANTS) Participants = 1,Related Adverse Events (Toxicity) (NUMBER) adverse events = 70,,
NCT02314364,A Trial of Integrating SBRT With Targeted Therapy in Stage IV Oncogene-driven NSCLC,A Phase II Trial of Integrating Stereotactic Body Radiation Therapy With Selective Targeted Therapy in Stage IV Oncogene-driven Non-Small Cell Lung Cancer,Massachusetts General Hospital,Massachusetts General Hospital,OTHER,COMPLETED,2014-12,2021-11-10,2023-10-25,INTERVENTIONAL,PHASE2,,,,Non-small Cell Lung Cancer Metastatic,"Non-small Cell Lung Cancer Metastatic; Targetable Oncogenes (EGFR, ALK, ROS1)",2,1,1,RADIATION,,,1,5,True,Yes,1-year Frequency of Distant Failures (DF) After Stereotactic Body Radiation Therapy (SBRT) (NUMBER) percentage of participants = 19 [7-36],Percentage of Participants With Grade 3 or Higher Toxicities Related to Stereotactic Body Radiation Therapy (SBRT) (COUNT_OF_PARTICIPANTS) Participants = 0; Median Progression Free Survival (MEDIAN) months = 23.4 [14-53]; Median Overall Survival (MEDIAN) months = 59.6; 2-year Overall Survival (NUMBER) percentage of participants = 88 [68-96]; 2-year Local Failure (LF) of Lesions Treated With Stereotactic Body Radiation Therapy (SBRT) (NUMBER) percentage of participants = 11 [3-27],,,,,,,,,Median Overall Survival (MEDIAN) months = 59.6; 2-year Overall Survival (NUMBER) percentage of participants = 88 [68-96],Median Progression Free Survival (MEDIAN) months = 23.4 [14-53],,,,,,
NCT02316002,Phase II Study of Pembrolizumab After Curative Intent Treatment for Oligometastatic Non-Small Cell Lung Cancer,Phase II Study of Pembrolizumab After Curative Intent Treatment for Oligometastatic Non-Small Cell Lung Cancer,Abramson Cancer Center at Penn Medicine,Abramson Cancer Center at Penn Medicine,OTHER,COMPLETED,2015-01-21,2018-09-30,2022-12,INTERVENTIONAL,PHASE2,,,,Oligometastatic Non-small Cell Lung Cancer (NSCLC),Oligometastatic Non-small Cell Lung Cancer (NSCLC),1,1,1,DRUG,,,1,0,True,Yes,Progression Free Survival (PFS) (MEAN) Months = 19.1 [9.4-28.7],,,,,,,,,,,Progression Free Survival (PFS) (MEAN) Months = 19.1 [9.4-28.7],,,,,,
NCT02336451,A Phase II Study to Evaluate the Efficacy and Safety of Oral Ceritinib in Patients With ALK-positive NSCLC Metastatic to the Brain and/or to Leptomeni,"A Phase II, Multi-center, Open-label, Five-arm Study to Evaluate the Efficacy and Safety of Oral Ceritinib Treatment for Patients With ALK-positive Non-small Cell Lung Cancer (NSCLC) Metastatic to the",Novartis,Novartis Pharmaceuticals,INDUSTRY,COMPLETED,2015-04-01,2019-02-06,2019-02-06,INTERVENTIONAL,PHASE2,,,,ALK-positive Non-small Cell Lung Cancer,ALK-positive Non-small Cell Lung Cancer,1,5,1,DRUG,,,1,27,True,Yes,Overall Response Rate (ORR) Per Investigator Assessment (NUMBER) Percentage of participants = 35.7 [21.6-52.0],Disease Control Rate (DCR) Per Investigator Assessment (NUMBER) Percentage of participants = 66.7 [50.5-80.4]; Overall Intracranial Response Rate (OIRR) Per Modified RECIST 1.1 Per Investigator Assessment (NUMBER) Percentage of participants = 39.3 [21.5-59.4]; Overall Intracranial Response Rate (OIRR) Per Modified RECIST 1.1 Per Blinded Independent Review Committee (BIRC) Assessment (NUMBER) Percentage of participants = 33.3 [17.3-52.8]; Intracranial Disease Control Rate (IDCR) Per Modified RECIST 1.1 Per Investigator Assessment at Weeks 8 & 16 (NUMBER) Percentage of participants = 71.4 [55.4-84.3]; Intracranial Disease Control Rate (IDCR) Per Modified RECIST 1.1 Per Investigator Assessment - Overall (NUMBER) Percentage of participants = 71.4 [55.4-84.3]; Intracranial Disease Control Rate (IDCR) Per Modified RECIST 1.1 Per BIRC Assessment at Weeks 8 & 16 (NUMBER) Percentage of participants = 76.2 [60.5-87.9]; Intracranial Disease Control Rate (IDCR) Per Modified RECIST 1.1 Per BIRC Assessment - Overall (NUMBER) Percentage of participants = 73.8 [58.0-86.1]; Time to Intracranial Tumor Response (TTIR) Per Modified RECIST 1.1 Per Investigator Assessment (MEDIAN) months = 1.87 [1.7-7.5]; Time to Intracranial Tumor Response (TTIR) Per Modified RECIST 1.1 Per BIRC Assessment (MEDIAN) months = 1.91 [1.7-5.6]; Duration of Intracranial Response (DOIR) by Modified RECIST 1.1 Per Investigator Assessment (MEDIAN) months = 9.2; Duration of Intracranial Response (DOIR) by Modified RECIST 1.1 Per BIRC Assessment (MEDIAN) months = 11.0; Overall Extracranial Response Rate (OERR) Per RECIST 1.1 Per Investigator & BIRC Assessment (NUMBER) Percentage of participants = 31.0 [17.6-47.1]; Extracranial Disease Control Rate (EDCR) Per RECIST 1.1 Per Investigator & BIRC Assessment - Overall (NUMBER) Percentage of participants = 69.0 [52.9-82.4]; Extracranial Disease Control Rate (EDCR) Per RECIST 1.1 Per Investigator & BIRC Assessment at Weeks 8 & 16 (NUMBER) Percentage of participants = 69.0 [52.9-82.4]; Time to Extracranial Tumor Response (TTER) Per RECIST 1.1 Per Investigator Assessment (MEDIAN) months = 1.87 [1.7-18.2]; Time to Extracranial Tumor Response (TTER) Per RECIST 1.1 Per BIRC Assessment (MEDIAN) months = 1.81 [1.7-12.9]; Duration of Extracranial Response (DOER) Per RECIST 1.1 Per Investigator Assessment (MEDIAN) months = 18.4; ; Overall Response Rate (ORR) (Whole Body) Per RECIST 1.1 Per BIRC Assessment (NUMBER) Percentage of participants = 23.8 [12.1-39.5]; Disease Control Rate (DCR) (Whole Body) Per RECIST 1.1 Per BIRC Assessment (NUMBER) Percentage of participants = 61.9 [45.6-76.4]; Time to Tumor Response (TTR) (Whole Body) Per RECIST 1.1 Per Investigator Assessment (MEDIAN) months = 1.87 [1.7-9.3]; Time to Tumor Response (TTR) (Whole Body) Per RECIST 1.1 Per BIRC Assessment (MEDIAN) months = 2.00 [1.7-12.9]; Duration of Response (DOR) (Whole Body) Per RECIST 1.1 Per Investigator Assessment (MEDIAN) months = 10.8; Duration of Response (DOR) (Whole Body) Per RECIST 1.1 Per BIRC Assessment (MEDIAN) months = 11.0; Progression Free Survival (PFS) (Whole Body) Per RECIST 1.1 Per Investigator & BIRC Assessment (MEDIAN) months = 7.2 [3.3-10.9]; Overall Survival (OS) (MEDIAN) months = 24.0; Pharmacokinetics (PK) of Ceritinib in Study Population: Cmax & Cmin (Trough) (GEOMETRIC_MEAN) ng/mL = 0,,,,,Duration of Response (DOR) (Whole Body) Per RECIST 1.1 Per Investigator Assessment (MEDIAN) months = 10.8; Duration of Response (DOR) (Whole Body) Per RECIST 1.1 Per BIRC Assessment (MEDIAN) months = 11.0,,,,Overall Survival (OS) (MEDIAN) months = 24.0,Progression Free Survival (PFS) (Whole Body) Per RECIST 1.1 Per Investigator & BIRC Assessment (MEDIAN) months = 7.2 [3.3-10.9],,,Overall Response Rate (ORR) Per Investigator Assessment (NUMBER) Percentage of participants = 35.7 [21.6-52.0]; Overall Intracranial Response Rate (OIRR) Per Modified RECIST 1.1 Per Investigator Assessment (NUMBER) Percentage of participants = 39.3 [21.5-59.4]; Overall Intracranial Response Rate (OIRR) Per Modified RECIST 1.1 Per Blinded Independent Review Committee (BIRC) Assessment (NUMBER) Percentage of participants = 33.3 [17.3-52.8]; Overall Extracranial Response Rate (OERR) Per RECIST 1.1 Per Investigator & BIRC Assessment (NUMBER) Percentage of participants = 31.0 [17.6-47.1]; Overall Response Rate (ORR) (Whole Body) Per RECIST 1.1 Per BIRC Assessment (NUMBER) Percentage of participants = 23.8 [12.1-39.5],,,
NCT02337530,Selumetinib in Patients Receiving Pemetrexed and Platinum-based Chemotherapy in Advanced or Metastatic KRAS Wildtype or Unknown Non-Squamous NSCLC,A Randomized Phase II Trial of Selumetinib in Patients Receiving Standard Pemetrexed and Platinum-based Chemotherapy for the Treatment of Advanced or Metastatic KRAS Wildtype or Unknown Non-Squamous N,Canadian Cancer Trials Group,Canadian Cancer Trials Group,NETWORK,COMPLETED,2015-05-26,2017-10-31,2019-06-18,INTERVENTIONAL,PHASE2,,,,Non-Small Cell Lung Cancer,Non-Small Cell Lung Cancer,1,3,4,DRUG,,,1,1,True,Yes,Objective Response Rate (COUNT_OF_PARTICIPANTS) Participants = 6,Progression Free Survival (MEDIAN) months = 7.2 [4.0-8.6],,,,,,,,Objective Response Rate (COUNT_OF_PARTICIPANTS) Participants = 6,,Progression Free Survival (MEDIAN) months = 7.2 [4.0-8.6],,,Objective Response Rate (COUNT_OF_PARTICIPANTS) Participants = 6,,,
NCT02347917,A Study of BBI608 in Combination With Pemetrexed and Cisplatin in Adult Patients With Malignant Pleural Mesothelioma,A Phase I/II Clinical Study of BBI608 in Combination With Pemetrexed and Cisplatin in Adult Patients With Malignant Pleural Mesothelioma,"Sumitomo Pharma Co., Ltd.","Sumitomo Pharma Co., Ltd.",INDUSTRY,COMPLETED,2015-02,2018-05-31,2018-05-31,INTERVENTIONAL,PHASE1; PHASE2,,,,Malignant Pleural Mesothelioma,Malignant Pleural Mesothelioma; Non-Small Cell Lung Cancer,2,1,3,DRUG,,,5,5,True,Yes,"Phase 1 Part: Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) and Adverse Drug Reactions (ADRs) (COUNT_OF_PARTICIPANTS) Participants = 4; Phase 1 Part: Number of Participants With Dose-limiting Toxicities (DLTs) (COUNT_OF_PARTICIPANTS) Participants = 0; Phase 1 Part: Maximum Observed Concentration (Cmax) and Minimum Observed Concentration (Cmin) of BBI608 When Administered With Pem and CDDP (MEAN) ng/mL = 307.5 [251-380]; Phase 1 Part: Area Under the Concentration-time Curve (MEAN) h*ng/mL = 1814.3 [900-2443]; Phase 2 Part: Progression-free Survival (PFS) (MEDIAN) month = 5.59",Best Overall Response (COUNT_OF_PARTICIPANTS) Participants = 0; Response Rate (RR) and Disease Control Rate (DCR) (COUNT_OF_PARTICIPANTS) Participants = 0; Overall Survival(OS) (MEDIAN) month = 19.81 [19.4-27.8]; Respiratory Function Tests (Vital Capacity [VC] and Forced Vital Capacity [FVC]) (MEDIAN) mL = 70.0 [-10-200]; Respiratory Function Tests (Forced Expiratory Volume in the First Second [FEV1]) (MEDIAN) L = 0.160 [-0.01-0.16],,,,,,,,,Overall Survival(OS) (MEDIAN) month = 19.81 [19.4-27.8],Phase 2 Part: Progression-free Survival (PFS) (MEDIAN) month = 5.59,,,Response Rate (RR) and Disease Control Rate (DCR) (COUNT_OF_PARTICIPANTS) Participants = 0,"Phase 1 Part: Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) and Adverse Drug Reactions (ADRs) (COUNT_OF_PARTICIPANTS) Participants = 4",,
NCT02349412,Early Palliative Care With Standard Care or Standard Care Alone in Improving Quality of Life of Patients With Incurable Lung or Non-colorectal Gastroi,Randomized Study of Early Palliative Care Integrated With Standard Oncology Care Versus Standard Oncology Care Alone in Patients With Incurable Lung or Non-Colorectal Gastrointestinal Malignancies,Alliance for Clinical Trials in Oncology,Alliance for Clinical Trials in Oncology,OTHER,COMPLETED,2015-06-25,2017-07-03,2019-07-15,INTERVENTIONAL,PHASE3,,,,Liver Cancer,Liver Cancer; Anxiety Disorder; Depression,10,2,1,OTHER,,,1,11,True,Yes,Change in Quality of Life (QOL) From Baseline to Week 12 Per the Functional Assessment of Cancer Therapy-General (FACT-G) (MEAN) units on a scale = 3.35,"Change in Quality of Life (QOL) From Baseline to Week 24 Per the Functional Assessment of Cancer Therapy-General (FACT-G) (MEAN) units on a scale = 3.80; Change in Quality of Life (QOL) From Baseline to Week 12 Per the Hospital Anxiety and Depression Scale (HADS) - Depression (MEAN) units on a scale = 0.54; Change in Quality of Life (QOL) From Baseline to Week 12 Per the Hospital Anxiety and Depression Scale (HADS) - Anxiety (MEAN) units on a scale = -1.13; Prognostic Understanding at Week-12 as Measured by ""Have You and Your Oncologist Discussed Any Particular Wishes About the Care You Would Want to Receive if You Were Dying?"" Question on the Prognosis and Treatment Perceptions Questionnaire (COUNT_OF_PARTICIPANTS) Participants = 30; ; ; ; ; ; ; ",,,,,,,,,,,,Change in Quality of Life (QOL) From Baseline to Week 12 Per the Functional Assessment of Cancer Therapy-General (FACT-G) (MEAN) units on a scale = 3.35; Change in Quality of Life (QOL) From Baseline to Week 24 Per the Functional Assessment of Cancer Therapy-General (FACT-G) (MEAN) units on a scale = 3.80; Change in Quality of Life (QOL) From Baseline to Week 12 Per the Hospital Anxiety and Depression Scale (HADS) - Depression (MEAN) units on a scale = 0.54; Change in Quality of Life (QOL) From Baseline to Week 12 Per the Hospital Anxiety and Depression Scale (HADS) - Anxiety (MEAN) units on a scale = -1.13,,,,
NCT02350764,Evaluate the Mediators of Sensitivity and Resistance to Nivolumab Plus Ipilimumab in Patients With Advanced NSCLCs,An Exploratory Study to Evaluate the Mediators of Sensitivity and Resistance to Nivolumab Plus Ipilimumab in Patients With Advanced NSCLCs,Memorial Sloan Kettering Cancer Center,Memorial Sloan Kettering Cancer Center,OTHER,COMPLETED,2015-01-20,2023-09-25,2023-09-25,INTERVENTIONAL,PHASE2,,,,Advanced Stage Non-small Cell Lung Cancer,Advanced Stage Non-small Cell Lung Cancer,1,1,2,DRUG,,,1,0,True,Yes,Best Overall Response Rate (Confirmed Partial + Complete Response) Will be Assessed as Part of This Study. Tumor Response Will be Assessed Using RECIST 1.1) (COUNT_OF_PARTICIPANTS) Participants = 7,,,Best Overall Response Rate (Confirmed Partial + Complete Response) Will be Assessed as Part of This Study. Tumor Response Will be Assessed Using RECIST 1.1) (COUNT_OF_PARTICIPANTS) Participants = 7,,,,,,,,,,,Best Overall Response Rate (Confirmed Partial + Complete Response) Will be Assessed as Part of This Study. Tumor Response Will be Assessed Using RECIST 1.1) (COUNT_OF_PARTICIPANTS) Participants = 7,,,
NCT02352948,"A Global Study to Assess the Effects of MEDI4736 (Durvalumab), Given as Monotherapy or in Combination With Tremelimumab Determined by PD-L1 Expression","A Phase III, Open Label, Randomised, Multi-centre, International Study of MEDI4736, Given as Monotherapy or in Combination With Tremelimumab Determined by PD-L1 Expression Versus Standard of Care in P",AstraZeneca,AstraZeneca,INDUSTRY,COMPLETED,2015-01-13,2018-02-09,2023-08-30,INTERVENTIONAL,PHASE3,,,,Non - Small Cell Lung Cancer NSCLC,Non - Small Cell Lung Cancer NSCLC,1,6,6,DRUG,,,2,8,True,Yes,Overall Survival (OS) (MEDIAN) months = 11.7 [8.2-17.4]; Progression-Free Survival (PFS) (MEDIAN) months = 3.8 [1.9-5.6],"OS, Contribution of the Components Analysis of Sub-study B (MEDIAN) months = 11.5 [8.7-14.1]; Percentage of Participants Alive at 12 Months (OS12) (NUMBER) percentage of participants = 49.3 [36.3-61.0]; PFS, Contribution of the Components Analysis of Sub-study B (MEDIAN) months = 3.5 [2.3-4.6]; Objective Response Rate (ORR) (NUMBER) percentage of participants = 35.5; Duration of Response (DoR) (MEDIAN) months = 9.5 [3.0-17.8]; Percentage of Participants Alive and Progression Free at 6 Months (APF6) (NUMBER) percentage of participants = 35.5 [23.9-47.3]; Percentage of Participants Alive and Progression Free at 12 Months (APF12) (NUMBER) percentage of participants = 19.4 [10.7-30.0]; Time From Randomisation to Second Progression (PFS2) of Sub-study B (MEDIAN) months = 9.1 [6.6-12.3]",,,,,Duration of Response (DoR) (MEDIAN) months = 9.5 [3.0-17.8],,,Objective Response Rate (ORR) (NUMBER) percentage of participants = 35.5,Overall Survival (OS) (MEDIAN) months = 11.7 [8.2-17.4],Progression-Free Survival (PFS) (MEDIAN) months = 3.8 [1.9-5.6],,,Objective Response Rate (ORR) (NUMBER) percentage of participants = 35.5,,,
NCT02364999,A Comparative Study Of PF-06439535 Plus Paclitaxel-Carboplatin And Bevacizumab Plus Paclitaxel-Carboplatin Patients With Advanced Non-Squamous NSCLC,"A PHASE 3 RANDOMIZED, DOUBLE-BLIND STUDY OF PF- 06439535 PLUS PACLITAXEL-CARBOPLATIN AND BEVACIZUMAB PLUS PACLITAXEL -CARBOPLATIN FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SQUAMOUS NO",Pfizer,Pfizer,INDUSTRY,COMPLETED,2015-04,2017-05,2017-12,INTERVENTIONAL,PHASE3,,,,Non-Small Cell Lung Cancer,Non-Small Cell Lung Cancer,1,2,4,DRUG,,,1,8,True,Yes,Objective Response Rate (ORR) by Week 19 (NUMBER) percentage of participants = 45.3 [40.01-50.57],Number of Participants With Treatment-Emergent Adverse Events (COUNT_OF_PARTICIPANTS) Participants = 344; Number of Participants With Laboratory Abnormalities (Without Regard to Baseline Abnormality) (COUNT_OF_PARTICIPANTS) Participants = 303; Duration of Response (DOR) (MEDIAN) weeks = 36.3 [31.6-43.6]; Progression Free Survival Rate at 55 Weeks (NUMBER) percentage of participants = 32.3 [26.9-37.8]; Survival Rate at 55 Weeks (NUMBER) percentage of participants = 65.8 [60.5-70.6]; Serum Concentration of Bevacizumab up to 1 Year (MEAN) ng/mL = 68.08; Number of Participants With Anti-Drug Antibody (ADA) (COUNT_OF_PARTICIPANTS) Participants = 1; Number of Participants With Neutralizing Antibody (NAb) (COUNT_OF_PARTICIPANTS) Participants = 1,,,,,Duration of Response (DOR) (MEDIAN) weeks = 36.3 [31.6-43.6],,,Objective Response Rate (ORR) by Week 19 (NUMBER) percentage of participants = 45.3 [40.01-50.57],,Progression Free Survival Rate at 55 Weeks (NUMBER) percentage of participants = 32.3 [26.9-37.8],,,Objective Response Rate (ORR) by Week 19 (NUMBER) percentage of participants = 45.3 [40.01-50.57],Number of Participants With Treatment-Emergent Adverse Events (COUNT_OF_PARTICIPANTS) Participants = 344,,
NCT02367794,A Study of Atezolizumab in Combination With Carboplatin + Paclitaxel or Carboplatin + Nab-Paclitaxel Compared With Carboplatin + Nab-Paclitaxel in Par,"A Phase III, Open-Label, Multicenter, Randomized Study Evaluating the Efficacy and Safety of Atezolizumab (MPDL3280A, Anti-PD-L1 Antibody) in Combination With Carboplatin+Paclitaxel or Atezolizumab in",Hoffmann-La Roche,Hoffmann-La Roche,INDUSTRY,COMPLETED,2015-06-11,2018-10-03,2021-02-17,INTERVENTIONAL,PHASE3,,,,Squamous Non-Small Cell Lung Cancer,Squamous Non-Small Cell Lung Cancer,1,3,4,DRUG,,,2,21,True,Yes,Progression Free Survival (PFS) as Determined by the Investigator Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) in the Intent-to-Treat (ITT) Population (MEDIAN) Months = 5.6 [5.5-5.7]; Overall Survival (OS) in the ITT Population (MEDIAN) Months = 13.5 [12.2-15.1],OS in the in the Teff Population (MEDIAN) Month = 16.4 [12.2-19.7]; PFS as Determined by the Investigator Using RECIST v1.1 in the Teff Population (MEDIAN) Months = 5.6 [5.1-5.7]; PFS as Determined by the Investigator Using RECIST v1.1 in the Tumor Cell (TC) 2/3 or Tumor-Infiltrating Immune Cell (IC) 2/3 Population (MEDIAN) Months = 5.6 [5.1-5.7]; PFS as Determined by the Investigator Using RECIST v1.1 in the TC1/2/3 or IC1/2/3 Population (MEDIAN) Months = 5.6 [5.3-5.7]; OS in the TC2/3 or IC2/3 Population (MEDIAN) Months = 14.5 [12.1-17.2]; OS in the TC1/2/3 or IC1/2/3 Population (MEDIAN) Months = 15.0 [12.4-17.2]; Percentage of Participants With Objective Response as Determined by the Investigator Using RECIST v1.1 in the ITT Population (NUMBER) Percentage of participants = 41.0; Duration of Response as Determined by the Investigator Using RECIST v1.1 in the ITT Population (MEDIAN) Months = 5.2 [4.4-5.6]; Event Free Rate at 1 and 2 Years in the ITT Population (NUMBER) Percentage of participants = 56.28; Time to Deterioration (TTD) in Patient-reported Lung Cancer Symptoms Using EORTC QLQ-C30 Symptom Subscales in the ITT Population (MEDIAN) Months = 3.2 [2.6-4.1]; TTD in Patient-reported Lung Cancer Symptoms Using EORTC QLQ-LC13 Symptom Subscales in the ITT Population (MEDIAN) Months = 2.6 [2.2-3.0]; Change From Baseline in Patient-reported Lung Cancer Symptoms Score Using the SILC Scale Symptom Severity Score in the ITT Population (MEAN) Units on a scale = 0.04; PFS as Determined by the Investigator Using RECIST v1.1 in the ITT Population (Arm A and Arm B) (MEDIAN) Months = 6.5 [5.7-7.1]; OS in the ITT Population (Arm A and Arm B) (MEDIAN) Months = 14.2 [12.3-16.8]; Percentage of Participants With Adverse Events (NUMBER) Percentage of participants = 97.0; Percentage of Participants With Anti-therapeutic Antibody (ATA) Response to Atezolizumab (NUMBER) Percentage of participants = 3.1; Maximum Observed Serum Atezolizumab Concentration (Cmax) (MEAN) µg/mL = 372; ; ; ; ,,,,,Duration of Response as Determined by the Investigator Using RECIST v1.1 in the ITT Population (MEDIAN) Months = 5.2 [4.4-5.6],,,,Overall Survival (OS) in the ITT Population (MEDIAN) Months = 13.5 [12.2-15.1]; OS in the in the Teff Population (MEDIAN) Month = 16.4 [12.2-19.7]; OS in the TC2/3 or IC2/3 Population (MEDIAN) Months = 14.5 [12.1-17.2]; OS in the TC1/2/3 or IC1/2/3 Population (MEDIAN) Months = 15.0 [12.4-17.2]; OS in the ITT Population (Arm A and Arm B) (MEDIAN) Months = 14.2 [12.3-16.8],Progression Free Survival (PFS) as Determined by the Investigator Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) in the Intent-to-Treat (ITT) Population (MEDIAN) Months = 5.6 [5.5-5.7]; PFS as Determined by the Investigator Using RECIST v1.1 in the Teff Population (MEDIAN) Months = 5.6 [5.1-5.7]; PFS as Determined by the Investigator Using RECIST v1.1 in the Tumor Cell (TC) 2/3 or Tumor-Infiltrating Immune Cell (IC) 2/3 Population (MEDIAN) Months = 5.6 [5.1-5.7]; PFS as Determined by the Investigator Using RECIST v1.1 in the TC1/2/3 or IC1/2/3 Population (MEDIAN) Months = 5.6 [5.3-5.7]; PFS as Determined by the Investigator Using RECIST v1.1 in the ITT Population (Arm A and Arm B) (MEDIAN) Months = 6.5 [5.7-7.1],,,,Percentage of Participants With Adverse Events (NUMBER) Percentage of participants = 97.0,,
NCT02392507,A Study of Nab-Paclitaxel and Carboplatin Plus Necitumumab (LY3012211) in Participants With Stage IV Squamous NSCLC,"A Single-Arm, Multicenter, Open-Label, Phase 2 Study of Nab®-Paclitaxel (Abraxane®) and Carboplatin Chemotherapy Plus Necitumumab (LY3012211) in the First-Line Treatment of Patients With Stage IV Squa",Eli Lilly and Company,Eli Lilly and Company,INDUSTRY,COMPLETED,2015-10-12,2018-01-29,2019-11-06,INTERVENTIONAL,PHASE2,,,,"Carcinoma, Non-Small Cell Lung Cancer (NSCLC)","Carcinoma, Non-Small Cell Lung Cancer (NSCLC)",1,1,3,DRUG,,,1,6,True,Yes,Percentage of Participants Who Achieve Best Overall Tumor Response of Complete Response or Partial Response (Objective Tumor Response Rate [ORR]) (NUMBER) percentage of participants = 51.0,"Progression Free Survival (PFS) (MEDIAN) Months = 5.59 [4.24-7.69]; Overall Survival (OS) (MEDIAN) Months = 15.54; Percentage of Participants Who Achieve Best Overall Disease Response of Complete Response (CR), Partial Response (PR) or Stable Disease (SD) (Disease Control Rate [DCR]) (NUMBER) percentage of participants = 78.4; Pharmacokinetics (PK): Minimum Concentration (Cmin) of Necitumumab, Nab-Paclitaxel, and Carboplatin (GEOMETRIC_MEAN) nanogram per milliliter (ng/mL) = 65.2; PK: Maximum Concentration (Cmax) of Necitumumab, Nab-Paclitaxel, and Carboplatin (GEOMETRIC_MEAN) ng/mL = 231; Immunogenicity: Number of Participants Developing Anti-drug Antibodies to Necitumumab (COUNT_OF_PARTICIPANTS) Participants = 3",,"Percentage of Participants Who Achieve Best Overall Tumor Response of Complete Response or Partial Response (Objective Tumor Response Rate [ORR]) (NUMBER) percentage of participants = 51.0; Percentage of Participants Who Achieve Best Overall Disease Response of Complete Response (CR), Partial Response (PR) or Stable Disease (SD) (Disease Control Rate [DCR]) (NUMBER) percentage of participants = 78.4",,,,,,,Overall Survival (OS) (MEDIAN) Months = 15.54,Progression Free Survival (PFS) (MEDIAN) Months = 5.59 [4.24-7.69],"Percentage of Participants Who Achieve Best Overall Tumor Response of Complete Response or Partial Response (Objective Tumor Response Rate [ORR]) (NUMBER) percentage of participants = 51.0; Percentage of Participants Who Achieve Best Overall Disease Response of Complete Response (CR), Partial Response (PR) or Stable Disease (SD) (Disease Control Rate [DCR]) (NUMBER) percentage of participants = 78.4",,Percentage of Participants Who Achieve Best Overall Tumor Response of Complete Response or Partial Response (Objective Tumor Response Rate [ORR]) (NUMBER) percentage of participants = 51.0,,,
NCT02403271,A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Solid Tumors,"A Multi-Center Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination With Durvalumab (MEDI4736), in Subjects With Relapsed or Refractory Solid Tumors",Pharmacyclics LLC.,Pharmacyclics LLC.,INDUSTRY,COMPLETED,2015-03,2017-08,2017-08,INTERVENTIONAL,PHASE1; PHASE2,,,,Non-Small Cell Lung Cancer,Non-Small Cell Lung Cancer; Breast Cancer; Pancreatic Cancer,3,2,2,DRUG,,,2,7,True,Yes,Phase 1b: Number of Participants With Adverse Events as a Measure of Safety and Tolerability of Ibrutinib and Durvalumab (MEDI4736) and to Find the Recommended Phase II Dose. (NUMBER) participants = 6; Phase 2: Efficacy of Ibrutinib in Combination With Durvalumab (MEDI4736) in Participants With Relapsed or Refractory Solid Tumors by Assessing the ORR Per RECIST 1.1. (COUNT_OF_PARTICIPANTS) Participants = 2,Phase 1b/2: Pharmacokinetics (Cmax) of Ibrutinib (MEAN) ng/mL = 218; Phase 1b/2: Pharmacokinetics (AUC0-24h) of Ibrutinib (MEAN) h.ng/mL = 2126; Phase 1b/2: Pharmacokinetics (Cmax) of Durvalumab (MEDI4736) (GEOMETRIC_MEAN) μg/mL = 386; Phase 1b/2: Pharmacokinetics (Ctrough) of Durvalumab (MEDI4736) (GEOMETRIC_MEAN) μg/mL = 168; ; Phase 2: Number of Participants With Adverse Events as a Measure of Safety and Tolerability of Ibrutinib and Durvalumab (MEDI4736) (COUNT_OF_PARTICIPANTS) Participants = 122; Phase 2: Pharmacodynamics (MEAN) percentage of BTK binding site occupancy = 87.8,,,,,,,,Phase 2: Efficacy of Ibrutinib in Combination With Durvalumab (MEDI4736) in Participants With Relapsed or Refractory Solid Tumors by Assessing the ORR Per RECIST 1.1. (COUNT_OF_PARTICIPANTS) Participants = 2,,,,,,Phase 1b: Number of Participants With Adverse Events as a Measure of Safety and Tolerability of Ibrutinib and Durvalumab (MEDI4736) and to Find the Recommended Phase II Dose. (NUMBER) participants = 6; Phase 2: Number of Participants With Adverse Events as a Measure of Safety and Tolerability of Ibrutinib and Durvalumab (MEDI4736) (COUNT_OF_PARTICIPANTS) Participants = 122,,
NCT02409342,A Study of Atezolizumab (MPDL3280A) Compared With a Platinum Agent (Cisplatin or Carboplatin) + (Pemetrexed or Gemcitabine) in Participants With Stage,"A Phase III, Open Label, Randomized Study of Atezolizumab (Anti-PD-L1 Antibody) Compared With a Platinum Agent (Cisplatin or Carboplatin) in Combination With Either Pemetrexed or Gemcitabine for PD-L1",Hoffmann-La Roche,Hoffmann-La Roche,INDUSTRY,COMPLETED,2015-07-20,2020-02-04,2022-03-08,INTERVENTIONAL,PHASE3,,,,"Non-Squamous Non-Small Cell Lung Cancer, Squamous Non-Small Cell Lung Cancer","Non-Squamous Non-Small Cell Lung Cancer, Squamous Non-Small Cell Lung Cancer",1,2,5,DRUG,,,2,21,True,Yes,Overall Survival (OS) in the TC3 or IC3-WT Populations (MEDIAN) Months = 13.1 [7.4-16.5]; Overall Survival (OS) in the TC2/3 or IC2/3-WT and TC1/2/3 or IC1/2/3-WT Populations (MEDIAN) Months = 16.1 [12.6-18.0],Progression-free Survival (PFS) in the TC3 or IC3-WT Populations (NUMBER) Months = 5.0 [4.2-5.7]; Progression-free Survival (PFS) in the TC2/3 or IC2/3-WT and TC1/2/3 or IC1/2/3-WT Populations (NUMBER) Months = 5.5 [4.5-5.7]; Percentage of Participants With Objective Response (ORR) in the TC3 or IC3-WT Populations (NUMBER) Percentage of participants = 28.6; Percentage of Participants With Objective Response (ORR) in the TC2/3 or IC2/3-WT and TC1/2/3 or IC1/2/3-WT Populations (NUMBER) Percentage of participants = 32.1; Duration of Response (DOR) in the TC3 or IC3-WT Populations (NUMBER) Months = 6.7 [5.5-17.3]; Duration of Response (DOR) in the TC2/3 or IC2/3-WT and TC1/2/3 or IC1/2/3-WT Populations (NUMBER) Months = 5.8 [5.1-9.8]; Percentage of Participants Who Are Alive at 1 Year in the TC3 or IC3-WT Populations (NUMBER) Percentage of participants = 50.64 [40.00-61.27]; Percentage of Participants Who Are Alive at 2 Years in the TC3 or IC3-WT Populations (NUMBER) Percentage of participants = 24.79 [13.11-36.47]; Percentage of Participants Who Are Alive at 1 Year in the TC2/3 or IC2/3-WT and TC1/2/3 or IC1/2/3-WT Populations (NUMBER) Percentage of participants = 58.65 [50.95-66.35]; Percentage of Participants Who Are Alive at 2 Years in the TC2/3 or IC2/3-WT and TC1/2/3 or IC1/2/3-WT Populations (NUMBER) Percentage of participants = 35.42 [27.91-42.94]; Time to Deterioration (TTD) in Patient-reported Lung Cancer Symptoms Score as Assessed by the Symptoms in Lung Cancer (SILC) Scale Symptom Score in the TC3 or IC3-WT Populations (MEDIAN) Months = 3.4 [1.3-12.4]; Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations (MEAN) Score on a scale = 0.57; ; OS in Participants With PD-L1 Expression (MEDIAN) Months = 16.1 [9.8-17.4]; Investigator-Assessed PFS in Participants With PD-L1 Expression According to RECIST v1.1 (MEDIAN) Months = 4.9 [4.0-5.6]; OS in Participants With Blood Tumor Mutational Burden (bTMB) (MEDIAN) Months = 10.3 [7.1-16.9]; Investigator-Assessed PFS in Participants With bTMB According to RECIST v1.1 (MEDIAN) Months = 4.3 [3.1-5.4]; Minimum Observed Serum Concentration (Cmin) of Atezolizumab (MEAN) micrograms per milliliter (μg/ mL) = 76.7; Maximum Observed Serum Concentration (Cmax) of Atezolizumab (MEAN) micrograms per milliliter (μg/ mL) = 411; Percentage of Participants With at Least One Adverse Event (NUMBER) Percentage of participants = 95.1; Percentage of Participants With Anti-therapeutic Antibodies (ATAs) (NUMBER) Percentage of participants = 1.4,,,,,Duration of Response (DOR) in the TC3 or IC3-WT Populations (NUMBER) Months = 6.7 [5.5-17.3]; Duration of Response (DOR) in the TC2/3 or IC2/3-WT and TC1/2/3 or IC1/2/3-WT Populations (NUMBER) Months = 5.8 [5.1-9.8],,,,Overall Survival (OS) in the TC3 or IC3-WT Populations (MEDIAN) Months = 13.1 [7.4-16.5]; Overall Survival (OS) in the TC2/3 or IC2/3-WT and TC1/2/3 or IC1/2/3-WT Populations (MEDIAN) Months = 16.1 [12.6-18.0]; OS in Participants With PD-L1 Expression (MEDIAN) Months = 16.1 [9.8-17.4]; OS in Participants With Blood Tumor Mutational Burden (bTMB) (MEDIAN) Months = 10.3 [7.1-16.9],Progression-free Survival (PFS) in the TC3 or IC3-WT Populations (NUMBER) Months = 5.0 [4.2-5.7]; Progression-free Survival (PFS) in the TC2/3 or IC2/3-WT and TC1/2/3 or IC1/2/3-WT Populations (NUMBER) Months = 5.5 [4.5-5.7]; Investigator-Assessed PFS in Participants With PD-L1 Expression According to RECIST v1.1 (MEDIAN) Months = 4.9 [4.0-5.6]; Investigator-Assessed PFS in Participants With bTMB According to RECIST v1.1 (MEDIAN) Months = 4.3 [3.1-5.4],,,,,,
NCT02409368,"An Open-Label, Multicenter Clinical Trial With Nivolumab (BMS-936558) Monotherapy in Subjects With Advanced or Metastatic Squamous Cell (Sq) Non-Small","An Open-Label, Multicenter Clinical Trial With Nivolumab (BMS-936558) Monotherapy in Subjects With Advanced or Metastatic Squamous Cell (Sq) Non-Small Cell Lung Cancer (NSCLC) Who Have Received at Lea",Bristol-Myers Squibb,Bristol-Myers Squibb,INDUSTRY,COMPLETED,2015-04-29,2018-03-07,2021-08-27,INTERVENTIONAL,PHASE2,,,,Non-Small Cell Lung Cancer,Non-Small Cell Lung Cancer,1,1,1,DRUG,,,1,5,True,Yes,"Number of Participants With High Grade (Grade 3, 4 and 5) Treatment Related Select Adverse Events (COUNT_OF_PARTICIPANTS) Participants = 1",Number of Participants With High Grade Select Adverse Events (COUNT_OF_PARTICIPANTS) Participants = 2; Median Time to Onset of Any Grade Select Adverse Events (MEDIAN) Weeks = 12.79 [4.0-121.6]; ; Overall Survival (MEDIAN) Months = 12.1 [9.9-13.4]; Objective Response Rate (ORR) (NUMBER) Percentage = 8.0 [4.2-13.6],,,,,,,,Objective Response Rate (ORR) (NUMBER) Percentage = 8.0 [4.2-13.6],Overall Survival (MEDIAN) Months = 12.1 [9.9-13.4],,,,Objective Response Rate (ORR) (NUMBER) Percentage = 8.0 [4.2-13.6],"Number of Participants With High Grade (Grade 3, 4 and 5) Treatment Related Select Adverse Events (COUNT_OF_PARTICIPANTS) Participants = 1; Number of Participants With High Grade Select Adverse Events (COUNT_OF_PARTICIPANTS) Participants = 2; Median Time to Onset of Any Grade Select Adverse Events (MEDIAN) Weeks = 12.79 [4.0-121.6]",,
NCT02411448,A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RE,"A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination With Ramucirumab or Placebo in Previously Untreated Patients With EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer",Eli Lilly and Company,Eli Lilly and Company,INDUSTRY,ACTIVE_NOT_RECRUITING,2015-05-06,2019-01-23,2025-12,INTERVENTIONAL,PHASE3,,,,Metastatic Non-Small Cell Lung Cancer,Metastatic Non-Small Cell Lung Cancer,1,3,5,DRUG,,,2,10,True,Yes,Part B: Progression Free Survival (PFS) (MEDIAN) Months = 19.4 [15.4-21.6]; Number of Participants With Treatment-Emergent Adverse Events (COUNT_OF_PARTICIPANTS) Participants = 14,"; Part B: Percentage of Participants With Complete Response (CR) or Partial Response (PR) (Objective Response Rate [ORR]) (NUMBER) percentage of participants = 76.3 [70.8-81.9]; Part B: Percentage of Participants With CR, PR, or Stable Disease (SD) (Disease Control Rate [DCR]) (NUMBER) percentage of participants = 95.1 [92.3-97.9]; Part B: Duration of Response (DoR) (MEDIAN) months = 18.0 [13.9-19.8]; Part B: Pharmacokinetics (PK): Minimum Concentration (Cmin) of Ramucirumab (GEOMETRIC_MEAN) microgram per milliliter (µg/mL) = 39.6; Part B: Number of Participants With Anti-Ramucirumab Antibodies (COUNT_OF_PARTICIPANTS) Participants = 14; Part B: Best Change From Baseline on the Lung Cancer Symptom Scale (LCSS) (LEAST_SQUARES_MEAN) millimeter = -17.07; Part B: Change From Baseline on the EuroQol 5-Dimension, 5-Level Questionnaire (EQ-5D-5L) Index Score (MEAN) score on a scale = 0.02; Part B: Change From Baseline on the EuroQol 5-Dimension, 5-Level Questionnaire (EQ-5D-5L) Index Score (MEAN) score on a scale = 0.02; Part B: Change From Baseline on the EuroQol 5-Dimension, 5-Level Questionnaire (EQ-5D-5L) Index Score (MEAN) score on a scale = 0.01",,Part B: Percentage of Participants With Complete Response (CR) or Partial Response (PR) (Objective Response Rate [ORR]) (NUMBER) percentage of participants = 76.3 [70.8-81.9],,,Part B: Duration of Response (DoR) (MEDIAN) months = 18.0 [13.9-19.8],,,Part B: Percentage of Participants With Complete Response (CR) or Partial Response (PR) (Objective Response Rate [ORR]) (NUMBER) percentage of participants = 76.3 [70.8-81.9],,Part B: Progression Free Survival (PFS) (MEDIAN) Months = 19.4 [15.4-21.6],Part B: Percentage of Participants With Complete Response (CR) or Partial Response (PR) (Objective Response Rate [ORR]) (NUMBER) percentage of participants = 76.3 [70.8-81.9],"Part B: Change From Baseline on the EuroQol 5-Dimension, 5-Level Questionnaire (EQ-5D-5L) Index Score (MEAN) score on a scale = 0.02; Part B: Change From Baseline on the EuroQol 5-Dimension, 5-Level Questionnaire (EQ-5D-5L) Index Score (MEAN) score on a scale = 0.02; Part B: Change From Baseline on the EuroQol 5-Dimension, 5-Level Questionnaire (EQ-5D-5L) Index Score (MEAN) score on a scale = 0.01",Part B: Percentage of Participants With Complete Response (CR) or Partial Response (PR) (Objective Response Rate [ORR]) (NUMBER) percentage of participants = 76.3 [70.8-81.9],Number of Participants With Treatment-Emergent Adverse Events (COUNT_OF_PARTICIPANTS) Participants = 14,,
NCT02423343,"A Study of Galunisertib (LY2157299) in Combination With Nivolumab in Advanced Refractory Solid Tumors and in Recurrent or Refractory NSCLC, or Hepatoc","A Phase 1b/2 Dose Escalation and Cohort Expansion Study of the Safety, Tolerability and Efficacy of a Novel Transforming Growth Factor-beta Receptor I Kinase Inhibitor (Galunisertib) Administered in C",Eli Lilly and Company,Eli Lilly and Company,INDUSTRY,COMPLETED,2015-01-01,2018-12-13,2020-07-08,INTERVENTIONAL,PHASE1; PHASE2,,,,Solid Tumor,Solid Tumor; Non-Small Cell Lung Cancer Recurrent; Hepatocellular Carcinoma Recurrent,3,6,2,DRUG,,,1,8,True,Yes,Phase 1b: Maximum Tolerated Dose (MTD) of Galunisertib in Combination With Nivolumab (NUMBER) milligrams (mg) = 300,Pharmacokinetics (PK): Minimum Concentration (Cmin) of Nivolumab (MEAN) micrograms per milliliter (µg/mL) = 33.5 [19.9-53.6]; PK: Area Under the Plasma Concentration -Time Curve of Galunisertib From Time Zero to 24 Hours (AUC [0-24h]) at Steady State (GEOMETRIC_MEAN) micrograms*hour per liter (μg*h/L) = 3060; Number of Participants With Anti-Nivolumab Antibodies When Administered in Combination With Galunisertib (COUNT_OF_PARTICIPANTS) Participants = 0; Phase 2: Progression Free Survival (PFS) (MEDIAN) months = 5.26 [1.77-9.20]; Phase 2: Percentage of Participants Who Achieve Best Overall Tumor Response of Complete Response or Partial Response: Objective Response Rate (ORR) (NUMBER) Percentage of Participants = 24.0; Phase 2: Duration of Response (DoR) (MEDIAN) months = 9.03 [1.97-35]; Phase 2: Time to Response (MEDIAN) months = 4.2 [0.5-35]; Phase 2: Overall Survival (OS) (MEDIAN) months = 11.99 [8.15-16.23],,Phase 2: Percentage of Participants Who Achieve Best Overall Tumor Response of Complete Response or Partial Response: Objective Response Rate (ORR) (NUMBER) Percentage of Participants = 24.0,,,Phase 2: Duration of Response (DoR) (MEDIAN) months = 9.03 [1.97-35],,,Phase 2: Percentage of Participants Who Achieve Best Overall Tumor Response of Complete Response or Partial Response: Objective Response Rate (ORR) (NUMBER) Percentage of Participants = 24.0,Phase 2: Overall Survival (OS) (MEDIAN) months = 11.99 [8.15-16.23],Phase 2: Progression Free Survival (PFS) (MEDIAN) months = 5.26 [1.77-9.20],Phase 2: Percentage of Participants Who Achieve Best Overall Tumor Response of Complete Response or Partial Response: Objective Response Rate (ORR) (NUMBER) Percentage of Participants = 24.0,,Phase 2: Percentage of Participants Who Achieve Best Overall Tumor Response of Complete Response or Partial Response: Objective Response Rate (ORR) (NUMBER) Percentage of Participants = 24.0,,,
NCT02424617,A Study of BGB324 (Bemcentinib) in Combination With Erlotinib in Patients With Non-Small Cell Lung Cancer,A Multi-Center Open-Label Phase 1/2 Study of BGB324 in Combination With Erlotinib in Patients With Stage IIIb or Stage IV Non-Small Cell Lung Cancer,BerGenBio ASA,BerGenBio ASA,INDUSTRY,COMPLETED,2015-04-19,2021-08-25,2021-08-25,INTERVENTIONAL,PHASE1; PHASE2,,,,Non-Small Cell Lung Cancer,Non-Small Cell Lung Cancer,1,4,4,DRUG,,,5,8,True,Yes,"Number of Participants With Treatment-emergent Adverse Events (TEAE) (COUNT_OF_PARTICIPANTS) Participants = 8; Number of Participants With Clinically Significant Laboratory Abnormalities (COUNT_OF_PARTICIPANTS) Participants = 1; Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status at End of Study (COUNT_OF_PARTICIPANTS) Participants = 1; Number of Participants With Clinically Significant Change From Baseline in Physical Examination, Vital Signs, and 12- Lead Triplicate Electrocardiogram (ECG) Parameters up to End of Study (COUNT_OF_PARTICIPANTS) Participants = 0; Number of Participants With Clinically Significant Abnormalities in Echocardiogram and Multi-gated Acquisition (MUGA) Scan (COUNT_OF_PARTICIPANTS) Participants = 0",Area Under the Curve (AUC) Over 24 Hours at Steady State of Bemcentinib (MEAN) nanogram*hours per milliliter = 6590; Maximum Observed Plasma Concentration (Cmax) of Bemcentinib (MEAN) nanogram per milliliter = 282; Time to Reach Maximum Plasma Concentration (Tmax) of Bemcentinib (MEDIAN) hours = 6.5 [6-8]; AUC Over 24 Hours at Steady State of Erlotinib (MEAN) nanogram*hours per milliliter = 40432.333; Cmax of Erlotinib (MEAN) nanogram per milliliter = 1840.286; ; Dose Limiting Toxicity (DLT) Assessment (COUNT_OF_PARTICIPANTS) Participants = 2; Time To Progression (TTP) (MEDIAN) Months = 8.2 [2.8-30.7],,,,,,,,,,,,,,Number of Participants With Treatment-emergent Adverse Events (TEAE) (COUNT_OF_PARTICIPANTS) Participants = 8; Dose Limiting Toxicity (DLT) Assessment (COUNT_OF_PARTICIPANTS) Participants = 2,,Time To Progression (TTP) (MEDIAN) Months = 8.2 [2.8-30.7]
NCT02426658,Pemetrexed Disodium in Treating Patients With Stage IV Non-small Cell Lung Cancer and ECOG Performance Status 3,A Pilot Study Evaluating Pemetrexed in ECOG Performance Status 3 Patients With Stage IV Non-squamous Non-small Cell Lung Cancer,Wake Forest University Health Sciences,Wake Forest University Health Sciences,OTHER,COMPLETED,2015-05,2018-04-19,2022-10-07,INTERVENTIONAL,PHASE2,,,,Stage IV Non-Small Cell Lung Cancer,Stage IV Non-Small Cell Lung Cancer,1,1,3,DRUG; OTHER,,,2,3,True,Yes,"Change in Quality of Life (QOL), Assessed by the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core-30 (QLQ-C30) and QLQ-Lung Cancer 13-item (LC13) (MEAN) score on a scale = 51.2821; Time to Tumor Progression (MEDIAN) months = 2.0 [1.0-10.7]","Incidence of Hematologic Toxicity, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0 (COUNT_OF_PARTICIPANTS) Participants = 13; Overall Survival (MEDIAN) months = 2.4 [1.0-10.7]; Response Rate (COUNT_OF_PARTICIPANTS) Participants = 1",,,,,,,,,Overall Survival (MEDIAN) months = 2.4 [1.0-10.7],,,"Change in Quality of Life (QOL), Assessed by the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core-30 (QLQ-C30) and QLQ-Lung Cancer 13-item (LC13) (MEAN) score on a scale = 51.2821",Response Rate (COUNT_OF_PARTICIPANTS) Participants = 1,"Incidence of Hematologic Toxicity, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0 (COUNT_OF_PARTICIPANTS) Participants = 13",,
NCT02434081,NIvolumab COmbination With Standard First-line Chemotherapy and Radiotherapy in Locally Advanced Stage IIIA/B Non-Small Cell Lung Carcinoma,A Phase II Trial Evaluating the Safety and Efficacy of the Addition of Concurrent Anti-PD 1 Nivolumab to Standard First-line Chemotherapy and Radiotherapy in Locally Advanced Stage IIIA/B Non-Small Ce,ETOP IBCSG Partners Foundation,ETOP IBCSG Partners Foundation,NETWORK,COMPLETED,2015-11-25,2020-02-29,2020-03-31,INTERVENTIONAL,PHASE2,,,,Non-small Cell Lung Cancer Stage III,Non-small Cell Lung Cancer Stage III,1,1,1,DRUG,,,1,5,True,Yes,Grade ≥3 Pneumonitis (CTCAE v4.0) up to 6 Months Post-radiotherapy (COUNT_OF_PARTICIPANTS) Participants = 71,Progression-free Survival by RECIST v1.1 (PFS) (MEDIAN) months = 12.7 [10.1-22.8]; (Grade ≥3) Pneumonitis-free Rate (NUMBER) percentage of participants = 87.0 [76.4-93.0]; Objective Response Rate (ORR) (NUMBER) percentage of patients with OR = 73.4 [62.3-82.7]; Time to Treatment Failure (TTF). (MEDIAN) months = 9.2 [6.4-12.4]; Overall Survival (OS) (MEDIAN) months = 38.8,,,,,,,,Objective Response Rate (ORR) (NUMBER) percentage of patients with OR = 73.4 [62.3-82.7],Overall Survival (OS) (MEDIAN) months = 38.8,Progression-free Survival by RECIST v1.1 (PFS) (MEDIAN) months = 12.7 [10.1-22.8],,,Objective Response Rate (ORR) (NUMBER) percentage of patients with OR = 73.4 [62.3-82.7],,Time to Treatment Failure (TTF). (MEDIAN) months = 9.2 [6.4-12.4],
NCT02437136,"Ph1b/2 Dose-Escalation Study of Entinostat With Pembrolizumab in Non-small Cell Lung Cancer (NSCLC) With Expansion Cohorts in NSCLC, Melanoma, and Col","A Phase 1b/2, Open-label, Dose Escalation Study of Entinostat in Combination With Pembrolizumab in Patients With Non-small Cell Lung Cancer, With Expansion Cohorts in Patients With Non-small Cell Lung",Syndax Pharmaceuticals,Syndax Pharmaceuticals,INDUSTRY,COMPLETED,2015-08-26,2022-09-29,2022-09-29,INTERVENTIONAL,PHASE1; PHASE2,,,,Non-Small Cell Lung Cancer,Non-Small Cell Lung Cancer; Melanoma; Mismatch Repair-Proficient Colorectal Cancer,3,7,2,DRUG,,,1,14,True,Yes,"Phase 2: Objective Response Rate (ORR), as Assessed Using Immune Response RECIST (irRECIST) (NUMBER) percentage of participants = 22.2 [6.4-47.6]","Phase 2: Clinical Benefit Rate (CBR), as Assessed Using irRECIST (NUMBER) percentage of participants = 33.3 [13.3-59.0]; Phase 2: CBR, as Assessed Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) (NUMBER) percentage of participants = 22.2 [6.4-47.6]; Phase 2: Progression Free Survival (PFS), as Assessed Using irRECIST (COUNT_OF_PARTICIPANTS) Participants = 3; Phase 2: PFS, as Assessed Using RECIST 1.1 (COUNT_OF_PARTICIPANTS) Participants = 3; Phase 2: PFS Duration, as Determined by the Local Investigator Using irRECIST (MEDIAN) months = 2.76 [1.18-4.07]; Phase 2: PFS Duration, as Determined by the Local Investigator Using RECIST 1.1 (MEDIAN) months = 2.76 [1.18-4.07]; Phase 2: Overall Survival (MEDIAN) months = 25.20; Phase 2: Duration of Response, as Assessed Using irRECIST (MEDIAN) months = 15.61; ; Phase 2: Time to Response, as Assessed Using irRECIST (MEDIAN) months = 4.30 [2.69-9.63]; Phase 2: Time to Response, as Assessed Using RECIST 1.1 (MEDIAN) months = 4.29 [2.69-5.88]; Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), AEs Resulting in the Permanent Discontinuation of Study Drug, and Death (COUNT_OF_PARTICIPANTS) Participants = 6; Phase 1b: Number of Participants With at Least One Dose Limiting Toxicities (DLTs) (COUNT_OF_PARTICIPANTS) Participants = 0; Phase 1b: Recommended Phase 2 Dose (RP2D) (NUMBER) mg = 5","Phase 2: Clinical Benefit Rate (CBR), as Assessed Using irRECIST (NUMBER) percentage of participants = 33.3 [13.3-59.0]",,,,"Phase 2: Duration of Response, as Assessed Using irRECIST (MEDIAN) months = 15.61",,,"Phase 2: Objective Response Rate (ORR), as Assessed Using Immune Response RECIST (irRECIST) (NUMBER) percentage of participants = 22.2 [6.4-47.6]",Phase 2: Overall Survival (MEDIAN) months = 25.20,"Phase 2: Progression Free Survival (PFS), as Assessed Using irRECIST (COUNT_OF_PARTICIPANTS) Participants = 3; Phase 2: PFS Duration, as Determined by the Local Investigator Using irRECIST (MEDIAN) months = 2.76 [1.18-4.07]; Phase 2: PFS Duration, as Determined by the Local Investigator Using RECIST 1.1 (MEDIAN) months = 2.76 [1.18-4.07]",,,"Phase 2: Objective Response Rate (ORR), as Assessed Using Immune Response RECIST (irRECIST) (NUMBER) percentage of participants = 22.2 [6.4-47.6]","Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), AEs Resulting in the Permanent Discontinuation of Study Drug, and Death (COUNT_OF_PARTICIPANTS) Participants = 6",,
NCT02438722,"S1403, Afatinib Dimaleate With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage IV or Recurrent, EGFR Mutation Positive Non-small ","A Randomized Phase II/III Trial of Afatinib Plus Cetuximab Versus Afatinib Alone in Treatment-Naive Patients With Advanced, EGFR Mutation Positive Non-small Cell Lung Cancer (NSCLC)",SWOG Cancer Research Network,SWOG Cancer Research Network,NETWORK,ACTIVE_NOT_RECRUITING,2015-05-07,2018-09-25,2025-11-15,INTERVENTIONAL,PHASE2; PHASE3,,,,Recurrent Non-Small Cell Lung Carcinoma,Recurrent Non-Small Cell Lung Carcinoma; Stage IV Non-Small Cell Lung Cancer,2,2,3,BIOLOGICAL; DRUG; OTHER,,,2,4,True,Yes,2-year Overall Survival Rate (NUMBER) percentage of participants = 67 [55-76]; Progression-Free Survival (MEDIAN) months = 11.9 [9.9-17.8],Response Rates (NUMBER) percentage of participants = 67 [55-77]; Time to Treatment Discontinuation (MEDIAN) months = 12.7 [10.8-17.6]; Time to Treatment Failure (MEDIAN) months = 10.8 [7.7-12.9]; Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs (NUMBER) Participants = 1,,,,,,,,,2-year Overall Survival Rate (NUMBER) percentage of participants = 67 [55-76],Progression-Free Survival (MEDIAN) months = 11.9 [9.9-17.8],,,Response Rates (NUMBER) percentage of participants = 67 [55-77],Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs (NUMBER) Participants = 1,Time to Treatment Failure (MEDIAN) months = 10.8 [7.7-12.9],
NCT02439450,A Study of Combination Therapies With Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer,"A Phase 1b/2 Study of Viagenpumatucel-L (HS-110) in Combination With Multiple Treatment Regimens in Patients With Non-Small Cell Lung Cancer (The ""DURGA"" Trial)",Heat Biologics,Heat Biologics,INDUSTRY,COMPLETED,2015-04-15,2021-05-03,2022-11-04,INTERVENTIONAL,PHASE1; PHASE2,,,,Non-small Cell Lung Cancer,Non-small Cell Lung Cancer,1,4,4,BIOLOGICAL; DRUG,,,1,0,True,Yes,Phase 1b: Frequency of Treatment Emergent Adverse Events (TEAEs) as Assessed by CTCAE v4.03. (COUNT_OF_PARTICIPANTS) Participants = 47,,,,,,,,,,,,,,,Phase 1b: Frequency of Treatment Emergent Adverse Events (TEAEs) as Assessed by CTCAE v4.03. (COUNT_OF_PARTICIPANTS) Participants = 47,,
NCT02442349,Phase II Single Arm Study of AZD9291 to Treat NSCLC Patients in Asia Pacific,"A Phase II, Open Label, Single-arm Study to Assess the Safety and Efficacy of AZD9291 in Asia Pacific Patients With Locally Advanced/Metastatic Non-Small Cell Lung Cancer Whose Disease Has Progressed ",AstraZeneca,AstraZeneca,INDUSTRY,ACTIVE_NOT_RECRUITING,2015-06-22,2016-03-04,2025-12-31,INTERVENTIONAL,PHASE2,,,,Non-Small Cell Lung Cancer,Non-Small Cell Lung Cancer,1,1,1,DRUG,,,1,5,True,Yes,ORR According to RECIST 1.1 by Independent Review (NUMBER) % of participants = 62.0 [54.2-69.5],DoR According to RECIST 1.1 by Independent Review (MEDIAN) Months = 9.9 [8.3-12.9]; DCR According to RECIST 1.1 by Independent Review (NUMBER) % of participants = 88.0 [82.0-92.5]; Tumour Shrinkage According to RECIST 1.1 by Independent Review (MEAN) % change from baseline in target lesion = -46.1; PFS According to RECIST 1.1 by Independent Review (MEDIAN) Months = 9.7 [7.0-11.1]; Overall Survival (OS) (MEDIAN) Months = 23.2 [20.0-26.7],,,,,DoR According to RECIST 1.1 by Independent Review (MEDIAN) Months = 9.9 [8.3-12.9],,,ORR According to RECIST 1.1 by Independent Review (NUMBER) % of participants = 62.0 [54.2-69.5],Overall Survival (OS) (MEDIAN) Months = 23.2 [20.0-26.7],PFS According to RECIST 1.1 by Independent Review (MEDIAN) Months = 9.7 [7.0-11.1],,,,,,
NCT02450539,A Study of Abemaciclib (LY2835219) in Participants With Stage IV Squamous Non-small Cell Lung Cancer,A Randomized Phase 2 Study of Abemaciclib (LY2835219) Versus Docetaxel in Patients With Stage IV Squamous Non-Small Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy,Eli Lilly and Company,Eli Lilly and Company,INDUSTRY,COMPLETED,2015-08-06,2017-03-31,2020-07-29,INTERVENTIONAL,PHASE2,,,,Non-Small Cell Lung Cancer Stage IV,Non-Small Cell Lung Cancer Stage IV,1,2,2,DRUG,,,1,9,True,Yes,Progression Free Survival (PFS) (MEDIAN) months = 2.53 [1.68-2.89],Pharmacokinetics (PK): Clearance of Abemaciclib (GEOMETRIC_MEAN) Liters/hour (L/h) = 21.3; PK: Volume of Distribution of Abemaciclib (GEOMETRIC_MEAN) Liters (L) = 769; Overall Survival (OS) (MEDIAN) Months = 7 [5.00-8.78]; Percentage of Participants With Complete Response (CR) or Partial Response (PR) (Overall Response Rate [ORR]) (NUMBER) percentage participants = 2.8; Percentage of Participants Who Exhibit Stable Disease (SD) or Confirmed Response (CR) or Partial Response (PR): Disease Control Rate (DCR) (NUMBER) percentage participants = 50.9; ; Change From Baseline in MD Anderson Symptom Inventory-Lung Cancer (MDASI-LC) Scores (LEAST_SQUARES_MEAN) units on a scale = 0.19; Change From Baseline in EuroQol 5-Dimensional 5-Level (EQ-5D-5L) Questionnaire EQ VAS Overall Self-rated Health Score (LEAST_SQUARES_MEAN) units on a scale = -5.49; Change From Baseline in EuroQol 5-Dimensional 5-Level (EQ-5D-5L) Questionnaire Index Value (LEAST_SQUARES_MEAN) units on a scale = -0.05,,Percentage of Participants With Complete Response (CR) or Partial Response (PR) (Overall Response Rate [ORR]) (NUMBER) percentage participants = 2.8,,,,,,,Overall Survival (OS) (MEDIAN) Months = 7 [5.00-8.78],Progression Free Survival (PFS) (MEDIAN) months = 2.53 [1.68-2.89],Percentage of Participants With Complete Response (CR) or Partial Response (PR) (Overall Response Rate [ORR]) (NUMBER) percentage participants = 2.8; Percentage of Participants Who Exhibit Stable Disease (SD) or Confirmed Response (CR) or Partial Response (PR): Disease Control Rate (DCR) (NUMBER) percentage participants = 50.9,Change From Baseline in EuroQol 5-Dimensional 5-Level (EQ-5D-5L) Questionnaire EQ VAS Overall Self-rated Health Score (LEAST_SQUARES_MEAN) units on a scale = -5.49; Change From Baseline in EuroQol 5-Dimensional 5-Level (EQ-5D-5L) Questionnaire Index Value (LEAST_SQUARES_MEAN) units on a scale = -0.05,Percentage of Participants With Complete Response (CR) or Partial Response (PR) (Overall Response Rate [ORR]) (NUMBER) percentage participants = 2.8,,,
NCT02450903,LDK378 in Patients With ALK Positive NSCLC Previously Treated With Alectinib.,"A Phase II, Multi-center, Open-label, Single-Arm Study to Evaluate the Efficacy and Safety of Oral LDK378 Treatment for Patients With ALK-Positive Non-Small Cell Lung Cancer Previously Treated With Al",Novartis,Novartis Pharmaceuticals,INDUSTRY,COMPLETED,2015-08-21,2017-07-31,2018-05-24,INTERVENTIONAL,PHASE2,,,,Non-Small-Cell Lung Cancer,Non-Small-Cell Lung Cancer,1,1,1,DRUG,,,1,6,True,Yes,Overall Response Rate (ORR) to LDK378 by Investigator Assessment (NUMBER) Percentage of participants = 25.0 [8.7-49.1],Disease Control Rate (DCR) (NUMBER) Percentage of participants = 70.0 [45.7-88.1]; Time to Tumor Response (TTR) (MEAN) Months = 1.8; Duration of Response (DOR) (MEDIAN) Months = 6.3 [3.5-9.2]; Progression Free Survival (PFS) (MEDIAN) Months = 3.7 [1.9-5.3]; Overall Survival (OS) (NUMBER) Months = 17.3; Overall Intracranial Response Rate (OIRR) (NUMBER) Percentage of participants = 0.0 [0.0-84.2],,,,,Duration of Response (DOR) (MEDIAN) Months = 6.3 [3.5-9.2],,,,Overall Survival (OS) (NUMBER) Months = 17.3,Progression Free Survival (PFS) (MEDIAN) Months = 3.7 [1.9-5.3],,,Overall Response Rate (ORR) to LDK378 by Investigator Assessment (NUMBER) Percentage of participants = 25.0 [8.7-49.1]; Overall Intracranial Response Rate (OIRR) (NUMBER) Percentage of participants = 0.0 [0.0-84.2],,,
NCT02453282,Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC),"A Phase III Randomized, Open-Label, Multi-Center, Global Study of MEDI4736 in Combination With Tremelimumab Therapy or MEDI4736 Monotherapy Versus Standard of Care Platinum-Based Chemotherapy in First",AstraZeneca,AstraZeneca,INDUSTRY,ACTIVE_NOT_RECRUITING,2015-07-21,2018-10-04,2025-12-31,INTERVENTIONAL,PHASE3,,,,Non-Small-Cell Lung Carcinoma NSCLC,Non-Small-Cell Lung Carcinoma NSCLC,1,3,8,BIOLOGICAL; DRUG,,,2,27,True,Yes,"Overall Survival (OS); PD-L1 (TC >=25%) Analysis Set Population, Durvalumab Monotherapy Vs SoC Chemotherapy and Durvalumab + Tremelimumab Vs SoC Chemotherapy (MEDIAN) months = 16.3 [12.2-20.8]; Progression-Free Survival (PFS); PD-L1 (TC >=25%) Analysis Set Population, Durvalumab + Tremelimumab Vs SoC Chemotherapy (MEDIAN) months = 3.9 [2.8-5.0]","OS; PD-L1 (TC >=25%) Analysis Set Population, Durvalumab + Tremelimumab Vs Durvalumab Monotherapy (MEDIAN) months = 16.3 [12.2-20.8]; OS; PD-L1 (TC >=1%) Analysis Set Population (MEDIAN) months = 14.6 [10.5-17.7]; OS; FAS Population (MEDIAN) months = 12.3 [10.1-14.9]; PFS; PD-L1 (TC >=25%) Analysis Set Population, Durvalumab Monotherapy Vs SoC Chemotherapy and Durvalumab + Tremelimumab Vs Durvalumab Monotherapy (MEDIAN) months = 4.7 [3.1-6.3]; PFS; PD-L1 (TC >=1%) Analysis Set Population (MEDIAN) months = 3.6 [2.8-4.2]; PFS; FAS Population (MEDIAN) months = 2.8 [2.6-3.1]; Objective Response Rate (ORR); PD-L1 (TC >=25%) Analysis Set Population (NUMBER) percentage of participants = 35.6; ORR; PD-L1 (TC >=1%) Analysis Set Population (NUMBER) percentage of participants = 26.5; ORR; FAS Population (NUMBER) percentage of participants = 22.2; ; ; ; Percentage of Participants Alive and Progression Free at 12 Months (APF12); PD-L1 (TC >=25%) Analysis Set Population (NUMBER) percentage of participants = 32.3 [24.8-39.9]; Percentage of Participants APF12; PD-L1 (TC >=1%) Analysis Set Population (NUMBER) percentage of participants = 27.0 [21.6-32.6]; Percentage of Participants APF12; FAS Population (NUMBER) percentage of participants = 22.5 [18.1-27.1]; Time From Randomization to Second Progression (PFS2); PD-L1 (TC >=25%) Analysis Set Population (MEDIAN) months = 12.7 [9.4-16.1]; PFS2; PD-L1 (TC >=1%) Analysis Set Population (MEDIAN) months = 10.6 [8.0-12.7]; PFS2; FAS Population (MEDIAN) months = 9.3 [7.9-10.6]; Change From Baseline in Disease-Related Symptoms as Assessed by European Organisation for Research and Treatment of Cancer Quality of Life Questionnaires (EORTC QLQ) at 12 Months (MEAN) units on a scale = 1.2; ; ; Maximum Serum Concentration at Steady State (Cmax_ss) of Durvalumab (MEAN) mcg/mL = 625.3; Cmax_ss of Tremelimumab (MEAN) mcg/mL = 24.8; Trough Serum Concentration at Steady State (Ctrough_ss) of Durvalumab (MEAN) mcg/mL = 139.5; Ctrough_ss of Tremelimumab (MEAN) mcg/mL = 4.9; Number of Participants With Anti-Drug Antibody (ADA) Response to Durvalumab (COUNT_OF_PARTICIPANTS) Participants = 17; Number of Participants With ADA Response to Tremelimumab (COUNT_OF_PARTICIPANTS) Participants = 33",,,,,,,,Objective Response Rate (ORR); PD-L1 (TC >=25%) Analysis Set Population (NUMBER) percentage of participants = 35.6,"Overall Survival (OS); PD-L1 (TC >=25%) Analysis Set Population, Durvalumab Monotherapy Vs SoC Chemotherapy and Durvalumab + Tremelimumab Vs SoC Chemotherapy (MEDIAN) months = 16.3 [12.2-20.8]","Progression-Free Survival (PFS); PD-L1 (TC >=25%) Analysis Set Population, Durvalumab + Tremelimumab Vs SoC Chemotherapy (MEDIAN) months = 3.9 [2.8-5.0]",,Change From Baseline in Disease-Related Symptoms as Assessed by European Organisation for Research and Treatment of Cancer Quality of Life Questionnaires (EORTC QLQ) at 12 Months (MEAN) units on a scale = 1.2,Objective Response Rate (ORR); PD-L1 (TC >=25%) Analysis Set Population (NUMBER) percentage of participants = 35.6,,,
NCT02477826,"An Investigational Immuno-therapy Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum-doublet Chemotherapy, Compared to Plati","An Open-Label, Randomized Phase 3 Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum Doublet Chemotherapy Versus Platinum Doublet Chemotherapy in Subjects With Chemotherapy-N",Bristol-Myers Squibb,Bristol-Myers Squibb,INDUSTRY,COMPLETED,2015-08-05,2024-10-25,2024-10-25,INTERVENTIONAL,PHASE3,,,,Non-Small Cell Lung Cancer,Non-Small Cell Lung Cancer,1,4,7,DRUG,,,2,2,True,Yes,Progression-Free Survival Per BICR (MEDIAN) months = 5.06 [4.07-6.31]; Overall Survival (MEDIAN) months = 17.12 [14.95-20.17],Objective Response Rate (ORR) Per BICR (NUMBER) percentage of participants = 36.4 [31.6-41.3]; Percentage of Participants With Symptom Deterioration at Week 12 Assessed Via Lung Cancer Symptom Scale (NUMBER) percentage of participants = 31.3 [26.8-36.1],,,,,,,,Objective Response Rate (ORR) Per BICR (NUMBER) percentage of participants = 36.4 [31.6-41.3],Overall Survival (MEDIAN) months = 17.12 [14.95-20.17],Progression-Free Survival Per BICR (MEDIAN) months = 5.06 [4.07-6.31],,,Objective Response Rate (ORR) Per BICR (NUMBER) percentage of participants = 36.4 [31.6-41.3],,,
NCT02486718,Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [,"A Phase III, Open-Label, Randomized Study to Investigate the Efficacy and Safety of Atezolizumab (Anti-PD-L1 Antibody) Compared With Best Supportive Care Following Adjuvant Cisplatin-Based Chemotherap",Hoffmann-La Roche,Hoffmann-La Roche,INDUSTRY,ACTIVE_NOT_RECRUITING,2015-10-31,2024-01-26,2035-08-30,INTERVENTIONAL,PHASE3,,,,Non-Small Cell Lung Cancer,Non-Small Cell Lung Cancer,1,2,6,DRUG,,,3,12,True,Yes,Disease-Free Survival (DFS) in Intent-to-treat (ITT) Population (MEDIAN) months = 65.6; DFS in All Randomized Stage II-IIIA Population (MEDIAN) months = 57.4; DFS in the Programmed Death-ligand 1 (PD-L1) SP263 ≥ 1% Tumor Cell (TC) Subpopulation Within the Stage II-IIIA Population (MEDIAN) months = 68.5,; Disease-free Rate at Year 3 in ITT Population (NUMBER) percentage of participants = 61.43 [57.09-65.77]; Disease-free Rate at Year 3 in All Randomized Stage II-IIIA Population (NUMBER) percentage of participants = 59.30 [54.61-63.98]; Disease-free Rate at Year 3 in PD-L1 (SP263 ≥ 1% TC) Subpopulation Within the Stage II-IIIA Population (NUMBER) percentage of participants = 62.72 [56.54-68.90]; Disease-free Rate at Year 5 in ITT Population (NUMBER) percentage of participants = 51.96 [47.45-56.46]; Disease-free Rate at Year 5 in All Randomized Stage II-IIIA Population (NUMBER) percentage of participants = 49.28 [44.47-54.10]; Disease-free Rate at Year 5 in PD-L1 (SP263 ≥ 1% TC) Subpopulation Within the Stage II-IIIA Population (NUMBER) percentage of participants = 53.15 [46.69-59.61]; ; ; Percentage of Participants With Anti-Therapeutic Antibodies (ATAs) to Atezolizumab (NUMBER) percentage of participants = 31.2; Maximum Plasma Concentration (Cmax) of Atezolizumab (GEOMETRIC_MEAN) micrograms/millilitres (μg/ml) = 367; Minimum Serum Concentration (Cmin) at Steady-State Within a Dosing Interval of Atezolizumab (GEOMETRIC_MEAN) μg/ml = 367,,,Disease-Free Survival (DFS) in Intent-to-treat (ITT) Population (MEDIAN) months = 65.6; DFS in All Randomized Stage II-IIIA Population (MEDIAN) months = 57.4; DFS in the Programmed Death-ligand 1 (PD-L1) SP263 ≥ 1% Tumor Cell (TC) Subpopulation Within the Stage II-IIIA Population (MEDIAN) months = 68.5,,,,,,,,,,,,,
NCT02498613,A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors,A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors,National Cancer Institute (NCI),National Cancer Institute (NCI),NIH,ACTIVE_NOT_RECRUITING,2016-08-31,2022-06-22,2026-04-10,INTERVENTIONAL,PHASE2,,,,Advanced Malignant Solid Neoplasm,Advanced Malignant Solid Neoplasm; Metastatic Lung Non-Small Cell Carcinoma; Metastatic Lung Small Cell Carcinoma,26,1,5,DRUG; OTHER; PROCEDURE,,,1,2,True,Yes,Objective Response Rate (NUMBER) proportion of participants = 0.08 [0.01-0.15],Incidence of Adverse Events (NUMBER) Adverse Events = 60; Progression-free Survival (MEDIAN) months = 3.8 [0.1-13.3],,,,,,,,Objective Response Rate (NUMBER) proportion of participants = 0.08 [0.01-0.15],,Progression-free Survival (MEDIAN) months = 3.8 [0.1-13.3],,,Objective Response Rate (NUMBER) proportion of participants = 0.08 [0.01-0.15],Incidence of Adverse Events (NUMBER) Adverse Events = 60,,
NCT02504372,Study of Pembrolizumab (MK-3475) vs Placebo for Participants With Non-small Cell Lung Cancer After Resection With or Without Standard Adjuvant Therapy,"A Randomized, Phase 3 Trial With Anti-PD-1 Monoclonal Antibody Pembrolizumab (MK-3475) Versus Placebo for Patients With Early Stage NSCLC After Resection and Completion of Standard Adjuvant Therapy (P",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,INDUSTRY,ACTIVE_NOT_RECRUITING,2015-11-06,2023-01-24,2026-01-21,INTERVENTIONAL,PHASE3,,,,Non-small Cell Lung Cancer,Non-small Cell Lung Cancer,1,2,2,BIOLOGICAL; OTHER,,,2,7,True,Yes,Disease-Free Survival (DFS) (MEDIAN) Months = 53.8 [46.2-67.0]; DFS in Programmed Death Ligand-1 (PDL-1) Strong Positive Participants With Tumor Proportion Score (TPS) ≥50% (MEDIAN) Months = 67.0,DFS in PDL-1 Strong Positive Participants With TPS ≥1% (MEDIAN) Months = 58.7 [46.2-76.7]; ; ; ; ; Number of Participants Who Experienced an Adverse Event (AE) (COUNT_OF_PARTICIPANTS) Participants = 556; Number of Participants Who Discontinued Study Treatment Due to an AE (COUNT_OF_PARTICIPANTS) Participants = 116,,,Disease-Free Survival (DFS) (MEDIAN) Months = 53.8 [46.2-67.0]; DFS in Programmed Death Ligand-1 (PDL-1) Strong Positive Participants With Tumor Proportion Score (TPS) ≥50% (MEDIAN) Months = 67.0; DFS in PDL-1 Strong Positive Participants With TPS ≥1% (MEDIAN) Months = 58.7 [46.2-76.7],,,,,,,,,,,Number of Participants Who Discontinued Study Treatment Due to an AE (COUNT_OF_PARTICIPANTS) Participants = 116,,
NCT02511106,"AZD9291 Versus Placebo in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chem","A Phase III, Double-blind, Randomized, Placebo-controlled Multi-centre, Study to Assess the Efficacy and Safety of AZD9291 Versus Placebo, in Patients With Epidermal Growth Factor Receptor Mutation Po",AstraZeneca,AstraZeneca,INDUSTRY,ACTIVE_NOT_RECRUITING,2015-10-21,2022-04-11,2029-01-31,INTERVENTIONAL,PHASE3,,,,Stage IB-IIIA Non-small Cell Lung Carcinoma,Stage IB-IIIA Non-small Cell Lung Carcinoma,1,2,3,DRUG,,,1,7,True,Yes,Assess the Efficacy of AZD9291 Compared to Placebo as Measured by Disease Free Survival (DFS). (MEDIAN) Months = 65.8; Assess the Efficacy of AZD9291 Compared to Placebo as Measured by Disease Free Survival (DFS). (MEDIAN) Months = 65.8,"Disease Free Survival (DFS) Rate at 2, 3 and 5 Years (NUMBER) Percentage of participants = 90.0 [85.2-93.3]; Disease Free Survival (DFS) Rate at 2, 3 and 5 Years (NUMBER) Percentage of participants = 90.1 [86.2-92.9]; ; ; Overall Survival Rate at 2, 3 and 5 Years (NUMBER) Percentage of participants = 99.5 [96.8-99.9]; Overall Survival Rate at 2, 3 and 5 Years (NUMBER) Percentage of participants = 99.4 [97.5-99.8]; Patient Health-related Quality of Life and Symptoms (HRQoL) by SF-36v2 Health Survey. (MEAN) Unit on a scale = 1.026; Plasma Concentrations of AZD9291 (GEOMETRIC_MEAN) nM = 380.2563; Plasma Concentrations of AZ5104 Metabolites (GEOMETRIC_MEAN) nM = 44.4619; Plasma Concentrations of AZ7550 Metabolites (GEOMETRIC_MEAN) nM = 44.3492",,,"Assess the Efficacy of AZD9291 Compared to Placebo as Measured by Disease Free Survival (DFS). (MEDIAN) Months = 65.8; Assess the Efficacy of AZD9291 Compared to Placebo as Measured by Disease Free Survival (DFS). (MEDIAN) Months = 65.8; Disease Free Survival (DFS) Rate at 2, 3 and 5 Years (NUMBER) Percentage of participants = 90.0 [85.2-93.3]; Disease Free Survival (DFS) Rate at 2, 3 and 5 Years (NUMBER) Percentage of participants = 90.1 [86.2-92.9]",,,,,,"Overall Survival Rate at 2, 3 and 5 Years (NUMBER) Percentage of participants = 99.5 [96.8-99.9]; Overall Survival Rate at 2, 3 and 5 Years (NUMBER) Percentage of participants = 99.4 [97.5-99.8]",,,Patient Health-related Quality of Life and Symptoms (HRQoL) by SF-36v2 Health Survey. (MEAN) Unit on a scale = 1.026,,,,
NCT02535338,Erlotinib Hydrochloride and Onalespib Lactate in Treating Patients With Recurrent or Metastatic EGFR-Mutant Non-small Cell Lung Cancer,A Phase 1/2 Trial of Erlotinib and Onalespib Lactate in EGFR-Mutant Non-Small Cell Lung Cancer,National Cancer Institute (NCI),National Cancer Institute (NCI),NIH,COMPLETED,2016-04-11,2021-09-03,2021-09-08,INTERVENTIONAL,PHASE1; PHASE2,,,,Recurrent Lung Non-Small Cell Carcinoma,Recurrent Lung Non-Small Cell Carcinoma; Stage IV Lung Non-Small Cell Cancer AJCC v7,2,1,4,DRUG; OTHER,,,3,3,True,Yes,Number of Participants With at Least One Dose Limiting Toxicity (DLT) (NUMBER) participants = 2; Recommended Phase II Dose (NUMBER) mg/m2 = 120; Number of Participants With Dose Limiting Toxicities. (COUNT_OF_PARTICIPANTS) Participants = 2,Number of Subject With Overall Response (COUNT_OF_PARTICIPANTS) Participants = 0; ; Number of Subject With Overall Response (Recommended Phase II Dose) (COUNT_OF_PARTICIPANTS) Participants = 0,,,,,,,,,,,,,,Number of Participants With at Least One Dose Limiting Toxicity (DLT) (NUMBER) participants = 2,,
NCT02542293,Study of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE),"A Phase III Randomized, Open-Label, Multi-Center, Global Study of MEDI4736 in Combination With Tremelimumab Therapy Versus Standard of Care Platinum-Based Chemotherapy in First-Line Treatment of Patie",AstraZeneca,AstraZeneca,INDUSTRY,ACTIVE_NOT_RECRUITING,2015-11-03,2020-09-21,2025-12-31,INTERVENTIONAL,PHASE3,,,,Non Small Cell Lung Carcinoma NSCLC,Non Small Cell Lung Carcinoma NSCLC,1,2,6,BIOLOGICAL; DRUG,,,2,18,True,Yes,Overall Survival (OS); Global Cohort: Blood Tumor Mutational Burden (bTMB) ≥20 Mutations Per Megabase (Mut/Mb) Analysis Set (MEDIAN) months = 11.7 [8.6-15.2]; OS; China Cohort: China Programmed Cell Death Ligand 1 (PD-L1) Negative NSCLC Analysis Set (MEDIAN) months = 15.0 [10.5-27.4],"OS; Global Cohort: bTMB ≥16 Mut/Mb, bTMB ≥12 Mut/Mb, PD-L1-Negative NSCLC, bTMB <20 Mut/Mb, bTMB Non-Evaluable Population, tTMB ≥14 Mut/Mb, tTMB ≥12 Mut/Mb, tTMB ≥10 Mut/Mb, and tTMB ≥8 Mut/Mb Analysis Sets (MEDIAN) months = 12.1 [8.6-15.0]; OS; Global and China Cohorts: FAS, PD-L1 Tumor Cell (TC) ≥25%, and PD-L1 TC ≥50% Analysis Sets (MEDIAN) months = 10.9 [9.3-12.6]; Progression-Free Survival (PFS); Global Cohort: bTMB ≥20 Mut/Mb, bTMB ≥16 Mut/Mb, bTMB ≥12 Mut/Mb, tTMB ≥14 Mut/Mb, tTMB ≥12 Mut/Mb, tTMB ≥10 Mut/Mb, and tTMB ≥8 Mut/Mb Analysis Sets (MEDIAN) months = 4.2 [2.7-5.6]; PFS; Global and China Cohorts: PD-L1-Negative NSCLC, FAS, PD-L1 TC ≥25%, and PD-L1 TC ≥50% Analysis Sets (MEDIAN) months = 4.1 [2.8-5.2]; Objective Response Rate (ORR); Global Cohort: bTMB ≥20 Mut/Mb, bTMB ≥16 Mut/Mb, bTMB ≥12 Mut/Mb, tTMB ≥14 Mut/Mb, tTMB ≥12 Mut/Mb, tTMB ≥10 Mut/Mb, and tTMB ≥8 Mut/Mb Analysis Sets (NUMBER) percentage of participants = 27.5; ORR; Global and China Cohorts: PD-L1-Negative NSCLC, FAS, PD-L1 TC ≥25%, and PD-L1 TC ≥50% Analysis Sets (NUMBER) percentage of participants = 23.1; Duration of Response (DoR); Global Cohort: bTMB ≥20 Mut/Mb, bTMB ≥16 Mut/Mb, and bTMB ≥12 Mut/Mb Analysis Sets (MEDIAN) months = 11.6 [6.7-21.5]; DoR; Global and China Cohorts: PD-L1-Negative NSCLC and FAS Analysis Sets (MEDIAN) months = 10.2 [2.8-18.8]; Alive and Progression-Free at 12 Months (APF12); Global Cohort: bTMB ≥20 Mut/Mb, bTMB ≥16 Mut/Mb, and bTMB ≥12 Mut/Mb Analysis Sets (NUMBER) percentage of participants = 25.6 [15.7-36.6]; APF12; Global and China Cohorts: PD-L1-Negative NSCLC and FAS Analysis Sets (NUMBER) percentage of participants = 18.2 [10.9-26.9]; Time From Randomization to Second Progression or Death (PFS2); Global Cohort: bTMB ≥20 Mut/Mb, bTMB ≥16 Mut/Mb, and bTMB ≥12 Mut/Mb Analysis Sets (MEDIAN) months = 10.6 [8.5-14.4]; PFS2; Global and China Cohorts: PD-L1-Negative NSCLC and FAS Analysis Sets (MEDIAN) months = 9.1 [6.9-12.8]; OS at Months 12, 18 and 24; Global Cohort: bTMB ≥20 Mut/Mb, bTMB ≥16 Mut/Mb, and bTMB ≥12 Mut/Mb Analysis Sets (NUMBER) percentage of participants = 49.3 [37.1-60.4]; OS at Months 12, 18 and 24; Global and China Cohorts: PD-L1-Negative NSCLC and FAS Analysis Sets (NUMBER) percentage of participants = 47.8 [37.2-57.6]; ; ; Number of Participants With Anti-Drug Antibody (ADA) Response to Durvalumab (COUNT_OF_PARTICIPANTS) Participants = 26; Number of Participants With ADA Response to Tremelimumab (COUNT_OF_PARTICIPANTS) Participants = 49",,,,,"Duration of Response (DoR); Global Cohort: bTMB ≥20 Mut/Mb, bTMB ≥16 Mut/Mb, and bTMB ≥12 Mut/Mb Analysis Sets (MEDIAN) months = 11.6 [6.7-21.5]",,,"Objective Response Rate (ORR); Global Cohort: bTMB ≥20 Mut/Mb, bTMB ≥16 Mut/Mb, bTMB ≥12 Mut/Mb, tTMB ≥14 Mut/Mb, tTMB ≥12 Mut/Mb, tTMB ≥10 Mut/Mb, and tTMB ≥8 Mut/Mb Analysis Sets (NUMBER) percentage of participants = 27.5","Overall Survival (OS); Global Cohort: Blood Tumor Mutational Burden (bTMB) ≥20 Mutations Per Megabase (Mut/Mb) Analysis Set (MEDIAN) months = 11.7 [8.6-15.2]; OS at Months 12, 18 and 24; Global Cohort: bTMB ≥20 Mut/Mb, bTMB ≥16 Mut/Mb, and bTMB ≥12 Mut/Mb Analysis Sets (NUMBER) percentage of participants = 49.3 [37.1-60.4]; OS at Months 12, 18 and 24; Global and China Cohorts: PD-L1-Negative NSCLC and FAS Analysis Sets (NUMBER) percentage of participants = 47.8 [37.2-57.6]","Progression-Free Survival (PFS); Global Cohort: bTMB ≥20 Mut/Mb, bTMB ≥16 Mut/Mb, bTMB ≥12 Mut/Mb, tTMB ≥14 Mut/Mb, tTMB ≥12 Mut/Mb, tTMB ≥10 Mut/Mb, and tTMB ≥8 Mut/Mb Analysis Sets (MEDIAN) months = 4.2 [2.7-5.6]",,,"Objective Response Rate (ORR); Global Cohort: bTMB ≥20 Mut/Mb, bTMB ≥16 Mut/Mb, bTMB ≥12 Mut/Mb, tTMB ≥14 Mut/Mb, tTMB ≥12 Mut/Mb, tTMB ≥10 Mut/Mb, and tTMB ≥8 Mut/Mb Analysis Sets (NUMBER) percentage of participants = 27.5",,,
NCT02544633,Phase 2 Study of MGCD265 in Patients With Non-Small Cell Lung Cancer With Activating Genetic Alterations in MET,"Phase 2, Parallel-Arm Study of MGCD265 in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor",Mirati Therapeutics Inc.,Mirati Therapeutics Inc.,INDUSTRY,COMPLETED,2015-10,2018-04-30,2019-01,INTERVENTIONAL,PHASE2,,,,Non-Small Cell Lung Cancer,Non-Small Cell Lung Cancer,1,4,1,DRUG,,,1,16,True,Yes,Objective Response Rate (NUMBER) percentage of participants = 10.7 [2.27-28.23],Duration of Response (MEDIAN) days = 85 [82-132]; Progression Free Survival (MEDIAN) months = 3.95 [2.11-4.18]; 1-Year Survival Rate (NUMBER) percentage = 50.47 [27.49-69.62]; Overall Survival (MEDIAN) months = 16.32; Number of Patients Experiencing Treatment-emergent Adverse Events (COUNT_OF_PARTICIPANTS) Participants = 28; Blood Plasma Concentration of MGCD265 - AUC0-6 (GEOMETRIC_MEAN) h*ng/mL = 250.8; Blood Plasma Concentration of MGCD265 - Cmax (GEOMETRIC_MEAN) ng/mL = 69.77; Blood Plasma Concentration of MGCD265 - Ctrough (GEOMETRIC_MEAN) ng/mL = 264; Blood Plasma Concentration of MGCD265 - Accumulation Ratio AUC0-6 (GEOMETRIC_MEAN) ratio = 6.42; Blood Plasma Concentration of MGCD265 - Accumulation Ratio Cmax (GEOMETRIC_MEAN) ratio = 4.07; Blood Plasma Concentration of MGCD265 - Peak to Trough Ratio (GEOMETRIC_MEAN) ratio = 1.09; Blood Plasma Concentration of MGCD265 - Tmax (MEDIAN) hours = 6.00 [2.00-6.00]; Assess Correlation Between Selected Tumor Gene Alterations Using Different Analytical Techniques in Tumor Tissue and Circulating Tumor Deoxyribonucleic Acid (ctDNA) - MET Activating Mutations (COUNT_OF_PARTICIPANTS) Participants = 9; Assess Correlation Between Selected Tumor Gene Alterations Using Different Analytical Techniques in Tumor Tissue and Circulating Tumor Deoxyribonucleic Acid (ctDNA) - MET Gene Amplifications (COUNT_OF_PARTICIPANTS) Participants = 8; Assess Change in Genetic Alteration Status in ctDNA With MGCD265 Treatment Over Time in the Selected Population (NUMBER) participants = 2; Blood Plasma Concentration of Soluble MET (sMET) Biomarker (MEAN) pg/mL = 443494.7,,,,,Duration of Response (MEDIAN) days = 85 [82-132],,,Objective Response Rate (NUMBER) percentage of participants = 10.7 [2.27-28.23],Overall Survival (MEDIAN) months = 16.32,Progression Free Survival (MEDIAN) months = 3.95 [2.11-4.18],,,Objective Response Rate (NUMBER) percentage of participants = 10.7 [2.27-28.23],Number of Patients Experiencing Treatment-emergent Adverse Events (COUNT_OF_PARTICIPANTS) Participants = 28,,
NCT02572843,Anti-PD-L1 in Stage IIIA(N2) Non-small Cell Lung Cancer (NSCLC),Anti-PD-L1 Antibody MEDI4736 in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non-small Cell Lung Cancer (NSCLC). A Multicenter Single-arm Phase II Trial.,Swiss Cancer Institute,Swiss Cancer Institute,OTHER,COMPLETED,2016-06-16,2020-01-20,2024-03-19,INTERVENTIONAL,PHASE2,,,,NSCLC Non-small Cell Lung Cancer,NSCLC Non-small Cell Lung Cancer,1,1,1,DRUG,,,1,6,True,Yes,Event-free Survival (EFS) Rate (NUMBER) percentage of participants = 73.4 [62.7-81.5],Median Event-free Survival (EFS) (MEDIAN) years = 4.0; Overall Survival (OS) Rate (NUMBER) percentage of participants = 91.0 [81.0-95.8]; Objective Response (OR) After Neoadjuvant Chemotherapy (FAS) (NUMBER) percentage of participants = 43.3 [31.2-56.0]; Objective Response (OR) After Neoadjuvant Immunotherapy (FAS II) (NUMBER) percentage of participants = 58.1 [44.8-70.5]; Pathological Responses (pCR) (NUMBER) percentage of participants = 18.2 [9.1-30.9]; ,,,,,,Event-free Survival (EFS) Rate (NUMBER) percentage of participants = 73.4 [62.7-81.5]; Median Event-free Survival (EFS) (MEDIAN) years = 4.0,,,Overall Survival (OS) Rate (NUMBER) percentage of participants = 91.0 [81.0-95.8],,,,,,,
NCT02574078,A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC),A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Ca,Bristol-Myers Squibb,Bristol-Myers Squibb,INDUSTRY,COMPLETED,2015-11-23,2020-04-15,2020-04-15,INTERVENTIONAL,PHASE1; PHASE2,,,,Non-Small Cell Lung Cancer,Non-Small Cell Lung Cancer,1,10,11,DRUG; OTHER,,,3,4,True,Yes,"Progression-Free Survival (PFS), Groups A-D Only (MEDIAN) Months = 15.0; Overall Survival (OS), Groups A-C Only (MEDIAN) Months = 20.0; Percentage of Participants With Treatment-related Adverse Events (AEs) Leading to Both Study Drugs Discontinuation, Group E Only (NUMBER) Percentage of participants = 38.5","Duration of Response (DOR), Groups A-D Only (MEDIAN) months = 12.780 [4.140-20.435]; Objective Response Rate (ORR), Groups A-E (NUMBER) Percentage of participants = 23.1 [5.0-53.8]; ; Progression-Free Survival (PFS), Group E Only (MEDIAN) months = 9.63 [0.95-20.11]",,,,,"Duration of Response (DOR), Groups A-D Only (MEDIAN) months = 12.780 [4.140-20.435]",,,"Objective Response Rate (ORR), Groups A-E (NUMBER) Percentage of participants = 23.1 [5.0-53.8]","Overall Survival (OS), Groups A-C Only (MEDIAN) Months = 20.0","Progression-Free Survival (PFS), Groups A-D Only (MEDIAN) Months = 15.0; Progression-Free Survival (PFS), Group E Only (MEDIAN) months = 9.63 [0.95-20.11]",,,"Objective Response Rate (ORR), Groups A-E (NUMBER) Percentage of participants = 23.1 [5.0-53.8]","Percentage of Participants With Treatment-related Adverse Events (AEs) Leading to Both Study Drugs Discontinuation, Group E Only (NUMBER) Percentage of participants = 38.5",,
NCT02576574,Avelumab in First-line NSCLC (JAVELIN Lung 100),"A Phase III, Open-label, Multicenter Trial of Avelumab (MSB0010718C) Versus Platinum-based Doublet as a First-line Treatment of Recurrent or Stage IV PD-L1+NSCLC",EMD Serono,"EMD Serono Research & Development Institute, Inc.",INDUSTRY,COMPLETED,2015-10-29,2021-12-06,2024-01-29,INTERVENTIONAL,PHASE3,,,,First Line Non-Small Cell Lung Cancer,First Line Non-Small Cell Lung Cancer,1,3,9,DRUG,,,4,28,True,Yes,Progression Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) Assessed by Independent Review Committee (IRC) in High Programmed Death Ligand 1 (PD-L1) + Full Analysis Set (FAS) (MEDIAN) months = 8.4 [5.4-12.6]; Progression Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) Assessed by Independent Review Committee (IRC) in High Programmed Death Ligand 1 (PD-L1) + Modified Full Analysis Set (mFAS) (MEDIAN) months = 7.5 [4.2-11.1]; Overall Survival (OS) in High Programmed Death Ligand 1 (PD-L1) + Full Analysis Set (FAS) (MEDIAN) months = 20.1 [15.0-24.3]; Overall Survival (OS) in High Programmed Death Ligand 1 (PD-L1)+ Modified Full Analysis Set (mFAS) (MEDIAN) months = 19.3 [14.0-28.1],"Progression Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) Assessed by Independent Review Committee (IRC) in Moderate and High Programmed Death Ligand 1 (PD-L1)+ Full Analysis Set (FAS) (MEDIAN) months = 6.9 [5.4-9.6]; Progression Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) Assessed by Independent Review Committee (IRC) in Moderate and High Programmed Death Ligand 1 (PD-L1)+ Modified Full Analysis Set (mFAS) (MEDIAN) months = 5.6 [2.8-8.2]; Overall Survival (OS) in Moderate and High Programmed Death Ligand 1 (PD-L1)+ Full Analysis Set (FAS) (MEDIAN) months = 18.7 [14.6-21.7]; Overall Survival (OS) in Moderate and High Programmed Death Ligand 1 (PD-L1)+ Modified Full Analysis Set (mFAS) (MEDIAN) months = 16.8 [12.5-21.3]; Overall Survival (OS) in Full Analysis Set (FAS) (MEDIAN) months = 15.0 [12.5-19.1]; Overall Survival (OS) in Modified Full Analysis Set (mFAS) (MEDIAN) months = 15.4 [12.1-18.1]; Percentage of Participants With Confirmed Objective Response According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) as Assessed by Independent Review Committee (IRC) in High PD-L1+ Full Analysis Set (NUMBER) percentage of participants = 37.7 [30.0-46.0]; Percentage of Participants With Confirmed Objective Response According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) as Assessed by Independent Review Committee (IRC) in High PD-L1+ Modified Full Analysis Set (MEDIAN) percentage of participants = 34.6 [26.5-43.5]; Percentage of Participants With Confirmed Objective Response According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) as Assessed by Independent Review Committee (IRC) in Moderate and High PD-L1+ Full Analysis Set (NUMBER) percentage of participants = 33.5 [27.3-40.2]; Percentage of Participants With Confirmed Objective Response According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) as Assessed by Independent Review Committee (IRC) in Moderate and High PD-L1+ Modified Full Analysis Set (NUMBER) percentage of participants = 30.6 [24.0-37.8]; Duration of Response (DOR) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) as Assessed by Independent Review Committee (IRC) in High Programmed Death Ligand 1 (PD-L1)+ Full Analysis Set (FAS) (MEDIAN) months = 35.9 [1.4-60.8]; Duration of Response (DOR) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) as Assessed by Independent Review Committee (IRC) in High Programmed Death Ligand 1 (PD-L1)+ Modified Full Analysis Set (mFAS) (MEDIAN) months = 19.4 [3.8-43.9]; Change From Baseline in European Quality Of Life 5-dimensions (EQ-5D-5L) Visual Analog Scale (VAS) in High PD-L1+ Health-related Quality of Life (HRQoL) Analysis Set at End of Treatment (MEAN) millimeter (mm) = -6.2; Change From Baseline in European Quality Of Life 5-dimensions (EQ-5D-5L) Visual Analog Scale (VAS) in High Programmed Death Ligand 1 (PD-L1)+ Modified HRQoL Analysis Set (MEAN) millimeter = -10.3; Change From Baseline in European Organization for the Research and Treatment of Cancer Quality of Life (EORTC QLQ-C30) Global Health Status at End of Treatment (EOT) in High Programmed Death Ligand 1 (PD-L1)+ HRQoL Analysis Set (MEAN) score on a scale = -0.3; Change From Baseline in European Organization for the Research and Treatment of Cancer Quality of Life (EORTC QLQ-C30) Global Health Status at End of Treatment (EOT) in High Programmed Death Ligand 1 (PD-L1)+ Modified HRQoL Analysis Set (MEAN) score on a scale = -12.9; Change From Baseline in European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Lung Cancer 13 (EORTC QLQ-LC13) at End of Treatment (EOT) in High Programmed Death Ligand 1 (PD-L1)+ HRQoL Analysis Set (MEAN) score on a scale = 7.3; Change From Baseline in European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Lung Cancer 13 (EORTC QLQ-LC13) at End of Treatment (EOT) in High Programmed Death Ligand 1 (PD-L1)+ Modified HRQoL Analysis Set (MEAN) score on a scale = 6.1; Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and AEs of Special Interest (AESIs) (COUNT_OF_PARTICIPANTS) Participants = 346; Number of Participants With Shift From Baseline to Greater Than or Equal to (>=) Grade 3 in Laboratory Parameter Values Based on National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE), Version 4.03 (COUNT_OF_PARTICIPANTS) Participants = 4; Number of Participants With Maximal On-Treatment Changes From Baseline in Vital Signs - Maximal Body Temperature Increase (COUNT_OF_PARTICIPANTS) Participants = 271; Number of Participants With Maximal On-Treatment Changes From Baseline in Vital Signs - Maximal Weight Increase/Decrease (COUNT_OF_PARTICIPANTS) Participants = 302; Number of Participants With Maximal On-Treatment Changes From Baseline in Vital Signs - Maximal Heart Rate Increase/Decrease (COUNT_OF_PARTICIPANTS) Participants = 206; Number of Participants With Maximal On-Treatment Changes From Baseline in Vital Signs - Maximal Systolic Blood Pressure Increase/Decrease and Maximal Diastolic Blood Pressure Increase/Decrease (COUNT_OF_PARTICIPANTS) Participants = 219; Number of Participants With Maximal On-Treatment Changes From Baseline in Vital Signs - Maximal Respiration Rate Increase/Decrease (COUNT_OF_PARTICIPANTS) Participants = 221; Number of Participants With Potentially Clinically Significant Abnormalities (PCSA) in Electrocardiogram (ECG) Parameters (COUNT_OF_PARTICIPANTS) Participants = 1; Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance: Baseline Score Versus (Vs) Worst Post-baseline Score (COUNT_OF_PARTICIPANTS) Participants = 50; Number of Participants With At Least One Positive Anti-Drug Antibodies (ADAs) and Neutralizing Antibodies (NAbs) for Avelumab (COUNT_OF_PARTICIPANTS) Participants = 66",,,,,Duration of Response (DOR) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) as Assessed by Independent Review Committee (IRC) in High Programmed Death Ligand 1 (PD-L1)+ Full Analysis Set (FAS) (MEDIAN) months = 35.9 [1.4-60.8]; Duration of Response (DOR) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) as Assessed by Independent Review Committee (IRC) in High Programmed Death Ligand 1 (PD-L1)+ Modified Full Analysis Set (mFAS) (MEDIAN) months = 19.4 [3.8-43.9],,,,Overall Survival (OS) in High Programmed Death Ligand 1 (PD-L1) + Full Analysis Set (FAS) (MEDIAN) months = 20.1 [15.0-24.3]; Overall Survival (OS) in High Programmed Death Ligand 1 (PD-L1)+ Modified Full Analysis Set (mFAS) (MEDIAN) months = 19.3 [14.0-28.1]; Overall Survival (OS) in Moderate and High Programmed Death Ligand 1 (PD-L1)+ Full Analysis Set (FAS) (MEDIAN) months = 18.7 [14.6-21.7]; Overall Survival (OS) in Moderate and High Programmed Death Ligand 1 (PD-L1)+ Modified Full Analysis Set (mFAS) (MEDIAN) months = 16.8 [12.5-21.3]; Overall Survival (OS) in Full Analysis Set (FAS) (MEDIAN) months = 15.0 [12.5-19.1]; Overall Survival (OS) in Modified Full Analysis Set (mFAS) (MEDIAN) months = 15.4 [12.1-18.1],Progression Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) Assessed by Independent Review Committee (IRC) in High Programmed Death Ligand 1 (PD-L1) + Full Analysis Set (FAS) (MEDIAN) months = 8.4 [5.4-12.6]; Progression Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) Assessed by Independent Review Committee (IRC) in High Programmed Death Ligand 1 (PD-L1) + Modified Full Analysis Set (mFAS) (MEDIAN) months = 7.5 [4.2-11.1]; Progression Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) Assessed by Independent Review Committee (IRC) in Moderate and High Programmed Death Ligand 1 (PD-L1)+ Full Analysis Set (FAS) (MEDIAN) months = 6.9 [5.4-9.6]; Progression Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) Assessed by Independent Review Committee (IRC) in Moderate and High Programmed Death Ligand 1 (PD-L1)+ Modified Full Analysis Set (mFAS) (MEDIAN) months = 5.6 [2.8-8.2],,Change From Baseline in European Quality Of Life 5-dimensions (EQ-5D-5L) Visual Analog Scale (VAS) in High PD-L1+ Health-related Quality of Life (HRQoL) Analysis Set at End of Treatment (MEAN) millimeter (mm) = -6.2; Change From Baseline in European Quality Of Life 5-dimensions (EQ-5D-5L) Visual Analog Scale (VAS) in High Programmed Death Ligand 1 (PD-L1)+ Modified HRQoL Analysis Set (MEAN) millimeter = -10.3; Change From Baseline in European Organization for the Research and Treatment of Cancer Quality of Life (EORTC QLQ-C30) Global Health Status at End of Treatment (EOT) in High Programmed Death Ligand 1 (PD-L1)+ HRQoL Analysis Set (MEAN) score on a scale = -0.3; Change From Baseline in European Organization for the Research and Treatment of Cancer Quality of Life (EORTC QLQ-C30) Global Health Status at End of Treatment (EOT) in High Programmed Death Ligand 1 (PD-L1)+ Modified HRQoL Analysis Set (MEAN) score on a scale = -12.9; Change From Baseline in European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Lung Cancer 13 (EORTC QLQ-LC13) at End of Treatment (EOT) in High Programmed Death Ligand 1 (PD-L1)+ HRQoL Analysis Set (MEAN) score on a scale = 7.3; Change From Baseline in European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Lung Cancer 13 (EORTC QLQ-LC13) at End of Treatment (EOT) in High Programmed Death Ligand 1 (PD-L1)+ Modified HRQoL Analysis Set (MEAN) score on a scale = 6.1,,"Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and AEs of Special Interest (AESIs) (COUNT_OF_PARTICIPANTS) Participants = 346; Number of Participants With Shift From Baseline to Greater Than or Equal to (>=) Grade 3 in Laboratory Parameter Values Based on National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE), Version 4.03 (COUNT_OF_PARTICIPANTS) Participants = 4",,
NCT02578680,Study of Pemetrexed+Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Participants With First Line Metastatic Nonsquamous Non-small Cel,"A Randomized, Double-Blind, Phase III Study of Platinum+Pemetrexed Chemotherapy With or Without Pembrolizumab (MK-3475) in First Line Metastatic Non-squamous Non-small Cell Lung Cancer Subjects (KEYNO",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,INDUSTRY,COMPLETED,2016-01-15,2017-11-08,2023-06-22,INTERVENTIONAL,PHASE3,,,,Non-Small-Cell Lung Carcinoma,Non-Small-Cell Lung Carcinoma,1,2,8,BIOLOGICAL; DIETARY_SUPPLEMENT; DRUG,,,2,4,True,Yes,Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as Assessed by Blinded Central Imaging (MEDIAN) Months = 8.8 [7.6-9.2]; ,Overall Response Rate (ORR) Per RECIST 1.1 as Assessed by Blinded Central Imaging (NUMBER) Percentage of Participants = 47.6 [42.6-52.5]; Duration of Response (DOR) Per RECIST 1.1 as Assessed by Blinded Central Imaging (MEDIAN) Months = 11.2 [1.1-18.0]; Number of Participants Who Experienced an Adverse Event (AE) (COUNT_OF_PARTICIPANTS) Participants = 404; Number of Participants Who Discontinued Any Study Drug Due to an AE (COUNT_OF_PARTICIPANTS) Participants = 112,,,,,Duration of Response (DOR) Per RECIST 1.1 as Assessed by Blinded Central Imaging (MEDIAN) Months = 11.2 [1.1-18.0],,,,,Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as Assessed by Blinded Central Imaging (MEDIAN) Months = 8.8 [7.6-9.2],,,Overall Response Rate (ORR) Per RECIST 1.1 as Assessed by Blinded Central Imaging (NUMBER) Percentage of Participants = 47.6 [42.6-52.5],Number of Participants Who Discontinued Any Study Drug Due to an AE (COUNT_OF_PARTICIPANTS) Participants = 112,,
NCT02581787,SABR-ATAC: A Trial of TGF-beta Inhibition and Stereotactic Ablative Radiotherapy for Early Stage Non-small Cell Lung Cancer,Fresolimumab and Stereotactic Ablative Radiotherapy in Early Stage Non-small Cell Lung Cancer,Stanford University,Maximilian Diehn,OTHER,COMPLETED,2016-08,2023-03-02,2023-03-02,INTERVENTIONAL,PHASE1; PHASE2,,,,Stage IA Non-Small Cell Lung Carcinoma,Stage IA Non-Small Cell Lung Carcinoma; Stage IB Non-Small Cell Lung Carcinoma,2,3,2,BIOLOGICAL; RADIATION,,,2,1,True,Yes,Number of Participants Experiencing Dose Limiting Toxicities (DLTs) of Fresolimumab When Combined With SABR (Phase I) (COUNT_OF_PARTICIPANTS) Participants = 0; Number of Participants With Late Radiation Induced Fibrosis (COUNT_OF_PARTICIPANTS) Participants = 5,Number of Participants With Late Radiation Induced Fibrosis (Phase 1 Patients) (COUNT_OF_PARTICIPANTS) Participants = 1,,,,,,,,,,,,,,,,
NCT02581943,Effect of Pembrolizumab With or Without Carboplatin and Paclitaxel on Immune Response in Patients With Recurrent or Stage IIIB-IV Non-small Cell Lung ,Immune Response in Patients With Recurrent or Metastatic Non-small Cell Lung Cancer and Performance Status of 2 Treated With a Combination of Pembrolizumab and Low Dose Weekly Carboplatin/Paclitaxel,Wake Forest University Health Sciences,Wake Forest University Health Sciences,OTHER,COMPLETED,2016-06-17,2022-11-19,2022-12-28,INTERVENTIONAL,PHASE2,,,,Recurrent Non-Small Cell Lung Carcinoma,Recurrent Non-Small Cell Lung Carcinoma; Stage IIIB Non-Small Cell Lung Cancer; Stage IV Non-Small Cell Lung Cancer,3,2,5,BIOLOGICAL; DRUG; OTHER,,,5,2,True,Yes,"Duration of Response (MEDIAN) days = 98 [0-326]; Change in Effect of Treatment in Immune Markers From Baseline to End of Treatment (up to 2 Years) (MEDIAN) cells = 1.82 [-2.11-4.73]; Objective Response Rate (ORR), Assessed Using RECIST (COUNT_OF_PARTICIPANTS) Participants = 6; Overall Survival (MEDIAN) months = 8.4 [5.0-29.8]; Progression Free Survival (MEDIAN) months = 4.3 [1.9-12.0]",Number of Participants With Reported Adverse Events - CTCAE Version 4.0 (NUMBER) participants with adverse event = 21; Change in Immune Markers From Baseline to End of Treatment (up to 2 Years) With Treatment Response (MEDIAN) Cells = -0.54 [-2.8-3.7],,,,,Duration of Response (MEDIAN) days = 98 [0-326],,,"Objective Response Rate (ORR), Assessed Using RECIST (COUNT_OF_PARTICIPANTS) Participants = 6",Overall Survival (MEDIAN) months = 8.4 [5.0-29.8],Progression Free Survival (MEDIAN) months = 4.3 [1.9-12.0],,,"Objective Response Rate (ORR), Assessed Using RECIST (COUNT_OF_PARTICIPANTS) Participants = 6",Number of Participants With Reported Adverse Events - CTCAE Version 4.0 (NUMBER) participants with adverse event = 21,,
NCT02591615,Optimal Sequencing of Pembrolizumab (MK-3475) and Standard Platinum-based Chemotherapy in First-Line NSCLC,Randomized Phase II Trial Evaluating the Optimal Sequencing of PD-1 Inhibition With Pembrolizumab (MK-3475) and Standard Platinum-based Chemotherapy in Patients With Chemotherapy Naive Stage IV Non-sm,"Alliance Foundation Trials, LLC.","Alliance Foundation Trials, LLC.",OTHER,COMPLETED,2016-03,2019-01-04,2020-07-04,INTERVENTIONAL,PHASE2,,,,Non-Small Cell Lung Cancer,Non-Small Cell Lung Cancer,1,2,4,DRUG,,,1,2,True,Yes,Overall Response Rate (ORR) Per RECIST 1.1 (NUMBER) proportion of participants = 0.395 [0.249-0.541],Compare Progression-Free Survival (PFS) Per RECIST 1.1 (MEDIAN) Months = 5.8 [4.4-10.6]; Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability) (NUMBER) participants = 9,,,,,,,,,,Compare Progression-Free Survival (PFS) Per RECIST 1.1 (MEDIAN) Months = 5.8 [4.4-10.6],,,Overall Response Rate (ORR) Per RECIST 1.1 (NUMBER) proportion of participants = 0.395 [0.249-0.541],Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability) (NUMBER) participants = 9,,
NCT02599194,18F-FSPG PET/CT for Cancer Patients on Therapy,An Exploratory Study of the Role of 18F-FSPG PET/CT Imaging for Cancer Patients Receiving Therapy,Stanford University,Andrei Iagaru,OTHER,COMPLETED,2015-07,2016-12-14,2016-12-14,INTERVENTIONAL,PHASE2,,,,B-Cell Neoplasm,B-Cell Neoplasm; Estrogen Receptor Negative; HER2/Neu Negative,16,1,2,DRUG,,,1,2,True,Yes,Change From Baseline in Standard Uptake Value Maximum (SUVmax) Post-treatment (NUMBER) g/mL = -1.69,Number of Treatment-Related Adverse Events (NUMBER) adverse events = 0; ,,,,,,,,,,,,,,Number of Treatment-Related Adverse Events (NUMBER) adverse events = 0,,
NCT02604342,Alectinib Versus Pemetrexed or Docetaxel in Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) Participants Previou,"Randomized, Multicenter, Phase III, Open-Label Study of Alectinib Versus Pemetrexed or Docetaxel in Anaplastic Lymphoma Kinase-Positive Advanced Non Small Cell Lung Cancer Patients Previously Treated ",Hoffmann-La Roche,Hoffmann-La Roche,INDUSTRY,COMPLETED,2015-11-03,2017-01-26,2018-08-13,INTERVENTIONAL,PHASE3,,,,Non-small Cell Lung Cancer,Non-small Cell Lung Cancer,1,2,3,DRUG,,,1,23,True,Yes,Progression-Free Survival (PFS) Using Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Investigator (MEDIAN) months = 10.9 [8.1-15.5],"Percentage of Participants With CNS Objective Response Rate (ORR) With Measurable CNS Metastases at Baseline Using RECIST Version 1.1 as Assessed By IRC (NUMBER) percentage of participants = 66.7; PFS Using RECIST Version 1.1 as Assessed by IRC (MEDIAN) months = 7.1 [6.3-10.8]; Percentage of Participants With Objective Response of CR or PR Using RECIST Version 1.1 as Assessed by Investigator and IRC (NUMBER) percentage of participants = 50.6; Percentage of Participants With Disease Control Using RECIST Version 1.1 as Assessed by Investigator and IRC (NUMBER) percentage of participants = 86.1; Duration of Response (DOR) Using RECIST Version 1.1 as Assessed by Investigator and IRC (MEDIAN) months = 12.0 [8.3-23.5]; PFS in C-ITT Population Using RECIST Version 1.1 as Assessed by Investigator and IRC (MEDIAN) months = 9.7; ; Percentage of Participants With Disease Control in C-ITT Population Using RECIST Version 1.1 as Assessed by IRC (NUMBER) percentage of participants = 82.7; Percentage of Participants With ORR in C-ITT Population Using RECIST Version 1.1 as Assessed by IRC (NUMBER) percentage of participants = 48.1; Duration of Response for Lesions in the CNS (C-DOR) Using RECIST Version 1.1 as Assessed by IRC (MEDIAN) months = 13.9 [6.2-13.9]; Overall Survival (OS) (MEDIAN) months = 27.8; Plasma Concentration of Alectinib (GEOMETRIC_MEAN) nanogram/milliliter (ng/mL) = 559; Plasma Concentration of Alectinib Metabolite (GEOMETRIC_MEAN) ng/mL = 240; Compliance of European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core-30 (EORTC QLQ-C30) Over Time (NUMBER) percentage of participants = 92.4; Compliance of European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Lung Cancer-13 (EORTC QLQ-LC13) Over Time (NUMBER) percentage of participants = 92.4; Compliance of European Quality of Life (EuroQoL) 5 Dimension 5 Levels (EQ-5D-5L) Questionnaire Over Time (NUMBER) percentage of participants = 88.9; Time to Deterioration (TTD) in Lung Cancer Symptoms Using EORTC QLQ-LC13 Score for ITT Population (MEDIAN) months = 18.1; ; Time to Deterioration (TTD) in Lung Cancer Symptoms Using EORTC QLQ-LC30 Score for ITT Population (MEDIAN) months = 13.3; Time to Deterioration (TTD) in Lung Cancer Symptoms Using EORTC QLQ-LC30 Score for C-ITT Population (MEDIAN) months = 16.6; TTD in Composite of Three Symptoms (Cough, Dyspnea, and Chest Pain) Using EORTC QLQ-LC13 Score for C-ITT Population (MEDIAN) months = 2.8 [0.9-5.6]; TTD in Composite of Three Symptoms (Cough, Dyspnea, and Chest Pain) Using EORTC QLQ-LC13 Score for ITT Population (MEDIAN) months = 1.4 [0.9-4.2]; Percentage of Participants With Adverse Events (AEs) (NUMBER) Percentage of Participants = 89.6",,Percentage of Participants With Objective Response of CR or PR Using RECIST Version 1.1 as Assessed by Investigator and IRC (NUMBER) percentage of participants = 50.6,,,Duration of Response (DOR) Using RECIST Version 1.1 as Assessed by Investigator and IRC (MEDIAN) months = 12.0 [8.3-23.5]; Duration of Response for Lesions in the CNS (C-DOR) Using RECIST Version 1.1 as Assessed by IRC (MEDIAN) months = 13.9 [6.2-13.9],,,Percentage of Participants With CNS Objective Response Rate (ORR) With Measurable CNS Metastases at Baseline Using RECIST Version 1.1 as Assessed By IRC (NUMBER) percentage of participants = 66.7; Percentage of Participants With ORR in C-ITT Population Using RECIST Version 1.1 as Assessed by IRC (NUMBER) percentage of participants = 48.1,Overall Survival (OS) (MEDIAN) months = 27.8,Progression-Free Survival (PFS) Using Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Investigator (MEDIAN) months = 10.9 [8.1-15.5]; PFS Using RECIST Version 1.1 as Assessed by IRC (MEDIAN) months = 7.1 [6.3-10.8]; PFS in C-ITT Population Using RECIST Version 1.1 as Assessed by Investigator and IRC (MEDIAN) months = 9.7,Percentage of Participants With Objective Response of CR or PR Using RECIST Version 1.1 as Assessed by Investigator and IRC (NUMBER) percentage of participants = 50.6,Compliance of European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core-30 (EORTC QLQ-C30) Over Time (NUMBER) percentage of participants = 92.4; Compliance of European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Lung Cancer-13 (EORTC QLQ-LC13) Over Time (NUMBER) percentage of participants = 92.4; Compliance of European Quality of Life (EuroQoL) 5 Dimension 5 Levels (EQ-5D-5L) Questionnaire Over Time (NUMBER) percentage of participants = 88.9,Percentage of Participants With CNS Objective Response Rate (ORR) With Measurable CNS Metastases at Baseline Using RECIST Version 1.1 as Assessed By IRC (NUMBER) percentage of participants = 66.7,Percentage of Participants With Adverse Events (AEs) (NUMBER) Percentage of Participants = 89.6,,
NCT02613507,Efficacy Study of Nivolumab Compared to Docetaxel in Subjects Previously Treated With Advanced or Metastatic Non Small Cell Lung Cancer,An Open-label Randomized Multinational Phase 3 Trial of Nivolumab Versus Docetaxel in Previously Treated Subjects With Advanced or Metastatic Non-small Cell Lung Cancer (CheckMate 078: CHECKpoint Path,Bristol-Myers Squibb,Bristol-Myers Squibb,INDUSTRY,COMPLETED,2015-12-11,2017-09-15,2023-11-24,INTERVENTIONAL,PHASE3,,,,Non-Small Cell Lung Cancer,Non-Small Cell Lung Cancer,1,2,2,DRUG,,,2,8,True,Yes,Median Overall Survival (MEDIAN) Months = 11.99 [10.35-14.00]; Overall Survival Rate (NUMBER) percentage = 72.4 [67.3-76.9],Objective Response Rate (ORR) (NUMBER) Percentage of participants = 17.5 [13.6-21.9]; Overall Survival (OS) in Subpopulations (MEDIAN) Months = 11.99 [10.18-14.55]; Progression Free Survival (PFS) (MEDIAN) Months = 2.79 [2.37-3.65]; Progression Free Survival Rate (NUMBER) Percentage = 29.3 [24.4-34.3]; Time to Treatment Failure (TTF) (MEDIAN) Months = 2.60 [1.81-2.92]; Number of Participants Experiencing Treatment-Related Adverse Events (AEs) (COUNT_OF_PARTICIPANTS) Participants = 220; Number of Participants Experiencing Treatment-Related Serious Adverse Events (SAEs) (COUNT_OF_PARTICIPANTS) Participants = 34; Disease Related Symptom Deterioration Rate by Week 12 and Week 24 (NUMBER) Percentage of participants = 29.9 [25.0-35.1],,,,,,,,Objective Response Rate (ORR) (NUMBER) Percentage of participants = 17.5 [13.6-21.9],Median Overall Survival (MEDIAN) Months = 11.99 [10.35-14.00]; Overall Survival Rate (NUMBER) percentage = 72.4 [67.3-76.9]; Overall Survival (OS) in Subpopulations (MEDIAN) Months = 11.99 [10.18-14.55],Progression Free Survival (PFS) (MEDIAN) Months = 2.79 [2.37-3.65]; Progression Free Survival Rate (NUMBER) Percentage = 29.3 [24.4-34.3],,,Objective Response Rate (ORR) (NUMBER) Percentage of participants = 17.5 [13.6-21.9],Number of Participants Experiencing Treatment-Related Adverse Events (AEs) (COUNT_OF_PARTICIPANTS) Participants = 220; Number of Participants Experiencing Treatment-Related Serious Adverse Events (SAEs) (COUNT_OF_PARTICIPANTS) Participants = 34,Time to Treatment Failure (TTF) (MEDIAN) Months = 2.60 [1.81-2.92],
NCT02616393,Phase 2 Study of Study of Tesevatinib in Subjects With NSCLC and Brain or Leptomeningeal Metastases,"A Phase 2, Multicenter Study of Tesevatinib in Subjects With Non-Small Cell Lung Cancer, EGFR Activating Mutation, Prior Treatment With a Tyrosine Kinase Inhibitor, and Brain Metastases or Leptomening","Kadmon Corporation, LLC","Kadmon Corporation, LLC",INDUSTRY,COMPLETED,2015-11,2018-04-03,2018-04-03,INTERVENTIONAL,PHASE2,,,,Non-Small Cell Lung Cancer,Non-Small Cell Lung Cancer; Leptomeningeal Metastases; Brain Metastases,3,3,1,DRUG,,,2,9,True,Yes,Best Overall Response Rate (ORR) of Subjects With BM (NUMBER) Percentage of participants (%) = 15.4 [2-45]; Best ORR of Subjects With LM (NUMBER) Percentage of participants (%) = 0,"Median Progression-free Survival (PFS) (MEDIAN) Weeks = 9.29 [4.14-27.43]; Probability of PFS at 12 Weeks and 24 Weeks--Cohort A (BM Only) and Cohort B (LM Only) (NUMBER) Probability = 0.4762 [0.1823-0.7237]; Probability of PFS at 24 Weeks--Cohort C (BM-IP Only) (NUMBER) Probability = 0.6667 [0.0541-0.9452]; Probability of OS at 12 Weeks and at 24 Weeks--Cohort A (BM Only) and Cohort B (LM Only) (NUMBER) Probability = 0.8462 [0.5122-0.9591]; Median Time to Progression (TTP)--Cohort A (BM), Cohort B (LM), Cohort C (BM-IP) (MEDIAN) Weeks = 21.43 [4.14-27.43]; Probability of TTP at 12 Weeks and 24 Weeks--Non-CNS Cohort A (BM Only) and Cohort B (LM Only) (NUMBER) Probability = 0.5625 [0.1468-0.8415]; Probability of TTP at 24 Weeks--CNS (NUMBER) Probability = 0.3636 [0.0584-0.6976]; Quality of Life (QoL): Mean Change From Baseline in EORTC-QLQ-C30 Questionnaire Scores (MEAN) Score on a scale = 59.2; Quality of Life (QoL): Mean Change From Baseline in EORTC-QLQ-BN20 Questionnaire Scores (MEAN) Score on a scale = 34.0",,,,,,,,Best ORR of Subjects With LM (NUMBER) Percentage of participants (%) = 0,Probability of OS at 12 Weeks and at 24 Weeks--Cohort A (BM Only) and Cohort B (LM Only) (NUMBER) Probability = 0.8462 [0.5122-0.9591],Median Progression-free Survival (PFS) (MEDIAN) Weeks = 9.29 [4.14-27.43]; Probability of PFS at 12 Weeks and 24 Weeks--Cohort A (BM Only) and Cohort B (LM Only) (NUMBER) Probability = 0.4762 [0.1823-0.7237]; Probability of PFS at 24 Weeks--Cohort C (BM-IP Only) (NUMBER) Probability = 0.6667 [0.0541-0.9452],,Quality of Life (QoL): Mean Change From Baseline in EORTC-QLQ-C30 Questionnaire Scores (MEAN) Score on a scale = 59.2; Quality of Life (QoL): Mean Change From Baseline in EORTC-QLQ-BN20 Questionnaire Scores (MEAN) Score on a scale = 34.0,Best Overall Response Rate (ORR) of Subjects With BM (NUMBER) Percentage of participants (%) = 15.4 [2-45],,,"Median Time to Progression (TTP)--Cohort A (BM), Cohort B (LM), Cohort C (BM-IP) (MEDIAN) Weeks = 21.43 [4.14-27.43]; Probability of TTP at 12 Weeks and 24 Weeks--Non-CNS Cohort A (BM Only) and Cohort B (LM Only) (NUMBER) Probability = 0.5625 [0.1468-0.8415]; Probability of TTP at 24 Weeks--CNS (NUMBER) Probability = 0.3636 [0.0584-0.6976]"
NCT02638090,Pembro and Vorinostat for Patients With Stage IV Non-small Cell Lung Cancer (NSCLC),A Phase I/II Study of Pembrolizumab and Vorinostat in Patients With Immune Therapy Naïve and Immune Therapy Pretreated Stage IV NSCLC,H. Lee Moffitt Cancer Center and Research Institute,H. Lee Moffitt Cancer Center and Research Institute,OTHER,ACTIVE_NOT_RECRUITING,2016-03-22,2024-01-21,2026-01-21,INTERVENTIONAL,PHASE1; PHASE2,,,,Lung Cancer,Lung Cancer; Non-small Cell Lung Cancer,2,4,2,DRUG,,,1,1,True,Yes,Phase I: Maximum Tolerated Dose (MTD) (NUMBER) Milligrams of Vorinostat = 400,Phase II: Progression Free Survival (PFS) Per Treatment Arm (MEDIAN) Months = 4.5 [2.1-9.3],,,,,,,,,,Phase II: Progression Free Survival (PFS) Per Treatment Arm (MEDIAN) Months = 4.5 [2.1-9.3],,,,,,
NCT02642042,Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer,A Phase II Trial of Trametinib With Docetaxel in Patients With KRAS Mutation Positive Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease Following One or Two Prior Systemic Therapies,National Cancer Institute (NCI),National Cancer Institute (NCI),NIH,ACTIVE_NOT_RECRUITING,2016-07-18,2019-05-15,2026-03-19,INTERVENTIONAL,PHASE2,,,,KRAS Gene Mutation,KRAS Gene Mutation; Recurrent Lung Non-Small Cell Carcinoma; Stage IV Lung Non-Small Cell Cancer AJCC v7,3,1,3,DRUG; OTHER,,,1,9,True,Yes,Response Rate (Confirmed and Unconfirmed Complete and Partial Responses) in All KRAS Mutant Participants (NUMBER) proportion of participants = 0.33 [0.21-0.47],Response Rate (Confirmed and Unconfirmed Complete and Partial Responses) in Participants With G12C KRAS Mutation (NUMBER) proportion of participants = 0.26 [0.09-0.51]; Response Rate (Confirmed and Unconfirmed Complete and Partial Responses) in Participants With Non-G12C KRAS Mutation (NUMBER) proportion of participants = 0.37 [0.21-0.55]; Progression Free Survival in All KRAS Mutant Participants (NUMBER) months = 4.1 [3.1-5.1]; Progression Free Survival in Participants With G12C KRAS Mutation (NUMBER) months = 3.3 [1.5-4.3]; Progression Free Survival in Participants With Non-G12C KRAS Mutation (NUMBER) months = 4.1 [3.4-5.6]; Overall Survival in All KRAS Mutants (NUMBER) months = 10.9 [8.0-14.0]; Overall Survival in Participants With G12C KRAS Mutation (NUMBER) months = 8.8 [4.9-10.9]; Overall Survival in Participants With Non-G12C KRAS Mutation (NUMBER) months = 12.2 [8.0-18.8]; Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs (NUMBER) Participants = 1,,,,,,,,,Overall Survival in All KRAS Mutants (NUMBER) months = 10.9 [8.0-14.0]; Overall Survival in Participants With G12C KRAS Mutation (NUMBER) months = 8.8 [4.9-10.9]; Overall Survival in Participants With Non-G12C KRAS Mutation (NUMBER) months = 12.2 [8.0-18.8],Progression Free Survival in All KRAS Mutant Participants (NUMBER) months = 4.1 [3.1-5.1]; Progression Free Survival in Participants With G12C KRAS Mutation (NUMBER) months = 3.3 [1.5-4.3]; Progression Free Survival in Participants With Non-G12C KRAS Mutation (NUMBER) months = 4.1 [3.4-5.6],Response Rate (Confirmed and Unconfirmed Complete and Partial Responses) in All KRAS Mutant Participants (NUMBER) proportion of participants = 0.33 [0.21-0.47]; Response Rate (Confirmed and Unconfirmed Complete and Partial Responses) in Participants With G12C KRAS Mutation (NUMBER) proportion of participants = 0.26 [0.09-0.51]; Response Rate (Confirmed and Unconfirmed Complete and Partial Responses) in Participants With Non-G12C KRAS Mutation (NUMBER) proportion of participants = 0.37 [0.21-0.55],,Response Rate (Confirmed and Unconfirmed Complete and Partial Responses) in All KRAS Mutant Participants (NUMBER) proportion of participants = 0.33 [0.21-0.47]; Response Rate (Confirmed and Unconfirmed Complete and Partial Responses) in Participants With G12C KRAS Mutation (NUMBER) proportion of participants = 0.26 [0.09-0.51]; Response Rate (Confirmed and Unconfirmed Complete and Partial Responses) in Participants With Non-G12C KRAS Mutation (NUMBER) proportion of participants = 0.37 [0.21-0.55],Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs (NUMBER) Participants = 1,,
NCT02648724,Sym015 (Anti-MET) in Patients With Advanced Solid Tumor Malignancies,"An Open-Label, Multicenter Phase 1a/2a Trial Investigating the Safety, Tolerability and Antitumor Activity of Multiple Doses of Sym015, a Monoclonal Antibody Mixture Targeting MET, in Patients With Ad",Symphogen A/S,Symphogen A/S,INDUSTRY,COMPLETED,2016-03,2020-12,2020-12,INTERVENTIONAL,PHASE1; PHASE2,,,,Oncology,Oncology; MET Gene Amplification; NSCLC,5,7,1,DRUG,,,2,17,True,Yes,"Part 1: Occurrence of DLTs During Cycle 1 of Sym015 Administration (NUMBER) Number of DLTs = 0; Part 2: Documented, Confirmed Objective Response (OR) (COUNT_OF_PARTICIPANTS) Participants = 0",; Immunogenicity of Sym015: Part 1. (COUNT_OF_PARTICIPANTS) Participants = 0; Immunogenicity of Sym015: Part 2. (COUNT_OF_PARTICIPANTS) Participants = 0; Part 1: Area Under the Concentration-time Curve in a Dosing Interval (AUC) Following 1st Dose (MEDIAN) h*μg/mL = 17900 [17100-24500]; Part 2: Area Under the Concentration-time Curve in a Dosing Interval (AUC) (MEDIAN) h*ug/mL = 34000 [17300-51800]; Part 1: Cmax (MEDIAN) ug/mL = 146 [141-151]; Part 2: Cmax (MEDIAN) ug/mL = 420 [310-700]; Part 1: Time to Reach Maximum Concentration (Tmax) (MEDIAN) hours = 2.1 [2-5]; Part 2: Time to Reach Maximum Concentration (Tmax) (MEDIAN) hours = 2.5 [1-44]; Part 1: Trough Concentration (Ctrough) (MEDIAN) μg/mL = 23.1 [19.2-31.5]; Part 2: Trough Concentration (Ctrough) (MEDIAN) μg/mL = 84.1 [24-429]; Part 1: Elimination Half-life (T½) (MEDIAN) hours = 179 [116-179]; Part 2: Elimination Half-life (T½) (MEDIAN) hours = 150 [87-217]; Part 1: Clearance (CL) (MEDIAN) mL/h = 0.3 [0.3-0.3]; Part 2: Clearance (CL) (MEDIAN) mL/h/kg = 0.4 [0.2-0.5]; Part 2: Additional Preliminary Evaluation of the Antitumor Activity of Sym015 When Administered at the Q2W RP2D in a Subset of Patients. Assessed by OR. (COUNT_OF_PARTICIPANTS) Participants = 0; Part 2: Additional Preliminary Evaluation of the Antitumor Activity of Sym015 When Administered at the Q2W RP2D in a Subset of Patients. Assessed by DCR. (COUNT_OF_PARTICIPANTS) Participants = 2,,,,,,,,,,,,,,,,
NCT02657434,A Study of Atezolizumab in Combination With Carboplatin or Cisplatin + Pemetrexed Compared With Carboplatin or Cisplatin + Pemetrexed in Participants ,"A Phase III, Open-Label, Randomized Study of Atezolizumab (MPDL3280A, Anti-Pd-L1 Antibody) in Combination With Carboplatin or Cisplatin + Pemetrexed Compared With Carboplatin or Cisplatin + Pemetrexed",Hoffmann-La Roche,Hoffmann-La Roche,INDUSTRY,COMPLETED,2016-04-30,2019-07-18,2022-12-13,INTERVENTIONAL,PHASE3,,,,Non-Small Cell Lung Cancer,Non-Small Cell Lung Cancer,1,2,4,DRUG,,,2,13,True,Yes,Progression Free Survival (PFS) as Assessed by the Investigator Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) (MEDIAN) Months = 5.2 [4.3-5.6]; Overall Survival (OS) (MEDIAN) Months = 13.6 [11.0-15.7],Overall Survival Rate at Year 1 (NUMBER) Percentage = 55.04 [49.21-60.87]; Overall Survival Rate Year 2 (NUMBER) Percentage = 34.01 [28.40-39.62]; Percentage of Participants With an Objective Response (Complete Response [CR] or Partial Response [PR]) Assessed by the Investigator Using RECIST V1.1 (NUMBER) Percentage of Participants = 37.4; Duration of Response (DOR) as Determined by the Investigator Using RECIST v1.1 (NUMBER) Months = 6.4 [4.4-7.6]; Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by European Organization for the Research and Treatment of Cancer (EORTC) Quality-of-Life Questionnaire-Core 30 (QLQ-C30) Symptom Score (MEAN) Units on a scale = -1.95; Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score (MEAN) Units on a scale = -2.50; Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score (MEAN) Units on a scale = 0.20; Minimum Observed Serum Atezolizumab Concentration (Cmin) (MEAN) μg/mL = 69.8; Maximum Observed Serum Atezolizumab Concentration (Cmax) (MEAN) μg/mL = 403; ; ; ; Percentage of Participants With Anti-Therapeutic Antibodies (ATAs) of Atezolizumab (NUMBER) Percentage of Participants = 1.8,,Percentage of Participants With an Objective Response (Complete Response [CR] or Partial Response [PR]) Assessed by the Investigator Using RECIST V1.1 (NUMBER) Percentage of Participants = 37.4,,,Duration of Response (DOR) as Determined by the Investigator Using RECIST v1.1 (NUMBER) Months = 6.4 [4.4-7.6],,,,Overall Survival (OS) (MEDIAN) Months = 13.6 [11.0-15.7]; Overall Survival Rate at Year 1 (NUMBER) Percentage = 55.04 [49.21-60.87]; Overall Survival Rate Year 2 (NUMBER) Percentage = 34.01 [28.40-39.62],Progression Free Survival (PFS) as Assessed by the Investigator Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) (MEDIAN) Months = 5.2 [4.3-5.6],Percentage of Participants With an Objective Response (Complete Response [CR] or Partial Response [PR]) Assessed by the Investigator Using RECIST V1.1 (NUMBER) Percentage of Participants = 37.4,,,,,
NCT02658097,"Pembrolizumab Alone or Sequentially Following Single Fraction Non-ablative Radiation to One of the Target Lesions, in Previously Treated Patients With","A Phase II Trial of Pembrolizumab Sequentially Following Single Fraction Non-ablative Radiation to One of the Target Lesions, in Previously Treated Patients With Stage IV NSCLC",Case Comprehensive Cancer Center,Case Comprehensive Cancer Center,OTHER,COMPLETED,2017-06-07,2022-02-26,2023-03-10,INTERVENTIONAL,PHASE2,,,,Stage IV Non-Small Cell Lung Cancer,Stage IV Non-Small Cell Lung Cancer,1,1,2,DRUG; RADIATION,,,1,4,True,Yes,Number of Patients With Each Response as Measured by RECIST 1.1 (COUNT_OF_PARTICIPANTS) Participants = 0,Median Time of Progression Free Survival (MEDIAN) months = 3.5; Median Time of Overall Survival (MEDIAN) months = 9.2; Number of Patients With Local Control of Disease With SFRT (COUNT_OF_PARTICIPANTS) Participants = 9; Duration of Local Control of Disease With SFRT (MEAN) months = 13,,,,,,,,,Median Time of Overall Survival (MEDIAN) months = 9.2,Median Time of Progression Free Survival (MEDIAN) months = 3.5,,,,,,
NCT02658890,An Investigational Immuno-therapy Study of BMS-986205 Given in Combination With Nivolumab and in Combination With Both Nivolumab and Ipilimumab in Can,A Phase 1/2a Study of BMS-986205 Administered in Combination With Nivolumab (Anti-PD-1 Monoclonal Antibody) and in Combination With Both Nivolumab and Ipilimumab (Anti-CTLA-4 Monoclonal Antibody) in A,Bristol-Myers Squibb,Bristol-Myers Squibb,INDUSTRY,COMPLETED,2016-04-14,2021-10-26,2021-10-26,INTERVENTIONAL,PHASE1; PHASE2,,,,Advanced Cancer,Advanced Cancer; Melanoma; Non-Small Cell Lung Cancer,3,3,3,DRUG,,,9,16,True,Yes,"Number of Participants With AEs, SAEs, AEs Leading to Discontinuation and Deaths (COUNT_OF_PARTICIPANTS) Participants = 1; Number of Treated Participant With Laboratory Abnormalities - Thyroid (COUNT_OF_PARTICIPANTS) Participants = 0; Number of Treated Participant With Laboratory Abnormalities - Liver (COUNT_OF_PARTICIPANTS) Participants = 0; Number of Participants With a Best Overall Response (BOR) - Parts 2 and 3 (COUNT_OF_PARTICIPANTS) Participants = 0; Percentage of Participants With an Objective Response Rate (ORR)- Parts 2 and 3 (NUMBER) Percentage of participants = 0 [0.0-18.5]; Median Duration of Response (DoR) - Parts 2 and 3 (MEDIAN) Weeks = 134.14; Progression Free Survival Rate (PFSR) at 24 Weeks - Parts 2 and 3 (NUMBER) Percentage of participants = 6.6 [0.4-25.8]; ; ",Cmax (GEOMETRIC_MEAN) ng/mL = 94.884; Tmax (MEDIAN) hours = 3.050 [2.95-6]; AUC(TAU) (GEOMETRIC_MEAN) h*ng/mL = 700.886; Ctrough (GEOMETRIC_MEAN) ng/mL = 12.020; CLT/F (GEOMETRIC_MEAN) L/h = 12.024; Accumulation Index (AI) - AUC(TAU) (GEOMETRIC_MEAN) Ratio = 2.966; Accumulation Index (AI) - Cmax (GEOMETRIC_MEAN) Ratio = 1.603; Change From Baseline in Serum Kynurenine (MEAN) microMolars = -208.7; Percent Change From Baseline in Serum Kynurenine (MEAN) Percent change = -37.7; Number of Participants With a Best Overall Response (BOR) - Part 1 and Clinical Pharmacology Substudies (COUNT_OF_PARTICIPANTS) Participants = 0; Percentage of Participants With an Objective Response Rate (ORR) - Part 1 and Clinical Pharmacology Substudies (NUMBER) Percentage of participants = 0 [0-97.5]; Median Duration of Response (DoR) - Part 1 and Clinical Pharmacology Substudies (MEDIAN) Weeks = 52.14; ; ; ; Number of Participants With a Positive Anti-Drug Antibody (ADA) Test (COUNT_OF_PARTICIPANTS) Participants = 1,,,,,Median Duration of Response (DoR) - Parts 2 and 3 (MEDIAN) Weeks = 134.14; Median Duration of Response (DoR) - Part 1 and Clinical Pharmacology Substudies (MEDIAN) Weeks = 52.14,,,Percentage of Participants With an Objective Response Rate (ORR)- Parts 2 and 3 (NUMBER) Percentage of participants = 0 [0.0-18.5]; Percentage of Participants With an Objective Response Rate (ORR) - Part 1 and Clinical Pharmacology Substudies (NUMBER) Percentage of participants = 0 [0-97.5],,Progression Free Survival Rate (PFSR) at 24 Weeks - Parts 2 and 3 (NUMBER) Percentage of participants = 6.6 [0.4-25.8],,,Percentage of Participants With an Objective Response Rate (ORR)- Parts 2 and 3 (NUMBER) Percentage of participants = 0 [0.0-18.5]; Percentage of Participants With an Objective Response Rate (ORR) - Part 1 and Clinical Pharmacology Substudies (NUMBER) Percentage of participants = 0 [0-97.5],"Number of Participants With AEs, SAEs, AEs Leading to Discontinuation and Deaths (COUNT_OF_PARTICIPANTS) Participants = 1",,
NCT02659059,Nivolumab in Combination With Ipilimumab (Part 1); Nivolumab Plus Ipilimumab in Combination With Chemotherapy (Part 2) as First Line Therapy in Stage ,A Study of Nivolumab in Combination With Ipilimumab (Part 1); and Nivolumab Plus Ipilimumab in Combination With Chemotherapy (Part 2) as First Line Therapy in Stage IV Non-Small Cell Lung Cancer (NSCL,Bristol-Myers Squibb,Bristol-Myers Squibb,INDUSTRY,COMPLETED,2016-02-15,2018-06-22,2022-03-07,INTERVENTIONAL,PHASE2,,,,Non-Small-Cell Lung Cancer,Non-Small-Cell Lung Cancer,1,2,3,BIOLOGICAL; DRUG,,,5,12,True,Yes,Objective Response Rate (ORR) by PD-L1 Positive and Negative Levels - Part 1 (NUMBER) Percentage of participants = 41.3 [33.0-50.0]; Number of Participants With Dose Limiting Toxicities (DLTs) - Part 2 (COUNT_OF_PARTICIPANTS) Participants = 1; Number of Participants With Adverse Events (AEs) - Part 2 (COUNT_OF_PARTICIPANTS) Participants = 36; Number of Participants With Laboratory Abnormalities in Hepatic Tests - Part 2 (COUNT_OF_PARTICIPANTS) Participants = 2; Number of Participants With Laboratory Abnormalities in Thyroid Tests - Part 2 (COUNT_OF_PARTICIPANTS) Participants = 10,Overall Survival (OS) - Part 1 (MEDIAN) Months = 20.83 [14.46-25.20]; Overall Survival (OS) - Part 2 (MEDIAN) Months = 19.35 [6.54-35.42]; Progression Free Survival (PFS) - Part 1 (MEDIAN) Months = 5.19 [3.06-5.82]; Progression Free Survival (PFS) - Part 2 (MEDIAN) Months = 10.81 [5.26-16.13]; Objective Response Rate (ORR) - Part 1 (NUMBER) Percentage of participants = 32.3 [26.9-38.0]; Objective Response Rate (ORR) - Part 2 (NUMBER) Percentage of participants = 47.2 [30.4-64.5]; Overall Survival (OS) by PD-L1 Expression Levels - Part 1 (MEDIAN) Months = 26.51 [17.12-43.17]; Progression Free Survival (PFS) by PD-L1 Expression Levels - Part 1 (MEDIAN) Months = 6.80 [4.17-10.97]; Objective Response Rate (ORR) by PD-L1 Expression Levels-Part 1 (NUMBER) Percentage of participants = 44.2 [35.8-52.9]; Overall Survival (OS) by Tumor Mutation Burden (TMB) Levels - Part 1 (MEDIAN) Months = 47.31; Progression Free Survival (PFS) by Tumor Mutation Burden (TMB) Levels - Part 1 (MEDIAN) Months = 10.84 [3.61-22.21]; Objective Response Rate (ORR) by Tumor Mutation Burden (TMB) Levels - Part 1 (NUMBER) Percentage of participants = 52.1 [37.2-66.7],,,,,,,,Objective Response Rate (ORR) by PD-L1 Positive and Negative Levels - Part 1 (NUMBER) Percentage of participants = 41.3 [33.0-50.0]; Objective Response Rate (ORR) - Part 1 (NUMBER) Percentage of participants = 32.3 [26.9-38.0]; Objective Response Rate (ORR) - Part 2 (NUMBER) Percentage of participants = 47.2 [30.4-64.5]; Objective Response Rate (ORR) by PD-L1 Expression Levels-Part 1 (NUMBER) Percentage of participants = 44.2 [35.8-52.9]; Objective Response Rate (ORR) by Tumor Mutation Burden (TMB) Levels - Part 1 (NUMBER) Percentage of participants = 52.1 [37.2-66.7],Overall Survival (OS) - Part 1 (MEDIAN) Months = 20.83 [14.46-25.20]; Overall Survival (OS) - Part 2 (MEDIAN) Months = 19.35 [6.54-35.42]; Overall Survival (OS) by PD-L1 Expression Levels - Part 1 (MEDIAN) Months = 26.51 [17.12-43.17]; Overall Survival (OS) by Tumor Mutation Burden (TMB) Levels - Part 1 (MEDIAN) Months = 47.31,Progression Free Survival (PFS) - Part 1 (MEDIAN) Months = 5.19 [3.06-5.82]; Progression Free Survival (PFS) - Part 2 (MEDIAN) Months = 10.81 [5.26-16.13]; Progression Free Survival (PFS) by PD-L1 Expression Levels - Part 1 (MEDIAN) Months = 6.80 [4.17-10.97]; Progression Free Survival (PFS) by Tumor Mutation Burden (TMB) Levels - Part 1 (MEDIAN) Months = 10.84 [3.61-22.21],,,Objective Response Rate (ORR) by PD-L1 Positive and Negative Levels - Part 1 (NUMBER) Percentage of participants = 41.3 [33.0-50.0]; Objective Response Rate (ORR) - Part 1 (NUMBER) Percentage of participants = 32.3 [26.9-38.0]; Objective Response Rate (ORR) - Part 2 (NUMBER) Percentage of participants = 47.2 [30.4-64.5]; Objective Response Rate (ORR) by PD-L1 Expression Levels-Part 1 (NUMBER) Percentage of participants = 44.2 [35.8-52.9]; Objective Response Rate (ORR) by Tumor Mutation Burden (TMB) Levels - Part 1 (NUMBER) Percentage of participants = 52.1 [37.2-66.7],Number of Participants With Adverse Events (AEs) - Part 2 (COUNT_OF_PARTICIPANTS) Participants = 36,,
NCT02664181,Rational EpigenetiC Immunotherapy for SEcond Line Therapy in Patients With NSCLC: PRECISE Trial,"Phase II Evaluation of Nivolumab, an Immune Checkpoint Inhibitor Alone or in Combination With Oral Decitabine/Tetrahydrouridine as Second Line Therapy for Non-small Cell Lung Cancer",Case Comprehensive Cancer Center,Case Comprehensive Cancer Center,OTHER,COMPLETED,2017-06-06,2019-07-02,2024-05-19,INTERVENTIONAL,PHASE2,,,,Lung Cancer,Lung Cancer; Non-small Cell Lung Cancer,2,2,3,DRUG,,,1,3,True,Yes,Objective Response by Response Evaluation Criteria in Solid Tumors (RECIST1.1) (COUNT_OF_PARTICIPANTS) Participants = 1,Time-to-Progression (MEDIAN) days = 227 [45-754]; Overall Survival (MEDIAN) Days = 844 [127-1183]; Overall Survival - Long Term Follow-up (LTFU) (MEAN) months = 5 [3-7],,,,,,,,,Overall Survival (MEDIAN) Days = 844 [127-1183]; Overall Survival - Long Term Follow-up (LTFU) (MEAN) months = 5 [3-7],,,,,,,
NCT02666105,Exemestane in Post-Menopausal Women With NSCLC,Phase II Trial of Exemestane in Previously Treated Post-Menopausal Women With Advanced Non-Small Cell Lung Cancer,"Masonic Cancer Center, University of Minnesota","Masonic Cancer Center, University of Minnesota",OTHER,COMPLETED,2018-09-27,2022-02-28,2022-02-28,INTERVENTIONAL,PHASE2,,,,Non-Small Cell Lung Cancer,Non-Small Cell Lung Cancer,1,1,1,DRUG,,,1,3,True,Yes,,Toxicity Assessment (NUMBER) Adverse Events = 14; Progression-free Survival (NUMBER) Percentage of participants = 17 [1-52]; Quality of Life Assessment (MEDIAN) Score on a scale = 44 [44-45],,,,,,,,,,Progression-free Survival (NUMBER) Percentage of participants = 17 [1-52],,Quality of Life Assessment (MEDIAN) Score on a scale = 44 [44-45],,Toxicity Assessment (NUMBER) Adverse Events = 14,,
NCT02681549,Pembrolizumab Plus Bevacizumab for Treatment of Brain Metastases in Metastatic Melanoma or Non-small Cell Lung Cancer (NSCLC),A Phase 2 Trial of Pembrolizumab Plus Bevacizumab in Patients With Metastatic Melanoma or Non-small Cell Lung Cancer With Untreated Brain Metastases,Yale University,Yale University,OTHER,COMPLETED,2016-05-01,2024-09-11,2025-03-31,INTERVENTIONAL,PHASE2,,,,Melanoma,Melanoma; Non-small Cell Lung Cancer; Brain Metastasis,3,2,1,DRUG,,,1,4,True,Yes,Brain Metastasis Response Rate (BMRR) (NUMBER) percentage of participants = 54.1,Steroid Use (COUNT_OF_PARTICIPANTS) Participants = 3; Overall Response Rate (ORR) (NUMBER) percentage of participants = 54.1; Progression-free Survival (PFS) (MEDIAN) years = 2.2; Safety and Toxicity of Combination Pembrolizumab and Bevacizumab Assessed Using Common Terminology Criteria for Adverse Events v. 4. (COUNT_OF_PARTICIPANTS) Participants = 32,,,,,,,,,,Progression-free Survival (PFS) (MEDIAN) years = 2.2,,,Brain Metastasis Response Rate (BMRR) (NUMBER) percentage of participants = 54.1; Overall Response Rate (ORR) (NUMBER) percentage of participants = 54.1,Safety and Toxicity of Combination Pembrolizumab and Bevacizumab Assessed Using Common Terminology Criteria for Adverse Events v. 4. (COUNT_OF_PARTICIPANTS) Participants = 32,,
NCT02684461,Phase II Trial of Sequential Consolidation With Pembrolizumab Followed by Nab-paclitaxel,Phase II Trial of Sequential Consolidation With Pembrolizumab Followed by Nab-paclitaxel After Standard First-Line Induction Chemotherapy in Advanced NSCLC,UNC Lineberger Comprehensive Cancer Center,UNC Lineberger Comprehensive Cancer Center,OTHER,COMPLETED,2016-09-13,2021-11-19,2021-11-19,INTERVENTIONAL,PHASE2,,,,Non Small Cell Lung Cancer,Non Small Cell Lung Cancer,1,3,1,DRUG,,,1,6,True,Yes,Overall Survival (MEDIAN) months = 27.6,Progression Free Survival (PFS) (MEDIAN) months = 10.1; Overall Rates of Response (ORR) (COUNT_OF_PARTICIPANTS) Participants = 1; Rates of Response in Arm A and Arm B (COUNT_OF_PARTICIPANTS) Participants = 1; Toxicity Profile (COUNT_OF_PARTICIPANTS) Participants = 2; Quality of Life (QOL) End of Treatment (COUNT_OF_PARTICIPANTS) Participants = 4; Quality of Life (QOL) 7 Weeks (COUNT_OF_PARTICIPANTS) Participants = 3,,,,,,,,,Overall Survival (MEDIAN) months = 27.6,Progression Free Survival (PFS) (MEDIAN) months = 10.1,,Quality of Life (QOL) End of Treatment (COUNT_OF_PARTICIPANTS) Participants = 4; Quality of Life (QOL) 7 Weeks (COUNT_OF_PARTICIPANTS) Participants = 3,,Toxicity Profile (COUNT_OF_PARTICIPANTS) Participants = 2,,
NCT02705820,Switch Maintenance Pembrolizumab in Patients With NSCLC After First Line Platinum Doublet Chemotherapy,A Phase II Study of Switch Maintenance Pembrolizumab in Patients With Non Small Cell Lung Cancer (NSCLC) Who do Not Progress After First Line Platinum Doublet Chemotherapy. (SWIPE),Bank of Cyprus Oncology Centre,Bank of Cyprus Oncology Centre,OTHER,COMPLETED,2016-04-25,2023-05-02,2023-05-02,INTERVENTIONAL,PHASE2,,,,Metastatic Non Small Cell Lung Cancer,Metastatic Non Small Cell Lung Cancer,1,1,1,DRUG,,,1,6,True,Yes,Immune Related Progression Free Survival (irPFS) at 1 Year (COUNT_OF_PARTICIPANTS) Participants = 16,Response Rates Using RECIST Version 1.1 (COUNT_OF_PARTICIPANTS) Participants = 1; Response Rates With Immune Related Response Criteria (irRC) (COUNT_OF_PARTICIPANTS) Participants = 1; Radiological Progression Free Survival (PFS) Using RECIST Criteria Version 1.1 (MEDIAN) months = 2.1 [0.0-4.2]; Immune-related PFS Using irRC (MEDIAN) months = 6.3 [4.2-8.4]; Overall Survival (MEDIAN) months = 12.2 [7.8-16.6]; Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0 (COUNT_OF_PARTICIPANTS) Participants = 48,,,,,,,,,Overall Survival (MEDIAN) months = 12.2 [7.8-16.6],Immune Related Progression Free Survival (irPFS) at 1 Year (COUNT_OF_PARTICIPANTS) Participants = 16; Radiological Progression Free Survival (PFS) Using RECIST Criteria Version 1.1 (MEDIAN) months = 2.1 [0.0-4.2]; Immune-related PFS Using irRC (MEDIAN) months = 6.3 [4.2-8.4],,,Response Rates Using RECIST Version 1.1 (COUNT_OF_PARTICIPANTS) Participants = 1; Response Rates With Immune Related Response Criteria (irRC) (COUNT_OF_PARTICIPANTS) Participants = 1,Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0 (COUNT_OF_PARTICIPANTS) Participants = 48,,
NCT02713529,Safety and Efficacy Study of AMG 820 and Pembrolizumab Combination in Select Advanced Solid Tumor Cancer,A Phase1b/2 Study Assessing Safety and Anti-tumor Activity of AMG 820 in Combination With Pembrolizumab in Select Advanced Solid Tumors,"AmMax Bio, Inc.","AmMax Bio, Inc.",INDUSTRY,COMPLETED,2016-04-14,2019-01-02,2019-05-17,INTERVENTIONAL,PHASE1; PHASE2,,,,Pancreatic Cancer,Pancreatic Cancer; Colorectal Cancer; Non-Small Cell Lung Cancer,3,1,1,BIOLOGICAL,,,5,13,True,Yes,Participants With Dose Limiting Toxicities (DLT) (COUNT_OF_PARTICIPANTS) Participants = 0; Participants With Treatment -Emergent Adverse Events (TEAEs) (COUNT_OF_PARTICIPANTS) Participants = 8; Participants With Treatment -Emergent Adverse Events (TEAEs) Related to AMG 820 Treatment (COUNT_OF_PARTICIPANTS) Participants = 5; Participants With Treatment -Emergent Adverse Events (TEAEs) Related to Pembrolizumab Treatment (COUNT_OF_PARTICIPANTS) Participants = 5; Objective Response Rate (ORR) Per Immune-Related Response Evaluation Criteria in Solid Tumors (irRECIST) (NUMBER) percentage of participants = 0.0 [0.00-0.00],Time to Response (TTR) Per Immune-Related Response Evaluation Criteria in Solid Tumors (irRECIST) For Participants Who Responded (MEAN) month = 2.1587 [2.004-2.168]; Time to Progression (TTP) for Participants Who Had Progressive Disease (MEAN) month = 2.1865 [0.460-5.552]; Kaplan-Meier Estimates for Overall Survival (OS) at Month 6 and Month 12 (NUMBER) percentage of participants = 59.077 [32.25-78.28]; Kaplan-Meier Estimates for Progression-Free Survival (PFS) as Per irRECIST at Month 6 and Month 12 (NUMBER) percentage of participants = 10.476 [1.23-31.40]; AMG 820 Pharmacokinetic Parameter by Dose Group: Time of Maximum Observed Concentration (Tmax) During Treatment Cycles 1 + 2 (MEDIAN) hour = 2.0 [1.0-170]; AMG 820 Pharmacokinetic Parameter by Dose Group: Maximum Observed Drug Concentration (Cmax) During Treatment Cycles 1 + 2 (GEOMETRIC_MEAN) ug/mL = 331; AMG 820 Pharmacokinetic Parameter by Dose Group: Area Under the Curve Last (AUClast) During Treatment Cycles 1 + 2 (GEOMETRIC_MEAN) hr*ug/mL = 55100; AMG 820 Pharmacokinetic Parameter by Dose Group: Area Under the Curve Over the Dose Interval (AUCtau) During Treatment Cycles 1 + 2 (GEOMETRIC_MEAN) hr*ug/mL = 59300; AMG 820 Pharmacokinetic Parameter by Dose Group: Minimum Observed Drug Concentration (Cmin) During Treatment Cycles 1 + 2 (GEOMETRIC_MEAN) ug/mL = 49.9; AMG 820 Pharmacokinetic Parameter by Dose Group: Terminal Elimination Half-life (t1/2z) During Treatment Cycles 1 + 2 (GEOMETRIC_MEAN) hour = 217; AMG 820 Pharmacokinetic Parameter by Dose Group: Volume of Distribution (Vz) During Treatment Cycles 1 + 2 (GEOMETRIC_MEAN) liter = 5200; AMG 820 Pharmacokinetic Parameter by Dose Group: Drug Clearance (CL) During Treatment Cycles 1 + 2 (GEOMETRIC_MEAN) liter/hour = 16.6; AMG 820 Pharmacokinetic Parameter by Dose Group: Accumulation Ratio (AR) (GEOMETRIC_MEAN) ratio = 1.23,,,,,,,,Objective Response Rate (ORR) Per Immune-Related Response Evaluation Criteria in Solid Tumors (irRECIST) (NUMBER) percentage of participants = 0.0 [0.00-0.00],Kaplan-Meier Estimates for Overall Survival (OS) at Month 6 and Month 12 (NUMBER) percentage of participants = 59.077 [32.25-78.28],Kaplan-Meier Estimates for Progression-Free Survival (PFS) as Per irRECIST at Month 6 and Month 12 (NUMBER) percentage of participants = 10.476 [1.23-31.40],,,Objective Response Rate (ORR) Per Immune-Related Response Evaluation Criteria in Solid Tumors (irRECIST) (NUMBER) percentage of participants = 0.0 [0.00-0.00],Participants With Treatment -Emergent Adverse Events (TEAEs) (COUNT_OF_PARTICIPANTS) Participants = 8; Participants With Treatment -Emergent Adverse Events (TEAEs) Related to AMG 820 Treatment (COUNT_OF_PARTICIPANTS) Participants = 5; Participants With Treatment -Emergent Adverse Events (TEAEs) Related to Pembrolizumab Treatment (COUNT_OF_PARTICIPANTS) Participants = 5,,Time to Progression (TTP) for Participants Who Had Progressive Disease (MEAN) month = 2.1865 [0.460-5.552]
NCT02730247,Clinical Trial of the Safety and Efficacy of the Addition of Ramucirumab to Nab-paclitaxel in Previously Treated Patients With Advanced Non-small Cell,A Phase II Clinical Trial of the Safety and Efficacy of the Addition of Ramucirumab to Nab-paclitaxel in Previously Treated Patients With Advanced Non-small Cell Lung Cancer (NSCLC),University of Pittsburgh,"Liza Villaruz, MD",OTHER,COMPLETED,2017-07-05,2019-09-08,2019-09-08,INTERVENTIONAL,PHASE2,,,,Non-small Cell Lung Cancer,Non-small Cell Lung Cancer,1,1,2,DRUG,,,5,3,True,Yes,"Progression-free Survival (PFS) (MEDIAN) months = 8.16; Worst Grade of Adverse Event Experienced (NUMBER) percentage of participants = 57.1 [20.0-87.6]; Worst Grade of Adverse Event Experienced, at Least Possibly Related to Treatment (NUMBER) percentage of participants = 14.3 [1.5-64.8]; Worst Grade of Adverse Event Experienced, at Least Probably Related to Treatment (NUMBER) percentage of participants = 14.3 [1.3-68.4]; Worst Grade of Adverse Event Experienced, Definitely Related to Treatment (NUMBER) proportion of participants = 71.4 [29.3-93.8]",Best Overall Response (MEDIAN) percentage of participants = 67.7 [22.3-95.7]; Overall Survival (OS) (MEDIAN) months = 7.42; Median EuroQol Five Dimension Questionnaire (EQ-5D-5L) Score (MEDIAN) EQ-5D-5L score = 1 [0-2],,,,,,,,,Overall Survival (OS) (MEDIAN) months = 7.42,Progression-free Survival (PFS) (MEDIAN) months = 8.16,,Median EuroQol Five Dimension Questionnaire (EQ-5D-5L) Score (MEDIAN) EQ-5D-5L score = 1 [0-2],,,,
NCT02737501,ALTA-1L Study: A Study of Brigatinib Versus Crizotinib in Anaplastic Lymphoma Kinase Positive (ALK+) Advanced Non-small Cell Lung Cancer (NSCLC) Parti,A Phase 3 Multicenter Open-label Study of Brigatinib (AP26113) Versus Crizotinib in Patients With ALK-positive Advanced Lung Cancer,Takeda,Ariad Pharmaceuticals,INDUSTRY,COMPLETED,2016-05-26,2020-07-28,2021-01-29,INTERVENTIONAL,PHASE3,,,,Non-small Cell Lung Cancer,Non-small Cell Lung Cancer; Lung Cancer; Advanced Malignancies,4,3,2,DRUG,,,1,9,True,Yes,Progression-free Survival (PFS) (MEDIAN) months = 24.016 [18.46-43.20],Confirmed Objective Response Rate (ORR) (NUMBER) percentage of participants = 74.5 [66.30-81.52]; Confirmed Intracranial ORR (iORR) (NUMBER) percentage of participants = 66.0 [50.69-79.14]; Intracranial Progression Free Survival (MEDIAN) months = 23.951 [12.91-30.78]; ; Duration of Response (DOR) (MEDIAN) months = 33.150 [1.84-50.60]; Time to Response (TTR) (MEDIAN) months = 1.840 [1.02-29.47]; Disease Control Rate (DCR) (NUMBER) percentage of participants = 85.4 [78.36-90.85]; Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) (NUMBER) percentage of participants = 100; Change From Baseline in Global Health Status/Quality of Life as Assessed by EORTC QLQ-C30 (Version 3.0) (MEAN) score on a scale = 4.007,,,,,Duration of Response (DOR) (MEDIAN) months = 33.150 [1.84-50.60],,,Confirmed Objective Response Rate (ORR) (NUMBER) percentage of participants = 74.5 [66.30-81.52]; Confirmed Intracranial ORR (iORR) (NUMBER) percentage of participants = 66.0 [50.69-79.14],,Progression-free Survival (PFS) (MEDIAN) months = 24.016 [18.46-43.20]; Intracranial Progression Free Survival (MEDIAN) months = 23.951 [12.91-30.78],,Change From Baseline in Global Health Status/Quality of Life as Assessed by EORTC QLQ-C30 (Version 3.0) (MEAN) score on a scale = 4.007,Confirmed Objective Response Rate (ORR) (NUMBER) percentage of participants = 74.5 [66.30-81.52],Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) (NUMBER) percentage of participants = 100,,
NCT02754882,A Study Comparing SB8 and Avastin® in Patients With Advanced Non-squamous Non-small Cell Lung Cancer,"A Phase 3, Randomised, Double-blind Study to Compare the Efficacy, Safety, PK and Immunogenicity Between SB8 (Proposed Bevacizumab Biosimilar) and Avastin® in Subjects With Metastatic or Recurrent Non","Samsung Bioepis Co., Ltd.","Samsung Bioepis Co., Ltd.",INDUSTRY,COMPLETED,2016-07-05,2018-01-24,2018-10-09,INTERVENTIONAL,PHASE3,,,,Lung Cancer,Lung Cancer; Non-small Cell Lung Cancer,2,2,4,DRUG,,,1,8,True,Yes,Percentage of Participants With Best Overall Response (Best Overall Response Rate[ORR]) by 24 Weeks (NUMBER) percentage of participants = 42.8,Progression Free Survival (MEDIAN) months = 8.50 [7.40-9.70]; Overall Survival (MEDIAN) months = 14.90 [13.30-17.10]; Duration of Response (DoR) (MEAN) months = 6.38; Number of Participants With Treatment-related Adverse Events Using National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) v4.03 (COUNT_OF_PARTICIPANTS) Participants = 348; Pharmacokinetics: Trough Level [Ctrough] (MEAN) ug/mL = 0.0000; Pharmacokinetics: Maximum Plasma Concentration [Cmax] (MEAN) ug/mL = 306.0352; Immunogenicity Assessments (Anti-drug Antibodies) (COUNT_OF_PARTICIPANTS) Participants = 15; Immunogenicity Assessments (Neutralizing Antibodies) (COUNT_OF_PARTICIPANTS) Participants = 0,,,,,Duration of Response (DoR) (MEAN) months = 6.38,,,,Overall Survival (MEDIAN) months = 14.90 [13.30-17.10],Progression Free Survival (MEDIAN) months = 8.50 [7.40-9.70],,,Percentage of Participants With Best Overall Response (Best Overall Response Rate[ORR]) by 24 Weeks (NUMBER) percentage of participants = 42.8,Number of Participants With Treatment-related Adverse Events Using National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) v4.03 (COUNT_OF_PARTICIPANTS) Participants = 348,,
NCT02773238,FLARE RT for Patients With Stage IIB-IIIB Non-small Cell Lung Cancer: Personalizing Radiation Therapy Using PET/CT and SPECT/CT Imaging,Personalized Radiation Therapy Through Functional Lung Avoidance and Response-Adaptive Dose Escalation: Utilizing Multimodal Molecular Imaging to Improve the Therapeutic Ratio (FLARE RT),University of Washington,University of Washington,OTHER,COMPLETED,2016-05-20,2023-06-01,2023-12-01,INTERVENTIONAL,PHASE2,,,,Stage IIB Lung Non-Small Cell Carcinoma AJCC v7,Stage IIB Lung Non-Small Cell Carcinoma AJCC v7; Stage IIIA Lung Non-Small Cell Cancer AJCC v7; Stage IIIB Lung Non-Small Cell Cancer AJCC v7,3,1,9,OTHER; PROCEDURE; RADIATION,,,1,5,True,Yes,Overall Survival (OS) Rate (NUMBER) percentage of patients = 54.2 [41.8-70.4],Radiation Pneumonitis Defined as Common Terminology Criteria for Adverse Events Version 4 Grade 2 or Higher Pneumonitis (COUNT_OF_PARTICIPANTS) Participants = 17; Local-Regional Progression as Defined by Response Evaluation Criteria In Solid Tumors (RECIST) Criteria (NUMBER) percentage of patients = 12.2 [4.9-23.2]; Progression-free Survival (PFS) (NUMBER) percentage of patients = 53.1 [40.9-69]; Change in Pulmonary Function-forced Expiratory Volume in 1 Second (FEV1) (MEAN) liters = -0.15; Change in Pulmonary Function (Diffusing Capacity of the Lungs for Carbon Monoxide [DLCO]) (MEAN) percentage of predicted lung function = -8,,,,,,,,,Overall Survival (OS) Rate (NUMBER) percentage of patients = 54.2 [41.8-70.4],Progression-free Survival (PFS) (NUMBER) percentage of patients = 53.1 [40.9-69],,,,Radiation Pneumonitis Defined as Common Terminology Criteria for Adverse Events Version 4 Grade 2 or Higher Pneumonitis (COUNT_OF_PARTICIPANTS) Participants = 17,,
NCT02774278,A Study of Erlotinib (Tarceva) in Participants With Non-Small Cell Lung Cancer (NSCLC),MERIT - A Phase II Marker Identification Trial for Tarceva in Second Line NSCLC Patients,Hoffmann-La Roche,Hoffmann-La Roche,INDUSTRY,COMPLETED,2005-07,2009-06,2009-06,INTERVENTIONAL,PHASE2,,,,Non-Squamous Non-Small Cell Lung Cancer,Non-Squamous Non-Small Cell Lung Cancer,1,1,1,DRUG,,,3,2,True,Yes,Number of Differentially Expressed Genes Associated With Clinical Benefit (NUMBER) genes = 0; Number of Epidermal Growth Factor Receptor (EGFR) Mutation Participants Who Achieved Clinical Benefit (NUMBER) participants = 6; Number of KRAS Mutation Participants Who Achieved Clinical Benefit (NUMBER) participants = 4,"Percentage of Participants With Overall Response of Complete Response (CR) or Partial Response (PR) Using Response Evaluation Criteria in Solid Tumors (RECIST) (NUMBER) percentage of participants = 15.2 [11.1-20.1]; Percentage of Participants With Clinical Benefit (CR, PR, or Stable Disease [SD] for at Least 12 Weeks After Study Entry) Using RECIST (NUMBER) percentage of participants = 31.4 [25.9-37.4]",,Percentage of Participants With Overall Response of Complete Response (CR) or Partial Response (PR) Using Response Evaluation Criteria in Solid Tumors (RECIST) (NUMBER) percentage of participants = 15.2 [11.1-20.1],,,,,,,,,Percentage of Participants With Overall Response of Complete Response (CR) or Partial Response (PR) Using Response Evaluation Criteria in Solid Tumors (RECIST) (NUMBER) percentage of participants = 15.2 [11.1-20.1],,,,,
NCT02775435,A Study of Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With First Line Metastatic Squamous No,"A Randomized, Double-Blind, Phase III Study of Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy With or Without Pembrolizumab (MK-3475) in First Line Metastatic Squamous Non-small Cell Lung Cancer S",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,INDUSTRY,COMPLETED,2016-06-09,2018-04-03,2023-09-14,INTERVENTIONAL,PHASE3,,,,Non-small Cell Lung Cancer,Non-small Cell Lung Cancer,1,2,5,BIOLOGICAL; DRUG,,,2,4,True,Yes,Progression-free Survival (PFS) as Assessed by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) (MEDIAN) Months = 6.4 [6.2-8.3]; Overall Survival (OS) (MEDIAN) Months = 15.9,Objective Response Rate (ORR) as Assessed by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) (NUMBER) Percentage of Participants = 57.9 [51.9-63.8]; Duration of Response (DOR) as Assessed by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) (MEDIAN) Months = 7.7 [1.1-14.7]; Number of Participants Who Experienced an Adverse Event (AE) (COUNT_OF_PARTICIPANTS) Participants = 274; Number of Participants Who Discontinued Study Treatment Due to an Adverse Event (AE) (COUNT_OF_PARTICIPANTS) Participants = 80,,,,,Duration of Response (DOR) as Assessed by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) (MEDIAN) Months = 7.7 [1.1-14.7],,,Objective Response Rate (ORR) as Assessed by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) (NUMBER) Percentage of Participants = 57.9 [51.9-63.8],Overall Survival (OS) (MEDIAN) Months = 15.9,Progression-free Survival (PFS) as Assessed by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) (MEDIAN) Months = 6.4 [6.2-8.3],,,Objective Response Rate (ORR) as Assessed by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) (NUMBER) Percentage of Participants = 57.9 [51.9-63.8],,,
NCT02795156,Study Assessing Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations,Phase II Study to Evaluate the Activity of Commercially Available Molecularly Matched Targeted Therapies in Selected Tumor Types Based on Genomic Alterations,"SCRI Development Innovations, LLC","SCRI Development Innovations, LLC",OTHER,COMPLETED,2016-09-28,2022-08-17,2022-08-17,INTERVENTIONAL,PHASE2,,,,Non-small Cell Lung Carcinoma,"Non-small Cell Lung Carcinoma; Urothelial Carcinoma; Gastrointestinal Carcinoma, Non-colon",4,4,3,DRUG,,,1,3,True,Yes,Overall Response Rate (ORR) in Each Arm Receiving Targeted Therapy Based on Relevant Genomic Alterations (NUMBER) percentage of participants = 10.3 [2.87-24.22],Clinical Benefit Rate in Each Arm Receiving Targeted Therapy Based on Relevant Genomic Alterations (NUMBER) percentage of participants = 15.4 [5.86-30.5]; Time to Treatment Failure (TTF) in Each Arm Receiving Targeted Therapy Based on Relevant Genomic Alterations (MEDIAN) months = 2.1 [1.6-2.8]; Progression-Free Survival in Each Arm Receiving Targeted Therapy Based on Relevant Genomic Alterations (MEDIAN) months = 3.2 [2.7-4.4],Clinical Benefit Rate in Each Arm Receiving Targeted Therapy Based on Relevant Genomic Alterations (NUMBER) percentage of participants = 15.4 [5.86-30.5],,,,,,,,,Progression-Free Survival in Each Arm Receiving Targeted Therapy Based on Relevant Genomic Alterations (MEDIAN) months = 3.2 [2.7-4.4],,,Overall Response Rate (ORR) in Each Arm Receiving Targeted Therapy Based on Relevant Genomic Alterations (NUMBER) percentage of participants = 10.3 [2.87-24.22],,Time to Treatment Failure (TTF) in Each Arm Receiving Targeted Therapy Based on Relevant Genomic Alterations (MEDIAN) months = 2.1 [1.6-2.8],
NCT02803203,Osimertinib and Bevacizumab as Treatment for EGFR-mutant Lung Cancers,A Phase 1/2 Study of Combination Osimertinib and Bevacizumab as Treatment for Patients With EGFR-mutant Lung Cancers,Memorial Sloan Kettering Cancer Center,Memorial Sloan Kettering Cancer Center,OTHER,COMPLETED,2016-06-29,2022-03-01,2022-03-01,INTERVENTIONAL,PHASE1; PHASE2,,,,Non-small Cell Lung Cancer,Non-small Cell Lung Cancer; EGFR-mutant Lung Cancers,2,1,2,DRUG,,,3,0,True,Yes,Osimertinib Maximum Tolerated Dose (MTD) (Phase I) (NUMBER) mg = 80; Bevacizumab Maximum Tolerated Dose (MTD) (Phase I) (NUMBER) mg/kg = 15; Progression-free Survival (Phase II) (COUNT_OF_PARTICIPANTS) Participants = 34,,,,,,,,,,,Progression-free Survival (Phase II) (COUNT_OF_PARTICIPANTS) Participants = 34,,,,,,
NCT02818920,Neoadjuvant Pembrolizumab,"Pembrolizumab Prior to Surgery for Stage 1B, 2 or 3A Non-small Cell Lung Cancer (NSCLC): A Phase II Study",Duke University,Neal Ready MD PhD,OTHER,ACTIVE_NOT_RECRUITING,2017-01,2019-03-19,2026-03,INTERVENTIONAL,PHASE2,,,,Non-small Cell Lung Carcinoma,Non-small Cell Lung Carcinoma,1,1,1,DRUG,,,1,0,True,Yes,Surgical Feasibility Rate as Measured by the Number of Subjects Who Undergo Surgery Following Neoadjuvant Pembrozulimab (COUNT_OF_PARTICIPANTS) Participants = 24,,,,,,,,,,,,,,,,,
NCT02823990,TG4010 and Nivolumab in Patients With Lung Cancer,Phase II Trial of TG4010 Plus Nivolumab in Previously Treated Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC),"University of California, Davis","Megan Daly, MD",OTHER,COMPLETED,2016-12-14,2021-02-24,2021-02-24,INTERVENTIONAL,PHASE2,,,,Recurrent Non-Small Cell Lung Carcinoma,Recurrent Non-Small Cell Lung Carcinoma; Stage I Non-Small Cell Lung Cancer; Stage II Non-Small Cell Lung Cancer,6,1,2,BIOLOGICAL,,,1,6,True,Yes,ORR Defined as the Proportion of Patients Whose Best Overall Response (BOR) is Either Complete Response (CR) or Partial Response (PR) According to RECIST 1.1 (NUMBER) Proportion of evaluable participants = 0.083,"Disease Control Rate (DCR) Defined as the Proportion of Patients Whose Best Overal Response is Either CR, PR or SD, Assessed by RECIST 1.1 (NUMBER) Proportion of evaluable participants = 0.25; Duration of Response (DOR) Defined as Patients Whose Best Overall Response is CR or PR (Confirmed Response) (MEAN) years = 4 [4-4]; Number of Participants With Adverse Events Reported Per CTCAE v4.0 (COUNT_OF_PARTICIPANTS) Participants = 13; Overall Survival (OS) (MEDIAN) days = 220 [171-341]; Progression Free Survival (PFS) Defined by RECIST 1.1 (MEDIAN) days = 41 [39-124]; Stable Disease (SD) Rate Defined as the Proportion of Patients Whose Best Overall Response (BOR) is SD, Assessed by RECIST 1.1 (NUMBER) Proportion of evaluable participants = 0.17",,ORR Defined as the Proportion of Patients Whose Best Overall Response (BOR) is Either Complete Response (CR) or Partial Response (PR) According to RECIST 1.1 (NUMBER) Proportion of evaluable participants = 0.083; Duration of Response (DOR) Defined as Patients Whose Best Overall Response is CR or PR (Confirmed Response) (MEAN) years = 4 [4-4],,,Duration of Response (DOR) Defined as Patients Whose Best Overall Response is CR or PR (Confirmed Response) (MEAN) years = 4 [4-4],,,ORR Defined as the Proportion of Patients Whose Best Overall Response (BOR) is Either Complete Response (CR) or Partial Response (PR) According to RECIST 1.1 (NUMBER) Proportion of evaluable participants = 0.083,Overall Survival (OS) (MEDIAN) days = 220 [171-341],Progression Free Survival (PFS) Defined by RECIST 1.1 (MEDIAN) days = 41 [39-124],"ORR Defined as the Proportion of Patients Whose Best Overall Response (BOR) is Either Complete Response (CR) or Partial Response (PR) According to RECIST 1.1 (NUMBER) Proportion of evaluable participants = 0.083; Disease Control Rate (DCR) Defined as the Proportion of Patients Whose Best Overal Response is Either CR, PR or SD, Assessed by RECIST 1.1 (NUMBER) Proportion of evaluable participants = 0.25; Duration of Response (DOR) Defined as Patients Whose Best Overall Response is CR or PR (Confirmed Response) (MEAN) years = 4 [4-4]",,,Number of Participants With Adverse Events Reported Per CTCAE v4.0 (COUNT_OF_PARTICIPANTS) Participants = 13,,
NCT02838420,A Study to Evaluate and Compare the Efficacy and Safety of Alectinib Versus Crizotinib and to Evaluate the Pharmacokinetics of Alectinib in Asian Part,"Randomized, Multicenter, Phase III, Open-Label Study of Alectinib Versus Crizotinib in Asian Patients With Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer",Hoffmann-La Roche,Hoffmann-La Roche,INDUSTRY,ACTIVE_NOT_RECRUITING,2016-08-03,2018-05-31,2026-06-30,INTERVENTIONAL,PHASE3,,,,Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer,Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer,1,2,2,DRUG,,,1,12,True,Yes,,; ; ; ; ; ; Percentage of Participants With Non-serious Adverse Events and Serious Adverse Events (NUMBER) Percentage of Participants = 15.2; ; ; Area Under the Plasma Concentration-time Curve (AUC) of Alectinib and Its Metabolite (MEAN) Hours*nanogram/milliliter (hr*ng/mL) = 1590; Maximum Plasma Concentration Observed (Cmax) of Alectinib and Its Metabolite (MEAN) Nanograms/milliliter (ng/mL) = 255; Time to Cmax (Tmax) of Alectinib and Its Metabolite (MEAN) Hour (hr) = 5.61,,,,,,,,,,,,,,Percentage of Participants With Non-serious Adverse Events and Serious Adverse Events (NUMBER) Percentage of Participants = 15.2,,
NCT02839265,FLT3 Ligand Immunotherapy and Stereotactic Radiotherapy for Advanced Non-small Cell Lung Cancer,FLT3 Ligand Immunotherapy and Stereotactic Radiotherapy for Advanced Non-small Cell Lung Cancer,Albert Einstein College of Medicine,Albert Einstein College of Medicine,OTHER,COMPLETED,2016-07,2022-10-05,2024-11-22,INTERVENTIONAL,PHASE2,,,,Non-small Cell Lung Cancer (NSCLC),Non-small Cell Lung Cancer (NSCLC),1,1,2,DRUG; RADIATION,,,1,4,True,Yes,Progression-Free Survival (COUNT_OF_PARTICIPANTS) Participants = 14,Dose Limiting Toxicities (DLTs) (COUNT_OF_PARTICIPANTS) Participants = 4; Radiographic Response Rate Based on Response Evaluation Criteria in Solid Tumors (RECIST) (COUNT_OF_PARTICIPANTS) Participants = 0; Radiographic Response Rate Based on PET Response Criteria in Solid Tumors (PERCIST) (COUNT_OF_PARTICIPANTS) Participants = 0; Overall Survival (OS) (COUNT_OF_PARTICIPANTS) Participants = 3,,,,,,,,,Overall Survival (OS) (COUNT_OF_PARTICIPANTS) Participants = 3,Progression-Free Survival (COUNT_OF_PARTICIPANTS) Participants = 14,,,Radiographic Response Rate Based on Response Evaluation Criteria in Solid Tumors (RECIST) (COUNT_OF_PARTICIPANTS) Participants = 0; Radiographic Response Rate Based on PET Response Criteria in Solid Tumors (PERCIST) (COUNT_OF_PARTICIPANTS) Participants = 0,,,
NCT02841579,Osimertinib (AZD9291) in First-line Locally Advanced or Metastatic NSCLC Patients With EGFR and EGFR T790M,A Phase IIa Clinical Trial to Evaluate the Safety and Efficacy of Osimertinib (AZD9291) in First-line Patients With EGFR Mutation-positive Locally Advanced or Metastatic NSCLC and Concomitant EGFR T79,MedSIR,MedSIR,OTHER,COMPLETED,2016-09-02,2018-12,2020-02-14,INTERVENTIONAL,PHASE2,,,,Non-Small Cell Lung Cancer,Non-Small Cell Lung Cancer,1,1,1,DRUG,,,1,13,True,Yes,Objective Response Rate (ORR) (NUMBER) percentage of patients = 77.3 [54.6-89.3],Overall Survival (OS) (MEDIAN) months = 28.39; Duration of Response (DoR) (MEDIAN) months = 20.0; Disease Control Rate (COUNT_OF_PARTICIPANTS) Participants = 19; Tumor Shrinkage (COUNT_OF_PARTICIPANTS) Participants = 17; Overall Plasma EGFR Mutation Status at Baseline (COUNT_OF_PARTICIPANTS) Participants = 15; Overall Plasma Acquired Resistance to Osimertinib (AZD9291) (COUNT_OF_PARTICIPANTS) Participants = 7; Number of Participants With Grade 3 or 4 Adverse Events and SAEs (COUNT_OF_PARTICIPANTS) Participants = 10; Progression-free Survival (MEDIAN) months = 23.1; Overall Plasma EGFR Mutation Status at Two Weeks After the First Study Dose (COUNT_OF_PARTICIPANTS) Participants = 5; Overall Plasma EGFR Mutation Status at Disease Progression (COUNT_OF_PARTICIPANTS) Participants = 8; Plasma EGFR Thr790Met Mutation Status at Baseline (COUNT_OF_PARTICIPANTS) Participants = 2; Plasma EGFR Thr790Met Mutation Status at Two Weeks After the First Study Dose (COUNT_OF_PARTICIPANTS) Participants = 2; Plasma EGFR Thr790Met Mutation Status at Disease Progression (COUNT_OF_PARTICIPANTS) Participants = 2,,,,,Duration of Response (DoR) (MEDIAN) months = 20.0,,,Objective Response Rate (ORR) (NUMBER) percentage of patients = 77.3 [54.6-89.3],Overall Survival (OS) (MEDIAN) months = 28.39,Progression-free Survival (MEDIAN) months = 23.1,,,Objective Response Rate (ORR) (NUMBER) percentage of patients = 77.3 [54.6-89.3],Number of Participants With Grade 3 or 4 Adverse Events and SAEs (COUNT_OF_PARTICIPANTS) Participants = 10,,
NCT02848651,A Study of Atezolizumab as First-line Monotherapy for Advanced or Metastatic Non-Small Cell Lung Cancer,A Phase II Single-Arm Study of Atezolizumab Monotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer: Clinical Evaluation of Novel Blood-Based Diagnostics,"Genentech, Inc.","Genentech, Inc.",INDUSTRY,COMPLETED,2016-09-23,2019-05-14,2019-05-14,INTERVENTIONAL,PHASE2,,,,Non-Small Cell Lung Cancer,Non-Small Cell Lung Cancer,1,1,1,DRUG,,,2,8,True,Yes,"Percentage of Participants With Objective Response Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) as Determined by Investigator (NUMBER) Percentage of Participants = 17.1 [11.62-23.86]; Progression-Free Survival (PFS) Per RECIST v1.1 as Determined by Investigator, by Positive Versus Negative bTMB Groups (MEDIAN) Months = 3.55 [2.63-4.30]","Progression-Free Survival (PFS) Per RECIST v1.1 as Determined by Investigator (MEDIAN) Months = 4.14 [2.76-4.90]; Duration of Response (DOR) Per RECIST v1.1 as Determined by Investigator (NUMBER) Months = 16.33; Disease Control Rate (DCR) Per RECIST v1.1 as Determined by Investigator (NUMBER) Percentage = 32.9 [25.50-40.74]; Overall Survival (OS) (MEDIAN) Months = 14.82 [12.68-21.29]; Percentage of Participants With Adverse Events (NUMBER) Percentage of Participants = 100; Percentage of Participants Who Are Alive and Progression-Free (Per RECIST v1.1) at 6, 9, 12, and 18 Months by Various bTMB Quantiles (NUMBER) Percentage of Participants = 35.67 [23.91-47.43]; OS by Various bTMB Cutoff Points 16 and 20 (MEDIAN) Months = 13.37 [11.70-18.00]; Percentage of Participants With Objective Response (Per RECIST v1.1) by Various bTMB Quantiles (NUMBER) Percentage of Participants = 7.1 [2.86-15.32]",,,,,Duration of Response (DOR) Per RECIST v1.1 as Determined by Investigator (NUMBER) Months = 16.33,,,,Overall Survival (OS) (MEDIAN) Months = 14.82 [12.68-21.29]; OS by Various bTMB Cutoff Points 16 and 20 (MEDIAN) Months = 13.37 [11.70-18.00],"Progression-Free Survival (PFS) Per RECIST v1.1 as Determined by Investigator, by Positive Versus Negative bTMB Groups (MEDIAN) Months = 3.55 [2.63-4.30]; Progression-Free Survival (PFS) Per RECIST v1.1 as Determined by Investigator (MEDIAN) Months = 4.14 [2.76-4.90]",,,,Percentage of Participants With Adverse Events (NUMBER) Percentage of Participants = 100,,
NCT02855125,A Randomized Phase 2 Trial of TAS-114 in Combination With S-1 Versus S-1,"A Randomized, Open-Label, Multi-Center, International Phase 2 Study of TAS-114 in Combination With S-1 in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer","Taiho Oncology, Inc.","Taiho Oncology, Inc.",INDUSTRY,COMPLETED,2016-08-29,2017-09-30,2017-11-30,INTERVENTIONAL,PHASE2,,,,Advanced or Metastatic Non-small Cell Lung Cancer,Advanced or Metastatic Non-small Cell Lung Cancer,1,2,2,DRUG,,,1,5,True,Yes,Progression-free Survival (PFS) Based on Central Independent Review (MEDIAN) months = 3.65 [2.69-5.16],Overall Survival (OS) (MEDIAN) months = 7.92 [6.28-10.78]; Overall Response Rate (ORR) Based on Central Independent Review (NUMBER) percentage of participants = 19.7 [10.6-31.8]; Disease Control Rate (DCR) Based on Central Independent Review (NUMBER) percentage of participants = 80.3 [68.2-89.4]; Duration of Response (DR) Based on Central Independent Review (MEDIAN) months = 3.38 [2.37-4.86]; Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs) (COUNT_OF_PARTICIPANTS) Participants = 64,,,,,Duration of Response (DR) Based on Central Independent Review (MEDIAN) months = 3.38 [2.37-4.86],,,,Overall Survival (OS) (MEDIAN) months = 7.92 [6.28-10.78],Progression-free Survival (PFS) Based on Central Independent Review (MEDIAN) months = 3.65 [2.69-5.16],,,Overall Response Rate (ORR) Based on Central Independent Review (NUMBER) percentage of participants = 19.7 [10.6-31.8],Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs) (COUNT_OF_PARTICIPANTS) Participants = 64,,
NCT02864251,A Study of Nivolumab + Chemotherapy or Nivolumab + Ipilimumab Versus Chemotherapy in Non-Small Cell Lung Cancer (NSCLC) Participants With Epidermal Gr,"Open-Label, Randomized Trial of Nivolumab (BMS-936558) Plus Pemetrexed/Platinum or Nivolumab Plus Ipilimumab (BMS-734016) vs Pemetrexed Plus Platinum in Stage IV or Recurrent Non-Small Cell Lung Cance",Bristol-Myers Squibb,Bristol-Myers Squibb,INDUSTRY,COMPLETED,2017-03-17,2022-01-20,2022-10-17,INTERVENTIONAL,PHASE3,,,,Non-Small-Cell Lung Carcinoma,Non-Small-Cell Lung Carcinoma,1,3,5,BIOLOGICAL; DRUG,,,1,5,True,Yes,Progression Free Survival (PFS) by Blinded Independent Centralized Review (BICR) (MEDIAN) Months = 5.59 [4.47-6.80],Overall Survival (OS) (MEDIAN) Months = 19.35 [16.13-20.99]; Objective Response Rate (ORR) by Blinded Independent Centralized Review (BICR) (NUMBER) Percent of Participants = 30.6 [23.2-38.8]; Duration of Response (DOR) by Blinded Independent Centralized Review (BICR) (MEDIAN) Months = 6.67 [4.17-12.45]; 9 Month Progression Free Survival Rates (PFSR) by Blinded Independent Centralized Review (BICR) (NUMBER) Percent of Participants = 25.9 [18.4-34.0]; 12 Month Progression Free Survival Rates (PFSR) by Blinded Independent Centralized Review (BICR) (NUMBER) Percent of Participants = 21.2 [14.3-29.1],,,,,Duration of Response (DOR) by Blinded Independent Centralized Review (BICR) (MEDIAN) Months = 6.67 [4.17-12.45],,,Objective Response Rate (ORR) by Blinded Independent Centralized Review (BICR) (NUMBER) Percent of Participants = 30.6 [23.2-38.8],Overall Survival (OS) (MEDIAN) Months = 19.35 [16.13-20.99],Progression Free Survival (PFS) by Blinded Independent Centralized Review (BICR) (MEDIAN) Months = 5.59 [4.47-6.80]; 9 Month Progression Free Survival Rates (PFSR) by Blinded Independent Centralized Review (BICR) (NUMBER) Percent of Participants = 25.9 [18.4-34.0]; 12 Month Progression Free Survival Rates (PFSR) by Blinded Independent Centralized Review (BICR) (NUMBER) Percent of Participants = 21.2 [14.3-29.1],,,Objective Response Rate (ORR) by Blinded Independent Centralized Review (BICR) (NUMBER) Percent of Participants = 30.6 [23.2-38.8],,,
NCT02864992,Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION),A Phase II Single-arm Trial to Investigate Tepotinib in Advanced (Locally Advanced or Metastatic) Non-small Cell Lung Cancer With METex14 Skipping Alterations or MET Amplification (VISION),EMD Serono,"EMD Serono Research & Development Institute, Inc.",INDUSTRY,ACTIVE_NOT_RECRUITING,2016-09-13,2022-05-16,2025-10-31,INTERVENTIONAL,PHASE2,,,,Advanced (Stage IIIB/IV) Non-small Cell Lung Cancer (NSCLC) With MET Exon 14 (METex14) Skipping Alte,Advanced (Stage IIIB/IV) Non-small Cell Lung Cancer (NSCLC) With MET Exon 14 (METex14) Skipping Alterations or MET Amplification; Lung Adenocarcinoma Stage IIIB/IV,2,3,1,DRUG,,,3,14,True,Yes,Part 1: Cohort A: Objective Response According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Independent Review Committee (IRC) (NUMBER) percentage of participants = 46.7 [38.6-55.0]; Part 1: Cohort B: Objective Response According to Response Evaluation Criteria in Solid Tumors Version 1.1 as Assessed by Independent Review Committee (IRC) (NUMBER) percentage of participants = 41.7 [22.1-63.4]; Part 2: Cohort C: Objective Response According to Response Evaluation Criteria in Solid Tumors Version 1.1 as Assessed by Independent Review Committee (IRC) (NUMBER) percentage of participants = 54.7 [46.6-62.5],; ; ; ; ; ; ; ; ; ; ; ; ; ; ,,,,,,,,,,,,,,,,
NCT02879617,A Clinical Trial of Durvalumab (MEDI4736) as 1st Line Therapy in Advanced Non-small Cell Lung Cancer Patients,A Phase II Clinical Trial Evaluating the Safety and Efficacy of Durvalumab (MEDI4736) as 1st Line Therapy in Advanced Non-small Cell Lung Cancer (NSCLC) Patients With Eastern Cooperative Oncology Grou,Academic Thoracic Oncology Medical Investigators Consortium,Academic Thoracic Oncology Medical Investigators Consortium,INDUSTRY,COMPLETED,2017-04-04,2022-06-04,2022-06-04,INTERVENTIONAL,PHASE2,,,,Non-Small Cell Lung Cancer NSCLC,Non-Small Cell Lung Cancer NSCLC,1,1,1,DRUG,,,4,19,True,Yes,Overall Survival (OS) (MEDIAN) months = 6.00 [4.00-10.00]; Overall Survival (OS12) (NUMBER) participants = 15; Overall Survival (OS24) (NUMBER) participants = 8; Treatment-related Adverse Events ≥ Grade 3 (COUNT_OF_PARTICIPANTS) Participants = 1,Progression-Free Survival (PFS) (MEDIAN) months = 3.00 [1.00-4.00]; Progression-Free Survival (PFS) at 12 Months (NUMBER) participants = 7; Progression-Free Survival (PFS) at 24 Months (NUMBER) participants = 4; Progression-Free Survival (PFS) by PD-L1 Expression at 12 Months (NUMBER) participants = 1; Progression-Free Survival (PFS) by PD-L1 Expression Status at 24 Months (NUMBER) participants = 0; Overall Survival by PD-L1 Expression Status at 12 Months (NUMBER) participants = 5; Overall Survival by PD-L1 Expression Status at 24 Months (NUMBER) participants = 3; Overall Response Rate (ORR) (NUMBER) percentage of participants = 26; Overall Response Rate (ORR) in Patients With PD-L1 Expression Status = 0 (NUMBER) percentage of participants = 31; Overall Response Rate (ORR) in Patients With PD-L1 Expression Status = 0%<PD-L1<50%. (NUMBER) percentage of participants = 30; Overall Response Rate (ORR) in Patients With PD-L1 Expression Status ≥50% (NUMBER) percentage of participants = 25; Health Related Quality of Life (HRQL) - FACT-G (MEAN) score on a scale = 78.2908; Health Related Quality of Life (HRQL) - FACT-G (MEAN) score on a scale = 76.6788; Health Related Quality of Life (HRQL) - FACT-G (MEAN) score on a scale = 80.5103; Health Related Quality of Life (HRQL) - FACT-G (MEAN) score on a scale = 80.0166; FACT Lung Cancer Subscale (LCS) (MEAN) score on a scale = 18.5; FACT Lung Cancer Subscale (LCS) (MEAN) score on a scale = 17.4090; FACT Lung Cancer Subscale (LCS) (MEAN) score on a scale = 19.6346; FACT Lung Cancer Subscale (LCS) (MEAN) score on a scale = 17.9444,,,,,,,,,Overall Survival (OS) (MEDIAN) months = 6.00 [4.00-10.00]; Overall Survival (OS12) (NUMBER) participants = 15; Overall Survival (OS24) (NUMBER) participants = 8; Overall Survival by PD-L1 Expression Status at 12 Months (NUMBER) participants = 5; Overall Survival by PD-L1 Expression Status at 24 Months (NUMBER) participants = 3,Progression-Free Survival (PFS) (MEDIAN) months = 3.00 [1.00-4.00]; Progression-Free Survival (PFS) at 12 Months (NUMBER) participants = 7; Progression-Free Survival (PFS) at 24 Months (NUMBER) participants = 4; Progression-Free Survival (PFS) by PD-L1 Expression at 12 Months (NUMBER) participants = 1; Progression-Free Survival (PFS) by PD-L1 Expression Status at 24 Months (NUMBER) participants = 0,,Health Related Quality of Life (HRQL) - FACT-G (MEAN) score on a scale = 78.2908; Health Related Quality of Life (HRQL) - FACT-G (MEAN) score on a scale = 76.6788; Health Related Quality of Life (HRQL) - FACT-G (MEAN) score on a scale = 80.5103; Health Related Quality of Life (HRQL) - FACT-G (MEAN) score on a scale = 80.0166,Overall Response Rate (ORR) (NUMBER) percentage of participants = 26; Overall Response Rate (ORR) in Patients With PD-L1 Expression Status = 0 (NUMBER) percentage of participants = 31; Overall Response Rate (ORR) in Patients With PD-L1 Expression Status = 0%<PD-L1<50%. (NUMBER) percentage of participants = 30; Overall Response Rate (ORR) in Patients With PD-L1 Expression Status ≥50% (NUMBER) percentage of participants = 25,Treatment-related Adverse Events ≥ Grade 3 (COUNT_OF_PARTICIPANTS) Participants = 1,,
NCT02879994,"Pembrolizumab in Treating Patients With EGFR Mutant, Tyrosine Kinase Inhibitor Naive Advanced Non-Small Cell Lung Cancer","A Phase II Study of Pembrolizumab in EGFR Mutant, Tyrosine Kinase Inhibitor Naïve Treatment Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)",Jonsson Comprehensive Cancer Center,Jonsson Comprehensive Cancer Center,OTHER,COMPLETED,2016-09-15,2017-11-30,2019-01-03,INTERVENTIONAL,PHASE2,,,,Stage IIIA Non-Small Cell Lung Cancer,Stage IIIA Non-Small Cell Lung Cancer; Stage IIIB Non-Small Cell Lung Cancer; Stage IV Non-Small Cell Lung Cancer,3,1,2,BIOLOGICAL; OTHER,,,1,2,True,Yes,Overall Response Rate (ORR) Determined as the Percentage of Patients Achieving Complete Response or Partial Response as Respectively Defined in RECIST 1.1 (COUNT_OF_PARTICIPANTS) Participants = 1,Number of Participants With Adverse Events According to the National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0 (COUNT_OF_PARTICIPANTS) Participants = 11; Efficacy (Progression Free Survival (PFS) and Overall Survival (OS)) Assessed by RECIST 1.1 (MEAN) days = 119 [42-123],,Overall Response Rate (ORR) Determined as the Percentage of Patients Achieving Complete Response or Partial Response as Respectively Defined in RECIST 1.1 (COUNT_OF_PARTICIPANTS) Participants = 1,,,,,,,Efficacy (Progression Free Survival (PFS) and Overall Survival (OS)) Assessed by RECIST 1.1 (MEAN) days = 119 [42-123],Efficacy (Progression Free Survival (PFS) and Overall Survival (OS)) Assessed by RECIST 1.1 (MEAN) days = 119 [42-123],Overall Response Rate (ORR) Determined as the Percentage of Patients Achieving Complete Response or Partial Response as Respectively Defined in RECIST 1.1 (COUNT_OF_PARTICIPANTS) Participants = 1,,Overall Response Rate (ORR) Determined as the Percentage of Patients Achieving Complete Response or Partial Response as Respectively Defined in RECIST 1.1 (COUNT_OF_PARTICIPANTS) Participants = 1,Number of Participants With Adverse Events According to the National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0 (COUNT_OF_PARTICIPANTS) Participants = 11,,
NCT02888743,Durvalumab and Tremelimumab With or Without High or Low-Dose Radiation Therapy in Treating Patients With Metastatic Colorectal or Non-small Cell Lung ,A Phase 2 Study of MEDI4736 (Durvalumab) and Tremelimumab Alone or in Combination With High or Low-Dose Radiation in Metastatic Colorectal and NSCLC,National Cancer Institute (NCI),National Cancer Institute (NCI),NIH,ACTIVE_NOT_RECRUITING,2017-08-14,2023-12-31,2026-01-02,INTERVENTIONAL,PHASE2,,,,Metastatic Colorectal Carcinoma,Metastatic Colorectal Carcinoma; Metastatic Lung Non-Small Cell Carcinoma; Stage IV Colorectal Cancer AJCC v7,6,5,3,BIOLOGICAL; RADIATION,,,1,6,True,Yes,Overall Response Rate (COUNT_OF_PARTICIPANTS) Participants = 3,Progression-free Survival (PFS) (MEDIAN) Months = 4.0 [2.1-7.0]; Overall Survival (OS) (MEDIAN) Months = 9.7; Objective Response Per Immune-related Response (irRC) Criteria (COUNT_OF_PARTICIPANTS) Participants = 0; Incidence of Grade 3-5 Adverse Events (NUMBER) Percentage of participants = 11.5 [3-27]; Local Control Rate and Abscopal Response Rate (COUNT_OF_PARTICIPANTS) Participants = 9; Prognostic Effect of PD-L1 Expression (MEAN) Percent expression = 15.8,,,,,,,,,Overall Survival (OS) (MEDIAN) Months = 9.7,Progression-free Survival (PFS) (MEDIAN) Months = 4.0 [2.1-7.0],,,Overall Response Rate (COUNT_OF_PARTICIPANTS) Participants = 3; Local Control Rate and Abscopal Response Rate (COUNT_OF_PARTICIPANTS) Participants = 9,Incidence of Grade 3-5 Adverse Events (NUMBER) Percentage of participants = 11.5 [3-27],,
NCT02898116,"Phase 1/2 Study of Ensartinib and Durvalumab, in ALK-rearranged Non-small Cell Lung Cancer","A Phase 1/2 Study of ALK Inhibitor, Ensartinib (X-396), and Anti-PD-L1, Durvalumab (MEDI4736), in Subjects With ALK-rearranged (ALK-positive) Non-small Cell Lung Cancer (NSCLC)",Ludwig Institute for Cancer Research,Ludwig Institute for Cancer Research,OTHER,COMPLETED,2017-05-10,2017-08-04,2017-08-04,INTERVENTIONAL,PHASE1; PHASE2,,,,Non-small Cell Lung Cancer,Non-small Cell Lung Cancer; Carcinoma; NSCLC,3,1,2,DRUG,,,1,2,True,Yes,Number of Subjects With Treatment-emergent Adverse Events (NUMBER) participants = 2,Number of Subjects With Best Overall Tumor Response at the Last Assessment (COUNT_OF_PARTICIPANTS) Participants = 0; Number of Subjects With Immune-related Tumor Response at the Last Assessment (COUNT_OF_PARTICIPANTS) Participants = 0,,,,,,,,,,,,,,Number of Subjects With Treatment-emergent Adverse Events (NUMBER) participants = 2,,
NCT02927301,A Study of Atezolizumab as Neoadjuvant and Adjuvant Therapy in Resectable Non-Small Cell Lung Cancer (NSCLC) - Lung Cancer Mutation Consortium (LCMC3),"A Phase II, Open-Label, Multicenter, Single-Arm Study to Investigate the Efficacy and Safety of Atezolizumab as Neoadjuvant and Adjuvant Therapy in Patients With Stage IB, II, IIIA, or Selected IIIB R","Genentech, Inc.","Genentech, Inc.",INDUSTRY,COMPLETED,2017-04-20,2020-05-07,2023-09-05,INTERVENTIONAL,PHASE2,,,,Non-Small Cell Lung Cancer,Non-Small Cell Lung Cancer,1,1,1,DRUG,,,1,7,True,Yes,Percentage of Participants With Major Pathologic Response (MPR) (NUMBER) percentage of participants = 20.3,Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) for PD-L1-Positive Versus PD-L1-Negative Participants (NUMBER) percentage of participants = 13.3 [5.9-24.6]; Percentage of Participants With Major Pathologic Response for PD-L1-Positive Versus PD-L1-Negative Participants (NUMBER) percentage of participants = 29.8 [18.4-43.4]; Number of Participants With at Least One Adverse Event (COUNT_OF_PARTICIPANTS) Participants = 177; Percentage of Participants With Major Pathologic Response (MPR) by Mutation Load (NUMBER) percentage of participants = 16.7 [8.3-28.5]; Percentage of Participants With Major Pathologic Response (MPR) by Neoantigen Score (NUMBER) percentage of participants = 19.4 [7.5-37.5]; Percentage of Participants With Major Pathologic Response (MPR) by Gene Expression Signatures: Gene Set Variation Analysis (GSVA) (NUMBER) percentage of participants = 17.6 [3.8-43.4]; Percentage of Participants With Major Pathologic Response (MPR) by Gene Expression Signatures: xCell Immune Score (NUMBER) percentage of participants = 29.4 [10.3-56.0],,,,,,,,Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) for PD-L1-Positive Versus PD-L1-Negative Participants (NUMBER) percentage of participants = 13.3 [5.9-24.6],,,,,Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) for PD-L1-Positive Versus PD-L1-Negative Participants (NUMBER) percentage of participants = 13.3 [5.9-24.6],,,
NCT02955758,Pembrolizumab in Patients With Metastatic Non-squamous Non-small Cell Lung Cancer,A Phase 2 Trial of Pembrolizumab in Metastatic Non-squamous NSCLC Examining Circulating Tumor DNA Levels as a Surrogate Biomarker of Response,Stanford University,Joel Neal,OTHER,COMPLETED,2016-10,2024-04-09,2024-04-09,INTERVENTIONAL,PHASE2,,,,Metastatic Non-Squamous Non-Small Cell Lung Carcinoma,Metastatic Non-Squamous Non-Small Cell Lung Carcinoma,1,1,1,BIOLOGICAL,,,1,4,True,Yes,Correlation of Tumor-informed CAPP-Seq ctDNA Analysis With Radiologic Tumor Assessments (NUMBER) Percent Accuracy = 100,Overall Response Rate (ORR) (NUMBER) participants = 2; PFS Measured Using RECIST v1.1 Criteria (MEDIAN) Months = 2.6 [1.3-4.9]; Overall Survival (OS) (MEDIAN) Months = 13.3 [10.3-27.8]; Incidence of Adverse Events Graded According to Common Terminology Criteria for Adverse Events Version 4.03 (COUNT_OF_PARTICIPANTS) Participants = 25,,,,,,,,,Overall Survival (OS) (MEDIAN) Months = 13.3 [10.3-27.8],PFS Measured Using RECIST v1.1 Criteria (MEDIAN) Months = 2.6 [1.3-4.9],,,Overall Response Rate (ORR) (NUMBER) participants = 2,Incidence of Adverse Events Graded According to Common Terminology Criteria for Adverse Events Version 4.03 (COUNT_OF_PARTICIPANTS) Participants = 25,,
NCT02983045,A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advance,"A Phase 1/2, Open-label, Multicenter Study of the Combination of NKTR-214 and Nivolumab or the Combination of NKTR-214, Nivolumab, and Other Anti-Cancer Therapies in Patients With Select Locally Advan",Nektar Therapeutics,Nektar Therapeutics,INDUSTRY,COMPLETED,2016-12-19,2022-04-28,2022-04-28,INTERVENTIONAL,PHASE1; PHASE2,,,,Melanoma,Melanoma; Renal Cell Carcinoma; Non Small Cell Lung Cancer,7,4,4,DRUG,,,3,0,True,Yes,Part 1 Dose Escalation: Incidence of Dose-limiting Toxicity (DLT) During the DLT Evaluation Window (COUNT_OF_PARTICIPANTS) Participants = 0; Part 3 Schedule Finding: Incidence of Dose-limiting Toxicity (DLT) During the DLT Evaluation Window (COUNT_OF_PARTICIPANTS) Participants = 1; Part 2 and Part 4: Objective Response Rate (ORR) Per RECIST 1.1 at Recommended Phase 2 Dose (RP2D) (COUNT_OF_PARTICIPANTS) Participants = 64,,,,,,,,,Part 2 and Part 4: Objective Response Rate (ORR) Per RECIST 1.1 at Recommended Phase 2 Dose (RP2D) (COUNT_OF_PARTICIPANTS) Participants = 64,,,,,Part 2 and Part 4: Objective Response Rate (ORR) Per RECIST 1.1 at Recommended Phase 2 Dose (RP2D) (COUNT_OF_PARTICIPANTS) Participants = 64,Part 1 Dose Escalation: Incidence of Dose-limiting Toxicity (DLT) During the DLT Evaluation Window (COUNT_OF_PARTICIPANTS) Participants = 0; Part 3 Schedule Finding: Incidence of Dose-limiting Toxicity (DLT) During the DLT Evaluation Window (COUNT_OF_PARTICIPANTS) Participants = 1,,
NCT02988817,Enapotamab Vedotin (HuMax-AXL-ADC) Safety Study in Patients With Solid Tumors,"First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of Axl-specific Antibody-drug Conjugate (Enapotamab Vedotin, HuMax®-AXL-ADC) in Patients With Solid Tumors",Genmab,Genmab,INDUSTRY,COMPLETED,2016-11-23,2021-11-12,2021-11-12,INTERVENTIONAL,PHASE1; PHASE2,,,,Ovarian Cancer,Ovarian Cancer; Cervical Cancer; Endometrial Cancer,8,1,1,BIOLOGICAL,,,5,20,True,Yes,Number of Participants With Dose-limiting Toxicities (DLTs) for Dose-escalation Part (COUNT_OF_PARTICIPANTS) Participants = 0; Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs) (COUNT_OF_PARTICIPANTS) Participants = 1; Number of Participants With Treatment-emergent Infusion-related AEs and TEAEs Related to Enapotamab Vedotin (COUNT_OF_PARTICIPANTS) Participants = 0; Number of Participants With >= Grade 3 TEAEs as Assessed by National Cancer Institute - Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 4.03 (COUNT_OF_PARTICIPANTS) Participants = 0; Number of Participants With Grade 3 or 4 Laboratory Results (COUNT_OF_PARTICIPANTS) Participants = 0,Area Under the Plasma Concentration-time Curve From Time 0 to Infinity (AUC0-inf) of Conjugated Enapotamab Vedotin for 1Q3W Dose-escalation Part (GEOMETRIC_MEAN) day*ug/mL = 6.143; Area Under the Plasma Concentration-time Curve From Time 0 to Last Measurable Concentration (AUC0-last) of Conjugated Enapotamab Vedotin for 1Q3W Dose-escalation Part (GEOMETRIC_MEAN) day*ug/mL = 5.509; Maximum Observed Plasma Concentration (Cmax) of Conjugated Enapotamab Vedotin for Dose-escalation Part (GEOMETRIC_MEAN) ug/mL = 7.250; Total Clearance (CL) of Conjugated Enapotamab Vedotin in Dose-escalation Part (GEOMETRIC_MEAN) L/day = 4.053; Time of Maximum Plasma Concentration (Tmax) of Conjugated Enapotamab Vedotin for Dose-escalation Part (MEDIAN) Day = 0.06 [0.06-0.06]; Half-life Lambda-z (t1/2) of Conjugated Enapotamab Vedotin for Dose-escalation Part (MEDIAN) Day = 0.87 [0.87-0.87]; Volume of Distribution at Steady State (Vss) of Conjugated Enapotamab Vedotin for Dose-escalation Part (GEOMETRIC_MEAN) L/day = 4.909; AUC0-inf of Free Toxin Monomethyl Auristatin E (MMAE) for 1Q3W Dose-escalation Part (GEOMETRIC_MEAN) day*pg/mL = 3832.48; AUC0-last of MMAE for 1Q3W Dose-escalation Part (GEOMETRIC_MEAN) day*pg/mL = 3364.64; Cmax of MMAE for Dose-escalation Part (GEOMETRIC_MEAN) pg/mL = 700.000; Total CL of MMAE in Dose-escalation Part (GEOMETRIC_MEAN) L/day = 6497.09; Tmax of MMAE for Dose-escalation Part (MEDIAN) Day = 2.95 [2.95-2.95]; t1/2 of MMAE for Dose-escalation Part (MEDIAN) Day = 2.19 [2.19-2.19]; Number of Participants With Antidrug Antibodies (ADAs) Confirmed Positive to Enapotamab Vedotin (COUNT_OF_PARTICIPANTS) Participants = 0; Number of Participants With Objective Response (OR) Based on Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) As Assessed by Investigator (COUNT_OF_PARTICIPANTS) Participants = 0; Number of Participants With Best Cancer Antigen 125 (CA-125) Response (COUNT_OF_PARTICIPANTS) Participants = 0; Duration of Response (DoR) Based on RECIST v1.1 as Assessed by Investigator for Expansion Part (MEDIAN) Months = 4.2; Progression Free Survival (PFS) as Assessed by Investigator (MEDIAN) Months = 6.7; ; Change in AXL Expression (Total Tumor H-score) From Baseline to EOT Visit for Expansion Part (MEAN) Score on a scale = -8.0,,,,,Duration of Response (DoR) Based on RECIST v1.1 as Assessed by Investigator for Expansion Part (MEDIAN) Months = 4.2,,,,,Progression Free Survival (PFS) as Assessed by Investigator (MEDIAN) Months = 6.7,,,,Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs) (COUNT_OF_PARTICIPANTS) Participants = 1; Number of Participants With >= Grade 3 TEAEs as Assessed by National Cancer Institute - Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 4.03 (COUNT_OF_PARTICIPANTS) Participants = 0,,
NCT02998528,A Neoadjuvant Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Versus Chemotherapy Alone in Early Stage Non-Small Cell Lung Cancer (N,"Randomized, OpenLabel, Phase 3 Trial of Nivolumab Plus Ipilimumab or Nivolumab Plus Platinum Doublet Chemotherapy Versus Platinum Doublet Chemotherapy in Early Stage NSCLC",Bristol-Myers Squibb,Bristol-Myers Squibb,INDUSTRY,COMPLETED,2017-03-04,2021-09-08,2024-12-06,INTERVENTIONAL,PHASE3,,,,Non Small Cell Lung Cancer,Non Small Cell Lung Cancer,1,3,9,BIOLOGICAL; DRUG,,,2,3,True,Yes,Event-Free Survival (EFS) (MEDIAN) Months = 20.80 [14.03-26.71]; Pathologic Complete Response (pCR) Rate (COUNT_OF_PARTICIPANTS) Participants = 4,Major Pathologic Response (MPR) Rate (COUNT_OF_PARTICIPANTS) Participants = 16; ; Time to Death or Distant Metastases (TTDM) (MEDIAN) Months = 26.71,,Pathologic Complete Response (pCR) Rate (COUNT_OF_PARTICIPANTS) Participants = 4,,,,Event-Free Survival (EFS) (MEDIAN) Months = 20.80 [14.03-26.71],,,,,,,,,,
NCT03001882,An Exploratory Study of the Effects of Nivolumab Combined With Ipilimumab in Patients With Treatment-Naive Stage IV or Recurrent Non-Small Cell Lung C,An Exploratory Study of the Biologic Effects and Biomarkers of Nivolumab in Combination With Ipilimumab in Subjects With Treatment-Naive Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC),Bristol-Myers Squibb,Bristol-Myers Squibb,INDUSTRY,COMPLETED,2017-03-29,2022-02-17,2023-04-24,INTERVENTIONAL,PHASE2,,,,Non-Small Cell Lung Cancer,Non-Small Cell Lung Cancer,1,1,2,BIOLOGICAL,,,3,9,True,Yes,Objective Response Rate (ORR) Per Investigator by Blood TMB (bTMB) Within PD-L1 Subgroup (TMB Cut-point = 16 Mutations/MB) (NUMBER) Percent of Participants = 30 [6.7-65.2]; Objective Response Rate (ORR) Per Investigator by Blood TMB (bTMB) Within PD-L1 Subgroup (Blood TMB Cut-point = 21-mutations/MB) (NUMBER) Percent of Participants = 33.3 [4.3-77.7]; Objective Response Rate (ORR) Per Investigator by Tissue TMB Within PD-L1 Subgroup (Tissue TMB Cut-point = 10-mutations/MB) (NUMBER) Percent of Participants = 25.0 [3.2-65.1],Objective Response Rate (ORR) for All Treated Participants by Investigator Per RECIST 1.1 (NUMBER) Percent of Participants = 29.0 [14.2-48.0]; Disease Control Rate (DCR) for Part 1 (NUMBER) Percent of Participants = 58.1 [39.1-75.5]; Duration of Response (DOR) for Part 1 (MEDIAN) Months = 24.56 [1.9-61.7]; Time to Response (TTR) for Part 1 (MEDIAN) Months = 1.84 [1.6-3.7]; Progression Free Survival (PFS) (MEDIAN) Months = 3.71 [1.97-8.90]; Overall Survival (OS) (MEDIAN) Months = 9.63 [4.47-20.57]; Number of Participants With Adverse Events (AEs) for Study Part 2 (COUNT_OF_PARTICIPANTS) Participants = 169; Number of Participants With Serious Adverse Events (SAEs) for Study Part 2 (COUNT_OF_PARTICIPANTS) Participants = 102; Number of Participants With Select Adverse Events (AEs) for Study Part 2 (COUNT_OF_PARTICIPANTS) Participants = 68,,,,,Duration of Response (DOR) for Part 1 (MEDIAN) Months = 24.56 [1.9-61.7],,,Objective Response Rate (ORR) Per Investigator by Blood TMB (bTMB) Within PD-L1 Subgroup (TMB Cut-point = 16 Mutations/MB) (NUMBER) Percent of Participants = 30 [6.7-65.2]; Objective Response Rate (ORR) Per Investigator by Blood TMB (bTMB) Within PD-L1 Subgroup (Blood TMB Cut-point = 21-mutations/MB) (NUMBER) Percent of Participants = 33.3 [4.3-77.7]; Objective Response Rate (ORR) Per Investigator by Tissue TMB Within PD-L1 Subgroup (Tissue TMB Cut-point = 10-mutations/MB) (NUMBER) Percent of Participants = 25.0 [3.2-65.1]; Objective Response Rate (ORR) for All Treated Participants by Investigator Per RECIST 1.1 (NUMBER) Percent of Participants = 29.0 [14.2-48.0],Overall Survival (OS) (MEDIAN) Months = 9.63 [4.47-20.57],Progression Free Survival (PFS) (MEDIAN) Months = 3.71 [1.97-8.90],,,Objective Response Rate (ORR) Per Investigator by Blood TMB (bTMB) Within PD-L1 Subgroup (TMB Cut-point = 16 Mutations/MB) (NUMBER) Percent of Participants = 30 [6.7-65.2]; Objective Response Rate (ORR) Per Investigator by Blood TMB (bTMB) Within PD-L1 Subgroup (Blood TMB Cut-point = 21-mutations/MB) (NUMBER) Percent of Participants = 33.3 [4.3-77.7]; Objective Response Rate (ORR) Per Investigator by Tissue TMB Within PD-L1 Subgroup (Tissue TMB Cut-point = 10-mutations/MB) (NUMBER) Percent of Participants = 25.0 [3.2-65.1]; Objective Response Rate (ORR) for All Treated Participants by Investigator Per RECIST 1.1 (NUMBER) Percent of Participants = 29.0 [14.2-48.0],Number of Participants With Adverse Events (AEs) for Study Part 2 (COUNT_OF_PARTICIPANTS) Participants = 169; Number of Participants With Serious Adverse Events (SAEs) for Study Part 2 (COUNT_OF_PARTICIPANTS) Participants = 102; Number of Participants With Select Adverse Events (AEs) for Study Part 2 (COUNT_OF_PARTICIPANTS) Participants = 68,,
NCT03003468,Pembrolizumab + Imprime PGG for Metastatic Non-small Cell Lung Cancer After Progression on First-Line Therapy: Big Ten Cancer Research Consortium BTCR,A Phase Ib/II Study of Anti-PD-1 Antibody Pembrolizumab and Imprime PGG for Patients With Metastatic Non-small Cell Lung Cancer After Progression on First-Line Therapy: Big Ten Cancer Research Consort,Big Ten Cancer Research Consortium,"Lawrence Feldman, MD",OTHER,COMPLETED,2017-07-11,2021-11-22,2022-11-28,INTERVENTIONAL,PHASE1; PHASE2,,,,Non-Small Cell Lung Cancer,Non-Small Cell Lung Cancer,1,1,3,DRUG,,,2,4,True,Yes,Phase Ib: Maximum Tolerated Dose (NUMBER) mg = 4; Progression Free Survival (MEDIAN) Months = 2.6 [1.4-7],Adverse Events (AEs) (COUNT_OF_PARTICIPANTS) Participants = 13; Clinical Benefit Rate (CBR) (NUMBER) Percentage of participants = 47 [23-67]; Progression Free Survival (PFS) at 6 Months (NUMBER) Percentage of participants = 37 [20-55]; Overall Survival (OS) (MEDIAN) Months = 11.1 [7.8-18],Clinical Benefit Rate (CBR) (NUMBER) Percentage of participants = 47 [23-67],,,,,,,,Overall Survival (OS) (MEDIAN) Months = 11.1 [7.8-18],Progression Free Survival (MEDIAN) Months = 2.6 [1.4-7]; Progression Free Survival (PFS) at 6 Months (NUMBER) Percentage of participants = 37 [20-55],,,,Adverse Events (AEs) (COUNT_OF_PARTICIPANTS) Participants = 13,,
NCT03003962,Study of Durvalumab Alone or Chemotherapy for Patients With Advanced Non Small-Cell Lung Cancer (PEARL),"A Phase III Randomized, Open-Label, Multi-Center Study of Durvalumab (MEDI4736) Versus Standard of Care (SoC) Platinum-Based Chemotherapy as First Line Treatment in Patients With PD-L1-High Expression",AstraZeneca,AstraZeneca,INDUSTRY,ACTIVE_NOT_RECRUITING,2017-01-02,2022-10-27,2026-06-30,INTERVENTIONAL,PHASE3,,,,Non Small Cell Lung Carcinoma NSCLC,Non Small Cell Lung Carcinoma NSCLC,1,2,6,DRUG,,,2,42,True,Yes,Overall Survival (OS) (MEDIAN) months = 14.6 [12.2-16.9]; OS in Participants With LREM (MEDIAN) months = 14.6 [12.6-17.2],OS in PD-L1 TC >= 50% Analysis Set (MEDIAN) months = 14.6 [12.0-17.7]; OS in PD-L1 TC >= 50% LREM Analysis Set (MEDIAN) months = 14.9 [12.6-19.0]; Progression Free Survival (PFS) Based on Investigator Assessment According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) (MEDIAN) months = 5.4 [4.2-5.7]; PFS Based on Investigator Assessment According to RECIST 1.1 in LREM Analysis Set (MEDIAN) months = 5.5 [4.4-6.4]; PFS Based on Investigator Assessment According to RECIST 1.1 in PD-L1 TC >= 50% Analysis Set (MEDIAN) months = 5.6 [4.7-6.5]; PFS Based on Investigator Assessment According to RECIST 1.1 in PD-L1 TC >= 50% LREM Analysis Set (MEDIAN) months = 5.7 [5.3-7.0]; Objective Response Rate (ORR) as Per RECIST 1.1 Using Investigator Assessment (NUMBER) percentage of participants = 37.6 [0.324-0.430]; ORR as Per RECIST 1.1 Using Investigator Assessment in PD-L1 TC >= 25% LREM Analysis Set (NUMBER) percentage of participants = 38.5 [0.327-0.445]; ORR as Per RECIST 1.1 Using Investigator Assessment in PD-L1 TC >= 50% Analysis Set (NUMBER) percentage of participants = 42.1 [0.359-0.485]; ORR as Per RECIST 1.1 Using Investigator Assessment in PD-L1 TC >= 50% LREM Analysis Set (NUMBER) percentage of participants = 44.0 [0.371-0.510]; Duration of Response (DoR) as Per RECIST 1.1 Using Investigator Assessment (MEDIAN) months = 11.9 [9.7-18.7]; DoR as Per RECIST 1.1 Using Investigator Assessment in PD-L1 TC >=25% LREM Analysis Set (MEDIAN) months = 11.6 [8.2-15.7]; DoR as Per RECIST 1.1 Using Investigator Assessment in PD-L1 TC >=50% Analysis Set (MEDIAN) months = 12.2 [8.3-21.2]; DoR as Per RECIST 1.1 Using Investigator Assessment in PD-L1 TC >=50% LREM Analysis Set (MEDIAN) months = 12.2 [8.2-19.7]; Alive and Progression-Free at 12 Months (APF12) (NUMBER) percentage of participants = 25.5 [20.8-30.4]; APF12 in PD-L1 TC >= 25% LREM Analysis Set (NUMBER) percentage of participants = 24.1 [19.1-29.5]; APF12 in PD-L1 TC >= 50% Analysis Set (NUMBER) percentage of participants = 26.1 [20.7-31.9]; APF12 in PD-L1 TC >= 50% LREM Analysis Set (NUMBER) percentage of participants = 26.5 [20.5-32.8]; Time From Randomization to Second Progression (PFS2) (MEDIAN) months = 11.3 [9.8-12.7]; PFS2 in PD-L1 TC >= 25% LREM Analysis Set (MEDIAN) months = 11.8 [10.1-12.9]; PFS2 in PD-L1 TC >= 50% Analysis Set (MEDIAN) months = 11.3 [9.7-12.9]; PFS2 in PD-L1 TC >= 50% LREM Analysis Set (MEDIAN) months = 12.0 [10.1-13.8]; OS at 18 Months (NUMBER) percentage of participants = 42.5 [37.1-47.7]; OS at 18 Months in PD-L1 TC > = 25% LREM Analysis Set (NUMBER) percentage of participants = 43.0 [37.1-48.8]; OS at 18 Months in PD-L1 TC >= 50% Analysis Set (NUMBER) percentage of participants = 43.2 [36.9-49.3]; OS at 18 Months in PD-L1 TC >= 50% LREM Analysis Set (NUMBER) percentage of participants = 44.3 [37.4-51.0]; OS at 24 Months (NUMBER) percentage of participants = 34.6 [29.5-39.7]; OS at 24 Months in PD-L1 TC > = 25% LREM Analysis Set (NUMBER) percentage of participants = 34.7 [29.1-40.3]; OS at 24 Months in PD-L1 TC >= 50% Analysis Set (NUMBER) percentage of participants = 37.0 [31.0-43.1]; OS at 24 Months in PD-L1 TC >= 50% LREM Analysis Set (NUMBER) percentage of participants = 36.9 [30.3-43.5]; Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) 30-Item Core Quality of Life Questionnaire Version 3 (QLQ-C30) (MEAN) scores on a scale = -0.7; Change From Baseline in EORTC QLQ-C30 in PD-L1 TC >= 25% LREM Analysis Set (MEAN) scores on a scale = -1.4; Time to Deterioration of EORTC QLQ-C30 (MEDIAN) months = 7.3 [5.5-9.1]; Time to Deterioration of EORTC QLQ-C30 in PD-L1 TC >= 25% LREM Analysis Set (MEDIAN) months = 7.4 [5.6-9.2]; Change From Baseline in EORTC 13-Item Lung Cancer Quality of Life Questionnaire (QLQ-LC13) (MEAN) scores on a scale = -6.4; Change From Baseline in EORTC QLQ-LC13 in PD-L1 TC >= 25% LREM Analysis Set (MEAN) scores on a scale = -6.6; Time to Deterioration of EORTC QLQ-LC13 (MEDIAN) months = 7.5 [6.4-10.1]; Time to Deterioration of EORTC QLQ-LC13 in PD-L1 TC >= 25% LREM Analysis Set (MEDIAN) months = 9.2 [6.4-12.3]; Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status (NUMBER) number of participants = 267; Number of Participants With ECOG Performance Status in PD-L1 TC >=25% LREM Analysis Set (NUMBER) number of participants = 221; Percentage of Participants With Antidrug Antibody (ADA) Response to Durvalumab (NUMBER) percentage of participants = 0.8; Percentage of Participants With ADA Response to Durvalumab in LREM Analysis Set (NUMBER) percentage of participants = 1.0,,,,,Duration of Response (DoR) as Per RECIST 1.1 Using Investigator Assessment (MEDIAN) months = 11.9 [9.7-18.7]; DoR as Per RECIST 1.1 Using Investigator Assessment in PD-L1 TC >=25% LREM Analysis Set (MEDIAN) months = 11.6 [8.2-15.7]; DoR as Per RECIST 1.1 Using Investigator Assessment in PD-L1 TC >=50% Analysis Set (MEDIAN) months = 12.2 [8.3-21.2]; DoR as Per RECIST 1.1 Using Investigator Assessment in PD-L1 TC >=50% LREM Analysis Set (MEDIAN) months = 12.2 [8.2-19.7],,,Objective Response Rate (ORR) as Per RECIST 1.1 Using Investigator Assessment (NUMBER) percentage of participants = 37.6 [0.324-0.430]; ORR as Per RECIST 1.1 Using Investigator Assessment in PD-L1 TC >= 25% LREM Analysis Set (NUMBER) percentage of participants = 38.5 [0.327-0.445]; ORR as Per RECIST 1.1 Using Investigator Assessment in PD-L1 TC >= 50% Analysis Set (NUMBER) percentage of participants = 42.1 [0.359-0.485]; ORR as Per RECIST 1.1 Using Investigator Assessment in PD-L1 TC >= 50% LREM Analysis Set (NUMBER) percentage of participants = 44.0 [0.371-0.510],Overall Survival (OS) (MEDIAN) months = 14.6 [12.2-16.9]; OS in Participants With LREM (MEDIAN) months = 14.6 [12.6-17.2]; OS in PD-L1 TC >= 50% Analysis Set (MEDIAN) months = 14.6 [12.0-17.7]; OS in PD-L1 TC >= 50% LREM Analysis Set (MEDIAN) months = 14.9 [12.6-19.0]; OS at 18 Months (NUMBER) percentage of participants = 42.5 [37.1-47.7]; OS at 18 Months in PD-L1 TC > = 25% LREM Analysis Set (NUMBER) percentage of participants = 43.0 [37.1-48.8]; OS at 18 Months in PD-L1 TC >= 50% Analysis Set (NUMBER) percentage of participants = 43.2 [36.9-49.3]; OS at 18 Months in PD-L1 TC >= 50% LREM Analysis Set (NUMBER) percentage of participants = 44.3 [37.4-51.0]; OS at 24 Months (NUMBER) percentage of participants = 34.6 [29.5-39.7]; OS at 24 Months in PD-L1 TC > = 25% LREM Analysis Set (NUMBER) percentage of participants = 34.7 [29.1-40.3]; OS at 24 Months in PD-L1 TC >= 50% Analysis Set (NUMBER) percentage of participants = 37.0 [31.0-43.1]; OS at 24 Months in PD-L1 TC >= 50% LREM Analysis Set (NUMBER) percentage of participants = 36.9 [30.3-43.5],Progression Free Survival (PFS) Based on Investigator Assessment According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) (MEDIAN) months = 5.4 [4.2-5.7]; PFS Based on Investigator Assessment According to RECIST 1.1 in LREM Analysis Set (MEDIAN) months = 5.5 [4.4-6.4]; PFS Based on Investigator Assessment According to RECIST 1.1 in PD-L1 TC >= 50% Analysis Set (MEDIAN) months = 5.6 [4.7-6.5]; PFS Based on Investigator Assessment According to RECIST 1.1 in PD-L1 TC >= 50% LREM Analysis Set (MEDIAN) months = 5.7 [5.3-7.0],,Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) 30-Item Core Quality of Life Questionnaire Version 3 (QLQ-C30) (MEAN) scores on a scale = -0.7; Change From Baseline in EORTC 13-Item Lung Cancer Quality of Life Questionnaire (QLQ-LC13) (MEAN) scores on a scale = -6.4,Objective Response Rate (ORR) as Per RECIST 1.1 Using Investigator Assessment (NUMBER) percentage of participants = 37.6 [0.324-0.430],,,
NCT03004183,SBRT and Oncolytic Virus Therapy Before Pembrolizumab for Metastatic TNBC and NSCLC,Phase II Window of Opportunity Trial of Stereotactic Body Radiation Therapy and In Situ Oncolytic Virus Therapy in Metastatic Triple Negative Breast Cancer and Metastatic Non-Small Cell Lung Cancer Fo,The Methodist Hospital Research Institute,The Methodist Hospital Research Institute,OTHER,COMPLETED,2017-07-01,2022-07-22,2024-01-09,INTERVENTIONAL,PHASE2,,,,Metastatic Non-small Cell Lung Cancer,Metastatic Non-small Cell Lung Cancer; Metastatic Triple-negative Breast Cancer,2,1,4,BIOLOGICAL; DRUG; RADIATION,,,1,6,True,Yes,Objective Response Rate (COUNT_OF_PARTICIPANTS) Participants = 4,Duration of Response (MEDIAN) Months = 2 [1-7]; Overall Survival Rate (MEDIAN) Months = 6.6 [0-50]; Number of Participants With Treatment-related Adverse Events (COUNT_OF_PARTICIPANTS) Participants = 2; Antitumor Activity (COUNT_OF_PARTICIPANTS) Participants = 4; Clinical Benefit Rate (COUNT_OF_PARTICIPANTS) Participants = 24; Progression-free Survival in Months (MEDIAN) months = 2.5298 [1.05-48.53],Clinical Benefit Rate (COUNT_OF_PARTICIPANTS) Participants = 24,,,,Duration of Response (MEDIAN) Months = 2 [1-7],,,Objective Response Rate (COUNT_OF_PARTICIPANTS) Participants = 4,Overall Survival Rate (MEDIAN) Months = 6.6 [0-50],Progression-free Survival in Months (MEDIAN) months = 2.5298 [1.05-48.53],,,Objective Response Rate (COUNT_OF_PARTICIPANTS) Participants = 4,Number of Participants With Treatment-related Adverse Events (COUNT_OF_PARTICIPANTS) Participants = 2,,
NCT03014648,Evaluating the Efficacy of Atezolizumab in Advanced Non-small Cell Lung Cancer (NSCLC),A Phase II Clinical Trial Evaluating the Efficacy of Atezolizumab in Advanced Non-small Cell Lung Cancer (NSCLC) in Patients Previously Treated With PD-1-directed Therapy,University of Pittsburgh,"Liza Villaruz, MD",OTHER,COMPLETED,2017-07-18,2021-12-31,2022-03-31,INTERVENTIONAL,PHASE2,,,,Advanced Non-small Cell Lung Cancer,Advanced Non-small Cell Lung Cancer,1,1,1,DRUG,,,1,10,True,Yes,Best Overall Response (BOR) (COUNT_OF_PARTICIPANTS) Participants = 2,Duration of Response (DOR) (NUMBER) months = 6; Progression-free Survival (PFS) (MEDIAN) months = 4.00 [2.00-9.00]; 6-month Progression-free Survival (PFS) (COUNT_OF_PARTICIPANTS) Participants = 3; 12-month Progression-free Survival (PFS) (COUNT_OF_PARTICIPANTS) Participants = 1; 24-month Progression-free Survival (PFS) (COUNT_OF_PARTICIPANTS) Participants = 1; Overall Survival (OS) (MEDIAN) months = 7.00; 6-month Overall Survival (OS) (COUNT_OF_PARTICIPANTS) Participants = 4; 12-month Overall Survival (OS) (COUNT_OF_PARTICIPANTS) Participants = 3; 24-month Overall Survival (OS) (COUNT_OF_PARTICIPANTS) Participants = 1; Adverse Events ≥ Grade 3 (COUNT_OF_PARTICIPANTS) Participants = 1,,,,,Duration of Response (DOR) (NUMBER) months = 6,,,,Overall Survival (OS) (MEDIAN) months = 7.00; 6-month Overall Survival (OS) (COUNT_OF_PARTICIPANTS) Participants = 4; 12-month Overall Survival (OS) (COUNT_OF_PARTICIPANTS) Participants = 3; 24-month Overall Survival (OS) (COUNT_OF_PARTICIPANTS) Participants = 1,Progression-free Survival (PFS) (MEDIAN) months = 4.00 [2.00-9.00]; 6-month Progression-free Survival (PFS) (COUNT_OF_PARTICIPANTS) Participants = 3; 12-month Progression-free Survival (PFS) (COUNT_OF_PARTICIPANTS) Participants = 1; 24-month Progression-free Survival (PFS) (COUNT_OF_PARTICIPANTS) Participants = 1,,,,Adverse Events ≥ Grade 3 (COUNT_OF_PARTICIPANTS) Participants = 1,,
NCT03037385,"Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Oth","A Phase 1/2 Study of the Highly-selective RET Inhibitor, BLU-667, in Patients With Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors",Hoffmann-La Roche,Hoffmann-La Roche,INDUSTRY,COMPLETED,2017-03-17,2024-03-21,2024-03-21,INTERVENTIONAL,PHASE1; PHASE2,,,,RET-altered Non Small Cell Lung Cancer,RET-altered Non Small Cell Lung Cancer; Medullary Thyroid Cancer; RET-altered Papillary Thyroid Cancer,40,2,1,DRUG,,,3,41,True,Yes,Phase 1 : Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of Pralsetinib (NUMBER) mg = 400; Phase 1 and Phase 2: Number of Participants With AEs and Serious AEs (SAEs) (NUMBER) percentage of participants = 37; Phase 2: Overall Response Rate (ORR) (NUMBER) percentage of participants = 63.1 [54.2-71.4],Phase 1: ORR (NUMBER) percentage of participants = 0; Phase 1 and Phase 2: ORR in RET-fusion Positive NSCLC Participants With Specific RET Gene Status (NUMBER) percentage of participants = 63.7 [53.0-73.6]; Phase 1 and Phase 2: ORR in RET-mutation MTC Participants With Specific RET Gene Status (NUMBER) percentage of participants = 53.7 [37.4-69.3]; ; Phase 1 and Phase 2: Clinical Benefit Rate (CBR) in RET-fusion Positive NSCLC Participants With Specific RET Gene Status (NUMBER) percentage of participants = 76.9 [66.9-85.1]; Phase 1 and Phase 2: CBR in RET-mutation MTC Participants With Specific RET Gene Status (NUMBER) percentage of participants = 78.0 [62.4-89.4]; ; Phase 1 and Phase 2: Disease Control Rate (DCR) in RET-fusion Positive NSCLC Participants With Specific RET Gene Status (NUMBER) percentage of participants = 93.4 [86.2-97.5]; Phase 1 and Phase 2: DCR in RET-mutation MTC Participants With Specific RET Gene Status (NUMBER) percentage of participants = 95.1 [83.5-99.4]; ; Phase 1 and Phase 2: Duration of Response (DOR) in RET-mutation NSCLC Participants With Specific RET Gene Status (MEDIAN) months = 15.1 [8.8-34.2]; Phase 1 and Phase 2: DOR in RET-mutation MTC Participants With Specific RET Gene Status (MEDIAN) months = 18.4 [15.1-25.8]; ; Phase 2: DOR (MEDIAN) months = 31.8 [15.1-40.4]; Phase 2: CBR (NUMBER) percentage of participants = 74.6 [66.2-81.8]; Phase 2: DCR (NUMBER) percentage of participants = 91.5 [85.4-95.7]; Phase 2: Progression-free Survival (PFS) (MEDIAN) months = 16.4 [11.4-23.5]; Phase 2: Overall Survival (OS) (MEDIAN) months = 39.7 [27.8-53.2]; Phase 2: Intracranial ORR in RET-fusion Positive NSCLC Central Nervous System (CNS) Metastases Participants (NUMBER) percentage of participants = 53.8 [25.1-80.8]; Phase 2: Intracranial CBR in RET-fusion Positive NSCLC CNS Metastases Participants (NUMBER) percentage of participants = 61.5 [31.6-86.1]; Phase 2: Intracranial DCR in RET-fusion Positive NSCLC CNS Metastases Participants (NUMBER) percentage of participants = 76.9 [46.2-95.0]; Phase 2: Intracranial DOR in RET-fusion Positive NSCLC CNS Metastases Participants (MEDIAN) months = 28.3; Phase 1: Maximum Plasma Concentration (Cmax) (GEOMETRIC_MEAN) nanograms per milliliters (ng/mL) = 346; Phase 1: Time to Maximum Plasma Concentration (Tmax) (MEDIAN) hour = 3.04 [2.08-4.00]; Phase 1: Time of Last Quantifiable Plasma Drug Concentration (Tlast) (MEDIAN) hours = 24.0 [24.0-24.0]; Phase 1: Area Under the Plasma Concentration Versus Time Curve From Time 0 to 24 Hours Postdose (AUC0-24) (GEOMETRIC_MEAN) hours*nanograms/milliliter (hours*ng/ml) = 4450; Phase 1: Plasma Drug Concentration at 24 Hours Postdose (C24hr) (GEOMETRIC_MEAN) ng/mL = 110; Phase 1: Apparent Volume of Distribution (Vz/F) (GEOMETRIC_MEAN) liters = 96.1; Phase 1: Terminal Elimination Half-Life (t½) (MEDIAN) hours = 16.3 [11.8-20.8]; Phase 1: Apparent Oral Clearance (CL/F) (GEOMETRIC_MEAN) liters per hour (L/hr) = 4.26; Phase 1: Accumulation Ratio for Cmax (RCmax) (GEOMETRIC_MEAN) ratio = 1.04; Phase 1: Accumulation Ratio for AUC (RAUC) (GEOMETRIC_MEAN) ratio = 1.43; Phase 2: Cmax (GEOMETRIC_MEAN) ng/mL = 1680; Phase 2: Tmax (MEDIAN) hours = 4.00 [1.90-23.7]; Phase 2: Tlast (MEDIAN) hours = 23.9 [2.40-24.8]; Phase 2: AUC0-24 (GEOMETRIC_MEAN) hours*ng/mL = 20400; Phase 2: C24hr (GEOMETRIC_MEAN) ng/mL = 540; Phase 2: t½ (GEOMETRIC_MEAN) hours = 13.4; Phase 2: CL/F (GEOMETRIC_MEAN) liters per hour (L/hour) = 13.4; Phase 1: Percent Change From Baseline in Dual Specificity Phosphatase 6 (DUSP6) (MEAN) percent change = 0; Phase 1: Percent Change From Baseline in Sprout Receptor Tyrosine Kinase Signaling Antagonist 4 (SPRY4) (MEAN) percent change = 0,Phase 1 and Phase 2: Clinical Benefit Rate (CBR) in RET-fusion Positive NSCLC Participants With Specific RET Gene Status (NUMBER) percentage of participants = 76.9 [66.9-85.1]; Phase 1 and Phase 2: CBR in RET-mutation MTC Participants With Specific RET Gene Status (NUMBER) percentage of participants = 78.0 [62.4-89.4]; Phase 2: CBR (NUMBER) percentage of participants = 74.6 [66.2-81.8]; Phase 2: Intracranial CBR in RET-fusion Positive NSCLC CNS Metastases Participants (NUMBER) percentage of participants = 61.5 [31.6-86.1],,,,Phase 1 and Phase 2: Duration of Response (DOR) in RET-mutation NSCLC Participants With Specific RET Gene Status (MEDIAN) months = 15.1 [8.8-34.2]; Phase 1 and Phase 2: DOR in RET-mutation MTC Participants With Specific RET Gene Status (MEDIAN) months = 18.4 [15.1-25.8]; Phase 2: DOR (MEDIAN) months = 31.8 [15.1-40.4]; Phase 2: Intracranial DOR in RET-fusion Positive NSCLC CNS Metastases Participants (MEDIAN) months = 28.3,,,Phase 1: ORR (NUMBER) percentage of participants = 0; Phase 1 and Phase 2: ORR in RET-fusion Positive NSCLC Participants With Specific RET Gene Status (NUMBER) percentage of participants = 63.7 [53.0-73.6]; Phase 1 and Phase 2: ORR in RET-mutation MTC Participants With Specific RET Gene Status (NUMBER) percentage of participants = 53.7 [37.4-69.3]; Phase 2: Intracranial ORR in RET-fusion Positive NSCLC Central Nervous System (CNS) Metastases Participants (NUMBER) percentage of participants = 53.8 [25.1-80.8],Phase 2: Overall Survival (OS) (MEDIAN) months = 39.7 [27.8-53.2],Phase 2: Progression-free Survival (PFS) (MEDIAN) months = 16.4 [11.4-23.5],,,Phase 2: Overall Response Rate (ORR) (NUMBER) percentage of participants = 63.1 [54.2-71.4],Phase 1 and Phase 2: Number of Participants With AEs and Serious AEs (SAEs) (NUMBER) percentage of participants = 37,,
NCT03049618,"Recombinant EphB4-HSA Fusion Protein and Pembrolizumab, MK-3475","A Phase IIa Trial of sEphB4-HSA in Combination With Anti PD-1 Antibody (Pembrolizumab, MK3475) in Patients With Non-small Cell Lung and Head/Neck Cancer",University of Southern California,University of Southern California,OTHER,COMPLETED,2017-03-10,2024-09-04,2024-09-04,INTERVENTIONAL,PHASE2,,,,ALK Gene Mutation,ALK Gene Mutation; BRAF Gene Mutation; EGFR Gene Mutation,12,2,3,BIOLOGICAL; OTHER,,,1,4,True,Yes,Overall Response Rate (ORR) (COUNT_OF_PARTICIPANTS) Participants = 6,Duration of Response (MEDIAN) Months = 3.7 [1.8-8.9]; Number of Participants With Adverse Events (NUMBER) participants = 25; Overall Survival (OS) (MEDIAN) Months = 8.6 [3.2-13.7]; Progression Free Survival (PFS) (MEDIAN) Months = 2.6 [1.3-4.1],,,,,Duration of Response (MEDIAN) Months = 3.7 [1.8-8.9],,,,Overall Survival (OS) (MEDIAN) Months = 8.6 [3.2-13.7],Progression Free Survival (PFS) (MEDIAN) Months = 2.6 [1.3-4.1],,,Overall Response Rate (ORR) (COUNT_OF_PARTICIPANTS) Participants = 6,Number of Participants With Adverse Events (NUMBER) participants = 25,,
NCT03081689,Neo-Adjuvant Immunotherapy With Nivolumab for Non Small Cell Lung Cancer Patients,Neo - Adjuvant Chemo / Immunotherapy for the Treatment of Resectable Stage IIIA Non Small Cell Lung Cancer (NSCLC): A Phase II Multicenter Exploratory Study,Spanish Lung Cancer Group,Spanish Lung Cancer Group,OTHER,COMPLETED,2017-04-15,2023-09-15,2023-10-18,INTERVENTIONAL,PHASE2,,,,Non Small Cell Lung Cancer,Non Small Cell Lung Cancer,1,1,3,DRUG,,,1,1,True,Yes,Progression Free Survival (NUMBER) percentage of participants = 77.1 [59.9-87.7],Overall Survival (NUMBER) percentage of participants = 89.9 [74.5-96.2],,,,,,,,,Overall Survival (NUMBER) percentage of participants = 89.9 [74.5-96.2],Progression Free Survival (NUMBER) percentage of participants = 77.1 [59.9-87.7],,,,,,
NCT03083808,Phase II Trial of Continuation Therapy in Advanced NSCLC,A Phase II Trial of Chemotherapy Plus Pembrolizumab in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Previously Treated With PD-1 or PD-L1 Inhibitor: Big Ten Cancer Research Consortium BTC,Big Ten Cancer Research Consortium,"Greg Durm, MD",OTHER,COMPLETED,2017-03-20,2021-12-14,2022-03-03,INTERVENTIONAL,PHASE2,,,,Non-Small-Cell Lung Cancer,Non-Small-Cell Lung Cancer,1,1,1,DRUG,,,1,5,True,Yes,Progression Free Survival (PFS) (MEDIAN) months = 5.1 [3.6-8],Clinical Benefit Rate (CBR) (COUNT_OF_PARTICIPANTS) Participants = 24; Objective Response Rate (ORR) (NUMBER) percentage of participants = 23.5 [10.8-41.2]; Overall Survival (OS) (MEDIAN) months = 24.5 [15.6-30.9]; Number of Participants With Adverse Events (COUNT_OF_PARTICIPANTS) Participants = 35; Progression Free Survival (PFS) by irRECIST (MEDIAN) months = 5.2 [3.6-9.8],Clinical Benefit Rate (CBR) (COUNT_OF_PARTICIPANTS) Participants = 24,,,,,,,Objective Response Rate (ORR) (NUMBER) percentage of participants = 23.5 [10.8-41.2],Overall Survival (OS) (MEDIAN) months = 24.5 [15.6-30.9],Progression Free Survival (PFS) (MEDIAN) months = 5.1 [3.6-8]; Progression Free Survival (PFS) by irRECIST (MEDIAN) months = 5.2 [3.6-9.8],,,Objective Response Rate (ORR) (NUMBER) percentage of participants = 23.5 [10.8-41.2],Number of Participants With Adverse Events (COUNT_OF_PARTICIPANTS) Participants = 35,,
NCT03087760,Trial of Consolidation Pembrolizumab After Concurrent Chemotherapy and Proton Reirradiation for Thoracic Recurrences of Non-Small Cell Lung Cancer,Phase II Trial of Consolidation Pembrolizumab After Concurrent Chemotherapy and Proton Reirradiation for Thoracic Recurrences of Non-Small Cell Lung Cancer,Abramson Cancer Center at Penn Medicine,Abramson Cancer Center at Penn Medicine,OTHER,COMPLETED,2017-11-29,2023-09-12,2023-09-12,INTERVENTIONAL,PHASE2,,,,Non-small Cell Lung Cancer,Non-small Cell Lung Cancer,1,1,1,DRUG,,,1,1,True,Yes,Number of Subjects With Progression Free Survival (COUNT_OF_PARTICIPANTS) Participants = 6,Number of Participants Who Experienced a Grade 3+ Adverse Event (COUNT_OF_PARTICIPANTS) Participants = 10,,,,,,,,,,Number of Subjects With Progression Free Survival (COUNT_OF_PARTICIPANTS) Participants = 6,,,,,,
NCT03090737,Safety Study of Nivolumab to Treat Advanced or Metastatic Non-small Cell Lung Cancer,"An Open-label, Single-arm Phase II Safety Study of Nivolumab in Participants With Advanced or Metastatic Non-small Cell Lung Cancer Who Have Progressed During or After Receiving at Least One Prior Sys",Bristol-Myers Squibb,Bristol-Myers Squibb,INDUSTRY,COMPLETED,2017-06-02,2021-02-16,2022-03-14,INTERVENTIONAL,PHASE2,,,,Non-Small Cell Lung Cancer,Non-Small Cell Lung Cancer,1,1,1,BIOLOGICAL,,,1,4,True,Yes,The Number of Participants Experiencing High Grade (Grades 3-4 and Grade 5) Drug-Related Select Adverse Events (AE) (COUNT_OF_PARTICIPANTS) Participants = 3,Progression Free Survival (PFS) (MEDIAN) Months = 3.68 [3.06-4.50]; Objective Response Rate (ORR) (NUMBER) Percentage of participants = 17.1 [11.0-24.7]; Overall Survival (OS) (MEDIAN) Months = 10.58 [8.34-14.69]; Duration of Response (DOR) (MEDIAN) Months = 35.45 [10.87-47.31],,,,,Duration of Response (DOR) (MEDIAN) Months = 35.45 [10.87-47.31],,,Objective Response Rate (ORR) (NUMBER) Percentage of participants = 17.1 [11.0-24.7],Overall Survival (OS) (MEDIAN) Months = 10.58 [8.34-14.69],Progression Free Survival (PFS) (MEDIAN) Months = 3.68 [3.06-4.50],,,Objective Response Rate (ORR) (NUMBER) Percentage of participants = 17.1 [11.0-24.7],The Number of Participants Experiencing High Grade (Grades 3-4 and Grade 5) Drug-Related Select Adverse Events (AE) (COUNT_OF_PARTICIPANTS) Participants = 3,,
NCT03117049,Study of ONO-4538 in Non-Squamous Non-Small Cell Lung Cancer (TASUKI-52),"A Multicenter, Randomized, Double-Blind Trial in Subjects With Non-Squamous Non-Small Cell Lung Cancer (TASUKI-52)",Ono Pharmaceutical Co. Ltd,Ono Pharmaceutical Co. Ltd,INDUSTRY,COMPLETED,2017-06-13,2020-02-10,2023-12-04,INTERVENTIONAL,PHASE3,,,,Non-Small Cell Lung Cancer,Non-Small Cell Lung Cancer,1,2,5,DRUG,,,1,5,True,Yes,Progression Free Survival (PFS) as Assessed by the Independent Radiology Review Committee (IRRC) (MEDIAN) months = 12.1 [9.8-14.0],Overall Survival (OS) (MEDIAN) months = 25.4; Objective Response Rate (ORR [as Assessed by the IRRC]) (NUMBER) percentage of participants = 61.5 [55.4-67.2]; Disease Control Rate (DCR [as Assessed by the IRRC]) (NUMBER) percentage of participants = 87.3 [82.7-91.0]; Duration of Response (DOR [as Assessed by the IRRC]) (MEDIAN) months = 11.0 [1.1-25.8]; Best Overall Response (BOR [as Assessed by the IRRC]) (COUNT_OF_PARTICIPANTS) Participants = 14,,,,,Duration of Response (DOR [as Assessed by the IRRC]) (MEDIAN) months = 11.0 [1.1-25.8],,,Objective Response Rate (ORR [as Assessed by the IRRC]) (NUMBER) percentage of participants = 61.5 [55.4-67.2],Overall Survival (OS) (MEDIAN) months = 25.4,Progression Free Survival (PFS) as Assessed by the Independent Radiology Review Committee (IRRC) (MEDIAN) months = 12.1 [9.8-14.0],,,Objective Response Rate (ORR [as Assessed by the IRRC]) (NUMBER) percentage of participants = 61.5 [55.4-67.2],,,
NCT03123783,CD40 Agonistic Antibody APX005M (Sotigalimab) in Combination With Nivolumab,A Study to Evaluate the Safety and Efficacy of the CD40 Agonistic Antibody APX005M Administered in Combination With Nivolumab in Subjects With Non-small Cell Lung Cancer and Subjects With Metastatic M,"Apexigen America, Inc.","Apexigen America, Inc.",INDUSTRY,COMPLETED,2017-07-10,2020-11-16,2020-11-16,INTERVENTIONAL,PHASE1; PHASE2,,,,Cancer,Cancer; Non Small Cell Lung Cancer Metastatic; Metastatic Melanoma,5,6,2,DRUG,,,3,4,True,Yes,Number of Participants Experiencing Dose-limiting Toxicities (DLTs) (COUNT_OF_PARTICIPANTS) Participants = 0; ; Phase 2 Evaluate the Objective Response Rate (ORR) by RECIST 1.1 and iRECIST in Each Cohort / Group (NUMBER) Percentage of participants = 16.67 [8.57-28.07],Safety of the APX005M and Nivolumab Combination (Phase 2) (COUNT_OF_PARTICIPANTS) Participants = 52; ; Median Progression-free Survival (PFS) (Phase 2) (MEDIAN) Months = 4.11 [3.45-5.52]; 6-month PFS Rate (Phase 2) (NUMBER) Percentage of participants = 33.10 [20.10-46.68],,,,,,,,Phase 2 Evaluate the Objective Response Rate (ORR) by RECIST 1.1 and iRECIST in Each Cohort / Group (NUMBER) Percentage of participants = 16.67 [8.57-28.07],,Median Progression-free Survival (PFS) (Phase 2) (MEDIAN) Months = 4.11 [3.45-5.52]; 6-month PFS Rate (Phase 2) (NUMBER) Percentage of participants = 33.10 [20.10-46.68],,,Phase 2 Evaluate the Objective Response Rate (ORR) by RECIST 1.1 and iRECIST in Each Cohort / Group (NUMBER) Percentage of participants = 16.67 [8.57-28.07],,,
NCT03132532,Platinum Doublet Chemotherapy and Proton Beam Radiation Therapy in Treating Patients With Stage II-III Non-small Cell Lung Cancer That Cannot Be Remov,Phase II Trial of Standard Platinum Doublet Chemotherapy + Various Proton Beam Therapy (PBT) Doses in Order to Determine the Optimal Dose of PBT for Unresectable Stage 2/3 Non-Small Cell Lung Cancer,Mayo Clinic,Mayo Clinic,OTHER,COMPLETED,2017-07-31,2023-12-23,2023-12-23,INTERVENTIONAL,PHASE2,,,,Recurrent Lung Non-Small Cell Carcinoma,Recurrent Lung Non-Small Cell Carcinoma; Stage II Lung Cancer AJCC v8; Stage III Lung Cancer AJCC v8,4,2,8,DRUG; OTHER; RADIATION,,,1,4,True,Yes,Proportion of Participants With Progression Free Survival (PFS) (NUMBER) proportion of participants = 0.6 [0.362-0.995],Overall Survival (OS) (COUNT_OF_PARTICIPANTS) Participants = 4; Number of Participants With Adverse Events (COUNT_OF_PARTICIPANTS) Participants = 9; Proportion of Participants With Local-regional Failure (NUMBER) proportion of participants = 0.2 [0.057-0.51]; Proportion of Participants With Distant Metastasis (NUMBER) proportion of participants = 0.1 [0.018-0.40],,,,,,,,,Overall Survival (OS) (COUNT_OF_PARTICIPANTS) Participants = 4,Proportion of Participants With Progression Free Survival (PFS) (NUMBER) proportion of participants = 0.6 [0.362-0.995],,,,Number of Participants With Adverse Events (COUNT_OF_PARTICIPANTS) Participants = 9,,
NCT03133546,Osimertinib and Bevacizumab Versus Osimertinib Alone as Second-line Treatment in Stage IIIb-IVb NSCLC With Confirmed EGFRm and T790M (BOOSTER),A Randomised Phase II Trial of Osimertinib and Bevacizumab Versus Osimertinib Alone as Second-line Treatment in Stage IIIb-IVb NSCLC With Confirmed EGFRm and T790M,ETOP IBCSG Partners Foundation,ETOP IBCSG Partners Foundation,NETWORK,COMPLETED,2017-05-31,2021-02-22,2024-02-29,INTERVENTIONAL,PHASE2,,,,Non Small Cell Lung Cancer Metastatic,Non Small Cell Lung Cancer Metastatic,1,2,2,DRUG,,,1,4,True,Yes,Progression Free Survival (PFS) (MEDIAN) months = 15.4 [9.2-18],Objective Response Rate (ORR) (COUNT_OF_PARTICIPANTS) Participants = 43; Disease Control Rate (DCR) (COUNT_OF_PARTICIPANTS) Participants = 70; Adverse Events (COUNT_OF_PARTICIPANTS) Participants = 76; Overall Survival (OS) (MEDIAN) months = 24.0 [17.8-32.1],,,,,,,,Objective Response Rate (ORR) (COUNT_OF_PARTICIPANTS) Participants = 43,Overall Survival (OS) (MEDIAN) months = 24.0 [17.8-32.1],Progression Free Survival (PFS) (MEDIAN) months = 15.4 [9.2-18],,,Objective Response Rate (ORR) (COUNT_OF_PARTICIPANTS) Participants = 43,Adverse Events (COUNT_OF_PARTICIPANTS) Participants = 76,,
NCT03137771,Maintenance Chemotherapy With or Without Local Consolidative Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer,Maintenance Systemic Therapy Versus Local Consolidative Therapy (LCT) Plus Maintenance Systemic Therapy for Limited Metastatic Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II/III Trial,NRG Oncology,NRG Oncology,OTHER,ACTIVE_NOT_RECRUITING,2017-04-07,2023-12-20,2028-12,INTERVENTIONAL,PHASE2,,,,Recurrent Non-Small Cell Lung Carcinoma,Recurrent Non-Small Cell Lung Carcinoma; Stage IV Non-Small Cell Lung Cancer,2,2,8,DRUG; RADIATION,,,2,4,True,Yes,[Phase II] Progression-free Survival (MEDIAN) months = 11.1 [6.9-21.4]; ,In-Field Local Failure (NUMBER) percentage of participants = 15.3 [8.1-24.6]; Development of New Lesions (NUMBER) percentage of participants = 32.5 [21.8-43.5]; Number of Participants by Highest Grade Adverse Event Reported (COUNT_OF_PARTICIPANTS) Participants = 7; Duration of Maintenance Chemotherapy (MEDIAN) months = 5.46 [2.07-17.95],,,,,,,,,,[Phase II] Progression-free Survival (MEDIAN) months = 11.1 [6.9-21.4],,,,,,
NCT03141359,Use of High Dose Radiation Followed by Chemotherapy and Radiation to Treat Locally Advanced NSCLC,LCI-LUN-NSC-SBRT-001: Phase II Prospective Trial of Primary Lung Tumor Stereotactic Body Radiation Therapy Followed by Concurrent Mediastinal Chemoradiation and Adjuvant Immunotherapy for Locally-Adva,Wake Forest University Health Sciences,Wake Forest University Health Sciences,OTHER,ACTIVE_NOT_RECRUITING,2017-05-12,2023-07-12,2027-07,INTERVENTIONAL,PHASE2,,,,Lung Cancer Stage II,Lung Cancer Stage II; Lung Cancer Stage III; Non Small Cell Lung Cancer,3,1,7,DRUG; RADIATION,,,1,11,True,Yes,Number of Participants Progression Free and Surviving at 12 Months (COUNT_OF_PARTICIPANTS) Participants = 37,; ; Radiologic Clinical Complete Response (COUNT_OF_PARTICIPANTS) Participants = 28; Number of Participants With an Objective Response (COUNT_OF_PARTICIPANTS) Participants = 45; ; ; ; ; European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Cancer (EORTC QLQ-C30) Global Health Status Quality of Life Score (LEAST_SQUARES_MEAN) score on a scale = 66.25; European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Lung Cancer (EORTC QLQ-LC13) Symptom Scores (LEAST_SQUARES_MEAN) score on a scale = 25.64; MD Anderson Symptom Inventory - Lung Cancer (MDASI-LC) Total Symptom + Interference Score (LEAST_SQUARES_MEAN) score on a scale = 1.56,,Radiologic Clinical Complete Response (COUNT_OF_PARTICIPANTS) Participants = 28,,,,,,,,,,European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Cancer (EORTC QLQ-C30) Global Health Status Quality of Life Score (LEAST_SQUARES_MEAN) score on a scale = 66.25; European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Lung Cancer (EORTC QLQ-LC13) Symptom Scores (LEAST_SQUARES_MEAN) score on a scale = 25.64,,,,
NCT03150875,A Study Comparing the Efficacy and Safety Between IBI308 and Docetaxel in Patients With Advanced or Metastatic NSCLC,"Efficacy and Safety Evaluation of IBI308 Versus Docetaxel in Patients With Advanced or Metastatic Squamous Cell Lung Cancer After Failure of First-line Platinum-based Therapy- a Randomized, Open-label",Innovent Biologics (Suzhou) Co. Ltd.,Innovent Biologics (Suzhou) Co. Ltd.,INDUSTRY,COMPLETED,2017-09-01,2023-02-22,2023-02-22,INTERVENTIONAL,PHASE3,,,,Non-small Cell Lung Cancer,Non-small Cell Lung Cancer,1,2,2,DRUG,,,1,4,True,Yes,Overall Survival (MEDIAN) Months = 11.79 [10.28-15.27],Progression-free Survival by Investigators' Assessment (MEDIAN) Months = 4.3 [4.04-5.78]; Overall Response Rate (ORR) Per RECIST v1.1 as Assessed by Investigators (NUMBER) Percentage of participants = 25.5 [18.6-33.4]; Duration of Response (DOR) Per RECIST v1.1 as Assessed by Investigators (MEDIAN) Months = 12.45 [4.86-25.33]; Percentage of Participants Experiencing Treatment-emergent Adverse Events (TEAE) (NUMBER) Percentage of participants = 97.20,,,,,Duration of Response (DOR) Per RECIST v1.1 as Assessed by Investigators (MEDIAN) Months = 12.45 [4.86-25.33],,,,Overall Survival (MEDIAN) Months = 11.79 [10.28-15.27],Progression-free Survival by Investigators' Assessment (MEDIAN) Months = 4.3 [4.04-5.78],,,Overall Response Rate (ORR) Per RECIST v1.1 as Assessed by Investigators (NUMBER) Percentage of participants = 25.5 [18.6-33.4],Percentage of Participants Experiencing Treatment-emergent Adverse Events (TEAE) (NUMBER) Percentage of participants = 97.20,,
NCT03158129,Nivolumab With or Without Ipilimumab or Chemotherapy in Treating Patients With Previously Untreated Stage I-IIIA Non-small Cell Lung Cancer,Phase II Study of Induction Checkpoint Blockade for Untreated Stage I-IIIA Non-Small Cell Lung Cancers Amenable for Surgical Resection,M.D. Anderson Cancer Center,M.D. Anderson Cancer Center,OTHER,COMPLETED,2017-06-16,2024-11-13,2024-11-13,INTERVENTIONAL,PHASE2,,,,Stage I Lung Non-Small Cell Cancer AJCC v7,Stage I Lung Non-Small Cell Cancer AJCC v7; Stage IA Lung Non-Small Cell Carcinoma AJCC v7; Stage IB Lung Non-Small Cell Carcinoma AJCC v7,7,4,6,BIOLOGICAL; DRUG,,,1,7,True,Yes,Major Pathologic Response (mPR) (COUNT_OF_PARTICIPANTS) Participants = 5,Pathologic Complete Response (pCR) (COUNT_OF_PARTICIPANTS) Participants = 2; Radiographic Response (COUNT_OF_PARTICIPANTS) Participants = 0; ; ; Residual Tumor Classification (COUNT_OF_PARTICIPANTS) Participants = 21; 30-day Postoperative Complication (COUNT_OF_PARTICIPANTS) Participants = 8; 90-day Mortality (COUNT_OF_PARTICIPANTS) Participants = 1,,Pathologic Complete Response (pCR) (COUNT_OF_PARTICIPANTS) Participants = 2,,,,,,,,,,,,,,
NCT03164616,Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON).,"A Phase III, Randomized, Multi-Center, Open-Label, Comparative Global Study to Determine the Efficacy of Durvalumab or Durvalumab and Tremelimumab in Combination With Platinum-Based Chemotherapy for F",AstraZeneca,AstraZeneca,INDUSTRY,ACTIVE_NOT_RECRUITING,2017-06-01,2021-03-12,2027-11-15,INTERVENTIONAL,PHASE3,,,,Non Small Cell Lung Cancer NSCLC,Non Small Cell Lung Cancer NSCLC,1,3,7,DRUG,,,2,12,True,Yes,Progression-Free Survival (PFS); D + SoC Compared With SoC Alone (MEDIAN) months = 5.5 [4.7-6.5]; Overall Survival (OS); D + SoC Compared With SoC Alone (MEDIAN) months = 13.3 [11.4-14.7],"PFS; T + D + SoC Compared With SoC Alone and T + D + SoC Compared With D + SoC (MEDIAN) months = 6.2 [5.0-6.5]; OS; T + D + SoC Compared With SoC Alone and T + D + SoC Compared With D + SoC (MEDIAN) months = 14.0 [11.7-16.1]; Objective Response Rate (ORR) (NUMBER) percentage of patients = 46.3; Best Objective Response (BoR) (COUNT_OF_PARTICIPANTS) Participants = 2; Duration of Response (DoR) (MEDIAN) months = 7.4; Time From Randomization to Second Progression (PFS2) (MEDIAN) months = 10.4 [9.4-12.2]; Pharmacokinetics (PK) of Durvalumab; Peak and Trough Serum Concentrations (GEOMETRIC_MEAN) micrograms/milliliter (μg/mL) = 418.80; PK of Tremelimumab; Peak and Trough Serum Concentrations (GEOMETRIC_MEAN) μg/mL = 23.17; Number of Patients With Anti-Drug Antibody (ADA) Response to Durvalumab (COUNT_OF_PARTICIPANTS) Participants = 42; Number of Patients With ADA Response to Tremelimumab (COUNT_OF_PARTICIPANTS) Participants = 44; Time to Deterioration of Global Health Status / Health-Related Quality of Life (HRQoL) and Patient Reported Outcome (PRO) Symptoms, Assessed Using European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ) (MEDIAN) months = 8.3 [6.4-10.2]; Time to Deterioration of PRO Symptoms, Assessed Using EORTC QLQ-Lung Cancer Module 13 (QLQ-LC13) (MEDIAN) months = 9.7 [7.3-13.3]",,,,,Duration of Response (DoR) (MEDIAN) months = 7.4,,,Objective Response Rate (ORR) (NUMBER) percentage of patients = 46.3,Overall Survival (OS); D + SoC Compared With SoC Alone (MEDIAN) months = 13.3 [11.4-14.7],Progression-Free Survival (PFS); D + SoC Compared With SoC Alone (MEDIAN) months = 5.5 [4.7-6.5],,"Time to Deterioration of Global Health Status / Health-Related Quality of Life (HRQoL) and Patient Reported Outcome (PRO) Symptoms, Assessed Using European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ) (MEDIAN) months = 8.3 [6.4-10.2]",Objective Response Rate (ORR) (NUMBER) percentage of patients = 46.3,,,
NCT03164772,Phase 1/2 Study of Combination Immunotherapy and Messenger Ribonucleic Acid (mRNA) Vaccine in Subjects With NSCLC,A Phase 1/2 Study of Combination Immunotherapy and mRNA Vaccine in Subjects With Non-small Cell Lung Cancer (NSCLC),Ludwig Institute for Cancer Research,Ludwig Institute for Cancer Research,OTHER,COMPLETED,2017-12-20,2021-10-29,2021-10-29,INTERVENTIONAL,PHASE1; PHASE2,,,,Metastatic Non-small Cell Lung Cancer,Metastatic Non-small Cell Lung Cancer; NSCLC,2,2,4,BIOLOGICAL; DEVICE; DRUG,,,1,11,True,Yes,Number of Subjects With Treatment-Emergent Adverse Events (TEAEs) (COUNT_OF_PARTICIPANTS) Participants = 23,Median PFS by RECIST 1.1 as Estimated Using the Kaplan-Meier Method (MEDIAN) months = 2 [1.8-7.3]; Number of Subjects Without Progression at 8 and 24 Weeks by RECIST 1.1 (COUNT_OF_PARTICIPANTS) Participants = 11; Median PFS by irRECIST as Estimated Using the Kaplan-Meier Method (MEDIAN) months = 2 [1.8-13.6]; Number of Subjects Without Progression at 8 and 24 Weeks by irRECIST (COUNT_OF_PARTICIPANTS) Participants = 11; Number of Subjects With Best Overall Tumor Response By RECIST 1.1 (COUNT_OF_PARTICIPANTS) Participants = 0; Number of Subjects With Objective Responses at 8 and 24 Weeks By RECIST 1.1 (COUNT_OF_PARTICIPANTS) Participants = 5; Duration of Response (DoR) By RECIST 1.1 (MEDIAN) weeks = 43.1 [24.1-53.5]; Number of Subjects With Best Overall Tumor Response By irRECIST (COUNT_OF_PARTICIPANTS) Participants = 0; Number of Subjects With Objective Responses at 8 and 24 Weeks By irRECIST (COUNT_OF_PARTICIPANTS) Participants = 5; Duration of Response (DoR) by irRECIST (MEDIAN) weeks = 43.1 [24.1-53.5]; Median Overall Survival (OS) as Estimated Using the Kaplan-Meier Method (MEDIAN) months = 23.5,,,,,Duration of Response (DoR) By RECIST 1.1 (MEDIAN) weeks = 43.1 [24.1-53.5]; Duration of Response (DoR) by irRECIST (MEDIAN) weeks = 43.1 [24.1-53.5],,,,Median Overall Survival (OS) as Estimated Using the Kaplan-Meier Method (MEDIAN) months = 23.5,Median PFS by RECIST 1.1 as Estimated Using the Kaplan-Meier Method (MEDIAN) months = 2 [1.8-7.3]; Median PFS by irRECIST as Estimated Using the Kaplan-Meier Method (MEDIAN) months = 2 [1.8-13.6],,,,Number of Subjects With Treatment-Emergent Adverse Events (TEAEs) (COUNT_OF_PARTICIPANTS) Participants = 23,,
NCT03190174,Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers,"A Phase 1/2 Study Using Nivolumab and ABI-009 for Advanced Sarcoma, Advanced Carcinoma Treated With PD1 Inhibitors, and Tumors With Genetic Mutations Sensitive to mTOR Inhibitors","Sarcoma Oncology Research Center, LLC","Sarcoma Oncology Research Center, LLC",OTHER,COMPLETED,2017-08-24,2021-12-01,2021-12-02,INTERVENTIONAL,PHASE1; PHASE2,,,,Ewing Sarcoma,Ewing Sarcoma; PEComa; Epithelioid Sarcoma,14,1,2,BIOLOGICAL; DRUG,,,1,3,True,Yes,Maximum Tolerated Dose of ABI-009 (NUMBER) mg/m^2 = 100,Disease Control Rate (COUNT_OF_PARTICIPANTS) Participants = 22; Progression Free Survival (COUNT_OF_PARTICIPANTS) Participants = 22; Overall Survival (COUNT_OF_PARTICIPANTS) Participants = 22,,,,,,,,,Overall Survival (COUNT_OF_PARTICIPANTS) Participants = 22,Progression Free Survival (COUNT_OF_PARTICIPANTS) Participants = 22,,,,,,
NCT03191786,A Study of Atezolizumab Compared With a Single-Agent Chemotherapy in Treatment Naïve Participants With Locally Advanced or Recurrent or Metastatic Non,"A Phase III, Open-Label, Multicenter, Randomized Study to Investigate the Efficacy and Safety of Atezolizumab Compared With Chemotherapy in Patients With Treatment Naïve Advanced or Recurrent (Stage I",Hoffmann-La Roche,Hoffmann-La Roche,INDUSTRY,COMPLETED,2017-09-11,2022-04-30,2023-10-25,INTERVENTIONAL,PHASE3,,,,Non-Small Cell Lung Cancer,Non-Small Cell Lung Cancer,1,2,3,DRUG,,,1,11,True,Yes,Overall Survival (OS) (MEDIAN) Months = 10.3 [9.4-11.9],"OS Rates at the 6, 12, 18, 24-Months Timepoints (NUMBER) Percentage of participants = 64.0 [58.6-69.5]; Percentage of Participants With Objective Response, as Determined by the Investigator Using Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST v1.1) (NUMBER) Percentage of participants = 16.9 [12.8-21.6]; Progression-Free Survival (PFS), as Determined by the Investigator Using RECIST v1.1 (MEDIAN) Months = 4.2 [3.7-5.5]; Duration of Response (DOR), as Determined by the Investigator Using RECIST v1.1 (MEDIAN) Months = 14.0 [8.1-20.3]; Percentage of Participants With At Least One Adverse Event (AE) (NUMBER) Percentage of participants = 91.7; Change From Baseline in European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 (EORTC-QLQ-C30) Score (MEAN) units of a scale = 54.70; Change From Baseline in EORTC QLQ Supplementary Lung Cancer Module 13 (EORTC QLQ-LC13) Score (MEAN) units of a scale = 34.30; ; ; OS in Participants With Programmed Death-Ligand 1 (PD-L1) Positive Status (MEDIAN) Months = 9.4 [7.0-11.3]; PFS as Determined by the Investigator Using RECIST v1.1 in Participants With PD-L1 Positive Status (MEDIAN) Months = 4.2 [2.9-5.8]",,,,,"Duration of Response (DOR), as Determined by the Investigator Using RECIST v1.1 (MEDIAN) Months = 14.0 [8.1-20.3]",,,,"Overall Survival (OS) (MEDIAN) Months = 10.3 [9.4-11.9]; OS Rates at the 6, 12, 18, 24-Months Timepoints (NUMBER) Percentage of participants = 64.0 [58.6-69.5]; OS in Participants With Programmed Death-Ligand 1 (PD-L1) Positive Status (MEDIAN) Months = 9.4 [7.0-11.3]","Progression-Free Survival (PFS), as Determined by the Investigator Using RECIST v1.1 (MEDIAN) Months = 4.2 [3.7-5.5]; PFS as Determined by the Investigator Using RECIST v1.1 in Participants With PD-L1 Positive Status (MEDIAN) Months = 4.2 [2.9-5.8]",,Change From Baseline in European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 (EORTC-QLQ-C30) Score (MEAN) units of a scale = 54.70,,,,
NCT03195491,A Study of Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Second-Line Nivolumab Monotherapy in Asia,"An Open Label, Safety Study of Participants With Non-Small Cell Lung Cancer Receiving Second-Line Nivolumab Monotherapy in Asia",Bristol-Myers Squibb,Bristol-Myers Squibb,INDUSTRY,COMPLETED,2017-12-25,2021-06-08,2021-06-08,INTERVENTIONAL,PHASE3,,,,Lung Cancer,Lung Cancer; Non-Small Cell Lung Cancer,2,1,1,BIOLOGICAL,,,1,10,True,Yes,Number of Non-HBV Participants Experiencing High Grade Treatment-Related Select Adverse Events (COUNT_OF_PARTICIPANTS) Participants = 2,Number of HBV Participants Experiencing High Grade Treatment-Related Select Adverse Events (COUNT_OF_PARTICIPANTS) Participants = 0; Number of Participants Experiencing Adverse Events (AEs) (COUNT_OF_PARTICIPANTS) Participants = 375; Overall Survival (OS) (MEDIAN) Months = 14.16 [12.25-18.07]; Progression-Free Survival (PFS) (MEDIAN) Months = 3.61 [2.33-3.75]; Number of Participants Experiencing Laboratory Abnormalities in Specific Liver Tests (COUNT_OF_PARTICIPANTS) Participants = 16; Number of Participants Experiencing Serious Adverse Events (SAEs) (COUNT_OF_PARTICIPANTS) Participants = 157; Objective Response Rate (NUMBER) Percentage of participants = 14.88 [11.47-18.85]; ; Number of Participants Experiencing Laboratory Abnormalities in Specific Thyroid Tests (COUNT_OF_PARTICIPANTS) Participants = 87; Time to Treatment Failure (TTF) (MEDIAN) Months = 2.23 [1.94-3.52],,,,,,,,Objective Response Rate (NUMBER) Percentage of participants = 14.88 [11.47-18.85],Overall Survival (OS) (MEDIAN) Months = 14.16 [12.25-18.07],Progression-Free Survival (PFS) (MEDIAN) Months = 3.61 [2.33-3.75],,,Objective Response Rate (NUMBER) Percentage of participants = 14.88 [11.47-18.85],Number of Non-HBV Participants Experiencing High Grade Treatment-Related Select Adverse Events (COUNT_OF_PARTICIPANTS) Participants = 2; Number of HBV Participants Experiencing High Grade Treatment-Related Select Adverse Events (COUNT_OF_PARTICIPANTS) Participants = 0; Number of Participants Experiencing Adverse Events (AEs) (COUNT_OF_PARTICIPANTS) Participants = 375; Number of Participants Experiencing Serious Adverse Events (SAEs) (COUNT_OF_PARTICIPANTS) Participants = 157,Time to Treatment Failure (TTF) (MEDIAN) Months = 2.23 [1.94-3.52],
NCT03197467,Neoadjuvant Anti PD-1 Immunotherapy in Resectable Non-small Cell Lung Cancer,Neoadjuvant Anti PD-1 Immunotherapy in Resectable Non-small Cell Lung Cancer [NEOMUN],AIO-Studien-gGmbH,AIO-Studien-gGmbH,OTHER,COMPLETED,2018-06-18,2021-10-30,2023-05-05,INTERVENTIONAL,PHASE2,,,,Non-small Cell Lung Cancer (NSCLC),Non-small Cell Lung Cancer (NSCLC),1,1,1,DRUG,,,5,5,True,Yes,Number of Patients Treated in Compliance With Protocol (COUNT_OF_PARTICIPANTS) Participants = 29; Tumor Response According to RECIST 1.1 Criteria (COUNT_OF_PARTICIPANTS) Participants = 0; Tumor Response Evaluation - Pathologic Response (COUNT_OF_PARTICIPANTS) Participants = 4; Tumor Response Evaluation - Δ Tumor Size (MEDIAN) mm = -4.0 [-13.5-0.0]; Tumor Response - Δ PET Activity (MEDIAN) standardized uptake value [SUV] = -1 [-7-2],Disease-free Survival at 6 Months (NUMBER) Probablity of DFS in % = 86.2 [67.3-94.6]; Disease-free Survival at 12 Months (NUMBER) Probablity of DFS in % = 86.2 [67.3-94.6]; Overall Survival at 12 Months (NUMBER) Probability of OS in % = 93.1 [75.1-98.2]; Overall Survival at 18 Months (NUMBER) Probability of OS in % = 89.7 [71.3-96.5]; Overall Survival at 24 Months (NUMBER) Probability of OS in % = 86.2 [67.3-94.6],,,Disease-free Survival at 6 Months (NUMBER) Probablity of DFS in % = 86.2 [67.3-94.6]; Disease-free Survival at 12 Months (NUMBER) Probablity of DFS in % = 86.2 [67.3-94.6],,,,,,Overall Survival at 12 Months (NUMBER) Probability of OS in % = 93.1 [75.1-98.2]; Overall Survival at 18 Months (NUMBER) Probability of OS in % = 89.7 [71.3-96.5]; Overall Survival at 24 Months (NUMBER) Probability of OS in % = 86.2 [67.3-94.6],,,,,,,
NCT03215706,A Study of Nivolumab and Ipilimumab Combined With Chemotherapy Compared to Chemotherapy Alone in First Line NSCLC,"A Phase 3, Randomized Study of Nivolumab Plus Ipilimumab in Combination With Chemotherapy vs Chemotherapy Alone as First Line Therapy in Stage IV Non-Small Cell Lung Cancer",Bristol-Myers Squibb,Bristol-Myers Squibb,INDUSTRY,COMPLETED,2017-08-24,2019-08-16,2024-10-18,INTERVENTIONAL,PHASE3,,,,Non-Small Cell Lung Cancer,Non-Small Cell Lung Cancer,1,2,6,BIOLOGICAL; DRUG,,,1,10,True,Yes,Overall Survival (OS) (MEDIAN) Months = 14.13 [13.24-16.16],Progression Free Survival (PFS) by BICR (MEDIAN) Months = 6.74 [5.55-8.05]; Objective Response Rate (ORR) by BICR (NUMBER) Percentage of Participants = 38.0 [32.9-43.2]; Duration of Response (DoR) (MEDIAN) Months = 13.01 [8.71-20.21]; Time to Response (TTR) (MEDIAN) Months = 2.53 [1.1-52.1]; Objective Response Rate (ORR) by BICR by PD-LI Tumor Cell Expression (NUMBER) Percentage of Participants = 42.6 [35.8-49.7]; PFS by BICR by PD-L1 Tumor Cell Expression (MEDIAN) Months = 5.78 [4.40-7.66]; OS by PD-L1 Tumor Cell Expression (MEDIAN) Months = 17.74 [13.67-20.27]; PFS by BICR by Tumor Mutational Burden (MEDIAN) Months = 8.94 [5.55-13.01]; ORR by BICR by Tumor Mutational Burden (NUMBER) Percentage of Participants = 45.5 [35.6-55.8]; OS by Tumor Mutational Burden (MEDIAN) Months = 15.05 [12.45-20.76],,,,,Duration of Response (DoR) (MEDIAN) Months = 13.01 [8.71-20.21],,,Objective Response Rate (ORR) by BICR (NUMBER) Percentage of Participants = 38.0 [32.9-43.2]; Objective Response Rate (ORR) by BICR by PD-LI Tumor Cell Expression (NUMBER) Percentage of Participants = 42.6 [35.8-49.7]; ORR by BICR by Tumor Mutational Burden (NUMBER) Percentage of Participants = 45.5 [35.6-55.8],Overall Survival (OS) (MEDIAN) Months = 14.13 [13.24-16.16]; OS by PD-L1 Tumor Cell Expression (MEDIAN) Months = 17.74 [13.67-20.27]; OS by Tumor Mutational Burden (MEDIAN) Months = 15.05 [12.45-20.76],Progression Free Survival (PFS) by BICR (MEDIAN) Months = 6.74 [5.55-8.05]; PFS by BICR by PD-L1 Tumor Cell Expression (MEDIAN) Months = 5.78 [4.40-7.66]; PFS by BICR by Tumor Mutational Burden (MEDIAN) Months = 8.94 [5.55-13.01],,,Objective Response Rate (ORR) by BICR (NUMBER) Percentage of Participants = 38.0 [32.9-43.2]; Objective Response Rate (ORR) by BICR by PD-LI Tumor Cell Expression (NUMBER) Percentage of Participants = 42.6 [35.8-49.7],,,
NCT03217071,Pembrolizumab With and Without Radiotherapy for Non-Small Cell Lung Cancer,"PembroX: Enhancing the Immunogenicity of Non-Small Cell Lung Cancer With Pembrolizumab +/- Stereotactic Radiotherapy Delivered in the Preoperative Window, A Randomized Phase II Study With Correlative ","University of California, San Francisco",Sue Yom,OTHER,COMPLETED,2017-10-04,2022-03-31,2022-03-31,INTERVENTIONAL,PHASE2,,,,Non Small Cell Lung Cancer,Non Small Cell Lung Cancer,1,2,3,DRUG; PROCEDURE; RADIATION,,,2,6,True,Yes,Change in the Mean Number of Infiltrating Absolute Cluster of Differentiation 3 (CD3+) T Cells/ μm2 (MEAN) CD3+ T cells/ μm2 = 2976.00007 [851-722704]; Percentage of Participants Achieving a Two-fold Increase CD3+ T Cells/μm2 (NUMBER) percentage of participants = 40,Percentage of Participants With Treatment-Related Adverse Events (AEs) (NUMBER) percentage of participants = 100; Percentage of Participants With Grade 3 or Higher Immune-related AEs (NUMBER) percentage of participants = 16.66; Median Overall Survival in Months (MEDIAN) months = 12 [2.13-12]; Median Relapse Free Survival (MEDIAN) months = 12 [2.13-12]; ; Percentage of Participants Determined to Have Unresectable Tumors After Progression (NUMBER) percentage of participants = 0,,,,,,,,,Median Overall Survival in Months (MEDIAN) months = 12 [2.13-12],,,,,Percentage of Participants With Treatment-Related Adverse Events (AEs) (NUMBER) percentage of participants = 100,,
NCT03239340,A Molecular Profiling Study of Patients With EGFR Mutation-positive Locally Advanced or Metastatic NSCLC Treated With Osimertinib,"A Multicentre, Open-label, Single-arm, Molecular Profiling Study of Patients With EGFR Mutation-positive Locally Advanced or Metastatic NSCLC Treated With Osimertinib",AstraZeneca,AstraZeneca,INDUSTRY,COMPLETED,2018-05-30,2023-09-19,2023-09-19,INTERVENTIONAL,PHASE2,,,,EGFR Mutation Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer,EGFR Mutation Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer,1,1,1,DRUG,,,1,14,True,Yes,Proportion of Patients With a Given Tumour Genetic and Proteomic Marker at the Point of Disease Progression (NUMBER) Percentage of participants = 2.0 [0.05-10.45],Progression Free Survival (PFS) (MEDIAN) Months = 16.4 [12.7-20.3]; Objective Response Rate (ORR) (NUMBER) Percentage of participants = 73.4 [65.66-80.17]; Duration of Response (DoR) (MEDIAN) Months = 18.8 [14.2-22.3]; Disease Control Rate (DCR) (NUMBER) Percentage of participants = 94.8 [90.02-97.73]; Time to Treatment Discontinuation or Death (TTD) (MEDIAN) Months = 20.0 [16.3-23.8]; Time to First Subsequent Therapy or Death (TFST) (MEDIAN) Months = 32.1 [24.0-47.7]; PFS in Patient Subgroups Defined by Molecular Profile: Epidermal Growth Factor Receptor (EGFR) Tumor Mutation at Baseline (MEDIAN) Months = 22.0 [16.0-27.6]; PFS in Patient Subgroups Defined by Molecular Profile: Detectable in Plasma-Derived ctDNA at Baseline (MEDIAN) Months = 19.6 [12.7-24.0]; ORR in Patient Subgroups Defined by Molecular Profile: EGFR Tumor Mutation at Baseline (NUMBER) Percentage of participants = 82.4 [72.57-89.77]; ORR in Patient Subgroups Defined by Molecular Profile: Detectable in Plasma Derived ctDNA at Baseline (NUMBER) Percentage of participants = 85.5 [74.22-93.14]; TTD in Patient Subgroups Defined by Molecular Profile: EGFR Tumor Mutation at Baseline (MEDIAN) Months = 25.5 [19.6-32.1]; TTD in Patient Subgroups Defined by Molecular Profile: Detectable in Plasma Derived ctDNA at Baseline (MEDIAN) Months = 24.5 [17.8-29.6]; Tumour Shrinkage/Depth of Response in Patient Subgroups Defined by Molecular Profile: EGFR Tumor Mutation at Baseline (MEDIAN) Percentage change = -59.68 [-100.0-6.5]; Tumour Shrinkage/Depth of Response in Patient Subgroups Defined by Molecular Profile: Detectable in Plasma Derived ctDNA at Baseline (MEDIAN) Percentage change = -60.80 [-100.0-6.5],,,,,Duration of Response (DoR) (MEDIAN) Months = 18.8 [14.2-22.3],,,Objective Response Rate (ORR) (NUMBER) Percentage of participants = 73.4 [65.66-80.17]; ORR in Patient Subgroups Defined by Molecular Profile: EGFR Tumor Mutation at Baseline (NUMBER) Percentage of participants = 82.4 [72.57-89.77]; ORR in Patient Subgroups Defined by Molecular Profile: Detectable in Plasma Derived ctDNA at Baseline (NUMBER) Percentage of participants = 85.5 [74.22-93.14],,Progression Free Survival (PFS) (MEDIAN) Months = 16.4 [12.7-20.3]; PFS in Patient Subgroups Defined by Molecular Profile: Epidermal Growth Factor Receptor (EGFR) Tumor Mutation at Baseline (MEDIAN) Months = 22.0 [16.0-27.6]; PFS in Patient Subgroups Defined by Molecular Profile: Detectable in Plasma-Derived ctDNA at Baseline (MEDIAN) Months = 19.6 [12.7-24.0],,,Objective Response Rate (ORR) (NUMBER) Percentage of participants = 73.4 [65.66-80.17],,,
NCT03242915,Pembrolizumab Plus Chemotherapy in NSCLC With Targetable Genetic Alterations After Progression on Targeted Agents,Phase II Study of Pembrolizumab in Combination With Platinum-based Chemotherapy in Nonsmall Cell Lung Cancer Patients With Targetable Genetic Alterations Previously Treated With Appropriate Targeted A,University of Michigan Rogel Cancer Center,University of Michigan Rogel Cancer Center,OTHER,COMPLETED,2017-10-03,2025-02-20,2025-02-20,INTERVENTIONAL,PHASE2,,,,Non-small Cell Lung Cancer,Non-small Cell Lung Cancer,1,1,3,DRUG,,,1,2,True,Yes,The Percentage of Patients That Respond to Treatment (NUMBER) percentage of patients = 46 [27-67],Progression Free Survival (PFS) Time (MEDIAN) Months = 8.3 [7.2-16.5]; Overall Survival (OS) Time (MEDIAN) Months = 22.2,,,,,,,,,Overall Survival (OS) Time (MEDIAN) Months = 22.2,Progression Free Survival (PFS) Time (MEDIAN) Months = 8.3 [7.2-16.5],,,,,,
NCT03285321,Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer (NSCLC),Phase II Study of Consolidation Immunotherapy With Nivolumab and Ipilimumab or Nivolumab Alone Following Concurrent Chemoradiotherapy for Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer (NSCLC,Big Ten Cancer Research Consortium,"Greg Durm, MD",OTHER,COMPLETED,2017-09-15,2023-10-13,2024-02-06,INTERVENTIONAL,PHASE2,,,,Non-small Cell Lung Cancer,Non-small Cell Lung Cancer,1,2,3,DRUG,,,1,3,True,Yes,Progression Free Survival (PFS) at 18-month (NUMBER) Percentage of participants = 65.5 [49.8-77.3],Overall Survival (OS) (MEDIAN) Months = 32; Time to Metastatic Disease (TTMD) at 36 Month (NUMBER) Percentage of participants = 79.7 [61-90.1]; Number of Participants With Adverse Events (COUNT_OF_PARTICIPANTS) Participants = 54,,,,,,,,,Overall Survival (OS) (MEDIAN) Months = 32,Progression Free Survival (PFS) at 18-month (NUMBER) Percentage of participants = 65.5 [49.8-77.3],,,,Number of Participants With Adverse Events (COUNT_OF_PARTICIPANTS) Participants = 54,,
NCT03293680,Pembrolizumab in Elderly Patients With Advanced Lung Cancer,"Survival, Quality of Life and Self-reported Outcomes of Elderly Patients With Advanced Non-small Cell Lung Cancer Treated With Pembrolizumab (MK-3475) in the First Line Setting",Spanish Lung Cancer Group,Spanish Lung Cancer Group,OTHER,COMPLETED,2017-01-15,2023-04-28,2023-07-15,INTERVENTIONAL,PHASE2,,,,Non Small Cell Lung Cancer,Non Small Cell Lung Cancer,1,1,1,DRUG,,,1,6,True,Yes,Overall Survival (MEDIAN) Months = 19.2 [11.3-25.5],Changes in Health-related Quality of Life With Lung Cancer Symptom Scale (MEDIAN) units on a scale = 66.7 [16.7-100]; Impact on Functional Assessments Measured With Barthel Scale (MEAN) units on a scale = 100 [50-100]; Progression-free Survival (PFS) (MEDIAN) Months = 6.1 [4.6-8.6]; Overall Survival Rate at 2 Years. (NUMBER) percentage of participants = 40.2 [28.6-51.5]; OS for Patients With a PD-L1 Under 50% (MEAN) Months = 16.5 [6.8-24.6]; OS for Patients With a PD-L1 Greater Than or Equal to 50% (MEDIAN) Months = 23.3 [14.8-36],,,,,,,,,Overall Survival (MEDIAN) Months = 19.2 [11.3-25.5]; Overall Survival Rate at 2 Years. (NUMBER) percentage of participants = 40.2 [28.6-51.5]; OS for Patients With a PD-L1 Under 50% (MEAN) Months = 16.5 [6.8-24.6]; OS for Patients With a PD-L1 Greater Than or Equal to 50% (MEDIAN) Months = 23.3 [14.8-36],Progression-free Survival (PFS) (MEDIAN) Months = 6.1 [4.6-8.6],,Changes in Health-related Quality of Life With Lung Cancer Symptom Scale (MEDIAN) units on a scale = 66.7 [16.7-100],,,,
NCT03296163,A Study Comparing MB02 and Avastin® in Subjects With Stage IIIB/IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC),"A Randomized, Multicenter, Multinational, Double-Blind Study to Assess the Efficacy and Safety of MB02 (Bevacizumab Biosimilar Drug) Versus Avastin® in Combination With Carboplatin and Paclitaxel for ",mAbxience Research S.L.,mAbxience Research S.L.,INDUSTRY,COMPLETED,2018-02-06,2019-07-03,2020-02-27,INTERVENTIONAL,PHASE3,,,,Non-small Cell Lung Cancer,Non-small Cell Lung Cancer,1,2,4,DRUG,,,1,4,True,Yes,Objective Response Rate (ORR) at Week 18 (NUMBER) Percentage of participants = 40.3 [34.9-46.0],Progression-free Survival (PFS) (MEDIAN) weeks = 36.0 [33.0-36.43]; ; Incidence of Treatment-emergent Adverse Events (TEAEs) (NUMBER) participants = 288; Immunogenicity Assessments (Anti-drug Antibodies [ADA] and Neutralizing Antibodies [NAb]) (NUMBER) participants = 53,,,,,,,,Objective Response Rate (ORR) at Week 18 (NUMBER) Percentage of participants = 40.3 [34.9-46.0],,Progression-free Survival (PFS) (MEDIAN) weeks = 36.0 [33.0-36.43],,,Objective Response Rate (ORR) at Week 18 (NUMBER) Percentage of participants = 40.3 [34.9-46.0],Incidence of Treatment-emergent Adverse Events (TEAEs) (NUMBER) participants = 288,,
NCT03313804,Priming Immunotherapy in Advanced Disease With Radiation,Priming Immunotherapy in Advanced Disease With Radiation,University of Kentucky,"John L. Villano, MD, PhD",OTHER,ACTIVE_NOT_RECRUITING,2017-10-26,2024-02-16,2026-01,INTERVENTIONAL,PHASE2,,,,Non-small Cell Lung Cancer,Non-small Cell Lung Cancer; Squamous Cell Carcinoma of the Head and Neck,2,1,2,DRUG; RADIATION,,,1,3,True,Yes,Proportion of Participants Alive and Without Progression (NUMBER) proportion of participants = .66,; ; ,,,,,,,,,,,,,,,,
NCT03329911,A Comparative Study of BAT1706 and EU Avastin® in Patients With Advanced Non Squamous Non Small Cell Lung Cancer,"A Multicenter, Randomized, Double Blind, Phase III Study of BAT1706 Versus EU Avastin® Plus Chemotherapy in Patients With Advanced Non Squamous Non Small Cell Lung Cancer",Bio-Thera Solutions,Bio-Thera Solutions,INDUSTRY,COMPLETED,2017-10-20,2019-11-05,2021-05-27,INTERVENTIONAL,PHASE3,,,,Non-squamous Non-small Cell Lung Cancer,Non-squamous Non-small Cell Lung Cancer,1,2,4,DRUG,,,1,6,True,Yes,Overall Response Rate (COUNT_OF_PARTICIPANTS) Participants = 156,; ; ; ; ; ,,,,,,,,,,,,,Overall Response Rate (COUNT_OF_PARTICIPANTS) Participants = 156,,,
NCT03334617,Phase II Umbrella Study of Novel Anti-cancer Agents in Participants With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy,"An Open-Label, Multi-Drug, Biomarker-Directed, Multi-Centre Phase II Umbrella Study in Patients With Non-Small Cell Lung Cancer, Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy (HUDSON).",AstraZeneca,AstraZeneca,INDUSTRY,ACTIVE_NOT_RECRUITING,2017-12-18,2024-09-13,2026-09-11,INTERVENTIONAL,PHASE2,,,,Non-Small Cell Lung Cancer,Non-Small Cell Lung Cancer,1,22,8,DRUG,,,1,10,True,Yes,Percentage of Participants With Objective Response Per Response Evaluation Criteria in Solid Tumours Version 1.1 (RECIST v1.1) (NUMBER) Percentage of Participants = 9.5 [2.6-23.4],Overall Survival (OS) (MEDIAN) Months = 9.63 [5.26-15.97]; Progression-Free Survival (PFS) Per RECIST v1.1 (MEDIAN) Months = 2.79 [1.41-5.26]; Best Percentage Change From Baseline in Tumour Size (MEAN) Percent Change in Tumor Size = -0.79; Percentage of Participants With Disease Control (DC) Per RECIST v1.1 (NUMBER) Percentage of Participants = 38.1 [23.6-54.4]; ; Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs) (COUNT_OF_PARTICIPANTS) Participants = 20; Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs (COUNT_OF_PARTICIPANTS) Participants = 7; Number of Participants With Abnormal Vital Signs Reported as TEAEs (COUNT_OF_PARTICIPANTS) Participants = 6; Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs (COUNT_OF_PARTICIPANTS) Participants = 2; Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs (COUNT_OF_PARTICIPANTS) Participants = 0,,,,,,,,,Overall Survival (OS) (MEDIAN) Months = 9.63 [5.26-15.97],Progression-Free Survival (PFS) Per RECIST v1.1 (MEDIAN) Months = 2.79 [1.41-5.26],,,,Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs) (COUNT_OF_PARTICIPANTS) Participants = 20,,
NCT03347838,Nivolumab for the Reversal of Squamous Dysplasia in High Risk Current and Former Smokers,PD-1 Immune Checkpoint Inhibition for the Reversal of Squamous Dysplasia in High Risk Current and Former Smokers With or Without a History of Lung Cancer,"University of Colorado, Denver","University of Colorado, Denver",OTHER,ACTIVE_NOT_RECRUITING,2019-01-30,2025-06-18,2026-12-31,INTERVENTIONAL,PHASE2,,,,Bronchial Dysplasia,Bronchial Dysplasia; Tobacco Smoking; History of Non-Small Cell Lung Cancer,4,1,1,DRUG,,,1,2,True,Yes,Improvement in Endobronchial Histology (COUNT_OF_PARTICIPANTS) Participants = 10,; ,,,,,,,,,,,,,,,,
NCT03353675,A Study Evaluating the Efficacy and the Safety of First-line Chemotherapy Combined With the Therapeutic Vaccine Named TG4010 and Nivolumab in Patients,A Phase II Study Evaluating the Efficacy and the Safety of First-line Chemotherapy Combined With TG4010 and Nivolumab in Patients With Advanced Non-squamous Non-Small Cell Lung Cancer (NSCLC),Transgene,Transgene,INDUSTRY,COMPLETED,2018-01-05,2019-11-20,2021-02-17,INTERVENTIONAL,PHASE2,,,,Non Small Cell Lung Cancer Metastatic,Non Small Cell Lung Cancer Metastatic,1,1,3,BIOLOGICAL; DRUG,,,1,5,True,Yes,Objective Response Rate (ORR) (NUMBER) percentage of participants = 32.5 [20.4-46.6],Progression Free Survival (PFS) (MEDIAN) Months = 5.7 [1.5-11.1]; Disease Control Rate (DCR) (NUMBER) percentage of participants = 75.0 [61.3-85.8]; Overall Survival (MEDIAN) Months = 14.9; Duration of Overall Response (DoR) (MEDIAN) Weeks = 74.9 [19.4-92.6]; Number of Participants With Adverse Events or Abnormalities (COUNT_OF_PARTICIPANTS) Participants = 44,,,,,,,,Objective Response Rate (ORR) (NUMBER) percentage of participants = 32.5 [20.4-46.6],Overall Survival (MEDIAN) Months = 14.9,Progression Free Survival (PFS) (MEDIAN) Months = 5.7 [1.5-11.1],,,Objective Response Rate (ORR) (NUMBER) percentage of participants = 32.5 [20.4-46.6],Number of Participants With Adverse Events or Abnormalities (COUNT_OF_PARTICIPANTS) Participants = 44,,
NCT03358875,Comparison of Efficacy and Safety of Tislelizumab (BGB-A317) Versus Docetaxel as Treatment in the Second- or Third-line Setting in Participants With N,"A Phase 3, Open-Label, Multicenter, Randomized Study to Investigate the Efficacy and Safety of BGB-A317 (Anti-PD1 Antibody) Compared With Docetaxel in Patients With Non-Small Cell Lung Cancer Who Have",BeiGene,BeiGene,INDUSTRY,COMPLETED,2017-11-30,2021-07-15,2024-01-18,INTERVENTIONAL,PHASE3,,,,Non-small Cell Lung Cancer,Non-small Cell Lung Cancer,1,2,2,DRUG,,,2,10,True,Yes,Overall Survival (OS) in All Participants (Co-primary Endpoint) (MEDIAN) months = 17.2 [15.28-20.04]; Overall Survival (OS) in Programmed Cell Death Protein Ligand-1 (PD-L1)-Positive Participants (Co-primary Endpoint) (MEDIAN) months = 19.3 [16.49-22.60],"Objective Response Rate (ORR) in All Participants (NUMBER) percentage of participants = 22.6 [19.14-26.40]; Objective Response Rate in PD-L1-Positive Participants (NUMBER) percentage of participants = 37.4 [31.13-44.09]; Duration of Response (DOR) for All Responders (MEDIAN) months = 13.5 [8.54-19.58]; Duration of Response (DOR) in PD-L1-Positive Responders (MEDIAN) months = 11.9 [8.31-19.58]; Progression-free Survival (PFS) in All Participants (MEDIAN) months = 4.2 [3.88-5.52]; Progression-free Survival in PD-L1 Positive Participants (MEDIAN) months = 6.5 [6.24-8.28]; Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Global Health Status (GHS)/Quality of Life (QOL) Score (LEAST_SQUARES_MEAN) score on a scale = 2.4 [0.62-4.12]; Change From Baseline in EORTC Quality of Life Questionnaire Lung Cancer 13 Items (QLQ-LC13) Coughing, Dyspnoea, and Chest Pain Scores (LEAST_SQUARES_MEAN) score on a scale = -7.8 [-10.23--5.30]; Change From Baseline in European Quality of Life 5-Dimensions, 5-level (EQ-5D-5L) Visual Analogue Scale (VAS) (MEAN) score on a scale = 1.0; Number of Participants With Treatment-emergent Adverse Events (TEAEs) (COUNT_OF_PARTICIPANTS) Participants = 518",,,,,Duration of Response (DOR) for All Responders (MEDIAN) months = 13.5 [8.54-19.58]; Duration of Response (DOR) in PD-L1-Positive Responders (MEDIAN) months = 11.9 [8.31-19.58],,,Objective Response Rate (ORR) in All Participants (NUMBER) percentage of participants = 22.6 [19.14-26.40]; Objective Response Rate in PD-L1-Positive Participants (NUMBER) percentage of participants = 37.4 [31.13-44.09],Overall Survival (OS) in All Participants (Co-primary Endpoint) (MEDIAN) months = 17.2 [15.28-20.04]; Overall Survival (OS) in Programmed Cell Death Protein Ligand-1 (PD-L1)-Positive Participants (Co-primary Endpoint) (MEDIAN) months = 19.3 [16.49-22.60],Progression-free Survival (PFS) in All Participants (MEDIAN) months = 4.2 [3.88-5.52]; Progression-free Survival in PD-L1 Positive Participants (MEDIAN) months = 6.5 [6.24-8.28],,"Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Global Health Status (GHS)/Quality of Life (QOL) Score (LEAST_SQUARES_MEAN) score on a scale = 2.4 [0.62-4.12]; Change From Baseline in EORTC Quality of Life Questionnaire Lung Cancer 13 Items (QLQ-LC13) Coughing, Dyspnoea, and Chest Pain Scores (LEAST_SQUARES_MEAN) score on a scale = -7.8 [-10.23--5.30]; Change From Baseline in European Quality of Life 5-Dimensions, 5-level (EQ-5D-5L) Visual Analogue Scale (VAS) (MEAN) score on a scale = 1.0",Objective Response Rate (ORR) in All Participants (NUMBER) percentage of participants = 22.6 [19.14-26.40]; Objective Response Rate in PD-L1-Positive Participants (NUMBER) percentage of participants = 37.4 [31.13-44.09],Number of Participants With Treatment-emergent Adverse Events (TEAEs) (COUNT_OF_PARTICIPANTS) Participants = 518,,
NCT03377023,Phase I/II Study of Nivolumab and Ipilimumab Combined With Nintedanib in Non Small Cell Lung Cancer,Phase I/II Study of Nivolumab and Ipilimumab Combined With Nintedanib in Non Small Cell Lung Cancer,H. Lee Moffitt Cancer Center and Research Institute,H. Lee Moffitt Cancer Center and Research Institute,OTHER,ACTIVE_NOT_RECRUITING,2018-02-02,2023-11-28,2025-11,INTERVENTIONAL,PHASE1; PHASE2,,,,Non Small Cell Lung Cancer,"Non Small Cell Lung Cancer; Lung Cancer, Nonsmall Cell; Non Small Cell Lung Cancer Metastatic",3,3,3,DRUG,,,2,3,True,Yes,Phase 1 - Maximum Tolerated Dose (MTD) (NUMBER) miligrams nintedanib = 150; Phase 2 - Objective Response Rate (ORR) Per Treatment Arm (NUMBER) percentage of participants = 40.9 [21.5-63.3],Phase 2: Disease Control Rate (DCR) (NUMBER) percentage of participants = 72.7 [49.6-88.4]; Phase 2: Overall Survival (OS) (MEDIAN) months = 17.1 [5.5-46.9]; Phase 2: Progression-free Survival (PFS) (MEDIAN) months = 5.5 [2.9-36.0],,,,,,,,Phase 2 - Objective Response Rate (ORR) Per Treatment Arm (NUMBER) percentage of participants = 40.9 [21.5-63.3],Phase 2: Overall Survival (OS) (MEDIAN) months = 17.1 [5.5-46.9],Phase 2: Progression-free Survival (PFS) (MEDIAN) months = 5.5 [2.9-36.0],,,Phase 2 - Objective Response Rate (ORR) Per Treatment Arm (NUMBER) percentage of participants = 40.9 [21.5-63.3],,,
NCT03425643,Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Sta,"A Phase III, Randomized, Double-blind Trial of Platinum Doublet Chemotherapy +/-Pembrolizumab (MK-3475) as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage II, IIIA, and Resectable ",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,INDUSTRY,ACTIVE_NOT_RECRUITING,2018-04-24,2023-07-10,2026-06-29,INTERVENTIONAL,PHASE3,,,,Non-small Cell Lung Cancer,Non-small Cell Lung Cancer,1,2,5,BIOLOGICAL; DRUG,,,2,7,True,Yes,Event Free Survival (EFS) (MEDIAN) Months = 47.2; ,Major Pathological Response (mPR) Rate (NUMBER) Percentage of Participants = 30.2 [25.7-35.0]; Pathological Complete Response (pCR) Rate (NUMBER) Percentage of Participants = 18.1 [14.5-22.3]; Change From Baseline in Neoadjuvant Phase in European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) Global Health Status (Item 29) Score (LEAST_SQUARES_MEAN) Sore on a scale = -9.31 [-11.67--6.94]; Change From Baseline in Adjuvant Phase in European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) Global Health Status (Item 29) Score (LEAST_SQUARES_MEAN) Sore on a scale = -1.52 [-3.67-0.63]; ; Number of Participants Who Experience Perioperative Complications (COUNT_OF_PARTICIPANTS) Participants = 233; ,,Pathological Complete Response (pCR) Rate (NUMBER) Percentage of Participants = 18.1 [14.5-22.3],,,,,,,,,,Change From Baseline in Neoadjuvant Phase in European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) Global Health Status (Item 29) Score (LEAST_SQUARES_MEAN) Sore on a scale = -9.31 [-11.67--6.94]; Change From Baseline in Adjuvant Phase in European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) Global Health Status (Item 29) Score (LEAST_SQUARES_MEAN) Sore on a scale = -1.52 [-3.67-0.63],,,,
NCT03433469,Osimertinib in Treating Participants With Stage I-IIIA EGFR-mutant Non-small Cell Lung Cancer Before Surgery,"A Phase II Study to Evaluate Neoadjuvant Osimertinib Therapy in Patients With Surgically Resectable, EGFR-Mutant Non-Small Cell Lung Cancer","University of California, San Francisco","University of California, San Francisco",OTHER,ACTIVE_NOT_RECRUITING,2018-07-31,2023-01-31,2026-10-31,INTERVENTIONAL,PHASE2,,,,Stage I Non-Small Cell Lung Cancer,Stage I Non-Small Cell Lung Cancer; Stage IA Non-Small Cell Lung Cancer; Stage IB Non-Small Cell Lung Cancer,7,1,2,DRUG; PROCEDURE,,,1,9,True,Yes,Percentage of Participants With a Major Pathological Response (MPR) (NUMBER) percentage of participants = 14.8 [5.9-32.5],Objective Response Rates (ORR) (NUMBER) percentage of participants = 0 [0-12.5]; ; ; ; Median Percentage Change in Tumor Burden (Depth of Response) (MEDIAN) percent change = -32 [-40--18]; Pathologic Complete Response Rate (pCR) (NUMBER) percentage of participants = 0 [0-12.5]; Percentage of Participants With of Treatment-related Adverse Events (AEs) (NUMBER) percentage of participants = 100; Percentage of Participants Unable to Undergo Surgical Resection (NUMBER) percentage of participants = 11.1 [3.9-28.1]; Percentage of Surgical Complications (NUMBER) percentage of participants = 62.5 [42.7-78.8],,Pathologic Complete Response Rate (pCR) (NUMBER) percentage of participants = 0 [0-12.5],,,,,,Objective Response Rates (ORR) (NUMBER) percentage of participants = 0 [0-12.5],,,,,Objective Response Rates (ORR) (NUMBER) percentage of participants = 0 [0-12.5]; Pathologic Complete Response Rate (pCR) (NUMBER) percentage of participants = 0 [0-12.5],Percentage of Participants With of Treatment-related Adverse Events (AEs) (NUMBER) percentage of participants = 100,,
NCT03434418,A Study Osimertinib in Patients With Stage 4 Non-small Cell Lung Cancer With Uncommon EGFR Mutations,A Single Arm Phase II Study Osimertinib in Patients With Stage 4 Non-small Cell Lung Cancer With Uncommon EGFR Mutations,Duke University,Duke University,OTHER,COMPLETED,2018-06-30,2022-10-12,2022-10-12,INTERVENTIONAL,PHASE2,,,,Non Small Cell Lung Cancer,Non Small Cell Lung Cancer,1,1,1,DRUG,,,1,3,True,Yes,Objective Response Rate as Assessed by the Investigator Using Response Evaluation Criteria In Solid Tumors (RECIST 1.1) (COUNT_OF_PARTICIPANTS) Participants = 8,Progression Free Survival (PFS) as Measured by Response Evaluation Criteria In Solid Tumors (RECIST 1.1) (MEDIAN) months = 10.5 [5.0-15.2]; Number of Participants With Adverse Events (AEs) as Measured by Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03 (COUNT_OF_PARTICIPANTS) Participants = 13; Overall Survival as Noted by Follow-up Via Composite of Telephone or Medical Record Review. (MEDIAN) months = 13.8 [9.3-29.2],,,,,,,,Objective Response Rate as Assessed by the Investigator Using Response Evaluation Criteria In Solid Tumors (RECIST 1.1) (COUNT_OF_PARTICIPANTS) Participants = 8,Overall Survival as Noted by Follow-up Via Composite of Telephone or Medical Record Review. (MEDIAN) months = 13.8 [9.3-29.2],Progression Free Survival (PFS) as Measured by Response Evaluation Criteria In Solid Tumors (RECIST 1.1) (MEDIAN) months = 10.5 [5.0-15.2],,,Objective Response Rate as Assessed by the Investigator Using Response Evaluation Criteria In Solid Tumors (RECIST 1.1) (COUNT_OF_PARTICIPANTS) Participants = 8,Number of Participants With Adverse Events (AEs) as Measured by Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03 (COUNT_OF_PARTICIPANTS) Participants = 13,,
NCT03455829,"G1T38, a CDK 4/6 Inhibitor, in Combination With Osimertinib in EGFR-Mutant Non-Small Cell Lung Cancer","Phase 1b/2 Safety, Pharmacokinetic, and Efficacy Study of G1T38 in Combination With Osimertinib in Patients With EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer (NSCLC)","G1 Therapeutics, Inc.","G1 Therapeutics, Inc.",INDUSTRY,COMPLETED,2018-03-29,2021-12-14,2022-02-14,INTERVENTIONAL,PHASE1; PHASE2,,,,"Carcinoma, Non-Small-Cell Lung","Carcinoma, Non-Small-Cell Lung; Lung Cancer; Non-small Cell Lung Cancer",3,5,2,DRUG,,,1,6,True,Yes,Dose Limiting Toxicity (COUNT_OF_PARTICIPANTS) Participants = 0,Progression Free Survival (PFS) (MEDIAN) months = 19.3; Best Overall Tumor Response (COUNT_OF_PARTICIPANTS) Participants = 0; Pharmacokinetics of G1T38 and Metabolite G1T30: Maximum Plasma Concentration (Cmax) (MEAN) ng/mL = 27.229; Pharmacokinetics of G1T38 and Metabolite G1T30: Area Under Curve - Plasma Concentration (AUC) Infinity (MEAN) h*ng/mL = 319.6; Pharmacokinetics of G1T38 and Metabolite G1T30: Plasma: Terminal Half Life (T1/2) (MEAN) hour = 13.83; Pharmacokinetics of G1T38: Plasma - Volume of Distribution (MEAN) Liter = 14000,,,,,,,,,,Progression Free Survival (PFS) (MEDIAN) months = 19.3,,,,Dose Limiting Toxicity (COUNT_OF_PARTICIPANTS) Participants = 0,,
NCT03473925,Efficacy and Safety Study of Navarixin (MK-7123) in Combination With Pembrolizumab (MK-3475) in Adults With Selected Advanced/Metastatic Solid Tumors ,A Phase II Study of Navarixin (MK-7123) in Combination With Pembrolizumab (MK-3475) in Participants With Selected Advanced/Metastatic Solid Tumors,Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,INDUSTRY,COMPLETED,2018-04-10,2021-05-19,2021-05-19,INTERVENTIONAL,PHASE2,,,,Solid Tumors,Solid Tumors; Non-small Cell Lung Cancer; Castration Resistant Prostate Cancer,4,2,2,BIOLOGICAL; DRUG,,,4,9,True,Yes,Objective Response Rate (ORR) Based on Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) (NUMBER) Percentage of participants = 3.9 [0.5-13.5]; Number of Participants With Dose-limiting Toxicities (DLTs) During Treatment Cycle 1 (COUNT_OF_PARTICIPANTS) Participants = 2; Number of Participants Who Experience at Least One Adverse Event (AE) (COUNT_OF_PARTICIPANTS) Participants = 50; Number of Participants Who Discontinue Study Treatment Due to an AE (COUNT_OF_PARTICIPANTS) Participants = 4,Objective Response Rate (ORR) Per Modified RECIST 1.1 for Immune-based Therapeutics (iRECIST) (NUMBER) Percentage of participants = 0.0 [0.0-8.2]; Progression-free Survival (PFS) Per RECIST 1.1 (MEDIAN) Months = 1.8 [1.0-2.0]; PFS Per iRECIST (MEDIAN) Months = 4.1 [2.1-7.1]; Overall Survival (OS) (MEDIAN) Months = 6.5 [3.0-9.7]; Absolute Neutrophil Counts (ANC) (MEAN) 10^9 cells/L = 3.6 [3.03-4.12]; Navarixin Area Under the Plasma Concentration-Time Curve (AUC) From Time 0 to Infinity (AUC0-inf) (GEOMETRIC_MEAN) h*ng/mL = 523; Navarixin Area Under the Plasma Concentration-Time Curve From Time 0 to Last (AUC0-last) (GEOMETRIC_MEAN) h*ng/mL = 451; Navarixin Maximum Plasma Concentration (Cmax) (GEOMETRIC_MEAN) ng/mL = 172; ,,,,,,,,Objective Response Rate (ORR) Based on Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) (NUMBER) Percentage of participants = 3.9 [0.5-13.5]; Objective Response Rate (ORR) Per Modified RECIST 1.1 for Immune-based Therapeutics (iRECIST) (NUMBER) Percentage of participants = 0.0 [0.0-8.2],Overall Survival (OS) (MEDIAN) Months = 6.5 [3.0-9.7],Progression-free Survival (PFS) Per RECIST 1.1 (MEDIAN) Months = 1.8 [1.0-2.0]; PFS Per iRECIST (MEDIAN) Months = 4.1 [2.1-7.1],,,Objective Response Rate (ORR) Based on Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) (NUMBER) Percentage of participants = 3.9 [0.5-13.5]; Objective Response Rate (ORR) Per Modified RECIST 1.1 for Immune-based Therapeutics (iRECIST) (NUMBER) Percentage of participants = 0.0 [0.0-8.2],Number of Participants Who Discontinue Study Treatment Due to an AE (COUNT_OF_PARTICIPANTS) Participants = 4,,
NCT03515837,Study of Pemetrexed + Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With Tyrosine Kinase Inhibitor- (TKI)-Resistant Epiderma,"A Randomized, Double-Blind, Phase 3 Study of Pemetrexed + Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in TKI-resistant EGFR-mutated Tumors in Metastatic Non-squamous Non-small Cell L",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,INDUSTRY,COMPLETED,2018-06-29,2023-01-17,2023-10-02,INTERVENTIONAL,PHASE3,,,,Non-small Cell Lung Cancer,Non-small Cell Lung Cancer,1,2,5,BIOLOGICAL; DRUG,,,2,6,True,Yes,Progression-free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) (MEDIAN) Months = 5.6 [5.5-5.8]; Overall Survival (OS) (MEDIAN) Months = 15.9 [13.7-18.8],Objective Response Rate (ORR) Per RECIST 1.1 (NUMBER) Percentage of Participants = 29.0 [23.4-35.1]; Duration of Response (DOR) Per RECIST 1.1 (MEDIAN) Months = 6.3 [5.9-8.3]; Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Global Health Status (Item 29) and Quality of Life (Item 30) Combined Score (LEAST_SQUARES_MEAN) Score on a Scale = -0.46 [-3.17-2.25]; ; Percentage of Participants Who Experienced an Adverse Event (AE) (NUMBER) Percentage of Participants = 97.6; Percentage of Participants Who Discontinued Study Treatment Due to AEs (NUMBER) Percentage of Participants = 19.2,,,,,Duration of Response (DOR) Per RECIST 1.1 (MEDIAN) Months = 6.3 [5.9-8.3],,,Objective Response Rate (ORR) Per RECIST 1.1 (NUMBER) Percentage of Participants = 29.0 [23.4-35.1],Overall Survival (OS) (MEDIAN) Months = 15.9 [13.7-18.8],Progression-free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) (MEDIAN) Months = 5.6 [5.5-5.8],,Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Global Health Status (Item 29) and Quality of Life (Item 30) Combined Score (LEAST_SQUARES_MEAN) Score on a Scale = -0.46 [-3.17-2.25],Objective Response Rate (ORR) Per RECIST 1.1 (NUMBER) Percentage of Participants = 29.0 [23.4-35.1],,,
NCT03519971,Study of Durvalumab Given With Chemoradiation Therapy in Patients With Unresectable Non-small Cell Lung Cancer,"A Phase III, Randomized, Placebo-controlled, Double-blind, Multi-center, International Study of Durvalumab Given Concurrently With Platinum-based Chemoradiation Therapy in Patients With Locally Advanc",AstraZeneca,AstraZeneca,INDUSTRY,ACTIVE_NOT_RECRUITING,2018-03-29,2023-09-07,2025-12-01,INTERVENTIONAL,PHASE3,,,,Non-Small Cell Lung Cancer,Non-Small Cell Lung Cancer,1,2,7,DRUG; OTHER; RADIATION,,,1,12,True,Yes,Progression-Free Survival (PFS) (MEDIAN) months = 13.8 [9.5-16.9],Objective Response Rate (ORR) (NUMBER) percentage of participants = 60.7 [53.9-67.2]; Overall Survival (OS) (MEDIAN) months = 36.4 [26.2-45.6]; Percentage of Participants Alive at 24 Months From Randomization (OS24) (NUMBER) percentage of participants = 58.4 [51.6-64.7]; Complete Response Rate (CRR) (NUMBER) percentage of participants = 1.8 [0.5-4.6]; Duration of Response (DoR) (MEDIAN) months = 30.7; Disease Control Rate (DCR) (NUMBER) percentage of participants = 65.8; Time to Death or Distant Metastasis (TTDM) (MEDIAN) months = 51.0; Time From Randomization to Second Progression (PFS2) (MEDIAN) months = 27.8 [21.8-35.8]; Serum Concentration of Durvalumab (GEOMETRIC_MEAN) microgram per milliliter = 452.21; Number of Participants With Anti-Drug Antibody (ADA) Response to Durvalumab (COUNT_OF_PARTICIPANTS) Participants = 20; Change From Baseline in Disease-Related Symptoms as Assessed by European Organisation for Research and Treatment of Cancer Quality of Life Questionnaires (EORTC QLQ) at Average Over 12 Months (MEAN) units on a scale = -0.5 [-2.3-1.4]; Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) (NUMBER) percentage of participants = 98.6,,Complete Response Rate (CRR) (NUMBER) percentage of participants = 1.8 [0.5-4.6],,,Duration of Response (DoR) (MEDIAN) months = 30.7,,,Objective Response Rate (ORR) (NUMBER) percentage of participants = 60.7 [53.9-67.2],Overall Survival (OS) (MEDIAN) months = 36.4 [26.2-45.6],Progression-Free Survival (PFS) (MEDIAN) months = 13.8 [9.5-16.9],,Change From Baseline in Disease-Related Symptoms as Assessed by European Organisation for Research and Treatment of Cancer Quality of Life Questionnaires (EORTC QLQ) at Average Over 12 Months (MEAN) units on a scale = -0.5 [-2.3-1.4],Objective Response Rate (ORR) (NUMBER) percentage of participants = 60.7 [53.9-67.2]; Complete Response Rate (CRR) (NUMBER) percentage of participants = 1.8 [0.5-4.6],Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) (NUMBER) percentage of participants = 98.6,,
NCT03520842,Regorafenib and Methotrexate in Treating Participants With Recurrent or Metastatic KRAS Mutated Non-Small Cell Lung Cancer,Study of Regorafenib in Combination With Oral Methotrexate for KRAS Mutated Non-Small Cell Lung Cancer (NSCLC),Stanford University,Stanford University,OTHER,COMPLETED,2018-08-14,2022-06-15,2022-06-15,INTERVENTIONAL,PHASE2,,,,KRAS Gene Mutation,KRAS Gene Mutation; Metastatic Malignant Neoplasm in the Brain; Recurrent Non-Small Cell Lung Carcinoma,4,1,3,DRUG; OTHER,,,1,5,True,Yes,Progression Free Survival (PFS) (MEDIAN) months = 3.7 [1.8-8.6],Objective Response Rate (ORR) (MEDIAN) percentage of participants = 16.7 [3.5-41.4]; Disease Control Rate (DCR) (MEDIAN) percentage of participants = 66.7 [41.0-86.7]; Number of Participants With Adverse Events (COUNT_OF_PARTICIPANTS) Participants = 17; Trough Serum Concentration of Methotrexate (MEAN) μmol/L = 0.04; Maximum Serum Concentration (Cmax) of Methotrexate (MEAN) μmol/L = 0.43,,,,,,,,Objective Response Rate (ORR) (MEDIAN) percentage of participants = 16.7 [3.5-41.4],,Progression Free Survival (PFS) (MEDIAN) months = 3.7 [1.8-8.6],,,Objective Response Rate (ORR) (MEDIAN) percentage of participants = 16.7 [3.5-41.4],Number of Participants With Adverse Events (COUNT_OF_PARTICIPANTS) Participants = 17,,
NCT03521154,A Global Study to Assess the Effects of Osimertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer (LAURA,"A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter, International Study of Osimertinib as Maintenance Therapy in Patients With Locally Advanced, Unresectable EGFR Mutation-positive",AstraZeneca,AstraZeneca,INDUSTRY,ACTIVE_NOT_RECRUITING,2018-07-19,2024-01-05,2027-04-13,INTERVENTIONAL,PHASE3,,,,Non Small Cell Lung Cancer (Stage III),Non Small Cell Lung Cancer (Stage III),1,2,2,DRUG,,,1,15,True,Yes,Progression-free Survival (PFS) by Blinded Independent Central Review (BICR) (MEDIAN) Months = 39.13,"Number of Participants With Progression-free Survival (PFS) Events in Patients With EGFR Ex19del or L858R Mutation (COUNT_OF_PARTICIPANTS) Participants = 26; Number of Participants With Progression-free Survival (PFS) Events in Patients With EGFR Mutations Ex19del or L858R Detectable in Plasma-derived ctDNA (COUNT_OF_PARTICIPANTS) Participants = 4; ; Overall Survival (Count) (COUNT_OF_PARTICIPANTS) Participants = 28; Overall Survival (Duration) (MEDIAN) Months = 53.95; Objective Response Rate by Blinded Independent Central Review (BICR) (NUMBER) % of participants = 57.3 [48.8-65.6]; Duration of Response, Unconfirmed by Blinded Independent Central Review (BICR) (MEDIAN) Months = 36.9; Disease Control Rate by Blinded Independent Central Review (BICR) (NUMBER) % of participants = 88.8 [82.5-93.5]; Tumour Shrinkage by Blinded Independent Central Review (BICR) (MEDIAN) % change from baseline = -43.3 [-100-144]; Proportion With Tumour Shrinkage by Blinded Independent Central Review (BICR) (NUMBER) Proportion of participants = 0.92; ; Time to Study Treatment Discontinuation (MEDIAN) Months = 40.28; Time to First Subsequent Treatment (MEDIAN) Months = 43.83; ; Second Progression-free Survival (PFS2) (MEDIAN) Months = 48.20",,,,,"Duration of Response, Unconfirmed by Blinded Independent Central Review (BICR) (MEDIAN) Months = 36.9",,,Objective Response Rate by Blinded Independent Central Review (BICR) (NUMBER) % of participants = 57.3 [48.8-65.6],Overall Survival (Count) (COUNT_OF_PARTICIPANTS) Participants = 28; Overall Survival (Duration) (MEDIAN) Months = 53.95,Progression-free Survival (PFS) by Blinded Independent Central Review (BICR) (MEDIAN) Months = 39.13; Number of Participants With Progression-free Survival (PFS) Events in Patients With EGFR Ex19del or L858R Mutation (COUNT_OF_PARTICIPANTS) Participants = 26; Number of Participants With Progression-free Survival (PFS) Events in Patients With EGFR Mutations Ex19del or L858R Detectable in Plasma-derived ctDNA (COUNT_OF_PARTICIPANTS) Participants = 4; Second Progression-free Survival (PFS2) (MEDIAN) Months = 48.20,,,Objective Response Rate by Blinded Independent Central Review (BICR) (NUMBER) % of participants = 57.3 [48.8-65.6],,,
NCT03523702,The Selective Personalized Radio-Immunotherapy for Locally Advanced NSCLC Trial,The Selective Personalized Radio-Immunotherapy for Locally Advanced NSCLC Trial (SPRINT),Albert Einstein College of Medicine,Albert Einstein College of Medicine,OTHER,COMPLETED,2018-08-30,2022-11-18,2022-11-18,INTERVENTIONAL,PHASE2,,,,"Non-small Cell Lung Cancer, NSCLC","Non-small Cell Lung Cancer, NSCLC",1,1,1,DRUG,,,1,5,True,Yes,Progression-Free Survival (PFS) (COUNT_OF_PARTICIPANTS) Participants = 19,Freedom From Distant Metastasis (COUNT_OF_PARTICIPANTS) Participants = 17; Intrathoracic Disease Progression (COUNT_OF_PARTICIPANTS) Participants = 22; Overall Survival (OS) (COUNT_OF_PARTICIPANTS) Participants = 23; Radiographic Response Rate Based on Response Evaluation Criteria in Solid Tumors (RECIST) (COUNT_OF_PARTICIPANTS) Participants = 1; ,,,,,,,,,Overall Survival (OS) (COUNT_OF_PARTICIPANTS) Participants = 23,Progression-Free Survival (PFS) (COUNT_OF_PARTICIPANTS) Participants = 19,,,Radiographic Response Rate Based on Response Evaluation Criteria in Solid Tumors (RECIST) (COUNT_OF_PARTICIPANTS) Participants = 1,,,
NCT03526900,Atezolizumab in Combination With Carboplatin Plus Pemetrexed in Chemotherapy-naïve Patients With Asymptomatic Brain Metastasis,Phase II Non-randomized Study of a Atezolizumab (MPDL3280A) in Combination With Carboplatin Plus Pemetrexed in Patients Who Are Chemotherapy-naïve and Have Stage IV Non-squamous Non-small Cell Lung Ca,Spanish Lung Cancer Group,Spanish Lung Cancer Group,OTHER,COMPLETED,2018-07-07,2022-03-31,2022-09-15,INTERVENTIONAL,PHASE2,,,,Non-small Cell Lung Cancer Stage IV,Non-small Cell Lung Cancer Stage IV,1,1,1,DRUG,,,1,1,True,Yes,Efficacy of Atezolizumab + CBDCA + Pemetrexed by Evaluating PFS Rate (NUMBER) percentage of participants = 62.2 [47.1-76.2],Efficacy of Atezolizumab + CBDCA + Pemetrexed by Measuring Objective Response. (COUNT_OF_PARTICIPANTS) Participants = 18,,,,,,,,,,Efficacy of Atezolizumab + CBDCA + Pemetrexed by Evaluating PFS Rate (NUMBER) percentage of participants = 62.2 [47.1-76.2],,,,,,
NCT03563716,A Study of Tiragolumab in Combination With Atezolizumab in Chemotherapy-Naïve Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer,"A Phase II, Randomized, Blinded, Placebo-Controlled Study of Tiragolumab, An Anti-TIGIT Antibody, In Combination With Atezolizumab In Chemotherapy-Naïve Patients With Locally Advanced Or Metastatic No","Genentech, Inc.","Genentech, Inc.",INDUSTRY,ACTIVE_NOT_RECRUITING,2018-08-10,2019-06-30,2025-08-31,INTERVENTIONAL,PHASE2,,,,Non-small Cell Lung Cancer,Non-small Cell Lung Cancer,1,2,3,DRUG,,,2,6,True,Yes,Objective Response Rate (ORR) (NUMBER) percentage of participants = 16.2 [6.69-25.66]; Progression Free Survival (PFS) (MEDIAN) months = 3.58 [2.73-4.44],; ; ; ; ; ,,,,,,,,Objective Response Rate (ORR) (NUMBER) percentage of participants = 16.2 [6.69-25.66],,Progression Free Survival (PFS) (MEDIAN) months = 3.58 [2.73-4.44],,,Objective Response Rate (ORR) (NUMBER) percentage of participants = 16.2 [6.69-25.66],,,
NCT03573947,Phase II Clinical Trial of NIVO-IPI-TAXANE in Untreated Metastatic NSCLC,"A Phase II Clinical Trial of Combination Nivolumab (Opdivo), Ipilimumab (Yervoy), and Paclitaxel in Patients With Untreated Metastatic Non-Small Cell Lung Cancer (NSCLC) (The OPTIMAL Trial) [TOP 1705]",Duke University,Jeffrey Clarke,OTHER,COMPLETED,2018-10-02,2023-03-12,2023-06-15,INTERVENTIONAL,PHASE2,,,,Non-small Cell Lung Cancer,Non-small Cell Lung Cancer,1,1,3,DRUG,,,1,2,True,Yes,"Progression-free Survival (PFS) as Determined by the Investigator Using Response Evaluation Criteria In Solid Tumors RECIST 1.1 (Brand Name) or Death, Whichever Occurs First (MEDIAN) months = 9.4 [5.9-16.6]","Description of the Safety and Adverse Events of the Combination Nivolumab, Ipilimumab, and Paclitaxel in Untreated, Metastatic NSCLC. (COUNT_OF_PARTICIPANTS) Participants = 24; Estimate the Overall Response Rate With the Study Combination. (COUNT_OF_PARTICIPANTS) Participants = 2",,,,,,,,,,"Progression-free Survival (PFS) as Determined by the Investigator Using Response Evaluation Criteria In Solid Tumors RECIST 1.1 (Brand Name) or Death, Whichever Occurs First (MEDIAN) months = 9.4 [5.9-16.6]",,,Estimate the Overall Response Rate With the Study Combination. (COUNT_OF_PARTICIPANTS) Participants = 2,"Description of the Safety and Adverse Events of the Combination Nivolumab, Ipilimumab, and Paclitaxel in Untreated, Metastatic NSCLC. (COUNT_OF_PARTICIPANTS) Participants = 24",,
NCT03583086,Phase I/II Eval Safety & Prelim Activity Nivolumab Comb W/Vorolanib Pts W/Refractory Thoracic Tumors,Phase 1/2 Study to Evaluate the Safety and Preliminary Activity of Nivolumab in Combination With Vorolanib in Patients With Refractory Thoracic Tumors,Vanderbilt-Ingram Cancer Center,Vanderbilt-Ingram Cancer Center,OTHER,COMPLETED,2018-07-10,2024-02-21,2024-04-27,INTERVENTIONAL,PHASE1; PHASE2,,,,Thymic Carcinoma,Thymic Carcinoma; Non-small Cell Lung Cancer; Refractory Thoracic Tumors,4,6,2,BIOLOGICAL; DRUG,,,6,0,True,Yes,Recommended Phase II Combination Dose in Phase I (Per Common Terminology Criteria for Adverse Events (CTCAE) Criteria Version 5) (NUMBER) mg = 200; Objective Response Rate in Phase II. (NUMBER) percentage of participants = 11.1 [0-27.8]; Progression Free Survival in Phase II (MEDIAN) months = 1.97 [1.54-4.60]; Duration of Response in Phase II. (MEDIAN) months = 2.7; Disease Control Rate in Phase II. Best Response Per Response Evaluation Criteria in Solid Tumors (RECIST) (NUMBER) percentage of participants = 44.4 [22.2-66.7]; Overall Survival in Phase II. (MEDIAN) months = 10.81,,,,,,Duration of Response in Phase II. (MEDIAN) months = 2.7,,,Objective Response Rate in Phase II. (NUMBER) percentage of participants = 11.1 [0-27.8],Overall Survival in Phase II. (MEDIAN) months = 10.81,Progression Free Survival in Phase II (MEDIAN) months = 1.97 [1.54-4.60],,,Objective Response Rate in Phase II. (NUMBER) percentage of participants = 11.1 [0-27.8],Recommended Phase II Combination Dose in Phase I (Per Common Terminology Criteria for Adverse Events (CTCAE) Criteria Version 5) (NUMBER) mg = 200,,
NCT03594747,A Study of Tislelizumab in Combination With Chemotherapy Versus Chemotherapy in Advanced Lung Cancer,"A Phase 3, Multicenter, Randomized Open-Label Study to Compare the Efficacy and Safety of Tislelizumab (BGB A317, Anti-PD1 Antibody) Combined With Paclitaxel Plus Carboplatin or Nab Paclitaxel Plus Ca",BeiGene,BeiGene,INDUSTRY,COMPLETED,2018-07-30,2020-09-30,2023-04-28,INTERVENTIONAL,PHASE3,,,,Non-Small Cell Lung Cancer,Non-Small Cell Lung Cancer,1,3,4,DRUG,,,2,10,True,Yes,Progression Free Survival (PFS) by Independent Review Committee (IRC) Assessment as of Data Cut-off Date of 06DEC2019 (MEDIAN) Months = 7.6 [5.95-9.79]; PFS by IRC Assessment as of Data Cut-off Date of 30SEP2020 (MEDIAN) Months = 7.7 [6.74-10.41],Overall Survival (OS) (MEDIAN) Months = 26.1 [18.99-33.81]; Objective Response Rate (ORR) by IRC Assessment (NUMBER) Percentage of participants = 74.2 [65.4-81.7]; ORR by Investigator Assessment (NUMBER) Percentage of participants = 70.0 [61.0-78.0]; Duration of Response (DOR) by IRC Assessment (MEDIAN) Months = 8.4 [5.03-18.69]; DOR by Investigator Assessment (MEDIAN) Months = 10.6 [7.03-16.23]; PFS by Investigator Assessment (MEDIAN) Months = 9.6 [7.62-11.76]; PFS by IRC Based on Programmed Death Ligand 1 (PD-L1) Expression (MEDIAN) Months = 7.6 [5.5-14.5]; European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Lung Cancer (EORTC QLQ-LC13) (LEAST_SQUARES_MEAN) Score on a scale = 0.4 [-5.0-5.9]; European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) Global Health Status (LEAST_SQUARES_MEAN) Score on a scale = 2.4 [-3.4-8.2]; Number of Participants With Adverse Events (COUNT_OF_PARTICIPANTS) Participants = 120,,,,,Duration of Response (DOR) by IRC Assessment (MEDIAN) Months = 8.4 [5.03-18.69]; DOR by Investigator Assessment (MEDIAN) Months = 10.6 [7.03-16.23],,,Objective Response Rate (ORR) by IRC Assessment (NUMBER) Percentage of participants = 74.2 [65.4-81.7]; ORR by Investigator Assessment (NUMBER) Percentage of participants = 70.0 [61.0-78.0],Overall Survival (OS) (MEDIAN) Months = 26.1 [18.99-33.81],Progression Free Survival (PFS) by Independent Review Committee (IRC) Assessment as of Data Cut-off Date of 06DEC2019 (MEDIAN) Months = 7.6 [5.95-9.79]; PFS by IRC Assessment as of Data Cut-off Date of 30SEP2020 (MEDIAN) Months = 7.7 [6.74-10.41]; PFS by Investigator Assessment (MEDIAN) Months = 9.6 [7.62-11.76]; PFS by IRC Based on Programmed Death Ligand 1 (PD-L1) Expression (MEDIAN) Months = 7.6 [5.5-14.5],,European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Lung Cancer (EORTC QLQ-LC13) (LEAST_SQUARES_MEAN) Score on a scale = 0.4 [-5.0-5.9]; European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) Global Health Status (LEAST_SQUARES_MEAN) Score on a scale = 2.4 [-3.4-8.2],Objective Response Rate (ORR) by IRC Assessment (NUMBER) Percentage of participants = 74.2 [65.4-81.7],Number of Participants With Adverse Events (COUNT_OF_PARTICIPANTS) Participants = 120,,
NCT03631199,Study of Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy With or Without Canakinumab in Previously Untreated Locally Adv,"A Randomized, Double-blind, Placebo-controlled, Phase III Study Evaluating the Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy With or Without Canakinumab as First Line T",Novartis,Novartis Pharmaceuticals,INDUSTRY,ACTIVE_NOT_RECRUITING,2018-12-21,2021-08-09,2027-06-07,INTERVENTIONAL,PHASE3,,,,Non-small Cell Lung Cancer,Non-small Cell Lung Cancer,1,5,8,DRUG,,,3,28,True,Yes,"Part 1 (Safety Run-in): Number of Participants With Dose-limiting Toxicities (DLTs) (COUNT_OF_PARTICIPANTS) Participants = 0; Part 2 (Double-blind, Randomized, Placebo-controlled): Progression-free Survival (PFS) Per Investigator Assessment Using RECIST v1.1 (MEDIAN) months = 6.77 [5.62-7.75]; Part 2 (Double-blind, Randomized, Placebo-controlled): Overall Survival (OS) Per Investigator Assessment Using RECIST v1.1 (MEDIAN) months = 20.83","Part 1 (Safety Run-in): Overall Response Rate (ORR) Per Investigator Assessment Using RECIST v1.1 (NUMBER) percentage of participants = 20.0 [2.5-55.6]; Part 2 (Double-blind, Randomized, Placebo-controlled): Overall Response Rate (ORR) Per Investigator Assessment Using RECIST v1.1 (NUMBER) percentage of participants = 45.6 [40.1-51.3]; Part 1 (Safety run-in): Disease Control Rate (DCR) Per Investigator Assessment Using RECIST v1.1 (NUMBER) percentage of participants = 70.0 [34.8-93.3]; Part 2 (Double-blind, Randomized, Placebo-controlled): Disease Control Rate (DCR) Per Investigator Assessment Using RECIST v1.1 (NUMBER) percentage of participants = 86.9 [82.7-90.4]; Part 1 (Safety run-in): Duration of Response (DOR) Per Investigator Assessment Using RECIST v1.1 (MEDIAN) months = 7.43; Part 2 (Double-blind, Randomized, Placebo-controlled): Duration of Response (DOR) Per Investigator Assessment Using RECIST v1.1 (MEDIAN) months = 14.26; ; ; Part 2 (Double-blind, Randomized, Placebo-controlled): Number of Participants With Antidrug Antibodies (ADA) of Canakinumab (COUNT_OF_PARTICIPANTS) Participants = 3; ; Part 2 (Double-blind, Randomized, Placebo-controlled): Antidrug Antibodies (ADA) of Pembrolizumab (COUNT_OF_PARTICIPANTS) Participants = 2; Part 1 (Safety Run-in): Serum Canakinumab Concentration (GEOMETRIC_MEAN) μg/mL = 0; Part 2 (Double-blind, Randomized, Placebo-controlled): Serum Canakinumab Concentration (GEOMETRIC_MEAN) μg/mL = 0; Part 1 (Safety Run-in): Serum Pembrolizumab Concentration (GEOMETRIC_MEAN) μg/mL = 0; Part 2 (Double-blind, Randomized, Placebo-controlled): Serum Pembrolizumab Concentration (GEOMETRIC_MEAN) μg/mL = 0; Part 1 (Safety Run-in): Plasma Pemetrexed Concentration (GEOMETRIC_MEAN) μg/mL = 0; Part 2 (Double-blind, Randomized, Placebo-controlled): Plasma Pemetrexed Concentration (GEOMETRIC_MEAN) μg/mL = 0; Part 1 (Safety Run-in): Plasma Cisplatin Concentration (GEOMETRIC_MEAN) μg/mL = 0; Part 2 (Double-blind, Randomized, Placebo-controlled): Plasma Cisplatin Concentration (GEOMETRIC_MEAN) μg/mL = 0; Part 1 (Safety Run-in): Plasma Carboplatin Concentration (GEOMETRIC_MEAN) μg/mL = 0; Part 2 (Double-blind, Randomized, Placebo-controlled): Plasma Carboplatin Concentration (GEOMETRIC_MEAN) μg/mL = 0; Part 1 (Safety Run-in): Plasma Paclitaxel Concentration (GEOMETRIC_MEAN) μg/mL = 0; Part 2 (Double-blind, Randomized, Placebo-controlled): Plasma Paclitaxel Concentration (GEOMETRIC_MEAN) μg/mL = 0; Part 2 (Double-blind, Randomized, Placebo-controlled): Plasma Nab-paclitaxel Concentration (GEOMETRIC_MEAN) μg/mL = 0; ; Part 2 (Double-blind, Randomized, Placebo-controlled): Time to Definitive Deterioration in Global Health Status/Quality of Life, Shortness of Breath and Pain Per EORTC QLQ-C30 Questionnaire (MEDIAN) months = 17.54; Part 2 (Double-blind, Randomized, Placebo-controlled): Change From Baseline in Score as Per the EuroQol 5 Dimension 5 Level (EQ-5D-5L) Questionnaire (MEAN) score on a scale = 0.766; Part 2 (Double-blind, Randomized, Placebo-controlled): Change From Baseline in Score as Per the EuroQol 5 Dimension 5 Level (EQ-5D-5L) Questionnaire - Visual Analog Scale (VAS) (MEAN) score on a scale = 0.1",,,,,"Part 1 (Safety run-in): Duration of Response (DOR) Per Investigator Assessment Using RECIST v1.1 (MEDIAN) months = 7.43; Part 2 (Double-blind, Randomized, Placebo-controlled): Duration of Response (DOR) Per Investigator Assessment Using RECIST v1.1 (MEDIAN) months = 14.26",,,,"Part 2 (Double-blind, Randomized, Placebo-controlled): Overall Survival (OS) Per Investigator Assessment Using RECIST v1.1 (MEDIAN) months = 20.83","Part 2 (Double-blind, Randomized, Placebo-controlled): Progression-free Survival (PFS) Per Investigator Assessment Using RECIST v1.1 (MEDIAN) months = 6.77 [5.62-7.75]",,"Part 2 (Double-blind, Randomized, Placebo-controlled): Time to Definitive Deterioration in Global Health Status/Quality of Life, Shortness of Breath and Pain Per EORTC QLQ-C30 Questionnaire (MEDIAN) months = 17.54; Part 2 (Double-blind, Randomized, Placebo-controlled): Change From Baseline in Score as Per the EuroQol 5 Dimension 5 Level (EQ-5D-5L) Questionnaire (MEAN) score on a scale = 0.766; Part 2 (Double-blind, Randomized, Placebo-controlled): Change From Baseline in Score as Per the EuroQol 5 Dimension 5 Level (EQ-5D-5L) Questionnaire - Visual Analog Scale (VAS) (MEAN) score on a scale = 0.1","Part 1 (Safety Run-in): Overall Response Rate (ORR) Per Investigator Assessment Using RECIST v1.1 (NUMBER) percentage of participants = 20.0 [2.5-55.6]; Part 2 (Double-blind, Randomized, Placebo-controlled): Overall Response Rate (ORR) Per Investigator Assessment Using RECIST v1.1 (NUMBER) percentage of participants = 45.6 [40.1-51.3]",,,
NCT03631706,M7824 Versus Pembrolizumab as a First-line (1L) Treatment in Participants With Programmed Death-ligand 1 (PD-L1) Expressing Advanced Non-small Cell Lu,"An Adaptive Phase III, Multicenter, Randomized, Open-Label, Controlled Study of M7824 (Bintrafusp Alfa) Versus Pembrolizumab as a First-line Treatment in Patients With PD-L1 Expressing Advanced Non-sm",EMD Serono,"EMD Serono Research & Development Institute, Inc.",INDUSTRY,COMPLETED,2018-10-01,2021-06-07,2024-06-25,INTERVENTIONAL,PHASE3,,,,Non-small Cell Lung Cancer,Non-small Cell Lung Cancer,1,2,2,DRUG,,,2,3,True,Yes,Progression-Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST Version 1.1) Assessed by Independent Review Committee (IRC) (MEDIAN) months = 7.0 [0.0-19.4]; Overall Survival (OS) (MEDIAN) months = 21.1 [0.2-22.1],Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Related TEAEs According to National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 5.0 (COUNT_OF_PARTICIPANTS) Participants = 150; Percentage of Participants With Unconfirmed Best Overall Response According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) as Assessed by Independent Review Committee (IRC) (NUMBER) percentage of participants = 46.7 [38.6-55.0]; ,,,,,,,,,Overall Survival (OS) (MEDIAN) months = 21.1 [0.2-22.1],Progression-Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST Version 1.1) Assessed by Independent Review Committee (IRC) (MEDIAN) months = 7.0 [0.0-19.4],,,,Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Related TEAEs According to National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 5.0 (COUNT_OF_PARTICIPANTS) Participants = 150,,
NCT03631784,"A Trial of Pembrolizumab in Combination With Chemotherapy and Radiotherapy in Stage III NSCLC (KEYNOTE-799, MK-3475-799)","A Phase 2 Trial of Pembrolizumab (MK-3475) in Combination With Platinum Doublet Chemotherapy and Radiotherapy for Participants With Unresectable, Locally Advanced Stage III Non-Small Cell Lung Cancer ",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,INDUSTRY,COMPLETED,2018-10-19,2021-10-18,2024-03-19,INTERVENTIONAL,PHASE2,,,,Non-small Cell Lung Cancer,Non-small Cell Lung Cancer,1,2,8,DRUG; RADIATION,,,2,4,True,Yes,Percentage of Participants Who Developed Grade 3 or Higher Pneumonitis (NUMBER) Percentage of Participants = 8.0 [4.3-13.6]; Overall Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) (NUMBER) Percentage of Participants = 71.4 [62.1-79.6],Progression Free Survival (PFS) Per Response Criteria in Solid Tumors Version 1.1 (RECIST 1.1) (MEDIAN) Months = 29.0 [16.6-48.5]; Overall Survival (OS) (MEDIAN) Months = 35.6 [26.1-44.2]; Number of Participants Who Experienced an Adverse Event (AE) (COUNT_OF_PARTICIPANTS) Participants = 108; Number of Participants Who Discontinued From Study Treatment Due to an AE (COUNT_OF_PARTICIPANTS) Participants = 48,,,,,,,,,Overall Survival (OS) (MEDIAN) Months = 35.6 [26.1-44.2],Progression Free Survival (PFS) Per Response Criteria in Solid Tumors Version 1.1 (RECIST 1.1) (MEDIAN) Months = 29.0 [16.6-48.5],,,Overall Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) (NUMBER) Percentage of Participants = 71.4 [62.1-79.6],Number of Participants Who Discontinued From Study Treatment Due to an AE (COUNT_OF_PARTICIPANTS) Participants = 48,,
NCT03663205,A Study Evaluating the Efficacy and Safety of Tislelizumab Versus Chemotherapy in Advanced Non-Squamous Non-small Cell Lung Cancer,"A Phase 3, Open-Label, Multicenter, Randomized Study to Investigate the Efficacy and Safety of Tislelizumab (BGB-A317) (Anti-PD1 Antibody) Combined With Platinum-Pemetrexed Versus Platinum-Pemetrexed ",BeiGene,BeiGene,INDUSTRY,COMPLETED,2018-07-23,2020-01-23,2023-04-26,INTERVENTIONAL,PHASE3,,,,Non-Small Cell Lung Cancer,Non-Small Cell Lung Cancer,1,2,4,DRUG,,,1,10,True,Yes,Progression Free Survival (PFS) Assessed by Independent Review Committee (IRC) Assessment (MEDIAN) Months = 9.7 [7.72-11.53],Objective Response Rate (ORR) by IRC Assessment (NUMBER) Percentage of participants = 57.8 [51.1-64.4]; Duration of Response (DOR) by IRC Assessment (MEDIAN) Months = 10.6 [8.38-17.64]; Overall Survival (OS) (MEDIAN) Months = 21.4 [17.91-25.40]; PFS by Investigator Assessment (MEDIAN) Months = 9.7 [7.66-11.70]; ORR by Investigator Assessment (NUMBER) Percentage of participants = 57.4 [50.6-64.0]; DOR by Investigator Assessment (MEDIAN) Months = 14.5 [9.72-18.66]; Change From Baseline in European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Lung Cancer (EORTC QLQ-LC13) (LEAST_SQUARES_MEAN) Score on a scale = -13.0 [-16.6--9.4]; Change From Baseline in European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) Global Health Status (LEAST_SQUARES_MEAN) Score on a scale = 0.9 [-2.0-3.8]; Number of Participants With Adverse Events (COUNT_OF_PARTICIPANTS) Participants = 222; PFS by IRC Based on Programmed Death Ligand 1 (PD-L1) Expression (MEDIAN) Months = 7.6 [5.0-9.7],,,,,Duration of Response (DOR) by IRC Assessment (MEDIAN) Months = 10.6 [8.38-17.64]; DOR by Investigator Assessment (MEDIAN) Months = 14.5 [9.72-18.66],,,Objective Response Rate (ORR) by IRC Assessment (NUMBER) Percentage of participants = 57.8 [51.1-64.4]; ORR by Investigator Assessment (NUMBER) Percentage of participants = 57.4 [50.6-64.0],Overall Survival (OS) (MEDIAN) Months = 21.4 [17.91-25.40],Progression Free Survival (PFS) Assessed by Independent Review Committee (IRC) Assessment (MEDIAN) Months = 9.7 [7.72-11.53]; PFS by Investigator Assessment (MEDIAN) Months = 9.7 [7.66-11.70]; PFS by IRC Based on Programmed Death Ligand 1 (PD-L1) Expression (MEDIAN) Months = 7.6 [5.0-9.7],,Change From Baseline in European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Lung Cancer (EORTC QLQ-LC13) (LEAST_SQUARES_MEAN) Score on a scale = -13.0 [-16.6--9.4]; Change From Baseline in European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) Global Health Status (LEAST_SQUARES_MEAN) Score on a scale = 0.9 [-2.0-3.8],Objective Response Rate (ORR) by IRC Assessment (NUMBER) Percentage of participants = 57.8 [51.1-64.4],Number of Participants With Adverse Events (COUNT_OF_PARTICIPANTS) Participants = 222,,
NCT03664024,"Biomarkers of Response to Pembrolizumab Combined With Chemotherapy in Non-Small Cell Lung Cancer (KEYNOTE-782, MK-3475-782)","A Phase II Trial to Investigate Genetic Markers of Response to Pembrolizumab (MK-3475, SCH 900475) Combined With Chemotherapy as a First-line Treatment for Non-Small Cell Lung Cancer (KEYNOTE-782)",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,INDUSTRY,COMPLETED,2018-10-30,2021-11-05,2021-11-05,INTERVENTIONAL,PHASE2,,,,Non-Small Cell Lung Cancer,Non-Small Cell Lung Cancer,1,1,4,DRUG,,,2,4,True,Yes,Objective Response Rate (NUMBER) Percentage of Participants = 40.2 [31.2-49.6]; Tumor Mutation Burden (TMB) in Cell-free Circulating Tumor Deoxyribonucleic Acid (ctDNA) (MEAN) Mut/MB = 9,Progression Free Survival (PFS) (MEDIAN) Months = 7.2 [5.6-9.8]; Overall Survival (OS) (MEDIAN) Months = 18.1 [13.5-25.6]; Percentage of Participants Who Experienced One or More Adverse Events (AEs) (NUMBER) Percentage of Participants = 100; Percentage of Participants Discontinuing Study Intervention Due to an AE. (NUMBER) Percentage of Participants = 38.5,,,,,,,,Objective Response Rate (NUMBER) Percentage of Participants = 40.2 [31.2-49.6],Overall Survival (OS) (MEDIAN) Months = 18.1 [13.5-25.6],Progression Free Survival (PFS) (MEDIAN) Months = 7.2 [5.6-9.8],,,Objective Response Rate (NUMBER) Percentage of Participants = 40.2 [31.2-49.6],Percentage of Participants Who Experienced One or More Adverse Events (AEs) (NUMBER) Percentage of Participants = 100,,
NCT03679767,A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203),A Phase 2 Study of INCMGA00012 (PD-1 Inhibitor) in Participants With Selected Solid Tumors (POD1UM-203),Incyte Corporation,Incyte Corporation,INDUSTRY,COMPLETED,2019-01-09,2021-04-15,2022-06-28,INTERVENTIONAL,PHASE2,,,,Metastatic Non-small Cell Lung Cancer,Metastatic Non-small Cell Lung Cancer; Locally Advanced Urothelial Cancer; Metastatic Urothelial Cancer,7,4,1,DRUG,,,1,13,True,Yes,Overall Response Rate (ORR) (NUMBER) percentage of participants = 40.0 [23.9-57.9],; Disease Control Rate (DCR) (NUMBER) percentage of participants = 54.3 [36.6-71.2]; Progression-free Survival (PFS) (MEDIAN) months = 3.6; ; Number of Participants With Treatment-emergent Adverse Events (TEAEs) (COUNT_OF_PARTICIPANTS) Participants = 32; First-dose Cmax of Retifanlimab (MEAN) milligrams per Liter (mg/L) = 143; Cmax of Retifanlimab at Steady-state (MEAN) mg/L = 181; First-dose Tmax of Retifanlimab (MEDIAN) hours = 0.500 [0.500-1.00]; Tmax of Retifanlimab at Steady-state (MEDIAN) hours = 0.500 [0.500-1.00]; First-dose Cmin of Retifanlimab (MEAN) mg/L = 18.0; Cmin of Retifanlimabv at Steady-state (MEAN) mg/L = 38.2; First-dose AUC0-t of Retifanlimab (MEAN) day*mg/L = 1620; AUC0-t of Retifanlimab at Steady-state (MEAN) day*mg/L = 2030,,,,,,,,,,Progression-free Survival (PFS) (MEDIAN) months = 3.6,,,Overall Response Rate (ORR) (NUMBER) percentage of participants = 40.0 [23.9-57.9],Number of Participants With Treatment-emergent Adverse Events (TEAEs) (COUNT_OF_PARTICIPANTS) Participants = 32,,
NCT03682224,Exparel and Marcaine for Pain Management in Thoracoscopic Lobectomy Patients,"A Prospective, Randomized, Single-Blind, Active Control Trial to Compare Safety and Effectiveness Of Liposomal Bupivacaine (Exparel) to Standard Bupivacaine HCl (Marcaine) for Pain Management in Patie",Southern Illinois University,Southern Illinois University,OTHER,COMPLETED,2018-07-05,2022-09-03,2022-09-03,INTERVENTIONAL,PHASE3,,,,Non Small Cell Lung Cancer,Non Small Cell Lung Cancer; Lung Cancer Stage 1,2,2,2,DRUG,,,1,4,True,Yes,Total Morphine Equivalents Consumed (MEDIAN) MEq = 48 [23-71],"VAS Pain Score (MEDIAN) score on a scale = 4.8 [4.3-6.2]; Treatment Cost (MEDIAN) United States Dollars = 22,775 [19,930-30,659]; Pharmacy Cost (MEDIAN) United States Dollars = 1052 [970-1295]; Mortality (COUNT_OF_PARTICIPANTS) Participants = 0",,,,,,,,,,,,,,,,
NCT03689855,Ramucirumab and Atezolizumab After Progression on Any Immune Checkpoint Blocker in NSCLC,Ramucirumab and Atezolizumab After Progression on Any Immune Checkpoint Blocker in NSCLC (RamAtezo-1),Washington University School of Medicine,Washington University School of Medicine,OTHER,COMPLETED,2019-06-05,2021-07-16,2024-04-22,INTERVENTIONAL,PHASE2,,,,Non-small Cell Lung Cancer,Non-small Cell Lung Cancer; Non Small Cell Lung Cancer; NSCLC,3,1,4,DRUG; PROCEDURE,,,1,4,True,Yes,Overall Response Rate (ORR) (COUNT_OF_PARTICIPANTS) Participants = 1,Clinical Benefit Rate (CBR) (COUNT_OF_PARTICIPANTS) Participants = 16; Toxicity and Tolerability as Measured by Number of Participants Who Experienced Adverse Events (COUNT_OF_PARTICIPANTS) Participants = 8; Overall Survival (OS) (MEDIAN) months = 16.3 [7.1-20.9]; Progression-free Survival (PFS) (MEDIAN) months = 1.0 [1.0-2.3],Clinical Benefit Rate (CBR) (COUNT_OF_PARTICIPANTS) Participants = 16,,,,,,,,Overall Survival (OS) (MEDIAN) months = 16.3 [7.1-20.9],Progression-free Survival (PFS) (MEDIAN) months = 1.0 [1.0-2.3],,,Overall Response Rate (ORR) (COUNT_OF_PARTICIPANTS) Participants = 1,Toxicity and Tolerability as Measured by Number of Participants Who Experienced Adverse Events (COUNT_OF_PARTICIPANTS) Participants = 8,,
NCT03693300,A Study to Determine Safety of Durvalumab After Sequential Chemo Radiation in Patients With Unresectable Stage III Non-Small Cell Lung Cancer,"A Phase II, Open-Label, Multi-Centre, International Safety Study of Durvalumab Following Sequential Chemotherapy and Radiation Therapy in Patients With Stage III, Unresectable Non-Small Cell Lung Canc",AstraZeneca,AstraZeneca,INDUSTRY,COMPLETED,2019-04-16,2022-12-13,2023-04-21,INTERVENTIONAL,PHASE2,,,,Non-small Cell Lung Cancer (NSCLC),Non-small Cell Lung Cancer (NSCLC),1,2,1,DRUG,,,1,8,True,Yes,Number of Patients With Grade 3 and Grade 4 Treatment-related Adverse Events (TRAEs) (COUNT_OF_PARTICIPANTS) Participants = 7,"Progression-free Survival (PFS) (MEDIAN) Months = 13.1 [7.36-19.91]; Percentage of Patients Progression-free at 12 Months (NUMBER) Percentage of patient = 51.1 [41.29-60.02]; Overall Survival (OS) (MEDIAN) Months = 39.0; Percentage of Patients Alive (NUMBER) Percentage of patient = 83.9 [75.73-89.57]; Objective Response Rate (ORR) (COUNT_OF_PARTICIPANTS) Participants = 24; ; Lung Cancer Mortality (MEDIAN) Months = 41.8; Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), Adverse Event of Special Interests (AESIs), and Immune-mediated Adverse Event (imAEs) (COUNT_OF_PARTICIPANTS) Participants = 108",,,,,,,,Objective Response Rate (ORR) (COUNT_OF_PARTICIPANTS) Participants = 24,Overall Survival (OS) (MEDIAN) Months = 39.0,Progression-free Survival (PFS) (MEDIAN) Months = 13.1 [7.36-19.91],,,Objective Response Rate (ORR) (COUNT_OF_PARTICIPANTS) Participants = 24,"Number of Patients With Grade 3 and Grade 4 Treatment-related Adverse Events (TRAEs) (COUNT_OF_PARTICIPANTS) Participants = 7; Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), Adverse Event of Special Interests (AESIs), and Immune-mediated Adverse Event (imAEs) (COUNT_OF_PARTICIPANTS) Participants = 108",,
NCT03704688,Trial of Trametinib and Ponatinib in Patients With KRAS Mutant Advanced Non-Small Cell Lung Cancer,A Phase 1 Trial of Trametinib and Ponatinib in Patients With KRAS Mutant Advanced Non-Small Cell Lung Cancer,Memorial Sloan Kettering Cancer Center,Memorial Sloan Kettering Cancer Center,OTHER,COMPLETED,2018-10-09,2022-02-04,2022-02-04,INTERVENTIONAL,PHASE1; PHASE2,,,,Non Small Cell Lung Cancer,Non Small Cell Lung Cancer; KRAS Gene Mutation,2,6,6,DRUG,,,2,0,True,Yes,"Maximum Tolerated Dose of Ponatinib, Phase I (NUMBER) mg of ponatinib = 30; Overall Response Rate (COUNT_OF_PARTICIPANTS) Participants = 1",,,,,,,,,,,,,,Overall Response Rate (COUNT_OF_PARTICIPANTS) Participants = 1,,,
NCT03717155,Study of Avelumab and Cetuximab Plus Gemcitabine and Cisplatin in Participants With NSCLC,"A Phase IIa, Single-arm, Multicenter Study to Investigate the Clinical Activity and Safety of Avelumab in Combination With Cetuximab Plus Gemcitabine and Cisplatin in Participants With Advanced Squamo","Merck KGaA, Darmstadt, Germany","Merck KGaA, Darmstadt, Germany",INDUSTRY,COMPLETED,2018-10-30,2020-09-30,2021-05-27,INTERVENTIONAL,PHASE2,,,,Squamous Non-Small Cell Lung Cancer,Squamous Non-Small Cell Lung Cancer,1,1,5,DRUG,,,1,10,True,Yes,Percentage of Participants With Confirmed Best Objective Response (BOR) According to Response Evaluation Criteria In Solid Tumors (RECIST) Version 1.1 Assessed by Investigator (NUMBER) percentage of participants = 34.9 [21.0-50.9],"Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Treatment-Related Adverse Events (AEs), Treatment-Related Grade >=3 TEAEs and Immune-related Treatment Emergent AEs (irTEAEs) (COUNT_OF_PARTICIPANTS) Participants = 41; Progression-Free Survival (PFS) Time Per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 (MEDIAN) Months = 6.1 [4.3-9.0]; Duration of Response (DOR) (MEDIAN) Months = 7.1 [4.2-12.5]; Immediate Observed Serum Concentration at End of Infusion (Ceoi) of Avelumab (GEOMETRIC_MEAN) microgram per milliliter (mcg/mL) = 206; Immediate Observed Serum Concentration at End of Infusion (Ceoi) of Cetuximab (GEOMETRIC_MEAN) mcg/mL = 109; Serum Trough Concentration Levels (Ctrough) of Avelumab (GEOMETRIC_MEAN) mcg/mL = 28.8; Serum Trough Concentration Levels (Ctrough) of Cetuximab (GEOMETRIC_MEAN) mcg/mL = 12.1; Overall Survival (OS) (MEDIAN) Months = 10.1 [8.6-14.5]; Number of Participants With Positive Anti-Drug Antibody (ADA) of Avelumab (COUNT_OF_PARTICIPANTS) Participants = 7; Number of Participants With Positive Anti-Drug Antibody (ADA) of Cetuximab (COUNT_OF_PARTICIPANTS) Participants = 1",,,,,Duration of Response (DOR) (MEDIAN) Months = 7.1 [4.2-12.5],,,,Overall Survival (OS) (MEDIAN) Months = 10.1 [8.6-14.5],Progression-Free Survival (PFS) Time Per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 (MEDIAN) Months = 6.1 [4.3-9.0],,,,"Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Treatment-Related Adverse Events (AEs), Treatment-Related Grade >=3 TEAEs and Immune-related Treatment Emergent AEs (irTEAEs) (COUNT_OF_PARTICIPANTS) Participants = 41",,
NCT03735121,A Study to Investigate Atezolizumab Subcutaneous in Patients With Previously Treated Locally Advanced or Metastatic Non-Small Cell Lung Cancer,"A Randomized, Multicenter, Phase Ib/III Study to Investigate the Pharmacokinetics, Efficacy, and Safety of Atezolizumab Subcutaneous Compared With Atezolizumab Intravenous in Patients With Previously ",Hoffmann-La Roche,Hoffmann-La Roche,INDUSTRY,COMPLETED,2018-12-27,2022-04-26,2024-11-11,INTERVENTIONAL,PHASE3,,,,Non-Small Cell Lung Cancer,Non-Small Cell Lung Cancer,1,5,2,DRUG,,,3,26,True,Yes,Part 1: Serum Trough Concentration (Ctrough) of Atezolizumab at Cycle 1 (GEOMETRIC_MEAN) micrograms per milliliter (μg/mL) = 121; Part 2: Observed Serum Ctrough of Atezolizumab at Cycle 1 (GEOMETRIC_MEAN) μg/mL = 85.4; Part 2: Area Under the Concentration-Time Curve From Time Zero to 21 Days (AUC 0-21 d) at Cycle 1 (GEOMETRIC_MEAN) micrograms day per mL (μg*day/mL) = 3327.9,"Part 1: Maximum Observed Serum Concentration (Cmax) of Atezolizumab (GEOMETRIC_MEAN) μg/mL = 251; Part 1: Time to Maximum Serum Concentration (Tmax) of Atezolizumab (MEDIAN) days = 3.02 [2.93-7.80]; Part 1: Area Under the Concentration-time Curve (AUClast) of Atezolizumab (GEOMETRIC_MEAN) μg*day/mL = 3870; ; Part 1: Percentage of Participants With Adverse Events (AEs) (NUMBER) percentage of participants = 100; Part 2: Percentage of Participants With AEs (NUMBER) percentage of participants = 85.5; Part 2: Model Predicted Ctrough of Atezolizumab at Cycle 1 (GEOMETRIC_MEAN) μg/mL = 88.7; Part 2: Model Predicted Ctrough at Steady State (Ctrough,ss) of Atezolizumab (GEOMETRIC_MEAN) μg/mL = 179; Part 2: Model Predicted AUC at Steady State (AUCss) of Atezolizumab (GEOMETRIC_MEAN) ug*day/mL = 6107; Part 2: Objective Response Rate (ORR) (NUMBER) percentage of participants = 10.5 [5.7-17.3]; Part 2: Progression-free Survival (PFS) (MEDIAN) months = 2.9 [1.8-4.2]; Part 2: Overall Survival (OS) (MEDIAN) months = 10.1 [7.5-12.3]; Part 2: Duration of Response (DOR) (MEDIAN) months = 11.2; Part 2: Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Item Library (IL) 57 Physical Functioning Score (MEAN) score on a scale = 74.53; Part 2: Change From Baseline in EORTC IL57 Role Functioning Score (MEAN) score on a scale = 74.93; Part 2: Change From Baseline in EORTC IL57 Global Health Status Score (MEAN) score on a scale = 66.52; Part 2: Overall Satisfaction With Treatment Over Time, Assessed by the Modified Satisfaction With Therapy (SWT) Scale of the Cancer Therapy Satisfaction Questionnaire (CTSQ) (MEAN) score on a scale = 77.29; Part 2: Percentage of Participants by Their Responses to AE's Burden Over Time, Assessed by the Treatment-related Symptom Burden Item From the EORTC IL57 (NUMBER) percentage of participants = 49.6; Part 2: Percentage of Participants With Ant-Drug Antibodies (ADAs) to Atezolizumab After SC or IV Administration (NUMBER) percentage of participants = 14.3; Part 2: Percentage of Participants With ADAs to rHuPH20 After SC Administration (NUMBER) percentage of participants = 5.7; Part 2: Percentage of Health Care Professionals (HCPs) by Their Response to Question 2 of HCP SC Versus IV Perspective Questionnaire (NUMBER) percentage of HCPs = 24.0; Part 2: Percentage of HCPs by Their Response to Question 3 of the HCP SC Versus IV Perspective Questionnaire (NUMBER) percentage of HCPs = 74.0; Part 2: Percentage of HCPs by Their Response to Question 4 of the HCP SC Versus IV Perspective Questionnaire (NUMBER) percentage of HCPs = 32.0; Part 2: Percentage of HCPs by Their Response to Question 2 of the HCP SC Perspective Questionnaire (NUMBER) percentage of HCPs = 78.6; Part 2: Percentage of HCPs by Their Response to Question 3 of the HCP SC Perspective Questionnaire (NUMBER) percentage of HCPs = 54.8; Part 2: Percentage of HCPs by Their Response to Question 4 of the HCP SC Perspective Questionnaire (NUMBER) percentage of HCPs = 34.5",,,,,Part 2: Duration of Response (DOR) (MEDIAN) months = 11.2,,,Part 2: Objective Response Rate (ORR) (NUMBER) percentage of participants = 10.5 [5.7-17.3],Part 2: Overall Survival (OS) (MEDIAN) months = 10.1 [7.5-12.3],Part 2: Progression-free Survival (PFS) (MEDIAN) months = 2.9 [1.8-4.2],,,Part 2: Objective Response Rate (ORR) (NUMBER) percentage of participants = 10.5 [5.7-17.3],Part 1: Percentage of Participants With Adverse Events (AEs) (NUMBER) percentage of participants = 100,,
NCT03735680,"A Study to Evaluate ONM-100, an Intraoperative Fluorescence Imaging Agent for the Detection of Cancer","A Phase 2a, Single-dose, Open-label Study to Evaluate Diagnostic Performance, Safety & Timing of Postdose Imaging of ONM-100, an Intraoperative Fluorescence Imaging Agent for the Detection of Cancer, ","OncoNano Medicine, Inc.","OncoNano Medicine, Inc.",INDUSTRY,COMPLETED,2019-08-09,2021-10-14,2021-11-18,INTERVENTIONAL,PHASE2,,,,Breast Cancer,Breast Cancer; Head and Neck Squamous Cell Carcinoma; Colorectal Cancer,7,1,1,DRUG,,,2,6,True,Yes,Measure Mean Fluorescence Intensity of Histologically Confirmed Tumor vs Normal Tissue in Patients Undergoing Routine Surgery [Tumor to Background Ratio (TBR)] (MEAN) ratio = 1.098; Incidence Rate of All Treatment-emergent Adverse Events (TEAEs) From Time of ONM-100 Administration Through Day 28 (COUNT_OF_PARTICIPANTS) Participants = 2,Evaluate Pharmacokinetic Parameters: Cmax (GEOMETRIC_MEAN) μg/mL = 26.5; Evaluate Pharmacokinetic Parameters: Tmax (MEDIAN) hr = 0.25 [0.22-1.12]; Evaluate Pharmacokinetic Parameters: AUC (GEOMETRIC_MEAN) hr x μg/mL = 433; Evaluate Pharmacokinetic Parameters: CL (GEOMETRIC_MEAN) L/hr = 0.053; Evaluate Pharmacokinetic Parameters: Vz (GEOMETRIC_MEAN) L = 3.78; Evaluate Pharmacokinetic Parameters: t1/2 (GEOMETRIC_MEAN) hr = 49.0,,,,,,,,,,,,,,Incidence Rate of All Treatment-emergent Adverse Events (TEAEs) From Time of ONM-100 Administration Through Day 28 (COUNT_OF_PARTICIPANTS) Participants = 2,,
NCT03743051,A Study to Evaluate the Efficacy and Safety of Anamorelin HCl for the Treatment of Malignancy Associated Weight Loss and Anorexia in Adult Patients Wi,"A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Anamorelin HCl for the Treatment of Malignancy Associated Weight Loss and Anorexia in A",Helsinn Healthcare SA,Helsinn Healthcare SA,INDUSTRY,COMPLETED,2019-03-05,2023-02-11,2023-02-11,INTERVENTIONAL,PHASE3,,,,Cachexia; Cancer,Cachexia; Cancer; Non Small Cell Lung Cancer,2,2,2,DRUG,,,2,4,True,Yes,Mean Change From Baseline in Body Weight Over 12 Weeks (LEAST_SQUARES_MEAN) Change from baseline in body weight (kg) = 1.938; Mean Change From Baseline in 5-item Anorexia Symptom Subscale (5-IASS) Over 12 Weeks (LEAST_SQUARES_MEAN) score on a scale = 3.816,Duration of Treatment Benefit (Weeks) From Baseline Over 12 Weeks in Body Weight (≥0 kg) (LEAST_SQUARES_MEAN) Weeks = 9.871; Duration of Treatment Benefit (Weeks) From Baseline Over 12 Weeks in Body Weight (≥1.5 kg) (LEAST_SQUARES_MEAN) Weeks = 4.967; Duration of Treatment Benefit (Weeks) From Baseline Over 12 Weeks in 5-IASS (≥0 Points) (LEAST_SQUARES_MEAN) Weeks = 10.523; Duration of Treatment Benefit (Weeks) From Baseline Over 12 Weeks in 5-IASS (≥3 Points) (LEAST_SQUARES_MEAN) Weeks = 6.185,,,,,,,,,,,,,,,,
NCT03743064,A Study to Evaluate the Efficacy and Safety of Anamorelin HCl for the Treatment of Malignancy Associated Weight Loss and Anorexia in Adult Patients Wi,"A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Anamorelin HCl for the Treatment of Malignancy Associated Weight Loss and Anorexia in A",Helsinn Healthcare SA,Helsinn Healthcare SA,INDUSTRY,COMPLETED,2019-05-06,2022-12-27,2022-12-27,INTERVENTIONAL,PHASE3,,,,Cachexia; Cancer,Cachexia; Cancer; Non Small Cell Lung Cancer,2,2,2,DRUG,,,2,4,True,Yes,Mean Change From Baseline in Body Weight Over 12 Weeks (LEAST_SQUARES_MEAN) kg = 1.822; Mean Change From Baseline in 5-item Anorexia Symptom Subscale (5-IASS) Over 12 Weeks (LEAST_SQUARES_MEAN) score on a scale = 3.432,Duration in Treatment Benefit (Weeks) From Baseline Over 12 Weeks in Body Weight (≥0 kg) (LEAST_SQUARES_MEAN) weeks = 8.859; Duration in Treatment Benefit (Weeks) From Baseline Over 12 Weeks in Body Weight (≥1.5 kg) (LEAST_SQUARES_MEAN) weeks = 5.490; Duration of Treatment Benefit (Weeks) From Baseline Over 12 Weeks in 5-IASS (≥0 Points) (LEAST_SQUARES_MEAN) weeks = 9.470; Duration of Treatment Benefit (Weeks) From Baseline Over 12 Weeks in 5-IASS (≥3 Points) (LEAST_SQUARES_MEAN) weeks = 5.143,,,,,,,,,,,,,,,,
NCT03775486,Study of Durvalumab+Olaparib or Durvalumab After Treatment With Durvalumab and Chemotherapy in Patients With Lung Cancer (ORION),"A Phase II Randomized, Multi-Center, Double-Blind, Global Study to Determine the Efficacy and Safety of Durvalumab Plus Olaparib Combination Therapy Compared With Durvalumab Monotherapy as Maintenance",AstraZeneca,AstraZeneca,INDUSTRY,ACTIVE_NOT_RECRUITING,2018-12-21,2021-01-11,2026-09-27,INTERVENTIONAL,PHASE2,,,,Non-small Cell Lung Cancer NSCLC,Non-small Cell Lung Cancer NSCLC,1,2,8,DRUG,,,1,11,True,Yes,Progression-free Survival (COUNT_OF_PARTICIPANTS) Participants = 40,Overall Survival (COUNT_OF_PARTICIPANTS) Participants = 44; Objective Response Rate (COUNT_OF_PARTICIPANTS) Participants = 22; Duration of Response (NUMBER) percent = 90.5; Progression-free Survival in Homologous Recombination Repair Related Gene Mutation (HRRm) Population (COUNT_OF_PARTICIPANTS) Participants = 1; Concentration of Durvalumab (GEOMETRIC_MEAN) μg/mL = 417.152; Change From Baseline in European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ)-Lung Cancer (LC)13 (MEAN) change from baseline score = -1.27; Time to Deterioration in European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ)-Lung Cancer (LC)13 (MEDIAN) months = 10.0 [5.6-12.2]; Change From Baseline in EORTC Quality of Life Questionnaire (QLQ) QLQ-C30 (MEAN) change from baseline score = 0.15; Time to Deterioration in EORTC Quality of Life Questionnaire (QLQ) QLQ-C30 (MEDIAN) time to deterioration (months) = 8.8 [5.6-10.8]; Presence of Anti-drug Antibodies (ADAs) for Durvalumab (COUNT_OF_PARTICIPANTS) Participants = 11; Number of Participants With Treatment-Related Adverse Events (COUNT_OF_PARTICIPANTS) Participants = 83,,,,,Duration of Response (NUMBER) percent = 90.5,,,Objective Response Rate (COUNT_OF_PARTICIPANTS) Participants = 22,Overall Survival (COUNT_OF_PARTICIPANTS) Participants = 44,Progression-free Survival (COUNT_OF_PARTICIPANTS) Participants = 40; Progression-free Survival in Homologous Recombination Repair Related Gene Mutation (HRRm) Population (COUNT_OF_PARTICIPANTS) Participants = 1,,Change From Baseline in European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ)-Lung Cancer (LC)13 (MEAN) change from baseline score = -1.27; Time to Deterioration in European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ)-Lung Cancer (LC)13 (MEDIAN) months = 10.0 [5.6-12.2]; Change From Baseline in EORTC Quality of Life Questionnaire (QLQ) QLQ-C30 (MEAN) change from baseline score = 0.15; Time to Deterioration in EORTC Quality of Life Questionnaire (QLQ) QLQ-C30 (MEDIAN) time to deterioration (months) = 8.8 [5.6-10.8],Objective Response Rate (COUNT_OF_PARTICIPANTS) Participants = 22,Number of Participants With Treatment-Related Adverse Events (COUNT_OF_PARTICIPANTS) Participants = 83,,
NCT03822351,Durvalumab Alone or in Combination With Novel Agents in Subjects With NSCLC,"A Phase 2 Open-label, Multicenter, Randomized, Multidrug Platform Study of Durvalumab (MEDI4736) Alone or in Combination With Novel Agents in Subjects With Locally Advanced, Unresectable (Stage III) N",MedImmune LLC,MedImmune LLC,INDUSTRY,COMPLETED,2018-12-19,2023-07-18,2023-07-18,INTERVENTIONAL,PHASE2,,,,Stage III Non-small Cell Lung Cancer,Stage III Non-small Cell Lung Cancer; Unresectable,2,3,3,DRUG,,,1,12,True,Yes,Objective Response (OR) Rate as a Measure of Antitumor Activity of Durvalumab Alone vs Durvalumab in Combination With Novel Agents (NUMBER) Percentage of Participants = 23.9 [14.3-35.9],Presence of Adverse Events as a Measure of Safety and Tolerability of Durvalumab Alone and in Combination With Novel Agents (COUNT_OF_PARTICIPANTS) Participants = 65; Presence of Clinically Significant Laboratory Values as a Measure of Safety and Tolerability of Durvalumab Alone and in Combination With Novel Agents (COUNT_OF_PARTICIPANTS) Participants = 1; Presence of Abnormalities in Vital Signs as a Measure of Safety and Tolerability of Durvalumab Alone and in Combination With Novel Agents (COUNT_OF_PARTICIPANTS) Participants = 3; ; Disease Control (DC) as a Measure of Efficacy of Durvalumab Alone vs Durvalumab in Combination With Novel Agents (NUMBER) Percentage of Participants = 58.2 [45.5-70.2]; Progression-Free Survival (PFS) as a Measure of Efficacy of Durvalumab Alone vs Durvalumab in Combination With Novel Agents (MEDIAN) Months = 7.3 [4.0-13.8]; Progression-Free Survival 12 Month Landmark Rate (PFS-12) as a Measure of Efficacy of Durvalumab Alone vs Durvalumab in Combination With Novel Agents (NUMBER) Percentage of Participants = 37.6 [24.7-50.4]; Overall Survival (OS) as a Measure of Efficacy of Durvalumab Alone vs Durvalumab in Combination With Novel Agents (MEDIAN) Months = 40.9; Pharmacokinetics of Durvalumab Alone and in Combination With Novel Agents (GEOMETRIC_MEAN) Micrograms per milliliter = 318.0; Pharmacokinetics of Novel Agents in Combination With Durvalumab (GEOMETRIC_MEAN) Micrograms per milliliter = 581.6; Presence of Detectable Anti-Drug Antibody (ADA) Response to Durvalumab Alone and in Combination With Novel Agents (COUNT_OF_PARTICIPANTS) Participants = 3; Presence of Detectable Anti-Drug Antibody (ADA) Response to Novel Agents in Combination With Durvalumab (COUNT_OF_PARTICIPANTS) Participants = 0,,,,,,,,,Overall Survival (OS) as a Measure of Efficacy of Durvalumab Alone vs Durvalumab in Combination With Novel Agents (MEDIAN) Months = 40.9,Progression-Free Survival (PFS) as a Measure of Efficacy of Durvalumab Alone vs Durvalumab in Combination With Novel Agents (MEDIAN) Months = 7.3 [4.0-13.8]; Progression-Free Survival 12 Month Landmark Rate (PFS-12) as a Measure of Efficacy of Durvalumab Alone vs Durvalumab in Combination With Novel Agents (NUMBER) Percentage of Participants = 37.6 [24.7-50.4],,,,Presence of Adverse Events as a Measure of Safety and Tolerability of Durvalumab Alone and in Combination With Novel Agents (COUNT_OF_PARTICIPANTS) Participants = 65,,
NCT03829319,Safety and Efficacy Study of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) as First-line Int,"A Phase 3 Randomized, Placebo-controlled Study to Evaluate the Safety and Efficacy of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First-l",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,INDUSTRY,COMPLETED,2019-03-25,2023-08-11,2024-08-30,INTERVENTIONAL,PHASE3,,,,Nonsquamous Non-small Cell Lung Cancer,Nonsquamous Non-small Cell Lung Cancer,1,2,6,BIOLOGICAL; DRUG,,,5,15,True,Yes,Part 1: Number of Participants With a Dose-limiting Toxicity (DLT) (COUNT_OF_PARTICIPANTS) Participants = 2; Part 1: Number of Participants Who Experienced an Adverse Event (AE) (COUNT_OF_PARTICIPANTS) Participants = 13; Part 1: Number of Participants Who Discontinued Study Drug Due to an Adverse Event (COUNT_OF_PARTICIPANTS) Participants = 9; Part 2: Progression-free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) (MEDIAN) Months = 12.1 [10.4-14.1]; Part 2: Overall Survival (OS) (MEDIAN) Months = 21.8 [18.6-24.0],"Part 2: Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) (NUMBER) Percentage of Participants = 57.1 [50.1-63.8]; Part 2: Duration of Response (DOR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) (MEDIAN) Months = 1.6 [1.1-15.4]; Part 2: Number of Participants Who Experienced an Adverse Event (AE) (COUNT_OF_PARTICIPANTS) Participants = 372; Part 2: Number of Participants Who Discontinued Study Drug Due to an Adverse Event (COUNT_OF_PARTICIPANTS) Participants = 127; Part 2: Change From Baseline in Global Health Status (GHS) (European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 [EORTC QLQ-C30] Items 29 and 30) Score (LEAST_SQUARES_MEAN) Score on a Scale = 0.65 [-1.55-2.84]; Part 2: Change From Baseline in Cough (EORTC Quality of Life Questionnaire-Lung Cancer Module 13 [QLQ-LC13] Item 31) Score (LEAST_SQUARES_MEAN) Score on a scale = -11.77 [-14.72--8.81]; Part 2: Change From Baseline in Chest Pain (EORTC QLQ-LC13 Item 40) Score (LEAST_SQUARES_MEAN) Score on a scale = -4.61 [-7.26--1.96]; Part 2: Change From Baseline in Dyspnea (EORTC QLQ-C30 Item 8) Score (LEAST_SQUARES_MEAN) Score on a scale = -2.77 [-6.04-0.50]; Part 2: Change From Baseline in Physical Functioning (EORTC QLQ-C30 Items 1-5) Score (LEAST_SQUARES_MEAN) Score on a scale = -4.11 [-6.37--1.84]; Part 2: Time to True Deterioration (TTD) Based on Change From Baseline in Global Health Status (GHS)/Quality of Life (QoL) (EORTC QLQ-C30 Items 29 and 30) Score (MEDIAN) Months = 15.70; ; ; ; Part 2: TTD Based on Change From Baseline in Physical Functioning EORTC QLQ-C30 (Items 1 Through 5) Score (MEDIAN) Months = 16.82 [8.84-22.51]; Part 2: Time to True Deterioration (TTD) Based on Change From Baseline in the Composite Endpoint of Cough (EORTC QLQ-LC13 Item 31), Chest Pain (EORTC QLQ-LC13 Item 40), or Dyspnea (EORTC QLQ-C30 Item 8) (MEDIAN) Months = 8.28 [5.98-11.07]",,,,,Part 2: Duration of Response (DOR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) (MEDIAN) Months = 1.6 [1.1-15.4],,,Part 2: Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) (NUMBER) Percentage of Participants = 57.1 [50.1-63.8],Part 2: Overall Survival (OS) (MEDIAN) Months = 21.8 [18.6-24.0],Part 2: Progression-free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) (MEDIAN) Months = 12.1 [10.4-14.1],,Part 2: Change From Baseline in Global Health Status (GHS) (European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 [EORTC QLQ-C30] Items 29 and 30) Score (LEAST_SQUARES_MEAN) Score on a Scale = 0.65 [-1.55-2.84]; Part 2: Change From Baseline in Cough (EORTC Quality of Life Questionnaire-Lung Cancer Module 13 [QLQ-LC13] Item 31) Score (LEAST_SQUARES_MEAN) Score on a scale = -11.77 [-14.72--8.81]; Part 2: Time to True Deterioration (TTD) Based on Change From Baseline in Global Health Status (GHS)/Quality of Life (QoL) (EORTC QLQ-C30 Items 29 and 30) Score (MEDIAN) Months = 15.70,Part 2: Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) (NUMBER) Percentage of Participants = 57.1 [50.1-63.8],Part 1: Number of Participants With a Dose-limiting Toxicity (DLT) (COUNT_OF_PARTICIPANTS) Participants = 2,,
NCT03829332,Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-,"A Phase 3, Randomized, Double-blind Trial of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) in Participants With Treatment-naïve, Metastatic Nonsmall Cell Lung Cancer (NSCLC) Whose",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,INDUSTRY,COMPLETED,2019-03-13,2021-05-19,2024-04-24,INTERVENTIONAL,PHASE3,,,,Non-small Cell Lung Cancer,Non-small Cell Lung Cancer,1,2,3,BIOLOGICAL; DRUG,,,2,14,True,Yes,Progression-free Survival (PFS) as Assessed by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) (MEDIAN) Months = 6.6 [6.1-8.2]; Overall Survival (OS) (MEDIAN) Months = 14.1 [11.4-19.0],"Objective Response Rate (ORR) as Assessed by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) (NUMBER) Percentage of Participants = 40.5 [34.9-46.2]; Number of Participants Who Experienced an Adverse Event (AE) (COUNT_OF_PARTICIPANTS) Participants = 306; Number of Participants Who Discontinued Study Treatment Due to an Adverse Event (AE) (COUNT_OF_PARTICIPANTS) Participants = 98; Change From Baseline in European Organization for Research and Treatment (EORTC) Quality of Life Questionnaire-Core30 (QLQ-C30) Combined Global Health Status/Quality of Life (Items 29 & 30) Scale Combined Score (LEAST_SQUARES_MEAN) Score on a scale = -1.48 [-4.09-1.13]; Change From Baseline in Cough (EORTC Quality of Life Questionnaire-Lung Cancer Module 13 [QLQ-LC13] Item 31) Score (LEAST_SQUARES_MEAN) Score on a scale = -9.53 [-12.94--6.13]; Change From Baseline in Chest Pain (EORTC QLQ-LC13 Item 40) Score (LEAST_SQUARES_MEAN) Score on a scale = -4.64 [-7.45--1.84]; Change From Baseline in Dyspnea (EORTC QLQ-C30 Item 8) Score (LEAST_SQUARES_MEAN) Score on a scale = -1.35 [-4.75-2.04]; Change From Baseline in Physical Functioning (EORTC QLQ-C30 Items 1-5) Score (LEAST_SQUARES_MEAN) Score on a scale = -6.73 [-9.35--4.10]; ; ; ; ; Time to True Deterioration (TTD) Based on Change From Baseline in EORTC QLQ-C30 Physical Functioning (Items 1-5) Score (MEDIAN) Months = 18.8; Time to True Deterioration (TTD) Based on Change From Baseline in the Composite Endpoint of Cough (EORTC QLQ-LC13 Item 31), Chest Pain (EORTC QLQ-LC13 Item 40), or Dyspnea (EORTC QLQ-C30 Item 8) (MEDIAN) Months = 5.78",,,,,,,,Objective Response Rate (ORR) as Assessed by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) (NUMBER) Percentage of Participants = 40.5 [34.9-46.2],Overall Survival (OS) (MEDIAN) Months = 14.1 [11.4-19.0],Progression-free Survival (PFS) as Assessed by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) (MEDIAN) Months = 6.6 [6.1-8.2],,Change From Baseline in European Organization for Research and Treatment (EORTC) Quality of Life Questionnaire-Core30 (QLQ-C30) Combined Global Health Status/Quality of Life (Items 29 & 30) Scale Combined Score (LEAST_SQUARES_MEAN) Score on a scale = -1.48 [-4.09-1.13]; Change From Baseline in Cough (EORTC Quality of Life Questionnaire-Lung Cancer Module 13 [QLQ-LC13] Item 31) Score (LEAST_SQUARES_MEAN) Score on a scale = -9.53 [-12.94--6.13],Objective Response Rate (ORR) as Assessed by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) (NUMBER) Percentage of Participants = 40.5 [34.9-46.2],,,
NCT03831932,Telaglenastat Hydrochloride and Osimertinib in Treating Patients With EGFR-Mutated Stage IV Non-small Cell Lung Cancer,A Phase Ib Study of Osimertinib (AZD9291) and Telaglenastat (CB-839) HCl in Patients With EGFR Mutant Non-Small Cell Lung Cancer,National Cancer Institute (NCI),National Cancer Institute (NCI),NIH,ACTIVE_NOT_RECRUITING,2020-03-16,2024-06-12,2026-03-14,INTERVENTIONAL,PHASE1; PHASE2,,,,Advanced Lung Non-Small Cell Carcinoma,Advanced Lung Non-Small Cell Carcinoma; Metastatic Lung Non-Small Cell Carcinoma; Stage IV Lung Cancer AJCC v8,3,1,7,DRUG; PROCEDURE,,,1,3,True,Yes,Recommended Phase II Dose (RP2D) (NUMBER) milligrams = 800,; ; ,,,,,,,,,,,,,,,,
NCT03836066,Atezolizumab Plus Bevacizumab in First Line NSCLC Patients,A Phase II Open Label Study of Atezolizumab in Combination With Bevacizumab as First Line Treatment for Locally Advanced or Metastasic High-intermediate Tumor Mutation Burden Selected Non-squamous Non,Fundación GECP,Fundación GECP,OTHER,COMPLETED,2019-05-15,2024-10-21,2024-10-21,INTERVENTIONAL,PHASE2,,,,Non Small Cell Lung Cancer,Non Small Cell Lung Cancer,1,1,1,DRUG,,,1,0,True,Yes,Efficacy of Atezolizumab in Combination With Bevacizumab - PFS (MEDIAN) Months = 11.3 [8.1-16.5],,,,,,,,,,,Efficacy of Atezolizumab in Combination With Bevacizumab - PFS (MEDIAN) Months = 11.3 [8.1-16.5],,,,,,
NCT03845296,Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP ,A Phase II Study of Rucaparib in Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP Sub-Study),SWOG Cancer Research Network,SWOG Cancer Research Network,NETWORK,COMPLETED,2019-04-16,2022-01-01,2024-09-21,INTERVENTIONAL,PHASE2,,,,Deleterious BRCA1 Gene Mutation,Deleterious BRCA1 Gene Mutation; Deleterious BRCA2 Gene Mutation; Loss of Heterozygosity,11,1,1,DRUG,,,1,4,True,Yes,Overall Response Rate (NUMBER) Percentage of participants = 8 [0-19],Investigator-Assessed Progression-Free Survival (IA-PFS) (MEDIAN) months = 2.9 [1.6-6.2]; Overall Survival (OS) (MEDIAN) months = 8.2 [4.4-15.3]; ; Number of Participants With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs (NUMBER) Participants = 2,,,,,,,,,Overall Survival (OS) (MEDIAN) months = 8.2 [4.4-15.3],Investigator-Assessed Progression-Free Survival (IA-PFS) (MEDIAN) months = 2.9 [1.6-6.2],,,Overall Response Rate (NUMBER) Percentage of participants = 8 [0-19],Number of Participants With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs (NUMBER) Participants = 2,,
NCT03847519,Study of ADXS-503 With or Without Pembro in Subjects With Metastatic Non-Small Cell Lung Cancer,"A Phase 1/2, Open-Label Study of ADXS-503 Alone and in Combination With Pembrolizumab in Subjects With Metastatic Squamous or Non-Squamous Non-Small Cell Lung Cancer","Advaxis, Inc.","Advaxis, Inc.",INDUSTRY,COMPLETED,2019-02-12,2022-02-22,2022-02-22,INTERVENTIONAL,PHASE1; PHASE2,,,,"Lung Cancer, Non-Small Cell","Lung Cancer, Non-Small Cell; Metastatic Squamous Cell Carcinoma; Metastatic Non-Squamous Cell Carcinoma",3,3,2,DRUG,,,2,2,True,Yes,Safety/Tolerability of ADXS-503 Monotherapy in Part A and ADXS-503 With Pembrolizumab in Part B: Graded Per Comment Terminology Criteria for Adverse Events (CTCAE) Version 4.03 (COUNT_OF_PARTICIPANTS) Participants = 4; Preliminary Anti-tumor Activity of ADXS-503 + Pembrolizumab in Part C as Assessed by the Objective Response Rate (ORR) (COUNT_OF_PARTICIPANTS) Participants = 0,Preliminary Anti-tumor Activity of ADXS-503 Alone in Part A and ADXS-503 With Pembrolizumab in Part B as Assessed by the Objective Response Rate (ORR) (COUNT_OF_PARTICIPANTS) Participants = 0; Safety/Tolerability of ADXS-503 With Pembrolizumab in Part C: Graded Per Comment Terminology Criteria for Adverse Events (CTCAE) Version 4.03 (COUNT_OF_PARTICIPANTS) Participants = 2,,,,,,,,Preliminary Anti-tumor Activity of ADXS-503 + Pembrolizumab in Part C as Assessed by the Objective Response Rate (ORR) (COUNT_OF_PARTICIPANTS) Participants = 0; Preliminary Anti-tumor Activity of ADXS-503 Alone in Part A and ADXS-503 With Pembrolizumab in Part B as Assessed by the Objective Response Rate (ORR) (COUNT_OF_PARTICIPANTS) Participants = 0,,,,,Preliminary Anti-tumor Activity of ADXS-503 + Pembrolizumab in Part C as Assessed by the Objective Response Rate (ORR) (COUNT_OF_PARTICIPANTS) Participants = 0; Preliminary Anti-tumor Activity of ADXS-503 Alone in Part A and ADXS-503 With Pembrolizumab in Part B as Assessed by the Objective Response Rate (ORR) (COUNT_OF_PARTICIPANTS) Participants = 0,Safety/Tolerability of ADXS-503 Monotherapy in Part A and ADXS-503 With Pembrolizumab in Part B: Graded Per Comment Terminology Criteria for Adverse Events (CTCAE) Version 4.03 (COUNT_OF_PARTICIPANTS) Participants = 4; Safety/Tolerability of ADXS-503 With Pembrolizumab in Part C: Graded Per Comment Terminology Criteria for Adverse Events (CTCAE) Version 4.03 (COUNT_OF_PARTICIPANTS) Participants = 2,,
NCT03850444,Study of Pembrolizumab (MK-3475) Versus Platinum-Based Chemotherapy for Participants With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Advanced or ,"A Randomized, Open Label, Phase III Study of Overall Survival Comparing Pembrolizumab (MK-3475) Versus Platinum Based Chemotherapy in Treatment Naïve Subjects With PD-L1 Positive Advanced or Metastati",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,INDUSTRY,COMPLETED,2016-08-01,2018-09-04,2022-09-08,INTERVENTIONAL,PHASE3,,,,Non-small Cell Lung Cancer,Non-small Cell Lung Cancer,1,2,4,BIOLOGICAL; DRUG,,,3,8,True,Yes,Overall Survival (OS) in Participants With a Tumor Proportion Score (TPS) of ≥50% (MEDIAN) Months = 20.0; Overall Survival (OS) in Participants With a Tumor Proportion Score (TPS) of ≥20% (MEDIAN) Months = 20.0; Overall Survival (OS) in Participants With a Tumor Proportion Score (TPS) of ≥1% (MEDIAN) Months = 20.0,Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR) in Participants With a Tumor Proportion Score (TPS) of ≥50% (MEDIAN) Months = 8.3 [4.2-10.6]; Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR) in Participants With a Tumor Proportion Score (TPS) of ≥20% (MEDIAN) Months = 6.3 [4.2-8.4]; Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR) in Participants With a Tumor Proportion Score (TPS) of ≥1% (MEDIAN) Months = 6.3 [4.2-8.3]; Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR) in Participants With a Tumor Proportion Score (TPS) of ≥50% (NUMBER) Percentage of participants = 41.7 [30.2-53.9]; Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR) in Participants With a Tumor Proportion Score (TPS) of ≥20% (NUMBER) Percentage of participants = 35.6 [26.4-45.8]; Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR) in Participants With a Tumor Proportion Score (TPS) of ≥1% (NUMBER) Percentage of participants = 32.8 [24.8-41.7]; Number of Participants Who Experienced At Least One Adverse Event (AE) (COUNT_OF_PARTICIPANTS) Participants = 126; Number of Participants Who Discontinued Study Treatment Due to an Adverse Event (AE) (COUNT_OF_PARTICIPANTS) Participants = 26,,,,,,,,Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR) in Participants With a Tumor Proportion Score (TPS) of ≥50% (NUMBER) Percentage of participants = 41.7 [30.2-53.9]; Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR) in Participants With a Tumor Proportion Score (TPS) of ≥20% (NUMBER) Percentage of participants = 35.6 [26.4-45.8]; Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR) in Participants With a Tumor Proportion Score (TPS) of ≥1% (NUMBER) Percentage of participants = 32.8 [24.8-41.7],Overall Survival (OS) in Participants With a Tumor Proportion Score (TPS) of ≥50% (MEDIAN) Months = 20.0; Overall Survival (OS) in Participants With a Tumor Proportion Score (TPS) of ≥20% (MEDIAN) Months = 20.0; Overall Survival (OS) in Participants With a Tumor Proportion Score (TPS) of ≥1% (MEDIAN) Months = 20.0,Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR) in Participants With a Tumor Proportion Score (TPS) of ≥50% (MEDIAN) Months = 8.3 [4.2-10.6]; Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR) in Participants With a Tumor Proportion Score (TPS) of ≥20% (MEDIAN) Months = 6.3 [4.2-8.4]; Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR) in Participants With a Tumor Proportion Score (TPS) of ≥1% (MEDIAN) Months = 6.3 [4.2-8.3],,,Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR) in Participants With a Tumor Proportion Score (TPS) of ≥50% (NUMBER) Percentage of participants = 41.7 [30.2-53.9]; Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR) in Participants With a Tumor Proportion Score (TPS) of ≥20% (NUMBER) Percentage of participants = 35.6 [26.4-45.8]; Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR) in Participants With a Tumor Proportion Score (TPS) of ≥1% (NUMBER) Percentage of participants = 32.8 [24.8-41.7],,,
NCT03875092,A Study of Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With First Line Metastatic Squamous No,"A Randomized, Double-Blind, Phase III Study of Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy With or Without Pembrolizumab (MK-3475) in First Line Metastatic Squamous Non-small Cell Lung Cancer S",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,INDUSTRY,COMPLETED,2017-04-21,2020-09-30,2023-09-14,INTERVENTIONAL,PHASE3,,,,Non-small Cell Lung Cancer,Non-small Cell Lung Cancer,1,2,4,BIOLOGICAL; DRUG,,,2,4,True,Yes,Progression-free Survival (PFS) as Assessed by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) (MEDIAN) Months = 8.3 [6.2-10.5]; Overall Survival (OS) (MEDIAN) Months = 30.1,Objective Response Rate (ORR) as Assessed by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) (NUMBER) Percentage of Participants = 80.0 [68.2-88.9]; Duration of Response (DOR) as Assessed by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) (MEDIAN) Months = 7.1 [4.9-14.4]; Number of Participants Who Experienced an Adverse Event (AE) (COUNT_OF_PARTICIPANTS) Participants = 65; Number of Participants Who Discontinued Study Treatment Due to an Adverse Event (AE) (COUNT_OF_PARTICIPANTS) Participants = 8,,,,,Duration of Response (DOR) as Assessed by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) (MEDIAN) Months = 7.1 [4.9-14.4],,,Objective Response Rate (ORR) as Assessed by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) (NUMBER) Percentage of Participants = 80.0 [68.2-88.9],Overall Survival (OS) (MEDIAN) Months = 30.1,Progression-free Survival (PFS) as Assessed by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) (MEDIAN) Months = 8.3 [6.2-10.5],,,Objective Response Rate (ORR) as Assessed by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) (NUMBER) Percentage of Participants = 80.0 [68.2-88.9],,,
NCT03906071,Phase 3 Study of Sitravatinib Plus Nivolumab vs Docetaxel in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer,A Randomized Phase 3 Study of Sitravatinib in Combination With Nivolumab Versus Docetaxel in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer With Disease Progression On or After Platinu,Mirati Therapeutics Inc.,Mirati Therapeutics Inc.,INDUSTRY,COMPLETED,2019-07-15,2023-03-20,2025-09-30,INTERVENTIONAL,PHASE3,,,,Metastatic Non-Squamous Non-Small Cell Lung Cancer,Metastatic Non-Squamous Non-Small Cell Lung Cancer,1,2,3,BIOLOGICAL; DRUG,,,1,13,True,Yes,Overall Survival (OS) (MEDIAN) Months = 12.22 [10.41-13.93],Number of Participants With Treatment-Emergent Adverse Event (TEAEs) (COUNT_OF_PARTICIPANTS) Participants = 280; Number of Participants With Treatment-Emergent Adverse Events (TEAE) Leading to Study Drug Discontinuation (COUNT_OF_PARTICIPANTS) Participants = 77; Number of Participants With Maximum Post Baseline Hematology Grade Results (COUNT_OF_PARTICIPANTS) Participants = 118; Number of Participants With Maximum Post Baseline Chemistry Grade Results (COUNT_OF_PARTICIPANTS) Participants = 106; Objective Response Rate (ORR) Per Central Radiographic Assessment (NUMBER) Percentage of participants = 15.6 [11.57-20.37]; Duration of Response (DOR) Per Central Radiographic Assessment (MEDIAN) Months = 7.43 [5.36-13.08]; Clinical Benefit Rate Per Central Radiographic Assessment (NUMBER) Percentage of participants = 75.5 [70.08-80.43]; Progression-Free Survival (PFS) Per Central Radiographic Assessment (MEDIAN) Months = 4.40 [3.91-5.42]; 1-Year Survival Rate (NUMBER) Percentage of participants = 50.18 [44.05-55.99]; Change From Baseline in the Lung Cancer Symptom Scale (LCSS) Average Total Score (LEAST_SQUARES_MEAN) Score on a scale = 4.10 [1.87-6.33]; Change From Baseline in the European Quality of Life Five Dimensions Questionnaire (EQ-5D-5L) - Health Utility Index (HUI) (LEAST_SQUARES_MEAN) Score on a scale = -0.09 [-0.12--0.06]; Change From Baseline in the European Quality of Life Five Dimensions Questionnaire (EQ-5D-5L) - Visual Analogue Score (VAS) (LEAST_SQUARES_MEAN) Change in score on a scale = -4.74 [-7.21--2.27]; Sitravatinib Plasma Concentration by Time Point (MEAN) ng/mL = 2.73201,Clinical Benefit Rate Per Central Radiographic Assessment (NUMBER) Percentage of participants = 75.5 [70.08-80.43],,,,Duration of Response (DOR) Per Central Radiographic Assessment (MEDIAN) Months = 7.43 [5.36-13.08],,,Objective Response Rate (ORR) Per Central Radiographic Assessment (NUMBER) Percentage of participants = 15.6 [11.57-20.37],Overall Survival (OS) (MEDIAN) Months = 12.22 [10.41-13.93],Progression-Free Survival (PFS) Per Central Radiographic Assessment (MEDIAN) Months = 4.40 [3.91-5.42],,Change From Baseline in the European Quality of Life Five Dimensions Questionnaire (EQ-5D-5L) - Health Utility Index (HUI) (LEAST_SQUARES_MEAN) Score on a scale = -0.09 [-0.12--0.06]; Change From Baseline in the European Quality of Life Five Dimensions Questionnaire (EQ-5D-5L) - Visual Analogue Score (VAS) (LEAST_SQUARES_MEAN) Change in score on a scale = -4.74 [-7.21--2.27],Objective Response Rate (ORR) Per Central Radiographic Assessment (NUMBER) Percentage of participants = 15.6 [11.57-20.37],Number of Participants With Treatment-Emergent Adverse Events (TEAE) Leading to Study Drug Discontinuation (COUNT_OF_PARTICIPANTS) Participants = 77,,
NCT03915951,An Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600-mutant Non-small Cell Lung Cancer,"A Phase 2, Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600-mutant Non-small Cell Lung Cancer",Pfizer,Pfizer,INDUSTRY,COMPLETED,2019-06-04,2022-09-22,2025-10-03,INTERVENTIONAL,PHASE2,,,,Non-small Cell Lung Cancer,Non-small Cell Lung Cancer,1,1,2,DRUG,,,1,12,True,Yes,Percentage of Participants With Confirmed Objective Response (OR) as Determined by Independent Radiology Review (IRR) (NUMBER) Percentage of Participants = 74.6 [61.6-85.0],Percentage of Participants With Confirmed Objective Response (OR) by Investigator Assessment (NUMBER) Percentage of Participants = 62.7 [49.1-75.0]; ; Disease Control Rate (DCR) by IRR and Investigator Assessments (NUMBER) Percentage of Participants = 64.4 [50.9-76.4]; ; Time to Response (TTR) by IRR and Investigator Assessments (MEDIAN) Months = 1.86 [1.1-19.1]; ; Number of Participants With Treatment-Emergent Adverse Events (TEAEs) (COUNT_OF_PARTICIPANTS) Participants = 59; Number of Participants With Shifts From Grade ≤2 at Baseline to Grade 3 or 4 at Post-baseline in Hematology Laboratory Test Values Based on CTCAE Grade (COUNT_OF_PARTICIPANTS) Participants = 9; Number of Participants With Shifts From Grade ≤2 at Baseline to Grade 3 or 4 at Post-baseline in Chemistry Laboratory Test Values Based on CTCAE Grade (COUNT_OF_PARTICIPANTS) Participants = 6; Number of Participants With Notable Abnormal Vital Signs (COUNT_OF_PARTICIPANTS) Participants = 10; Number of Participants With Notable ECG (QTcF) Values (COUNT_OF_PARTICIPANTS) Participants = 12; Number of Participants With the Worst Post-baseline Left Ventricular Ejection Fraction (LVEF) Values Based on CTCAE Grade (COUNT_OF_PARTICIPANTS) Participants = 45,,,,,,,,,,,,,,Number of Participants With Treatment-Emergent Adverse Events (TEAEs) (COUNT_OF_PARTICIPANTS) Participants = 59,,
NCT03940703,A Study of Tepotinib Plus Osimertinib in Osimertinib Relapsed MET Amplified NSCLC (INSIGHT 2),"A Phase II, Two-arm Study to Investigate Tepotinib Combined With Osimertinib in MET Amplified, Advanced or Metastatic NSCLC Harboring Activating EGFR Mutations and Having Acquired Resistance to Prior ",EMD Serono,"EMD Serono Research & Development Institute, Inc.",INDUSTRY,ACTIVE_NOT_RECRUITING,2019-09-19,2023-05-11,2026-05-01,INTERVENTIONAL,PHASE2,,,,Non-small Cell Lung Cancer,Non-small Cell Lung Cancer,1,2,2,DRUG,,,2,45,True,Yes,Combined Therapy (Tepotinib+Osimertinib): Number of Participants Experiencing Dose-Limiting Toxicities (DLTs) According to National Cancer Institute Common Terminology Criteria for Adverse Events Version (NCI-CTCAE v 5.0) (COUNT_OF_PARTICIPANTS) Participants = 1; Combined Therapy: Objective Response According to Response Evaluation Criteria in Solid Tumors(RECIST)Version1.1as Per Independent Review Committee in Participants With MET Amplification Determined Centrally by Fluorescence in Situ Hybridization(FISH) (NUMBER) percentage of participants = 50.0 [39.7-60.3],"Combined Therapy: Objective Response According to Response Evaluation Criteria in Solid Tumors(RECIST)Version1.1as Per Independent Review Committee in Participants With MET Amplification Determined Centrally by Blood-Based Next Generation Sequencing (NUMBER) percentage of participants = 54.8 [36.0-72.7]; Monotherapy (Tepotinib): Objective Response According to Response Evaluation Criteria in Solid Tumors(RECIST)Version1.1 as Per Independent Review Committee in Participants With MET Amplification Determined Centrally by FISH (NUMBER) percentage of participants = 8.3 [0.2-38.5]; Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment-Related TEAEs (COUNT_OF_PARTICIPANTS) Participants = 126; Number of Participants With Clinically Significant Abnormalities in Laboratory Values Reported as Treatment Related TEAEs (COUNT_OF_PARTICIPANTS) Participants = 2; Number of Participants With Markedly Abnormal Vital Sign Measurements (COUNT_OF_PARTICIPANTS) Participants = 2; Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance: Baseline Score Versus (Vs) Worst Post-baseline Score (COUNT_OF_PARTICIPANTS) Participants = 14; Number of Participants With Clinically Significant Abnormalities in Electrocardiogram (ECG) Findings (COUNT_OF_PARTICIPANTS) Participants = 21; Combined Therapy: Objective Response According to Response Evaluation Criteria in Solid Tumors(RECIST)Version1.1 Assessed by Investigator in Participants With MET Amplification Determined Centrally by FISH (NUMBER) percentage of participants = 44.9 [34.8-55.3]; Combined Therapy (Tepotinib + Osimertinib): Number of Participants With Confirmed Complete Response (CR) Assessed by Independent Review Committee in Participants With MET Amplification Determined Centrally by FISH (COUNT_OF_PARTICIPANTS) Participants = 0; Combined Therapy (Tepotinib + Osimertinib): Number of Participants With Confirmed Complete Response (CR) Assessed by Investigator in Participants With MET Amplification Determined Centrally by FISH (COUNT_OF_PARTICIPANTS) Participants = 1; Combined Therapy (Tepotinib + Osimertinib): Duration of Response Assessed by Independent Review Committee in Participants With MET Amplification Determined Centrally by FISH (MEDIAN) months = 8.5; Combined Therapy (Tepotinib + Osimertinib): Duration of Response Assessed by Investigator in Participants With MET Amplification Determined Centrally by FISH (MEDIAN) months = 9.6; Combined Therapy (Tepotinib + Osimertinib): Disease Control Rate Assessed by Independent Review Committee in Participants With MET Amplification Determined Centrally by FISH (NUMBER) percentage of participants = 63.3 [52.9-72.8]; Combined Therapy (Tepotinib + Osimertinib): Disease Control Rate Assessed by Investigator in Participants With MET Amplification Determined Centrally by FISH (NUMBER) percentage of participants = 64.3 [54.0-73.7]; Combined Therapy (Tepotinib + Osimertinib): Progression-Free Survival (PFS) According to RECIST Version1.1 as Assessed by the Independent Review Committee in Participants With MET Amplification Determined Centrally by FISH (MEDIAN) months = 5.6 [4.2-8.1]; Combined Therapy (Tepotinib + Osimertinib): Progression-Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors(RECIST)Version1.1as Assessed by the Investigator in Participants With MET Amplification Determined Centrally by FISH (MEDIAN) months = 5.9 [4.2-8.5]; Combined Therapy (Tepotinib + Osimertinib): Overall Survival in Participants With MET Amplification Determined Centrally by FISH (MEDIAN) months = 17.8; Combined Therapy: Objective Response According to Response Evaluation Criteria in Solid Tumors(RECIST)Version1.1as Assessed by Investigator in Participants With MET Amplification Determined Centrally by Blood-Based Next Generation Sequencing (NUMBER) percentage of participants = 48.4 [30.2-66.9]; Combined Therapy (Tepotinib + Osimertinib): Number of Participants With Confirmed Complete Response (CR) Assessed by Independent Review Committee in Participants With MET Amplification Determined Centrally by Blood-Based Next Generation Sequencing (COUNT_OF_PARTICIPANTS) Participants = 0; Combined Therapy (Tepotinib + Osimertinib): Number of Participants With Confirmed Complete Response (CR) Assessed by Investigator in Participants With MET Amplification Determined Centrally by Blood-Based Next Generation Sequencing (COUNT_OF_PARTICIPANTS) Participants = 0; Combined Therapy (Tepotinib + Osimertinib): Duration of Response Assessed by Independent Review Committee in Participants With MET Amplification Determined Centrally by Blood-Based Next Generation Sequencing (MEDIAN) months = 5.7 [2.9-15.4]; Combined Therapy (Tepotinib + Osimertinib): Duration of Response Assessed by Investigator in Participants With MET Amplification Determined Centrally by Blood-Based Next Generation Sequencing (MEDIAN) months = 5.6 [2.9-9.6]; Combined Therapy (Tepotinib + Osimertinib): Disease Control Rate Assessed by Independent Review Committee in Participants With MET Amplification Determined Centrally by Blood-Based Next Generation Sequencing (NUMBER) percentage of participants = 64.5 [45.4-80.8]; Combined Therapy (Tepotinib + Osimertinib): Disease Control Rate Assessed by Investigator in Participants With MET Amplification Determined Centrally by Blood-Based Next Generation Sequencing (NUMBER) percentage of participants = 67.7 [48.6-83.3]; Combined Therapy (Tepotinib + Osimertinib): Progression-Free Survival (PFS) According to RECIST Version1.1 as Per Independent Review Committee in Participants With MET Amplification Determined Centrally by Blood-Based Next Generation Sequencing (MEDIAN) months = 5.5 [2.7-7.2]; Combined Therapy ((Tepotinib + Osimertinib): Progression-Free Survival (PFS) According to RECIST Version1.1 as Assessed by the Investigator in Participants With MET Amplification Determined Centrally by Blood-Based Next Generation Sequencing (MEDIAN) months = 5.6 [4.2-7.0]; Combined Therapy (Tepotinib + Osimertinib): Overall Survival in Participants With MET Amplification Determined Centrally by Blood-Based Next Generation Sequencing (MEDIAN) months = 13.7; Monotherapy (Tepotinib): Objective Response According to Response Evaluation Criteria in Solid Tumors(RECIST)Version1.1as Per Investigator in Participants With MET Amplification Determined Centrally by Fluorescence in Situ Hybridization(FISH) (NUMBER) percentage of participants = 8.3 [0.2-38.5]; Monotherapy (Tepotinib): Number of Participants With Confirmed Complete Response (CR) Assessed by Independent Review Committee in Participants With MET Amplification Determined Centrally by FISH (COUNT_OF_PARTICIPANTS) Participants = 0; Monotherapy (Tepotinib): Number of Participants With Confirmed Complete Response (CR) Assessed by Investigator in Participants With MET Amplification Determined Centrally by FISH (COUNT_OF_PARTICIPANTS) Participants = 0; Monotherapy (Tepotinib): Duration of Response Assessed by Independent Review Committee in Participants With MET Amplification Determined Centrally by FISH (MEDIAN) months = 2.8; Monotherapy (Tepotinib): Duration of Response Assessed by Investigator in Participants With MET Amplification Determined Centrally by FISH (MEDIAN) months = 2.8; Monotherapy (Tepotinib): Disease Control Rate Assessed by Independent Review Committee in Participants With MET Amplification Determined Centrally by FISH (NUMBER) percentage of participants = 25.0 [5.5-57.2]; Monotherapy (Tepotinib): Disease Control Rate Assessed by Investigator in Participants With MET Amplification Determined Centrally by FISH (NUMBER) percentage of participants = 25.0 [5.5-57.2]; Monotherapy (Tepotinib): Progression-Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors(RECIST)Version1.1as Assessed by the Independent Review Committee in Participants With MET Amplification Determined Centrally by FISH (MEDIAN) months = 2.7 [1.4-4.4]; Monotherapy (Tepotinib): Progression-Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors(RECIST)Version1.1as Assessed by the Investigator in Participants With MET Amplification Determined Centrally by FISH (MEDIAN) months = 2.6 [1.4-4.4]; Combined Therapy (Tepotinib + Osimertinib): Change From Baseline in European Quality Of Life 5-dimensions (EQ-5D-5L) Visual Analog Scale (VAS) at Safety Follow-up (42 Months) (MEAN) score on a scale = -11; Combined Therapy (Tepotinib + Osimertinib): Change From Baseline in European Organization for the Research and Treatment of Cancer Quality of Life (EORTC QLQ-C30) Global Health Status) at Safety Follow-up (42 Months) (MEAN) score on a scale = -6.5; Combined Therapy (Tepotinib + Osimertinib): Change From Baseline in Health-Related Quality of Life as Assessed by Non-Small Cell Lung Cancer Symptom Assessment Questionnaire (NSCLC-SAQ) at Safety Follow-up (42 Months) (MEAN) score on a scale = 2.0; Combined Therapy (Tepotinib + Osimertinib): Area Under the Plasma Concentration-Time Curve From Time Zero to the Last Sampling Time (AUC0-t) of Tepotinib and Its Metabolites (MSC2571109A, MSC2571107A), Osimertinib and Its Metabolite AZD5104 (GEOMETRIC_MEAN) nanogram*hour per milliliter (ng*h/mL) = 11600; Combined Therapy (Tepotinib + Osimertinib): Maximum Observed Plasma Concentration (Cmax) of Tepotinib and Its Metabolites (MSC2571109A, MSC2571107A), Osimertinib and Its Metabolite AZD5104 (GEOMETRIC_MEAN) nanogram per milliliter (ng/mL) = 660; Combined Therapy (Tepotinib + Osimertinib): Time to Reach Maximum Observed Plasma Concentration (Tmax) of Tepotinib and Its Metabolites (MSC2571109A, MSC2571107A), Osimertinib and Its Metabolite AZD5104 (MEDIAN) hours = 23.97 [6.00-24.00]; ; ; ",,Combined Therapy (Tepotinib + Osimertinib): Number of Participants With Confirmed Complete Response (CR) Assessed by Independent Review Committee in Participants With MET Amplification Determined Centrally by FISH (COUNT_OF_PARTICIPANTS) Participants = 0; Combined Therapy (Tepotinib + Osimertinib): Number of Participants With Confirmed Complete Response (CR) Assessed by Investigator in Participants With MET Amplification Determined Centrally by FISH (COUNT_OF_PARTICIPANTS) Participants = 1; Combined Therapy (Tepotinib + Osimertinib): Number of Participants With Confirmed Complete Response (CR) Assessed by Independent Review Committee in Participants With MET Amplification Determined Centrally by Blood-Based Next Generation Sequencing (COUNT_OF_PARTICIPANTS) Participants = 0; Combined Therapy (Tepotinib + Osimertinib): Number of Participants With Confirmed Complete Response (CR) Assessed by Investigator in Participants With MET Amplification Determined Centrally by Blood-Based Next Generation Sequencing (COUNT_OF_PARTICIPANTS) Participants = 0; Monotherapy (Tepotinib): Number of Participants With Confirmed Complete Response (CR) Assessed by Independent Review Committee in Participants With MET Amplification Determined Centrally by FISH (COUNT_OF_PARTICIPANTS) Participants = 0; Monotherapy (Tepotinib): Number of Participants With Confirmed Complete Response (CR) Assessed by Investigator in Participants With MET Amplification Determined Centrally by FISH (COUNT_OF_PARTICIPANTS) Participants = 0,,,Combined Therapy (Tepotinib + Osimertinib): Duration of Response Assessed by Independent Review Committee in Participants With MET Amplification Determined Centrally by FISH (MEDIAN) months = 8.5; Combined Therapy (Tepotinib + Osimertinib): Duration of Response Assessed by Investigator in Participants With MET Amplification Determined Centrally by FISH (MEDIAN) months = 9.6; Combined Therapy (Tepotinib + Osimertinib): Duration of Response Assessed by Independent Review Committee in Participants With MET Amplification Determined Centrally by Blood-Based Next Generation Sequencing (MEDIAN) months = 5.7 [2.9-15.4]; Combined Therapy (Tepotinib + Osimertinib): Duration of Response Assessed by Investigator in Participants With MET Amplification Determined Centrally by Blood-Based Next Generation Sequencing (MEDIAN) months = 5.6 [2.9-9.6]; Monotherapy (Tepotinib): Duration of Response Assessed by Independent Review Committee in Participants With MET Amplification Determined Centrally by FISH (MEDIAN) months = 2.8; Monotherapy (Tepotinib): Duration of Response Assessed by Investigator in Participants With MET Amplification Determined Centrally by FISH (MEDIAN) months = 2.8,,,,Combined Therapy (Tepotinib + Osimertinib): Overall Survival in Participants With MET Amplification Determined Centrally by FISH (MEDIAN) months = 17.8; Combined Therapy (Tepotinib + Osimertinib): Overall Survival in Participants With MET Amplification Determined Centrally by Blood-Based Next Generation Sequencing (MEDIAN) months = 13.7,Combined Therapy (Tepotinib + Osimertinib): Progression-Free Survival (PFS) According to RECIST Version1.1 as Assessed by the Independent Review Committee in Participants With MET Amplification Determined Centrally by FISH (MEDIAN) months = 5.6 [4.2-8.1]; Combined Therapy (Tepotinib + Osimertinib): Progression-Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors(RECIST)Version1.1as Assessed by the Investigator in Participants With MET Amplification Determined Centrally by FISH (MEDIAN) months = 5.9 [4.2-8.5]; Combined Therapy (Tepotinib + Osimertinib): Progression-Free Survival (PFS) According to RECIST Version1.1 as Per Independent Review Committee in Participants With MET Amplification Determined Centrally by Blood-Based Next Generation Sequencing (MEDIAN) months = 5.5 [2.7-7.2]; Combined Therapy ((Tepotinib + Osimertinib): Progression-Free Survival (PFS) According to RECIST Version1.1 as Assessed by the Investigator in Participants With MET Amplification Determined Centrally by Blood-Based Next Generation Sequencing (MEDIAN) months = 5.6 [4.2-7.0]; Monotherapy (Tepotinib): Progression-Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors(RECIST)Version1.1as Assessed by the Independent Review Committee in Participants With MET Amplification Determined Centrally by FISH (MEDIAN) months = 2.7 [1.4-4.4]; Monotherapy (Tepotinib): Progression-Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors(RECIST)Version1.1as Assessed by the Investigator in Participants With MET Amplification Determined Centrally by FISH (MEDIAN) months = 2.6 [1.4-4.4],,Combined Therapy (Tepotinib + Osimertinib): Change From Baseline in European Quality Of Life 5-dimensions (EQ-5D-5L) Visual Analog Scale (VAS) at Safety Follow-up (42 Months) (MEAN) score on a scale = -11; Combined Therapy (Tepotinib + Osimertinib): Change From Baseline in European Organization for the Research and Treatment of Cancer Quality of Life (EORTC QLQ-C30) Global Health Status) at Safety Follow-up (42 Months) (MEAN) score on a scale = -6.5; Combined Therapy (Tepotinib + Osimertinib): Change From Baseline in Health-Related Quality of Life as Assessed by Non-Small Cell Lung Cancer Symptom Assessment Questionnaire (NSCLC-SAQ) at Safety Follow-up (42 Months) (MEAN) score on a scale = 2.0,,Combined Therapy (Tepotinib+Osimertinib): Number of Participants Experiencing Dose-Limiting Toxicities (DLTs) According to National Cancer Institute Common Terminology Criteria for Adverse Events Version (NCI-CTCAE v 5.0) (COUNT_OF_PARTICIPANTS) Participants = 1; Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment-Related TEAEs (COUNT_OF_PARTICIPANTS) Participants = 126,,
NCT03950674,Study of Pemetrexed+Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Participants With First Line Metastatic Nonsquamous Non-small Cel,"A Randomized, Double-Blind, Phase III Study of Platinum+Pemetrexed Chemotherapy With or Without Pembrolizumab (MK-3475) in First Line Metastatic Non-squamous Non-small Cell Lung Cancer Subjects (KEYNO",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,INDUSTRY,COMPLETED,2016-02-22,2019-05-20,2023-06-22,INTERVENTIONAL,PHASE3,,,,Non-Small-Cell Lung Carcinoma,Non-Small-Cell Lung Carcinoma,1,2,8,BIOLOGICAL; DIETARY_SUPPLEMENT; DRUG,,,2,4,True,Yes,Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as Assessed by Blinded Central Imaging (MEDIAN) Months = 16.5 [8.8-21.1]; ,Overall Response Rate (ORR) Per RECIST 1.1 as Assessed by Blinded Central Imaging (NUMBER) Percentage of Participants = 56.0 [34.9-75.6]; Duration of Response (DOR) Per RECIST 1.1 as Assessed by Blinded Central Imaging (MEDIAN) Months = 13.6 [5.9-19.6]; Number of Participants Who Experienced an Adverse Event (AE) (COUNT_OF_PARTICIPANTS) Participants = 25; Number of Participants Who Discontinued Any Study Drug Due to an AE (COUNT_OF_PARTICIPANTS) Participants = 9,,,,,Duration of Response (DOR) Per RECIST 1.1 as Assessed by Blinded Central Imaging (MEDIAN) Months = 13.6 [5.9-19.6],,,,,Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as Assessed by Blinded Central Imaging (MEDIAN) Months = 16.5 [8.8-21.1],,,Overall Response Rate (ORR) Per RECIST 1.1 as Assessed by Blinded Central Imaging (NUMBER) Percentage of Participants = 56.0 [34.9-75.6],Number of Participants Who Discontinued Any Study Drug Due to an AE (COUNT_OF_PARTICIPANTS) Participants = 9,,
NCT03965689,"Testing the Combination of MLN4924 (Pevonedistat), Carboplatin, and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Who Have P",A Phase 2 Study of MLN4924 (Pevonedistat) in Combination With Carboplatin and Paclitaxel in Advanced NSCLC Previously Treated With Immunotherapy,National Cancer Institute (NCI),National Cancer Institute (NCI),NIH,ACTIVE_NOT_RECRUITING,2020-04-16,2022-09-07,2026-03-18,INTERVENTIONAL,PHASE2,,,,Metastatic Lung Non-Small Cell Squamous Carcinoma,Metastatic Lung Non-Small Cell Squamous Carcinoma; Metastatic Lung Non-Squamous Non-Small Cell Carcinoma; Stage IIIB Lung Cancer AJCC v8,8,1,3,DRUG,,,1,3,True,Yes,Number of Participants With an Overall Response (COUNT_OF_PARTICIPANTS) Participants = 0,"Duration of Progression Free Survival (PFS) (MEDIAN) months = 3.68 [0.46-19.67]; Overall Survival (OS) (MEDIAN) months = 7.73 [0.79-21.71]; Number of Participants Reporting Grade 3, 4, and 5 Adverse Events (COUNT_OF_PARTICIPANTS) Participants = 21",,,,,,,,,Overall Survival (OS) (MEDIAN) months = 7.73 [0.79-21.71],Duration of Progression Free Survival (PFS) (MEDIAN) months = 3.68 [0.46-19.67],,,,"Number of Participants Reporting Grade 3, 4, and 5 Adverse Events (COUNT_OF_PARTICIPANTS) Participants = 21",,
NCT03971474,Ramucirumab and Pembrolizumab Versus Standard of Care in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Non-Match,A Phase II Randomized Study of Ramucirumab Plus MK3475 (Pembrolizumab) Versus Standard of Care for Patients Previously Treated With Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer (,SWOG Cancer Research Network,SWOG Cancer Research Network,NETWORK,COMPLETED,2019-05-28,2022-04-14,2024-01-01,INTERVENTIONAL,PHASE2,,,,Recurrent Lung Non-Small Cell Carcinoma,Recurrent Lung Non-Small Cell Carcinoma; Stage IV Lung Cancer AJCC v8; Stage IVA Lung Cancer AJCC v8,4,2,7,BIOLOGICAL; DRUG,,,1,7,True,Yes,Overall Survival (OS) (MEDIAN) months = 11.6 [9.9-13.0],"Response Rate (RR) (NUMBER) Percentage of participants = 28 [19-37]; Disease Control Rate (DCR) (NUMBER) Percentage of participants = 73 [64-82]; Duration of Response (DOR) (MEDIAN) months = 5.6 [4.6-7.8]; Number of Participants With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs (NUMBER) Participants = 1; Investigator Assessed-progression-free Survival (IA-PFS) (MEDIAN) months = 5.2 [4.2-5.7]; Overall Survival (OS), Subgroup Analysis by Stratification Factors (NUMBER) Participants = 21; Investigator-Assessed Progression-Free Survival (IA-PFS), Subgroup Analysis by Stratification Factors (NUMBER) Participants = 34",,,,,Duration of Response (DOR) (MEDIAN) months = 5.6 [4.6-7.8],,,,"Overall Survival (OS) (MEDIAN) months = 11.6 [9.9-13.0]; Overall Survival (OS), Subgroup Analysis by Stratification Factors (NUMBER) Participants = 21","Investigator Assessed-progression-free Survival (IA-PFS) (MEDIAN) months = 5.2 [4.2-5.7]; Investigator-Assessed Progression-Free Survival (IA-PFS), Subgroup Analysis by Stratification Factors (NUMBER) Participants = 34",,,Response Rate (RR) (NUMBER) Percentage of participants = 28 [19-37],Number of Participants With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs (NUMBER) Participants = 1,,
NCT03974022,"Assessing an Oral EGFR Inhibitor, Sunvozertinib in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR or HER2 Mutation (WU-KONG1)","A Phase I/II, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics and Anti-tumor Efficacy of DZD9008 in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) With EG",Dizal Pharmaceuticals,Dizal Pharmaceuticals,INDUSTRY,ACTIVE_NOT_RECRUITING,2019-07-09,2024-07-29,2025-12,INTERVENTIONAL,PHASE1; PHASE2,,,,Non-Small Cell Lung Cancer,Non-Small Cell Lung Cancer,1,9,1,DRUG,,,2,16,True,Yes,Part A Dose Escalation: Dose Limiting Toxicities (DLTs). (COUNT_OF_PARTICIPANTS) Participants = 0; Part B: Objective Response Rate (ORR) According to RECIST 1.1 by an Independent Review Committee (IRC). (NUMBER) percentage of participants = 45.9 [33.6-58.5],"Part B: DCR According to RECIST 1.1 Using Assessments Performed by an IRC; DCR Using Investigators Assessments According to RECIST 1.1 (NUMBER) percentage of participants = 89.4 [80.8-95.0]; ; Part B: AEs/SAEs (NUMBER) participants = 91; Part A: Confirmed ORR and DCR by Investigator. (NUMBER) percentage of participants = 0 [0.0-70.8]; ; Part A: Confirmed ORR and DCR by Independent Review Committee (IRC). (NUMBER) percentage of participants = 62.1 [42.3-79.3]; Part A Dose Escalation and Expansion: Maximum Plasma Concentration (Cmax) of DZD9008 (GEOMETRIC_MEAN) ng/mL = 38.95; Part A Dose Escalation and Expansion: Area Under the Plasma Concentration-time Curve From Zero to the Last Measurable Concentration (AUC0-t) of DZD9008 (GEOMETRIC_MEAN) h*ng/mL = 1434; Part A Dose Escalation and Expansion: Cmax,ss, at Steady State of DZD9008 (GEOMETRIC_MEAN) ng/mL = 82.85; Part A Dose Escalation and Expansion: AUCss, at Steady State of DZD9008 (GEOMETRIC_MEAN) h*ng/mL = 1506; Part A Food Effect: Maximum Plasma Concentration (Cmax) of DZD9008 (GEOMETRIC_MEAN) ng/mL = 307.0; Part A Food Effect: Area Under the Plasma Concentration-time Curve From Zero to the Last Measurable Concentration (AUC0-t) of DZD9008 (GEOMETRIC_MEAN) h*ng/mL = 8266; Part B: Maximum Plasma Concentration (Cmax) of DZD9008 and DZ0753 (GEOMETRIC_MEAN) ng/mL = 173.4; Part B: Area Under the Plasma Concentration-time Curve From Zero to the Last Measurable Concentration (AUC0-t) of DZD9008 and DZ0753. (GEOMETRIC_MEAN) h*ng/mL = 2423; Part B: Cmax,ss, at Steady State of DZD9008 and DZ0753 (GEOMETRIC_MEAN) ng/mL = 342.8; Part B: AUCss, at Steady State of DZD9008 and DZ0753. (GEOMETRIC_MEAN) h*ng/mL = 6286",,,,,,,,Part B: Objective Response Rate (ORR) According to RECIST 1.1 by an Independent Review Committee (IRC). (NUMBER) percentage of participants = 45.9 [33.6-58.5]; Part A: Confirmed ORR and DCR by Investigator. (NUMBER) percentage of participants = 0 [0.0-70.8]; Part A: Confirmed ORR and DCR by Independent Review Committee (IRC). (NUMBER) percentage of participants = 62.1 [42.3-79.3],,,,,Part B: Objective Response Rate (ORR) According to RECIST 1.1 by an Independent Review Committee (IRC). (NUMBER) percentage of participants = 45.9 [33.6-58.5],Part B: AEs/SAEs (NUMBER) participants = 91,,
NCT03976375,Efficacy and Safety of Pembrolizumab (MK-3475) With Lenvatinib (E7080/MK-7902) vs. Docetaxel in Participants With Metastatic Non-Small Cell Lung Cance,"A Phase 3, Multicenter, Randomized, Open-label Trial to Compare the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Lenvatinib (E7080/MK-7902) Versus Docetaxel in Previously Treated",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,INDUSTRY,COMPLETED,2019-06-26,2023-08-11,2024-08-22,INTERVENTIONAL,PHASE3,,,,Metastatic Non-Small Cell Lung Cancer,Metastatic Non-Small Cell Lung Cancer,1,3,3,BIOLOGICAL; DRUG,,,2,16,True,Yes,Overall Survival (OS) (MEDIAN) Months = 11.3 [9.4-13.2]; Progression-free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) (MEDIAN) Months = 5.6 [4.2-6.5],"Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) - Pembrolizumab+Lenvatinib vs. Docetaxel (NUMBER) Percentage of Participants = 22.7 [16.9-29.4]; Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) - Pembrolizumab+Lenvatinib vs. Lenvatinib Monotherapy (NUMBER) Percentage of Participants = 22.7 [16.9-29.4]; Duration of Response (DOR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) (MEDIAN) Months = 6.9; Number of Participants Experiencing an Adverse Event (AE) (NUMBER) Participants = 179; Number of Participants Discontinuing Study Treatment Due to an AE (NUMBER) Participants = 68; Change From Baseline in European Organization for Research and Treatment (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Combined Global Health Status / Quality of Life (Items 29 & 30) Scale Combined Score (LEAST_SQUARES_MEAN) Scores on a scale = -2.48 [-5.44-0.49]; Change From Baseline in EORTC Quality of Life Questionnaire Lung Cancer Module 13 (QLQ-LC13) Cough (Item 31) Scale Score (LEAST_SQUARES_MEAN) Scores on a scale = -4.17 [-8.08--0.27]; Change From Baseline in EORTC QLQ-LC13 Chest Pain (Item 40) Scale Score (LEAST_SQUARES_MEAN) Scores on a scale = -1.40 [-4.92-2.12]; Change From Baseline in EORTC QLQ-C30 Dyspnea (Item 8) Scale Score (LEAST_SQUARES_MEAN) Scores on a scale = -2.92 [-7.08-1.23]; Change From Baseline in EORTC QLQ-C30 Physical Functioning (Items 1 to 5) Scale Combined Score (LEAST_SQUARES_MEAN) Scores on a scale = -5.58 [-8.51--2.65]; Time to True Deterioration (TTD) in EORTC QLQ-C30 Combined Global Health Status / Quality of Life (Items 29 & 30) Scale Combined Score (MEDIAN) Months = 8.51; ; ; ; Time to True Deterioration (TTD) in EORTC QLQ-C30 Physical Functioning (Items 1 to 5) Scale Combined Score (MEDIAN) Months = 6.70 [5.36-9.86]; Time to True Deterioration (TTD) in EORTC Composite Symptom Score for Cough (QLQ-LC13 Item 31), Chest Pain (QLQ-LC13 Item 40), or Dyspnea (QLQ-C30 Item 8) (MEDIAN) Months = 9.20 [5.59-12.62]",,,,,Duration of Response (DOR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) (MEDIAN) Months = 6.9,,,Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) - Pembrolizumab+Lenvatinib vs. Docetaxel (NUMBER) Percentage of Participants = 22.7 [16.9-29.4]; Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) - Pembrolizumab+Lenvatinib vs. Lenvatinib Monotherapy (NUMBER) Percentage of Participants = 22.7 [16.9-29.4],Overall Survival (OS) (MEDIAN) Months = 11.3 [9.4-13.2],Progression-free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) (MEDIAN) Months = 5.6 [4.2-6.5],,Change From Baseline in European Organization for Research and Treatment (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Combined Global Health Status / Quality of Life (Items 29 & 30) Scale Combined Score (LEAST_SQUARES_MEAN) Scores on a scale = -2.48 [-5.44-0.49]; Change From Baseline in EORTC Quality of Life Questionnaire Lung Cancer Module 13 (QLQ-LC13) Cough (Item 31) Scale Score (LEAST_SQUARES_MEAN) Scores on a scale = -4.17 [-8.08--0.27]; Time to True Deterioration (TTD) in EORTC QLQ-C30 Combined Global Health Status / Quality of Life (Items 29 & 30) Scale Combined Score (MEDIAN) Months = 8.51,Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) - Pembrolizumab+Lenvatinib vs. Docetaxel (NUMBER) Percentage of Participants = 22.7 [16.9-29.4]; Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) - Pembrolizumab+Lenvatinib vs. Lenvatinib Monotherapy (NUMBER) Percentage of Participants = 22.7 [16.9-29.4],Number of Participants Discontinuing Study Treatment Due to an AE (NUMBER) Participants = 68,,
NCT03977467,Atezolizumab and Tiragolumab in Patients With NSCLC or Advanced Solid Tumors Having Had Prior Treatment With a PD-1 Inhibitor,A Phase II Study of Atezolizumab and Tiragolumab in Patients With NSCLC or Advanced Solid Tumors Who Have Had Prior Treatment With a PD-1 Inhibitor,"SCRI Development Innovations, LLC","SCRI Development Innovations, LLC",OTHER,COMPLETED,2019-08-30,2024-08-09,2024-08-09,INTERVENTIONAL,PHASE2,,,,Non-Small Cell Lung Cancer,Non-Small Cell Lung Cancer; Solid Tumor,2,4,3,DRUG,,,1,2,True,Yes,Overall Response Rate (NUMBER) percentage of participants = 50.0,Incidence of Treatment-emergent Adverse Events (AEs) as a Measure of Safety (COUNT_OF_PARTICIPANTS) Participants = 4; Disease Control Rate (DCR) (NUMBER) percentage of participants = 50.0,,,,,,,,,,,,,Overall Response Rate (NUMBER) percentage of participants = 50.0,Incidence of Treatment-emergent Adverse Events (AEs) as a Measure of Safety (COUNT_OF_PARTICIPANTS) Participants = 4,,
NCT04003246,Phase II Concurrent Durvalumab and Radiotherapy for for Stage III Non-Small Cell Lung Cancer,Phase II Concurrent Durvalumab (MEDI4736) and Radiotherapy Followed by Consolidative Durvalumab (MEDI4736) for Stage III Non-Small Cell Lung Cancer (NSCLC),University of Texas Southwestern Medical Center,University of Texas Southwestern Medical Center,OTHER,COMPLETED,2020-04-03,2022-06-15,2024-11-05,INTERVENTIONAL,PHASE2,,,,Non Small Cell Lung Cancer,Non Small Cell Lung Cancer; Lung Cancer Stage III,2,1,2,DRUG; RADIATION,,,1,4,True,Yes,12-Month Progression-free Survival (PFS) Time (MEAN) days = 208 [0-365],Safety and Tolerability (NUMBER) Grade 3 or higher adverse events = 15; Overall Survival (MEAN) days = 486 [0-1460]; Distant Metastases Free Survival Time (MEAN) days = 501 [0-1677]; Local and Regional Control Time (MEAN) days = 457 [0-1677],,,,,,,,,Overall Survival (MEAN) days = 486 [0-1460],12-Month Progression-free Survival (PFS) Time (MEAN) days = 208 [0-365],,,,Safety and Tolerability (NUMBER) Grade 3 or higher adverse events = 15,,
NCT04026412,A Study of Nivolumab and Ipilimumab in Untreated Participants With Stage 3 Non-small Cell Lung Cancer (NSCLC) That is Unable or Not Planned to be Remo,"A Phase 3, Randomized, Open Label Study to Compare Nivolumab Plus Concurrent Chemoradiotherapy (CCRT) Followed by Nivolumab Plus Ipilimumab or Nivolumab Plus CCRT Followed by Nivolumab vs CCRT Followe",Bristol-Myers Squibb,Bristol-Myers Squibb,INDUSTRY,COMPLETED,2019-10-08,2024-03-22,2024-11-26,INTERVENTIONAL,PHASE3,,,,Non-Small Cell Lung Cancer (NSCLC),Non-Small Cell Lung Cancer (NSCLC),1,3,3,BIOLOGICAL,,,1,12,True,Yes,Arm A Vs Arm C - Progression-Free Survival (PFS) by RECIST 1.1 Per Blinded Independent Central Review (BICR) (MEDIAN) months = 16.69 [12.58-21.98],"Overall Survival (OS) (MEDIAN) months = 34.60; Arm B Vs Arm C and Arm A Vs Arm B- Progression-Free Survival (Irrespective of Subsequent Therapy) by RECIST 1.1 Per Blinded Independent Central Review (BICR) (MEDIAN) months = 16.82 [12.58-22.05]; Objective Response Rate (ORR) by BICR (NUMBER) percentage of participants = 67.6 [61.8-73.0]; Duration of Response (DoR) by RECIST 1.1 Per BICR (MEDIAN) months = 25.76 [2.1-47.9]; Time to Response (TTR) by RECIST 1.1 Per BICR (MEDIAN) months = 2.92 [0.9-22.2]; Progression Free Survival (PFS) by RECIST 1.1 Per Investigator Assessment (MEDIAN) months = 16.82 [13.83-20.40]; Objective Response Rate (ORR) by RECIST 1.1 Per Investigator Assessment (NUMBER) percentage of participants = 61.3 [55.4-67.0]; Duration of Response (DOR) by RECIST 1.1 Per Investigator Assessment (MEDIAN) months = 22.83 [0.0-47.4]; Time to Response (TTR) by RECIST 1.1 Per Investigator Assessment (MEDIAN) months = 2.96 [1.9-25.2]; Time to Death or Distant Metastases (TDDM) (MEDIAN) months = 30.65; Number of Participants With Adverse Events (AEs), Serious AEs and Select AEs (COUNT_OF_PARTICIPANTS) Participants = 279; Change From Baseline in Non-small Cell Lung Cancer (NSCLC)-Symptom Assessment Questionnaire (SAQ) Total Score at Week 48 (MEAN) Score on a Scale = -0.60",,,,,Duration of Response (DoR) by RECIST 1.1 Per BICR (MEDIAN) months = 25.76 [2.1-47.9]; Duration of Response (DOR) by RECIST 1.1 Per Investigator Assessment (MEDIAN) months = 22.83 [0.0-47.4],,,Objective Response Rate (ORR) by BICR (NUMBER) percentage of participants = 67.6 [61.8-73.0]; Objective Response Rate (ORR) by RECIST 1.1 Per Investigator Assessment (NUMBER) percentage of participants = 61.3 [55.4-67.0],Overall Survival (OS) (MEDIAN) months = 34.60,Arm A Vs Arm C - Progression-Free Survival (PFS) by RECIST 1.1 Per Blinded Independent Central Review (BICR) (MEDIAN) months = 16.69 [12.58-21.98]; Arm B Vs Arm C and Arm A Vs Arm B- Progression-Free Survival (Irrespective of Subsequent Therapy) by RECIST 1.1 Per Blinded Independent Central Review (BICR) (MEDIAN) months = 16.82 [12.58-22.05]; Progression Free Survival (PFS) by RECIST 1.1 Per Investigator Assessment (MEDIAN) months = 16.82 [13.83-20.40],,,Objective Response Rate (ORR) by BICR (NUMBER) percentage of participants = 67.6 [61.8-73.0]; Objective Response Rate (ORR) by RECIST 1.1 Per Investigator Assessment (NUMBER) percentage of participants = 61.3 [55.4-67.0],"Number of Participants With Adverse Events (AEs), Serious AEs and Select AEs (COUNT_OF_PARTICIPANTS) Participants = 279",,
NCT04035486,A Study of Osimertinib With or Without Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor Non-Small Cell Lun,"A Phase III, Open-label, Randomized Study of Osimertinib With or Without Platinum Plus Pemetrexed Chemo, as First-line Treatment in Patients With Epidermal Growth Factor Receptor (EGFR) Mutation Posit",AstraZeneca,AstraZeneca,INDUSTRY,ACTIVE_NOT_RECRUITING,2019-07-02,2023-04-03,2026-12-22,INTERVENTIONAL,PHASE3,,,,Non-Small Cell Lung Cancer,Non-Small Cell Lung Cancer,1,2,3,DRUG,,,3,29,True,Yes,Adverse Events Graded by Common Terminology Criteria for Adverse Event v5 (Safety Run-In Treatment Arms Only) (COUNT_OF_PARTICIPANTS) Participants = 1; Progression-free Survival (PFS) (Randomized Component) (MEDIAN) Months = 25.5; Sensitivity Analysis for Progression-free Survival (PFS) by Blinded Independent Central Review (BICR) Assessment (Randomized Component) (MEDIAN) Months = 29.4,"; Duration of Response (DoR) (Safety Run-In Treatment Arms Only) (MEAN) Months = 27.5; Objective Response Rate (ORR) (Safety Run-In Treatment Arms Only) (NUMBER) Percent of Participants = 86.7 [69.28-96.24]; Depth of Response (Percent Change From Baseline in Tumor Diameter) (Safety Run-In Treatment Arms Only) (MEAN) Percent change from baseline = -57.72; Disease Control Rate (DCR) by Investigator (Safety Run-In Treatment Arms Only) (COUNT_OF_PARTICIPANTS) Participants = 3; ; Landmark Overall Survival (LOS) at 1, 2, and 3 Years (Randomized Component) (NUMBER) percent of participants = 88.8 [84.4-92.0]; Objective Response Rate (ORR) (Randomized Component) (NUMBER) Percent of Participants = 84.40 [79.51-88.30]; Duration of Response (DoR) (Randomized Component) (MEDIAN) Months = 24.0 [20.9-27.8]; Depth of Response (Percent Change From Baseline in Tumor Diameter) (Randomized Component) (LEAST_SQUARES_MEAN) Percent change from baseline = -50.77 [-53.75--47.78]; Disease Control Rate (DCR) by Investigator (Randomized Component) (NUMBER) Percent of Participants = 96.22 [93.14-97.95]; Progression Free Survival 2 (PFS2) (Randomized Component) (MEDIAN) Months = 30.6; Time to First Subsequent Therapy (TFST) or Death (Randomized Component) (MEDIAN) Months = 30.7; ; Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 Items (EORTC QLQ-C30) (Randomized Component) (LEAST_SQUARES_MEAN) Scores on a Scale = 2.37 [0.70-4.04]; Median Time to Deterioration in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 Items (EORTC QLQ-C30) (Randomized Component) (MEDIAN) Months = 25.5; Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Lung Cancer 13 Items (EORTC QLQ-LC13) (Randomized Component) (LEAST_SQUARES_MEAN) Scores on a Scale = -13.23 [-14.85--11.62]; ; Concordance of Epidermal Growth Factor Receptor (EGFR) Mutation Status Between the Local EGFR Mutation Test and the Central Cobas® EGFR Mutation Test v2 Results: Exon 19 Deletion (Randomized Component) (COUNT_OF_PARTICIPANTS) Participants = 98; Concordance of Epidermal Growth Factor Receptor (EGFR) Mutation Status Between the Local EGFR Mutation Test and the Central Cobas® EGFR Mutation Test v2 Results: L858R (Randomized Component) (COUNT_OF_PARTICIPANTS) Participants = 145; Progression-free Survival (PFS) by Investigator by Plasma Epidermal Growth Factor Receptor Mutation Status: Exon 19 Deletion - Participants With an Event (Randomized Component) (COUNT_OF_PARTICIPANTS) Participants = 65; Progression-free Survival (PFS) by Investigator by Plasma Epidermal Growth Factor Receptor Mutation Status: L858R - Participants With an Event (Randomized Component) (COUNT_OF_PARTICIPANTS) Participants = 55; Plasma Concentration of Osimertinib When Given With or Without Chemotherapy (Randomized Component) (GEOMETRIC_MEAN) nM = 430.6; Plasma Concentration of Metabolite AZ5104 When Osimertinib is Given With or Without Chemotherapy (Randomized Component) (GEOMETRIC_MEAN) nM = 51.74; Mean Cmin,ss and Mean Cmax,ss of Osimertinib (Randomized Component) (GEOMETRIC_MEAN) nmol/L = 392.5; Mean Cmin,ss and Mean Cmax,ss of AZ5104 (Randomized Component) (GEOMETRIC_MEAN) nmol/L = 45.34; Mean AUCss of Osimertinib (Randomized Component) (GEOMETRIC_MEAN) h*nmol/L = 11840; Mean AUCss of AZ5104 (Randomized Component) (GEOMETRIC_MEAN) h*nmol/L = 1277; Mean CLss/F of Osimertinib (Randomized Component) (GEOMETRIC_MEAN) L/h = 13.52",,,,,Duration of Response (DoR) (Safety Run-In Treatment Arms Only) (MEAN) Months = 27.5; Duration of Response (DoR) (Randomized Component) (MEDIAN) Months = 24.0 [20.9-27.8],,,Objective Response Rate (ORR) (Safety Run-In Treatment Arms Only) (NUMBER) Percent of Participants = 86.7 [69.28-96.24]; Objective Response Rate (ORR) (Randomized Component) (NUMBER) Percent of Participants = 84.40 [79.51-88.30],"Landmark Overall Survival (LOS) at 1, 2, and 3 Years (Randomized Component) (NUMBER) percent of participants = 88.8 [84.4-92.0]",Progression-free Survival (PFS) (Randomized Component) (MEDIAN) Months = 25.5; Sensitivity Analysis for Progression-free Survival (PFS) by Blinded Independent Central Review (BICR) Assessment (Randomized Component) (MEDIAN) Months = 29.4; Progression Free Survival 2 (PFS2) (Randomized Component) (MEDIAN) Months = 30.6; Progression-free Survival (PFS) by Investigator by Plasma Epidermal Growth Factor Receptor Mutation Status: Exon 19 Deletion - Participants With an Event (Randomized Component) (COUNT_OF_PARTICIPANTS) Participants = 65; Progression-free Survival (PFS) by Investigator by Plasma Epidermal Growth Factor Receptor Mutation Status: L858R - Participants With an Event (Randomized Component) (COUNT_OF_PARTICIPANTS) Participants = 55,,Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 Items (EORTC QLQ-C30) (Randomized Component) (LEAST_SQUARES_MEAN) Scores on a Scale = 2.37 [0.70-4.04]; Median Time to Deterioration in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 Items (EORTC QLQ-C30) (Randomized Component) (MEDIAN) Months = 25.5; Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Lung Cancer 13 Items (EORTC QLQ-LC13) (Randomized Component) (LEAST_SQUARES_MEAN) Scores on a Scale = -13.23 [-14.85--11.62],Objective Response Rate (ORR) (Safety Run-In Treatment Arms Only) (NUMBER) Percent of Participants = 86.7 [69.28-96.24]; Objective Response Rate (ORR) (Randomized Component) (NUMBER) Percent of Participants = 84.40 [79.51-88.30],Adverse Events Graded by Common Terminology Criteria for Adverse Event v5 (Safety Run-In Treatment Arms Only) (COUNT_OF_PARTICIPANTS) Participants = 1,,
NCT04068896,"Study of NGM120 in Subjects With Advanced Solid Tumors, Pancreatic Cancer, and Prostate Cancer Using Combination Therapy","A Phase 1/2 Dose-Finding Study Followed by Expansion Cohorts of NGM120, a GFRAL Antagonist Monoclonal Antibody Blocking GDF15 Signaling, in Subjects With Advanced Solid Tumors and Pancreatic Cancer Us","NGM Biopharmaceuticals, Inc","NGM Biopharmaceuticals, Inc",INDUSTRY,COMPLETED,2019-10-16,2023-09-21,2024-01-08,INTERVENTIONAL,PHASE1; PHASE2,,,,Pancreatic Cancer,Pancreatic Cancer; Metastatic Castration-resistant Prostate Cancer; Bladder Cancer,11,6,6,BIOLOGICAL; OTHER,,,3,0,True,Yes,To Determine the Safety and Tolerability of NGM120 in Subjects (COUNT_OF_PARTICIPANTS) Participants = 1; To Determine the Safety and Tolerability of NGM120 (COUNT_OF_PARTICIPANTS) Participants = 2; To Determine the Safety and Tolerability of NGM120 (COUNT_OF_PARTICIPANTS) Participants = 0,,,,,,,,,,,,,,,,,
NCT04120454,Ramucirumab and Pembrolizumab for the Treatment of EGFR Mutant Recurrent or Metastatic Non-small Cell Lung Cancer,An Investigator-Sponsored Phase 2 Single Arm Trial of Ramucirumab and Pembrolizumab in Patients With EGFR Mutant Non-Small Cell Lung Cancer,Ohio State University Comprehensive Cancer Center,Ohio State University Comprehensive Cancer Center,OTHER,COMPLETED,2020-06-17,2023-08-19,2023-08-19,INTERVENTIONAL,PHASE2,,,,Metastatic Lung Non-Small Cell Carcinoma,Metastatic Lung Non-Small Cell Carcinoma; Recurrent Lung Non-Small Cell Carcinoma; Stage IV Lung Cancer AJCC v8,5,1,2,BIOLOGICAL,,,1,4,True,Yes,Overall Response Rate (NUMBER) percentage of participants = 0,Number of Adverse Events (NUMBER) Number of Events = 4; Clinical Benefit Rate (Complete Response + Partial Response + Stable Disease) (NUMBER) percentage of participants = 50; Progression-free Survival (MEDIAN) months = 1.4; Overall Survival (MEDIAN) months = 7.03,Clinical Benefit Rate (Complete Response + Partial Response + Stable Disease) (NUMBER) percentage of participants = 50,Clinical Benefit Rate (Complete Response + Partial Response + Stable Disease) (NUMBER) percentage of participants = 50,,,,,,,Overall Survival (MEDIAN) months = 7.03,Progression-free Survival (MEDIAN) months = 1.4,Clinical Benefit Rate (Complete Response + Partial Response + Stable Disease) (NUMBER) percentage of participants = 50,,Overall Response Rate (NUMBER) percentage of participants = 0,Number of Adverse Events (NUMBER) Number of Events = 4,,
NCT04154956,"SAR408701 Versus Docetaxel in Previously Treated, Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Positive Metastatic Non-squamous","Randomized, Open-label, Phase 3 Study of SAR408701 Versus Docetaxel in Previously Treated, Metastatic Nonsquamous, Non-small-cell Lung Cancer Patients With CEACAM5-positive Tumors",Sanofi,Sanofi,INDUSTRY,ACTIVE_NOT_RECRUITING,2020-02-06,2023-09-22,2026-03-31,INTERVENTIONAL,PHASE3,,,,Non-small Cell Lung Cancer Metastatic,Non-small Cell Lung Cancer Metastatic,1,2,2,DRUG,,,2,8,True,Yes,Progression-free Survival (PFS) (MEDIAN) months = 5.39 [3.713-6.998]; Overall Survival (OS) (MEDIAN) months = 12.81 [11.795-14.160],Objective Response Rate (ORR) (NUMBER) percentage of participants = 21.7 [16.04-28.26]; Time to Deterioration (TTD) in Disease-related Symptoms as Determined by European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire and Lung Cancer-specific Module With 13 Items (EORTC QLQ LC-13) (MEDIAN) months = 2.83 [2.103-4.304]; TTD in Physical Function as Determined by European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Cancer-specific Module With 30 Items (EORTC QLQ C30) (MEDIAN) months = 7.46 [5.552-15.211]; TTD in Role Function Measured by EORTC QLQ C30 (MEDIAN) months = 5.55 [3.713-6.308]; ; ; ; Duration of Response (DOR) (MEDIAN) months = 11.07 [5.158-19.844],,,,,Duration of Response (DOR) (MEDIAN) months = 11.07 [5.158-19.844],,,Objective Response Rate (ORR) (NUMBER) percentage of participants = 21.7 [16.04-28.26],Overall Survival (OS) (MEDIAN) months = 12.81 [11.795-14.160],Progression-free Survival (PFS) (MEDIAN) months = 5.39 [3.713-6.998],,Time to Deterioration (TTD) in Disease-related Symptoms as Determined by European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire and Lung Cancer-specific Module With 13 Items (EORTC QLQ LC-13) (MEDIAN) months = 2.83 [2.103-4.304]; TTD in Physical Function as Determined by European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Cancer-specific Module With 30 Items (EORTC QLQ C30) (MEDIAN) months = 7.46 [5.552-15.211],Objective Response Rate (ORR) (NUMBER) percentage of participants = 21.7 [16.04-28.26],,,
NCT04181788,"Sasanlimab (PF-06801591, PD-1 Inhibitor) in Participants With Advanced Malignancies","A Phase 1b/2 Open-Label Study to Evaluate Pharmacokinetics, Safety, Efficacy, and Pharmacodynamics of PF-06801591 (PD-1 Inhibitor) in Participants With Advanced Malignancies",Pfizer,Pfizer,INDUSTRY,ACTIVE_NOT_RECRUITING,2020-03-18,2022-03-03,2026-06-09,INTERVENTIONAL,PHASE1; PHASE2,,,,Advanced Malignancies,Advanced Malignancies; Non-small-cell Lung Cancer,2,4,1,DRUG,,,3,9,True,Yes,"Phase 1b: Number of Participants With Dose-Limiting Toxicities (DLT) (COUNT_OF_PARTICIPANTS) Participants = 0; Phase 2: AUCτ of PF-06801591 at Steady State (GEOMETRIC_MEAN) microgram*hour per milliliter (μg*hr/mL) = 20800; Phase 2: Ctrough of PF-06801591 at Steady State, at Week 12 (GEOMETRIC_MEAN) microgram per milliliter (μg/mL) = 21.48",; ; ; ; ; ; ; ; ,,,,,,,,,,,,,,,,
NCT04194944,A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer,"LIBRETTO-431: A Multicenter, Randomized, Open-Label, Phase 3 Trial Comparing Selpercatinib to Platinum-Based and Pemetrexed Therapy With or Without Pembrolizumab as Initial Treatment of Advanced or Me",Eli Lilly and Company,Eli Lilly and Company,INDUSTRY,ACTIVE_NOT_RECRUITING,2020-02-17,2023-05-01,2030-06,INTERVENTIONAL,PHASE3,,,,Non-Small Cell Lung Cancer,Non-Small Cell Lung Cancer,1,2,5,DRUG,,,2,23,True,Yes,Progression Free Survival (PFS) by Blinded Independent Central Review (BICR) (With Pembrolizumab) (MEDIAN) Months = 24.84; PFS by BICR (With or Without Pembrolizumab) (MEDIAN) Months = 24.84,Percentage of Participant With Disease Control Rate (DCR) by BICR (With Pembrolizumab) (NUMBER) Percentage of Participants = 89.1 [82.5-93.9]; Percentage of Participant With DCR by BICR (With or Without Pembrolizumab) (NUMBER) Percentage of Participants = 89.3 [83.4-93.7]; ; ; Overall Response Rate (ORR): Percentage of Participants With Complete Response (CR) or Partial Response (PR) by BICR (With Pembrolizumab) (NUMBER) Percentage of participants = 83.7 [76.2-89.6]; ORR: Percentage of Participants With CR or PR by BICR (With or Without Pembrolizumab) (NUMBER) Percentage of Participants = 83.6 [77.0-89.0]; Duration of Response (DoR) by BICR (With Pembrolizumab) (MEDIAN) Months = 24.18; DOR by BICR (With or Without Pembrolizumab) (MEDIAN) Months = 24.18; ; OS (With or Without Pembrolizumab) (MEDIAN) Months = 33.05; Intracranial ORR: Percentage of Participants With Intracranial CR or PR Per RECIST (Response Evaluation Criteria in Solid Tumors) 1.1 by BICR (With Pembrolizumab) (NUMBER) Percentage of participants = 81 [58.1-94.6]; Intracranial ORR: Percentage of Participants With Intracranial CR or PR Per RECIST 1.1 by BICR (With or Without Pembrolizumab) (NUMBER) Percentage of participants = 84.0 [63.9-95.5]; ; ; ; ; ; ; ; ; ; ; ,,Overall Response Rate (ORR): Percentage of Participants With Complete Response (CR) or Partial Response (PR) by BICR (With Pembrolizumab) (NUMBER) Percentage of participants = 83.7 [76.2-89.6]; ORR: Percentage of Participants With CR or PR by BICR (With or Without Pembrolizumab) (NUMBER) Percentage of Participants = 83.6 [77.0-89.0]; Intracranial ORR: Percentage of Participants With Intracranial CR or PR Per RECIST (Response Evaluation Criteria in Solid Tumors) 1.1 by BICR (With Pembrolizumab) (NUMBER) Percentage of participants = 81 [58.1-94.6]; Intracranial ORR: Percentage of Participants With Intracranial CR or PR Per RECIST 1.1 by BICR (With or Without Pembrolizumab) (NUMBER) Percentage of participants = 84.0 [63.9-95.5],,,Duration of Response (DoR) by BICR (With Pembrolizumab) (MEDIAN) Months = 24.18; DOR by BICR (With or Without Pembrolizumab) (MEDIAN) Months = 24.18,,,,OS (With or Without Pembrolizumab) (MEDIAN) Months = 33.05,Progression Free Survival (PFS) by Blinded Independent Central Review (BICR) (With Pembrolizumab) (MEDIAN) Months = 24.84; PFS by BICR (With or Without Pembrolizumab) (MEDIAN) Months = 24.84,Overall Response Rate (ORR): Percentage of Participants With Complete Response (CR) or Partial Response (PR) by BICR (With Pembrolizumab) (NUMBER) Percentage of participants = 83.7 [76.2-89.6]; ORR: Percentage of Participants With CR or PR by BICR (With or Without Pembrolizumab) (NUMBER) Percentage of Participants = 83.6 [77.0-89.0]; Intracranial ORR: Percentage of Participants With Intracranial CR or PR Per RECIST (Response Evaluation Criteria in Solid Tumors) 1.1 by BICR (With Pembrolizumab) (NUMBER) Percentage of participants = 81 [58.1-94.6]; Intracranial ORR: Percentage of Participants With Intracranial CR or PR Per RECIST 1.1 by BICR (With or Without Pembrolizumab) (NUMBER) Percentage of participants = 84.0 [63.9-95.5],,Overall Response Rate (ORR): Percentage of Participants With Complete Response (CR) or Partial Response (PR) by BICR (With Pembrolizumab) (NUMBER) Percentage of participants = 83.7 [76.2-89.6],,,
NCT04205812,"Platinum-Based Chemotherapy With/Without INCMGA00012, an Anti-PD-1 Antibody, in Non-Small Cell Lung Cancer","A Randomized, Double Blind, Phase 3 Study of Platinum-Based Chemotherapy With or Without INCMGA00012 in First-Line Metastatic Squamous and Nonsquamous Non-Small Cell Lung Cancer (POD1UM-304)",Incyte Corporation,Incyte Corporation,INDUSTRY,ACTIVE_NOT_RECRUITING,2020-09-11,2023-12-15,2026-08-28,INTERVENTIONAL,PHASE3,,,,Metastatic Squamous Non-Small Cell Lung Cancer,Metastatic Squamous Non-Small Cell Lung Cancer; Metastatic Nonsquamous Non-Small Cell Lung Cancer,2,4,7,DRUG,,,1,11,True,Yes,Overall Survival (MEDIAN) months = 13.4 [11.0-16.7],Progression-free Survival (PFS) (MEDIAN) months = 5.5 [4.4-5.7]; Objective Response Rate (NUMBER) percentage of participants = 38.5 [31.6-45.8]; Duration of Response (MEDIAN) months = 6.1 [4.2-8.3]; Number of Participants With Any Treatment-emergent Adverse Event (TEAE) in the Randomized Treatment Period (COUNT_OF_PARTICIPANTS) Participants = 183; Number of Participants Who Discontinued Study Drug Due to TEAEs in the Randomized Treatment Period (COUNT_OF_PARTICIPANTS) Participants = 9; Number of Participants With Any TEAE in the Monotherapy Treatment Period (COUNT_OF_PARTICIPANTS) Participants = 50; Number of Participants Who Discontinued Study Drug Due to TEAEs in the Monotherapy Treatment Period (COUNT_OF_PARTICIPANTS) Participants = 4; Cmax1 of Retifanlimab When Administered With Chemotherapy (GEOMETRIC_MEAN) milligrams per liter (mg/L) = 109; AUC1 of Retifanlimab When Administered With Chemotherapy (GEOMETRIC_MEAN) mg/L x day = 775; Cmaxss of Retifanlimab When Administered With Chemotherapy (GEOMETRIC_MEAN) mg/L = 109; AUCss of Retifanlimab When Administered With Chemotherapy (GEOMETRIC_MEAN) mg/L x day = 791,,,,,Duration of Response (MEDIAN) months = 6.1 [4.2-8.3],,,Objective Response Rate (NUMBER) percentage of participants = 38.5 [31.6-45.8],Overall Survival (MEDIAN) months = 13.4 [11.0-16.7],Progression-free Survival (PFS) (MEDIAN) months = 5.5 [4.4-5.7],,,Objective Response Rate (NUMBER) percentage of participants = 38.5 [31.6-45.8],,,
NCT04248829,Clinical Trial of YH25448(Lazertinib) as the First-line Treatment in Patients With EGFR Mutation Positive Locally Advanced or Metastatic NSCLC (LASER3,"A Phase III, Randomized, Double-blind Study to Assess the Efficacy and Safety of Lazertinib Versus Gefitinib as the First-line Treatment in Patients With Epidermal Growth Factor Receptor Sensitizing M",Yuhan Corporation,Yuhan Corporation,INDUSTRY,ACTIVE_NOT_RECRUITING,2020-02-13,2022-07-29,2026-06,INTERVENTIONAL,PHASE3,,,,Non-Small Cell Lung Cancer,Non-Small Cell Lung Cancer,1,2,4,DRUG,,,1,11,True,Yes,Progression-Free Survival (PFS) According to RECIST v1.1 by Investigator Assessment (MEDIAN) Months = 20.6 [17.8-26.1],Objective Response Rate (ORR) According to RECIST v1.1 by Investigator Assessments (NUMBER) Percentage of participants = 76.0 [69.4-81.8]; Duration of Response (DoR) According to RECIST v1.1 by Investigator Assessments (MEDIAN) Months = 19.4 [16.6-24.9]; Disease Control Rate (DCR) According to RECIST v1.1 by Investigator Assessments (NUMBER) Percentage of participants = 93.9 [89.5-96.8]; ; ; Overall Survival (OS) (COUNT_OF_PARTICIPANTS) Participants = 49; ; ; ; ; ,,,,,Duration of Response (DoR) According to RECIST v1.1 by Investigator Assessments (MEDIAN) Months = 19.4 [16.6-24.9],,,Objective Response Rate (ORR) According to RECIST v1.1 by Investigator Assessments (NUMBER) Percentage of participants = 76.0 [69.4-81.8],Overall Survival (OS) (COUNT_OF_PARTICIPANTS) Participants = 49,Progression-Free Survival (PFS) According to RECIST v1.1 by Investigator Assessment (MEDIAN) Months = 20.6 [17.8-26.1],,,Objective Response Rate (ORR) According to RECIST v1.1 by Investigator Assessments (NUMBER) Percentage of participants = 76.0 [69.4-81.8],,,
NCT04249362,Study of Durvalumab Following Radiation Therapy in Patients With Stage 3 Unresectable NSCLC Ineligible for Chemotherapy,"A Phase II, Open-label, Multicenter, International Study of Durvalumab Following Radiation Therapy in Patients With Stage III, Unresectable Non-Small Cell Lung Cancer Who Are Ineligible for Chemothera",AstraZeneca,AstraZeneca,INDUSTRY,COMPLETED,2020-11-26,2023-03-30,2024-11-25,INTERVENTIONAL,PHASE2,,,,Non-small Cell Lung Cancer,Non-small Cell Lung Cancer,1,2,1,DRUG,,,1,11,True,Yes,Number of Patients With Grade 3 and Grade 4 Possibly-related Adverse Events (PRAEs) (COUNT_OF_PARTICIPANTS) Participants = 5,Median Progression-free Survival (mPFS) (MEDIAN) Months = 10.3 [7.49-16.56]; Progression-free Survival at 6 Months (PFS6) (NUMBER) Percentage of patients = 67.1 [51.96-78.43]; Progression-free Survival at 12 Months (PFS12) (NUMBER) Percentage of patients = 46.8 [31.88-60.36]; Median Overall Survival (mOS) (MEDIAN) Months = 21.1; Overall Survival at 12 Months (OS12) (NUMBER) Percentage of patients = 64.0 [49.01-75.58]; Objective Response Rate (ORR) (NUMBER) Percentage of patients = 34.0 [21.5-48.3]; Duration of Response (DoR) (MEDIAN) Weeks = 56.9; Lung Cancer Mortality (MEDIAN) Months = 30.9; Number of Patients With Events (AEs) (COUNT_OF_PARTICIPANTS) Participants = 50; Number of Patients With Adverse Events of Special Interests (AESIs) (COUNT_OF_PARTICIPANTS) Participants = 25; Number of Patients With Immune-mediated Adverse Events (imAEs) (COUNT_OF_PARTICIPANTS) Participants = 11,,,,,Duration of Response (DoR) (MEDIAN) Weeks = 56.9,,,Objective Response Rate (ORR) (NUMBER) Percentage of patients = 34.0 [21.5-48.3],Median Overall Survival (mOS) (MEDIAN) Months = 21.1; Overall Survival at 12 Months (OS12) (NUMBER) Percentage of patients = 64.0 [49.01-75.58],Median Progression-free Survival (mPFS) (MEDIAN) Months = 10.3 [7.49-16.56]; Progression-free Survival at 6 Months (PFS6) (NUMBER) Percentage of patients = 67.1 [51.96-78.43]; Progression-free Survival at 12 Months (PFS12) (NUMBER) Percentage of patients = 46.8 [31.88-60.36],,,Objective Response Rate (ORR) (NUMBER) Percentage of patients = 34.0 [21.5-48.3],Number of Patients With Grade 3 and Grade 4 Possibly-related Adverse Events (PRAEs) (COUNT_OF_PARTICIPANTS) Participants = 5; Number of Patients With Adverse Events of Special Interests (AESIs) (COUNT_OF_PARTICIPANTS) Participants = 25; Number of Patients With Immune-mediated Adverse Events (imAEs) (COUNT_OF_PARTICIPANTS) Participants = 11,,
NCT04383938,Phase 1/2 Study of APR-246 in Combination With Pembrolizumab in Subjects With Solid Tumor Malignancies,Study of APR-246 in Combination With Pembrolizumab in Subjects With Solid Tumor Malignancies,Aprea Therapeutics,Aprea Therapeutics,INDUSTRY,COMPLETED,2020-06-25,2022-04-30,2022-04-30,INTERVENTIONAL,PHASE1; PHASE2,,,,Bladder Cancer,Bladder Cancer; Gastric Cancer; Non Small Cell Lung Cancer,6,4,1,DRUG,,,2,0,True,Yes,To Evaluate the Safety of APR-246 in Combination With Pembrolizumab in Subjects With Solid Tumors. (NUMBER) participants = 6; To Confirm the Recommended Phase 2 Dose (RP2D) for APR-246 in Combination With Pembrolizumab (NUMBER) g/d = 4.5,,,,,,,,,,,,,,,,,
NCT04484142,Study of DS-1062a in Advanced or Metastatic Non-small Cell Lung Cancer With Actionable Genomic Alterations (TROPION-Lung05),"Phase 2, Single-arm, Open-label Study of DS-1062a in Advanced or Metastatic Non-small Cell Lung Cancer With Actionable Genomic Alterations and Progressed On or After Applicable Targeted Therapy and Pl",Daiichi Sankyo,Daiichi Sankyo,INDUSTRY,ACTIVE_NOT_RECRUITING,2021-03-30,2023-03-10,2025-12-12,INTERVENTIONAL,PHASE2,,,,Non-small Cell Lung Cancer,Non-small Cell Lung Cancer,1,1,1,DRUG,,,1,7,True,Yes,Percentage of Participants With Objective Response Rate (ORR) Based on Blinded Independent Central Review (BICR) (NUMBER) percentage of participants = 35.8 [27.8-44.4],; ; ; ; ; ; ,,,,,,,,Percentage of Participants With Objective Response Rate (ORR) Based on Blinded Independent Central Review (BICR) (NUMBER) percentage of participants = 35.8 [27.8-44.4],,,,,Percentage of Participants With Objective Response Rate (ORR) Based on Blinded Independent Central Review (BICR) (NUMBER) percentage of participants = 35.8 [27.8-44.4],,,
NCT04533451,Testing the Effects of MK-3475 (Pembrolizumab) With or Without the Usual Chemotherapy Treatment for Patients 70 Years of Age and Older With Advanced N,Older Non-Small Cell Lung Cancer Patients (>/= 70 Years of Age) Treated With First-Line MK-3475 (Pembrolizumab)+/- Chemotherapy (Oncologist's/Patient's Choice),Alliance for Clinical Trials in Oncology,Alliance for Clinical Trials in Oncology,OTHER,ACTIVE_NOT_RECRUITING,2020-11-16,2023-10-31,2027-05-31,INTERVENTIONAL,PHASE2,,,,Metastatic Lung Adenocarcinoma,Metastatic Lung Adenocarcinoma; Metastatic Lung Non-Small Cell Carcinoma; Recurrent Lung Adenocarcinoma,7,2,6,DRUG; OTHER,,,1,3,True,Yes,Incidence of Grade 3 or Worse Adverse Events Post Registration (COUNT_OF_PARTICIPANTS) Participants = 11,Overall Survival (OS) (MEDIAN) months = 16.4; Quality of Life (QOL): Linear Analogue Self-Assessment [LASA] Questionnaire (MEAN) score on a scale = 0.0 [-1-1]; Comprehensive Geriatric Assessment Risk Score (COUNT_OF_PARTICIPANTS) Participants = 14,,,,,,,,,Overall Survival (OS) (MEDIAN) months = 16.4,,,Quality of Life (QOL): Linear Analogue Self-Assessment [LASA] Questionnaire (MEAN) score on a scale = 0.0 [-1-1],,Incidence of Grade 3 or Worse Adverse Events Post Registration (COUNT_OF_PARTICIPANTS) Participants = 11,,
NCT04606771,A Study Comparing Savolitinib Plus Osimertinib vs Savolitinib Plus Placebo in Patients With EGFRm+ and MET Amplified Advanced NSCLC,"A Multi-centre Phase II, Double-Blind, Randomised Study of Savolitinib in Combination With Osimertinib vs Savolitinib in Combination With Placebo in Patients With EGFRm+ and MET Amplified Locally Adva",AstraZeneca,AstraZeneca,INDUSTRY,ACTIVE_NOT_RECRUITING,2020-09-28,2022-12-21,2026-03-30,INTERVENTIONAL,PHASE2,,,,Non-Small Cell Lung Cancer,Non-Small Cell Lung Cancer,1,2,2,DRUG,,,1,11,True,Yes,Objective Response Rate (ORR) (NUMBER) Percentage of participants = 57.1 [28.86-82.34],"Progression-free Survival (PFS) (MEDIAN) Months = 7.36; Duration of Response (DoR) (MEDIAN) Weeks = 30.57; Tumour Size Assessment (TSA) (MEAN) Percentage change = -35.0; ; Total Clearance in EGFR Mutations at 6-weeks After Therapy Initiation (Percentage Change From Baseline in EGFR Mutation Allele Frequencies). (MEAN) Allele Frequency = -93.6; Total Clearance in EGFR Mutations at 6-weeks After Therapy Initiation (Absolute Change From Baseline in EGFR Mutation Allele Frequencies). (MEAN) Allele Frequency = -17.4; PK Concentration Ratios on Multiple Dosing (NUMBER) Geometric mean ratio = 0.8812; AUCss of Savolitinib, Osimertinib and Their Metabolites, (M2 and M3 for Savolitinib; AZ5104 for Osimertinib) (GEOMETRIC_MEAN) h*ng/mL = 7875; Cssmax of Savolitinib, Osimertinib and Their Metabolites, (M2 and M3 for Savolitinib; AZ5104 for Osimertinib) (GEOMETRIC_MEAN) ng/mL = 1282; Tssmax of Savolitinib, Osimertinib and Their Metabolites, (M2 and M3 for Savolitinib; AZ5104 for Osimertinib) (MEDIAN) h = 3.00 [1.00-5.62]; CLss/F of Savolitinib, Osimertinib and Their Metabolites, (M2 and M3 for Savolitinib; AZ5104 for Osimertinib) (GEOMETRIC_MEAN) L/h = 38.10",,,,,Duration of Response (DoR) (MEDIAN) Weeks = 30.57,,,Objective Response Rate (ORR) (NUMBER) Percentage of participants = 57.1 [28.86-82.34],PK Concentration Ratios on Multiple Dosing (NUMBER) Geometric mean ratio = 0.8812,Progression-free Survival (PFS) (MEDIAN) Months = 7.36,,,Objective Response Rate (ORR) (NUMBER) Percentage of participants = 57.1 [28.86-82.34],,,
NCT04619004,HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer,HERTHENA-Lung01: A Phase 2 Randomized Open-Label Study of Patritumab Deruxtecan (U3-1402) in Subjects With Previously Treated Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer (NS,Daiichi Sankyo,Daiichi Sankyo,INDUSTRY,ACTIVE_NOT_RECRUITING,2021-02-02,2022-11-21,2026-01-30,INTERVENTIONAL,PHASE2,,,,Non-Small Cell Lung Cancer Metastatic,Non-Small Cell Lung Cancer Metastatic; Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor,2,2,2,DRUG,,,1,8,True,Yes,Objective Response Rate (ORR) as Assessed by Blinded Independent Central Review (BICR) (COUNT_OF_PARTICIPANTS) Participants = 64,Duration of Response (DoR) (MEDIAN) months = 6.0 [4.4-7.2]; Progression-free Survival (PFS) (MEDIAN) months = 5.5 [5.1-5.9]; Objective Response Rate (ORR) as Assessed by the Investigator (COUNT_OF_PARTICIPANTS) Participants = 56; Disease Control Rate (DCR) (COUNT_OF_PARTICIPANTS) Participants = 166; Time to Tumor Response (TTR) (MEAN) months = 2.2; Best Percentage Change in the Sum of Diameters (SoD) of Measurable Tumors (MEAN) percentage change from baseline = -25.66; ; ,,,,,Duration of Response (DoR) (MEDIAN) months = 6.0 [4.4-7.2],,,Objective Response Rate (ORR) as Assessed by Blinded Independent Central Review (BICR) (COUNT_OF_PARTICIPANTS) Participants = 64; Objective Response Rate (ORR) as Assessed by the Investigator (COUNT_OF_PARTICIPANTS) Participants = 56,,Progression-free Survival (PFS) (MEDIAN) months = 5.5 [5.1-5.9],,,Objective Response Rate (ORR) as Assessed by Blinded Independent Central Review (BICR) (COUNT_OF_PARTICIPANTS) Participants = 64; Objective Response Rate (ORR) as Assessed by the Investigator (COUNT_OF_PARTICIPANTS) Participants = 56,,,
NCT04623775,A Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Parti,A Phase 2 Randomized Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurr,Bristol-Myers Squibb,Bristol-Myers Squibb,INDUSTRY,ACTIVE_NOT_RECRUITING,2021-02-17,2024-01-11,2026-02-27,INTERVENTIONAL,PHASE2,,,,Non-small Cell Lung Cancer,Non-small Cell Lung Cancer; Recurrent Non-small Cell Lung Cancer; Metastatic Non-small Cell Lung Cancer,3,4,7,BIOLOGICAL; DRUG,,,2,17,True,Yes,TRAEs Leading to Discontinuation Within 12 Weeks of First Dose in Part 1 (NUMBER) Percentage of Participants = 5.6 [1.6-13.8]; ORR Per RECISTS v1.1 by BICR in Part 2 (NUMBER) Percentage of Participants = 50.6 [43.8-57.4],TRAEs Leading to Discontinuation in Part 1 (COUNT_OF_PARTICIPANTS) Participants = 21; Number of Participants With a Treatment Related AEs in Part 1 (COUNT_OF_PARTICIPANTS) Participants = 75; Number of Participants With Treatment Releted SAEs in Part 1 (COUNT_OF_PARTICIPANTS) Participants = 20; Number of Participants With Treatment Releted Select AEs in Part 1 (COUNT_OF_PARTICIPANTS) Participants = 18; ORR by PD-L1 Expression Per RECISTS v1.1 by BICR in Part 2 (NUMBER) Percentage of Participants = 48.6 [38.2-59.0]; DoR Per RECISTS v1.1 by BICR in Part 2 (MEDIAN) Months = 8.41; Number of Participants With a AE in Part 2 (COUNT_OF_PARTICIPANTS) Participants = 158; Number of Participants With a Treatment Related AEs in Part 2 (COUNT_OF_PARTICIPANTS) Participants = 147; Number of Participants With a Treatment Related SAEs in Part 2 (COUNT_OF_PARTICIPANTS) Participants = 34; Number of Participants With Endocrine Immune-mediated Adverse Events in Part 2 (COUNT_OF_PARTICIPANTS) Participants = 2; ; ; ; ; ; ; ,,,,,DoR Per RECISTS v1.1 by BICR in Part 2 (MEDIAN) Months = 8.41,,,ORR Per RECISTS v1.1 by BICR in Part 2 (NUMBER) Percentage of Participants = 50.6 [43.8-57.4]; ORR by PD-L1 Expression Per RECISTS v1.1 by BICR in Part 2 (NUMBER) Percentage of Participants = 48.6 [38.2-59.0],,,,,,Number of Participants With a AE in Part 2 (COUNT_OF_PARTICIPANTS) Participants = 158; Number of Participants With Endocrine Immune-mediated Adverse Events in Part 2 (COUNT_OF_PARTICIPANTS) Participants = 2,,
NCT04644237,Trastuzumab Deruxtecan in Participants With HER2-mutated Metastatic Non-small Cell Lung Cancer (NSCLC),"A Phase 2, Multicenter, Randomized Study of Trastuzumab Deruxtecan in Subjects With HER2-mutated Metastatic Non-small Cell Lung Cancer (NSCLC) (DESTINY-LUNG02)",Daiichi Sankyo,Daiichi Sankyo,INDUSTRY,COMPLETED,2021-03-19,2022-12-23,2024-08-23,INTERVENTIONAL,PHASE2,,,,Non-Small Cell Lung Cancer,Non-Small Cell Lung Cancer,1,2,1,DRUG,,,1,12,True,Yes,Percentage of Participants With Confirmed Objective Response Rate by Blinded Independent Central Review Following Intravenous Administration of Trastuzumab Deruxtecan in Participants With Metastatic Non-small Cell Lung Cancer (NUMBER) percentage of participants = 50.0 [39.9-60.1],"Percentage of Participants With Confirmed Objective Response Rate by Investigator Following Intravenous Administration of Trastuzumab Deruxtecan in Participants With Metastatic Non-small Cell Lung CancerTumors (NUMBER) Percentage of participants = 46.1 [36.2-56.2]; Duration of Response Following Intravenous Administration of Trastuzumab Deruxtecan in Participants With Metastatic Non-small Cell Lung Cancer (MEDIAN) months = 11.1 [8.3-15.5]; Disease Control Rate Following Intravenous Administration of Trastuzumab Deruxtecan in Participants With Metastatic Non-small Cell Lung Cancer (NUMBER) Percentage of participants = 90.2 [82.7-95.2]; Progression-free Survival Following Intravenous Administration of Trastuzumab Deruxtecan in Participants With Metastatic Non-small Cell Lung Cancer (MEDIAN) months = 9.7 [8.2-11.3]; Overall Survival Following Intravenous Administration of Trastuzumab Deruxtecan in Participants With Metastatic Non-small Cell Lung Cancer Tumors (MEDIAN) months = 19.0; The Percentage of Participants Reporting Treatment-emergent Adverse Events Following Intravenous Administration of Trastuzumab Deruxtecan in Participants With Metastatic Non-small Cell Lung Cancer Tumors (COUNT_OF_PARTICIPANTS) Participants = 101; Pharmacokinetic Parameter Maximum Serum Concentration (Cmax) for Trastuzumab Deruxtecan, Total Anti-HER2 Antibody, and Active Metabolite MAAA-1181a (MEAN) µg/mL = 148; Pharmacokinetic Parameter Minimum Observed Concentration (Ctrough) for Trastuzumab Deruxtecan, Total Anti-HER2 Antibody, and Active Metabolite MAAA-1181a (MEAN) µg/mL = 5.47; Pharmacokinetic Parameter Area Under the Serum Concentration-Time Curve (AUC) for Trastuzumab Deruxtecan, Total Anti-HER2 Antibody, and Active Metabolite MAAA-1181a (MEAN) µg × d/mL = 658; Number of Participants With Anti-Drug Antibodies (ADA) Following Intravenous Administration of Trastuzumab Deruxtecan in Participants With Metastatic Non-small Cell Lung Cancer Tumors (COUNT_OF_PARTICIPANTS) Participants = 2; Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life Questionnaire (QLQ-C30) and EORTC Quality of Life Questionnaire for Lung Cancer Trials (QLQ-LC13) Scores (MEAN) score on scale = -1.11; Time to Deterioration in European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life Questionnaire (QLQ-C30) Scores (MEDIAN) months = 8.6 [4.9-11.4]",,,,,Duration of Response Following Intravenous Administration of Trastuzumab Deruxtecan in Participants With Metastatic Non-small Cell Lung Cancer (MEDIAN) months = 11.1 [8.3-15.5],,,Percentage of Participants With Confirmed Objective Response Rate by Blinded Independent Central Review Following Intravenous Administration of Trastuzumab Deruxtecan in Participants With Metastatic Non-small Cell Lung Cancer (NUMBER) percentage of participants = 50.0 [39.9-60.1]; Percentage of Participants With Confirmed Objective Response Rate by Investigator Following Intravenous Administration of Trastuzumab Deruxtecan in Participants With Metastatic Non-small Cell Lung CancerTumors (NUMBER) Percentage of participants = 46.1 [36.2-56.2],Overall Survival Following Intravenous Administration of Trastuzumab Deruxtecan in Participants With Metastatic Non-small Cell Lung Cancer Tumors (MEDIAN) months = 19.0,Progression-free Survival Following Intravenous Administration of Trastuzumab Deruxtecan in Participants With Metastatic Non-small Cell Lung Cancer (MEDIAN) months = 9.7 [8.2-11.3],,Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life Questionnaire (QLQ-C30) and EORTC Quality of Life Questionnaire for Lung Cancer Trials (QLQ-LC13) Scores (MEAN) score on scale = -1.11; Time to Deterioration in European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life Questionnaire (QLQ-C30) Scores (MEDIAN) months = 8.6 [4.9-11.4],Percentage of Participants With Confirmed Objective Response Rate by Blinded Independent Central Review Following Intravenous Administration of Trastuzumab Deruxtecan in Participants With Metastatic Non-small Cell Lung Cancer (NUMBER) percentage of participants = 50.0 [39.9-60.1]; Percentage of Participants With Confirmed Objective Response Rate by Investigator Following Intravenous Administration of Trastuzumab Deruxtecan in Participants With Metastatic Non-small Cell Lung CancerTumors (NUMBER) Percentage of participants = 46.1 [36.2-56.2],The Percentage of Participants Reporting Treatment-emergent Adverse Events Following Intravenous Administration of Trastuzumab Deruxtecan in Participants With Metastatic Non-small Cell Lung Cancer Tumors (COUNT_OF_PARTICIPANTS) Participants = 101,,
NCT04656652,Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterati,Phase 3 Randomized Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer (TROPION-LUNG01),Daiichi Sankyo,Daiichi Sankyo,INDUSTRY,ACTIVE_NOT_RECRUITING,2020-12-21,2024-05-10,2026-01-31,INTERVENTIONAL,PHASE3,,,,Non-small Cell Lung Cancer,Non-small Cell Lung Cancer,1,2,2,DRUG,,,2,3,True,Yes,Progression-free Survival (PFS) As Assessed by Blinded Independent Central Review (BICR) Per RECIST v1.1 Following DS-1062a Versus Docetaxel (MEDIAN) months = 4.4 [4.2-5.6]; Overall Survival (OS) Following DS-1062a Versus Docetaxel (MEDIAN) months = 12.9,Progression-free Survival (PFS) As Assessed by Investigator Per RECIST v1.1 Following DS-1062a Versus Docetaxel (MEDIAN) months = 4.4 [4.2-5.5]; Objective Response Rate (ORR) As Assessed by Blinded Independent Central Review (BICR) and Investigator As Per RECIST v1.1 Following DS-1062a Versus Docetaxel (COUNT_OF_PARTICIPANTS) Participants = 79; Duration of Response (DOR) As Assessed by Blinded Independent Central Review (BICR) and Investigator As Per RECIST v1.1 Following DS-1062a Versus Docetaxel (MEDIAN) months = 7.1 [5.6-10.9],,,,,Duration of Response (DOR) As Assessed by Blinded Independent Central Review (BICR) and Investigator As Per RECIST v1.1 Following DS-1062a Versus Docetaxel (MEDIAN) months = 7.1 [5.6-10.9],,,Objective Response Rate (ORR) As Assessed by Blinded Independent Central Review (BICR) and Investigator As Per RECIST v1.1 Following DS-1062a Versus Docetaxel (COUNT_OF_PARTICIPANTS) Participants = 79,Overall Survival (OS) Following DS-1062a Versus Docetaxel (MEDIAN) months = 12.9,Progression-free Survival (PFS) As Assessed by Blinded Independent Central Review (BICR) Per RECIST v1.1 Following DS-1062a Versus Docetaxel (MEDIAN) months = 4.4 [4.2-5.6]; Progression-free Survival (PFS) As Assessed by Investigator Per RECIST v1.1 Following DS-1062a Versus Docetaxel (MEDIAN) months = 4.4 [4.2-5.5],,,Objective Response Rate (ORR) As Assessed by Blinded Independent Central Review (BICR) and Investigator As Per RECIST v1.1 Following DS-1062a Versus Docetaxel (COUNT_OF_PARTICIPANTS) Participants = 79,,,
NCT04676412,Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-,"A Phase 3, Randomized, Double-blind Trial of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) in Participants With Treatment-naïve, Metastatic Nonsmall Cell Lung Cancer (NSCLC) Whose",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,INDUSTRY,COMPLETED,2019-10-23,2021-05-19,2024-03-29,INTERVENTIONAL,PHASE3,,,,Non-small Cell Lung Cancer,Non-small Cell Lung Cancer,1,2,3,BIOLOGICAL; DRUG,,,2,14,True,Yes,Progression-free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR) (MEDIAN) Months = 6.1 [4.2-8.7]; Overall Survival (OS) (MEDIAN) Months = 11.4,"Objective Response Rate (ORR) Per RECIST 1.1 as Assessed by BICR (NUMBER) Percentage of participants = 33.3 [19.6-49.5]; Number of Participants Who Experienced an Adverse Event (AE) (COUNT_OF_PARTICIPANTS) Participants = 49; Number of Participants Who Discontinued Study Treatment Due to an AE (COUNT_OF_PARTICIPANTS) Participants = 19; Change From Baseline in European Organization for Research and Treatment (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Combined Global Health Status / Quality of Life (Items 29 & 30) Scale Combined Score (LEAST_SQUARES_MEAN) Score on a scale = -2.43 [-8.69-3.83]; Change From Baseline in Cough (EORTC Quality of Life Questionnaire-Lung Cancer Module 13 [QLQ-LC13] Item 31) Score (LEAST_SQUARES_MEAN) Score on a scale = -2.97 [-9.97-4.04]; Change From Baseline in Chest Pain (EORTC QLQ-LC13 Item 40) Score (LEAST_SQUARES_MEAN) Score on a scale = -3.84 [-9.95-2.28]; Change From Baseline in Dyspnea (EORTC QLQ-C30 Item 8) Score (LEAST_SQUARES_MEAN) Score on a scale = 0.54 [-7.85-8.94]; Change From Baseline in Physical Functioning (EORTC QLQ-C30 Items 1-5) Score (LEAST_SQUARES_MEAN) Score on a scale = -5.15 [-10.78-0.48]; ; ; ; ; Time to True Deterioration (TTD) in the Composite Endpoint of EORTC QLQ-LC13 Cough (Item 31), EORTC QLQ-LC13 Chest Pain (Item 40), or EORTC QLQ-C30 Dyspnea (Item 8) (MEDIAN) Months = 5.78; ",,,,,,,,Objective Response Rate (ORR) Per RECIST 1.1 as Assessed by BICR (NUMBER) Percentage of participants = 33.3 [19.6-49.5],Overall Survival (OS) (MEDIAN) Months = 11.4,Progression-free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR) (MEDIAN) Months = 6.1 [4.2-8.7],,Change From Baseline in European Organization for Research and Treatment (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Combined Global Health Status / Quality of Life (Items 29 & 30) Scale Combined Score (LEAST_SQUARES_MEAN) Score on a scale = -2.43 [-8.69-3.83]; Change From Baseline in Cough (EORTC Quality of Life Questionnaire-Lung Cancer Module 13 [QLQ-LC13] Item 31) Score (LEAST_SQUARES_MEAN) Score on a scale = -2.97 [-9.97-4.04],Objective Response Rate (ORR) Per RECIST 1.1 as Assessed by BICR (NUMBER) Percentage of participants = 33.3 [19.6-49.5],Number of Participants Who Discontinued Study Treatment Due to an AE (COUNT_OF_PARTICIPANTS) Participants = 19,,
NCT04685135,Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation,A Randomized Phase 3 Study of MRTX849 Versus Docetaxel in Patients With Previously Treated Non-Small Cell Lung Cancer With KRAS G12C Mutation,Mirati Therapeutics Inc.,Mirati Therapeutics Inc.,INDUSTRY,ACTIVE_NOT_RECRUITING,2021-02-23,2023-12-30,2026-07-02,INTERVENTIONAL,PHASE3,,,,Metastatic Non Small Cell Lung Cancer,Metastatic Non Small Cell Lung Cancer; Advanced Non Small Cell Lung Cancer,2,2,2,DRUG,,,1,13,True,Yes,Progression-Free Survival (PFS) as Per Blinded Independent Central Review (MEDIAN) months = 5.49 [4.53-6.67],; Objective Response Rate (ORR) as Per Blinded Independent Central Review (NUMBER) percentage of participants = 31.9 [26.7-37.5]; Duration of Response (DOR) as Per Blinded Independent Central Review (MEDIAN) months = 8.31 [6.05-10.35]; ; Number of Participants With Treatment Emergent Adverse Events (TEAEs) (COUNT_OF_PARTICIPANTS) Participants = 298; Number of Participants With Maximum CTCAE Grade Laboratory Abnormality in Hematology Parameters (COUNT_OF_PARTICIPANTS) Participants = 50; Number of Participants With Maximum CTCAE Grade Laboratory Abnormality in Chemistry Parameters (COUNT_OF_PARTICIPANTS) Participants = 118; ; Change From Baseline in Lung Cancer Symptom Scale (LCSS) Average Total Score (LEAST_SQUARES_MEAN) Score on a sclae = -4.0 [-7.9--0.2]; Change From Baseline in Lung Cancer Symptom Scale (LCSS) Average Symptom Burden Index Score (LEAST_SQUARES_MEAN) Score on a sclae = -5.8 [-9.0--2.5]; Change From Baseline in Lung Cancer Symptom Scale (LCSS) 3-Item Global Index Score (LEAST_SQUARES_MEAN) Score on a sclae = -3.0 [-20.3-14.3]; Change From Baseline at End of Treatment in European Quality of Life Five Dimensions Questionnaire (EQ-5D-5L) Visual Analogue Scale Score (LEAST_SQUARES_MEAN) Score on a scale = 0.1 [-4.4-4.5]; Change From Baseline at End of Treatment in European Quality of Life Five Dimensions Questionnaire (EQ-5D-5L) Health Utility Index Score (LEAST_SQUARES_MEAN) Score on a scale = -0.0350 [-0.0977-0.0277],,,,,Duration of Response (DOR) as Per Blinded Independent Central Review (MEDIAN) months = 8.31 [6.05-10.35],,,Objective Response Rate (ORR) as Per Blinded Independent Central Review (NUMBER) percentage of participants = 31.9 [26.7-37.5],,Progression-Free Survival (PFS) as Per Blinded Independent Central Review (MEDIAN) months = 5.49 [4.53-6.67],,Change From Baseline at End of Treatment in European Quality of Life Five Dimensions Questionnaire (EQ-5D-5L) Visual Analogue Scale Score (LEAST_SQUARES_MEAN) Score on a scale = 0.1 [-4.4-4.5]; Change From Baseline at End of Treatment in European Quality of Life Five Dimensions Questionnaire (EQ-5D-5L) Health Utility Index Score (LEAST_SQUARES_MEAN) Score on a scale = -0.0350 [-0.0977-0.0277],Objective Response Rate (ORR) as Per Blinded Independent Central Review (NUMBER) percentage of participants = 31.9 [26.7-37.5],Number of Participants With Treatment Emergent Adverse Events (TEAEs) (COUNT_OF_PARTICIPANTS) Participants = 298,,
NCT04716933,Safety and Efficacy Study of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) as First-line Int,"A Phase 3 Randomized, Placebo-controlled Study to Evaluate the Safety and Efficacy of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First-l",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,INDUSTRY,COMPLETED,2019-11-05,2023-08-11,2024-08-30,INTERVENTIONAL,PHASE3,,,,Nonsquamous Non-small Cell Lung Cancer,Nonsquamous Non-small Cell Lung Cancer,1,2,6,BIOLOGICAL; DRUG,,,2,4,True,Yes,Part 2: Progression-free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) (MEDIAN) Months = 15.3 [12.2-19.6]; Part 2: Overall Survival (OS) (MEDIAN) Months = 26.6 [22.2-35.0],Part 2: Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) (NUMBER) Percentage of participants = 70.3 [60.4-79.0]; Part 2: Duration of Response (DOR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) (MEDIAN) Months = 17.0 [12.6-23.6]; Part 2: Number of Participants Who Experienced an Adverse Event (AE) (COUNT_OF_PARTICIPANTS) Participants = 101; Part 2: Number of Participants Who Discontinued Study Drug Due to an Adverse Event (COUNT_OF_PARTICIPANTS) Participants = 42,,,,,Part 2: Duration of Response (DOR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) (MEDIAN) Months = 17.0 [12.6-23.6],,,Part 2: Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) (NUMBER) Percentage of participants = 70.3 [60.4-79.0],Part 2: Overall Survival (OS) (MEDIAN) Months = 26.6 [22.2-35.0],Part 2: Progression-free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) (MEDIAN) Months = 15.3 [12.2-19.6],,,Part 2: Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) (NUMBER) Percentage of participants = 70.3 [60.4-79.0],,,
NCT04725188,Pembrolizumab/Vibostolimab Coformulation (MK-7684A) or Pembrolizumab/Vibostolimab Coformulation Plus Docetaxel Versus Docetaxel for Metastatic Non Sma,"A Phase 2, Multicenter, Randomized Study to Compare the Efficacy and Safety of MK-7684A or MK-7684A Plus Docetaxel Versus Docetaxel Monotherapy in the Treatment of Participants With Metastatic Non-sma",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,INDUSTRY,COMPLETED,2021-04-20,2023-01-26,2024-10-17,INTERVENTIONAL,PHASE2,,,,Metastatic Non Small Cell Lung Cancer,Metastatic Non Small Cell Lung Cancer,1,3,3,BIOLOGICAL; DRUG,,,1,5,True,Yes,Progression Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by Blinded Independent Central Review (BICR) Assessment (MEDIAN) Months = 5.6 [3.9-6.8],Objective Response Rate (ORR) Per RECIST 1.1 by BICR Assessment (NUMBER) Percentage of participants = 29.9 [20.5-40.6]; Overall Survival (OS) (MEDIAN) Months = 10.2 [8.6-14.9]; Duration of Response (DOR) Per RECIST 1.1 by BICR Assessment (MEDIAN) Months = 6.5 [5.3-10.7]; Number of Participants Who Experienced an Adverse Event (AE) (COUNT_OF_PARTICIPANTS) Participants = 85; Number of Participants Who Discontinued Study Treatment Due to an AE (COUNT_OF_PARTICIPANTS) Participants = 42,,,,,Duration of Response (DOR) Per RECIST 1.1 by BICR Assessment (MEDIAN) Months = 6.5 [5.3-10.7],,,Objective Response Rate (ORR) Per RECIST 1.1 by BICR Assessment (NUMBER) Percentage of participants = 29.9 [20.5-40.6],Overall Survival (OS) (MEDIAN) Months = 10.2 [8.6-14.9],Progression Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by Blinded Independent Central Review (BICR) Assessment (MEDIAN) Months = 5.6 [3.9-6.8],,,Objective Response Rate (ORR) Per RECIST 1.1 by BICR Assessment (NUMBER) Percentage of participants = 29.9 [20.5-40.6],Number of Participants Who Discontinued Study Treatment Due to an AE (COUNT_OF_PARTICIPANTS) Participants = 42,,
NCT04735068,Binimetinib and Hydroxychloroquine in Patients With Advanced KRAS Mutant Non-Small Cell Lung Cancer,The LIMIT KRAS Mutant NSCLC Trial: Lysosome Inhibition to Enhance MAPK Inhibition Targeting KRAS Mutant NSCLC: A Phase 2 Open Label Trial of Binimetinib and Hydroxychloroquine in Patients With Advance,Abramson Cancer Center at Penn Medicine,Abramson Cancer Center at Penn Medicine,OTHER,COMPLETED,2021-04-09,2022-08-21,2023-12-31,INTERVENTIONAL,PHASE2,,,,Non-Small Cell Lung Cancer,Non-Small Cell Lung Cancer; KRAS Mutation-Related Tumors,2,1,2,DRUG,,,2,2,True,Yes,Objective Response Rate (COUNT_OF_PARTICIPANTS) Participants = 9; Number of Patients With Adverse Events (COUNT_OF_PARTICIPANTS) Participants = 9,Progression-free Survival (PFS) (COUNT_OF_PARTICIPANTS) Participants = 1; Overall Survival (OS) (COUNT_OF_PARTICIPANTS) Participants = 1,,,,,,,,Objective Response Rate (COUNT_OF_PARTICIPANTS) Participants = 9,Overall Survival (OS) (COUNT_OF_PARTICIPANTS) Participants = 1,Progression-free Survival (PFS) (COUNT_OF_PARTICIPANTS) Participants = 1,,,Objective Response Rate (COUNT_OF_PARTICIPANTS) Participants = 9,Number of Patients With Adverse Events (COUNT_OF_PARTICIPANTS) Participants = 9,,
NCT04738487,Coformulation of Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab (MK-3475) Monotherapy for Programmed Cell Death 1 Ligand 1 (PD-L1) Positiv,"A Phase 3, Multicenter, Randomized, Double-Blind Study of MK-7684 With Pembrolizumab as a Coformulation (MK-7684A) Versus Pembrolizumab Monotherapy as First Line Treatment for Participants With PD-L1 ",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,INDUSTRY,ACTIVE_NOT_RECRUITING,2021-04-07,2024-09-05,2026-01-26,INTERVENTIONAL,PHASE3,,,,Lung Neoplasms,Lung Neoplasms; Non-Small-Cell Lung Carcinoma,2,2,2,BIOLOGICAL,,,1,49,True,Yes,Overall Survival (OS) in Participants With PD-L1 TPS ≥50% (MEDIAN) Months = 15.7 [12.4-24.0],OS in Participants With PD-L1 TPS ≥1% (MEDIAN) Months = 15.0 [12.7-17.4]; OS in Participants With PD-L1 TPS 1% to 49% (MEDIAN) Months = 14.3 [11.3-17.8]; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ,,,,,,,,,Overall Survival (OS) in Participants With PD-L1 TPS ≥50% (MEDIAN) Months = 15.7 [12.4-24.0]; OS in Participants With PD-L1 TPS ≥1% (MEDIAN) Months = 15.0 [12.7-17.4]; OS in Participants With PD-L1 TPS 1% to 49% (MEDIAN) Months = 14.3 [11.3-17.8],,,,,,,
NCT04880863,NAP in Combination With Docetaxel Following Obinutuzumab Pretreatment in Subjects With Checkpoint Inhibitor Pretreated Advanced or Metastatic NSCLC,"Phase 2a Open-Label, Multicenter Trial of Naptumomab Estafenatox (NAP) in Combination With Docetaxel Following Obinutuzumab Pretreatment in Subjects With Checkpoint Inhibitor Pretreated Advanced or Me",NeoTX Therapeutics Ltd.,NeoTX Therapeutics Ltd.,INDUSTRY,COMPLETED,2021-10-26,2024-01-30,2024-01-30,INTERVENTIONAL,PHASE2,,,,Non-small Cell Lung Cancer,Non-small Cell Lung Cancer,1,1,3,DRUG,,,1,5,True,Yes,Objective Response Rate (ORR) (NUMBER) percentage of responders = 15.6 [5.3-32.8],"Disease Control Rate (DCR) (NUMBER) percentage of patients with SD, PR, CR = 71.9 [53.3-86.3]; Duration of Response (DOR) (MEDIAN) months = 12.2 [1.6-17.7]; Progression-free Survival (PFS) (MEAN) months = 8.8 [6.1-15.2]; Overall Survival (OS) (MEAN) months = 8.8 [6.4-11.7]; Treatment-Emergent Adverse Events (TEAEs) (NUMBER) participants = 37",,"Disease Control Rate (DCR) (NUMBER) percentage of patients with SD, PR, CR = 71.9 [53.3-86.3]",,,Duration of Response (DOR) (MEDIAN) months = 12.2 [1.6-17.7],,,Objective Response Rate (ORR) (NUMBER) percentage of responders = 15.6 [5.3-32.8],Overall Survival (OS) (MEAN) months = 8.8 [6.4-11.7],Progression-free Survival (PFS) (MEAN) months = 8.8 [6.1-15.2],,,Objective Response Rate (ORR) (NUMBER) percentage of responders = 15.6 [5.3-32.8],Treatment-Emergent Adverse Events (TEAEs) (NUMBER) participants = 37,,
NCT04956692,Study of Pembrolizumab (MK-3475) Subcutaneous (SC) Versus Pembrolizumab Intravenous (IV) Administered With Platinum Doublet Chemotherapy in Participan,"A Randomized, Phase 3, Open-label Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Pembrolizumab Versus Intravenous Pembrolizumab, Administered With Platinum Doublet Chemotherapy, ",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,INDUSTRY,ACTIVE_NOT_RECRUITING,2021-08-05,2023-04-04,2026-10-14,INTERVENTIONAL,PHASE3,,,,Non-Small Cell Lung Cancer,Non-Small Cell Lung Cancer,1,2,7,BIOLOGICAL; DRUG,,,2,12,True,Yes,Cycle 1 Area Under The Curve From 0-3 Weeks (AUC 0-3wks) of Pembrolizumab (GEOMETRIC_MEAN) hr*µg/mL = 471.33 [452.22-491.26]; Cycle 6 Model-Based Minimal Concentration (Ctrough) of Pembrolizumab (GEOMETRIC_MEAN) µg/mL = 55.93 [53.05-58.96],; Cycle 1 Observed Ctrough of Pembrolizumab (GEOMETRIC_MEAN) µg/mL = 18.36 [17.19-19.61]; Cycle 1 Maximum Concentration (Cmax) of Pembrolizumab (GEOMETRIC_MEAN) µg/mL = 25.2 [23.8-26.6]; Cycle 6 AUC 0-3wks of Pembrolizumab (GEOMETRIC_MEAN) hr*µg/mL = 1403.8 [1342.0-1468.5]; Cycle 6 Cmax of Pembrolizumab (GEOMETRIC_MEAN) µg/mL = 65.6 [62.2-69.0]; Cycle 6 Observed Ctrough of Pembrolizumab (GEOMETRIC_MEAN) µg/mL = 57.17 [52.23-62.58]; ; ; ; ; ; ,,,,,,,,,,,,,,,,
NCT04967417,Pembrolizumab With Standard Cytotoxic Chemotherapy in Treatment Naive NSCLC Patients With Asymptomatic Brain Metastases,Pembrolizumab With Standard Cytotoxic Chemotherapy in Treatment Naive Non-small Cell Lung Cancer Patients With Asymptomatic Brain Metastases,Samsung Medical Center,Samsung Medical Center,OTHER,COMPLETED,2022-05-26,2024-06-30,2024-12-02,INTERVENTIONAL,PHASE2,,,,Non-small Cell Lung Cancer,Non-small Cell Lung Cancer,1,2,2,DRUG,,,1,6,True,Yes,Intracranial Objective Response Rate (COUNT_OF_PARTICIPANTS) Participants = 6,Progression Free Survival (PFS) (MEDIAN) Months = 7.23 [2.4-12.29]; Overall Survival (OS) (MEDIAN) Months = 10.45 [7.2-21.52]; Intracranial Duration of Response (MEDIAN) Months = 9.3 [3.98-20.34]; Intracranial Progression-free Survival (MEDIAN) Months = 9.82 [5.19-21.49]; Objective Response Rate (COUNT_OF_PARTICIPANTS) Participants = 6; Adverse Events (NUMBER) Number = 11,,,,,Intracranial Duration of Response (MEDIAN) Months = 9.3 [3.98-20.34],,,Intracranial Objective Response Rate (COUNT_OF_PARTICIPANTS) Participants = 6; Objective Response Rate (COUNT_OF_PARTICIPANTS) Participants = 6,Overall Survival (OS) (MEDIAN) Months = 10.45 [7.2-21.52],Progression Free Survival (PFS) (MEDIAN) Months = 7.23 [2.4-12.29]; Intracranial Progression-free Survival (MEDIAN) Months = 9.82 [5.19-21.49],,,Intracranial Objective Response Rate (COUNT_OF_PARTICIPANTS) Participants = 6; Objective Response Rate (COUNT_OF_PARTICIPANTS) Participants = 6,Adverse Events (NUMBER) Number = 11,,
NCT05001347,A Clinical Study of TJ004309 With Atezolizumab (TECENTRIQ®) in Patients With Ovarian Cancer and Selected Solid Tumors,A Phase 2 Clinical Study of TJ004309 in Combination With Atezolizumab (TECENTRIQ®) in Patients With Advanced or Metastatic Ovarian Cancers and Selected Advanced Solid Tumors,I-Mab Biopharma US Limited,I-Mab Biopharma US Limited,INDUSTRY,COMPLETED,2021-11-02,2023-02-08,2023-02-08,INTERVENTIONAL,PHASE2,,,,Ovarian Cancer,Ovarian Cancer; Head and Neck Cancer; Non Small Cell Lung Cancer,6,1,1,DRUG,,,1,1,True,Yes,To Assess the Efficacy of TJ004309 Combined With Atezolizumab in a Cohort of Patients With Platinum-resistant IO Naive Ovarian Carcinoma and a Separate Biomarker Enriched Cohort of Subjects With Selected Tumor Types (COUNT_OF_PARTICIPANTS) Participants = 1,o Assess the Efficacy of TJ004309 Combined With Atezolizumab in a Cohort of Patients With Platinum-resistant IO Naive Ovarian Carcinoma and a Separate Biomarker Enriched Cohort of Subjects With Selected Tumor Types (COUNT_OF_PARTICIPANTS) Participants = 0,,,,,,,,,,,,,,,,
NCT05005273,A Study to Assess BMS-986207 in Combination With Nivolumab and Ipilimumab as First-line Treatment for Participants With Stage IV Non-Small Cell Lung C,A Phase 2 Randomized Study of BMS-986207 in Combination With Nivolumab and Ipilimumab as First-line Treatment for Participants With Stage IV Non-Small Cell Lung Cancer,Bristol-Myers Squibb,Bristol-Myers Squibb,INDUSTRY,COMPLETED,2022-10-03,2022-12-27,2022-12-27,INTERVENTIONAL,PHASE2,,,,Non-Small Cell Lung Cancer,Non-Small Cell Lung Cancer,1,2,4,DRUG; OTHER,,,1,6,True,Yes,,"Progression Free Survival by Investigator (MEAN) Months = 2.3; ; ; ; Overall Survival (OS) (MEAN) Months = 2.3; Number of Participants Who Had AEs, SAEs, AEs Leading to Discontinuation and Deaths. (COUNT_OF_PARTICIPANTS) Participants = 0",,,,,,,,,Overall Survival (OS) (MEAN) Months = 2.3,Progression Free Survival by Investigator (MEAN) Months = 2.3,,,,"Number of Participants Who Had AEs, SAEs, AEs Leading to Discontinuation and Deaths. (COUNT_OF_PARTICIPANTS) Participants = 0",,
NCT05014815,Ociperlimab With Tislelizumab and Chemotherapy in Participants With Untreated Metastatic Non-Small Cell Lung Cancer,"AdvanTIG-205: A Phase 2, Randomized Study of Ociperlimab (BGB-A1217) and Tislelizumab With Chemotherapy in Patients With Previously Untreated Locally Advanced, Unresectable, or Metastatic Non-Small Ce",BeiGene,BeiGene,INDUSTRY,COMPLETED,2021-11-16,2024-09-04,2024-09-04,INTERVENTIONAL,PHASE2,,,,"Locally Advanced, Unresectable, or Metastatic Nonsmall Cell Lung Cancer (NSCLC)","Locally Advanced, Unresectable, or Metastatic Nonsmall Cell Lung Cancer (NSCLC); Nonsmall Cell Lung Cancer, Stage IIIB; Nonsmall Cell Lung Cancer, Stage IV",3,2,8,DRUG,,,1,4,True,Yes,Progression-free Survival (PFS) (MEDIAN) Months = 8.2 [6.2-10.6],Objective Response Rate (ORR) (NUMBER) percentage of participants = 41.9 [33.5-50.7]; Duration of Response (DOR) (MEDIAN) months = 10.4 [8.0-17.7]; Overall Survival (OS) (MEDIAN) Months = 20.6; Number of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) (COUNT_OF_PARTICIPANTS) Participants = 134,,,,,Duration of Response (DOR) (MEDIAN) months = 10.4 [8.0-17.7],,,Objective Response Rate (ORR) (NUMBER) percentage of participants = 41.9 [33.5-50.7],Overall Survival (OS) (MEDIAN) Months = 20.6,Progression-free Survival (PFS) (MEDIAN) Months = 8.2 [6.2-10.6],,,Objective Response Rate (ORR) (NUMBER) percentage of participants = 41.9 [33.5-50.7],Number of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) (COUNT_OF_PARTICIPANTS) Participants = 134,,
NCT05089734,Study of Sacituzumab Govitecan (SG) Versus Docetaxel in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC),"Open-Label, Global, Multicenter, Randomized, Phase 3 Study of Sacituzumab Govitecan Versus Docetaxel in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Progression on or A",Gilead Sciences,Gilead Sciences,INDUSTRY,ACTIVE_NOT_RECRUITING,2021-11-17,2023-11-29,2026-01,INTERVENTIONAL,PHASE3,,,,Non-Small Cell Lung Cancer,Non-Small Cell Lung Cancer,1,2,2,BIOLOGICAL; DRUG,,,1,8,True,Yes,Overall Survival (OS) (MEDIAN) months = 11.1 [9.4-12.3],Progression-free Survival (PFS) Assessed by Investigator Per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 (MEDIAN) months = 4.1 [3.0-4.4]; Objective Response Rate (ORR) Assessed by Investigator Per RECIST Version 1.1 (NUMBER) percentage of participants = 13.7 [10.0-18.1]; Duration of Response (DOR) Assessed by Investigator Per RECIST Version 1.1 (MEDIAN) months = 6.7 [4.4-9.8]; Disease Control Rate (DCR) Assessed by Investigator Per RECIST Version 1.1 (NUMBER) percentage of participants = 67.6 [61.9-72.8]; ; ; Time to First Deterioration in Shortness of Breath Domain as Measured by Non-small Cell Lung Cancer Symptom Assessment Questionnaire (NSCLC-SAQ) (MEDIAN) months = 2.8 [2.2-4.0]; Time to First Deterioration in NSCLC-SAQ Total Score (MEDIAN) months = 3.1 [2.5-3.9],,,,,Duration of Response (DOR) Assessed by Investigator Per RECIST Version 1.1 (MEDIAN) months = 6.7 [4.4-9.8],,,Objective Response Rate (ORR) Assessed by Investigator Per RECIST Version 1.1 (NUMBER) percentage of participants = 13.7 [10.0-18.1],Overall Survival (OS) (MEDIAN) months = 11.1 [9.4-12.3],Progression-free Survival (PFS) Assessed by Investigator Per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 (MEDIAN) months = 4.1 [3.0-4.4],,,Objective Response Rate (ORR) Assessed by Investigator Per RECIST Version 1.1 (NUMBER) percentage of participants = 13.7 [10.0-18.1],,,
NCT05171777,A Study to Evaluate Participant and Healthcare Professional Reported Preference for Subcutaneous Atezolizumab Compared With Intravenous Atezolizumab F,"A Randomized, Multicenter, Open-Label Cross-Over Study to Evaluate Participant and Healthcare Professional Reported Preference for Subcutaneous Atezolizumab Compared With Intravenous Atezolizumab Form",Hoffmann-La Roche,Hoffmann-La Roche,INDUSTRY,COMPLETED,2022-04-04,2023-11-09,2024-10-25,INTERVENTIONAL,PHASE2,,,,Non-small Cell Lung Cancer,Non-small Cell Lung Cancer,1,2,1,DRUG,,,1,27,True,Yes,Percentage of Participants Who Preferred Atezolizumab SC to Atezolizumab IV Assessed Using Patient Preference Questionnaire (PPQ) (NUMBER) percentage of participants = 71.67 [58.56-82.55],"Number of Participants by Their Level of Satisfaction With Atezolizumab SC and Atezolizumab IV Assessed Using Therapy Administration Satisfaction Questionnaire - Subcutaneous (TASQ-SC) and Intravenous (TASQ-IV) (COUNT_OF_PARTICIPANTS) Participants = 25; Percentage of Participants Who Select Atezolizumab SC for Treatment Continuation Period (NUMBER) percentage of participants = 78.2; Duration of Treatment Preparation According to Healthcare Professionals (HCPs) Response to Perception of Time, Assessed Using Question 1 of Healthcare Professional Questionnaires (HCPQs) - Drug Preparation Area (MEDIAN) minutes = 5.0 [1-40]; Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Drug Preparation Area (NUMBER) percentage of HCPs = 7.0; Percentage of HCPs by Their Response to Perception of Time/Resource Use for Atezolizumab SC and Atezolizumab IV, Assessed Using Questions 3 and 4 of HCPQ - Drug Preparation Area (NUMBER) percentage of HCPs = 71.9; Duration of Treatment Administration Activities According to HCPs Response to Perception of Time, Assessed Using Question 1 of HCPQs - Treatment Room (MEDIAN) minutes = 5 [5-5]; Percentage of HCPs by Their Response to Perception of Impact on Clinical Management and Clinical Efficiency of Atezolizumab SC and IV, Assessed Using Question 2 of HCPQ - Treatment Room (NUMBER) percentage of HCPs = 13.8; Percentage of HCPs by Their Response to Perception of Time/Resource Use and Convenience for Atezolizumab SC and Atezolizumab IV, Assessed Using Questions 3 to 7 of HCPQ - Treatment Room (NUMBER) percentage of HCPs = 72.4; Percentage of HCPs by Their Response to Perception of Time/Resource Use and Convenience for Atezolizumab SC and Atezolizumab IV, Assessed Using Questions 8 of HCPQ - Treatment Room (NUMBER) percentage of HCPs = 41.4; Change From Baseline Over Time in Physical Functioning Scale Score as Assessed by European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 (EORTC-QLQ-C30) (MEAN) score on a scale = 75.00; Change From Baseline Over Time in Role Functioning Scale Score as Assessed by EORTC-QLQ-C30 (MEAN) score on a scale = 77.46; Change From Baseline Over Time in Emotional Functioning Scale Score as Assessed by EORTC-QLQ-C30 (MEAN) score on a scale = 79.48; Change From Baseline Over Time in Cognitive Functioning Scale Score as Assessed by EORTC-QLQ-C30 (MEAN) score on a scale = 87.31; Change From Baseline Over Time in Social Functioning Scale Score as Assessed by EORTC-QLQ-C30 (MEAN) score on a scale = 82.95; Change From Baseline Over Time in Fatigue Scale Score as Assessed by EORTC-QLQ-C30 (MEAN) score on a scale = 30.81; Change From Baseline Over Time in Nausea and Vomiting Scale Score as Assessed by EORTC-QLQ-C30 (MEAN) score on a scale = 5.30; Change From Baseline Over Time in Pain Scale Score as Assessed by EORTC-QLQ-C30 (MEAN) score on a scale = 22.16; Change From Baseline Over Time in Dyspnoea Scale Score as Assessed by EORTC-QLQ-C30 (MEAN) score on a scale = 25.38; Change From Baseline Over Time in Insomnia Scale Score as Assessed by EORTC-QLQ-C30 (MEAN) score on a scale = 23.11; Change From Baseline Over Time in Appetite Loss Scale Score as Assessed by EORTC-QLQ-C30 (MEAN) score on a scale = 16.67; Change From Baseline Over Time in Constipation Scale Score as Assessed by EORTC-QLQ-C30 (MEAN) score on a scale = 19.32; Change From Baseline Over Time in Diarrhoea Scale Score as Assessed by EORTC-QLQ-C30 (MEAN) score on a scale = 5.68; Change From Baseline Over Time in Financial Difficulties Scale Score as Assessed by EORTC-QLQ-C30 (MEAN) score on a scale = 13.79; Change From Baseline Over Time in Health-related Quality of Life (HRQoL) Score as Assessed by GHS/QoL Scale of the EORTC-QLQ-C30 (MEAN) score on a scale = 67.05; Percentage of Participants With Ongoing Clinical Benefit (NUMBER) percentage of participants = 44.7; Percentage of Participants With Adverse Events (AEs) (NUMBER) percentage of participants = 59.4; Percentage of Participants With AEs During Treatment Cross-over Period (NUMBER) percentage of participants = 62.9",,,,,,,,,,,,Change From Baseline Over Time in Physical Functioning Scale Score as Assessed by European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 (EORTC-QLQ-C30) (MEAN) score on a scale = 75.00; Change From Baseline Over Time in Health-related Quality of Life (HRQoL) Score as Assessed by GHS/QoL Scale of the EORTC-QLQ-C30 (MEAN) score on a scale = 67.05,,Percentage of Participants With Adverse Events (AEs) (NUMBER) percentage of participants = 59.4,,
NCT05226598,Study of Pembrolizumab/Vibostolimab Coformulation (MK-7684A) in Combination With Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants W,"A Randomized, Double-Blind, Phase 3 Study of Pembrolizumab/Vibostolimab Coformulation (MK-7684A) in Combination With Chemotherapy Versus Pembrolizumab Plus Chemotherapy as First Line Treatment for Par",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,INDUSTRY,ACTIVE_NOT_RECRUITING,2022-03-24,2024-09-24,2026-01-09,INTERVENTIONAL,PHASE3,,,,Metastatic Non-Small Cell Lung Cancer,Metastatic Non-Small Cell Lung Cancer,1,2,7,BIOLOGICAL; DRUG,,,1,18,True,Yes,Overall Survival (OS) in Participants With Programmed Cell Death-Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥1% (MEDIAN) Months = 19.4 [17.2-23.9],Overall Survival (OS) in All Participants (MEDIAN) Months = 20.0 [17.0-22.5]; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ,,,,,,,,,Overall Survival (OS) in Participants With Programmed Cell Death-Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥1% (MEDIAN) Months = 19.4 [17.2-23.9]; Overall Survival (OS) in All Participants (MEDIAN) Months = 20.0 [17.0-22.5],,,,,,,
NCT05246514,A Single Arm Phase 2 Study to Evaluate Efficacy and Safety of Trastuzumab Deruxtecan for Patients With HER2 Mutant NSCLC,"An Open-label, Single-arm, Phase 2 Study to Evaluate the Efficacy and Safety of Trastuzumab Deruxtecan (T-DXd) for Patients With HER2-mutant Metastatic NSCLC Who Have Disease Progression on or After a",AstraZeneca,AstraZeneca,INDUSTRY,ACTIVE_NOT_RECRUITING,2022-07-13,2023-09-23,2026-03-16,INTERVENTIONAL,PHASE2,,,,HER2-mutant Non-Small Cell Lung Cancer,HER2-mutant Non-Small Cell Lung Cancer,1,1,1,DRUG,,,1,9,True,Yes,ICR-assessed ORR (Objective Response Rate) (NUMBER) Percentage of participants = 58.3 [46.1-69.8],Investigator-assessed ORR (Objective Response Rate) (NUMBER) Percentage of participants = 58.3 [46.1-69.8]; ; ICR-assessed and Investigator-assessed DCR (Disease Control Rate) (NUMBER) Percentage of participants = 91.7 [82.7-96.9]; ; ; ; ; ; ,,,,,,,,ICR-assessed ORR (Objective Response Rate) (NUMBER) Percentage of participants = 58.3 [46.1-69.8]; Investigator-assessed ORR (Objective Response Rate) (NUMBER) Percentage of participants = 58.3 [46.1-69.8],,,,,ICR-assessed ORR (Objective Response Rate) (NUMBER) Percentage of participants = 58.3 [46.1-69.8]; Investigator-assessed ORR (Objective Response Rate) (NUMBER) Percentage of participants = 58.3 [46.1-69.8],,,
NCT05253807,Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Relapsed or Refractory Advanced Non-Small Cell Lung Cancer With an FGFR ,"A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Advanced Non-Small Cell Lung Cancer With an FGFR Alteration Who Progressed ",Incyte Corporation,Incyte Corporation,INDUSTRY,COMPLETED,2022-04-29,2023-08-16,2023-08-16,INTERVENTIONAL,PHASE2,,,,Non-Small Cell Lung Cancer (NSCLC),Non-Small Cell Lung Cancer (NSCLC),1,2,1,DRUG,,,1,6,True,Yes,Objective Response Rate (ORR) in Cohort A (NUMBER) percentage of participants = 33.3 [0.84-90.57],ORR in Cohort B (NUMBER) percentage of participants = 0.0 [0.00-52.18]; Progression-free Survival (PFS) in Cohort A (MEDIAN) months = 8.31; ; ; Number of Participants With Any Treatment-emergent Adverse Event (TEAE) (COUNT_OF_PARTICIPANTS) Participants = 3; Number of Participants With Any Treatment-related TEAE According to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v5.0 (COUNT_OF_PARTICIPANTS) Participants = 3,,,,,,,,Objective Response Rate (ORR) in Cohort A (NUMBER) percentage of participants = 33.3 [0.84-90.57]; ORR in Cohort B (NUMBER) percentage of participants = 0.0 [0.00-52.18],,Progression-free Survival (PFS) in Cohort A (MEDIAN) months = 8.31,,,Objective Response Rate (ORR) in Cohort A (NUMBER) percentage of participants = 33.3 [0.84-90.57],Number of Participants With Any Treatment-related TEAE According to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v5.0 (COUNT_OF_PARTICIPANTS) Participants = 3,,
NCT05259696,Glycan Mediated Immune Regulation With a Bi-Sialidase Fusion Protein (GLIMMER-01),"A Phase 1/2, Open-Label, Single-Arm, Dose-Escalation and Dose-Expansion Study of the Safety, Tolerability, Pharmacokinetic, and Antitumor Activity of E-602 as a Single Agent and in Combination With Ce","Palleon Pharmaceuticals, Inc.","Palleon Pharmaceuticals, Inc.",INDUSTRY,COMPLETED,2022-02-11,2024-10-24,2024-10-24,INTERVENTIONAL,PHASE1; PHASE2,,,,Oncology,Oncology; Melanoma; Ovarian Cancer,17,4,2,BIOLOGICAL,,,1,0,True,Yes,Number of Participants Who Experienced AEs or SAEs (COUNT_OF_PARTICIPANTS) Participants = 5,,,,,,,,,,,,,,,Number of Participants Who Experienced AEs or SAEs (COUNT_OF_PARTICIPANTS) Participants = 5,,
NCT05546476,"Study of the Efficacy and Safety of Ponsegromab in Patients With Cancer, Cachexia and Elevated GDF-15","A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY, SAFETY AND TOLERABILITY OF PONSEGROMAB IN PATIENTS WITH CANCER, CACHEXIA, AND ELEVATED CONCENTRATIONS OF GDF-",Pfizer,Pfizer,INDUSTRY,COMPLETED,2022-11-21,2024-03-13,2025-04-23,INTERVENTIONAL,PHASE2,,,,Non-small Cell Lung Cancer,Non-small Cell Lung Cancer; Pancreatic Cancer; Colorectal Cancer,6,4,2,DRUG,,,1,12,True,Yes,,"Part A: Change From Baseline in Physical Activity at Week 12 (LEAST_SQUARES_MEAN) Minutes per day = -1.42 [-72.77-69.92]; Part A: Change From Baseline in Mean Activity Level During Maximum 6 Minutes at Week 12 (LEAST_SQUARES_MEAN) Arbitrary units per day (au/day) = 70.81 [-785.82-927.45]; Part A: Change From Baseline in Total Vector Magnitude at Week 12 (LEAST_SQUARES_MEAN) Total activity counts/100 per day = -1919.02 [-3450.37--387.68]; Part A: Change From Baseline in Gait at Week 12 (LEAST_SQUARES_MEAN) Meter per second (m/s) = -0.008 [-0.042-0.026]; Part A: Change From Baseline in Functional Assessment of Anorexia-Cachexia Therapy- Anorexia and Cachexia Subscale (FAACT-ACS) at Week 12 (LEAST_SQUARES_MEAN) Units on a scale = 0.52 [-1.60-2.63]; Part A: Change From Baseline in FAACT- 5-Item Anorexia Symptom Scale (5IASS) at Week 12 (LEAST_SQUARES_MEAN) Units on a scale = 0.15 [-0.97-1.27]; Part A: Change From Baseline in Cancer-Related Cachexia Symptom Diary (CRCSD) Scores at Week 12: Appetite, Nausea and Physical Fatigue (LEAST_SQUARES_MEAN) Units on a scale = -0.23 [-0.83-0.37]; Part A: Median Change From Baseline in CRCSD Scores at Week 12: Vomiting Frequency (MEDIAN) Units on a scale = 0.00 [0.0-0.0]; Part A: Number of Participants With Treatment Emergent Adverse Events (TEAE) (COUNT_OF_PARTICIPANTS) Participants = 36; Part A: Number of Participants With Incidence of Laboratory Test Abnormalities (COUNT_OF_PARTICIPANTS) Participants = 26; Part A: Number of Participants With Post-Baseline Vital Signs Meeting the Predefined Criteria (COUNT_OF_PARTICIPANTS) Participants = 0; Part A: Number of Participants With Clinically Significant Echocardiogram (ECG) Abnormalities (COUNT_OF_PARTICIPANTS) Participants = 0",,,,,,,,,,,,,,Part A: Number of Participants With Treatment Emergent Adverse Events (TEAE) (COUNT_OF_PARTICIPANTS) Participants = 36,,
NCT05722015,A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With,"A Phase 3 Randomized, Open-label Clinical Study to Evaluate the Pharmacokinetics and Safety of Subcutaneous Pembrolizumab Coformulated With Hyaluronidase (MK-3475A) Versus Intravenous Pembrolizumab, A",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,INDUSTRY,ACTIVE_NOT_RECRUITING,2023-02-14,2024-07-12,2028-05-22,INTERVENTIONAL,PHASE3,,,,Metastatic Non-small Cell Lung Cancer,Metastatic Non-small Cell Lung Cancer,1,2,9,BIOLOGICAL; DRUG,,,2,14,True,Yes,Cycle 1: Area Under the Curve From Time 0 to 6 Weeks (AUC0-6 Weeks) of Pembrolizumab After the First Dose (GEOMETRIC_MEAN) μg·day/mL = 1633.24; Cycle 3: Trough Serum Concentration (Ctrough) of Pembrolizumab at Steady State (GEOMETRIC_MEAN) μg/mL = 39.23,Cycle 1: Maximum Serum Concentration (Cmax) of Pembrolizumab After the First Dose (GEOMETRIC_MEAN) μg/mL = 64.88; Cycle 1: Trough Serum Concentration (Ctrough) of Pembrolizumab After the First Dose (GEOMETRIC_MEAN) μg/mL = 19.36; Cycle 3: Area Under the Curve From Time 0 to 6 Weeks (AUC0-6 Weeks) of Pembrolizumab at Steady State (GEOMETRIC_MEAN) μg·day/mL = 2798; Cycle 3: Maximum Serum Concentration (Cmax) of Pembrolizumab at Steady State (GEOMETRIC_MEAN) μg/mL = 98.96; ; ; ; ; ; ; ; ; ; ,,,,,,,,,,,,,,,,
NCT05775289,A Study of Tobemstomig Plus Platinum-Based Chemotherapy vs Pembrolizumab Plus Platinum-Based Chemotherapy in Participants With Previously Untreated No,"A Phase II, Randomized, Multicenter, Double-Blind, Controlled Study of Tobemstomig Plus Platinum-Based Chemotherapy Versus Pembrolizumab Plus Platinum-Based Chemotherapy in Patients With Previously Un",Hoffmann-La Roche,Hoffmann-La Roche,INDUSTRY,ACTIVE_NOT_RECRUITING,2023-03-15,2024-06-20,2026-06-01,INTERVENTIONAL,PHASE2,,,,Non-small Cell Lung Cancer,Non-small Cell Lung Cancer,1,2,5,DRUG,,,2,24,True,Yes,Progression-Free Survival (PFS) (MEDIAN) Months = 7.13; Objective Response Rate (ORR) (NUMBER) Percent of participants = 46.2 [36.28-56.34],; ; ; ; Change in Participant-reported Outcomes as Assessed by the European Organisation for Research and Treatment (EORTC): Physical Functioning (MEDIAN) Scores on a scale = 86.67 [6.7-100.0]; Change in Participant-reported Outcomes as Assessed by the EORTC: Global Health Status/Quality of Life (GHS/QoL) (MEDIAN) Scores on a scale = 66.67 [0.0-100.0]; Change in Participant-reported Outcomes as Assessed by the EORTC: Role Functioning (MEDIAN) Scores on a scale = 91.67 [0.0-100.0]; Change in Participant-reported Outcomes as Assessed by the EORTC: Lung Cancer Symptoms/How Much Did You Cough (MEDIAN) Scores on a scale = 2.00 [1.0-4.0]; Change in Participant-reported Outcomes as Assessed by the EORTC: Short of Breath When Rested (MEDIAN) Scores on a scale = 1.00 [1.0-4.0]; Change in Participant-reported Outcomes as Assessed by the EORTC: Short of Breath When Walked (MEDIAN) Scores on a scale = 1.00 [1.0-4.0]; Change in Participant-reported Outcomes as Assessed by the EORTC: Short of Breath Climbed Stairs (MEDIAN) Scores on a scale = 2.00 [1.0-4.0]; Change in Participant-reported Outcomes as Assessed by the EORTC: Pain in Chest (MEDIAN) Scores on a scale = 1.00 [1.0-3.0]; Change in Participant-reported Outcomes as Assessed by the EORTC: Need to Rest (MEDIAN) Scores on a scale = 2.00 [1.0-4.0]; Change in Participant-reported Outcomes as Assessed by the EORTC: Felt Weak (MEDIAN) Scores on a scale = 2.00 [1.0-4.0]; Change in Participant-reported Outcomes as Assessed by the EORTC: Tired (MEDIAN) Scores on a scale = 2.00 [1.0-4.0]; Change in Participant-reported Outcomes as Assessed by the EORTC: Aches/Pain in Bones (MEDIAN) Scores on a scale = 1.00 [1.0-4.0]; Number of Participants With Adverse Events (AEs) (NUMBER) Count of participants = 89; Maximum Serum Concentration (Cmax) of Tobemstomig (GEOMETRIC_MEAN) ug/mL = 188; Time of Maximum Concentration (Tmax) of Tobemstomig (MEDIAN) Day = 0.0649 [0.0208-9.13]; Clearance (CL) of Tobemstomig (GEOMETRIC_MEAN) mL/day = 246; Volume of Distribution at Steady State (Vss) of Tobemstomig (GEOMETRIC_MEAN) Liters = 3.65; Area Under the Concentration-time Curve (AUC) of Tobemstomig (GEOMETRIC_MEAN) day*ug/mL = 1470; Half-life (T1/2) of Tobemstomig (GEOMETRIC_MEAN) Day = 8.45; Percentage of Participants With Anti-drug Antibodies (ADAs) (NUMBER) Percentage of participants = 42.9,,,,,,,,Objective Response Rate (ORR) (NUMBER) Percent of participants = 46.2 [36.28-56.34],,Progression-Free Survival (PFS) (MEDIAN) Months = 7.13,,Change in Participant-reported Outcomes as Assessed by the EORTC: Global Health Status/Quality of Life (GHS/QoL) (MEDIAN) Scores on a scale = 66.67 [0.0-100.0],Objective Response Rate (ORR) (NUMBER) Percent of participants = 46.2 [36.28-56.34],Number of Participants With Adverse Events (AEs) (NUMBER) Count of participants = 89,,
NCT06212752,A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With,"A Phase 3 Randomized, Open-label Clinical Study to Evaluate the Pharmacokinetics and Safety of Subcutaneous Pembrolizumab Coformulated With Hyaluronidase (MK-3475A) Versus Intravenous Pembrolizumab, A",Merck Sharp & Dohme LLC,Merck Sharp & Dohme LLC,INDUSTRY,ACTIVE_NOT_RECRUITING,2023-06-13,2024-11-06,2028-05-22,INTERVENTIONAL,PHASE3,,,,Metastatic Non-small Cell Lung Cancer,Metastatic Non-small Cell Lung Cancer,1,2,9,BIOLOGICAL; DRUG,,,1,12,True,Yes,Objective Response Rate (ORR) (NUMBER) Percentage of participants = 64.3 [44.1-81.4],Cycle 1: Area Under the Curve From Time 0 to 6 Weeks (AUC0-6 Weeks) of Pembrolizumab After the First Dose (GEOMETRIC_MEAN) µg·day/mL = 1864.76; Cycle 3: Trough Serum Concentration (Ctrough) of Pembrolizumab at Steady State (GEOMETRIC_MEAN) µg/ml = 45.11; Cycle 1: Maximum Serum Concentration (Cmax) of Pembrolizumab After the First Dose (GEOMETRIC_MEAN) µg/ml = 71.54; Cycle 1: Trough Serum Concentration (Ctrough) of Pembrolizumab After the First Dose (GEOMETRIC_MEAN) µg/ml = 23.62; Cycle 3: Area Under the Curve From Time 0 to 6 Weeks (AUC0-6 Weeks) of Pembrolizumab at Steady State (GEOMETRIC_MEAN) µg•day/ml = 3116; Cycle 3: Maximum Serum Concentration (Cmax) of Pembrolizumab at Steady State (GEOMETRIC_MEAN) µg/mL = 108.1; ; ; ; ; ; ,,,,,,,,Objective Response Rate (ORR) (NUMBER) Percentage of participants = 64.3 [44.1-81.4],,,,,Objective Response Rate (ORR) (NUMBER) Percentage of participants = 64.3 [44.1-81.4],,,
